0001100682-24-000007.txt : 20240214 0001100682-24-000007.hdr.sgml : 20240214 20240214091945 ACCESSION NUMBER: 0001100682-24-000007 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 141 CONFORMED PERIOD OF REPORT: 20231230 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CENTRAL INDEX KEY: 0001100682 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 061397316 FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15943 FILM NUMBER: 24633027 BUSINESS ADDRESS: STREET 1: 251 BALLARDVALE ST CITY: WILMINGTON STATE: MA ZIP: 01887 BUSINESS PHONE: 781-222-6000 MAIL ADDRESS: STREET 1: 251 BALLARDVALE ST CITY: WILMINGTON STATE: MA ZIP: 01887 FORMER COMPANY: FORMER CONFORMED NAME: CHARLES RIVER LABORATORIES INTERNATIONAL INC DATE OF NAME CHANGE: 20000605 FORMER COMPANY: FORMER CONFORMED NAME: CHARLES RIVER LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19991208 10-K 1 crl-20231230.htm 10-K crl-20231230
00011006822023FYfalseP8Y0http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrentP5Yhttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations00011006822023-01-012023-12-3000011006822023-06-30iso4217:USD00011006822024-01-27xbrli:shares0001100682us-gaap:ServiceMember2023-01-012023-12-300001100682us-gaap:ServiceMember2021-12-262022-12-310001100682us-gaap:ServiceMember2020-12-272021-12-250001100682us-gaap:ProductMember2023-01-012023-12-300001100682us-gaap:ProductMember2021-12-262022-12-310001100682us-gaap:ProductMember2020-12-272021-12-2500011006822021-12-262022-12-3100011006822020-12-272021-12-25iso4217:USDxbrli:shares00011006822023-12-3000011006822022-12-3100011006822021-12-2500011006822020-12-260001100682us-gaap:CommonStockMember2020-12-260001100682us-gaap:AdditionalPaidInCapitalMember2020-12-260001100682us-gaap:RetainedEarningsMember2020-12-260001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-260001100682us-gaap:TreasuryStockCommonMember2020-12-260001100682crl:TotalEquityAttributabletoCommonShareholdersMember2020-12-260001100682us-gaap:NoncontrollingInterestMember2020-12-260001100682us-gaap:RetainedEarningsMember2020-12-272021-12-250001100682crl:TotalEquityAttributabletoCommonShareholdersMember2020-12-272021-12-250001100682us-gaap:NoncontrollingInterestMember2020-12-272021-12-250001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-272021-12-250001100682us-gaap:AdditionalPaidInCapitalMember2020-12-272021-12-250001100682us-gaap:CommonStockMember2020-12-272021-12-250001100682us-gaap:TreasuryStockCommonMember2020-12-272021-12-250001100682us-gaap:CommonStockMember2021-12-250001100682us-gaap:AdditionalPaidInCapitalMember2021-12-250001100682us-gaap:RetainedEarningsMember2021-12-250001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-250001100682us-gaap:TreasuryStockCommonMember2021-12-250001100682crl:TotalEquityAttributabletoCommonShareholdersMember2021-12-250001100682us-gaap:NoncontrollingInterestMember2021-12-250001100682us-gaap:RetainedEarningsMember2021-12-262022-12-310001100682crl:TotalEquityAttributabletoCommonShareholdersMember2021-12-262022-12-310001100682us-gaap:NoncontrollingInterestMember2021-12-262022-12-310001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-262022-12-310001100682us-gaap:AdditionalPaidInCapitalMember2021-12-262022-12-310001100682us-gaap:CommonStockMember2021-12-262022-12-310001100682us-gaap:TreasuryStockCommonMember2021-12-262022-12-310001100682us-gaap:CommonStockMember2022-12-310001100682us-gaap:AdditionalPaidInCapitalMember2022-12-310001100682us-gaap:RetainedEarningsMember2022-12-310001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001100682us-gaap:TreasuryStockCommonMember2022-12-310001100682crl:TotalEquityAttributabletoCommonShareholdersMember2022-12-310001100682us-gaap:NoncontrollingInterestMember2022-12-310001100682us-gaap:RetainedEarningsMember2023-01-012023-12-300001100682crl:TotalEquityAttributabletoCommonShareholdersMember2023-01-012023-12-300001100682us-gaap:NoncontrollingInterestMember2023-01-012023-12-300001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-300001100682us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-300001100682us-gaap:CommonStockMember2023-01-012023-12-300001100682us-gaap:TreasuryStockCommonMember2023-01-012023-12-300001100682us-gaap:CommonStockMember2023-12-300001100682us-gaap:AdditionalPaidInCapitalMember2023-12-300001100682us-gaap:RetainedEarningsMember2023-12-300001100682us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-300001100682us-gaap:TreasuryStockCommonMember2023-12-300001100682crl:TotalEquityAttributabletoCommonShareholdersMember2023-12-300001100682us-gaap:NoncontrollingInterestMember2023-12-30crl:segment0001100682crl:DiscoverAndSafetyAssessmentSegmentMember2023-01-012023-12-30crl:subsegment0001100682srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2023-12-300001100682srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2023-12-300001100682us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2023-12-300001100682us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2023-12-300001100682srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2023-12-300001100682srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-12-300001100682us-gaap:ComputerEquipmentMembersrt:MinimumMember2023-12-300001100682us-gaap:ComputerEquipmentMembersrt:MaximumMember2023-12-300001100682us-gaap:VehiclesMembersrt:MinimumMember2023-12-300001100682us-gaap:VehiclesMembersrt:MaximumMember2023-12-300001100682crl:VentureCapitalFundsInvestmentsMembersrt:MinimumMember2023-12-30xbrli:pure0001100682crl:VentureCapitalFundsInvestmentsMembersrt:MaximumMember2023-12-30crl:contract0001100682srt:MinimumMember2023-12-300001100682srt:MaximumMember2023-12-300001100682crl:NoveprimGroupMember2023-11-300001100682crl:NoveprimGroupMember2022-12-310001100682crl:NoveprimGroupMember2021-12-262022-12-310001100682crl:NoveprimGroupMember2021-12-262023-11-300001100682crl:NoveprimGroupMembersrt:MinimumMember2023-11-300001100682crl:NoveprimGroupMembersrt:MaximumMember2023-11-300001100682crl:SAMDITechIncMember2023-01-272023-01-270001100682crl:SAMDITechIncMember2023-01-270001100682crl:ExploraBioLabsMember2022-04-050001100682crl:ExploraBioLabsMember2022-04-052022-04-050001100682crl:VigeneBiosciencesIncMember2021-06-282021-06-280001100682crl:VigeneBiosciencesIncMember2021-06-280001100682crl:VigeneBiosciencesIncMembersrt:MaximumMember2021-06-280001100682crl:VigeneBiosciencesIncMember2022-12-310001100682crl:VigeneBiosciencesIncMember2023-12-300001100682crl:RetrogenixLimitedMember2021-03-302021-03-300001100682crl:RetrogenixLimitedMember2021-03-300001100682crl:CognateBioServicesIncMember2021-03-292021-03-290001100682crl:DistributedBioIncMember2020-12-312020-12-310001100682crl:DistributedBioIncMember2020-12-310001100682crl:DistributedBioIncMembersrt:MaximumMember2020-12-310001100682crl:DistributedBioIncMember2021-12-262022-12-310001100682crl:DistributedBioIncMember2023-12-300001100682crl:OtherAcquisitionsMember2021-03-032021-03-030001100682crl:OtherAcquisitionsMember2019-12-292020-12-260001100682crl:OtherAcquisitionsMember2021-03-030001100682crl:OtherAcquisitionsMember2023-12-3000011006822023-01-2700011006822022-04-050001100682crl:NoveprimGroupMember2023-12-300001100682crl:CognateBioServicesIncMember2021-03-290001100682crl:NoveprimGroupMemberus-gaap:CustomerRelationshipsMember2023-11-302023-11-300001100682us-gaap:CustomerRelationshipsMembercrl:SAMDITechIncMember2023-01-272023-01-270001100682us-gaap:CustomerRelationshipsMembercrl:ExploraBioLabsMember2022-04-052022-04-050001100682crl:NoveprimGroupMemberus-gaap:OtherIntangibleAssetsMember2023-11-302023-11-300001100682crl:SAMDITechIncMemberus-gaap:OtherIntangibleAssetsMember2023-01-272023-01-270001100682us-gaap:OtherIntangibleAssetsMembercrl:ExploraBioLabsMember2022-04-052022-04-050001100682crl:NoveprimGroupMember2023-11-302023-11-300001100682us-gaap:CustomerRelationshipsMembercrl:VigeneBiosciencesIncMember2021-06-282021-06-280001100682us-gaap:CustomerRelationshipsMembercrl:RetrogenixLimitedMember2021-03-302021-03-300001100682us-gaap:CustomerRelationshipsMembercrl:CognateBioServicesIncMember2021-03-292021-03-290001100682us-gaap:CustomerRelationshipsMembercrl:DistributedBioIncMember2020-12-312020-12-310001100682crl:VigeneBiosciencesIncMemberus-gaap:OtherIntangibleAssetsMember2021-06-282021-06-280001100682us-gaap:OtherIntangibleAssetsMembercrl:RetrogenixLimitedMember2021-03-302021-03-300001100682us-gaap:OtherIntangibleAssetsMembercrl:CognateBioServicesIncMember2021-03-292021-03-290001100682us-gaap:OtherIntangibleAssetsMembercrl:DistributedBioIncMember2020-12-312020-12-310001100682crl:AvianMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-12-200001100682crl:AvianMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-12-300001100682crl:AvianMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-12-262022-12-310001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercrl:RMSJapanOperationsMember2021-10-120001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercrl:RMSJapanOperationsMember2021-10-122021-10-120001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercrl:RMSJapanOperationsMember2021-09-262021-12-250001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercrl:CDMOSiteMember2021-10-120001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercrl:CDMOSiteMember2021-10-122021-10-120001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersrt:MaximumMembercrl:CDMOSiteMember2021-10-120001100682us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercrl:CDMOSiteMember2022-12-310001100682crl:AvianMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-12-190001100682us-gaap:TransferredOverTimeMembercrl:ResearchModelsAndServicesMember2023-01-012023-12-300001100682us-gaap:TransferredOverTimeMembercrl:ResearchModelsAndServicesMember2021-12-262022-12-310001100682us-gaap:TransferredOverTimeMembercrl:ResearchModelsAndServicesMember2020-12-272021-12-250001100682crl:ResearchModelsAndServicesMemberus-gaap:TransferredAtPointInTimeMember2023-01-012023-12-300001100682crl:ResearchModelsAndServicesMemberus-gaap:TransferredAtPointInTimeMember2021-12-262022-12-310001100682crl:ResearchModelsAndServicesMemberus-gaap:TransferredAtPointInTimeMember2020-12-272021-12-250001100682crl:ResearchModelsAndServicesMember2023-01-012023-12-300001100682crl:ResearchModelsAndServicesMember2021-12-262022-12-310001100682crl:ResearchModelsAndServicesMember2020-12-272021-12-250001100682us-gaap:TransferredOverTimeMembercrl:DiscoveryandSafetyAssessmentMember2023-01-012023-12-300001100682us-gaap:TransferredOverTimeMembercrl:DiscoveryandSafetyAssessmentMember2021-12-262022-12-310001100682us-gaap:TransferredOverTimeMembercrl:DiscoveryandSafetyAssessmentMember2020-12-272021-12-250001100682crl:DiscoveryandSafetyAssessmentMemberus-gaap:TransferredAtPointInTimeMember2023-01-012023-12-300001100682crl:DiscoveryandSafetyAssessmentMemberus-gaap:TransferredAtPointInTimeMember2021-12-262022-12-310001100682crl:DiscoveryandSafetyAssessmentMemberus-gaap:TransferredAtPointInTimeMember2020-12-272021-12-250001100682crl:DiscoveryandSafetyAssessmentMember2023-01-012023-12-300001100682crl:DiscoveryandSafetyAssessmentMember2021-12-262022-12-310001100682crl:DiscoveryandSafetyAssessmentMember2020-12-272021-12-250001100682us-gaap:TransferredOverTimeMembercrl:ManufacturingSupportMember2023-01-012023-12-300001100682us-gaap:TransferredOverTimeMembercrl:ManufacturingSupportMember2021-12-262022-12-310001100682us-gaap:TransferredOverTimeMembercrl:ManufacturingSupportMember2020-12-272021-12-250001100682crl:ManufacturingSupportMemberus-gaap:TransferredAtPointInTimeMember2023-01-012023-12-300001100682crl:ManufacturingSupportMemberus-gaap:TransferredAtPointInTimeMember2021-12-262022-12-310001100682crl:ManufacturingSupportMemberus-gaap:TransferredAtPointInTimeMember2020-12-272021-12-250001100682crl:ManufacturingSupportMember2023-01-012023-12-300001100682crl:ManufacturingSupportMember2021-12-262022-12-310001100682crl:ManufacturingSupportMember2020-12-272021-12-2500011006822023-12-312023-12-300001100682us-gaap:OperatingSegmentsMembercrl:ResearchModelsAndServicesMember2023-01-012023-12-300001100682us-gaap:OperatingSegmentsMembercrl:ResearchModelsAndServicesMember2021-12-262022-12-310001100682us-gaap:OperatingSegmentsMembercrl:ResearchModelsAndServicesMember2020-12-272021-12-250001100682crl:DiscoveryandSafetyAssessmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-300001100682crl:DiscoveryandSafetyAssessmentMemberus-gaap:OperatingSegmentsMember2021-12-262022-12-310001100682crl:DiscoveryandSafetyAssessmentMemberus-gaap:OperatingSegmentsMember2020-12-272021-12-250001100682us-gaap:OperatingSegmentsMembercrl:ManufacturingSupportMember2023-01-012023-12-300001100682us-gaap:OperatingSegmentsMembercrl:ManufacturingSupportMember2021-12-262022-12-310001100682us-gaap:OperatingSegmentsMembercrl:ManufacturingSupportMember2020-12-272021-12-250001100682us-gaap:CorporateNonSegmentMember2023-01-012023-12-300001100682us-gaap:CorporateNonSegmentMember2021-12-262022-12-310001100682us-gaap:CorporateNonSegmentMember2020-12-272021-12-250001100682country:US2023-01-012023-12-300001100682srt:EuropeMember2023-01-012023-12-300001100682country:CA2023-01-012023-12-300001100682srt:AsiaPacificMember2023-01-012023-12-300001100682crl:OtherMember2023-01-012023-12-300001100682country:US2023-12-300001100682srt:EuropeMember2023-12-300001100682country:CA2023-12-300001100682srt:AsiaPacificMember2023-12-300001100682crl:OtherMember2023-12-300001100682country:US2021-12-262022-12-310001100682srt:EuropeMember2021-12-262022-12-310001100682country:CA2021-12-262022-12-310001100682srt:AsiaPacificMember2021-12-262022-12-310001100682crl:OtherMember2021-12-262022-12-310001100682country:US2022-12-310001100682srt:EuropeMember2022-12-310001100682country:CA2022-12-310001100682srt:AsiaPacificMember2022-12-310001100682crl:OtherMember2022-12-310001100682country:US2020-12-272021-12-250001100682srt:EuropeMember2020-12-272021-12-250001100682country:CA2020-12-272021-12-250001100682srt:AsiaPacificMember2020-12-272021-12-250001100682crl:OtherMember2020-12-272021-12-250001100682country:US2021-12-250001100682srt:EuropeMember2021-12-250001100682country:CA2021-12-250001100682srt:AsiaPacificMember2021-12-250001100682crl:OtherMember2021-12-250001100682us-gaap:LandMember2023-12-300001100682us-gaap:LandMember2022-12-310001100682us-gaap:BuildingMember2023-12-300001100682us-gaap:BuildingMember2022-12-310001100682us-gaap:MachineryAndEquipmentMember2023-12-300001100682us-gaap:MachineryAndEquipmentMember2022-12-310001100682us-gaap:LeaseholdImprovementsMember2023-12-300001100682us-gaap:LeaseholdImprovementsMember2022-12-310001100682us-gaap:FurnitureAndFixturesMember2023-12-300001100682us-gaap:FurnitureAndFixturesMember2022-12-310001100682us-gaap:ComputerEquipmentMember2023-12-300001100682us-gaap:ComputerEquipmentMember2022-12-310001100682us-gaap:VehiclesMember2023-12-300001100682us-gaap:VehiclesMember2022-12-310001100682us-gaap:ConstructionInProgressMember2023-12-300001100682us-gaap:ConstructionInProgressMember2022-12-310001100682us-gaap:VentureCapitalFundsMember2022-12-310001100682us-gaap:VentureCapitalFundsMember2021-12-250001100682us-gaap:VentureCapitalFundsMember2020-12-260001100682us-gaap:VentureCapitalFundsMember2023-01-012023-12-300001100682us-gaap:VentureCapitalFundsMember2021-12-262022-12-310001100682us-gaap:VentureCapitalFundsMember2020-12-272021-12-250001100682us-gaap:VentureCapitalFundsMember2023-12-300001100682crl:StrategicInvestmentsMember2022-12-310001100682crl:StrategicInvestmentsMember2021-12-250001100682crl:StrategicInvestmentsMember2020-12-260001100682crl:StrategicInvestmentsMember2023-01-012023-12-300001100682crl:StrategicInvestmentsMember2021-12-262022-12-310001100682crl:StrategicInvestmentsMember2020-12-272021-12-250001100682crl:StrategicInvestmentsMember2023-12-300001100682us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-300001100682us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-300001100682us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:FairValueMeasurementsRecurringMember2023-12-300001100682us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001100682us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001100682us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001100682us-gaap:FairValueMeasurementsRecurringMember2022-12-310001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-12-250001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2020-12-260001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-12-300001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-12-262022-12-310001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2020-12-272021-12-250001100682crl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682crl:ContingentConsiderationMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682crl:ContingentConsiderationMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682crl:ContingentConsiderationMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-11-300001100682us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-300001100682crl:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2023-12-300001100682crl:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-12-310001100682crl:SeniorNotesDue2028Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2023-12-300001100682crl:SeniorNotesDue2028Memberus-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-300001100682crl:SeniorNotesDue2028Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2022-12-310001100682crl:SeniorNotesDue2028Memberus-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001100682us-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Member2023-12-300001100682us-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Member2022-12-310001100682us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Member2023-12-300001100682us-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-300001100682us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Member2022-12-310001100682us-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001100682crl:SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2022-12-310001100682crl:SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2023-12-300001100682crl:SeniorNotesDue2031Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2023-12-300001100682crl:SeniorNotesDue2031Memberus-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-300001100682crl:SeniorNotesDue2031Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMember2022-12-310001100682crl:SeniorNotesDue2031Memberus-gaap:SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001100682crl:ResearchModelsAndServicesMember2021-12-250001100682crl:DiscoveryandSafetyAssessmentMember2021-12-250001100682crl:ManufacturingSupportMember2021-12-250001100682crl:ResearchModelsAndServicesMember2022-12-310001100682crl:DiscoveryandSafetyAssessmentMember2022-12-310001100682crl:ManufacturingSupportMember2022-12-310001100682crl:ResearchModelsAndServicesMember2023-12-300001100682crl:DiscoveryandSafetyAssessmentMember2023-12-300001100682crl:ManufacturingSupportMember2023-12-300001100682crl:BiologicSolutionsMember2023-12-300001100682us-gaap:CustomerRelationshipsMember2023-12-300001100682us-gaap:CustomerRelationshipsMember2022-12-310001100682us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-300001100682us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001100682us-gaap:OrderOrProductionBacklogMember2023-12-300001100682us-gaap:OrderOrProductionBacklogMember2022-12-310001100682us-gaap:TrademarksAndTradeNamesMember2023-12-300001100682us-gaap:TrademarksAndTradeNamesMember2022-12-310001100682us-gaap:OtherIntangibleAssetsMember2023-12-300001100682us-gaap:OtherIntangibleAssetsMember2022-12-310001100682us-gaap:LineOfCreditMember2023-12-300001100682us-gaap:LineOfCreditMember2022-12-310001100682crl:OtherLongTermDebtMember2023-12-300001100682crl:OtherLongTermDebtMember2022-12-310001100682crl:SeniorNotesDue2026Memberus-gaap:SeniorNotesMember2020-12-272021-12-250001100682crl:ThreeBillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-06-260001100682crl:ThreeBillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:FederalFundsEffectiveSwapRateMember2021-06-262021-06-260001100682crl:ThreeBillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMembercrl:SecuredOvernightFinancingRateSOFRMember2021-06-262021-06-260001100682crl:ThreeBillionCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-12-300001100682crl:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2019-12-280001100682crl:SeniorNotesDue2029And2031Memberus-gaap:SeniorNotesMember2021-12-250001100682us-gaap:SeniorNotesMembercrl:SeniorNotesDue2029Member2021-12-250001100682crl:SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2021-12-250001100682crl:SeniorNotesDue2029And2031Memberus-gaap:SeniorNotesMember2020-12-272021-12-250001100682crl:SeniorNotesDue2026Memberus-gaap:SeniorNotesMember2018-12-290001100682us-gaap:MediumTermNotesMember2020-12-272021-12-250001100682us-gaap:RevolvingCreditFacilityMember2020-12-272021-12-250001100682us-gaap:ForeignExchangeForwardMembersrt:MinimumMember2021-12-250001100682us-gaap:ForeignExchangeForwardMembersrt:MinimumMember2022-12-310001100682us-gaap:ForeignExchangeForwardMembersrt:MaximumMember2021-12-250001100682us-gaap:ForeignExchangeForwardMembersrt:MaximumMember2022-12-310001100682us-gaap:ForeignExchangeForwardMemberus-gaap:InterestExpenseMember2021-12-262022-12-310001100682us-gaap:ForeignExchangeForwardMemberus-gaap:InterestExpenseMember2020-12-272021-12-250001100682us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-12-262022-12-310001100682us-gaap:ForeignExchangeForwardMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-12-272021-12-250001100682us-gaap:LetterOfCreditMember2023-12-300001100682us-gaap:LetterOfCreditMember2022-12-310001100682crl:AuthorizedShareRepurchaseProgramMember2023-12-300001100682us-gaap:AccumulatedTranslationAdjustmentMember2020-12-260001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-260001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-260001100682us-gaap:AccumulatedTranslationAdjustmentMember2020-12-272021-12-250001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-272021-12-250001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-272021-12-250001100682us-gaap:AccumulatedTranslationAdjustmentMember2021-12-250001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-250001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-250001100682us-gaap:AccumulatedTranslationAdjustmentMember2021-12-262022-12-310001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-262022-12-310001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-262022-12-310001100682us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001100682us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-300001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-300001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-300001100682us-gaap:AccumulatedTranslationAdjustmentMember2023-12-300001100682us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-300001100682us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-300001100682srt:MinimumMembercrl:NoveprimGroupMember2023-12-300001100682crl:NoveprimGroupMembersrt:MaximumMember2023-12-300001100682crl:VitalRiverMember2022-12-310001100682crl:VitalRiverMember2023-12-300001100682crl:VitalRiverMember2023-10-012023-12-300001100682crl:SupplierMember2020-12-260001100682crl:SupplierMember2022-06-300001100682crl:SupplierMember2022-06-012022-06-300001100682crl:SupplierMember2023-12-300001100682us-gaap:ForeignCountryMember2023-12-300001100682us-gaap:ForeignCountryMember2022-12-310001100682us-gaap:ForeignCountryMembercrl:TaxCreditCarryforwardsExpirationRange2Member2023-12-300001100682us-gaap:ForeignPlanMember2023-01-012023-12-300001100682us-gaap:FundedPlanMemberus-gaap:ForeignPlanMember2023-01-012023-12-300001100682us-gaap:ForeignPlanMember2021-12-262022-12-310001100682us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-300001100682us-gaap:PensionPlansDefinedBenefitMember2021-12-262022-12-310001100682us-gaap:PensionPlansDefinedBenefitMember2020-12-272021-12-250001100682us-gaap:EquitySecuritiesMember2023-12-300001100682us-gaap:DebtSecuritiesMember2023-12-300001100682crl:OtherPlanAssetCategoriesMember2023-12-300001100682us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2023-12-300001100682us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2023-12-300001100682us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2023-12-300001100682us-gaap:CashAndCashEquivalentsMember2023-12-300001100682us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2022-12-310001100682us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2022-12-310001100682us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2022-12-310001100682us-gaap:CashAndCashEquivalentsMember2022-12-310001100682us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2023-12-300001100682us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-300001100682us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-12-310001100682us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001100682us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001100682us-gaap:EquitySecuritiesMember2022-12-310001100682us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-300001100682us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-300001100682us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001100682us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001100682us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001100682us-gaap:DebtSecuritiesMember2022-12-310001100682us-gaap:FairValueInputsLevel1Memberus-gaap:EquityFundsMember2023-12-300001100682us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-300001100682us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:EquityFundsMember2023-12-300001100682us-gaap:FairValueInputsLevel1Memberus-gaap:EquityFundsMember2022-12-310001100682us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001100682us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001100682us-gaap:EquityFundsMember2022-12-310001100682us-gaap:FairValueInputsLevel1Membercrl:OtherPlanAssetCategoriesMember2023-12-300001100682crl:OtherPlanAssetCategoriesMemberus-gaap:FairValueInputsLevel2Member2023-12-300001100682crl:OtherPlanAssetCategoriesMemberus-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:FairValueInputsLevel1Membercrl:OtherPlanAssetCategoriesMember2022-12-310001100682crl:OtherPlanAssetCategoriesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001100682crl:OtherPlanAssetCategoriesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001100682crl:OtherPlanAssetCategoriesMember2022-12-310001100682us-gaap:FairValueInputsLevel1Member2023-12-300001100682us-gaap:FairValueInputsLevel2Member2023-12-300001100682us-gaap:FairValueInputsLevel3Member2023-12-300001100682us-gaap:FairValueInputsLevel1Member2022-12-310001100682us-gaap:FairValueInputsLevel2Member2022-12-310001100682us-gaap:FairValueInputsLevel3Member2022-12-310001100682us-gaap:PensionPlansDefinedBenefitMember2023-12-300001100682us-gaap:EmployeeStockOptionMember2020-12-272021-12-250001100682us-gaap:EmployeeStockOptionMember2023-01-012023-12-300001100682us-gaap:EmployeeStockOptionMember2021-12-262022-12-310001100682srt:MinimumMemberus-gaap:EmployeeStockOptionMember2021-12-262022-12-310001100682srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-300001100682srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-12-272021-12-250001100682srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-300001100682srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-12-272021-12-250001100682srt:MaximumMemberus-gaap:EmployeeStockOptionMember2021-12-262022-12-310001100682us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-01-012023-12-300001100682us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2021-12-262022-12-310001100682us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2020-12-272021-12-250001100682us-gaap:PerformanceSharesMembersrt:MinimumMember2023-12-300001100682us-gaap:PerformanceSharesMembersrt:MinimumMember2021-12-250001100682us-gaap:PerformanceSharesMembersrt:MinimumMember2022-12-310001100682us-gaap:PerformanceSharesMembersrt:MinimumMember2021-12-262022-12-310001100682us-gaap:PerformanceSharesMembersrt:MinimumMember2023-01-012023-12-300001100682us-gaap:PerformanceSharesMembersrt:MinimumMember2020-12-272021-12-250001100682us-gaap:CostOfSalesMember2023-01-012023-12-300001100682us-gaap:CostOfSalesMember2021-12-262022-12-310001100682us-gaap:CostOfSalesMember2020-12-272021-12-250001100682us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-300001100682us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-12-262022-12-310001100682us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-12-272021-12-250001100682us-gaap:EmployeeStockOptionMember2023-12-300001100682crl:RestrictedStockandRestrictedStockUnitsMember2022-12-310001100682crl:RestrictedStockandRestrictedStockUnitsMember2023-01-012023-12-300001100682crl:RestrictedStockandRestrictedStockUnitsMember2023-12-300001100682us-gaap:RestrictedStockMember2023-12-300001100682us-gaap:RestrictedStockMember2023-01-012023-12-300001100682us-gaap:RestrictedStockMember2021-12-262022-12-310001100682us-gaap:RestrictedStockMember2020-12-272021-12-250001100682us-gaap:PerformanceSharesMember2023-01-012023-12-300001100682us-gaap:PerformanceSharesMembercrl:PerformanceSharesGranteeGroupOneMember2023-01-012023-12-300001100682us-gaap:PerformanceSharesMembercrl:PerformanceSharesGranteeGroupOneMember2021-12-262022-12-310001100682us-gaap:PerformanceSharesMembercrl:PerformanceSharesGranteeGroupOneMember2020-12-272021-12-250001100682us-gaap:PerformanceSharesMember2021-12-262022-12-310001100682us-gaap:PerformanceSharesMember2020-12-272021-12-250001100682us-gaap:PerformanceSharesMember2023-12-300001100682us-gaap:PerformanceSharesMembercrl:PerformanceSharesGranteeGroupTwoMember2020-12-272021-12-250001100682crl:SeveranceAndTransitionCostsMemberus-gaap:CostOfSalesMemberus-gaap:ServiceMember2023-01-012023-12-300001100682us-gaap:CostOfSalesMembercrl:AssetImpairmentAndOtherCostsMemberus-gaap:ServiceMember2023-01-012023-12-300001100682us-gaap:CostOfSalesMemberus-gaap:ServiceMember2023-01-012023-12-300001100682us-gaap:ProductMembercrl:SeveranceAndTransitionCostsMemberus-gaap:CostOfSalesMember2023-01-012023-12-300001100682us-gaap:ProductMemberus-gaap:CostOfSalesMembercrl:AssetImpairmentAndOtherCostsMember2023-01-012023-12-300001100682us-gaap:ProductMemberus-gaap:CostOfSalesMember2023-01-012023-12-300001100682us-gaap:SellingGeneralAndAdministrativeExpensesMembercrl:SeveranceAndTransitionCostsMember2023-01-012023-12-300001100682us-gaap:SellingGeneralAndAdministrativeExpensesMembercrl:AssetImpairmentAndOtherCostsMember2023-01-012023-12-300001100682crl:SeveranceAndTransitionCostsMember2023-01-012023-12-300001100682crl:AssetImpairmentAndOtherCostsMember2023-01-012023-12-300001100682crl:SeveranceAndTransitionCostsMemberus-gaap:CostOfSalesMemberus-gaap:ServiceMember2021-12-262022-12-310001100682us-gaap:CostOfSalesMembercrl:AssetImpairmentAndOtherCostsMemberus-gaap:ServiceMember2021-12-262022-12-310001100682us-gaap:CostOfSalesMemberus-gaap:ServiceMember2021-12-262022-12-310001100682us-gaap:ProductMembercrl:SeveranceAndTransitionCostsMemberus-gaap:CostOfSalesMember2021-12-262022-12-310001100682us-gaap:ProductMemberus-gaap:CostOfSalesMembercrl:AssetImpairmentAndOtherCostsMember2021-12-262022-12-310001100682us-gaap:ProductMemberus-gaap:CostOfSalesMember2021-12-262022-12-310001100682us-gaap:SellingGeneralAndAdministrativeExpensesMembercrl:SeveranceAndTransitionCostsMember2021-12-262022-12-310001100682us-gaap:SellingGeneralAndAdministrativeExpensesMembercrl:AssetImpairmentAndOtherCostsMember2021-12-262022-12-310001100682crl:SeveranceAndTransitionCostsMember2021-12-262022-12-310001100682crl:AssetImpairmentAndOtherCostsMember2021-12-262022-12-310001100682crl:SeveranceAndTransitionCostsMemberus-gaap:CostOfSalesMemberus-gaap:ServiceMember2020-12-272021-12-250001100682us-gaap:CostOfSalesMembercrl:AssetImpairmentAndOtherCostsMemberus-gaap:ServiceMember2020-12-272021-12-250001100682us-gaap:CostOfSalesMemberus-gaap:ServiceMember2020-12-272021-12-250001100682us-gaap:ProductMembercrl:SeveranceAndTransitionCostsMemberus-gaap:CostOfSalesMember2020-12-272021-12-250001100682us-gaap:ProductMemberus-gaap:CostOfSalesMembercrl:AssetImpairmentAndOtherCostsMember2020-12-272021-12-250001100682us-gaap:ProductMemberus-gaap:CostOfSalesMember2020-12-272021-12-250001100682us-gaap:SellingGeneralAndAdministrativeExpensesMembercrl:SeveranceAndTransitionCostsMember2020-12-272021-12-250001100682us-gaap:SellingGeneralAndAdministrativeExpensesMembercrl:AssetImpairmentAndOtherCostsMember2020-12-272021-12-250001100682crl:SeveranceAndTransitionCostsMember2020-12-272021-12-250001100682crl:AssetImpairmentAndOtherCostsMember2020-12-272021-12-250001100682crl:AccruedCompensationMembercrl:SeveranceAndTransitionCostsMember2023-12-300001100682crl:AccruedCompensationMembercrl:SeveranceAndTransitionCostsMember2022-12-310001100682us-gaap:PendingLitigationMembercrl:USFishAndWildlifeServiceMember2023-12-3000011006822023-10-012023-12-300001100682crl:JamesFosterMember2023-01-012023-12-300001100682crl:JamesFosterMember2023-10-012023-12-300001100682crl:JamesFosterMember2023-12-300001100682crl:BirgitGirshickMember2023-01-012023-12-300001100682crl:BirgitGirshickMember2023-10-012023-12-300001100682crl:BirgitGirshickMember2023-12-300001100682crl:MsGirshickMember2023-01-012023-12-300001100682crl:MsGirshickMember2023-10-012023-12-300001100682crl:MsGirshickMember2023-12-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 10-K
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED December 30, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM                                    TO                                   
Commission File No. 001-15943
charlesriverlogoa01.jpg
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware 06-1397316
(State or Other Jurisdiction of
Incorporation or Organization)		 (I.R.S. Employer
Identification No.)
251 Ballardvale StreetWilmingtonMassachusetts01887
(Address of Principal Executive Offices)(Zip Code)
____________________________________________________________________________
(Registrant’s telephone number, including area code): (781) 222-6000
____________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTicker symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueCRLNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: Yes ☐ No ☒
Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.        Large accelerated filer ☑    Accelerated filer ☐    Non-accelerated filer ☐    
Smaller reporting company ☐    Emerging growth company ☐
If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐



Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒
On June 30, 2023, the aggregate market value of the registrant’s voting common stock held by non-affiliates of the registrant was approximately $10,686,736,278. As of January 27, 2024, there were 51,349,770 shares of the registrant’s common stock outstanding, $0.01 par value per share.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders currently scheduled to be held on May 8, 2024, which will be filed with the Securities and Exchange Commission (SEC) not later than 120 days after December 30, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the 2024 Proxy Statement expressly incorporated into this Annual Report on Form 10-K by reference, such document shall not be deemed filed as part of this Form 10-K.



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
ANNUAL REPORT ON FORM 10-K
FOR FISCAL YEAR 2023

TABLE OF CONTENTS
Item Page
PART I 
1
1A
1B
1C
2
3
4
PART II
5
6
7
7A
8
9
9A
9B
9C
PART III
10
11
12
13
14
PART IV
15
16


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PART I
Item 1. Business
General
This Annual Report on Form 10-K contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. that are based on our current expectations, estimates, forecasts and projections about the industries in which we operate and the beliefs and assumptions of our management. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “likely,” “may,” “designed,” “would,” “future,” “can,” “could” and other similar expressions, which are predictions of, indicate future events and trends or which do not relate to historical matters are intended to identify such forward-looking statements. These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict. For example, we may use forward-looking statements when addressing topics such as: our expectations regarding the availability of non-human primates and our ability to diversify our non-human primate supply chain; the outcome of (1) the U.S. government investigations and inquiries related to the non-human primate supply chain (including shipments of non-human primates from Cambodia received by the Company), (2) the putative securities class action lawsuit filed against us and certain current/former officers on May 19, 2023, and (3) the derivative lawsuit filed against members of the Board of Directors and certain current/former officers on November 8, 2023; the timing and impact of the development and implementation of enhanced procedures to reasonably ensure that non-human primates we source are purpose-bred; changes and uncertainties in the global economy and financial markets, including any changes in business, political, or economic conditions due to the November 16, 2022 announcement by the U.S. Department of Justice through the U.S. Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, including the number of shares to be repurchased, expected timing and duration, the amount of capital that may be expended and the treatment of repurchased shares; our ability to successfully execute our business strategy; our ability to timely build infrastructure to satisfy capacity needs and support business growth, our ability to fund our operations for the foreseeable future, the impact of unauthorized access into our information systems, including the timing and effectiveness of any enhanced security and monitoring present spending trends and other cost reduction activities by our clients; future actions by our management; the outcome of contingencies; changes in our business strategy, business practices and methods of generating revenue; the development and performance of our services and products; market and industry conditions, including competitive and pricing trends and the impact of those conditions, including on our allowances for credit losses; our strategic relationships with leading pharmaceutical and biotechnology companies, venture capital investments, and opportunities for future similar arrangements; our cost structure; our expectations regarding our acquisitions and divestitures, including their impact and projected timing; our expectations with respect to revenue growth and operating synergies (including the impact of specific actions intended to cause related improvements, particularly with respect to our CDMO business); the impact of specific actions intended to improve overall operating efficiencies and profitability (and our ability to accommodate future demand with our infrastructure), including gains and losses attributable to businesses we plan to close, consolidate, divest or repurpose and the impact of operations and cost structure alignment efforts (including as estimated on an annualized basis); our expectations with respect to study cancellation rates and the impact of such cancellations; changes in our expectations regarding future stock option, restricted stock, performance share units and other equity grants to employees and directors; expectations with respect to foreign currency exchange; assessing (or changing our assessment of) our tax positions for financial statement purposes; our liquidity; and the impact of litigation, including our ability to successfully defend litigation against us. In addition, these statements include the impact of economic and market conditions on us and our clients, the effects of our cost-saving actions and the steps to optimize returns to shareholders on an effective and timely basis; and our ability to withstand the current market conditions.
Forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document or, in the case of statements incorporated by reference, on the date of the document incorporated by reference. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in this Form 10-K under the sections entitled “Our Strategy,” “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” in our press releases and other financial filings with the SEC. We have no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or risks. New information, future events or risks may cause the forward-looking events we discuss in this report not to occur.
1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Corporate History
We began operating in 1947 and, since then, have undergone several changes to our business structure. Charles River Laboratories International, Inc. was incorporated in 1994 and we completed our initial public offering in 2000. Our stock is traded on the New York Stock Exchange under the symbol “CRL” and is included in the Standard & Poor’s 500 and Composite 1500 indices, the New York Stock Exchange (NYSE) Arca Biotechnology Index, the NYSE Composite and many of the Russell indices, among others. We are headquartered in Wilmington, Massachusetts. Our headquarters mailing address is 251 Ballardvale Street, Wilmington, MA, 01887, and the telephone number at that location is (781) 222-6000. Our Internet site is www.criver.com. Material contained on our Internet site is not incorporated by reference into this Form 10-K. Unless the context otherwise requires, references in this Form 10-K to “Charles River,” “we,” “us,” “the Company” or “our” refer to Charles River Laboratories International, Inc. and its subsidiaries.
This Form 10-K, as well as all other reports filed with the SEC, is available free of charge through the Investor Relations section of our Internet site (www.criver.com) as soon as practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
Overview
We are a leading, non-clinical global drug development partner with a mission to create healthier lives. We have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. We also provide a suite of products and services to support our clients’ manufacturing activities. Utilizing our broad portfolio of products and services enables our clients to create a more efficient and flexible drug development model, which reduces their costs, enhances their productivity and effectiveness, and increases speed to market.
The development of new drugs requires a steadily increasing investment of time and money. Various studies and reports estimate that it takes between 10 to 15 years, up to $2.5 billion excluding time costs and exploration of between 10,000 and 15,000 drug molecules to produce a single Food and Drug Administration (FDA)-approved drug.
Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening, and selection of a lead molecule for future drug development. Discovery activities typically extend anywhere from 4 to 7 years in conventional pharmaceutical research and development (R&D) timelines.
Development activities, which follow, and which can take up to 7 to 10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the non-clinical stage of the development process, a drug candidate is tested in vitro (non-animal, typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to establish drug safety prior to and in support of human clinical trials.
For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices and therapies. Over this time, we have built upon our core competency of in vivo biology to develop a diverse and expanding portfolio of products and services, which now encompasses the broader non-clinical drug research process. We are positioned to leverage our leading portfolio in non-clinical drug research in an efficient and cost-effective way to aid our clients in bringing their drugs to market faster.
Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world. In recent years, we have focused our efforts on improving the efficiency of our global operations to enhance our ability to support our clients. Our pharmaceutical and biotechnology clients are increasingly seeking full service, “one-stop” global partners to whom they can outsource more of their drug discovery and development efforts. It is estimated that the market for regulated safety assessment services is 60% outsourced or more, while emerging growth areas such as discovery and certain research model services are currently believed to be less outsourced.
We currently operate in 155 sites and in over 20 countries worldwide (excluding certain Insourcing Solutions sites). Our products and services, supported by our global infrastructure and deep scientific expertise, enable our clients to overcome many of the challenges of non-clinical life sciences research. In 2023, our total revenue was $4.1 billion.
We have three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing).
Through our RMS segment, we have provided foundational tools for the discovery of new molecules by supplying research models to the drug development industry since 1947. We continue to maintain our position as a global leader in the production
2
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
and sale of the most widely used research models, including over 140 different stocks and strains of purpose-bred rodents. We also provide a variety of related services that are designed to support our clients in the use of research models in drug discovery and development. We maintain multiple production centers, including barrier rooms and isolator facilities, on three continents (North America, Europe, and Asia). We are also a premier provider of high quality, purpose bred, large research models to the biomedical research community. Our RMS segment also includes our Insourcing Solutions business, which includes our CRADL™ (Charles River Accelerator and Development Lab) footprint. In 2023, RMS accounted for 19.2% of our total revenue and approximately 4,300 of our employees, including approximately 200 science professionals with advanced degrees.
Our DSA segment provides services that enable our clients to outsource their innovative drug discovery research, their related nonclinical and some clinical drug development activities, and regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines and medical devices. The demand for these services is driven by the needs of large global pharmaceutical companies that continue to transition to an outsourced drug development model, in addition to mid-size and emerging biotechnology companies, industrial and agrochemical companies and non-governmental organizations that rely on outsourcing. These entities may choose to outsource their discovery, development and safety activities to reduce fixed costs and to gain access to additional scientific expertise and capabilities.
We are the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide. We have extensive expertise in the discovery of nonclinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of compounds including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices. We currently provide discovery and safety assessment services at multiple facilities located in the United States (U.S.), Canada, and Europe. In 2023, our DSA segment represented 63.3% of our total revenue and employed approximately 13,400 of our employees including approximately 1,800 science professionals with advanced degrees.
Within our Manufacturing segment, we work with our clients and the biopharmaceutical industry to ensure the quality and safe production and release of commercial therapies and products manufactured both by our clients and internally for our clients. Our Manufacturing Segment is comprised of two businesses: Microbial Solutions and Biologics Solutions. Our Microbial Solutions products and services businesses provide in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our CDMO business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies. In 2023, Manufacturing accounted for 17.4% of our total revenue from continuing operations and approximately 3,000 of our employees, including approximately 400 science professionals with advanced degrees.
Research Models and Services. Our RMS segment is comprised of three businesses that provide foundational tools that enable our clients to discover new molecules: Research Models, Research Model Services and Cell Solutions.
Research Models. Our Research Models business is principally comprised of the production and sale of the most widely used small research models, primarily rodents. A significant portion of our Research Models business involves the commercial production and sale of small research models, principally purpose-bred rats and mice for use by researchers. The FDA and foreign regulatory agencies typically require that the safety and efficacy of new drug candidates be tested on research models like ours prior to testing in humans. As a result, our research models are an essential part of the drug discovery and development process.
We provide our research models to numerous clients around the world, including most pharmaceutical companies, a broad range of biotechnology companies, contract research organizations and many government agencies, hospitals, and academic institutions. We have a global footprint with production facilities strategically located in 7 countries, in close proximity to major biohubs and client concentrations. Our research models include commonly used laboratory strains, disease models and specialized strains with compromised immune systems, which are in demand as early-stage tools in the drug research and development process.
The research models we supply have been, and continue to be, some of the most extensively used in the world, largely as a result of our geographic footprint and continuous commitment to innovation, quality, and biosecurity. Our research models are bred and maintained in controlled environments, which are designed to ensure that the models are free of specific viral and bacterial agents and other contaminants that can disrupt research operations and distort scientific results. With our production capabilities, we are able to deliver consistently high-quality research models worldwide.
Our small research models include inbred, outbred, and hybrid strains, as well as mutant strains and genetically engineered models with biological features, which enable research aims. Certain of our research models are proprietary rodent models used to research treatments in several therapeutic areas. We are also a premier provider of high quality, purpose bred, large research models to the biomedical research community. While we provide some non-human primates directly to customers who utilize
3
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
them primarily for safety testing of new therapies, most of the non-human primates associated with our business are utilized in connection with our customers’ studies conducted by our Safety Assessment business. In both cases - non-human primates we provide directly to customers and non-human primates which are utilized in our Safety Assessment business – these large research models are sourced from Charles River audited and approved suppliers, some of which we have an ownership and/or operational involvement. See Note 2, “Acquisitions and Divestitures”, included in the notes to our consolidated financial statements included elsewhere in this Form 10-K for a description of the recent acquisition of Noveprim Group.
Research Model Services. RMS offers a variety of flexible solutions designed to support our clients' use of research models in basic research and screening pre-clinical drug candidates. These services address the need among pharmaceutical and biotechnology companies to outsource the non-core aspects of their drug discovery activities. Our services include those related to the maintenance and monitoring of research models, and managing research operations for government entities, academic organizations, and commercial clients. Our expanded service offering provides greater flexibility for our clients’ research and supports increased scientific complexity. We currently have three service offerings in research models services: Insourcing Solutions, Genetically Engineered Models and Services (GEMS), and Research Animal Diagnostic Services (RADS).
Insourcing Solutions. We manage the research operations of government entities, academic organizations and commercial clients (including recruitment, training, staffing and management services) both within our clients’ facilities and utilizing our Charles River Accelerator and Development Lab (CRADL™) offerings, where we provide vivarium space to our clients. Some research institutions prefer to retain certain elements of their research in-house, while outsourcing staffing and management, thus driving demand for our services. We believe that our expertise in early-stage drug research, and in particular research model care, scientific and technical support, facility operations, and discovery and development services, enhances the productivity and quality of our clients’ research programs.
Genetically Engineered Models and Services. We create, breed and maintain research models required by our clients for biomedical research activities. The creation of a genetically engineered model (GEM) is a critical scientific event, but it is only one step in the discovery process, and our scientists can advise clients on how to efficiently create custom models utilizing in-licensed technologies and approaches to modify the genome. Productive utilization of GEMs requires significant additional technical expertise in order to properly support basic and early discovery research. We provide breeding expertise and colony expansion, quarantine, health and genetic testing and monitoring, germplasm cryopreservation and rederivation, including assisted reproduction and model creation. Our team of project managers is supported by a proprietary, technologically advanced Internet Colony Management (ICM™) system that allows for real-time data exchange. We provide these services to clients around the world, including pharmaceutical and biotechnology companies, hospitals, universities, and government agencies.
Research Animal Diagnostic Services. We monitor and analyze the health profiles of our clients’ research models and research biologics by assessing infectious agents and pathology. We developed this capability internally to address the quality control of our research model business. We can serve as our clients’ sole-source testing laboratory, or as an alternative source supporting our clients’ internal laboratory capabilities. We believe we are the reference laboratory of choice for health assessment of laboratory research models and an industry leader in the field of laboratory animal diagnostics.
Cell Solutions. Our Cell Solutions business provides consenting human donor-derived cellular materials used in the development and production of cell therapies. The business supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. Our Cell Solutions business supports biotechnology and pharmaceutical companies, academic institutions and other research organizations who rely on high-quality, viable and functional human primary cells and blood components for biomedical and drug discovery research and cell therapy development, including clinical trials.
Discovery and Safety Assessment
Our DSA segment is comprised of two businesses: Discovery Services and Safety Assessment. We currently offer regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.
Discovery Services. Our Discovery Services business operates as a single source of services for discovering and characterizing novel drug candidates for preclinical development. We offer a full spectrum of discovery services from identification and validation of novel targets, chemical compounds and antibodies with actual or potential intellectual property value through to delivery of preclinical drug and therapeutic candidates ready for safety assessment. Our Discovery Services business includes services to streamline and enhance drug discovery programs for our clients, including expertise and capabilities in all stages of Discovery and all major modalities including small molecules, antibodies and cell and gene therapies. This seamless discovery organization, along with its broad capabilities allows us to better engage with clients at any stage of their drug discovery programs and support their complex scientific needs. Our Discovery Services business focuses on all of the major therapeutic areas, with a strategic focus on oncology, immunology and neuroscience. We believe there are growing opportunities to assist
4
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
our clients in a variety of drug discovery applications and platforms from target discovery to candidate selection and across the full range of modalities.
We are a leader in integrated drug discovery services. Our full suite of service offerings, together with our knowledge and expertise, allows us to engage and support our clients at any stage of their discovery or early-stage development programs, including the design and implementations of their research programs, and to stay with them through the entire drug discovery process. Our Discovery service capabilities include:
•target discovery and validation;
•target deconvolution through proteomics;
•hit identification and optimization to deliver candidate molecules across modalities, including computer-aided drug design;
•early nonclinical pharmacokinetic and pharmacodynamic studies, transporter-mediated drug-drug interaction, and in vitro and in vivo assays to assess mechanism, bioavailability and metabolism as required for regulatory approval of new drugs;
•In vivo Discovery Services, which are essential in early stage, non-clinical discovery research, and are directed at the identification, screening, optimization and selection of effective therapeutics agents in pharmacology models. These in vivo activities typically extend anywhere from 1 to 2 years in conventional pharmaceutical R&D timelines; and
•target engagement biomarker development to support non-clinical and potentially downstream clinical studies.
Additionally, we offer ion channel and drug transporter testing for both discovery and non-clinical purposes. We also provide these services at our clients’ laboratories with Charles River scientists as part of an insourcing service model.
Through comprehensive in vivo and in vitro offerings, Discovery Services helps to reduce the time needed to research, develop, and assess the efficacy of new therapeutics under development. Our offerings include businesses that provide critical data to advance novel therapeutics, as well as drug transporter assays and kits. We offer R&D expertise, capabilities and services globally to accelerate our clients’ drug discovery pipelines from lead generation to candidate selection. We complement and extend clients’ capabilities and expertise to improve their decision-making, increase their flexibility, and reduce their internal costs and product development timelines.
Through strategic partnerships, we also offer an artificial intelligence drug design platform, a human stem cell model platform, and 3D in vitro oncology models.
Safety Assessment. We offer a full range of safety assessment studies required for regulatory submission on a global basis across all therapeutic areas in the pharmaceutical, biotechnology, industrial chemical, agrochemicals, consumer products, veterinary medicines and medical devices industries. Our safety assessment business also provides expertise in a variety of therapeutic areas and modalities. Our Safety Assessment business is a global leader in both non-regulated and regulated (GLP) outsourced safety assessment services.
Toxicology. We provide a broad specialty toxicology offering from inhalation and infusion to developmental and reproductive toxicology. Our services include a broad offering of in vitro and in vivo capabilities and study types designed to identify possible safety risks as well as a broad offering of in vitro and in vivo studies in support of general toxicology (acute, sub-acute and chronic studies), genetic toxicology, safety pharmacology, off-target screening, receptor identification profiling, reproductive and developmental toxicology, juvenile toxicology, and carcinogenicity bioassays that are required for regulatory submissions supporting “first-in-human” to “first-to-the-market” strategies for potential human therapeutics. Additionally, we support safety studies in numerous specialty areas including abuse and seizure liability, ecotoxicology, environmental risk, musculoskeletal toxicology, neurotoxicology, ocular toxicology, ototoxicology, and phototoxicology. We have expertise in the design and execution of development programs in support of a broad diversity of therapeutic modalities in numerous laboratory species and test systems. We also support safety studies to test industrial chemical, agrochemicals, consumer products, veterinary medicines and medical devices. For human pharmaceutical candidates, once a lead candidate is selected, toxicology studies are required to support clinical trials in humans and for regulatory approval. These toxicology studies focus on assessing the safety of the potential therapeutic to determine if administration to humans might cause any unintended harmful effects. For new chemicals, industrial chemicals, agrochemicals, veterinary medicines, consumer products and medical devices, safety studies are performed to identify potential hazards to humans and the environment and are required for regulatory registration. Toxicology studies performed for any of these compounds are typically performed using in vitro and in vivo research models to identify any potential adverse effects that a compound has on an organism over a variety of doses and over various time periods of exposure.
Pathology Services. The ability to identify and characterize clinical and anatomic pathologic changes is critical in determining the safety and efficacy of potential new therapeutics, industrial and agricultural chemicals, veterinary medicines, and medical
5
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
devices. Key “go/no-go” decisions regarding continued product development are typically dependent on the identification, characterization and evaluation of fluid, tissue and cellular changes that our experts identify and interpret for our clients. We employ many highly trained veterinary anatomic and clinical pathologists and other scientists who use state-of-the-art techniques to identify potential test item-related changes. In addition to all standard anatomic and clinical pathology techniques, we provide specialized evaluations such as cytology, platelet function, assay development, immunohistochemistry, in situ hybridization, electron microscopy, image analysis, tissue morphometry and spatial analysis services.
Safety Pharmacology. Our clients are also required to conduct an assessment of safety pharmacology. This suite of studies is used to determine any effects on the vital organ systems of the body - cardiovascular, respiratory and central nervous system (CNS). Along with heart rate and blood pressure measurements, the cardiovascular assessment will also assess if the test article has the potential to alter cardiac ion channel currents and prolong the cardiac QT interval of the electrocardiogram. Additionally, effects on the CNS and respiratory systems are assessed to complete the battery of studies to evaluate the vital organ systems of the body. Supplemental studies can also be performed to assess the renal, gastrointestinal and autonomic nervous systems, as well as dependency potential. We have in vitro, ex vivo (use of cells, tissues or organs outside of an in vivo system) and in vivo assays and perform the screening prior to the initiation of first-in-human clinical trials. Our capabilities can also be used to investigate the mode of action behind an adverse effect found in a safety assessment study.
Bioanalysis, Drug Metabolism and Pharmacokinetics. In support of non-clinical drug safety testing and new chemical development, our clients are required to demonstrate appropriate stability in the collected biological sample, pharmacokinetics of their drug or compound in circulation, the presence of metabolites and, in the case of biologics, the presence or absence of anti-drug antibodies. We have scientific expertise in the sophisticated bioanalytical techniques required to satisfy these requirements for many drugs and chemicals. Once analysis is complete, our scientists evaluate the data to provide information on the pharmacokinetics and/or toxicokinetics of the drug or chemical and complete an evaluation of the biologic disposition of the drug or chemical and its potential metabolites. Pharmacokinetics refers to the understanding of what the body does to a drug or compound administered at therapeutic dose levels, including the process by which the drug is absorbed, distributed in the body, metabolized and excreted. Toxicokinetics refers to the same understanding as applied at higher doses that may result in adverse effects. These studies are routinely required for the full non-clinical assessment of the disposition of the drug or chemical and the results are used in the safety evaluation of the compound. After performing sample analysis in support of non-clinical studies, we also support the clinical bioanalysis required in clinical trials for drug development. In addition, our Laboratory Sciences group is able to measure a wide range of nonclinical and clinical biomarkers related to the safety and efficacy of the drugs and/or chemicals being developed.
Our Safety Assessment facilities comply with animal welfare requirements and GLP to the extent required by the FDA, Environmental Protection Agency, United States Department of Agriculture (USDA), European Medicines Agency, European Chemicals Agency and the Organization for Economic Co-operation and Development (OECD), Canadian Council on Animal Care (CCAC) as well as other international regulatory agencies. Furthermore, our early-stage discovery work, which is not subject to GLP regulations, is typically carried out under a quality management system. Our Safety Assessment facilities and Manufacturing facilities are regularly inspected by U.S. and other regulatory compliance monitoring authorities, our clients’ quality assurance departments and our own internal quality audit program.
Manufacturing Solutions
Our Manufacturing Solutions segment is comprised of two businesses: Microbial Solutions and Biologics Solutions.
Microbial Solutions. Our Microbial Solutions business operates as a rapid, efficient testing platform for microbial detection and identification of sterile and non-sterile applications. Microbial Solutions is a premier global provider of in vitro methods for conventional and rapid quality control testing, including FDA-mandated lot release testing for sterile biopharmaceutical products. The products and services are provided by our Endosafe®, Celsis® and Accugenix® businesses, which produce, globally distribute and service a comprehensive portfolio of endotoxin testing, microbial detection and identification kits, reagents, instruments, software, accessories, and laboratory services to a broad range of companies manufacturing and releasing products from the pharmaceutical, biotechnology, medical devices and consumer products companies. Our Endosafe® business provides lot release testing of medical devices and injectable drugs for endotoxin contamination. Our Celsis® business provides rapid microbial detection systems for lot release testing as well as raw materials and in-process for quality control testing in the pharmaceutical, medical device and consumer products industries. Our Accugenix® business provides state-of-the-art microbial identification services and products for manufacturing in the biopharmaceutical, medical device, nutraceutical and consumer care industries. We expect our comprehensive portfolio of offerings and global network of laboratories to drive increased adoption of our quality control testing solutions across both sterile and non-sterile applications.
Endosafe®. We are a market leader in endotoxin testing products and services, which are used for FDA-required quality control testing of injectable drugs and medical devices, their components, and the processes by which they are manufactured. Endotoxin testing is an in vitro process that uses a processed extract from horseshoe crabs, known as limulus amebocyte lysate (LAL). The LAL test is the first and most successful FDA-validated alternative to an in vivo test to date. Generally, the
6
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
extraction of the raw materials for LAL does not harm the crabs, which are subsequently returned to their natural ocean environment. We have worked closely with regulatory agencies in states where we collect to limit our impact on the horseshoe crab population.
One of the primary growth drivers in our Microbial Solutions business is our FDA-approved line of next-generation endotoxin testing products. This line is based on the Endosafe Portable Testing System (Endosafe® -PTS™) technology, which allows rapid endotoxin testing in the central laboratory or manufacturing environment. In recent years, we expanded the PTS product portfolio to include a multiple sample testing system known as the Endosafe®-MCS™ (multi-cartridge system) and the first fully automated robotic system developed specifically for high-volume endotoxin testing, Endosafe®-Nexus, to satisfy the demand of our clients who require higher sample throughput. We have seen expanded use of this rapid endotoxin testing technology as clients transition from traditional methods to our rapid cartridge technology and are seeking to meet data integrity requirements with our automated systems and software solutions. We recently launched Endosafe® Trillium®, our new animal-free recombinant test for endotoxin detection. Endosafe® Trillium® utilizes three biological proteins, which we believe provides superior accuracy and testing outcomes to competitors’ single-protein recombinant alternatives, as well as equivalence to LAL-based testing method. Endosafe® Trillium® represents a next-generation solution to our industry-leading Endosafe® bacterial endotoxin detection portfolio.
Celsis®. The Celsis® reagents and instrument systems are used for in-process and product-release testing to help ensure the safe and efficient manufacture of pharmaceutical and consumer products. Celsis® products utilize adenosine triphosphate bioluminescence technology for the rapid detection of microbial contamination delivering definitive results for some applications as fast as 24 hours. The product range includes reagent kits, instruments, software and services. The Celsis Advance II™, Celsis Accel™, and Celsis Adapt™ instruments and software automate the process for rapid microbial detection. We maintain a suite of products focused on sterility testing. Sterility testing is required prior to the release of sterile injectable products. The legacy method required a 14-day sample incubation period and was subjective. Using the Celsis® protocol and instrumentation, clients can detect contamination within 6 days and make definitive product release decisions. We also offer Celsis Complete™ and Celsis Advantage™ services. The Celsis Complete™ services supply both the documentation and testing required as part of a client sterility technology method validation process. This assists clients to complete their validation process very quickly without utilizing their own personnel resources. The Celsis Advantage product supplies the required documentation needed for the clients to conduct their own internal validation. The Celsis Adapt™ is an accessory instrument for the Celsis® rapid detection systems, which is used to prepare and concentrate samples and provide a rapid testing solution for advanced therapy medicinal products, cell therapies, gene therapies, and other cell-containing products.
Accugenix®. Our Accugenix® global lab network is the premier provider of ISO17025-accredited contract microbial identification services. Accugenix® is an industry leader in species-level identification and strain typing of bacteria and fungi that are recovered from manufacturing facilities. Utilizing state-of-the-art and proprietary technologies, coupled with scientific expertise and analysis from a network of ten global labs, Accugenix® excels in providing accurate, timely, and cost-effective microbial identification services and products required to meet internal quality standards and government regulations. Accugenix® also offers an in- house solution with our Axcess® instrument that allows clients to perform identification testing in their own lab with access to our proprietary library.
Biologics Solutions. Our Biologics Solutions (Biologics) business is comprised of our Biologics Testing Services business and CDMO business. Biologics provides clients with analytical testing and related capabilities to support the safe manufacture of their biologic drugs, as well as a suite of manufacturing services to produce our clients’ advanced therapeutics.
Our current Good Manufacturing Practices (cGMP) testing services facilities also grow and store well-characterized early-stage client cell lines and virus seed stocks for later development or manufacture of therapeutic proteins and vaccines for clinical trials. We further design and provide viral clearance programs according to GLP at our German facility and cGMP at our U.S. facility for Phase I, II and III human clinical studies as well as for market authorization.
Biologics Testing Services
Our Biologics Testing Services business encompasses process development and quality-control testing to support the manufacture of biologics. We perform specialized testing of biologics frequently outsourced by pharmaceutical and biotechnology companies globally and are a partner in navigating the complex pathway to biologic effectiveness. Our laboratories in the U.S., Germany, Ireland and France provide timely and regulatory-compliant services in the areas of analytical, molecular biology, virology, cell-based bioassays, bioanalysis, immunochemistry, microbiology, cell biology, in vivo and in vitro studies and related services. We provide analytical characterization, lot release and safety testing support for chemistry, manufacturing and controls and investigational new drug (IND) filings and confirm that biomanufacturing of clinical drug candidates and commercial drugs are consistent, correctly defined, stable and essentially contaminant free. This testing is required by the FDA, EMA and other international regulatory authorities for our clients to obtain new drug approvals, to maintain government-licensed manufacturing facilities and to manufacture and release market-approved therapeutic products for patient treatment.
7
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
To meet growing demand, we continue to expand our Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. We have also commissioned a biosafety level 3 (BSL3) facility to provide in vivo and in vitro testing services for BSL3 materials, such as SARS-CoV2.
CDMO Services
Our CDMO business operates in the three major areas of the high-growth advanced therapy CDMO market: cell therapy, viral vector, and plasmid DNA production. Our CDMO services include expertise in gene-modified and unmodified cell therapy manufacturing coupled with capabilities in viral vector manufacturing, as well as plasma DNA. Our CDMO services establish us as a premier scientific partner for cell and gene therapy development, testing, and manufacturing. The full integrated advanced therapeutics portfolio enables us to provide clients with an integrated solution from basic research and discovery through cGMP production; driving efficiency and accelerating clients’ speed-to-market by integrating preclinical CRO activities with manufacturing and testing. This provides our clients with a seamless experience across the value chain with the same advanced therapeutics scientific partner. Our cGMP CDMO facilities have the capability to manufacture and store raw materials, drug substance, and drug product, which are suitable for use in clinical trials as well as for commercial manufacturing.
Our Strategy
Our objective is to be the scientific partner of choice to accelerate biomedical research and therapeutic innovation. Our strategy is to deliver a comprehensive and integrated portfolio of drug discovery and non-clinical development products, services and solutions to support our clients’ discovery and early-stage drug research, process development, scale up, manufacturing and product release efforts, and enable them to bring new and improved therapies to market faster and more cost effectively.
We believe we have certain competitive advantages in executing this strategy because of our continuing focus on the following:
Integrated Early-Stage Portfolio. Our large, global portfolio of products, services and solutions focuses on drug discovery and early-stage development. We provide research models and associated services, discovery research studies and services and comprehensive safety assessment studies in both regulated and non-regulated environments. As such, we can collaborate with clients from target discovery through development candidate selection. When critical decisions are made regarding which therapeutics will progress from discovery to development, we continue to work alongside our clients as the drug candidates move downstream. Our recognized expertise in early-stage drug research and pharmacology provides us with a competitive advantage and enables our clients to make critical drug development decisions more quickly. We understand our clients’ therapies and the challenges they face during the discovery and development process, including mechanism of action, efficacy, drug metabolism, safety assessment and toxicological testing, which are all critical for making “go/no-go” decisions.
Comprehensive Biopharmaceutical Manufacturing Portfolio. We also offer a portfolio of products, services and solutions that supports the process development, scale up, quality control and production efforts of the biopharmaceutical industry. We provide products and services that support the development and release of clinical stage and commercialized biologics products, including CDMO services to manufacture advanced therapeutics for our clients. In particular, we are an industry leader in the areas of microbial detection and microbial identification to support process development and ongoing commercial production. Our portfolio spans a broad range of traditional and rapid methods, which provide the highest testing quality, enhanced productivity and reduced cycle time.
Deep Scientific Expertise. We provide a breadth and depth of scientific expertise across a broad range of therapeutic areas which may be too costly for our clients to build and/or maintain in-house. We provide essential capabilities, including medicinal chemistry, antibody engineering, in vitro biology, in vivo pharmacology, pathology, advanced modalities manufacturing, analytical testing for early and late stage products, immunology, biomarker assessment, biologics process development testing, microbial detection and identification and other specialty service areas that have high infrastructure costs or are cost-prohibitive for clients to maintain independently. We continue to expand our portfolio in key therapeutic and pharmacology areas to align with our clients’ internal drug discovery and development areas of focus. We also continue to enhance our small molecule, biologics, and advanced modalities portfolios in areas of greatest industry need, where outsourcing provides major benefits for our clients and where we could provide significant benefits given our unique early-stage development portfolio and global footprint.
Commitment to Animal Welfare. We are committed to being the worldwide leader in the humane care of research animals and implementation of the “4Rs” initiative (Replacement, Reduction, Refinement, and Responsibility). As researchers, we are responsible to our clients, our animals and the public for the health and well-being of the animals in our care. We work closely with the scientific community to understand how living conditions, handling procedures and reduction of stress play an important role in the quality and efficiency of research. We are committed to working with the industry to support development and to provide the best translational models to supplement or replace traditional models. These include in vitro models as well as in silico predictive tools. In the last 4 years, we have
8
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
invested approximately $200 million in alternative methodologies, including technologies and digital platforms that reduce/modify animal use via strategic acquisitions, partnerships, and internal investments.
Superior Quality and Client Support. We maintain scientific rigor and high-quality standards through management of key performance indicators and an intense focus on biosecurity and quality. These standards help to reduce research risk and allow clients to access our global portfolio of products and services with the confidence that they will obtain consistent results no matter where they choose to obtain their products or conduct their research.
Flexible and Customized Environment to Provide the Right Solutions. Each of our clients is different, with unique needs and specific requirements. We understand the importance of flexibility, and leverage the expertise embedded in our integrated, non-clinical portfolio to provide customized solutions tailored to the specific need or therapeutic area for a particular client. By utilizing our streamlined and efficient facilities, we help clients create a flexible and integrated infrastructure in order to improve their workload and staffing requirements. This allows our clients to optimize internal capacity and/or staff while ensuring the conduct of effective quality research for their projects. We provide enhanced value to clients who use us as a full-service integrated partner over a longer period of time.
Large, Global Partner. We believe there is an important advantage in being a full service, high-quality provider of research models and associated services, discovery and non-clinical in vivo and in vitro services and manufacturing solutions on a global scale. Many of our clients, especially large biopharmaceutical companies, have decided to limit the number of suppliers with which they work. They frequently choose to partner with large companies similar to Charles River, that can offer clients support across the non-clinical drug research process as a result of broader portfolios and experience in project management. This includes extensive scientific, technical and therapeutic area expertise, real-time access to data, documentation and data visualization through secure portals, provision of data in sponsor-specific formats for data warehousing needs, accelerated reporting, reduced standard reporting timelines and industry-leading Standard Exchange of Non-Clinical Data (SEND) capabilities, a global footprint, streamlined and simplified processes and communications, including professional project and relationship management. We are focused on leveraging our competitive advantages to ensure we are recognized as the premier preferred provider, thereby enabling us to build broader and deeper long-term strategic relationships with our clients.
Digital Enhancements. We believe the healthcare industry is at a unique inflection point post COVID, where vaccines and treatments were developed in record time, and there is increasing focus on personalized medicine and rare diseases. As the industry evolves, technology is playing an essential role. This technological revolution is not only helping streamline processes and operations, but the effects of this digitization directly impact patients. We are committed in our efforts to reduce the timeline to develop, safe and innovative new treatments for patients who desperately need them. To progress this forward, we strive to understand the true challenges that can slow drug research and development and re-imagine the way we work and collaborate to create digitally native solutions that improve efficiency, accelerate processes and enable automated, data driven outcomes. Our commitment to understanding the problem before finding a solution has enabled us to keep clients—and ultimately patients—at the center of the way we look at problems. By using client-centric design thinking, agile-based test and learn processes in short iterative cycles, and automating existing processes, we optimize client experiences and bring holistic solutions to pressing concerns.
Our clients’ R&D needs continue to evolve. These clients are increasingly emphasizing studies that have greater translation to the clinic so that they can make appropriate decisions regarding the progression of potential therapeutic entities earlier in the development process. The result is a focus on discovery services, including in vitro models and in vivo pharmacology studies consisting of efficacy and non-GLP DMPK (drug metabolism and pharmacokinetics) studies. Second, these clients are choosing to outsource additional discovery and safety assessment services to increase the efficiency and effectiveness of their drug selection processes.
We believe that this changing environment will provide enhanced outsourcing opportunities for us in the future. We remain optimistic that our clients are increasingly receptive to partnering with us as a means of meeting their discovery and non-clinical support needs. We believe that the successful development of new therapies and outsourcing by the pharmaceutical industry will continue to be positive drivers of demand for our products and services.
Global biopharmaceutical companies are continuing to make the decision to outsource more significant tranches of their drug discovery, development and manufacturing processes. The success of our business model is underscored by the fact that we have entered into strategic commercial relationships with leading global biopharmaceutical companies and expanded existing preferred provider agreements with other leading global biopharmaceutical companies. We also continue to broaden and extend our relationships with other research institutions across the portfolio.
We believe that larger biopharmaceutical companies will increasingly focus on efficiencies and execution. They will continue to reassess their core differentiators from R&D to commercialization, and which aspects of their drug discovery, development
9
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
and manufacturing processes they will choose to outsource. We expect they will also continue to be conservative in re-building infrastructure and expertise. This should lead to more opportunities for strategic outsourcing as larger pharmaceutical clients choose to utilize external resources rather than invest in internal infrastructure. By partnering with Charles River, we believe our clients can take advantage of efficiencies in their early-stage research activities that can result in months saved in getting a drug to market. In the aggregate, we believe that the evolving large biopharmaceutical R&D business model along with our focus on data and digitalization will make our essential products and services even more relevant to our clients, and allow them to leverage our integrated offerings and expertise to drive their research, non-clinical development and manufacturing efficiency and cost effectiveness.
We believe it is critical to participate in the strategic commercial partnering process because these relationships are likely to extend for multiple years and drive pull-through across our portfolio. Furthermore, both the client and Charles River invest heavily in the initial phases of the relationship to successfully transfer work streams and establish governance processes. Given this investment, clients are less likely to change partners at the conclusion of the initial relationship.
The evolving biopharmaceutical R&D business model, coupled with solid long-term biopharmaceutical industry fundamentals and a historically sustained funding environment, have also led to the continued creation of new biotechnology companies focused on developing innovative new therapies. The biopharmaceutical industry also continues to evolve and become more sophisticated, with research yielding new types of treatments with increasing complexity, and more targeted and individualized therapies. We believe that our portfolio provides flexible solutions and scientific expertise that meet the customized needs for virtual and small biotechnology companies, which have limited or no infrastructure. These clients also value our ability to provide a broad range of services where we work hand in hand with our clients to design, plan and manage integrated projects and programs. This includes classically outsourced services, “insourced” services and hybrid offerings blending resources from both our clients and our staff.
Our strategic imperatives and operational goals are centered around our intense focus on initiatives designed to allow us to drive profitable growth, enhance our operating efficiency and cost structure and better position ourselves to function successfully in the current and future business environment, which we believe will collectively enable us to maximize value for our shareholders.
In recent years, we have expanded our service capabilities into the high-growth, high-science sector of cell and gene therapy. Our goal is to deliver the fastest and highest quality end-to-end integrated solution to accelerate cell and gene therapy development and manufacturing globally by leveraging our comprehensive portfolio of cell and gene therapy capabilities with a consistent, easy-to-use, and customizable, high-science approach, while offering the flexibility to adapt and innovate to meet our client’s changing needs. In the cell and gene therapy sector, we aim to accelerate our clients’ path to market, to expand capabilities and geographic reach to complement our leading non-clinical portfolio, and to collaborate with our clients and partners to enable and commercialize the next generation of cell and gene therapy innovations. Our CDMO capabilities, combined with our comprehensive portfolio, most notably our Biologics Testing Solutions business, industry experience, and established infrastructure, helped solidify Charles River as a premier scientific partner for cell and gene therapy development, testing, and manufacturing.
We intend to continue to broaden the scope of the products and services that we provide across the drug discovery and non-clinical development continuum primarily through internal development, and, as needed, through focused acquisitions and partnerships. Acquisitions, such as our acquisitions of Distributed Bio, Retrogenix, Cognate, and Vigene in fiscal 2021, Explora BioLabs in fiscal 2022, and SAMDI and Noveprim in 2023, are an integral part of our growth strategy, both to expand our portfolio and broaden our geographic footprint. We are committed to a disciplined approach that seeks to target businesses that are a sound strategic fit. We aim to consistently deliver shareholder value, including the achievement of a hurdle rate for return on invested capital above our weighted average cost of capital.
Mergers, acquisitions, and partnerships remain one of our top, long-term priorities for disciplined capital deployment and enhancing growth strategy with focus on enhancing the breadth of our scientific capabilities, expanding our global scale, and maintaining our leadership position in advanced and emerging therapies. Our long-term strategy also includes growth through establishing relationships and exploring other opportunities and areas that have the potential to strengthen our broad-based portfolio of products and services. In particular, our focus has been to drive differentiation through technologies that enhance the speed to develop a clinical candidate and allow biopharmaceutical companies to make earlier go/no-go decisions. Among other arrangements, these relationships may include entering into license agreements, strategic technology partnerships or joint ventures that will allow us to access innovative capabilities and cutting-edge or nascent technologies with a modest investment component. Our ability to thoroughly assess these technologies and market opportunities may later result in an acquisition.
We also partner with a diverse set of leading venture capital firms around the world primarily investing in life sciences, health care and therapeutics with an emphasis on early-stage companies. Through these partnerships and close relationships, we gain insight into their company and asset portfolios and are thus able to promote our services for each of our businesses. We also view these partnerships as an investment in new and emerging sciences and technologies as they allow us to gain insights to
10
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
cutting-edge capabilities. Thus, we have the opportunity to establish ourselves as a provider of choice for a unique client group that has emerged as biopharmaceutical companies rationalize and prioritize their development pipelines.
We routinely evaluate strategic fit and fundamental performance of our businesses. As part of this ongoing assessment, we may determine certain capital could be better deployed in other long-term growth opportunities. Most recently, we divested our Avian Vaccine Services business in 2022, and RMS Japan and CDMO Sweden operations in 2021, as we determined these businesses were no longer a strategic fit.
Clients
Our clients consist primarily of major biopharmaceutical companies; many biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions and government agencies. We have stable, long-term relationships with many of our clients. During 2023, no single client accounted for more than 3.5% of our total revenue and no single client accounted for more than 8% of the revenue of any of our three business segments.
We continue to pursue a goal of expanding our relationships with our large biopharmaceutical clients, and with many of our larger mid-market clients. These relationships take different forms, from preferred provider arrangements to strategic partnerships. The structure of these relationships incentivizes clients to purchase more products and services across our non-clinical portfolio. Because of the strength of these relationships, we have better insight into our clients’ planning processes and, therefore, better visibility than in the past. For information regarding revenue attributable to each of our business segments for the last three fiscal years, please see Note 4, “Segment and Geographic Information” included in the Notes to Consolidated Financial Statements included elsewhere in this Form 10-K. For information regarding revenue and long-lived assets attributable to operations in the United States, Europe, Canada, Asia Pacific and other countries for each of the last three fiscal years, please review Note 4, “Segment and Geographic Information” included in the Notes to Consolidated Financial Statements included elsewhere in this Form 10-K.
Sales, Marketing and Customer Support
Our marketing efforts are focused on stimulating demand for further outsourcing across our entire services portfolio. We believe that our ability to provide solutions that address all aspects of early-stage drug research are increasingly attractive to our clients, and we continue to design and market our commercial activities to deliver flexible, customized programs designed by segment to meet our clients’ global and site-specific needs.
Our go-to-market approach employs a number of sales and marketing strategies, including dedicated sales teams for each of our major lines of business and global and key account managers who represent the entire portfolio. We also maintain several sales specialists that either have specific technical expertise (often degreed scientists) or cover unique markets.
In addition to our field sales teams and related specialists, we also have a team of alliance managers who are organized by key client within our market segments (global biopharmaceutical, small and mid-sized pharmaceutical and biotechnology companies, and academic and government institutions). This enhances our ability to meet client needs by offering customized, tailored solutions across our entire portfolio. In addition, our clients benefit by additional support from a combination of technical specialists with specific scientific and therapeutic area expertise. We also apply the use of dedicated sales specialists for certain technical product lines, such as in our Manufacturing businesses.
We sell our products and services principally through our direct sales and business development teams who work in North America, Europe and Asia. In addition to interactions with our direct sales force, our primary promotional activities include presenting scientific symposia to targeted audiences, publishing scientific papers, technical support pieces and white papers, and newsletters, hosting webinars and virtual seminars and making presentations at, and participating in, scientific conferences and trade shows in North America, Europe and Asia. We supplement these scientifically based marketing activities with digital marketing, advertising and website content. In certain areas, our direct sales force is supplemented by international distributors and agents.
Our internal strategic marketing and marketing operations teams support the field sales and business development teams while developing and implementing programs to build awareness about products and services and create opportunities for interaction with our clients in the biomedical research industry. We maintain client engagement, lead development support, digital experience, eCommerce, and event management departments, which address both our clients’ routine and more specialized needs and purposely serve as a scientific support and information resource for them. We frequently assist our clients in solving problems related to resourcing products and services, research support, non-clinical study design, regulatory consulting, protocol development and other areas in which our expertise is widely recognized as a valuable resource by our clients.
11
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Competition
Our goal is to be a leader in each of the markets in which we participate. We compete in the marketplace on the basis of our therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. We are able to offer a unique portfolio of early-stage products and services to support drug discovery and development.
We encounter a broad range of competitors of different sizes and capabilities in each of our three businesses segments. We also face competition from the internal discovery and development resources of our clients.
•For RMS, we have four main competitors of which one is a government funded, not-for-profit entity; one is a public company in the U.S.; one is privately held in Europe; and one is privately held in the U.S.
•For DSA, both our Discovery Services and Safety Assessment businesses have numerous competitors. Discovery Services has hundreds of competitors, but two main competitors: one is a public company in China and one is a public company in Europe. Safety Assessment has dozens of competitors of varying size, but one main competitor that is a division of a large public company in the U.S. Our DSA segment also competes with in-house departments of pharmaceutical and biotechnology companies, universities and teaching hospitals.
•For Manufacturing, each of our underlying businesses has several competitors. Microbial Solutions has four main competitors, of which three are public companies in Europe and one is a private company in the U.S. In addition to many smaller competitors, Biologics Solutions has five main competitors, of which three are public companies in the U.S., one is a public company in Europe, and one is a public company in China.
Industry Support and Animal Welfare
One of our core values is a concern for, and commitment to, animal welfare. Research animals are an important resource that further our knowledge of living systems and contribute to the discovery of life-saving drugs and procedures. We work hand-in-hand with the scientific community to understand how living conditions, handling procedures and stress play a role in the quality and efficiency of research. As researchers, we are responsible to our clients and the public for the health and well-being of the animals in our care.
We have been in the forefront of animal welfare improvements in our industry, and continue to show our commitment with special recognition programs for employees who demonstrate an extraordinary commitment in this critical aspect of our business. We created our own Humane Care Imperative (HCI), which is overseen by our Global Animal Welfare and Training corporate group. The goal of HCI is to ensure that we continue as a worldwide leader in the humane care of research animals and implementation of the 3Rs (Replacement, Reduction, and Refinement). In 2023, we added a fourth “R” to the longstanding 3Rs framework - Responsibility.
We are firmly committed to the 4Rs and to reducing the number of animals that we work with by emphasizing health, research animal behavioral management programs and genetic integrity to decrease study data variability. Whenever possible, we use technological advances such as new in vitro diagnostic tests for screening pathogens in laboratory rodents, microsampling and various in vitro assays. We support a wide variety of organizations and individuals working to further animal welfare and the 4Rs, as well as the interests of the biomedical research community. We also partner with clients to develop study designs decreasing the number of animal models needed and suggesting pilot studies where appropriate. We maintain a quarterly award program that recognizes our employees’ efforts to continually implement the 4Rs at our sites globally.
We provide scholarships for training in laboratory animal science, financial support to non-profit organizations that educate the public about the benefits of animal research and awards to outstanding leaders in the laboratory animal science field and the supporters of 4Rs.
In 2023, we established the management Office for Responsible Animal Usage to oversee responsible animal utilization and reduction practices, and operating standards of care. Our Board of Directors also established a new Responsible Animal Use Committee to assist the Company in improving our impact on responsible animal utilization, including evaluating and advising scientific and technological opportunities which may appropriately reduce the impact of animals in the Company’s operations. Additionally, in 2023 we committed to report to shareholders on an annual basis, beginning in 2024, on the measures the Company takes to reinforce confidence that the NHPs we import are purpose-bred.
Human Capital Resources
Employees
As of December 30, 2023, we had approximately 21,800 employees (including approximately 2,600 science professionals with advanced degrees, including Ph.D.s, D.V.M.s and M.D.s). Approximately 20,000 of our employees are considered full-time
12
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
employees, while approximately 1,400 are considered part-time employees. Our workforce was distributed geographically approximately as follows: 63% in North America, 30% in Europe, 4% in Asia, and 3% in other regions.
Our employees are not unionized in the U.S. Employees at some of our European facilities are represented by works councils, employee representative groups and/or unions, which is consistent with local customs for our industry. We collaborate with the works councils and believe we have good relationships with our employees.
Values
At Charles River, our values of Care, Lead, Own, and Collaborate guide our decisions and actions; they are standards we hold ourselves to each and every day and are critical to success in fulfilling our goals. In addition, our Charles River DNA are the behaviors based on these values that we use to make decisions, grow our future leaders, and pave the way for years ahead.
Talent Management and Engagement
Sustaining our company culture is a vital part of our strategy. Our culture is built on trust, inclusion, accountability, respect, and well-being. Our objective is to enable colleagues to connect with their work in a way that supports each other, our clients, and our communities. We strive to maintain an environment wherein every person has the ability to deliver on business commitments, while having purpose, being energized, continuously learning, and delivering quality outcomes that make a difference. Recently, we developed a unique employer brand that is infused in other aspects of our employee experience and in the past year, we have trained 1,400 managers on our inclusive hiring approach utilizing behavioral based interviewing that is aligned to our Charles River DNA. We pride ourselves on supporting our people both professionally and personally throughout their employee experience with us.
In order to attract, onboard, support, and retain such great talent, we provide our employees with opportunities for skill building and career advancement. Beginning with our onboarding program, our talent management approach is structured to be highly collaborative, encourages ownership, and provides the opportunity to contribute and develop through regular performance conversations, annual goal setting, and ongoing feedback. Furthermore, we have created a global learning strategy that includes technical training, mentoring and coaching approaches, tuition reimbursement, sabbaticals, leadership development programs, and on-the-job training. In fiscal 2023, we hired over 3,700 people and our voluntary turnover for all employees was approximately 11.5%. Additionally, we conduct regular talent reviews to identify and develop diverse leadership and key talent pipelines to deliver on short-term and long-term business strategy.
Our engagement surveys are in the form of frequent, shorter engagement “Pulse” surveys. These Pulse surveys were issued twice during 2023 and serve as a foundation for more meaningful conversations and actions between our people and people leaders to continue making Charles River a best place to work, learn, and grow.
In addition to growth opportunities, we strive to attract, motivate, and retain top talent by providing competitive compensation programs while rewarding outcomes and behaviors that align with our performance, culture, and values. While we perform pay equity audits in countries where they are legally required, we also perform a larger pay equity analysis on a global scale and take corrective action where appropriate as part of our continuing efforts to be competitive in the marketplace. Furthermore, our global job architecture generally allows for aligning pay by job role with market rates and serves as a career path tool to encourage a culture of advancement.
Health and Safety
We promote a healthy and safe workplace for our employees. We maintain a Global Policy on Safety & Sustainability and, as part of our efforts to promote our goals of working safely and sustainably, in early 2020 we implemented a management systems approach to improve our safety performance, which involves both employee and management engagement in and ownership of our site-level environment, health, safety, and sustainability programs globally. At every Charles River site globally, we have health and safety leaders that promote employee health and safety and keep site management engaged in their health and safety programs. We launched a Safety-First Culture initiative in 2022 to ensure that every person working for and on behalf of Charles River recognizes the importance of putting safe working practices first. As part of this campaign, all sites were requested to form safety committees comprised of both management and employees, initiate site safety champion recognition programs and all site general managers attended safety culture training as did many of our key executives. We also launched the first module of our people leader safety culture training and initiated a formal Environment, Health, Safety and Sustainability Assessment program with 12 site assessments in 2023.
Diversity, Equity and Inclusion
We are also committed to cultivating a welcoming and inclusive environment where every employee can succeed and thrive. Operating in 155 sites and in over 20 countries worldwide (excluding our Insourcing Solutions sites), we believe in treating our employees and prospective talent with dignity, decency, and respect. We recognize that employee diversity contributes to a more innovative workforce and see diversity and inclusivity as a strength for our business. Our commitment to equity spans
13
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
across our employment-related decisions, from hiring and promotions, to succession planning, compensation, performance, training and career development programs. Our aim is to continue to build a talented workforce reflective of the global communities in which we live and work, and it is critical that our people feel like valued members of our Company. We believe that we have taken positive steps to promote a sense of belonging for our employees in the workplace by building a Diversity, Equity & Inclusion team and Chief Executive Officer-chaired Diversity, Equity and Inclusion council; expanding diverse representation at our Board level; launching employee resource groups; facilitating training on mitigating unconscious bias and creating inclusion for our people leaders and talent acquisition teams; and rolling out a diverse candidate slates and diverse interview panel initiatives. We have also set goals to increase our belonging scores on our engagement surveys and increase participation in our employee resource groups. In addition to our internally focused efforts, we also actively engage with our clients and suppliers to share best practices. As of December 30, 2023, women made up approximately 60% of our global workforce, 59% of our U.S. workforce and 42% of our global executive leadership positions, defined as positions carrying the title of Vice President or higher. From our U.S. workforce, 32% identified as racial and ethnic minorities.
Backlog
Our backlog for our RMS, DSA and Manufacturing reportable segments was approximately $489 million, $2.5 billion and $143 million, respectively, as of December 30, 2023, as compared to $282 million, $3.1 billion and $116 million, respectively, as of December 31, 2022. Related services are performed over varying durations, from short to extended periods of time, which may be as long as several years. We maintain an order backlog to track anticipated revenue from studies and projects that either have not started, but are anticipated to begin in the near future, or are in process and have not been completed. We only recognize a study or project in backlog after we have received written evidence of a client’s intention to proceed. Canceled studies or projects are removed from backlog.
We believe our aggregate backlog as of any date is not necessarily a meaningful indicator of our future results for a variety of reasons. First, studies vary in duration (i.e., some studies or projects that are included in December 30, 2023 backlog may be completed in 2024, while others may be completed in later years). Second, the scope of studies or projects may change, which may either increase or decrease their value. Third, studies or projects included in backlog may be subject to bonus or penalty payments. Fourth, studies or projects may be terminated or delayed at any time by the client or regulatory authorities for a number of reasons, including the failure of a drug to satisfy safety and efficacy requirements, or a sponsor making a strategic decision that a study or service is no longer necessary. Delayed contracts remain in our backlog until a determination of whether to continue, modify or cancel the study has been made. We may not be able to realize all or most of the net revenues included in backlog or estimate the portion to be filled in the current year. Refer to Item 1A, “Risk Factors” and Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosed herein for our assessment of certain relevant risk factors.
Regulatory Matters
As our business operates in many distinct regional environments and in a variety of locations worldwide, we are subject to numerous, and sometimes overlapping, regulatory requirements.
The Animal Welfare Act (AWA) governs the care and use of certain species of animals used for research in the U.S. other than laboratory rats, mice and fish bred for use in research. As a result, most of our U.S. small animal research model operations are not subject to regulation under the AWA. For regulated species, the AWA and the associated Animal Care regulations require producers and those working with regulated species to provide veterinary care and to follow specific husbandry practices such as cage size, shipping conditions, sanitation and environmental enrichment to ensure the welfare of these animals. Separately, facilities using live vertebrate animals in research funded by the U.S. Public Health Service (PHS) must also adhere to the PHS Policy on Humane Care and Use of Laboratory Animals and follow “The Guide for the Care and Use of Laboratory Animals” published by the Board on Animal Health Sciences, Conservation, and Research.
We comply with licensing and registration requirement standards set by the USDA and U.S. Fish and Wildlife Service (USFWS), and similar applicable agencies in other global regions such as Canada, Europe and China for the care, handling and oversight of regulated species. Our DSA and RMS facilities that work with or produce research animals in North America and Europe are accredited, with the exception of new and recently acquired facilities that are in the process of planning for accreditation, by AAALAC International, a private, nonprofit organization that promotes the humane treatment of animals in science and education through voluntary accreditation and assessment programs.
Our import and export of animals and our operations in foreign countries are subject to applicable international agreements and conventions, as well as a variety of national, regional and local laws and regulations, which establish the standards for the humane treatment, care, handling and transport of animals by dealers and research facilities. We only use accredited and experienced transporters for importing and exporting animals who are specialists in their field. We comply with global requirements which are evaluated by import and export authorities at each point of exit and entry. Imported animals are
14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
quarantined in our quarantine facilities as required by government agencies and tested to ensure they meet both the government mandates and our own specifications for pathogens and health of the animals.
We conduct non-clinical safety assessment studies to support the submissions for approval or licensing of our clients’ products throughout the world. Many of these studies must comply with national statutory or regulatory requirements for GLP. GLP regulations describe a quality system for the scientific, operational and quality process and the conditions under which non-clinical studies are planned, performed, monitored, recorded, reported and archived. GLP compliance is required by such regulatory agencies as the FDA, European Medicines Agency, Medicines and Healthcare Products Regulatory Agency in the United Kingdom (U.K.), Health Products Regulatory Authority in Ireland, Health Canada and other similar monitoring authorities in the countries where we operate. GLP requirements are significantly harmonized throughout the world and our laboratories are capable of conducting studies in compliance with all applicable requirements.
Regulatory monitoring authorities such as the FDA, Medicines and Healthcare Products Regulatory Agency and OECD countries have indicated an increased emphasis on the management of electronic records and signatures generated by computerized systems to ensure data integrity. We have established corporate data integrity governance to manage regulatory requirements and client expectations regarding data quality within our regulated businesses. Although each business has a different impact on patient safety, all are expected to generate and preserve data with integrity. We recognize the importance of generating quality, reliable, sustainable data and have instituted several processes and established a global governance team with oversight responsibilities for our Data Integrity Compliance Plans to ensure we are consistent in our approach. To ensure that we have proper regulatory oversight over our electronic records, a dedicated quality function reviews our computerized system practices to ensure that appropriate record controls are in place and that a robust audit strategy confirms requirements are met for compliance.
At a global level, retention of data and controls for electronic systems, proprietary data and quality standards are covered by global policies. We also have controls in place such as quality manuals, policies and procedures, work instructions, document control processes, training, quality assurance and quality control processes and personnel, validated computerized systems and archiving requirements. Within businesses, procedures govern performance of activities to ensure data integrity throughout its life cycle.
Our Manufacturing businesses produce FDA regulated endotoxin test kits at an FDA registered facility. We also manufacture sterility and microbial limits test kits used in FDA Regulated pharmaceutical applications, reagents, cell banks used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products as well as an animal-free recombinant cascade reagent (rCR), Endosafe® Trillium®, which is an alternative to the natural LAL product. Additionally, several of our laboratories conduct biosafety and analytical testing such as identity, stability, sterility and potency and viral clearance testing in support of our clients’ manufacturing programs and to fulfill their validation requirements, as applicable.
Our comprehensive cell and gene therapy manufacturing services include Good Manufacturing Practices (GMP) production of cells from pre-clinical to commercial applications from a variety of starting materials. Many of these activities are subject to regulation and consequently require these businesses to be inspected by the FDA and other national and applicable state regulatory agencies under their respective cGMP regulations. These regulations require that we manufacture products or perform testing in a prescribed manner with respect to cGMP compliance, and maintain records of our manufacturing, testing and control activities. In addition, the specific activities of some of our businesses require us to hold specialized licenses and registrations for the manufacture, distribution and/or marketing of particular products globally.
Our Cell Solutions sites provide the starting material (leukopak) to customers that are typically in cell and gene therapy companies. Leukopaks are collected from eligible donors in compliance with applicable regulatory requirements. Donors consent using consent forms from an Institutional Review Board (IRB). Collections are performed under the supervision of licensed clinical staff and collections are managed in accordance with IRB-approved study protocols.
All of our GMP sites are subject to registration, licensing and regulation, as appropriate under international treaties and conventions, including national, regional and local laws relating to:
•the surface and air transportation of chemicals, biological reagents and laboratory specimens;
•the handling, use, storage and disposal of chemicals (including narcotics and psychotropic drugs), biological reagents, laboratory specimens, hazardous waste and radioactive materials;
•the procurement, handling, use, storage and disposal of human cells, tissues and cellular and tissue-based products for research purposes;
•the safety and health of employees and visitors to our facilities; and
•protection of the environment and general public.
15
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Global regulatory compliance programs are managed by a dedicated group responsible for regulatory affairs and compliance. Our compliance programs are also managed by global quality systems, such as vendor supplier programs, enterprise quality management systems and global computer system validation. Within each regulated business, we have established Quality Assurance Units (QAUs) responsible for risk based internal audit programs to manage regulatory requirements and client expectations. The QAUs operate independently from those individuals that direct and conduct studies, manufacturing or analytical testing. Our Data Integrity Compliance Program ensures that senior management and the QAU’s have proper oversight of our electronic records, inclusive of quality function reviews of our computerized system practices to ensure that appropriate record controls are in place and that a robust audit strategy confirms requirements for compliance.
While we expect that capital expenditures will be necessary to ensure that our existing sites remain in compliance with all applicable regulations, at this point we do not expect these expenditures to materially differ than our historical experience.
Intellectual Property
We develop and implement scientifically-driven products and procedures, including computer software, to maximize the quality and effectiveness of our offerings. Intellectual property rights, in the form of know-how, trade secrets, patents, trademarks, copyrights, and others are important to us and are valuable to our ability to provide significant benefits to our clients. Steps are taken to protect our intellectual property rights and include the execution of confidentiality agreements and securing registrations in relevant jurisdictions. In addition, we license technology from other companies when it enhances our product and services businesses. Licensing has recently become a larger company-wide initiative, particularly as we increase our focus on innovative technologies that further diversify and enhance our portfolio.
Corporate Governance
We are committed to operating our business with integrity and accountability. We strive to meet or exceed all of the corporate governance standards established by the NYSE, the SEC and the U.S. Federal government as implemented by the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and other applicable laws, rules and regulations. Nine of the eleven members of our Board of Directors are independent and have no significant financial, business or personal ties to us or management. Our Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee of our Board of Directors are each composed entirely of independent directors. The Board adheres to our Corporate Governance Guidelines and a Code of Business Conduct and Ethics that has been communicated to employees and posted on our website. We are diligent in complying with established accounting principles and are committed to providing financial information that is transparent, timely and accurate. We have a Related Person Transactions Policy designed to promote the timely identification of such transactions and to ensure we give appropriate consideration to any real or perceived conflicts in our commercial arrangements. We have an established global process through which employees, either directly or anonymously, can notify management (and the Audit Committee of the Board of Directors) of alleged accounting and auditing concerns or violations including fraud. Our internal Disclosure Committee meets regularly and operates pursuant to formal disclosure procedures and guidelines to help ensure that our public disclosures, including our periodic reports filed with the SEC, earnings releases and other written information that we disclose to the investment community are complete, accurate and timely. We continually monitor developments in the law and stock exchange regulations, as well as overall corporate governance trends and intend to adopt new procedures consistent with such developments to the extent applicable to and appropriate for our Company. Copies of our Corporate Governance Guidelines, Code of Business Conduct and Ethics and Related Person Transactions Policy are available on our website at http://ir.criver.com under the “Investor Relations - Corporate Governance” caption.
Information about Our Executive Officers
Below are the names, ages and principal occupations of each of our current executive officers. All such persons have been elected to serve until their successors are elected and qualified or until their earlier resignation or removal.
James C. Foster, age 73, joined us in 1976 as General Counsel. During his tenure, Mr. Foster has held various staff and managerial positions, and was named Chief Executive Officer and President in 1992 and our Chairman in 2000.
William D. Barbo, age 63, joined us in 1982 as a laboratory technician. Between 1982 and 2005, Mr. Barbo served in a variety of positions of increasing responsibilities. He was named Corporate Vice President of Research Models and Services in 2005, Corporate Senior Vice President of Global Sales and Marketing in 2010, and Corporate Executive Vice President and Chief Commercial Officer in October 2016.
Victoria Creamer, age 54, joined us in January 2019 as Senior Vice President, Chief People Officer. In October 2020, Ms. Creamer was promoted to Corporate Executive Vice President. Prior to joining the Company, from 2015 to December 2018, Ms. Creamer served as Senior Vice President, Human Resources and Communications for ITT, Inc., a manufacturing company, where she was responsible for providing vision, leadership and execution of the company’s people and communications strategies.
16
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Birgit Girshick, age 54, joined us in 1989 and originally held positions of increasing responsibility in our RMS Germany and RMS Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the RMS Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into our Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for our Biologics Solutions and Avian Vaccine Services business. In 2021, she also assumed responsibility for the company’s Cell and Gene Therapy CDMO business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services and Microbial Solutions businesses as well as the Global Information Technologies group to her responsibilities. Since 2023, Ms. Girshick also has general oversight of the Corporate Sales and Marketing team and our Corporate and External Affairs function.
Joseph W. LaPlume, age 50, joined us in 2005 as Senior Corporate Counsel. He became Deputy General Counsel in 2010, Vice President, Corporate Development in 2011, Senior Vice President in 2014 and Corporate Executive Vice President, Corporate Development and Strategy in January 2019. In his current role, he oversees all aspects of strategic planning and corporate development activities across business segments and geographies. Prior to joining us, Mr. LaPlume was a corporate lawyer at GTECH Corporation and in private practice at the law firms of Mintz Levin and Goulston & Storrs.
Shannon Parisotto, age 50, joined us in 2000 in our Nevada operation. Ms. Parisotto progressed through a number of finance management positions of increasing responsibility, and in 2010, was promoted to Corporate Vice President, Preclinical Services, Finance. In this role, Ms. Parisotto was responsible for the financial operations of the global Preclinical Services business. Beginning in 2011, Ms. Parisotto’s role was expanded to include additional business segments, and in 2015, she was promoted to the newly created position of Corporate Senior Vice President & Controller, Global Operations, where she worked collaboratively with Charles River’s business units to develop and implement business strategies. In 2020, Ms. Parisotto was promoted to Corporate Senior Vice President, Global Safety Assessment, where she was responsible for leading the Company’s global Safety Assessment organization, and positioning the business for continued, long-term growth and success. In October 2022, Ms. Parisotto was promoted to Corporate Executive Vice President, and assumed the additional oversight of the Discovery Services business to lead its strategic vision and operational growth, as well as enhance the synergies between the businesses and with clients across the global Discovery and Safety Assessment segment. Ms. Parisotto holds a B.S. in Accounting from the University of Nevada, Reno, an M.B.A. from the University of Phoenix, and is a Certified Public Accountant.
Flavia Pease, age 51, joined us in 2022 as Corporate Executive Vice President and Chief Financial Officer. Prior to joining Charles River, Ms. Pease served as Vice President and Group Chief Financial Officer of Johnson & Johnson’s global Medical Devices businesses since 2019. During her more than twenty-year tenure at Johnson & Johnson, Ms. Pease served as Vice President, Finance for Janssen North America from 2016 to 2019; Vice President of the Enterprise Program Management Office from 2014 to 2016; Vice President of Finance for Janssen Supply Chain from 2012 to 2014; and a Vice President of Finance, leading the integration of the Mentor and Acclarent acquisitions from 2009 to 2012. Ms. Pease began her career at Johnson & Johnson in 1998 with the LifeScan business and subsequently held finance leadership positions within Mergers and Acquisitions Analysis and Johnson & Johnson Medical Brazil.
Item 1A.    Risk Factors
Set forth below, elsewhere in this Form 10-K, and in other documents we file with the SEC are risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements contained in this Form 10-K. We note that factors set forth below, individually or in the aggregate, as well as additional risks and uncertainties either not presently known or that are currently believed to not be material to the business, may cause our actual results to differ materially from expected and historical results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties and the risks described below should be carefully considered together with the other information set forth in this report and in future documents we file with the SEC.
Risk Factor Summary
As noted above, we are subject to a number of risks that if realized could cause actual results to differ materially from the results contemplated herein. Some of the more significant risks and uncertainties we face include those summarized below. The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in this "Risk Factors"
17
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
section. Please carefully consider all of the information in this Form 10-K, including the full set of risks set forth in this "Risk Factors" section, and in our other filings with the SEC before making an investment decision regarding Charles River.
Business and Operational Risks
•We bear financial risk for contracts that may be terminated or reduced in scope, underpriced, subject to cost overruns or delays.
•Upgrading and integrating our business systems could result in implementation issues and business disruptions.
•We have in the past experienced and in the future could experience unauthorized access into our information systems.
•If we are not successful in executing our business strategy, including our failure in selecting and integrating the businesses and technologies we acquire, or in managing our current and future divestitures, our business may be adversely impacted.
•Our business is subject to risks relating to operating internationally, including changes in foreign currency exchange rates.
•Our operations might be affected by the occurrence of a natural disaster or other catastrophic event.
•Negative attention from special interest groups may impair our business.
Industry Risk Factors
•Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business.
•Demand volatility, risk of credit losses, or a reduction or delay in government funding of R&D may adversely affect our business.
•Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential healthcare reform, could decrease the need for the services we provide.
•Contract development and manufacturing services create a risk of liability, including risk that our products will not gain market acceptance and risk of failure to provide quality and timely service to customers.
•Contaminations in our animal populations can damage our inventory, harm our reputation for contaminant-free production, result in decreased sales and cause us to incur additional costs.
•The outsourcing trend in non-clinical stages of drug discovery and development may decrease, which could impair our growth.
•The industries in which we operate are highly competitive.
•New technologies may be developed, validated and increasingly used in biomedical research, which could reduce demand for some of our products and services.
•We may not be able to successfully develop and market new services and products.
•Costs increasing more rapidly than market prices could reduce profitability.
Legal and Regulatory Risk Factors
•Any failure by us to comply with applicable regulations and related guidance could harm our reputation and operating results, and compliance with new regulations and guidance may result in additional costs.
•Failure to comply with applicable data privacy and security laws in various jurisdictions could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions that could have a material adverse effect on our business.
•Failure to comply with U.S., state, local or international environmental, health and safety laws and regulations could result in fines and penalties and loss of licensure and have a material adverse effect upon the Company’s business.
•Changes in U.S. and International Tax Law, results of tax audits, or material changes in our stock price could have a material adverse impact on our effective tax rate and financial results.
•Non-clinical contract research services create a risk of liability.
•The failure to successfully obtain, maintain and enforce intellectual property rights and defend against assertions of third-parties to intellectual property rights could adversely affect us.
18
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
•Our by-laws designate the state courts located in the State of Delaware as the sole and exclusive forum for certain actions, which could limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable and may discourage lawsuits with respect to certain claims.
•We are involved in legal proceedings that could adversely affect our business, financial condition, and results of operations.
Labor and Employment Risk Factors
•We depend on key personnel and may not be able to retain these employees, which would harm our business.
•If we are unable to attract, hire or retain key team members or a highly skilled and diverse global workforce, it could have a negative impact on our business, financial condition or results of operations.
•We depend on the availability of, and good relations with, our team members.
Financial and Accounting Risk Factors
•Our debt level could adversely affect our business and growth prospects.
•Impairment of goodwill or other intangible assets may adversely impact future results of operations.
General Risk Factors
•Since we do not expect to pay any cash dividends for the foreseeable future, our shareholders will benefit from an investment in our common stock only if it appreciates in value.
•Our quarterly operating results may vary, which could negatively affect the market price of our common stock.
•Increasing focus on environmental, social and governance matters may impact our business, financial results or stock price.
Risk Factors
Business and Operational Risks
We bear financial risk for contracts that may be terminated or reduced in scope, underpriced, subject to cost overruns or delays.
Many of our agreements, including those which underlie our strategic relationships with some of our more significant clients, allow for termination or reduction in scope with little or no notice. In addition, we sell our products and services to our competitors, and similarly they sell products and services to us. For instance, we have historically entered into, and currently are party to, contracts with certain of our competitors to distribute specialty research models in locations where our competitors may not have distribution capabilities.
Our counterparties (including our clients who are competitors) may elect to terminate their agreements with us for various reasons including: the invocation of force majeure clauses, or the legal doctrines of impossibility or impracticability, or other similar legal doctrines; the products being tested fail to satisfy safety requirements; unexpected or undesired study results; production problems resulting in shortages of the drug being tested; a client’s decision to forego or terminate a particular study; our competitors’ establishment of alternative distribution channels; dissatisfaction with our performance under the agreement; the loss of funding for the particular research study; or general convenience/counterparty preference. If a counterparty terminates a contract with us, we are typically entitled under the terms of the contract to receive revenue earned to date as well as certain other costs and, in some cases, termination fees; however, in many cases we are not entitled to any termination fees in the event of a termination. Cancellation of a large contract or proximate delay, cancellation or conclusion of multiple contracts could materially adversely affect our business and, therefore, may adversely affect our operating results.
Furthermore, many of our contracts provide for services on a fixed price or fee-for-service with a cap basis and, accordingly, we bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates. Such underpricing or significant cost overruns could have an adverse effect on our business, results of operations, financial condition and cash flows.
Upgrading and integrating our business systems could result in implementation issues and business disruptions.
In recent years, we have been updating and consolidating platforms and automating processes in many parts of our business with a variety of systems, including in connection with the integration of acquired businesses. The expansion and ongoing implementation of operational systems may occur at a future date based on value to the business. In general, the process of planning and preparing for these types of integrated, wide-scale implementations is extremely complex and we are required to address a number of challenges, including information security assessment and remediation, regulatory requirements, data conversion, associated regulatory compliance, network and system cutover, user training, and integration with existing
19
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
processes or systems. As we build out IT infrastructure to support regulatory requirements for applications and data systems, we are doing so utilizing contemporary validation practices. As with all work conducted in our regulatory sites, these too are subject to government inspections. Incongruities in any of these areas could cause operational problems during implementation including inconsistent practices, delayed report and/or data shipments, missed sales, animal management/welfare issues, issues that require re-doing certain studies, personally identifiable information and data privacy issues, billing errors and accounting errors.
We have in the past experienced and in the future could experience unauthorized access into our information systems.
We operate large and complex information systems that contain significant amounts of client data. As a routine element of our business, we collect, analyze and retain substantial amounts of data pertaining to the non-clinical studies we conduct for our clients. Unauthorized third parties could attempt to gain entry to such information systems to steal data or disrupt the systems or for financial gain. Like other companies, we have on occasion experienced, and will continue to experience, threats and incursions to our data and systems, including malicious software and viruses, phishing, business email compromise and social engineering attacks or other cyber-attacks. The number and complexity of these threats continue to increase over time.
In March 2019, we detected evidence that an unauthorized third party, who we believe was well resourced and highly sophisticated, accessed certain of our information systems and copied data. We worked with a leading cyber security firm to assist in our investigation and coordinated with law enforcement authorities. Our investigation indicated that the affected information included client information. By the end of 2019, we disclosed that we had completed our remediation of the identified incident. As of the date of this filing, to our knowledge, we have not experienced an information security breach or material cybersecurity incident since that event. While we have implemented additional security safeguards since that event and continue to enhance existing safeguards, such efforts may not be successful, in which case we could suffer significant harm.
Further, we are at risk of being targeted, and we have in the past been victim to, business email compromise fraud, which results in payments being made to illegitimate bank accounts. Although these instances have not resulted in our incurring material losses, if similar instances occur in the future, we may incur such losses.
Our contracts with our clients typically contain provisions that require us to keep confidential the information generated from the studies we conduct. In the event the confidentiality of such information is compromised, whether by unauthorized access or other breaches, we could be exposed to significant harm, including termination of customer contracts, damage to our customer relationships, damage to our reputation and potential legal claims from customers, employees and other parties. In addition, we may face investigations by government regulators and agencies as a result of a breach.
For information regarding our processes and practices related to information and cybersecurity, please see Section 1C of this report, “Cybersecurity”.
If we are not successful in selecting and integrating the businesses and technologies we acquire or partner with, or in managing our current and future divestitures, our business may be adversely impacted.
During the last two decades, we have steadily expanded our business through numerous acquisitions and partnerships. However, businesses and technologies may not be available on terms and conditions we find acceptable. We risk spending time and money investigating and negotiating with potential acquisition or alliance partners, but not completing transactions.
Acquisitions and alliances involve numerous risks which may include:
•difficulties in achieving business and financial success (due to unplanned events such as the long-term economic impact of the COVID-19 pandemic and ongoing geopolitical conflicts, such as between the Russian Federation and Ukraine, and between Israel and Hamas);
•difficulties and expenses incurred in assimilating and integrating operations, services, products, information technology platforms, technologies or pre-existing relationships with our clients, distributors and suppliers;
•challenges with developing and operating new businesses, including those that are materially different from our existing businesses, which may require the development or acquisition of new internal capabilities and expertise;
•potential losses resulting from operational weaknesses or undiscovered liabilities of acquired companies that are not covered by the indemnifications we may obtain from sellers or any insurance we may acquire in connection with transactions;
•loss of key employees;
•the presence or absence of adequate internal controls and/or significant fraud in the financial systems of acquired companies;
•diversion of management’s attention from other business concerns;
20
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
•a more expansive regulatory environment;
•dilution to earnings, or in the event of acquisitions made through the issuance of our common stock to the shareholders of the acquired company, dilution to the percentage of ownership of our existing shareholders;
•differences in foreign business practices, customs and importation regulations, language and other cultural barriers in connection with the acquisition of foreign companies;
•new technologies and products may be developed that cause businesses or assets we acquire to become less valuable; and
•disagreements or disputes with prior owners of an acquired business, technology, service or product that may result in legal settlements, litigation expenses and diversion of our management’s attention.
If an acquired business, technology or an alliance does not meet our expectations, our results of operations may be adversely affected. Some of the same risks exist when we decide to sell a business, site, product line or service offering or decide to close a site. We continually evaluate the performance and strategic fit of our business to determine whether any divestitures are appropriate. Such divestitures could involve additional risks, other than those listed above, including: difficulties in the separation of operations, services, products, and personnel, the need to agree to retain or assume certain current or future liabilities in order to complete the divestitures, and write-offs, including those related to goodwill and other intangible assets and which could have an adverse effect on our results of operations and financial condition. In addition, we may encounter difficulty in finding buyers or alternative exit strategies at acceptable prices and terms, and in a timely manner. We may not be successful in managing these or any other significant risks that we encounter in divesting a business, site or product line or service offering and, as a result, we may not achieve some or all of the expected benefits of the divestitures.
Failure to execute our business strategy could adversely impact our growth and profitability.
Our strategy is to deliver a comprehensive and integrated portfolio of drug discovery and non-clinical development products, services and solutions to support our clients’ discovery and early-stage drug research, process development, scale up and manufacturing efforts, and enable them to bring new and improved therapies to market faster and more cost effectively. Separately, through our various Manufacturing segment businesses, we aim to be the premier provider of products and services that ensure our clients produce and release their products safely. If we are unable to successfully execute on this strategy, this could negatively impact our future results of operations and market capitalization.
Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our results of operations and financial condition. To address this issue, we typically pursue a number of strategies designed to improve our internal growth, including strengthening our presence in selected geographic markets through organic growth and strategic acquisitions and expanding our service offerings, including our expansion into the CDMO business. We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.
Furthermore, our strategy assumes a certain degree of capital and capacity growth development. Factors such as insufficient capital, inflation, supply chain interruptions, inadequate forecasting, increases in construction material costs, or labor shortages could interfere with the successful execution of our strategy and our ability to timely build infrastructure to satisfy capacity needs and support business growth. For additional discussion of our business strategy, please see the section above entitled “Our Strategy.”
Our business is subject to risks relating to operating internationally, including changes in foreign currency exchange rates.
A significant part of our revenue is derived from operations outside the U.S. We expect that international revenue will continue to account for a significant percentage of our total revenue for the foreseeable future.
Changes in foreign currency exchange rates could materially adversely impact our results. Foreign currencies we receive for sales and in which we record expenses outside the U.S. could be subject to unfavorable exchange rates with the U.S. dollar, resulting in a reduction in the amount of revenue and cash flow (and an increase in the amount of expenses) that we recognize and causing fluctuations in reported financial results. We also carry foreign currency exposure associated with differences between where we conduct business. For example, certain contracts are frequently denominated in currencies other than the currency in which we incur expenses related to those contracts. Where expenses are incurred in currencies other than those in which contracts are priced, fluctuations in the relative value of those currencies could have a material adverse effect on our results of operations.
Our exposure to currency exchange rate fluctuations results from the currency translation exposure associated with the preparation of our consolidated financial statements, as well as from the exposure associated with transactions of our subsidiaries that are denominated in a currency other than the respective subsidiary’s functional currency. While our financial results are reported in U.S. Dollars, the financial statements of many of our subsidiaries outside the U.S. are prepared using the
21
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
local currency as the functional currency. During consolidation, these results are translated into U.S. Dollars by applying appropriate exchange rates. As a result, fluctuations in the exchange rate of the U.S. Dollar relative to the local currencies in which our foreign subsidiaries report could cause significant fluctuations in our reported results. Moreover, as exchange rates vary, revenue and other operating results may differ materially from our expectations. Adjustments resulting from financial statement translations are included as a separate component of shareholders’ equity.
Other risks associated with our international business include:
•general economic and political conditions in the markets in which we operate;
•potentially negative consequences from changes in U.S. and/or foreign laws, including changes that may bar us from engaging in business transactions with certain clients, and changes in tax laws, or interpretations and enforcement thereof, notably tax regulations issued and to-be-issued with respect to the potential adoption of global minimum taxation requirements and potential changes to existing tax law by the current U.S. Presidential administration and Congress;
•ongoing uncertainties as a result of instability or changes in geopolitical conditions, including terrorist acts or military or political conflicts, such as those caused by the ongoing conflicts between Russia and Ukraine or Israel and Hamas (the potential escalation or geographic expansion of which could heighten other risks identified in this report);
•exchange controls, adverse tax consequences and legal restrictions on the repatriation of funds into the U.S.;
•difficulties and costs associated with staffing and managing foreign operations, including risks of work stoppages and/or strikes, as well as violations of local laws or anti-bribery laws such as the U.S. Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act and the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions;
•unexpected changes in regulatory requirements;
•the difficulties of compliance with a wide variety of foreign laws and regulations;
•unfavorable labor regulations in foreign jurisdictions;
•longer accounts receivable cycles in certain foreign countries;
•potentially reduced protection of our intellectual property rights in certain foreign countries; and
•compliance with export controls, import requirements and other trade regulations, including those relating to certain products of which there is limited supply.
These risks, individually or in the aggregate, could have an adverse effect on our results of operations and financial condition. For example, as mentioned above, we are subject to compliance with the FCPA, which prohibits companies and their third-party intermediaries from offering or making improper payments to foreign government officials for the purpose of obtaining or retaining business. Likewise, we are also subject to other international anti-bribery laws such as the UK Bribery Act which prohibit companies and their third-party intermediaries from offering or making improper payments to commercial parties. While our employees and third-party intermediaries are required to comply with these laws, we cannot be sure that our internal policies and procedures will always protect us from violations of these laws despite our commitment to legal compliance and corporate ethics. The occurrence or allegation of these types of risks may adversely affect our business, performance, prospects, value, financial condition and results of operations.
Our operations might be affected by the occurrence of a natural disaster or other catastrophic event.
We depend on our customers continued demand and solvency at our facilities for the continued operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite any precautions we take for natural disasters or other catastrophic events, these events, including terrorist attack, a pandemic, epidemic or outbreak of a disease, hurricanes, tornadoes, fire, floods and ice and snow storms, could result in damage to and closure of our or our customers’ facilities or the infrastructure on which such facilities rely. Such disruptions could include significant delays in the shipments of our products, reduce our capacity to provide services, adversely impact unique manufacturing capabilities, result in our customers’ inability to pay for our products or services and, ultimately, result in the loss of revenue and clients. Although we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our coverage might not be adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event affecting us or our customers could have a significant negative impact on our operations and financial performance.
Negative attention from special interest groups may impair our business.
The products and services that we provide our clients are essential to the drug discovery, development and manufacturing processes, and a significant amount are mandated by law. Notwithstanding, certain special interest groups categorically object
22
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
to the use of animals for valid research purposes. Historically, our core research model activities with rats, mice and other rodents have not been the subject of significant animal rights media attention. However, research activities involving animal models have been the subject of adverse attention, including shareholder proposals and attempts to disrupt carriers from transporting large research models and actions aimed at preventing expansion of operations . This has included periodic demonstrations near facilities operated by us and at our annual meetings, as well as shareholder proposals we received for some of our past Annual Meetings of Shareholders. Furthermore, the habitat of certain animals used for research purposes may be located in or near certain environmentally protected areas or conservation areas. Activities conducted by us or any of our agents within these areas may be legally challenged and result in similar negative attention and action from environmental protection activists, including advocacy for the expansion of environmental restrictions applicable to such areas. Any negative attention, threats, acts of vandalism or legal action directed against our animal research or procurement activities, or our third-party service providers, such as our airline carriers or suppliers, or that restrict our or their ability to access protected or conservation areas, could impair our ability to operate our business efficiently.
Industry Risk Factors
Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business.
We depend on a limited international source of supply for certain products, such as large research models, including non-human primates. Disruptions to their continued supply from time to time arise from colony health problems (including as a result of the spread of diseases), export or import laws/restrictions or embargoes, tariffs, inflation, international trade regulations, foreign government or economic instability, severe weather conditions, increased competition among suppliers for models, disruptions to the air travel system, activist campaigns, commercial disputes, supplier insolvency, geopolitical disputes, or other ordinary course or unanticipated events. Any disruption of supply could materially harm our business if we cannot remove the disruption or are unable to secure an alternative or secondary supply source on comparable commercial terms.
As with other industry participants, certain of our activities rely on a sufficient supply of large research models, which has seen increasing demand as compared to supply in recent years due to a variety of factors. First, the surge of research relating to COVID-19 increased short-term demand. Second, China previously supplied a significant portion of certain critical large research models, which have been subject to geographic export restrictions applicable to many animal species since the beginning of the COVID-19 pandemic. And third, in concert with legal matters affecting the Cambodian supply of non-human primates, the non-human primate supply chain globally has recently experienced constriction. More broadly, in November 2022 the U.S. Department of Justice (DOJ) announced that a Cambodia supplier of non-human primates and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States. While the Company was not named or referenced in the November 2022 proceedings, the Company shortly thereafter announced that Cambodia was the primary country of origin for non-human primates imports to Charles River, and that it had begun to operate under the expectation that for some time period supply of Cambodia-sourced non-human primates (which according to CDC statistics, account for approximately 60% of supply to the United States) would be difficult to obtain in the United States. Subsequent to the Company’s announcement, USFWS denied clearance to certain shipments of non-human primates the Company had received from Cambodia. And as noted in Item 3. “Legal Proceedings” in this Annual Report on Form 10-K, in February 2023 the Company was informed by the DOJ that in conjunction with the U.S. Fish and Wildlife Service (USFWS), they had commenced a grand jury investigation into the Company’s conduct regarding several shipments of non-human primates, which is occurring in parallel to a civil investigation being undertaken by the DOJ and USFWS. In connection with the civil investigation, the Company has voluntarily suspended planned future shipments of Cambodia non-human primates into the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported to the United States from Cambodia are purpose-bred. Accordingly, the Company believes that for some undetermined period of time it will not be able to import Cambodia-sourced non-human primates into the United States, and overall supply of non-human primates from Cambodia on a world-wide basis is more limited than previously.
While we continue to take steps to find alternative supply channels (and other global sources) and lock in supply (both for non-human primates and with respect to other limited supply products) with preferred sources through multi-year and/or minimum commitment contracts as well as through acquisitions of suppliers, there are limited sources and such mitigating efforts may not prove successful at ensuring a steady and timely supply or may require (and in the past have required) us to pay significantly higher prices for such products during periods of global shortage or restrictions on the importation or the transportation of models products. Limited global supply or regional restrictions on transportation for certain products may require us to source products from non-preferred vendors, which may not be successful. In addition, reductions in global air transportation routes may result in sourcing alternative transportation at an increased cost. Finally, we may be unable to obtain supply due to governmental restrictions or limitations, including (as noted above) non-human primates. An inability to obtain a sufficient and timely supply of critical products could adversely affect our business, financial results and results of operations.
23
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Portions of our Cell Solutions business depends on the availability of appropriate donors. Regulations intended to control infectious disease or requirements in cell therapy manufacturing processes could also result in a decreased pool of potential donors or integrity of inventory. Due to any pandemic, epidemic or outbreak in one or more regions in which our Cell Solutions business operates, the portion of the donor pool that typically donates may be unable, or unwilling to donate, thereby significantly reducing the availability of research products upon which we rely. In addition, healthcare concerns among the public may result in a decline in donations. If donor participation declines, we may not be able to reduce costs sufficiently to maintain profitability of the Cell Solutions business.
Our CDMO services establish us as a premier scientific partner for cell and gene therapy development, testing, and manufacturing; enable us to provide clients with an integrated solution from basic research and discovery through cGMP production; enable us to drive efficiency and accelerate clients’ speed-to-market by integrating manufacturing and the required testing; and enable our clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. Furthermore, our CDMO operations require various raw materials supplied primarily by third parties. We or our customers specify the raw materials and other items required to manufacture the applicable product and, in some cases, the customers specify the suppliers from whom we must purchase these raw materials. In certain instances, the raw materials and other items may only be supplied by a limited number of suppliers or in limited quantities. If third-party suppliers do not supply raw materials or other items on a timely basis, it may cause a manufacturing run to be delayed or canceled which could materially adversely affect our results of operations and financial condition.
Furthermore, in general, third-party suppliers may fail to provide us with raw materials and other items that meet the qualifications and specifications required by us or our customers. If third-party suppliers are not able to provide us with raw materials that meet our or our customers’ specifications on a timely basis, we may be unable to manufacture the product for our clients or it could prevent us from delivering products to our customers within required time frames. Any such delay in delivering products to our clients may create liability for us to our customers for breach of contract or cause us to experience order cancellations and loss of customers. In the event that we manufacture products with components or raw materials that do not meet our qualifications and specifications or those of our customers or governmental or regulatory authorities, we may become subject to product liability claims caused by defective raw materials or components from a third-party supplier or from a customer.
Demand volatility and risk of credit losses from clients may adversely affect our business.
Our business could be adversely affected by any significant decrease in drug R&D expenditures by pharmaceutical and biotechnology companies, as well as by academic institutions, government laboratories or private foundations. Similarly, economic factors and industry trends that affect our clients in these industries also affect their R&D budgets and, consequentially, our business as well.
Our clients include researchers at pharmaceutical and biotechnology companies. Our ability to continue to grow and win new business is dependent in large part upon the ability and willingness of the pharmaceutical and biotechnology industries to continue to spend on molecules in the non-clinical phases of R&D (and in particular discovery and safety assessment) and to outsource the products and services we provide. Furthermore, our clients (particularly larger biopharmaceutical companies) continue to search for ways to maximize the return on their investments with a focus on lowering R&D costs per drug candidate. Fluctuations in the expenditure amounts in each phase of the R&D budgets of these researchers and their organizations could have a significant effect on the demand for our products and services. R&D budgets fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities (including available resources of our biotechnology clients, particularly those that are cash-negative, who may be highly focused on rationing their liquid assets in a challenging funding environment), general economic conditions, institutional budgetary policies and the impact of government regulations, including potential drug pricing legislation. Available funding for biotechnology clients in particular may be affected by the capital markets, investment objectives of venture capital investors and priorities of biopharmaceutical industry sponsors.
Additionally, our business is exposed to the risk of credit losses, which arises from our extension of credit to clients. The collectability of accounts receivable may be adversely affected by various factors, including economic downturns, changes in clients’ financial conditions, and industry-specific challenges. A deterioration in the creditworthiness of our clients could result in the need to establish or increase our allowance for credit losses. We regularly assess the creditworthiness of our clients, establish credit limits, and monitor payment patterns. However, our ability to manage credit risk and maintain an adequate allowance for credit losses may be impacted by factors beyond our control, such as unforeseen economic conditions or significant shifts in client payment behavior. Additionally, changes in global or regional economic conditions may affect the overall credit environment and impact our customers' ability to fulfill their payment obligations.
For additional discussion of the factors that we believe have recently been influencing R&D budgets at our clients, please see the sections entitled “Our Strategy” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this Form 10-K.
24
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Additionally, we have business that depends on our supply of large research models to clients. Sudden or unexpected changes in demand, market conditions, or the regulatory environment for these models could have an adverse impact on our profitability. Increasing demand could harm relationships with customers if we are unable to alter production capacity, or purchase products from other suppliers, to fill orders adequately. Decreased demand could result in inventory surpluses, which could also significantly impact our results and operations. In particular, if the price of non-human primates increases significantly, or if we are unable to transport the non-human primates in our possession to our clients because of governmental restrictions or limitations, our business may be materially adversely affected. In addition, overall supply constraints with respect to large research models has led to an extremely dynamic pricing environment for non-human primates, which has, and could continue to, make it difficult to predict results, lead to reduced volumes, and require us to adjust operations.
Furthermore, our Cell Solutions operations are structured to produce research materials, such as blood products based on clients’ existing demand, and perceived potential changes in demand, for these products. Sudden or unexpected changes in demand for these products could have an adverse impact on our profitability. Increasing demand could harm relationships with clients if we are unable to alter production capacity, or purchase products from other suppliers, to fill orders adequately. This could result in a decrease in overall revenue and profits. Lack of access to sufficient capital, or lack of adequate time to properly (or the failure to adequately) respond to changes in demand, could result in declining revenue and profits, as clients transfer to other suppliers.
We also operate businesses which depend upon the regulatory approval of the products they manufactures for their contract development and manufacturing organization (CDMO) clients. As such, if these clients experience a delay in, or failure to receive, approval for any of their product candidates or fail to maintain regulatory approval of their products that we develop or manufacture, our revenue and profitability could be materially adversely affected. Additionally, if the FDA or a comparable foreign regulatory authority does not approve of our facilities for the manufacture of a client product, observes significant deficiencies or violations at its facilities or withdraws such approval in the future, our clients may choose to identify alternative manufacturing facilities and/or relationships, which could significantly impact our CDMO capacity and capabilities and results of operations therefrom.
A reduction or delay in government funding of R&D may adversely affect our business.
A portion of revenue, predominantly in our RMS segment, is derived from clients at academic institutions and research laboratories whose funding is partially dependent on both the level and timing of funding from government sources such as the U.S. National Institutes of Health (NIH) and similar domestic and international agencies, which can be difficult to forecast. We also sell directly to the NIH and these other agencies. Government funding of R&D is subject to the political process, which is inherently fluid and unpredictable. Our revenue may be adversely affected if our clients delay purchases as a result of uncertainties surrounding the approval of government budget proposals, included reduced allocations to government agencies that fund R&D activities. Government proposals to reduce or eliminate budgetary deficits have sometimes included reduced allocations to the NIH and other government agencies that fund R&D activities, or NIH funding may not be directed towards projects and studies that require the use of our products and services, both of which could adversely affect our business and our financial results.
Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential healthcare reform, could decrease the need for the services we provide.
Governmental agencies throughout the world strictly regulate the drug development process. Our business involves helping our customers navigate these regulatory processes. Accordingly, many regulations, and often new regulations, are expected to result in higher regulatory standards and often additional revenues for companies that service these industries. However, some changes in regulations, such as a relaxation in regulatory requirements or the introduction of streamlined or expedited drug approval procedures, or an increase in regulatory requirements that we have difficulty satisfying or that make our services less competitive, could eliminate or substantially reduce the demand for our services.
For example, in December 2022, the FDA Modernization Act 2.0 was passed, which requires the FDA to develop and implement a strategy to reduce the use of animals in testing while maintaining the safety and effectiveness of medical products and to explore the use of non-animal alternatives to animal testing. Eliminating the use of animals in research may have material adverse effects on our business, results of operations, or financial condition. While there have been significant advancements in the development of alternative methods, the complete elimination of animals in research will be a gradual process that may take many years to achieve. While we are committed to working with the industry to support development and to provide the best translational models to supplement or replace traditional models as part of our 4Rs initiative, the use of animals in research is highly regulated and proposed changes to current regulations will need to be carefully evaluated to ensure that they do not compromise the safety and efficacy of new drugs and medical treatments.
Although we believe we are currently in compliance in all material respects with applicable national, regional and local laws, as well as other accepted guidance used by oversight bodies (including the USDA, the standards set by the International Air
25
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Transport Association, the Convention on International Trade in Endangered Species of Wild Fauna and Flora, USFWS, The Centers for Disease Control, the Department of Transportation, the Department of State, the office of Laboratory Animal Welfare of NIH, the Drug Enforcement Agency, as well as numerous other oversight agencies in the jurisdictions in which we operate), failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions. For additional discussion of the factors specifically affecting our non-human primates including related oversight trade compliance agencies, please see the sections entitled “Item 1A. Risk Factors – Industry Risk Factors - Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business”, and “Item 3. Legal Proceedings” included elsewhere in this Form 10-K. In addition, if regulatory authorities were to mandate a significant reduction in safety assessment procedures that utilize research animals (as has been advocated by certain groups), certain segments of our business could be materially adversely affected.
Implementation of healthcare reform legislation may have certain benefits, but also may contain costs that could limit the profits that can be made from the development of new drugs. This could adversely affect R&D expenditures by pharmaceutical and biotechnology companies, which could in turn decrease the business opportunities available to us both in the U.S. and abroad. In addition, new laws or regulations may create a risk of liability, increase our costs or limit our service offerings. Furthermore, if health insurers were to change their practices with respect to reimbursements for pharmaceutical products, our clients may spend less or reduce their growth in spending on R&D.
While it is not possible to predict whether and when any such changes will occur, changes at the local, state or federal level, or in laws and regulations in effect in foreign jurisdictions in which we operate or have business relationships, may significantly impact our domestic and foreign businesses and/or those of our clients. Furthermore, modifications to international trade policy, public company reporting requirements, environmental regulation and antitrust enforcement may have a materially adverse impact on us, our suppliers or our clients.
Our Biologics Solutions business, financial condition and results of operations may be adversely affected if the products we manufacture and/or test for our customers do not gain market acceptance.
If the products we manufacture for our customers do not gain market acceptance or production volumes of key products that we manufacture for our customers decline, the financial condition and results of our operations may be adversely affected. For our CDMO services, we will depend on, and have no control over, market acceptance for the products that we will manufacture for our customers. Consumer demand for these products could be adversely affected by, among other things, delays in securing regulatory approvals, the emergence of competing or alternative products, including generic drugs, the emergence of new safety data for such products, the loss of patent and other intellectual property rights protection, reductions in private and government payment product subsidies or changing product marketing strategies.
CDMO services are highly complex and failure to provide quality and timely services to our CDMO customers, could adversely impact our business.
The CDMO services we offer can be highly complex, due in part to strict regulatory requirements and the inherent complexity of the services provided. A failure of our quality control systems in our facilities could cause problems in connection with facility operations for a variety of reasons, including equipment malfunction, viral contamination, failure to follow specific manufacturing instructions, protocols and standard operating procedures, problems with raw materials or environmental factors. Such issues could affect production of a single manufacturing run or manufacturing campaigns, requiring the destruction of products, or could halt manufacturing operations altogether. In addition, any failure to meet required quality standards may result in our failure to timely deliver products to our customers which, in turn, could damage our reputation for quality and service. Any such incident could, among other things, lead to increased costs, lost revenue, reimbursement to customers for lost drug substances, damage to and possibly termination of customer relationships, time and expense spent investigating and remediating the cause and, depending on the cause, similar losses with respect to other manufacturing runs. In addition, such issues could subject us to litigation, the cost of which could be significant.
Contaminations in our animal populations can damage our inventory, harm our reputation for contaminant-free production, result in decreased sales and cause us to incur additional costs.
Both small and large animal research models must be free of certain infectious agents, such as certain viruses, parasites, and bacteria, because the presence of these contaminants can distort or compromise the quality of research results and/or could adversely impact human or animal health. The presence of these infectious agents in our animal production facilities and certain service operations could impact the quality of our contaminant-free research model as well as our animal services businesses, including GEMS, harm our reputation for contaminant-free production and result in decreased sales. There also exists a risk that contaminations from models that we produce may affect our client’s facilities, with similar impact to them for which we could be liable for damages. In some cases, we may produce or import animals carrying infectious agents capable of causing disease in humans; and in the case of such a contamination or undiagnosed infection, there could be a possible risk of human exposure and infection and liability for damages to infected persons.
26
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
When considering our large research models, while some of these models are owned by us and maintained at our facilities, others are reserved for us and maintained at sites operated by the original provider. Accordingly, risk of contamination may be outside of our control, and we depend on the practices and protocols of third parties to ensure a contamination-free environment. A contamination may require extended CDC or CFIA quarantine with subsequent reduced sales as a result of lost client orders, as well as the potential for complete inventory loss and disinfection of the affected quarantine rooms. Furthermore, while we often negotiate for contractual risk indemnification, the third party may refuse to fulfill its indemnification obligation or may be unable to as a result of insolvency or other impediments.
Contaminations are unanticipated and difficult to predict and could adversely impact our financial results. If they occur, contaminations typically require cleaning up, renovating, disinfecting, retesting and restarting production or services. Such contaminations result in inventory loss, clean-up and start-up costs, and reduced sales as a result of lost client orders and potentially credits for prior shipments. In addition to microbiological contaminations, the potential for genetic contaminations also exists and may require us to restart the applicable animal colonies, and would result in inventory loss, additional start-up costs and possibly reduced sales. Contaminations also expose us to risks that clients will request compensation for damages in excess of our contractual indemnification requirements.
Further, many of our operations are comprised of complex mechanical systems that are subject to periodic failure, including aging fatigue. Such failures are unpredictable, and while we have made significant capital expenditures designed to create redundancy within these mechanical systems, strengthen our biosecurity, improve our operating procedures to protect against such contaminations, and replace impaired systems and equipment in advance of such events, failures and/or contaminations may still occur.
The outsourcing trend in non-clinical (discovery and safety assessment) stages of drug discovery and development may decrease, which could impair our growth.
Over the past decade, pharmaceutical and biotechnology companies have generally increased their outsourcing of non-clinical research support activities, such as discovery and safety assessment. While many industry analysts expect the outsourcing trend to continue to increase for the next several years (although with different growth rates for different phases of drug discovery and development), decreases in such outsourcing may result in a diminished growth rate in the sales of any one or more of our service lines and may adversely affect our financial condition and results of operations. For additional discussion of the factors that we believe have recently influenced outsourcing demand from our clients, please see the section entitled “Our Strategy” above.
The industries in which we operate are highly competitive.
The industries in which we operate are highly competitive. We compete for business with other non-clinical drug development partners and blood product and therapeutic services companies, other CDMOs, as well as internal discovery and development departments within our larger clients, who may have greater resources than ours. We also compete with universities and teaching hospitals for outsourced services. We compete on a variety of factors, including:
•reputation for on-time quality performance;
•reputation for regulatory compliance;
•reputation for responsive client service and support;
•expertise and experience in multiple specialized areas;
•scope and breadth of service and product offerings across the drug discovery and development spectrum;
•scope and breadth of service and product offerings across the manufacturing support spectrum;
•ability to provide flexible and customized solutions to support our clients’ drug discovery, non-clinical development, and manufacturing support needs;
•broad geographic availability (with consistent quality);
•price/value, spend and flexibility;
•technological and scientific expertise and efficient drug development processes;
•quality of facilities;
•financial stability;
•size;
•ability to acquire, process, analyze and report data in an accurate manner;
27
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
•ability to place orders through eCommerce channels; and
•accessibility of client data through secure portals.
If we do not compete successfully, our business will suffer. Increased competition might lead to price and other concessions that could adversely affect our operating results. The drug discovery and development services industry has continued to see a trend towards consolidation, particularly among the biotechnology companies, which are targets for each other and for large pharmaceutical companies. If this trend continues, it is likely to produce more competition among the larger companies, with respect to both clients and acquisition candidates. In addition, small, specialized entities considering entering the industries will continue to find lower barriers to entry, and private equity firms may determine that there are opportunities to acquire and consolidate these companies, thus further increasing possible competition. Our competition in the CDMO market includes full-service contract manufacturers and large pharmaceutical companies offering third-party manufacturing services to fill their excess capacity. Also, large pharmaceutical companies have been seeking to divest portions of their manufacturing capacity, and any such divested businesses may compete with us in the future. Furthermore, many of our CDMO competitors may have substantially greater financial, marketing, technical or other resources than we do. Moreover, additional competition may emerge, particularly in lower-cost jurisdictions such as India and China, which could, among other things, result in a decrease in the fees paid for our services, which may adversely affect our results of operations and financial condition.
More generally, our competitors or others might develop technologies, services or products that are more effective or commercially attractive than our current or future technologies, services or products, or that render our technologies, services or products less competitive or obsolete. If competitors introduce superior technologies, services or products and we cannot make enhancements to ours to remain competitive, our competitive position, and in turn our business, revenue and financial condition, would be materially and adversely affected. In the aggregate, these competitive pressures may affect the attractiveness of our technologies, services or products and could adversely affect our financial results.
New technologies may be developed, validated and increasingly used in biomedical research, which could reduce demand for some of our products and services.
The scientific community continues to develop cell-based and new alternative model methods (NAMs), which do not involve working with animals models and are designed to increase the translation from findings in early-stage discovery and pre-clinical studies to human studies, and vice-versa. As these methods continue to advance, they may supplement, and in some cases possibly replace or supplant methodologies that are currently in use, such as the use of traditional living animals in biomedical research. In addition, technological improvements, such as imaging and other translational biomarker technologies, could impact demand for animal research models. Further, manufacturers, including Charles River, have recently introduced recombinant versions of LAL, which has been historically derived from live animals. It is our strategy to explore new technologies to refine and potentially reduce the use of animal models and animal derived products as new in vitro and in silico methods become available and synthetically-manufactured products become validated with sufficient data to ensure public safety. For information regarding our efforts to support development and to provide the best translational models to supplement or replace traditional models, see “Our Strategy” included elsewhere in this Form 10-K. However, we may not be able to develop new products, inputs or processes effectively or in a timely manner to replace any lost sales. Lastly, other companies or entities may develop research models, inputs or processes with characteristics different from those that we produce, and that may be viewed as more desirable by some of our clients.
We may not be able to successfully develop and market new services and products.
We continue to seek opportunities to develop and market new services and products that complement or expand our existing business or service offerings. We believe our ability to innovate through internal research and development efforts and license or acquire new technologies from third parties are both critical to our ability to continue to meet the needs of our clients. Our ability to gain access to such technologies depends, in part, on our ability to convince innovators that we can successfully develop and commercialize their inventions. We cannot guarantee that we will be able to identify new technologies of interest to our clients. Even if we are able to identify these opportunities, negotiating license agreements on commercially acceptable terms may prove difficult. In addition, our ongoing internal research and development efforts may not always yield offerings that meet client demand. If we are unable to develop new services and products and/or create demand for those newly developed services and products, our future business, results of operations, financial condition and cash flows could be adversely affected.
Costs increasing more rapidly than market prices in certain of our businesses could reduce profitability.
The cost of collecting, processing and testing products has risen significantly in recent years and will likely continue to increase given stringency of demands on raw materials. These cost increases are related to new and improved testing procedures, increased regulatory requirements, and higher staff and supply costs, including labor inflation. Competition and fixed price contracts may limit our ability to maintain existing operating margins. Some competitors have greater resources than us to
28
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
sustain periods of marginally profitable or unprofitable sales. Costs increasing more rapidly than market prices may reduce profitability and may have a material adverse impact on our business and results of operations.
Legal and Regulatory Risk Factors
Any failure by us to comply with applicable regulations and related guidance could harm our reputation and operating results, and compliance with new regulations and guidance may result in additional costs.
Any failure on our part to comply with applicable regulations could result in the termination of ongoing research or the disqualification of data for submission on behalf of our clients to regulatory authorities. This could harm our reputation, our prospects for future work and our operating results. For example, the issuance of a notice of objectionable observations or a warning letter from the FDA based on a finding of a material violation affecting data integrity by us for GLP or cGMP requirements that are not addressed to the regulatory monitoring authorities’ satisfaction could materially and adversely affect us. If our operations are found to violate any applicable law or other governmental regulations, we might be subject to civil and criminal penalties, damages and fines or the temporary closure of our facilities. Any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business and damage our reputation.
Where applicable, our clients expect us to timely deliver their nonclinical data compliant with the FDA’s SEND (Standardization for Exchange of Nonclinical Data) standards. Notwithstanding, some of these standards require additional operating and capital expenses that will impact not only us and our industry competitors, but clients in the biomedical research community. Non-compliance with any of these expectations could lead to official action by a government authority, damage to our reputation and a potential loss of business.
In addition, regulations and guidance worldwide concerning the production and use of research animals for research purposes continue to evolve. Similarly, guidance has been and continues to be developed for other areas that impact the biomedical research community on both a national and international basis including transportation, mandated contingency planning, euthanasia guidance, import and export requirements of biological materials, health monitoring requirements and the use of disinfectants.
Our Cell Solutions business is subject to complex regulation by federal, state and local governments in the U.S. This business requires us to obtain many licenses, permits, authorizations, accreditations, approvals, and certificates to fully comply with appropriate regulations in every jurisdiction in which we operate and sell. Federal, state and local regulations do change, requiring prompt adoption to remain in a constant state of compliance. Changes in the regulations could require us to alter how we operate our business, potentially resulting in a significantly increased cost of compliance.
Our donor collection centers are registered with the FDA and the FDA periodically conducts inspections of those facilities and operations. At the conclusion of each inspection, the FDA provides us with a list of objectionable conditions and practices observed during the inspection that could result in additional enforcement actions. Failure to comply with the regulations enforced by the FDA could result in sanctions and/or remedies and have a material adverse effect on us.
We are required to comply with stringent, complex and evolving laws, rules, regulations and standards in many jurisdictions, as well as contractual obligations, relating to data privacy and security. Any actual or perceived failure to comply with these requirements could have a material adverse effect on our business.
We are required to comply with stringent, complex and frequently evolving laws, rules, regulations and standards in many jurisdictions, as well as contractual obligations, relating to data privacy and security. Ensuring that our collection, use, transfer, storage and other processing of personal information complies with such requirements can increase operating costs, impact the development of new products or services, and reduce operational efficiency.
Internationally, virtually every jurisdiction in which we operate has established its own data privacy and security legal framework with which we must comply. For example, we are required to comply with the European Union (EU) General Data Protection Regulation (GDPR), which became effective on May 25, 2018. The EU GDPR imposes stringent obligations regarding the collection, control, use, sharing, disclosure and other processing of personal data of individuals within the EU and European Economic Area (EEA). EU member states may also impose additional requirements in relation to personal data through their national implementing legislation.
The EU GDPR also imposes specific restrictions on the transfer of personal data to countries outside of the EU and EEA, including the use of appropriate safeguards to enable such transfers, such as Standard Contractual Clauses (SCCs) and the EU-US Data Privacy Framework (DPF). The EU-US DPF was adopted in July 2023 and provides US-based organizations who self-certify with a reliable mechanism for personal data transfers from the EU, United Kingdom, and Switzerland. Although these mechanisms are currently valid for purposes of transferring personal data, they could be subject to legal challenges and there is no assurance that we could satisfy or rely on these measures to lawfully transfer personal data. If we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we
29
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. While we have implemented controls and procedures to comply with the requirements of the EU GDPR, such procedures and controls may not be effective in ensuring compliance or preventing unauthorized transfers of personal data. Additionally, we are subject to the privacy and data protection laws of the UK, including the UK Data Protection Act of 2018 (UK GDPR). Similar to the EU GDPR, the UK GDPR imposes restrictions on the processing of personal data, as well as transfers of personal data from the UK to other countries. Failure to comply with the EU and/or the UK GDPR can result in significant fines and other liability.
Moreover, China adopted the Personal Information Protection Law (PIPL) and Data Security Law (DSL) in 2021, which promulgated national privacy and security requirements relating to the collection, processing, transfer and security of personal information in or from China. Violations of the PIPL or DSL could result in fines and penalties, suspension of data transfers, cancellation of business authorizations, personal liability for responsible company officers, as well as criminal and civil liability. In the event that the PIPL requires us to store data in China, or limits our ability to transfer data across borders, we may experience increased costs and business inefficiencies. Fines, corrective actions, or other penalties asserted due to alleged noncompliance may impose additional financial or operational costs, limit our ability to attract and retain local talent, or limit our ability to do business in China.
In the US, there are numerous federal and state data privacy and security laws, rules, and regulations governing the collection, use, disclosure, retention, security, transfer, storage and other processing of personal information, including federal and state data privacy laws, data breach notification laws, and data disposal laws. For example, at the federal level, we are subject the regulations of the Federal Trade Commission, which has the authority to regulate and enforce against unfair or deceptive acts or practices in or affecting commerce, including acts and practices with respect to data privacy and security. If our public statements about our use, collection, disclosure and other processing of personal information are alleged to be deceptive, unfair or misrepresentative of our actual practices, we may be subject to potential government or legal investigation or action. If we are found to have violated applicable laws or regulations, we may also be subject to penalties, fines, damages, injunctions or other outcomes that may adversely affect our operations and financial results. The United States Congress also has considered, and may in the future consider, various proposals from time to time for comprehensive federal data privacy legislation to which we may become subject if passed and which may adversely affect our operations and financial results.
At the state level, we are subject to laws and regulations like the California Consumer Privacy Act (CCPA) and the California Privacy Rights Act (CPRA). The CCPA and CPRA create transparency requirements for companies, grant California residents various rights with regard to their personal information, and impose additional data protection obligations on companies doing business in California. Failure to comply with the CCPA and CPRA may result in, among other things, significant civil penalties and injunctive relief, or potential statutory or actual damages. The CCPA and CPRA also provide a private right of action for data breaches that result in the loss of personal information. The CCPA and CPRA may impact our business activities and require compliance costs that adversely affect business, operating results, prospects and financial condition. These state statutes, and other similar state or federal laws that may be enacted in the future may require us to modify our data processing practices and policies, incur substantial compliance-related costs and expenses, and otherwise suffer adverse impacts on our business.
Additionally, while collecting research products from donors, we may collect, use, disclose, maintain and transmit donor information in ways that will be subject to many of the numerous state, federal and international laws and regulations governing the collection, use, disclosure, storage, transmission or confidentiality of patient-identifiable health information.
We have made changes to, and investments in, our business practices and will continue to monitor developments and make appropriate changes to help attain compliance with these evolving and complex laws, rules, regulations and standards. Any actual or perceived failure to comply with any such laws, rules, regulations, standards or contractual obligations could subject us to denial of the right to conduct business, significant fines, civil or criminal penalties, costly litigation (including class actions), government investigation or inquiries, enforcement actions, claims, proceedings, judgements, awards, penalties, sanctions or other adverse impacts that could have a material adverse effect on our business.
Failure to comply with U.S., state, local or international environmental, health and safety laws and regulations, including regulations issued by the Occupational Safety and Health Administration, Environmental Protection Agency, Nuclear Regulatory Agency and Department of Transportation, could result in fines and penalties and loss of licensure, and have a material adverse effect upon the Company’s business.
We are subject to licensing and regulation under laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as regulations relating to the safety and health of laboratory employees and protecting employees from the spread of COVID-19. Failure to comply with these laws and regulations could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions that could have a material adverse effect on our business. Other environmental laws may have similar consequences to us or our supplier, or
30
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
result in liability to us. In addition, compliance with future legislation could impose additional requirements on us that may be costly.
Changes in U.S. and International Tax Law, results of tax audits, or material changes in our stock price could have a material adverse impact on our effective tax rate and financial results.
As a global company, we are subject to taxation in numerous countries, states, and other jurisdictions. Changes to governmental laws and regulations, or their interpretations, including the adoption of global minimum taxation requirements and potential changes to existing tax law by the current U.S. Presidential administration and Congress, could impact our profits, effective tax rate and cash flows.
We receive substantial tax credits and incentives in Canada, from both the Canadian federal and Quebec governments, China, France, the U.K., and the U.S. Any reduction in the availability or amount of these tax credits and incentives or outcomes of tax controversies associated with these credits, could have a material adverse effect on our profits, cash flows and effective tax rate. Additionally, we are subject to regular audits with respect to various tax returns and processes in the jurisdictions in which we operate. Errors or omissions in tax returns, process failures, increase to tax rates or differences in interpretation of tax laws by tax authorities may lead to litigation, payments of additional taxes, penalties, and interest.
We are subject to regular review and audit by both domestic and foreign tax authorities. As a result, we have received, and may in the future receive, assessments in multiple jurisdictions, on various tax-related assertions. Any adverse outcome of such a review or audit could harm our financial condition and operating results, require adverse changes to our business practices, or subject us to additional litigation and regulatory inquiries. In addition, the determination of our worldwide provision for income taxes and other tax liabilities requires significant judgment and often involves uncertainty. Although we believe our estimates are reasonable, the ultimate tax outcome may differ from the amounts recorded in our financial statements and may affect our financial results in the period or periods for which such determination is made.
Our tax expense and liabilities are affected by certain factors, such as changes in our business operations, acquisitions, investments, entry into new businesses and geographies, intercompany transactions, changes in foreign currency exchange rates, changes in our stock price, changes to our forecasts of income and loss and the mix of jurisdictions to which they relate, and changes in our tax assets and liabilities and their valuation.
Non-clinical contract research services create a risk of liability.
As a global drug development partner, we face a range of potential liabilities, which may include:
•risks associated with errors or omissions in reporting of study detail in non-clinical studies that may lead to inaccurate reports, which may undermine the usefulness of a study or data from the study, or which may potentially advance studies absent the necessary support or inhibit studies from proceeding to the next level of testing;
•risks associated with our possible failure to properly care for our clients’ property, such as research models and samples, study compounds, records, work in progress, other archived materials or goods and materials in transit, while in our possession;
•risks that models in our breeding facilities or in facilities that we manage may be infected with diseases that may be harmful and even lethal to them or humans, despite preventive measures for the quarantine and handling of imported animals;
•risks that we may have errors and omissions and/or product liabilities related to our products designed to conduct lot release testing of medical devices, injectable drugs, food, beverages, and home and beauty products (primarily through our Microbial Solutions business), or in the testing of biologics and other services performed by our Biologics Solutions business, which could result in us or our clients failing to identify unsafe or contaminated materials;
•risk of transmitting dangerous infectious diseases, as a result of the failure of our screening and testing processes, or new pathogens that may be undetected by such processes; and
•recent acquisitions have expanded our business into the CDMO market, which entails additional risks of liability, including potential product liability claims, errors and omissions claims in connection with our services and potential liability under indemnification agreements between us and our officers and directors.
While we attempt to mitigate these risks through a variety of methods, it is impossible to completely eradicate such risks. In our RMS business, we mitigate these risks to the best of our abilities through our regimen of animal testing, quarantine procedures and veterinary staff vigilance, through which we seek to control the exposure of animal related disease or infections. In our Cell Solutions, DSA, and Manufacturing businesses, we attempt to reduce these risks through the negotiation of contractual risk transfer provisions, such as indemnification provisions, limitations of liability, and client insurance requirements.
31
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Contractual risk transfer indemnifications generally do not protect us against liability arising from certain of our own actions, such as negligence or misconduct. We could be materially and adversely affected if we are required to pay damages or bear the costs of defending any claim that is outside any contractual indemnification provision, or if a party does not fulfill its indemnification obligations or the damage is beyond the scope or level of insurance coverage. We also often contractually indemnify our clients (subject to a limitation of liability), similar to the way they indemnify us, and we may be materially adversely affected if we have to fulfill our indemnity obligations. Furthermore, either we or a party required to indemnify us may not be able to maintain such insurance coverage (either at all or on terms acceptable to us).
The failure to successfully obtain, maintain and enforce intellectual property rights and defend against assertions of third-parties to intellectual property rights could adversely affect us.
Many of our services, products and processes rely on intellectual property. In some cases, that intellectual property is owned by another party and licensed to us, sometimes exclusively. To protect our intellectual property rights, we primarily rely upon trade secret, patent, and copyright law, as well as contractual provisions relating to intellectual property ownership and control and confidentiality. Laws relating to intellectual property rights and contracts vary from country to country and are subject to change at any time. In addition, the agreements upon which we rely to protect our intellectual property might be breached, or might not be fully enforceable. Our intellectual property rights might not prevent our competitors from independently developing intellectual property that is similar to or duplicative of ours. Also, enforcement of our intellectual property rights may also require substantial investments of time, money, and oversight, and may not result in success. If we are unable to secure and maintain our intellectual property rights, or if we are unable to prevent misappropriation or infringement, our business could be adversely affected.
Furthermore, we respect third-party intellectual property rights, and make efforts to avoid violating valid and enforceable intellectual property rights, and seek to procure and pay for licenses from the holders of intellectual property rights that we seek to use. In some cases, we are asked to utilize components and processes that are provided to us by our clients.
Customers of our CDMO business, for example, may utilize intellectual property for the production of their products, the manufacture of which has been contracted to us. Failure by us and/or our customers to secure and maintain rights to third-party intellectual property rights could have a material adverse effect, including reduced revenue as a result in a delay or cancellation of the manufacture of products and involvement in judicial and administrative proceedings in which we are named as a party.
Further, the drug discovery, drug development, and drug manufacturing industry has a history of patent and other intellectual property litigation and these lawsuits will likely continue. This may be exacerbated by the increased use of cell-based and new alternative model methods not involving animal models, which may supplement and/or replace or supplant the use of traditional living animal models in biomedical research. Refer to “Risk Factors – New technologies may be developed, validated and increasingly used in biomedical research, which could reduce demand for some of our products and services.” herein for our assessment of certain other relevant risk factors on this topic. Litigation can be expensive, time consuming, and can divert management’s attention from other business concerns. If we do not prevail in an infringement lawsuit brought against us, we may be compelled by a court to pay substantial damages, including treble damages, and be ordered to stop the challenged activity, or obtain a license on unnegotiated and/or unfavorable terms.
Our by-laws designate the state courts located in the State of Delaware as the sole and exclusive forum for certain actions, including derivative actions, which could limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company and its directors, officers, other employees, or the Company's stockholders and may discourage lawsuits with respect to such claims.
Unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the Company, (2) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (3) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Company’s certificate of incorporation or the Company’s by-laws (in each case, as they may be amended from time to time), or (4) any action asserting a claim governed by the internal affairs doctrine shall be a state court located within the state of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware). However, this exclusive forum provision will not apply to suits brought under the federal securities laws for which the federal courts have exclusive jurisdiction. If a court were to find the choice of forum provision contained in our by-laws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business and financial condition. Furthermore, although we believe the exclusive forum provision benefits us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, this provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company and its directors, officers, or other employees and may discourage lawsuits with respect to such claims.
32
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
We are involved in legal proceedings that could adversely affect our business, financial condition, and results of operations.
We are involved in legal proceedings related to various matters, including securities litigation, and may become involved in other legal proceedings that arise from time to time in the future. For example, as discussed further in Part I, Item 3, Legal Proceedings, a putative securities class action and derivative securities lawsuit have been filed against the Company, and certain officers and directors, alleging that disclosures about the Company’s practices with respect to the importation of non-human primates were materially false or misleading.
Any claims against us, whether meritorious or not, can be time-consuming, result in costly litigation, be harmful to our reputation, require significant management attention, and divert significant resources. In addition, the expense of litigation and the timing of this expense from period to period are difficult to estimate and subject to change. Litigation and other claims are subject to inherent uncertainties and management’s view of these matters may change in the future. Given the uncertain nature of legal proceedings generally, we are not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome. We could incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.
Labor and Employment Risk Factors
We depend on key personnel and may not be able to retain these employees, which could harm our business.
Our success depends to a significant extent on the continued services of our senior management and other members of management who have skills and industry experience aligned with our strategic objectives. James C. Foster, our Chief Executive Officer and President since 1992 and Chairman since 2000, has held various positions with us for four decades. While we entered into an amended employment agreement with Mr. Foster in 2021, most members of our senior management do not have employment agreements, except in jurisdictions outside of the United States where employment contracts are common for most employees. If Mr. Foster or other members of senior management do not continue in their present positions, our business may be adversely impacted.
If we are unable to attract, hire or retain key team members or a highly skilled and diverse global workforce, it could have a negative impact on our business, financial condition or results of operations.
Because of the specialized scientific nature of our business, we are highly dependent upon attracting and retaining qualified scientific, technical and managerial personnel, while also ensuring an inclusive and diverse culture. We have a strong record of employee retention, and we strive to reduce the impact of the potential loss of existing employees by having an established organizational talent review process that identifies successors and potential talent needs. However, there is still significant competition for qualified personnel in the veterinary, pharmaceutical and biotechnology fields. Failure to retain qualified existing personnel and recruit additional key scientific, technical, and managerial personnel in a timely manner, could harm our business.
We depend on the availability of, and good relations with, our team members.
Our employees are not unionized in the U.S. and employees at some of our European facilities are represented by works councils, collective bargaining agreements, employee representative groups and/or unions, which is consistent with local customs for our industry. Our operations depend on the availability and relative costs of labor and maintaining good relations with employees, which includes supporting their overall wellbeing. If we fail to maintain good relations with our team members or with the labor organizations, we may experience labor strikes or work stoppages, which could adversely affect our financial results.
We acknowledge a specific risk associated with periodic reductions in our workforce. As part of our strategic and operational management, we, from time to time, undertake workforce reductions to align with evolving business trends, market dynamics, or operational efficiency goals. Such actions result in incremental severance and benefits costs and replacing lost talent in the future may result in higher costs, all of which could adversely affect our financial results.
Financial and Accounting Risk Factors
Our debt level could adversely affect our business and growth prospects.
As of December 30, 2023, we had $2.6 billion of debt and finance leases (debt). Our debt could have significant adverse effects on our business, including making it more difficult for us to obtain additional financing on favorable terms; requiring us to dedicate a substantial portion of our cash flows from operations to the repayment of debt and the interest on this debt; limiting our ability to capitalize on significant business opportunities; making us more vulnerable to rising interest rates, and reducing our flexibility to respond to changing business and economic conditions. Disruption in the financial market could also have a material adverse effect on our financial position, results of operations and liquidity. For additional information regarding our debt, please see Note 9, “Long-Term Debt and Finance Lease Obligations”, included in the notes to our consolidated financial statements included elsewhere in this Form 10-K.
33
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Impairment of long lived tangible assets and intangible assets (such as goodwill and other intangible assets) may adversely impact future results of operations.
We have intangible assets, including goodwill, on our balance sheet due to our acquisitions of businesses. The initial identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition involve use of management judgments and estimates. These estimates are based on, among other factors, projections of cash flows that arise from identifiable intangible assets of acquired businesses and discount rates based on an analysis of our weighted average cost of capital, adjusted for specific risks associated with the assets. Disruptions in global financial markets and deterioration of economic conditions could, among other things, impact the discount rate. Other assumptions used in the valuations and actual cash flows arising from a particular intangible asset could vary from projected cash flows, which could imply different carrying values from those established at the dates of acquisition and which could result in impairment of such assets.
If the future growth and operating results of our business are not as strong as anticipated, overall macroeconomic or industry conditions deteriorate and/or our market capitalization declines, this could impact the assumptions used in establishing the carrying value of goodwill or other intangible assets, as well as long-lived tangible assets, such as property, plant and equipment and operating lease right-of-use assets. Should disruption in the global financial markets and deterioration of economic conditions have a prolonged impact on our industry, triggering events may arise resulting in long-lived tangible asset, intangible asset, or goodwill impairments. To the extent long-lived tangible assets, intangible assets, or goodwill are impaired, their carrying value will be written down to their implied fair values and a charge will be made to our net income. Such an impairment charge could materially and adversely affect our operating results. As of December 30, 2023, the carrying amount of goodwill and other intangibles on our consolidated balance sheet was $4.0 billion, property, plant and equipment was $1.6 billion, and operating lease right-of-use assets was $394.0 million.
General Risk Factors
Since we do not expect to pay any cash dividends for the foreseeable future, our shareholders will benefit from an investment in our common stock only if it appreciates in value.
We have not declared or paid any cash dividends on our common stock, and do not anticipate that we will pay any dividends to holders of our common stock for the foreseeable future. Any payment of cash dividends will be at the discretion of our Board of Directors and will depend on our financial condition, capital requirements, legal requirements, earnings and other factors. Consequently, our shareholders should not rely on dividends to receive a return on their investment.
Our quarterly operating results may vary, which could negatively affect the market price of our common stock.
Our results of operations in any quarter may vary from quarter to quarter and are influenced by the risks discussed above, as well as: changes in the general global economy; changes in the mix of our products and services; cyclical buying patterns of our clients; the financial performance of our strategic and venture capital investments; certain acquisition-related adjustments, including change in fair value of contingent payments both receivable from or payable to counterparties; and the occasional extra week (“53rd week”) that we recognize in a fiscal year (and fourth fiscal quarter thereof), including 2022, due to our fiscal year ending on the last Saturday in December. We believe that operating results for any particular
quarter are not necessarily a meaningful indication of future results. Nonetheless, fluctuations in our quarterly operating results could negatively affect the market price of our common stock.
Increasing focus on environmental, social and governance (ESG) matters, including climate-related issues, may impact our business, financial results or stock price.
There has been increasing public focus by investors, clients, environmental activists, the media and governmental and nongovernmental organizations on a variety of ESG matters. If we are not effective in addressing ESG matters affecting our business, or setting and meeting relevant sustainability and climate-related goals, including our approved greenhouse gas emissions reduction targets, which have been approved by the Science Based Targets Initiative, our reputation and financial results may suffer. We may experience increased costs in order to execute upon our sustainability goals and measure achievement of those goals, which could have an adverse impact on our business and financial condition. Heightened stakeholder focus on ESG matters related to our business requires the continuous monitoring of various and evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet stakeholder expectations may result in noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract clients and an inability to attract and retain top talent. A failure to comply with new laws, regulations, or reporting requirements, could negatively impact our reputation and our business. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.
34
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Item 1B.    Unresolved Staff Comments
There are no unresolved comments to be reported in response to Item 1B.
Item 1C. Cybersecurity
Cybersecurity Risk Management and Strategy
Charles River places high importance on identifying and eliminating potential cybersecurity threats to its employees, customers, IT infrastructure, proprietary technologies and confidential information.
Our cybersecurity risk management is based on recognized industry governance frameworks, including the International Organization for Standardization (ISO), the National Institute of Standards and Technology (NIST), the Center for Internet Security Controls (CIS), and the Cloud Security Alliance (CSA). We use these frameworks together with information collected from internal and 3rd party assessments to develop policies such as our technology acceptable use policy for information assets, our access requirements for data, systems, or technologies, and policies for the protection and use of personal information of our employees and customers. We protect our IT assets through industry-standard techniques such as multifactor authentication, malware defenses, network and endpoint monitoring, and access review processes. We also work with our business units to leverage and implement foundational cybersecurity principles, such as security by design, defense-in-depth, least privilege, and resilience-focused backups, throughout our organization. We deliver cybersecurity awareness and confidential information protection training to our employees, and we send our employees ethical simulated phishing and spear-phishing emails to test their compliance with our policies.
We engage third parties to conduct annual penetration testing, and we use external risk assessors to measure our program to industry standard frameworks. Our information security management system is certified to the ISO/IEC 27001:2013 standard by the British Standards Institution (BSI); certificate IS 780367. We also collaborate with experts and industry partners to exchange information about threats, best practices, and trends.
Our cybersecurity risk management extends to risks associated with our use of third-party service and technology providers as well as partnerships with third parties we may enter into. For instance, we conduct risk and compliance assessments of third parties that request access to our IT resources and information or who provide technology products to Charles River.
Our cybersecurity risk management is an important part of our comprehensive business continuity program and enterprise risk management. Our global information security team periodically engages with a cross-functional group of Charles River subject-matter experts and leaders to assess and refine Charles River’s cybersecurity risk posture and preparedness. For example, we regularly evaluate and update contingency strategies for our business in the event that a portion of our IT systems were to be unavailable due to a cybersecurity incident. We practice our response to potential cybersecurity incidents through regular tabletop exercises. We also perform threat hunting and red team exercises.
Through these processes, during our fiscal year 2023 and through the date of this filing we did not identify risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced an undetected cybersecurity incident. For more information about these risks, please see the section titled “Item 1A. Risk Factors – Business and Operational Risk Factors - We have in the past experienced and in the future could experience unauthorized access into our information systems.”
Governance of Cybersecurity Risk Management
Our board of directors, as a whole, has oversight responsibility for Charles River’s strategic and operational risks. The Audit Committee of the Board of Directors has been delegated by the Board responsibility by reviewing and discussing Charles River’s risk assessment and risk management practices, including cybersecurity risks, with members of management. The Audit Committee, in turn, periodically discusses its review and assessment with the board of directors.
Our management team is responsible for day-to-day assessment and management of cybersecurity risks. On our management team, our Chief Information Officer has primary oversight of material risks from cybersecurity threats. The Chief Information Officer is Charles River’s Senior Vice President responsible for the Global Technology organization and for information protection at Charles River. The Chief Information Officer has more than 25 years of experience in the field, including serving as the Senior Vice President of Charles River’s Digital Transformation organization, leading the development and implementation of information technology strategies and roadmaps for digital and automation solutions.
Our Chief Information Security Officer reports to our Chief Information Officer. Our Chief Information Security Officer has more than 25 years of experience working in information technology-related roles, of which 10 years has been in information security leadership, and holds degrees in bio-medical engineering and computer science.
35
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Our Chief Information Officer and Chief Information Security Officer assess our cybersecurity readiness through internal assessment tools as well as third-party control tests, vulnerability assessments, audits, and evaluation against industry standards. We have governance and compliance structures that are designed to elevate issues relating to cybersecurity to our Chief Information Officer and Chief Information Security Officer, such as potential threats or vulnerabilities. We also employ various defensive and monitoring techniques based on industry frameworks and cybersecurity standards.
Our Chief Information Officer and our Chief Information Security Officer meet annually with the full Board, and periodically, but generally at least quarterly, with the Chief Executive Officer, Chief Operations Officer, and Audit Committee to review the company’s information technology systems and discuss key cybersecurity risks. Our Chief Information Security Officer has direct access to the Chair of our Audit Committee and keeps the Audit Committee apprised of any developments that may emerge in between regularly scheduled meetings that require its attention. Additionally, our Incident Response Plan includes escalation protocols to raise occurrences that require attention from the Audit Committee or the board of directors as a whole.
Item 2.    Properties
Approximately 60% of our real estate portfolio (by area) is owned including all facilities over 200,000 square feet. The remaining facilities are owned or covered by either land or facility leases. Within the DSA business, we own or lease large facilities (greater than 50,000 square feet) in 9 countries including the U.S., Canada, Scotland, France, China, Netherlands, and Hungary. We own large RMS facilities in Canada, France, England and the U.S with additional large facilities leased in China and the U.S. Manufacturing is supported in over 10 countries with large, owned properties in the U.S., Ireland, and China which are supplemented by additional leased facilities in the U.S., England, France, and Germany. None of our leases is individually material to our business operations.
Many of our leases have an option to renew and we believe that we will be able to successfully renew expiring leases on satisfactory terms. In each of our reportable segments, we believe that our facilities are adequate for our operations and that suitable additional space will be available when needed. For additional information, see Note 17. Leases included in Item 8, “Financial Statements and Supplementary Data” in this Form 10-K.
We track room utilization on an ongoing basis and, depending on the needs of our clients at given times, we may need to execute on contingency plans for expansion, which average between nine and twenty-four months to complete.
Specific sites may be expanded to accommodate the business requirements resulting from a targeted consolidation plan. We continue to employ a master site planning strategy to proactively evaluate our real estate needs. Sites and leases added to the portfolio by way of acquisition are integrated into our overall real estate strategy. In situations where the associated real estate is leased, and depending on the resolution of these situations, we may be encumbered with the remaining real estate lease obligations. In certain circumstances, we dispose of or consolidate operations, which could result in impairment charges.
Item 3.    Legal Proceedings
On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain recent shipments in the United States. The carrying value of the inventory related to these shipments is approximately $27 million as of December 30, 2023, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena, primarily related to the sourcing of non-human primates, and the Company is cooperating with the request. We are not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or
36
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities.
A putative securities class action was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. The Company filed a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.
On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The Company intends to file a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the derivative lawsuit to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.
Item 4.    Mine Safety Disclosures
Not applicable.
37
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PART II
Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock began trading on the New York Stock Exchange on June 23, 2000 under the symbol “CRL.” There were no equity securities that were not registered under the Securities Act of 1933, as amended, sold during fiscal year 2023.
Shareholders
As of January 27, 2024, there were 67 registered shareholders of the outstanding shares of common stock.
Issuer Purchases of Equity Securities
The following table provides information relating to our purchases of shares of our common stock during the fourth quarter of fiscal 2023:
Total Number
of Shares
Purchased		Average
Price Paid
per Share		Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs		Approximate Dollar
Value of Shares
That May Yet Be
Purchased Under the
Plans or Programs
(in thousands)
October 1, 2023 to October 28, 2023133 $195.40 — $129,105 
October 29, 2023 to November 25, 202317 167.72 — 129,105 
November 26, 2023 to December 30, 2023440 197.08 — 129,105 
Total590 —  
Our Board of Directors has authorized, in aggregate, a stock repurchase program of $1.3 billion. During the fourth quarter of fiscal year 2023, we did not repurchase any shares of common stock under our stock repurchase program or in open market trading. As of December 30, 2023, we had $129.1 million remaining on the authorized stock repurchase program.
Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements.
Comparison of 5-Year Cumulative Total Return
The following stock performance graph compares the annual percentage change in the Company’s cumulative total shareholder return on its Common Stock during a period commencing on December 29, 2018 and ending on December 30, 2023 (as measured by dividing (1) the sum of (A) the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and (B) the difference between the Company’s share price at the end and the beginning of the measurement period; by (2) the share price at the beginning of the measurement period) with the cumulative total return of the S&P 500 Index and the S&P 500 Health Care Index during such period. The Company has not paid any dividends on the Common Stock, and no dividends are included in the representation of the Company’s performance. The stock price performance on the graph below is not necessarily indicative of future price performance. The graph is not “soliciting material,” is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. Information used in the graph was obtained from Standards & Poor’s Institutional Market Services, a source believed to be reliable, but the Company is not responsible for any errors or omissions in such information.
38
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN
Among Charles River Laboratories International, Inc., The S&P 500 Index and
The S&P 500 Health Care Index
2839
Fiscal Year
201820192020202120222023
Charles River Laboratories International, Inc.$100 $136 $225 $330 $195 $212 
S&P 500100 131 156 200 164 207 
S&P 500 Health Care100 121 137 173 170 173 
Item 6.    Reserved
Not applicable.
39
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our consolidated financial statements and related notes appearing in Item 8, “Financial Statements and Supplementary Data” in this Annual Report on Form 10-K. A discussion of our results of operations for the fiscal year ended December 31, 2022 and a comparison of our results for the fiscal years ended December 31, 2022 and December 25, 2021 was included in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 22, 2023. In addition to historical consolidated financial information, the following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in Item 1A, “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Certain percentage changes may not recalculate due to rounding.
Overview
We are a leading, full service, non-clinical global drug development partner. For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. We also provide a suite of products and services to support our clients’ manufacturing activities, including our contract development and manufacturing organization (CDMO) business. Utilizing our broad portfolio of products and services enables our clients to create a more efficient and flexible drug development model, which reduces their costs, enhances their productivity and effectiveness, and increases speed to market.
Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world. We currently operate in 155 sites and in over 20 countries worldwide, which numbers exclude certain Insourcing Solutions (IS) sites.
Segment Reporting
Our three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Our RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Insourcing Solutions (IS), which provides colony management of our clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities as well as our own vivarium space, utilizing our Charles River Accelerator and Development Lab (CRADL) option. Cell Solutions provides controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow.
Our DSA segment is comprised of two businesses: Discovery Services and Safety Assessment. We provide regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.
Our Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO). In December of 2022, we sold the Avian Vaccine Services (Avian) business, reported in the Manufacturing segment, which supplied specific-pathogen-free chicken eggs and chickens.
40
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Fiscal Quarters
Our fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which occurred in fiscal year 2022.
Business Trends
In fiscal year 2023, biopharmaceutical clients reprioritized their drug development programs and were more cautious with their budgetary spending amidst the uncertainty in the broader market environment, including a slowdown in biotechnology funding activities, as well as macroeconomic challenges, including higher interest rates. The demand and pricing for our products and services continued to increase in fiscal year 2023, but at a slower pace than in recent years.
Despite the near-term market pressures, many of our pharmaceutical and biotechnology clients continued to benefit from the long-term value of strategic outsourcing to improve their operating efficiency and to access capabilities that they do not maintain internally. Many of our large biopharmaceutical clients have continued to increase investments in their drug discovery and early-stage development efforts and have strengthened their relationships with outsourced partners, like Charles River, and biotechnology companies to assist them in bringing new drugs to market. While these clients were more cautious with their early-stage R&D spending in fiscal year 2023, these large biopharmaceutical clients were the principal driver of revenue growth. A reduction in the biotechnology funding environment from peak levels in 2021 resulted in a moderation of demand from small and mid-size biotechnology clients. We have recently experienced an increase in our allowance for credit losses, which increased to $25.7 million as of December 30, 2023 from $11.3 million as of December 31, 2022 and may expect this trend to continue if the biotechnology funding environment remains consistent or further softens. Our ability to continue to deliver our leading suite of research and non-clinical development solutions has endeavored our clients to continue to choose to partner with us for our flexible and efficient outsourcing solutions, broad scientific capabilities, and global scale.
Revenue for RMS increased, principally driven by pricing. China reported healthy growth rates despite pressure from more cautious spending on biomedical research activity from clients within China. Demand for research model services continued to perform well, led by our Insourcing Solutions business, particularly our CRADL™ operations. Clients are increasingly adopting CRADL™’s flexible model to access vivarium space without having to invest in internal infrastructure. To support client demand, we have expanded CRADL™’s footprint both organically and through the acquisition of Explora BioLabs in April 2022. We are confident that research models and services will remain essential tools for our clients’ drug discovery and early-stage development efforts.
DSA continued to benefit from sustained trends in fiscal year 2023. The Safety Assessment revenue growth rate moderated due to our clients’ budgetary spending constraints but continued to report a solid growth rate for the fiscal year due to a combination of price increases and study volume. Safety Assessment growth was supported by the meaningful scale of the backlog for this business, although it has recently decreased. DSA backlog decreased to $2.45 billion as of December 30, 2023 from $3.15 billion as of December 31, 2022.
We believe that our comprehensive scientific capabilities and global scale, as well as the breadth and depth of our scientific expertise, quality, and responsiveness remain key criteria when our clients make the decision to outsource to us. Biotechnology clients continue to move their programs forward and utilize outsourcing to achieve their goal of more efficient and effective drug research to bring innovative new therapies to market. We continued to enhance our Discovery Services capabilities to provide clients with a comprehensive portfolio that enables them to start working with us at the earliest stages of the discovery process. We have accomplished this in recent years through acquisitions and by adding cutting-edge capabilities to our discovery toolkit through technology partnerships. In fiscal year 2023, demand in our Discovery Services business declined, as clients reprioritize their program and conserve their early-stage spending, which resulted in lower proposal activity and a longer lead time to commence new projects.
Revenue for our products and services that support our clients’ manufacturing activities increased across most of our Manufacturing Solutions businesses in fiscal year 2023 however, demand in this reportable segment was impacted by clients’ more cautious spending trends in fiscal year 2023, as well as destocking activities and other challenges associated with CDMO and biopharmaceutical clients. Demand for our cell and gene therapy CDMO services improved meaningfully in fiscal year 2023 as the initiatives that we have implemented to improve the performance of our CDMO business gained traction and generated a healthy pipeline of new business opportunities including working on two commercial products. Charles River remains a premier scientific partner for development, testing, and manufacturing of advanced drug modalities and the acquisition of the CDMO businesses in 2021, Cognate and Vigene, further enhanced our presence in the high-growth cell and gene therapy sector.
In response to recent trends described above, we have undertaken restructuring actions within all reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions, resulting in severance and transition costs; and costs related to the consolidation of facilities, resulting in asset impairment and accelerated depreciation
41
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
charges. Restructuring charges recognized during fiscal year 2023 were approximately $30 million, of which $18 million related to asset impairment and accelerated depreciation charges and $12 million related to severance charges. We expect that these effectuated actions as well as other upcoming planned actions will result in approximately $60 million to $70 million of cost savings on an annualized basis.
Recent Acquisitions
Our strategy is to augment internal growth of existing businesses with complementary acquisitions. We continue to make strategic acquisitions designed to expand our portfolio of products and services to support the drug discovery and development continuum. Our recent acquisitions are described below.
On November 30, 2023, we completed our acquisition of an additional 41% equity interest of Noveprim Group (“Noveprim”), a leading provider of non-human primates (“NHPs”) used for biomedical, pharmaceutical and toxicological research purposes, resulting in a 90% controlling interest. The acquisition strengthens and diversifies the supply chain for our DSA segment. We had previously acquired a 49% equity stake in 2022 for $90.0 million up-front and additional future contingent payments up to $5.0 million based on future performance. The total preliminary purchase price for the Noveprim acquisition is $374.8 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $198.8 million which includes a remeasurement gain on the 49% equity investment of $103.2 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $13.8 million. The acquisition was funded through a combination of available cash and proceeds from our Credit Facility. This business is reported as part of our DSA reportable segment for NHPs vertically integrated into our Safety Assessment supply chain and the RMS reportable segment for NHPs sold to third party customers.
On January 30, 2023, we acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by us of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from our Credit Facility. This business is reported as part of our DSA reportable segment.
On April 5, 2022, we acquired Explora BioLabs Holdings, Inc. (Explora BioLabs), a provider of contract vivarium research services, providing biopharmaceutical clients with turnkey in vivo vivarium facilities, management and related services to efficiently conduct their early-stage research activities. The acquisition of Explora BioLabs complements our existing Insourcing Solutions business, specifically our CRADL™ footprint, and offers incremental opportunities to partner with an emerging client base, many of which are engaged in cell and gene therapy development. The purchase price of Explora BioLabs was $284.5 million, net of $6.6 million in cash acquired. The acquisition was funded through proceeds from our Credit Facility. This business is reported as part of our RMS reportable segment.
Recent Divestiture
We routinely evaluate strategic fit and fundamental performance of our global infrastructure and divest operations that do not meet key business criteria or where capital could be better deployed in other long-term growth opportunities. On December 20, 2022, we completed the sale of our Avian Vaccine Services (Avian) business to a private investor group for a preliminary purchase price of $167 million in cash, subject to certain customary closing adjustments, and future contingent payments up to an additional $30 million. Prior to divestiture, this business was reported in our Manufacturing reportable segment.
U.S. Government Investigations into Non-Human Primate Supply Chain
On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are
42
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain recent shipments in the United States. The carrying value of the inventory related to these shipments is approximately $27 million as of December 30, 2023, which reflects the value of the shipments in accordance with our inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena, primarily related to the sourcing of non-human primates, and the Company is cooperating with the request. We are not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities. Refer to Item 1A, “Risk Factors” disclosed herein for our assessment of risk factors surrounding this matter.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S.). The preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses during the reported periods and related disclosures. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on our historical experience, trends in the industry, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from our estimates under different assumptions or conditions. Our significant accounting policies are more fully described in Note 1, “Description of Business and Summary of Significant Accounting Policies”, to our consolidated financial statements contained in Item 8, “Financial Statements and Supplementary Data” in this Annual Report on Form 10-K.
An accounting policy is deemed to be critical if the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the impact of the estimates and assumptions on our consolidated financial statements is or may be material. We believe the following represent our critical accounting policies and estimates used in the preparation of our financial statements:
Revenue Recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer (“transaction price”).
To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the amount to which we expect to be entitled. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, we do not extend payment terms beyond one year. Applying the practical expedient, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. Our contracts do not generally contain significant financing components.
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.
43
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Product revenue is generally recognized when the customer obtains control of our product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, we generally measure our progress using either cost-to-cost (input method) or right-to-invoice (output method). We use the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as we incur costs on our contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of our performance to date. During fiscal year 2023, $2.6 billion, or approximately 60%, of our total revenue recognized ($4.1 billion) is DSA service revenue transferred over time.
Intangible Assets (including Goodwill) and certain Biological Assets
We use assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The determination of the fair value of intangible assets (including goodwill) and certain biological assets, which represent a significant portion of the purchase price in certain recent acquisitions, requires the use of significant judgment with regard to (i) the fair value; and (ii) whether such assets are amortizable or non-amortizable and, if the former, the period and the method by which the asset will be amortized. We utilize commonly accepted valuation techniques, such as the income, cost and market approaches, as appropriate, in establishing the fair value of these assets. Typically, key assumptions include projections of cash flows that arise from these assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets.
In our recent acquisitions, customer relationship intangible assets (also referred to as client relationships) and certain biological assets have been the most significant identifiable assets acquired. To determine the fair value of the acquired client relationships and biological assets, we utilized the multiple period excess earnings model (a commonly accepted valuation technique), which includes the following key assumptions: projections of cash flows from the acquired entities, which included future revenue, cost of revenue, operating income margins, customer attrition rates, productivity rates; as well as discount rates based on a market participant’s weighted average cost of capital. The value of the client relationship acquired was $23 million for fiscal year 2023 and $64 million for fiscal year 2022. The value of the biological assets acquired was $168 million for fiscal year 2023.
We review definite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash flows arising from a particular intangible asset could vary from projected cash flows which could imply different carrying values from those established at the dates of acquisition and which could result in impairment of such asset. No significant impairments were recognized during fiscal years 2023 and 2022.
We evaluate goodwill for impairment annually, during the fourth quarter, and when events occur or circumstances change that may reduce the fair value of the asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts. Estimates of future cash flows require assumptions related to revenue and operating income growth, asset-related expenditures, working capital levels and other factors. Different assumptions from those made in our analysis could materially affect projected cash flows and our evaluation of goodwill for impairment.
We perform the quantitative impairment test where we compare the fair value of our reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units, then we would record an impairment loss equal to the difference. In fiscal years 2023 and 2022 we performed the quantitative goodwill impairment test for our reporting units. Fair value was determined by using a weighted combination of a market-based approach and an income approach, as this combination was deemed to be the most indicative of our fair value in an orderly transaction between market participants. Under the market-based approach, we utilized information about our company as well as publicly available industry information to determine earnings multiples and sales multiples that are used to value our reporting units. Under the income approach, we determined fair value based on the estimated future cash flows of each reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of the reporting unit and the rate of return an outside investor would expect to earn. Our 2023 and 2022 impairment tests indicated that goodwill was not impaired.
44
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Valuation and Impairment of Long-Lived Assets
Long-lived assets to be held and used, including property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Factors we consider important that could trigger an impairment review include, but are not limited to, the following:
•significant underperformance relative to expected historical or projected future operating results;
•significant negative industry or economic trends; or
•significant changes or developments in strategy or operations that negatively affect the utilization of our long-lived assets.
Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset, net of any sublease income, if applicable, and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. We measure any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in our current business model. Significant judgments are required to estimate future cash flows, including the selection of appropriate discount rates and other assumptions. We may also estimate fair value based on market prices for similar assets, as appropriate. Changes in these estimates and assumptions could materially affect the determination of fair value for these assets. Long-lived asset impairments of $42 million were recognized during fiscal year 2023 and no significant impairments were recognized during 2022.
Income Taxes
We prepare and file income tax returns based on our interpretation of each jurisdiction’s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and the effects of tax planning strategies. Our valuation allowance was $304.2 million as of December 30, 2023. In the event actual results differ from our estimates, we will adjust our estimates in future periods and may establish additional allowances or reversals as necessary.
We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the “more-likely-than-not” threshold or the liability becomes effectively settled through the controversy process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews; we have no plans to appeal or litigate any aspect of the tax position; and we believe that it is highly unlikely that the taxing authority would re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.
We generally receive a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock and performance share units held by employees. The stock price, timing, and amount of vesting and exercising of stock-based compensation could materially impact our current tax expense.
Our global operations make the effective tax rate sensitive to significant tax law changes. Several countries have begun to enact legislation to implement the Organization for Economic Cooperation and Development’s (OECD) international tax framework, including the Pillar II global minimum tax regime with effect from January 1, 2024 or later. We are currently monitoring these developments, but do not expect there to be a material financial impact.
45
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
New Accounting Pronouncements
For a discussion of new accounting pronouncements, refer to Note 1, “Description of Business and Summary of Significant Accounting Policies” to our consolidated financial statements contained in Item 8, “Financial Statements and Supplementary Data,” in this Annual Report on Form 10-K.
46
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Results of Operations
Consolidated Results of Operations and Liquidity
Revenue for fiscal year 2023 was $4.1 billion compared to $4.0 billion in fiscal year 2022. The 2023 increase as compared to the corresponding period in 2022 was $153.3 million, or 3.9%, and was primarily due to increased volume and pricing within our Safety Assessment business and our recent acquisition of Explora BioLabs; partially offset by the divestiture of our Avian business and the effect of changes in foreign currency exchange rates when compared to fiscal year 2022.
In fiscal year 2023, our operating income and operating income margin were $617.3 million and 14.9%, respectively, compared with $651.0 million and 16.4%, respectively, in fiscal year 2022. The decrease in operating income and operating income margins for fiscal year 2023 was primarily due to higher operating costs within our Manufacturing segment, restructuring and asset impairment charges principally in our DSA and Manufacturing segments, and the divestiture of the Avian business; partially offset by contributions of higher revenue described above.
Net income attributable to common shareholders decreased to $474.6 million in fiscal year 2023, from $486.2 million in the corresponding period of 2022. The decrease in net income attributable to common shareholders of $11.6 million was primarily due to lower operating income described above and higher interest expense due to higher interest rates on our variable debt, partially offset by lower income tax expense during fiscal year 2023 compared to the corresponding period of 2022.
During fiscal year 2023, our cash flows from operations was $683.9 million compared with $619.6 million for fiscal year 2022. The increase in net cash provided by operating activities was primarily driven by the amounts and timing of compensation payments and inventory purchases.
Revenue and Operating Income
The following tables present consolidated revenue by type and by reportable segment:
Fiscal Year
20232022$ change% change
(in thousands, except percentages)
Service revenue$3,440,019 $3,216,904 $223,115 6.9 %
Product revenue689,390 759,156 (69,766)(9.2)%
$4,129,409 $3,976,060 $153,349 3.9 %
Fiscal Year
20232022$ change% changeImpact of FX
(in thousands, except percentages)
RMS$792,343 $739,175 $53,168 7.2 %(0.6)%
DSA2,615,623 2,447,316 168,307 6.9 %0.3 %
Manufacturing721,443 789,569 (68,126)(8.6)%0.4 %
Total revenue$4,129,409 $3,976,060 $153,349 3.9 %0.2 %
Analysis of Segment Results
The following table presents operating income by reportable segment:
Fiscal Year
20232022$ change% changeImpact of FX
(in thousands, except percentages)
RMS$154,666 $160,410 $(5,744)(3.6)%(1.4)%
DSA606,076 532,889 73,187 13.7 %1.9 %
Manufacturing88,329 167,084 (78,755)(47.1)%1.3 %
Unallocated corporate(231,810)(209,408)(22,402)10.7 %(0.1)%
Total operating income$617,261 $650,975 $(33,714)(5.2)%1.6 %
Operating income % of revenue14.9 %16.4 %(150) bps
The following presents and discusses our consolidated financial results by each of our reportable segments:
47
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RMS
Fiscal Year
20232022$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$792,343 $739,175 $53,168 7.2 %(0.6)%
Cost of revenue (excluding amortization of intangible assets)509,970 455,607 54,363 11.9 %
Selling, general and administrative105,965 102,795 3,170 3.1 %
Amortization of intangible assets21,742 20,363 1,379 6.8 %
Operating income$154,666 $160,410 $(5,744)(3.6)%(1.4)%
Operating income % of revenue19.5 %21.7 %(220) bps
RMS revenue increased $53.2 million due primarily to higher research model services revenue, specifically the Insourcing Solutions business, which included the acquisition of Explora BioLabs contributing $15.6 million, higher small research model product revenue in North America and China, and higher large model product revenue due to the acquisition of Noveprim, which contributed $6.1 million; partially offset by the effect of changes in foreign currency exchange rates and the impact of the 53rd week in fiscal year 2022, which had contributed $7.4 million to revenue.
RMS operating income decreased $5.7 million compared to fiscal year 2022. RMS operating income as a percentage of revenue for fiscal year 2023 was 19.5%, a decrease of 220 bps from 21.7% for fiscal year 2022. Operating income and operating income as a percentage of revenue decreased due to higher amortization, operating, and staffing costs due to the acquisition of Explora BioLabs; mix of small research models products and services; and the effect of changes in foreign currency exchange rates.
DSA
Fiscal Year
20232022$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$2,615,623 $2,447,316 $168,307 6.9 %0.3 %
Cost of revenue (excluding amortization of intangible assets)1,675,472 1,617,760 57,712 3.6 %
Selling, general and administrative263,770 213,870 49,900 23.3 %
Amortization of intangible assets70,305 82,797 (12,492)(15.1)%
Operating income$606,076 $532,889 $73,187 13.7 %1.9 %
Operating income % of revenue23.2 %21.8 %140 bps
DSA revenue increased $168.3 million due primarily to service revenue which increased in the Safety Assessment business due to increased demand, principally biopharmaceutical clients, pricing of services, and the acquisition of SAMDI contributing $7.0 million to service revenue; partially offset by decreases in our Discovery Services business and the effect of changes in foreign currency exchange rates and the impact of the 53rd week in fiscal year 2022, which had contributed $37.1 million to revenue.
DSA operating income increased $73.2 million compared to fiscal year 2022. DSA operating income as a percentage of revenue for fiscal year 2023 was 23.2%, an increase of 140 bps from 21.8% for fiscal year 2022. Operating income and operating income as a percentage of revenue increased primarily due to the contribution of higher revenue described above and lower amortization of intangible assets; partially offset by higher legal costs incurred in connection with investigations by the U.S government into the non-human primate supply chain, asset impairment charges related to a Discovery Services site closure and a recently divested site related to our Safety Assessment business, and the absence of certain favorable acquisition-related adjustments to contingent consideration arrangements incurred during 2022 which are recorded in selling, general and administrative costs.
48
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Manufacturing
Fiscal Year
20232022$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$721,443 $789,569 $(68,126)(8.6)%0.4 %
Cost of revenue (excluding amortization of intangible assets)441,411 440,042 1,369 0.3 %
Selling, general and administrative146,311 139,027 7,284 5.2 %
Amortization of intangible assets45,392 43,416 1,976 4.6 %
Operating income$88,329 $167,084 $(78,755)(47.1)%1.3 %
Operating income % of revenue12.2 %21.2 %(900) bps
Manufacturing revenue decreased $68.1 million due primarily to the divestiture of our Avian business, which decreased revenue by $77.3 million, lower services revenue from our Biologics Testing business, and the impact of the 53rd week in fiscal year 2022 which contributed $8.2 million to revenue in the prior year; partially offset by increased CDMO and Microbial Solutions service revenue.
Manufacturing operating income decreased $78.8 million compared to fiscal year 2022. Manufacturing operating income as a percentage of revenue for fiscal year 2023 was 12.2%, a decrease of 900 bps from 21.2% for fiscal year 2022. Operating income and operating income as a percentage of revenue decreased primarily due to the divestiture of our Avian business, higher charges related to restructuring activities, and lower operating income due to higher operating costs within our Biologics Solutions business, an asset impairment charge, and the absence of a $19 million impact of a favorable ruling from tax authorities on certain indirect tax positions recorded within selling, general and administrative expense in the corresponding period in 2022.
Unallocated Corporate
Fiscal Year
20232022$ change% change
(in thousands, except percentages)
Unallocated corporate$231,810 $209,408 $22,402 10.7 %
Unallocated corporate % of revenue5.6 %5.3 %30 bps
Unallocated corporate costs consist of selling, general and administrative expenses that are not directly related or allocated to the reportable segments. The increase in unallocated corporate costs of $22.4 million, or 10.7%, compared to fiscal year 2022 is primarily related to an increase in our digital investments as well as higher variable compensation and benefits expenses. Costs as a percentage of revenue for fiscal year 2023 was 5.6%, an increase of 30 bps from 5.3% for fiscal year 2022.
Other Income (Expense)
Fiscal Year
December 30, 2023December 31, 2022$ change% change
(in thousands, except percentages)
Other income (expense):
Interest income$5,196 $780 $4,416 566.2 %
Interest expense(136,710)(59,291)(77,419)130.6 %
Other income, net95,537 30,523 65,014 213.0 %
Total other expense, net$(35,977)$(27,988)$(7,989)28.5 %
Interest expense for fiscal year 2023 was $136.7 million, an increase of $77.4 million, or 130.6%, compared to $59.3 million in fiscal year 2022. The increase was due primarily to higher interest rates, and the absence of $49.7 million of gains recognized in connection with a debt-related foreign exchange forward contract in the corresponding period in 2022.
Other income, net for fiscal year 2023 was $95.5 million, an increase of $65.0 million, or 213.0%, compared to $30.5 million for fiscal year 2022. The increase was due primarily to a gain on acquisition of $98.5 million for Noveprim, the absence of $46.5 million of foreign currency losses recognized in connection with a U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency, and lower net losses incurred on our venture capital, other strategic equity investments, and life insurance investments as compared to fiscal year 2022; partially offset by the absence of a gain on the divestiture of our Avian business of $123.4 million in fiscal year 2022.
49
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Income Taxes
Fiscal Year
20232022$ change% change
(in thousands, except percentages)
Provision for income taxes$100,914 $130,379 $(29,465)(22.6)%
Effective tax rate17.4 %20.9 %(350) bps
Income tax expense for fiscal year 2023 was $100.9 million, a decrease of $29.5 million compared to $130.4 million for fiscal year 2022. Our effective tax rate was 17.4% for fiscal year 2023 compared to 20.9% for fiscal year 2022. The decrease in our effective tax rate in fiscal year 2023 compared to fiscal year 2022 was primarily attributable to the impact of the non-taxable gain on Noveprim of $98.5 million; partially offset by a decreased tax benefit from stock-based compensation deductions.
Liquidity and Capital Resources
Liquidity and Cash Flows
We currently require cash to fund our working capital needs, capital expansion, acquisitions, and to pay our debt, lease, venture capital and strategic equity investments, and pension obligations. Our principal sources of liquidity have been our cash flows from operations, recent divestitures, supplemented by long-term borrowings. Based on our current business plan, we believe that our existing funds, when combined with cash generated from operations and our access to financing resources, are sufficient to fund our operations for the foreseeable future.
The following table presents our cash, cash equivalents and short-term investments:
December 30, 2023December 31, 2022
(in thousands)
Cash and cash equivalents:
Held in U.S. entities$2,234 $15,813 
Held in non-U.S. entities274,537 218,099 
Total cash and cash equivalents276,771 233,912 
Short-term investments:
Held in non-U.S. entities68 998 
Total cash, cash equivalents and short-term investments$276,839 $234,910 
The following table presents our net cash provided by operating activities:
Fiscal Year
20232022
(in thousands)
Net income$480,370 $492,608 
Adjustments to reconcile net income to net cash provided by operating activities305,908 279,586 
Changes in assets and liabilities(102,380)(152,554)
Net cash provided by operating activities$683,898 $619,640 
Net cash provided by cash flows from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for (1) non-cash operating items such as depreciation and amortization, stock-based compensation, loss on debt extinguishment and other financing costs, deferred income taxes, long-lived asset impairment changes, gains and/or losses on venture capital and strategic equity investments, gains and/or losses on divestitures, changes in fair value of contingent consideration, as well as (2) changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations. During fiscal year 2023, our cash flows from operations was $683.9 million compared with $619.6 million for fiscal year 2022. The increase in net cash provided by operating activities was primarily driven by the amounts and timing of compensation payments and inventory purchases.
50
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
The following table presents our net cash used in investing activities:
Fiscal Year
20232022
(in thousands)
Acquisitions of businesses and assets, net of cash acquired$(194,785)$(283,392)
Capital expenditures(318,528)(324,733)
Proceeds from sale of businesses, net— 163,275 
Investments, net(47,548)(153,725)
Other, net(2,294)(9,347)
Net cash used in investing activities$(563,155)$(607,922)
The primary use of cash used in investing activities in fiscal year 2023 related to the acquisitions of Noveprim and SAMDI, capital expenditures to support the growth of the business, and investments in certain venture capital and strategic equity investments. The primary use of cash used in investing activities in fiscal year 2022 related to the acquisition of Explora BioLabs, capital expenditures to support the growth of the business, and investments in certain venture capital and strategic equity investments; partially offset by proceeds from the sale of our Avian business.
The following table presents our net cash used in financing activities:
Fiscal Year
20232022
(in thousands)
Proceeds from long-term debt and revolving credit facility$776,353 $2,952,430 
Payments on long-term debt, revolving credit facility, and finance lease obligations(851,676)(2,932,636)
Proceeds from exercises of stock options25,597 25,110 
Purchase of treasury stock(24,155)(38,651)
Purchases of additional equity interests, net(4,784)(30,533)
Payment of contingent considerations(2,711)(10,356)
Other, net(4,145)(7,761)
Net cash used in financing activities$(85,521)$(42,397)
For fiscal year 2023, net cash used in financing activities was primarily driven by debt repayments on our Credit Facility offset by borrowings to fund the recent acquisition of Noveprim.
Net cash used in financing activities also reflected treasury stock purchases of $24.2 million made due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements, $4.8 million payment to purchase the remaining 8% interest in our Vital River subsidiary, $4.0 million of dividends paid to noncontrolling interests, and $2.7 million of contingent consideration payments; partially offset by proceeds from exercises of employee stock options of $25.6 million. We did not pay any dividends on our Common Stock in fiscal year 2023 and have no current plans to do so in the coming fiscal year.
For fiscal year 2022, net cash used in financing activities reflected the net proceeds of $19.8 million on our Credit Facility and finance lease obligations. Included in the net proceeds are the following amounts:
•Borrowings under our Credit Facility of $300 million, which were used primarily for the acquisition of Explora BioLabs;
•Net repayments of $100 million on our Credit Facility throughout fiscal year 2022;
•Payments of $2.0 billion partially offset by $1.9 billion of proceeds in connection with a non-U.S. Euro functional currency entity repaying Euro loans and replacing the Euro loans with U.S. dollar denominated loans. A series of forward currency contracts were executed to mitigate any foreign currency gains or losses on the U.S. dollar denominated loans. These proceeds and payments are presented as gross financing activities.
Net cash used in financing activities also reflected treasury stock purchases of $38.7 million made due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements, approximately $15 million payment to purchase an additional 10% interest in a subsidiary, $15.7 million payment to acquire the remaining 2% ownership interest in Cognate, $10.4 million of contingent consideration payments, and $5.3 million of dividends paid to noncontrolling interests; partially offset by proceeds from exercises of employee stock options of $25.1 million.
51
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financing and Market Risk
We are exposed to market risk from changes in interest rates and currency exchange rates, which could affect our future results of operations and financial condition. We manage our exposure to these risks through our regular operating and financing activities.
Amounts outstanding under our Credit Facility and our Senior Notes were as follows:
December 30, 2023December 31, 2022
(in thousands)
Revolving facility$1,129,243 $1,197,586 
4.25% Senior Notes due 2028500,000 500,000 
3.75% Senior Notes due 2029500,000 500,000 
4.0% Senior Notes due 2031500,000 500,000 
Total$2,629,243 $2,697,586 
The interest rates applicable to the Credit Facility are equal to (A) for revolving loans denominated in U.S. dollars, at the Company’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1.0%) or the adjusted SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon the Company’s leverage ratio. In March 2023 and in conjunction with the Credit Agreement second amendment (Second Amendment) the Company modified the variable rate on the Credit Facility from adjusted LIBOR to adjusted term SOFR. All outstanding U.S. dollar borrowings remained at adjusted LIBOR through their respective interest reset periods in April 2023 and were then set to term SOFR.
Our 2028 Senior Notes have semi annual interest payments due May 1 and November 1. Our 2029 and 2031 Senior Notes have semi annual interest payments due March 15 and September 15.
During the fourth fiscal quarter of 2022, we entered into an interest rate swap with a notional amount of $500 million to manage interest rate fluctuation related to our floating rate borrowings under the Credit Facility, at a fixed rate of 4.70%. In March 2023 and in conjunction with the Second Amendment, we modified the variable rate on our interest rate swap from 1-month LIBOR to 1-month term SOFR. Effective with the modification we will pay a fixed rate of 4.65% on our swap maturing November 2, 2024. The transition did not have an impact on our hedge accounting or a material impact to our consolidated financial statements.
Our off-balance sheet commitments related to our outstanding letters of credit as of December 30, 2023 were $21.6 million.
Foreign Currency Exchange Rate Risk
We operate on a global basis and have exposure to some foreign currency exchange rate fluctuations for our financial position, results of operations, and cash flows.
While the financial results of our global activities are reported in U.S. dollars, our foreign subsidiaries typically conduct their operations in their respective local currency. The principal functional currencies of our foreign subsidiaries are the Euro, British Pound, and Canadian Dollar. During fiscal year 2023, the most significant drivers of foreign currency translation adjustment we recorded as part of other comprehensive income (loss) were the British Pound, Euro, Canadian Dollar, and Hungarian Forint.
Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our financial position, results of operations, and cash flows. As the U.S. dollar strengthens against other currencies, the value of our non-U.S. revenue, expenses, assets, liabilities, and cash flows will generally decline when reported in U.S. dollars. The impact to net income as a result of a U.S. dollar strengthening will be partially mitigated by the value of non-U.S. expenses, which will decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue, expenses, assets, liabilities, and cash flows will generally increase when reported in U.S. dollars. For fiscal year 2023, our revenue would have decreased by $126.7 million and our operating income would have decreased by $2.8 million, if the U.S. dollar exchange rate had strengthened by 10%, with all other variables held constant.
We attempt to minimize this exposure by using certain financial instruments in accordance with our overall risk management and our hedge policy. We do not enter into speculative derivative agreements.
We entered into foreign exchange forward contracts during fiscal year December 31, 2022 to limit our foreign currency exposure related to a U.S. dollar denominated loan borrowed by a non-U.S. Euro functional currency entity under the Credit Facility. Refer to Note 11. Debt and Other Financing Arrangements to our consolidated financial statements contained in Item
52
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
8, “Financial Statements and Supplementary Data,” in this Annual Report on Form 10-K for further details regarding these types of forward contracts.
Repurchases of Common Stock
During fiscal year 2023, we did not repurchase any shares under our authorized $1.3 billion stock repurchase program. As of December 30, 2023, we had $129.1 million remaining on the authorized stock repurchase program. Our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements. During fiscal year 2023, we acquired 0.1 million shares for $24.2 million through such netting.
Commitments and Other Purchasing Arrangements
We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance, and other operating expenses. As of December 30, 2023, we had $757.4 million of operating leases inclusive of future minimum rental commitments under non-cancellable operating leases, net of income from subleases as well as $39.9 million of financing leases. The expected payments of our operating and finance lease liabilities over the next twelve months are $70.6 million and $3.8 million, respectively as of December 30, 2023.
In addition to the obligations on the balance sheet at December 30, 2023, we entered into unconditional purchase obligations in the ordinary course of business. Unconditional purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions, and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancellable at any time without penalty. As of December 30, 2023, we had approximately $390 million of unconditional purchase obligations, the majority of which are expected to be settled during 2024.
We invest in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. Our total commitment to the funds as of December 30, 2023 was $212.9 million, of which we funded $145.2 million through December 30, 2023.
Refer to Note 8. Venture Capital and Strategic Equity Investments to our consolidated financial statements contained in Item 8, “Financial Statements and Supplementary Data,” in this Annual Report on Form 10-K for further details.
In connection with certain business and asset acquisitions, we agreed to make additional payments based upon the achievement of certain financial targets and other milestones in connection with the respective acquisition. As of December 30, 2023, we had approximately $98 million of gross contingent payments, of which $33 million are expected to be paid.
We have certain federal and state income tax liabilities of $32.4 million relating to the one-time Transition Tax on unrepatriated earnings under the 2017 Tax Act. The Transition Tax will be paid, interest free, over an eight-year period through 2026.
Item 7A.    Quantitative and Qualitative Disclosures about Market Risk
The information called for by this item is incorporated herein by reference to “Item 7. Management’s Discussion and Analysis of Results of Operations - Liquidity and Capital Resources” of this Report; and Note 1 “Description of Business and Summary of Significant Accounting Policies - Fair Value” included in Item 8 of this Report.

53
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Item 8.    Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Consolidated Balance Sheets as of December 30, 2023 and December 31, 2022

54
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Charles River Laboratories International, Inc.:
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Charles River Laboratories International, Inc. and its subsidiaries (the “Company”) as of December 30, 2023 and December 31, 2022, and the related consolidated statements of income, comprehensive income, changes in equity and cash flows for each of the three years in the period ended December 30, 2023, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 30, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 30, 2023 and December 31, 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 30, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 30, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
As described in Management’s Report on Internal Control Over Financial Reporting, management has excluded Noveprim Group (“Noveprim”) from its assessment of internal control over financial reporting as of December 30, 2023, because it was acquired by the Company in a purchase business combination during 2023. We have also excluded Noveprim from our audit of internal control over financial reporting. Noveprim is a subsidiary whose total assets and total revenues excluded from management’s assessment and our audit of internal control over financial reporting represent less than 1%, respectively, of the related consolidated financial statement amounts as of and for the year ended December 30, 2023.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over
55
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Acquisition of Noveprim – Valuation of Biological Assets
As described in Notes 1 and 2 to the consolidated financial statements, on November 30, 2023, the Company completed the acquisition of Noveprim, resulting in a 90% controlling interest. Of the acquired long-term assets, $167.8 million of biological assets were recorded. The determination of the fair value of biological assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. To determine the fair value, management utilized the multiple period excess earnings model, which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue, cost of revenue, operating income margins, and productivity rates, as well as the discount rate based on market participant’s weighted average cost of capital.
The principal considerations for our determination that performing procedures relating to the valuation of biological assets acquired in the acquisition of Noveprim is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the biological assets acquired; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management’s significant assumptions related to the cost of revenue, productivity rates, and discount rate; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the acquisition accounting, including controls over management’s valuation of the biological assets acquired. These procedures also included, among others (i) reading the purchase agreement; (ii) testing management’s process for developing the fair value estimate of the biological assets acquired; (iii) evaluating the appropriateness of the multiple period excess earnings model; (iv) testing the completeness and accuracy of the underlying data used in the multiple period excess earnings model; and (v) evaluating the reasonableness of the significant assumptions used by management related to the cost of revenue, productivity rates, and discount rate. Evaluating management’s assumptions related to the cost of revenue and productivity rates involved considering (i) the past performance of Noveprim; (ii) the consistency with external research data; and (iii) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the multiple period excess earnings model and (ii) the reasonableness of the discount rate assumption.
Discovery and Safety Assessment Service Revenue Recognized Over Time Using the Input Method
As described in Notes 1 and 3 to the consolidated financial statements, the Company recognized Discovery and Safety Assessment (DSA) revenue from services and products transferred over time of $2,611.6 million for the year-ended December 30, 2023, of which the majority relates to services that are delivered to the customer based on the extent of progress towards completion of the performance obligation that management
56
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
measures using the cost-to-cost (input method). Management uses the input method measure of progress when it best depicts the transfer of value to the customer, which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the input method measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The cost calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred.
The principal considerations for our determination that performing procedures relating to DSA service revenue recognized over time using the input method is a critical audit matter are a high degree of auditor subjectivity and effort in performing procedures and evaluating audit evidence related to the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to DSA service revenue recognized over time using the input method, including controls over the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation, review of contracts, testing of budget versus actual costs incurred, and testing of revenue recognition. These procedures also included, among others (i) reading contracts and reports describing the results of services provided for a sample of DSA service contracts; (ii) testing management’s process for determining the amount of DSA service revenue recognized over time for a sample of DSA service contracts; (iii) evaluating the appropriateness of the input method used by management; (iv) evaluating the reasonableness of the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations through performing a retrospective comparison of actual costs incurred to historical estimated costs for completed service contracts; and (v) testing actual costs incurred for a sample of in-progress service contracts by examining evidence of costs incurred.

/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 14, 2024

We have served as the Company’s auditor since 1999.
57
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
 Fiscal Year
 202320222021
Service revenue$3,440,019 $3,216,904 $2,755,579 
Product revenue689,390 759,156 784,581 
Total revenue4,129,409 3,976,060 3,540,160 
Costs and expenses:   
Cost of services provided (excluding amortization of intangible assets)2,295,983 2,143,318 1,837,487 
Cost of products sold (excluding amortization of intangible assets)330,870 370,091 368,035 
Selling, general and administrative747,855 665,098 619,919 
Amortization of intangible assets137,440 146,578 124,857 
Operating income617,261 650,975 589,862 
Other income (expense):   
Interest income5,196 780 652 
Interest expense(136,710)(59,291)(73,910)
Other income (expense), net95,537 30,523 (35,894)
Income before income taxes581,284 622,987 480,710 
Provision for income taxes100,914 130,379 81,873 
Net income480,370 492,608 398,837 
Less: Net income attributable to noncontrolling interests5,746 6,382 7,855 
Net income attributable to common shareholders$474,624 $486,226 $390,982 
Earnings per common share   
Net income attributable to common shareholders:   
Basic$9.27 $9.57 $7.77 
Diluted$9.22 $9.48 $7.60 
Weighted-average number of common shares outstanding:
Basic51,227 50,812 50,293 
Diluted51,451 51,301 51,425 
See Notes to Consolidated Financial Statements.

58
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
Fiscal Year
202320222021
Net income$480,370 $492,608 $398,837 
Other comprehensive income (loss):
Foreign currency translation adjustment
70,651 (129,091)(29,493)
Pension and other post-retirement benefit plans (Note 14):
Prior service cost and (losses) gains arising during the period(5,376)24,471 (1,193)
Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans736 3,337 1,678 
Unrealized gains (losses) on hedging instruments2,490 (1,523)— 
Other comprehensive income (loss), before income taxes68,501 (102,806)(29,008)
Less: Income tax (benefit) expense related to items of other comprehensive income (Note 12)
4,071 (1,905)(3,965)
Comprehensive income, net of income taxes544,800 391,707 373,794 
Less: Comprehensive income related to noncontrolling interests, net of income taxes4,546 2,798 8,678 
Comprehensive income attributable to common shareholders, net of income taxes$540,254 $388,909 $365,116 
See Notes to Consolidated Financial Statements.

59
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
December 30, 2023December 31, 2022
Assets  
Current assets:  
Cash and cash equivalents$276,771 $233,912 
Trade receivables and contract assets, net of allowances for credit losses of $25,722 and $11,278, respectively
780,375 752,390 
Inventories380,259 255,809 
Prepaid assets87,879 89,341 
Other current assets83,378 107,580 
Total current assets1,608,662 1,439,032 
Property, plant and equipment, net1,639,741 1,465,655 
Venture capital and strategic equity investments243,811 311,602 
Operating lease right-of-use assets, net394,029 391,762 
Goodwill3,095,045 2,849,903 
Intangible assets, net864,051 955,275 
Deferred tax assets40,279 41,262 
Other assets309,383 148,279 
Total assets$8,195,001 $7,602,770 
Liabilities, Redeemable Noncontrolling Interests and Equity  
Current liabilities:  
Accounts payable$168,937 $205,915 
Accrued compensation213,290 197,078 
Deferred revenue241,820 264,259 
Accrued liabilities227,825 219,758 
Other current liabilities203,210 204,575 
Total current liabilities1,055,082 1,091,585 
Long-term debt, net and finance leases2,647,147 2,707,531 
Operating lease right-of-use liabilities419,234 389,745 
Deferred tax liabilities191,349 215,582 
Other long-term liabilities223,191 174,822 
Total liabilities4,536,003 4,579,265 
Commitments and contingencies (Notes 2, 11, 13, 14 and 18)
Redeemable noncontrolling interest56,722 42,427 
Equity:  
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding
— — 
Common stock, $0.01 par value; 120,000 shares authorized; 51,338 shares issued and outstanding as of December 30, 2023 and 50,944 shares issued and outstanding as of December 31, 2022
513 509 
Additional paid-in capital1,905,578 1,804,940 
Retained earnings1,887,218 1,432,901 
Treasury stock, at cost, zero shares as of December 30, 2023 and December 31, 2022
— — 
Accumulated other comprehensive loss(196,427)(262,057)
Total equity attributable to common shareholders3,596,882 2,976,293 
Noncontrolling interests (nonredeemable)5,394 4,785 
Total equity3,602,276 2,981,078 
Total liabilities, redeemable noncontrolling interests and equity$8,195,001 $7,602,770 
See Notes to Consolidated Financial Statements.
60
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 Fiscal Year
 202320222021
Cash flows relating to operating activities   
Net income$480,370 $492,608 $398,837 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization314,124 303,870 265,540 
Stock-based compensation72,048 73,617 71,474 
Loss on debt extinguishment and amortization of other financing costs3,967 4,118 29,964 
Deferred income taxes(50,903)(35,884)(24,006)
Long-lived asset impairment charges41,911 5,816 733 
(Gain) loss on venture capital and strategic equity investments, net(97,827)26,775 30,420 
Provision for credit losses18,225 6,706 1,657 
Loss (gain) on divestitures, net961 (123,405)(25,026)
Changes in fair value of contingent consideration arrangements1,810 (3,753)(34,303)
Other, net1,592 21,726 2,567 
Changes in assets and liabilities:   
Trade receivables and contract assets, net(33,434)(150,570)(26,633)
Inventories(62,301)(78,523)(25,159)
Accounts payable(20,427)(2,652)44,901 
Accrued compensation12,447 (42,164)44,304 
Deferred revenue(21,743)57,658 (13,402)
Customer contract deposits(15,564)30,457 16,925 
Other assets and liabilities, net38,642 33,240 2,006 
Net cash provided by operating activities683,898 619,640 760,799 
Cash flows relating to investing activities   
Acquisition of businesses and assets, net of cash acquired(194,785)(283,392)(1,293,095)
Capital expenditures(318,528)(324,733)(228,772)
Purchases of investments and contributions to venture capital investments(54,215)(158,274)(45,555)
Proceeds from sale of investments6,667 4,549 6,532 
Proceeds from sale of businesses, net— 163,275 122,694 
Other, net(2,294)(9,347)264 
Net cash used in investing activities(563,155)(607,922)(1,437,932)
Cash flows relating to financing activities   
Proceeds from long-term debt and revolving credit facility776,353 2,952,430 6,951,113 
Proceeds from exercises of stock options25,597 25,110 45,652 
Payments on long-term debt, revolving credit facility, and finance lease obligations(851,676)(2,932,636)(6,242,877)
Purchase of treasury stock(24,155)(38,651)(40,707)
Payment of debt extinguishment and financing costs— — (38,255)
Payments of contingent consideration(2,711)(10,356)(2,328)
Purchases of additional equity interests, net(4,784)(30,533)— 
Other, net(4,145)(7,761)— 
Net cash (used in) provided by financing activities(85,521)(42,397)672,598 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash8,044 25,579 17,730 
Net change in cash, cash equivalents, and restricted cash43,266 (5,100)13,195 
Cash, cash equivalents, and restricted cash, beginning of period241,214 246,314 233,119 
Cash, cash equivalents, and restricted cash, end of period$284,480 $241,214 $246,314 
See Notes to Consolidated Financial Statements.
61
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(in thousands)

Common stockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive Income (Loss)Treasury StockTotal Equity
Attributable
to Common
Shareholders		Noncontrolling
Interest		Total
Equity
SharesAmountSharesAmount
December 26, 202049,767 $498 $1,627,564 $625,414 $(138,874)— $— $2,114,602 $3,567 $2,118,169 
Net income— — — 390,982 — — — 390,982 2,480 393,462 
Other comprehensive (loss)— — — — (25,866)— — (25,866)— (25,866)
Dividends declared to noncontrolling interest— — — — — — — — (1,885)(1,885)
Adjustment to noncontrolling interest fair value— — (21,312)— — — — (21,312)— (21,312)
Issuance of stock under employee compensation plans861 8 45,639 — — — — 45,647 — 45,647 
Purchase of treasury shares— — — — — 148 (40,707)(40,707)— (40,707)
Retirement of treasury shares(148)(1)(5,061)(35,645)— (148)40,707 — — — 
Stock-based compensation— — 71,474 — — — — 71,474 — 71,474 
December 25, 202150,480 505 1,718,304 980,751 (164,740)— — 2,534,820 4,162 2,538,982 
Net income— — — 486,226 — — — 486,226 2,362 488,588 
Other comprehensive (loss)— — — — (97,317)— — (97,317)— (97,317)
Dividends declared to noncontrolling interest— — — — — — — — (1,739)(1,739)
Adjustment of redeemable noncontrolling interest to redemption value— — (7,507)— — — — (7,507)— (7,507)
Issuance of stock under employee compensation plans594 5 25,100 — — — — 25,105 — 25,105 
Purchase of treasury shares— — — — — 130 (38,651)(38,651)— (38,651)
Retirement of treasury shares(130)(1)(4,574)(34,076)— (130)38,651 — — — 
Stock-based compensation73,617 73,617 — 73,617 
December 31, 202250,944 509 1,804,940 1,432,901 (262,057)— — 2,976,293 4,785 2,981,078 
Net income— — — 474,624 — — — 474,624 2,254 476,878 
Other comprehensive income— — — — 65,630 — — 65,630 — 65,630 
Dividends declared to noncontrolling interest— — — — — — — — (1,645)(1,645)
Adjustment of redeemable noncontrolling interest to redemption value— — 5,694 — — — — 5,694 — 5,694 
Gain on purchase of remaining equity interest of Vital River redeemable noncontrolling interest— — 1,151 — — — — 1,151 — 1,151 
Issuance of stock under employee compensation plans499 5 25,592 — — — — 25,597 — 25,597 
Purchase of treasury shares— — — — — 105 (24,155)(24,155)— (24,155)
Retirement of treasury shares(105)(1)(3,847)(20,307)— (105)24,155 — — — 
Stock-based compensation72,048 72,048 — 72,048 
December 30, 202351,338 $513 $1,905,578 $1,887,218 $(196,427)— $— $3,596,882 $5,394 $3,602,276 
See Notes to Consolidated Financial Statements.

62
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Charles River Laboratories International, Inc. (the Company), together with its subsidiaries, is a full service, non-clinical global drug development partner. The Company has built upon its core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that enable the Company to support its clients from target identification through non-clinical development. The Company also provides a suite of products and services to support its clients’ manufacturing activities.
Principles of Consolidation
The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation.
The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which occurred in fiscal year 2022.
Segment Reporting
The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses.
Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities and utilizing our Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow.
The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.
The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO). In December of 2022, the Company sold the Avian Vaccine Services business (Avian), reported in the Manufacturing segment, which supplied specific-pathogen-free chicken eggs and chickens.
Use of Estimates
The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
63
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.
Newly Adopted Accounting Pronouncements
In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company participates in certain supplier finance programs that are immaterial to the consolidated financial statements and related disclosures.
Newly Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but does not believe there will be a material impact.
In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.
Cash, Cash Equivalents, and Investments
Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments.
Trade Receivables and Contract Assets, Net
The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 3.5% of revenue in fiscal years 2023, 2022, or 2021 or trade receivables as of December 30, 2023 or December 31, 2022.
Fair Value Measurements
The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
64
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy:
•Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,
•Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rate yield curves and foreign currency spot rates,
•Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.
Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:
•Cash equivalents - Valued at market prices determined through third-party pricing services;
•Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;
•Interest rate swap contracts - Valued using market observable inputs, such as interest rate yield curves;
•Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;
•Debt instruments - The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and
•Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes and certain option pricing models.
Inventories
The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell solutions, microbial solutions, and CDMO products. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with certain direct materials, costs of personnel directly involved in the care of the models, and allocation of facility overhead costs. For cell solutions inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions and CDMO inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold.
Property, Plant and Equipment, Net
Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.
Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset.
65
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:
Estimated
Useful Lives
(in years)
LandIndefinite
Buildings and building improvements
10 - 40
Machinery and equipment
3 - 20
Furniture and fixtures
5 - 10
Computer hardware and software
3 - 8
Vehicles
3 - 5
Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned.
When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Business Combinations
The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets and certain biological assets, which can represent a significant portion of the purchase price. The determination of the fair value of intangible and certain biological assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such assets are amortizable or non-amortizable and, if the former, the period and the method by which the asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of assets. Typically, key assumptions include projections of cash flows that arise from identifiable assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets.
In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) and certain biological assets are the most significant identifiable asset acquired. To determine the fair value of these acquired assets, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue, cost of revenue, operating income margins, customer attrition rates, and productivity rates; as well as discount rates based on a market participant’s weighted average cost of capital.
Contingent Consideration
The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets.
Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market.
Divestitures
The Company records divestitures at fair value less cost to sell with any related gain or loss from sale recorded within Other income (expense) on the Company’s consolidated statements of income. If the sale price includes contingent payments, these
66
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
are fair valued using a probability weighted model. If the business divested is part of a reporting unit, goodwill from the reporting unit is reallocated based on the fair value of the divested business compared to the fair value of the reporting unit.
Goodwill and Intangible Assets
Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts.
The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded.
Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values.
Valuation and Impairment of Long-Lived Assets
Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.
Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values.
Long-lived assets to be disposed of are carried at fair value less costs to sell.
Venture Capital Investments
The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance.
Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in Other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information.
Strategic Equity Investments
The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying consolidated statements of income.
67
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Derivative Contracts
The Company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The Company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. The Company uses an interest rate swap to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility.
The Company uses short-term forward currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans. The currency-exchange contracts principally hedge transactions denominated in Canadian dollars and euros. The Company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Life Insurance Contracts
Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. Gains and losses from life insurance contracts are recorded in Other income (expense), net in the accompanying consolidated statements of income. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. The Company held 44 contracts at December 30, 2023 with a face value of $82.4 million and 44 contracts with a face value of $74.5 million at December 31, 2022, which are recorded in Other assets.
Leases
At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments.
The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.
Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.
Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors.
68
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases.
The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements.
Stock-Based Compensation
The Company grants stock options, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period.
For stock options and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable.
The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of RSUs is based on the market value of the Company’s common stock on the date of grant.
Revenue Recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).
To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components.
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year, and recorded within service revenue. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the consolidated financial statements.
69
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date.
The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Cumulative catch-up adjustments to revenue are periodically recorded that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration), or a contract modification.
Income Taxes
The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements carrying amounts and their respective tax basis. The Company measures deferred tax assets and liabilities using the enacted tax rates in effect when the temporary differences are expected to be settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Foreign Currency Contracts
Foreign currency contracts are recorded at fair value in the Company’s consolidated balance sheets and are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loan. Any gains or losses on forward contracts associated with the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity under the Company’s Credit Facility are recognized immediately in Interest expense. Gains or losses incurred on the remeasurement of the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency is recorded in Other (expense) income, net.
70
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Translation of Foreign Currencies
For the Company’s subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive loss, a separate component of equity.
Pension and Other Post-Retirement Benefit Plans
The Company recognizes the funded status of its defined benefit pension and other post-retirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The Company measures plan assets and benefit obligations as of its fiscal year end.
The key assumptions used to calculate benefit obligations and related pension costs include expected long-term rate of return on plan assets, withdrawal and mortality rates, expected rate of increase in employee compensation levels and a discount rate. Assumptions are determined based on the Company’s data and appropriate market indicators, and evaluated each year as of the plan’s measurement date.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the Company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance.
The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and the current employee compensation strategy.
The Company is required to recognize as a component of Other comprehensive income, net of tax, the actuarial gains or losses and prior service costs or credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive income is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
The Company records the service cost component of the net periodic benefit cost within Cost of services provided and Selling, general, and administrative expenses and all other components of net periodic benefit cost within Other (expense) income, net in the consolidated statements of income.
The Company recognizes pension settlement gains or losses in the period when all of the following settlement criteria are met: there is an irrevocable action, the Company is relieved of primary responsibility for a benefit obligation, and significant risks related to the obligation and the assets used to effect the settlement are eliminated.
Earnings Per Share
Basic earnings per share is calculated by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Except where the result would be anti-dilutive to income from continuing operations, diluted earnings per share is computed using the treasury stock method, assuming the exercise of stock options and the vesting of RSUs, or evaluating the performance conditions for PSUs to assess whether the conditions have been met, as well as their related income tax effects.
Treasury Shares
The Company periodically retires treasury shares acquired through share repurchases and returns those shares to the status of authorized but unissued. The Company accounts for treasury stock transactions under the cost method. For each reacquisition of common stock, the number of shares and the acquisition price for those shares is added to the existing treasury stock count and total value. Thus, the average cost per share is re-averaged each time shares are acquired. When treasury shares are retired, the Company allocates the excess of the repurchase price over the par value of shares acquired to both retained earnings and additional paid-in-capital. The portion allocated to additional paid-in-capital is determined by applying a percentage, determined by dividing the number of shares to be retired by the number of shares issued, to the balance of additional paid-in-capital as of the retirement date.
2. ACQUISITIONS AND DIVESTITURES
Fiscal 2023 Acquisition
Noveprim Group
On November 30, 2023, the Company completed the acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest. The
71
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Company had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance. The total consideration allocable to the Noveprim acquisition is $374.8 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $198.8 million which includes a remeasurement gain on the 49% equity investment of $103.2 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $13.8 million. The contingent consideration fair value is estimated using a Monte Carlo Simulation model and the maximum contingent contractual payments are up to $55.0 million based on future performance and milestone achievements from in fiscal years 2023 through 2025. The Company has the call option right to purchase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller. The redemption price for the call/put is fixed and ranges from $47.0 million to $54.0 million depending on when exercised. The noncontrolling interest is classified as a redeemable noncontrolling interest in the mezzanine section of the consolidated balance sheet. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers.
SAMDI Tech, Inc.
On January 27, 2023, the Company acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by the Company of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment.
Fiscal 2022 Acquisition
Explora BioLabs Holdings, Inc.
On April 5, 2022, the Company acquired Explora BioLabs Holdings, Inc. (Explora BioLabs), a provider of contract vivarium research services, providing biopharmaceutical clients with turnkey in vivo vivarium facilities, management and related services to efficiently conduct their early-stage research activities. The acquisition of Explora BioLabs complements the Company’s existing Insourcing Solutions business, specifically the CRADL™ (Charles River Accelerator and Development Lab) footprint, and offers incremental opportunities to partner with an emerging client base, many of which are engaged in cell and gene therapy development. The purchase price of Explora BioLabs was $284.5 million, net of $6.6 million in cash. The acquisition was funded through proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s RMS reportable segment.
Fiscal 2021 Acquisitions
Vigene Biosciences, Inc.
On June 28, 2021, the Company acquired Vigene Biosciences, Inc. (Vigene), a gene therapy CDMO, providing viral vector-based gene delivery solutions. The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The purchase price of Vigene was $323.9 million, net of $2.7 million in cash. Included in the purchase price are contingent payments fair valued at $34.5 million, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $57.5 million based on future performance). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s Manufacturing reportable segment. As of December 30, 2023 and December 31, 2022 the fair value of the contingent consideration was zero as certain financial targets have not and are not expected to be achieved.
Retrogenix Limited
On March 30, 2021, the Company acquired Retrogenix Limited (Retrogenix), an outsourced discovery services provider specializing in bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances the Company’s scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash. Included in the purchase price are contingent payments fair valued at $6.9 million, which is the maximum potential payout, and was based on a probability-weighted approach. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment.
72
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Cognate BioServices, Inc.
On March 29, 2021, the Company acquired Cognate BioServices, Inc. (Cognate), a cell and gene therapy CDMO offering comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain. The acquisition of Cognate establishes the Company as a scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through cGMP production. The purchase price of Cognate was $877.9 million, net of $70.5 million in cash and includes $15.7 million of consideration for an approximate 2% ownership interest not initially acquired, but redeemed in April 2022 with the ultimate payout tied to performance in 2021. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility and senior notes (Senior Notes) issued in fiscal 2021. This business is reported as part of the Company’s Manufacturing reportable segment.
Distributed Bio, Inc.
On December 31, 2020, the Company acquired Distributed Bio, Inc. (Distributed Bio), a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. The acquisition of Distributed Bio expands the Company’s capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development. The purchase price of Distributed Bio was $97.0 million, net of $0.8 million in cash. The total consideration includes $80.8 million cash paid, settlement of $3.0 million in convertible promissory notes previously issued by the Company during prior fiscal years, and $14.1 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $21.0 million based on future performance and milestone achievements over a one-year period). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. During fiscal year 2022, $7.0 million of contingent consideration was paid as certain operational milestones were achieved. As of December 30, 2023, other financial targets associated with the contingent consideration were not met and the fair value of the remaining contingent consideration is zero.
Other Acquisition
On March 3, 2021, the Company acquired certain assets from a distributor that supports the Company’s DSA reportable segment. The purchase price was $35.4 million, which includes $19.5 million in cash paid ($5.5 million of which was paid in fiscal 2020), and $15.9 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $17.5 million based on future performance over a three-year period). The fair value of the net assets acquired included $17.3 million of goodwill, $15.2 million attributed to supplier relationships (to be amortized over a 4-year period), and $3.0 million of property, plant, and equipment. The business is reported as part of the Company’s DSA reportable segment. As of December 30, 2023, the fair value of the contingent consideration was zero as certain operational targets were not achieved.

73
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Purchase price information
The purchase price allocation for acquisitions during fiscal years 2023 and 2022 was as follows:
Noveprim Group(1)
SAMDI Tech, Inc.Explora BioLabs
November 30, 2023January 27, 2023April 5, 2022
(in thousands)
Trade receivables$1,308 $513 $7,679 
Inventories66,500 — — 
Other current assets (excluding cash)3,965 75 1,067 
Property, plant and equipment35,831 593 37,369 
Operating lease right-of-use asset, net104 — 48,613 
Goodwill (2)
172,349 37,129 215,752 
Definite-lived intangible assets9,500 33,070 70,100 
Other long-term assets (3)
167,907 6 556 
Deferred revenue— (43)(3,507)
Other current liabilities (16,378)(351)(15,507)
Operating lease right-of-use liabilities (Long-term)(97)— (57,193)
Deferred tax liabilities(12,984)(8,191)(18,601)
Other long-term liabilities(7,797)— (1,807)
Redeemable noncontrolling interest (4)
(45,374)— — 
Total purchase price allocation$374,834 $62,801 $284,521 
(1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
(2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is deductible for tax purposes.
(3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight year useful life.
(4) Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.
74
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The purchase price allocation for acquisitions during fiscal years 2021 was as follows:
VigeneRetrogenixCognateDistributed Bio
June 28, 2021March 30, 2021March 29, 2021December 31, 2020
(in thousands)
Trade receivables$3,548 $2,266 $18,566 $2,722 
Other current assets (excluding cash)1,657 209 14,128 221 
Property, plant and equipment7,649 400 52,082 2,382 
Operating lease right-of-use asset, net22,507 1,385 34,349 1,586 
Goodwill (1)
239,681 34,489 611,555 71,585 
Definite-lived intangible assets93,900 22,126 270,900 24,540 
Other long-term assets694 — 6,098 469 
Deferred revenue(4,260)(434)(20,539)(1,319)
Other current liabilities (2)
(6,319)(1,141)(45,388)(1,504)
Operating lease right-of-use liabilities (Long-term)(21,220)(1,205)(31,383)(1,123)
Deferred tax liabilities(13,958)(4,174)(32,503)(2,529)
Total purchase price allocation$323,879 $53,921 $877,865 $97,030 
(1) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes.
(2) In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17 million pertaining to indirect state sales taxes. During fiscal year 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period.
The definite-lived intangible assets acquired during fiscal years 2023 and 2022 were as follows:
Noveprim GroupSAMDI Tech, Inc.Explore BioLabs
Definite-Lived Intangible Assets(in thousands)
Client relationships$— $23,400 $64,000 
Other intangible assets9,500 9,670 6,100 
Total definite-lived intangible assets$9,500 $33,070 $70,100 
Weighted Average Amortization Life(in years)
Client relationships— 1513
Other intangible assets774
Total definite-lived intangible assets71212
The definite-lived intangible assets acquired during fiscal years 2021 were as follows:
VigeneRetrogenixCognateDistributed Bio
Definite-Lived Intangible Assets(in thousands)
Client relationships$87,500 $17,340 $257,200 $16,080 
Other intangible assets6,400 4,786 13,700 8,460 
Total definite-lived intangible assets$93,900 $22,126 $270,900 $24,540 
Weighted Average Amortization Life(in years)
Client relationships1213139
Other intangible assets2324
Total definite-lived intangible assets1111137
75
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The transaction and integration costs incurred for fiscal years 2023, 2022 and 2021 were as follows:
202320222021
(in thousands)
Transaction and Integration Costs
Selling, general and administrative expenses$12,379 $8,470 $39,099 
Divestitures
The Company routinely evaluates the strategic fit and fundamental performance of its global businesses, divesting operations that do not meet key business criteria. As part of this ongoing assessment, the Company determined that certain capital could be better deployed in other long-term growth opportunities.
Avian Vaccine Services
On December 20, 2022, the Company sold its Avian Vaccine Services business (Avian) to a private investor group for a purchase price of $167.3 million in cash, subject to certain customary closing adjustments. The Company may also earn up to $30.0 million of contingent payments, which are tied to certain annual results of the Avian business from January 2024 through December 2027. The contingent payments have been fair valued at $10.3 million using a discounted probability weighted model. The Avian business was reported in the Company’s Manufacturing reportable segment. During the fiscal year 2022, the Company recorded a gain on the divestiture of Avian of $123.4 million within Other income (expense) on the Company’s consolidated statements of income.
RMS Japan
On October 12, 2021, the Company sold its RMS Japan operations to The Jackson Laboratory for a purchase price of $70.9 million, which included $7.9 million in cash, $3.8 million pension over funding, and certain post-closing adjustments. During the three months ended December 25, 2021, the Company recorded a gain on the divestiture of the RMS Japan business of $20.0 million, net of costs to sell, a currency translation adjustment, and other adjustments related to certain ongoing arrangements with the buyer, which was included in Other income (expense), net within the Company’s consolidated statements of income. The RMS Japan business was reported in the Company’s RMS reportable segment.
CDMO Sweden
On October 12, 2021, the Company sold its gene therapy CDMO site in Sweden to a private investor group for a purchase price of $59.6 million, net of $0.2 million in cash and other post-closing adjustments that may impact the purchase price. Included in the purchase price are contingent payments fair valued at $15.3 million, which were estimated using a probability weighted model (the maximum contingent contractual payments are up to $25.0 million based on future performance), as well as a purchase obligation of approximately $10.0 million between the parties. During fiscal year 2022 the fair value of the contingent payments receivable was reduced from $15.3 million to $7.5 million, which was the balance as of December 30, 2023, as certain financial targets are not expected to be achieved. CDMO Sweden was acquired in March 2021 as part of the acquisition of Cognate and was reported in the Company’s Manufacturing reportable segment.
76
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The carrying amounts of the major classes of assets and liabilities associated with these divestitures were as follows:
December 19, 2022October 12, 2021
AvianRMS JapanCDMO Sweden
(in thousands)
Assets
Current assets
$30,545 $26,524 $8,187 
Property, plant, and equipment, net24,602 17,379 14,339 
Operating lease right-of-use assets, net611 — 19,733 
Goodwill3,168 4,129 27,764 
Client relationships, net1,629 — 14,089 
Other assets10 3,695 — 
Total assets$60,565 $51,727 $84,112 
Liabilities
Current liabilities$8,139 $8,705 $6,386 
Operating lease right-of-use liabilities331 — 18,221 
Long-term liabilities— 94 — 
Total liabilities$8,470 $8,799 $24,607 
3. REVENUE FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:
Timing of Revenue Recognition:202320222021
(in thousands)
RMS
Services and products transferred over time$377,947 $340,708 $263,659 
Services and products transferred at a point in time414,396 398,467 426,778 
Total RMS revenue792,343 739,175 690,437 
DSA
Services and products transferred over time2,611,564 2,440,646 2,103,415 
Services and products transferred at a point in time4,059 6,670 3,816 
Total DSA revenue2,615,623 2,447,316 2,107,231 
Manufacturing
Services and products transferred over time381,942 371,500 335,745 
Services and products transferred at a point in time339,501 418,069 406,747 
Total Manufacturing revenue721,443 789,569 742,492 
Total revenue$4,129,409 $3,976,060 $3,540,160 
77
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Contract Balances from Contracts with Customers
The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:
December 30, 2023December 31, 2022
(in thousands)
Assets from contracts with customers
Client receivables$578,077 $559,410 
Unbilled revenue228,020 204,258 
Total806,097 763,668 
Less: Allowance for credit losses(25,722)(11,278)
Trade receivables and contract assets, net$780,375 $752,390 
Liabilities from contracts with customers
Current deferred revenue$241,820 $264,259 
Long term deferred revenue (included in Other long-term liabilities)30,919 25,795 
Customer contract deposits (included in Other current-liabilities)85,554 91,640 
The Company recognized substantially all of the current contract assets and liabilities balances at December 31, 2022 and December 25, 2021 in revenues during fiscal years 2023 and 2022, respectively.
When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $41 million and $54 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively. Net provisions were $18.2 million, $6.7 million, and $1.7 million in fiscal years 2023, 2022, and 2021, respectively.
Transaction Price Allocated to Future Performance Obligations
The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of December 30, 2023. Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed and service revenue recognized in accordance with ASC 842, “Leases”. The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of December 30, 2023 was $986.0 million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately 50% of which is expected to occur within the next twelve months and the remainder recognized thereafter during the remaining contract term.
Other Performance Obligations
As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year.
202320222021
(in thousands)Affected Line Item in the Consolidated Statements of Income
Lease revenue$93,103 $60,118 $18,118 Service revenue
78
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
4. SEGMENT AND GEOGRAPHIC INFORMATION
The Company’s three reportable segments are RMS, DSA, and Manufacturing. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker.
The following table presents revenue and other financial information by reportable segment:
202320222021
(in thousands)
RMS   
Revenue$792,343 $739,175 $690,437 
Operating income154,666 160,410 166,814 
Depreciation and amortization55,570 49,274 39,123 
Capital expenditures52,819 44,136 61,188 
DSA 
Revenue$2,615,623 $2,447,316 $2,107,231 
Operating income606,076 532,889 406,978 
Depreciation and amortization174,719 179,465 177,254 
Capital expenditures204,891 189,563 101,477 
Manufacturing
Revenue$721,443 $789,569 $742,492 
Operating income88,329 167,084 246,390 
Depreciation and amortization79,982 72,950 46,195 
Capital expenditures58,134 87,084 58,877 
Unallocated corporate
Operating income (1)
$(231,810)$(209,408)$(230,320)
Depreciation and amortization3,853 2,181 2,968 
Capital expenditures2,684 3,950 7,230 
Consolidated
Revenue$4,129,409 $3,976,060 $3,540,160 
Operating income617,261 650,975 589,862 
Depreciation and amortization314,124 303,870 265,540 
Capital expenditures318,528 324,733 228,772 
(1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.
Revenue and long-lived assets by geographic area are as follows:
U.S.EuropeCanadaAsia PacificOtherConsolidated
(in thousands)
2023
Revenue$2,347,486 $1,076,937 $487,305 $200,833 $16,848 $4,129,409 
Long-lived assets964,176 407,375 157,483 74,605 36,102 1,639,741 
2022      
Revenue$2,342,158 $1,032,125 $398,982 $192,837 $9,958 $3,976,060 
Long-lived assets896,235 349,361 135,300 82,778 1,981 1,465,655 
2021     
Revenue$1,934,404 $1,036,465 $339,098 $222,902 $7,291 $3,540,160 
Long-lived assets755,400 323,405 145,274 64,864 2,125 1,291,068 
Included in the Other category above are operations located in Brazil, Israel, and Mauritius. Revenue represents sales originating in entities physically located in the identified geographic area. Long-lived assets consist of property, plant, and equipment, net.
79
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
5. SUPPLEMENTAL CASH FLOW INFORMATION
Fiscal Year
202320222021
(in thousands)
Cash paid for income taxes$90,374 $75,909 $75,441 
Cash paid for interest132,101 100,754 70,775 
Non-cash investing and financing activities:
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities$69,139 $88,612 $72,043 
Assets acquired under finance leases— 8,179 1,567 
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
December 30, 2023December 31, 2022
(in thousands)
Supplemental cash flow information:
Cash and cash equivalents$276,771 $233,912 
Restricted cash included in Other current assets5,803 6,192 
Restricted cash included in Other assets1,906 1,110 
Cash, cash equivalents, and restricted cash, end of period$284,480 $241,214 

6. INVENTORY
The composition of inventories is as follows:
December 30, 2023December 31, 2022
(in thousands)
Raw materials and supplies$42,296 $38,892 
Work in process59,727 48,367 
Finished products278,236 168,550 
Inventories$380,259 $255,809 
7. PROPERTY, PLANT AND EQUIPMENT, NET
The composition of property, plant and equipment, net is as follows:
December 30, 2023December 31, 2022
(in thousands)
Land$79,546 $58,192 
Buildings (1)
1,053,915 963,717 
Machinery and equipment (1)
984,867 850,353 
Leasehold improvements366,556 294,275 
Furniture and fixtures31,284 27,317 
Computer hardware and software (1)
254,413 227,797 
Vehicles (1)
6,746 5,421 
Construction in progress197,723 199,713 
Total2,975,050 2,626,785 
Less: Accumulated depreciation(1,335,309)(1,161,130)
Property, plant and equipment, net$1,639,741 $1,465,655 
(1) These balances include assets under finance leases. See Note 17. Leases.
Depreciation expense in fiscal years 2023, 2022 and 2021 was $176.7 million, $157.3 million and $140.7 million, respectively.
80
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
8. VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS
Venture capital investments are summarized below:
December 30, 2023December 31, 2022December 25, 2021
(in thousands)
Beginning balance$129,012 $149,640 $197,100 
Capital contributions17,410 14,485 18,023 
Distributions(15,685)(9,861)(40,205)
Gain (loss)(10,263)(24,398)(23,201)
Foreign currency translation684 (854)(2,077)
Ending balance$121,158 $129,012 $149,640 
The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. Strategic investments are summarized below:
December 30, 2023December 31, 2022December 25, 2021
(in thousands)
Beginning balance$182,590 $51,712 $24,704 
Purchase of investments34,028 142,477 35,540 
Distributions(9,381)(2,732)(789)
Gain (loss) (1)
108,090 (2,377)(7,219)
Reduction for acquisition of entities (1)
(197,753)— — 
Foreign currency translation5,079 (6,490)(524)
Ending balance$122,653 $182,590 $51,712 
(1) Refer to Note 2. Acquisitions for further discussion on the Noveprim and SAMDI acquisitions
9. FAIR VALUE
Assets and liabilities measured at fair value on a recurring basis are summarized below:
 December 30, 2023
 Level 1Level 2Level 3Total
Current assets measured at fair value:(in thousands)
Cash equivalents$— $29 $— $29 
Other assets:
Life insurance policies— 40,912 40,912 
Interest rate swap— 966 — 966 
Total assets measured at fair value$— $41,907 $— $41,907 
Other long-term liabilities measured at fair value:
Contingent consideration— — 33,265 33,265 
Interest rate swap— — — — 
Total liabilities measured at fair value$— $— $33,265 $33,265 
81
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 December 31, 2022
 Level 1Level 2Level 3Total
Current assets measured at fair value:(in thousands)
Cash equivalents$— $78 $— $78 
Other assets:
Life insurance policies— 34,527 — 34,527 
Total assets measured at fair value$— $34,605 $— $34,605 
Accrued liabilities measured at fair value:
Contingent consideration$— $— $13,431 $13,431 
Other long-term liabilities measured at fair value:
Contingent consideration— — — — 
Interest rate swap— 1,523 — 1,523 
Total liabilities measured at fair value$— $1,523 $13,431 $14,954 
During fiscal years 2023 and 2022, there were no transfers between fair value levels.
Contingent Consideration
The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions.
Fiscal Year
202320222021
(in thousands)
Beginning balance$13,431 $37,244 $2,328 
Additions33,265 3,838 71,559 
Payments(15,130)(11,476)(2,889)
Total gains or losses (realized/unrealized):
Adjustment of previously recorded contingent liability1,810 (15,340)(33,386)
Foreign currency translation(111)(835)(368)
Ending balance$33,265 $13,431 $37,244 
The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $98 million, of which the value accrued as of December 30, 2023 is approximately $33 million. The weighted average probability of achieving the maximum target is approximately 34%. The average volatility and weighted average cost of capital are approximately 30% and 12%, respectively.
Cash Flow Hedge
The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In November 2022, the Company entered into an interest rate swap with a notional amount of $500 million to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.700%.
In March 2023 and in conjunction with an amendment of the Credit Agreement (Second Amendment), the Company modified the variable rate on its interest rate swap from 1-month LIBOR to 1-month adjusted term SOFR. Effective with the modification, the Company will pay a fixed rate of 4.65% on its swap maturing November 2, 2024. The Company elected to apply the optional expedient in ASC 848, Reference Rate Reform, in connection with modifying its interest rate swap from LIBOR to SOFR that enabled it to consider the modification a continuation of the existing contract. As a result, the transition did not have an impact on the Company’s hedge accounting or a material impact to the Company’s financial statements.
Debt Instruments
The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other
82
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.
The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below:
December 30, 2023December 31, 2022
Book ValueFair ValueBook ValueFair Value
(in thousands)
4.25% Senior Notes due 2028
$500,000 $478,100 $500,000 $460,450 
3.75% Senior Notes due 2029
500,000 458,100 500,000 442,200 
4.00% Senior Notes due 2031
500,000 449,350 500,000 432,500 
10. GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:
RMS
DSA(1)
ManufacturingTotal
(in thousands)
December 25, 2021$283,524 $1,472,506 $955,851 $2,711,881 
Acquisitions215,752 — (592)215,160 
Divestitures— — (3,168)(3,168)
Foreign exchange(1,566)(38,905)(33,499)(73,970)
December 31, 2022497,710 1,433,601 918,592 2,849,903 
Acquisitions— 209,478 — 209,478 
Divestitures— — — — 
Foreign exchange(236)19,355 16,545 35,664 
December 30, 2023$497,474 $1,662,434 $935,137 $3,095,045 
(1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.
Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2023, 2022 and 2021, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired. After completing the quantitative testing for fiscal year 2023, all reporting units exceeded the carrying value by a significant amount except for the Biologics Solutions reporting unit which had a fair value that exceeded its carrying value by approximately 20%.
The increase in goodwill during fiscal year 2023 related to the acquisitions of Noveprim and SAMDI in the DSA reportable segment. The increase in goodwill during fiscal year 2022 related to the acquisition of Explora in the RMS reportable segment, partially offset by a decrease due to the Avian divestiture impacting the Manufacturing reportable segment.
83
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Intangible Assets, Net
The following table displays intangible assets, net by major class:
 December 30, 2023December 31, 2022
GrossAccumulated
Amortization 		NetGrossAccumulated
Amortization		Net
(in thousands)
Client relationships$1,528,780 $(721,322)$807,458 $1,491,926 $(591,417)$900,509 
Technology142,190 (111,764)30,426 129,626 (101,655)27,971 
Backlog$3,100 $(2,177)$923 $15,236 $(12,512)$2,724 
Trademarks and trade names11,878 (4,568)7,310 12,617 (4,410)8,207 
Other43,611 (25,677)17,934 37,985 (22,121)15,864 
Intangible assets$1,729,559 $(865,508)$864,051 $1,687,390 $(732,115)$955,275 
The decrease in intangible assets, net during fiscal year 2023 related primarily to normal amortization over the useful lives, partially offset by the acquisitions of Noveprim and SAMDI.
Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2023, 2022 and 2021 was $137.4 million, $146.6 million and $124.9 million, respectively. As of December 30, 2023, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:
Fiscal YearAmortization Expense
(in thousands)
2024$129,153 
2025$120,995 
2026$115,757 
2027$103,164 
2028$91,315 
11. DEBT AND OTHER FINANCING ARRANGEMENTS
Long-term debt, net and finance leases consists of the following:
December 30, 2023December 31, 2022
(in thousands)
Revolving facility$1,129,243 $1,197,586 
4.25% Senior Notes due 2028
500,000 500,000 
3.75% Senior Notes due 2029
500,000 500,000 
4.00% Senior Notes due 2031
500,000 500,000 
Other debt9,575 1,594 
Finance leases 28,550 30,646 
Total debt and finance leases2,667,368 2,729,826 
Less:
Current portion of long-term debt3,172 1,347 
Current portion of finance leases2,398 2,330 
Current portion of long-term debt and finance leases5,570 3,677 
Long-term debt and finance leases2,661,798 2,726,149 
Debt discount and debt issuance costs(14,651)(18,618)
Long-term debt, net and finance leases$2,647,147 $2,707,531 
As of December 30, 2023 and December 31, 2022, the weighted average interest rate on the Company’s debt was 4.93% and 4.58%, respectively. In fiscal year 2021, the Company prepaid $500 million of Senior Notes due in 2026 along with $21 million of related debt extinguishment costs and $13 million of accrued interest using proceeds from additional senior notes issued on the same day. The payment of the 2026 Senior Notes was accounted for as a debt extinguishment. Approximately $21 million
84
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
of debt extinguishment costs and $5 million of deferred financing costs write-offs were recorded in Interest expense during fiscal year 2021.
Revolving facility (Credit Facility)
The Company has a revolving credit facility “Credit Facility” that provides for up to $3.0 billion of multi-currency revolving credit. The Credit Facility has a maturity date of April 2026, with no required scheduled payment before that date. The interest rates applicable to the revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at the Company’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1.0%) or the adjusted SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon the Company’s leverage ratio. In March 2023 and in conjunction with the Second Amendment the Company modified the variable rate on the Credit Facility from adjusted LIBOR to adjusted term SOFR. All outstanding U.S. dollar borrowings remained at adjusted LIBOR through their respective interest reset periods in April 2023 and were then set to term SOFR.
The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0. As of December 30, 2023 and December 31, 2022, the Company was compliant with all financial covenants under the Credit Facility. The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company.
2028 Senior Notes
In fiscal year 2019, the Company issued $500 million of 4.25% Senior Notes due in 2028 (2028 Senior Notes) in an unregistered offering. Interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1.
2029 Senior Notes and 2031 Senior Notes
In fiscal year 2021, the Company issued $1 billion of debt split between $500 million of 3.75% Senior Notes due in 2029 (2029 Senior Notes), and $500 million of 4.00% Senior Notes due in 2031 (2031 Senior Notes), in an unregistered offering. Interest on the 2029 and 2031 Senior Notes is payable semi-annually on March 15 and September 15. Approximately $10 million of deferred financing costs were capitalized as part of this debt issuance. Proceeds from the 2029 and 2031 Senior Notes were used as follows: prepay the $500 million 2026 Senior Notes, $21 million of debt extinguishment costs, and $13 million of accrued interest; prepay the $146.9 million remaining term loan; pay down $135 million of the revolving facility; and pay for a portion of the Cognate acquisition, which occurred on March 29, 2021.
Foreign currency transactions
During fiscal years 2022 and 2021, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility, which were between $250 million and $400 million each. To limit this foreign currency exposure, the Company entered into foreign exchange forward contracts, which are not designated as hedging instruments. The gains and losses incurred on these transactions were as follows:
December 31, 2022December 25, 2021Affected Line Item in the Consolidated Statements of Income
(in thousands)(in thousands)
Gain (loss) on foreign exchange forward contract$49,712 $34,131 Interest expense
Gain (loss) on foreign debt remeasurement(46,529)(31,830)Other income (expense)
The Company did not have any U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility during fiscal year 2023.
85
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Principal Maturities
Principal maturities of existing debt for the periods set forth in the table below, are as follows:
Principal
(in thousands)
2024$3,172 
2025589 
20261,129,772 
20271,947 
2028501,947 
Thereafter1,001,391 
Total$2,638,818 
Letters of Credit
As of December 30, 2023 and December 31, 2022, the Company had $21.6 million and $18.6 million, respectively, in outstanding letters of credit.
12. EQUITY AND NONCONTROLLING INTERESTS
Earnings Per Share
The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:
Fiscal Year
202320222021
(in thousands)
Numerator:
Net income$480,370 $492,608 $398,837 
Less: Net income attributable to noncontrolling interests5,746 6,382 7,855 
Net income attributable to common shareholders$474,624 $486,226 $390,982 
Denominator:
Weighted-average shares outstanding—Basic51,227 50,812 50,293 
Effect of dilutive securities:
Stock options, restricted stock units and performance share units224 489 1,132 
Weighted-average shares outstanding—Diluted51,451 51,301 51,425 
Anti-dilutive common stock equivalents(1)
652 560 152 
(1) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Treasury Shares
The Company’s Board of Directors has authorized a $1.3 billion stock repurchase program. As of December 30, 2023, the Company had $129.1 million remaining on the authorized stock repurchase program.
The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired shares of 0.1 million in fiscal years 2023 and 2022, for $24.2 million and $38.7 million, respectively, from such netting.
Prior to the end of fiscal years 2023, 2022 and 2021, the Company’s Board of Directors approved the cancellation and return to the Company’s authorized and unissued capital stock, reducing treasury stock on the Company’s consolidated balance sheet. The Company allocated the excess of the repurchase price over the par value of shares acquired to reduce both retained earnings and additional paid-in capital.
86
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Accumulated Other Comprehensive Income (Loss)
Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:
Foreign Currency Translation Adjustment and OtherPension and Other Post-Retirement Benefit Plans
Net Unrealized Gain (Loss) on Cash Flow Hedge
Total
(in thousands)
December 26, 2020$(73,884)$(64,990)$— $(138,874)
Other comprehensive income before reclassifications (1)
(30,316)(1,193)— (31,509)
Amounts reclassified from accumulated other comprehensive income— 1,678 — 1,678 
Net current period other comprehensive (loss) income(30,316)485 — (29,831)
Income tax (benefit) expense(6,027)2,062 — (3,965)
December 25, 2021(98,173)(66,567)— (164,740)
Other comprehensive income before reclassifications (1)
(125,507)24,471 (1,523)(102,559)
Amounts reclassified from accumulated other comprehensive income — 3,337 — 3,337 
Net current period other comprehensive (loss) income(125,507)27,808 (1,523)(99,222)
Income tax (benefit) expense(5,895)4,355 (365)(1,905)
December 31, 2022(217,785)(43,114)(1,158)(262,057)
Other comprehensive (loss) income before reclassifications (1)
71,851 (5,376)2,490 68,965 
Amounts reclassified from accumulated other comprehensive income — 736 — 736 
Net current period other comprehensive (loss) income71,851 (4,640)2,490 69,701 
Income tax (benefit) expense4,065 (587)593 4,071 
December 30, 2023$(149,999)$(47,167)$739 $(196,427)
(1) The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real.
Nonredeemable Noncontrolling Interest
The Company has an investment in an entity whose financial results are consolidated in the Company’s financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying consolidated balance sheets. The activity within the nonredeemable noncontrolling interest (net income less dividends declared) during fiscal years 2023, 2022, and 2021 was not significant.
Redeemable Noncontrolling Interests
The Company holds a 90% ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at a fixed redemption value that ranges from $47.0 million to $54.0 million depending on when exercised, which represents a derivative embedded within the equity instrument. The Company has the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing the 41% equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $54.0 million. Additionally, the 10% noncontrolling interest holders may receive a dividend disproportionate to their equity ownership, which has an approximate fair value of $8 million. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the accreted redemption value using the interest method and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 10% interest, the noncontrolling interest is classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities.
87
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The Company held a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 31, 2022. The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. The redeemable noncontrolling interest was measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. The amount that the Company could be required to pay to purchase the remaining 8% equity interest was not limited. During the fourth quarter of fiscal 2023, the Company acquired the remaining 8% and as of December 2023, has paid $4.8 million of the total $24.4 million due. The remaining purchase price payable has been reclassified from the mezzanine section to Accrued liabilities on the consolidated balance sheet and is expected to be paid during fiscal year 2024.

In 2020, the Company acquired an 80% equity interest in a subsidiary, which included a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million, resulting in a remaining noncontrolling interest of 10%. Beginning in 2024, the Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at its appraised value. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest ($11.0 million as of December 30, 2023) or a predetermined floor, which represents a derivative embedded within the equity instrument. The amount that the Company could be required to pay to purchase the remaining 10% equity interest is not limited.
The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests:
Fiscal Year
202320222021
(in thousands)
Beginning balance$42,427 $53,010 $25,499 
Acquisition resulting in a 10% noncontrolling interest
45,374 — — 
Additional purchases reducing noncontrolling interest percentage
(24,148)(15,000)— 
Adjustments to redemption value(5,694)7,506 21,312 
Net income
3,492 4,020 5,375 
Dividends(2,378)(3,525)— 
Foreign currency translation(1,200)(3,584)824 
Other(1,151)— — 
Ending balance$56,722 $42,427 $53,010 
88
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
13. INCOME TAXES
The components of income from operations before income taxes and the related provision for income taxes are presented below:
 Fiscal Year
 202320222021
(in thousands)
Income before income taxes:   
U.S. $185,667 $280,075 $129,598 
Non-U.S. 395,617 342,912 351,112 
Total income before income taxes$581,284 $622,987 $480,710 
Income tax provision (benefit):   
Current:   
Federal$49,090 $75,052 $32,728 
Foreign85,356 68,644 60,197 
State17,817 19,790 9,257 
Total current152,263 163,486 102,182 
Deferred:   
Federal(42,987)(27,230)(27,486)
Foreign779 (1,134)13,891 
State(9,141)(4,743)(6,714)
Total deferred(51,349)(33,107)(20,309)
Total provision for income taxes$100,914 $130,379 $81,873 
Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows:
Fiscal Year
202320222021
U.S. statutory income tax rate21.0 %21.0 %21.0 %
Foreign tax rate differences1.5 0.4 0.1 
State income taxes, net of federal tax benefit1.7 2.3 0.8 
Non-deductible compensation0.8 0.9 1.2 
Research tax credits and enhanced deductions(5.0)(3.8)(5.0)
Stock-based compensation(0.1)(1.4)(4.3)
Enacted tax rate changes(0.1)0.4 3.0 
Tax on unremitted earnings1.7 1.6 1.8 
Impact of tax uncertainties(0.3)(1.3)0.7 
Impact of acquisitions and restructuring(4.2)2.0 (1.6)
Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)0.2 (0.8)— 
Global intangible low-taxed income1.5 0.8 1.3 
Foreign-derived intangible income(1.4)(1.4)(1.2)
Other0.1 0.2 (0.8)
Effective income tax rate17.4 %20.9 %17.0 %
89
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The components of deferred tax assets and liabilities are as follows:
December 30, 2023December 31, 2022
(in thousands)
Deferred tax assets:
Compensation$30,167 $26,341 
Accruals and reserves19,121 16,938 
Net operating loss and credit carryforwards379,959 382,932 
Operating lease liability117,449 100,156 
Capitalized R&D Expenditures
35,673 18,616 
Other12,190 8,516 
Valuation allowance(304,248)(294,753)
Total deferred tax assets290,311 258,746 
Deferred tax liabilities:
Goodwill and other intangibles(231,020)(256,234)
Depreciation related(57,791)(48,965)
Venture capital investments(8,350)(12,007)
Tax on unremitted earnings(25,080)(16,407)
Right-of-use assets(102,620)(91,716)
Other(16,520)(7,737)
Total deferred tax liabilities(441,381)(433,066)
Net deferred taxes$(151,070)$(174,320)
The Company has recognized its deferred tax assets on the belief that it is more likely than not that they will be realized. Exceptions primarily relate to deferred tax assets for net operating losses in Luxembourg, Sweden, state research and development tax credits, certain capital losses, and fixed assets in the U.K.
A reconciliation of the Company’s beginning and ending valuation allowance are as follows:
Fiscal Year
202320222021
Beginning balance$294,753 $315,645 $334,845 
Additions (reductions) charged to income tax provision, net963 1,929 1,023 
Additions due to acquisitions— — 7,747 
Reductions due to divestitures, restructuring— (5,337)(4,706)
Currency translation and other8,532 (17,484)(23,264)
Ending balance$304,248 $294,753 $315,645 
As of December 30, 2023, the Company had tax-effected deferred tax assets for net operating loss carryforwards of $336.0 million, as compared to $336.6 million as of December 31, 2022. Of this amount, $25.9 million are definite-lived and begin to expire in 2027, and the remainder of $310.1 million can be carried forward indefinitely. The Company has deferred tax assets for tax credit carryforwards of $41.5 million. The entire $41.5 million are definite-lived and begin to expire after 2039. Additionally, the Company records a benefit to operating income for research and development and other credits in Quebec, France, the Netherlands, and the U.K. related to its DSA facilities.
90
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows:
Fiscal Year
202320222021
(in thousands)
Beginning balance$23,242 $32,592 $24,970 
Additions to tax positions for current year3,093 4,756 9,544 
Additions to tax positions for prior years721 962 2,476 
Reductions to tax positions for prior years(4,058)(1,420)(1,330)
Settlements— (10,514)(1,870)
Expiration of statute of limitations(296)(3,134)(1,198)
Ending balance$22,702 $23,242 $32,592 
The $0.5 million decrease in unrecognized income tax benefits during fiscal year 2023 as compared to the corresponding period in 2022 is primarily attributable to prior year reductions to Canadian Scientific Research and Experimental Development (SR&ED) credits, partially offset by an additional year of SR&ED credit additions. The amount of unrecognized income tax benefits that, if recognized, would favorably impact the effective tax rate was $20.3 million as of December 30, 2023 and $20.3 million as of December 31, 2022. It is reasonably possible as of December 30, 2023 that the liability for unrecognized tax benefits for the uncertain tax position will decrease by approximately $5.2 million over the next twelve-month period. The Company continues to recognize interest and penalties related to unrecognized income tax benefits in income tax expense. The total amount of cumulative accrued interest related to unrecognized income tax benefits as of December 30, 2023 and December 31, 2022 was $1.3 million and $1.4 million, respectively. Interest expense recorded as a component of income taxes was immaterial for all periods. There were no accrued penalties related to unrecognized income tax benefits as of December 30, 2023 or as of December 31, 2022.
The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2019.
The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, France, and India. The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.
Prepaid income tax of $59.7 million and $88.6 million has been presented within Other current assets in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively. Accrued income taxes of $38.8 million and $39.9 million have been presented within Other current liabilities in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively.
14. EMPLOYEE BENEFIT PLANS
Pension Plans
The Charles River Pension Plan (U.K. Pension Plan) is a defined contribution and defined benefit pension plan covering certain U.K. employees. Benefits are based on participants’ final pensionable salary and years of service. Participants’ rights vest immediately. The plan was previously amended to exclude new participants from joining the defined benefit section of the plan and a defined contribution section was established for new entrants. Contributions under the defined contribution plan are determined as a percentage of gross salary. Additionally, the U.K. Pension Plan was amended such that the members of the defined benefit section of the plan ceased to accrue additional benefits; however, their benefits continue to be adjusted for changes in their final pensionable salary or a specified inflation index, as applicable. During fiscal 2023, the Company made no contributions to the U.K. Pension Plan. As of fiscal 2023 year-end, this plan was in a funded status of $35.7 million.
During 2022, the Company terminated a non-contributory defined benefit plan that covered certain employees in Canada (Canada Pension Plan). Upon settlement of the pension liability in fiscal year 2022, the Company recognized a $1.0 million loss related to the net periodic benefit cost recorded in Other expense in the consolidated statements of income.
In addition, the Company has several defined benefit plans in certain other countries in which it maintains an operating presence, including Canada, France, Germany, Italy, Mauritius, Netherlands, and Japan.
The net periodic benefit cost (income) associated with these plans for fiscal years 2023, 2022 and 2021 totaled $2.8 million, $0.1 million and $0.5 million, respectively.
91
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Charles River Laboratories Deferred Compensation Plan and Executive Supplemental Life Insurance Retirement Plan
The Company maintains a non-qualified deferred compensation plan, known as the Charles River Laboratories Deferred Compensation Plan (DCP), which allows a select group of eligible employees to defer a portion of their compensation. At the present time, no contributions are credited to the DCP, except as set forth below. Participants must specify the distribution date for deferred amounts at the time of deferral, in accordance with applicable IRS regulations. Generally, amounts may be paid in lump sum or installments upon retirement or termination of employment, or later if the employee terminates employment after age 55 and before age 65. Amounts may also be distributed during employment, subject to a minimum deferral requirement of three years.
The Company provides certain active employees an annual contribution into their DCP account of 10% of the employee’s base salary plus the lesser of their target annual bonus or actual annual bonus.
In addition to the DCP, certain officers and key employees also participate, or in the past participated, in the Company’s Executive Supplemental Life Insurance Retirement Plan (ESLIRP), which is a non-funded, non-qualified arrangement. Annual benefits under this plan will equal a percentage of the highest five consecutive years of compensation, offset by amounts payable under the U.S. Pension Plan and Social Security. In connection with the establishment of the DCP, certain active ESLIRP participants, who agreed to convert their accrued ESLIRP benefit to a comparable deferred compensation benefit, discontinued their direct participation in the ESLIRP. Instead, the present values of the accrued benefits of ESLIRP participants were credited to their DCP accounts, and future accruals are converted to present values and credited to their DCP accounts annually.
The net periodic benefit cost associated with these plans for fiscal years 2023, 2022 and 2021 totaled $2.8 million, $4.3 million and $4.3 million, respectively.
The Company has invested in several corporate-owned key-person life insurance policies with the intention of using these investments to fund the ESLIRP and the DCP. Participants have no interest in any such investments. As of December 30, 2023 and December 31, 2022, the cash surrender value of these life insurance policies were $48.4 million and $41.9 million, respectively.
92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans:
 December 30, 2023December 31, 2022
(in thousands)
Change in projected benefit obligations:  
Benefit obligation at beginning of year$205,551 $372,599 
Service cost2,474 3,213 
Interest cost9,941 6,140 
Benefit payments(6,239)(6,469)
Curtailment— (2,477)
Settlements— (11,939)
Transfer in due to acquisition1,106 — 
Actuarial (gain) loss3,600 (134,923)
Effect of foreign exchange8,442 (20,593)
Benefit obligation at end of year$224,875 $205,551 
Change in fair value of plan assets:
Fair value of plan assets at beginning of year$192,540 $335,631 
Actual return on plan assets5,578 (105,749)
Employer contributions1,744 4,558 
Settlements— (11,939)
Transfer in due to acquisition181 — 
Benefit payments(6,239)(6,469)
Effect of foreign exchange9,853 (23,492)
Fair value of plan assets at end of year$203,657 $192,540 
Net balance sheet liability$21,218 $13,011 
Amounts recognized in balance sheet:
Noncurrent assets$36,957 $39,185 
Current liabilities1,164 1,151 
Noncurrent liabilities57,011 51,045 
Actuarial gains and losses are driven by changes in economic assumptions, principally discount rates. Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows:
Fiscal Year
 20232022
(in thousands)
Net actuarial loss$58,855 $54,509 
Net prior service cost (credit)(121)(585)
Net amount recognized$58,734 $53,924 
The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows:
 December 30, 2023December 31, 2022
(in thousands)
Accumulated benefit obligation$54,310 $48,414 
Fair value of plan assets2,824 2,258 
93
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows:
 December 30, 2023December 31, 2022
(in thousands)
Projected benefit obligation$61,671 $55,304 
Fair value of plan assets3,496 3,108 
Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows:
Fiscal Year
 202320222021
(in thousands)
Service cost$2,474 $3,213 $3,455 
Interest cost9,941 6,140 5,492 
Expected return on plan assets(7,556)(7,322)(8,058)
Amortization of prior service credit(464)(506)(531)
Amortization of net loss1,231 2,869 4,528 
Net periodic benefit cost5,626 4,394 4,886 
Settlement— 981 (2,320)
Total benefit cost$5,626 $5,375 $2,566 
Assumptions
Weighted-average assumptions used to determine projected benefit obligations are as follows:
 December 30, 2023December 31, 2022
Discount rate4.7 %4.8 %
Rate of compensation increase3.2 %3.2 %
The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations.
Weighted-average assumptions used to determine net periodic benefit cost are as follows:
 December 30, 2023December 31, 2022December 25, 2021
Discount rate4.8 %1.8 %1.5 %
Expected long-term return on plan assets3.9 %2.4 %2.5 %
Rate of compensation increase3.2 %3.7 %3.0 %
In fiscal years 2023 and 2022, new mortality improvement scales were issued in the U.S. and the United Kingdom (U.K.) reflecting a decline in longevity projection from previous releases the Company adopted, which decreased the Company’s benefit obligations by $3.5 million and $0.2 million as of December 30, 2023 and December 31, 2022, respectively.
Plan Assets
The Company invests its pension assets with the objective of achieving a total long-term rate of return sufficient to fund future pension obligations and to minimize future pension contributions. The Company is willing to tolerate a commensurate level of risk to achieve this objective. The Company controls its risk by maintaining a diversified portfolio of asset classes. Plan assets did not include any of the Company’s common stock as of December 30, 2023 or December 31, 2022. The weighted-average target asset allocations are 7.0% to equity securities, 84.1% to fixed income securities and 8.9% to other securities.
94
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The fair value of the Company’s pension plan assets by asset category are as follows:
 December 30, 2023December 31, 2022
Level 1 Level 2Level 3Total Level 1 Level 2Level 3Total
(in thousands)
Cash and cash equivalents$446 $798 $— $1,244 $362 $5,153 $— $5,515 
Equity securities (1)
— 10,701 — 10,701 — 9,308 — 9,308 
Debt securities (2)
— 144,822 — 144,822 — 123,638 — 123,638 
Mutual funds (3)
9,207 10,368 — 19,575 8,380 9,372 — 17,752 
Other (4)
— 27,254 61 27,315 — 36,268 59 36,327 
Total$9,653 $193,943 $61 $203,657 $8,742 $183,739 $59 $192,540 
(1) This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end.
(2) This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations.
(3) This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end.
(4) This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end.
The activity within the Level 3 pension plan assets was not significant during the periods presented.
During fiscal year 2023, the Company did not contribute to the pension plans and expects to make $2.0 million in contributions in fiscal year 2024. During fiscal year 2023, the Company paid $1.7 million directly to certain participants outside of plan assets.
Expected benefit payments are estimated using the same assumptions used in determining the Company’s benefit obligation as of 2023. Benefit payments will depend on future employment and compensation levels, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for fiscal years 2029 through 2033, are as follows.
Fiscal YearPension Plans
(in thousands)
2024$6,558 
20256,703 
202646,898 
20277,633 
20288,843 
2029-203355,416 
Charles River Laboratories Employee Savings Plan
The Charles River Laboratories Employee Savings Plan is a defined contribution plan in the form of a qualified 401(k) plan in which substantially all U.S. employees are eligible to participate upon employment. The plan contains a provision whereby the Company matches a percentage of employee contributions. During fiscal years 2023, 2022 and 2021, the costs associated with this defined contribution plan totaled $31.6 million, $28.8 million and $24.0 million, respectively.
15. STOCK-BASED COMPENSATION
The Company has stock-based compensation plans under which employees and non-employee directors are granted stock-based awards such as stock options, RSUs, and PSUs.
During fiscal years 2023, 2022 and 2021, the primary share-based awards and their general terms and conditions are as follows:
•Stock options, which entitle the holder to purchase a specified number of shares of common stock at an exercise price equal to the closing market price of common stock on the date of grant; typically vest over 4 years; and typically expire 5 or 10 years from date of grant.
95
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
•RSUs, which represent an unsecured promise to grant at no cost a set number of shares of common stock upon the completion of the vesting schedule, and principally vest over 4 years. With respect to RSUs, recipients are not entitled to cash dividends and have no voting rights on the stock during the vesting period.
•PSUs, which entitle the holder to receive at no cost, a specified number of shares of common stock within a range of shares from zero to a specified maximum and typically vest over 3 years. Payout of this award is contingent upon achievement of certain performance and market conditions.
As of December 30, 2023, approximately 4.1 million shares were authorized for future grants under the Company’s share-based compensation plans. The Company settles employee share-based compensation awards with newly issued shares. The following table provides stock-based compensation by the financial statement line item in which it is reflected:
Fiscal Year
202320222021
(in thousands)
Cost of revenue$15,052 $14,853 $13,087 
Selling, general and administrative56,996 58,764 58,387 
Stock-based compensation, before income taxes72,048 73,617 71,474 
Provision for income taxes(10,907)(10,969)(10,299)
Stock-based compensation, net of income taxes$61,141 $62,648 $61,175 
No stock-based compensation related costs were capitalized in fiscal years 2023, 2022 and 2021.
Stock Options
The following table summarizes stock option activity under the Company’s stock-based compensation plans:
Number of sharesWeighted Average
Exercise Price		Weighted Average
Remaining
Contractual Life		Aggregate
Intrinsic
Value
(in thousands)(in years)(in thousands)
Options outstanding as of December 31, 2022882 $204.41   
Options granted130 $194.27   
Options exercised(195)$130.91   
Options canceled(28)$259.63   
Options outstanding as of December 30, 2023789 $218.97 6.5$28,935 
Options exercisable as of December 30, 2023408 $205.50 4.8$20,521 
Options expected to vest as of December 30, 2023381 $233.37 8.3$8,414 
The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Fiscal Year
202320222021
Expected life (in years)6.06.06.0
Expected volatility36 %33 %32 %
Risk-free interest rate3.8 %2.7 %1.0 %
Expected dividend yield0 %0 %0 %
The weighted-average grant date fair value of stock options granted was $80.98, $90.05 and $108.61 for fiscal years 2023, 2022 and 2021, respectively.
As of December 30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $18.5 million. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.4 years.
The total intrinsic value of options exercised during fiscal years 2023, 2022 and 2021 was $18.2 million, $33.2 million and $94.4 million, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the exercise price.
96
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Restricted Stock Units
The following table summarizes the restricted stock units activity for fiscal year 2023:
Restricted Stock UnitsWeighted Average Grant Date Fair Value
(in thousands)
December 31, 2022364 $226.43 
Granted265 $194.84 
Vested(134)$212.34 
Canceled(26)$231.70 
December 30, 2023469 $212.30 
As of December 30, 2023, the unrecognized compensation cost related to shares of unvested RSUs expected to vest was $65.8 million, which is expected to be recognized over an estimated weighted-average amortization period of 2.8 years. The total fair value of RSU grants that vested during fiscal years 2023, 2022 and 2021 was $28.4 million, $24.8 million and $22.8 million, respectively.
Performance Based Stock Award Program
The Company issues PSUs to certain corporate officers. The number of shares of common stock issued for each PSU is adjusted based on a performance condition linked to the Company’s financial performance. Certain awards are further adjusted based on a market condition, which is calculated based on the Company’s stock performance relative to a peer group over the three-year vesting period. The fair value of the market condition is reflected in the fair value of the award at grant date.
The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows:
Fiscal Year
202320222021
(shares in thousands)
PSUs granted146 134 64 
Weighted average grant date fair value$204.40 $210.42 $407.76 
Key assumptions:
Expected volatility 37 %39 %37 %
Risk-free interest rate4.2 %2.6 %0.2 %
Expected dividend yield0 %0 %0 %
Total shareholder return of 20-trading day average stock price on grant date
(9.8)%(32.7)%39.9 %
The maximum number of common shares to be issued upon vesting of PSUs is 0.3 million. For fiscal years 2023, 2022 and 2021, the Company recognized stock-based compensation related to PSUs of $28.1 million, $31.2 million and $31.8 million, respectively. The total fair value of PSUs that vested during fiscal years 2023, 2022 and 2021 was $34.4 million, $31.0 million and $26.0 million, respectively.
In fiscal year 2021, the Company also issued approximately 5,000 PSUs using a weighted-average grant date fair value per share of $477.52. These PSUs vest upon the achievement of financial targets and other performance measures.
16. RESTRUCTURING AND ASSET IMPAIRMENTS
The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment and accelerated depreciation charges.

97
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table presents restructuring costs by reportable segment:
Fiscal Year
202320222021
(in thousands)
RMS$3,479 $1,007 $7 
DSA16,176 851 3,114 
Manufacturing9,138 5,126 3,663 
Unallocated corporate889 1,229 72 
Total$29,682 $8,213 $6,856 
The following table presents restructuring costs as included within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
2023
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$7,408 $14,812 $22,220 
Cost of products sold (excluding amortization of intangible assets)1,146 3,262 4,408 
Selling, general and administrative3,054 — 3,054 
Total restructuring costs$11,608 $18,074 $29,682 
Fiscal Year
2022
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$928 $1,784 $2,712 
Cost of products sold (excluding amortization of intangible assets)532 1,765 2,297 
Selling, general and administrative2,441 763 3,204 
Total restructuring costs$3,901 $4,312 $8,213 
Fiscal Year
2021
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$1,898 $934 $2,832 
Cost of products sold (excluding amortization of intangible assets)— — — 
Selling, general and administrative2,819 1,205 4,024 
Total restructuring costs$4,717 $2,139 $6,856 
98
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Rollforward of Restructuring Activities
The following table provides a rollforward for all of the Company’s severance and transition costs related to all restructuring activities:
Fiscal Year
202320222021
(in thousands)
Beginning balance$1,300 $4,011 $5,818 
Expense (excluding non-cash charges)11,539 6,732 5,695 
Payments / utilization(7,800)(6,973)(5,604)
Other non-cash adjustments— (2,350)(1,831)
Foreign currency adjustments11 (120)(67)
Ending balance$5,050 $1,300 $4,011 
As of December 30, 2023 and December 31, 2022, $5.1 million and $1.3 million, respectively, of severance and other personnel related costs liabilities were included in accrued compensation and accrued liabilities within the Company’s consolidated balance sheets.
17. LEASES
Operating and Finance Leases
Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:
December 30, 2023December 31, 2022
(in thousands)
Operating leases
Operating lease right-of-use assets, net$394,029 $391,762 
Other current liabilities$54,908 $46,526 
Operating lease right-of-use liabilities419,234 389,745 
Total operating lease liabilities$474,142 $436,271 
Finance leases
Property, plant and equipment, net$29,422$31,875
Current portion of long-term debt and finance leases$2,398$2,330
Long-term debt, net and finance leases26,15228,316
Total finance lease liabilities$28,550$30,646
The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
202320222021
(in thousands)
Operating lease costs$65,380 $59,671 $45,728 
Finance lease costs:
Amortization of right-of-use assets2,745 3,035 3,337 
Interest on lease liabilities1,477 1,441 1,280 
Short-term lease costs3,581 2,954 2,441 
Variable lease costs22,159 13,965 4,623 
Sublease income(2,067)(1,912)(2,008)
Total lease costs$93,275 $79,154 $55,401 
99
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Other information related to leases was as follows:
Supplemental cash flow information
Fiscal Year
202320222021
(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases$60,239 $48,360 $42,576 
Operating cash flows from finance leases1,476 1,442 1,282 
Finance cash flows from finance leases2,297 2,257 3,202 
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities$75,987 $189,134 $142,764 
Right-of-use lease assets obtained in exchange for new finance lease liabilities— 8,179 1,567 
Lease term and discount rate
December 30, 2023December 31, 2022December 25, 2021
Weighted-average remaining lease term (in years)
Operating lease9.69.89.0
Finance lease12.713.611.7
Weighted-average discount rate
Operating lease4.7 %4.3 %3.6 %
Finance lease5.3 %5.3 %4.4 %
At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.
As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:
Operating LeasesFinance Leases
(in thousands)
2024$70,578 $3,796 
202563,433 3,513 
202658,494 3,038 
202759,946 2,999 
202857,953 2,988 
Thereafter286,215 23,562 
Total minimum future lease payments596,619 39,896 
Less: Imputed interest122,477 11,346 
Total lease liabilities$474,142 $28,550 
Total minimum future lease payments (predominantly operating leases) of approximately $161 million for leases that have not commenced as of December 30, 2023, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2024 and 2025 with lease terms of approximately 5 to 15 years.
100
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
18. COMMITMENTS AND CONTINGENCIES
Insurance
The Company maintains certain insurance policies that maintain large deductibles up to approximately $2 million, some with or without stop-loss limits, depending on market availability. Insurance policies at certain locations are based on a percentage of the insured assets, for which deductibles for certain property may exceed $22.0 million in the event of a catastrophic event. In addition, the Company purchased representation and warranty insurance in support of some acquisitions, in which deductibles could reach $4.0 million.
Litigation
On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain recent shipments in the United States. The carrying value of the inventory related to these shipments is approximately $27 million as of December 30, 2023, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena, primarily related to the sourcing of non-human primates, and the Company is cooperating with the request. We are not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities.
A putative securities class action was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. The Company filed a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.
On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The Company intends to file a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the derivative lawsuit to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.
101
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Aside from the matter above, the Company believes there are no other matters pending against the Company that could have a material impact on the Company’s business, financial condition, or results of operations.
Guarantees
The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.
Purchase Obligations
The Company enters into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. These unconditional purchase obligations exclude agreements that are cancellable at any time without penalty. The aggregate amount of the Company’s unconditional purchase obligations totaled approximately $390 million as of December 30, 2023 and the majority of these obligations are expected to be settled during 2024.
102

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A.    Controls and Procedures
(a)   Evaluation of Disclosure Controls and Procedures
Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated by the Securities Exchange Act of 1934, as amended (Exchange Act), the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, are effective, at a reasonable assurance level, as of December 30, 2023, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and management necessarily was required to apply its judgment in designing and evaluating the controls and procedures.
(b)   Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our CEO and CFO, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment and those criteria, management concluded that the Company maintained effective internal control over financial reporting as of December 30, 2023.
Our assessment of the effectiveness of our internal control over financial reporting as of December 30, 2023 excluded Noveprim, which was acquired by the Company in 2023. Noveprim, whose total assets and total revenues were excluded from the Company’s assessment, represented approximately less than 1%, respectively, of the related consolidated amounts as of and for the fiscal year ended December 30, 2023.
The effectiveness of our internal control over financial reporting as of December 30, 2023, has been audited by PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm, as stated in their report which appears in Item 8, “Financial Statements and Supplementary Data” in this Annual Report on Form 10-K.
(c) Changes in Internal Controls Over Financial Reporting
During fiscal year 2023, there were no material changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of the Exchange Act Rules 13a-15 or 15d-15 that occurred during the fourth quarter of 2023 that materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.
103

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Item 9B.    Other Information
During the quarter ended December 30, 2023, none of our officers or directors adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K., except as follows:
•On November 14, 2023, James Foster, our Chair, President, and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement, dated February 23, 2023 for the sale of up to 112,341 shares of common stock. Mr. Foster did not sell any shares pursuant to such plan, which, absent such termination, would have expired on March 1, 2025.

•On November 15, 2023, Birgit Girshick, our Corporate Executive Vice President & Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement, dated February 24, 2023 for the sale of up to 25,320 shares of common stock. Ms. Girshick did not sell any shares pursuant to such plan, which, absent such termination, would have expired on February 28, 2024.

•On November 22, 2023, Ms. Girshick entered into a Rule 10b5-1 trading arrangement for the sale of up to 22,362 shares of common stock, subject to certain conditions. The arrangement’s expiration date is February 28, 2025.
During the quarter ended December 30, 2023, the Company did not adopt or terminate any “Rule 10b5-1 trading arrangement” as defined in Item 408(a) of Regulation S-K.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.

104

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PART III
Item 10.    Directors, Executive Officers and Corporate Governance
A.    Directors and Compliance with Section 16(a) of the Exchange Act
Any information required by this Item regarding our directors and compliance with Section 16(a) of the Exchange Act by our officers and directors will be included in the 2024 Proxy Statement under the sections captioned “Nominees for Directors” and “Delinquent Section 16(a) Reports” and is incorporated herein by reference thereto. The information required by this Item regarding our corporate governance will be included in the 2024 Proxy Statement under the section captioned “Corporate Governance” and is incorporated herein by reference thereto.
B.    Our Executive Officers
The information required by this Item regarding our executive officers is reported in Part I of this Form 10-K under the heading “Item 1. Business”
C.    Audit Committee Financial Expert
The information required by this Item regarding the audit committee of the Board of Directors and financial experts will be included in the 2024 Proxy Statement under the section captioned “The Board of Directors and its Committees-Audit Committee and Financial Experts” and is incorporated herein by reference thereto.
D.    Insider Trading Policy
We have adopted an Insider Trading Policy governing the purchase, sale, and/or other dispositions of our securities by directors, officers, and employees of the Company. The Insider Trading Policy is designed to promote compliance with insider trading laws, rules, and regulations and any applicable listing standards. Our Insider Trading Policy is posted on our website and can be accessed by selecting the “Corporate Governance” link at http://ir.criver.com.
E.    Code of Ethics
We have adopted a Code of Business Conduct and Ethics that applies to all of our employees and directors, including our principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions. Our Code of Business Conduct and Ethics is posted on our website and can be accessed by selecting the “Corporate Governance” link at http://ir.criver.com. We will provide to any person, without charge, a copy of our Code of Business Conduct and Ethics. To obtain a copy, please mail a request to the Corporate Secretary, Charles River Laboratories International, Inc., 251 Ballardvale Street, Wilmington, MA 01887. Information on our website is not incorporated by reference in this annual report.
F.    Changes to Board Nomination Procedures
In December 2021, we amended our By-laws to include a proxy access by-law. Under our proxy access by-law, if a stockholder (or a group of up to 20 stockholders) who has owned at least 3% of our shares for at least three years and has complied with the other requirements set forth in our By-laws wants us to include director nominees (up to the greater of two nominees or 20% of the Board) in our proxy statement for an upcoming Annual Meeting, the nominations must be received in a timely manner, between 120 and 150 days prior to the anniversary of the date our proxy statement was first sent to stockholders in connection with the prior year’ annual meeting.
Item 11.    Executive Compensation
A.    Policies and Practices for Granting Certain Equity Awards.
The Compensation Committee of the Board of Directors is responsible for the review and approval of our policies and practices with respect to granting equity awards. The Compensation Committee typically targets the second quarter of our fiscal year, shortly after our annual meeting of shareholders and the release of our first quarter financial results, for granting annual stock awards to eligible recipients, absent an extraordinary event. The Compensation Committee believes this aligns timing of equity grants with the planning of annual salary increases (also in the second quarter of our fiscal year), allowing our managers to take a holistic view of total compensation.
The Compensation Committee seeks to structure equity grants so that they are awarded during an open window period as designated by our Insider Trading Policy, or, if Compensation Committee approval is provided during a non-window period, are typically made effective on the first business day following our press release with respect to financial results for the prior quarter. This policy is intended to ensure that options are awarded at a time when the exercise price fully reflects all recently disclosed information. In the case of new hires eligible to receive equity grants, grants are generally made on the first business day of the month following the date the individual commences employment.
105

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
All grants to executive officers are made by the Compensation Committee itself and not pursuant to any delegated authority.
We have never had any programs, policies, or practices which are intended to time stock option grants with the release of material, non-public information in a manner that would provide advantageous option exercise prices to grant recipients. Option exercise prices are, in all cases, equal to the closing price of our common stock on the date of grant.
B.     Actions to Recover Erroneously Awarded Compensation
At no point during or after the last completed fiscal year did we prepare an accounting statement that required the recovery of erroneously awarded compensation pursuant to the company’s clawback policy, nor was there an outstanding balance as of the end of the last completed fiscal year of erroneously awarded compensation to be recovered from the application of the policy to a prior restatement.
The remainder of the information required by this Item will be included in the 2024 Proxy Statement under the sections captioned “2023 Director Compensation,” “Compensation Discussion and Analysis,” “Executive Compensation and Related Information,” “Compensation Committee Interlocks and Insider Participation” and “Report of Compensation Committee,” and is incorporated herein by reference thereto.
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be included in the 2024 Proxy Statement under the sections captioned “Beneficial Ownership of Securities” and “Equity Compensation Plan Information” and is incorporated herein by reference thereto.
Item 13.    Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be included in the 2024 Proxy Statement under the sections captioned “Related Person Transaction Policy” and “Corporate Governance-Director Qualification Standards; Director Independence” and is incorporated herein by reference thereto.
Item 14.    Principal Accountant Fees and Services
The information required by this Item will be included in the 2024 Proxy Statement under the section captioned “Statement of Fees Paid to Independent Registered Public Accounting Firm” and is incorporated herein by reference thereto.
106

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
PART IV
Item 15.    Exhibits and Financial Statement Schedules
Item 15(a)(1) and (2) Financial Statements and Schedules
See "Index to Consolidated Financial Statements and Financial Statements Schedules" at Item 8 to this Annual Report on Form 10-K. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.
Item 15(a)(3) and Item 15(b) Exhibits
We have identified below each management contract and compensation plan filed as an exhibit to this Annual Report on Form 10-K.
Exhibit No.DescriptionFiled with this Form 10-KIncorporation by Reference
FormFiling DateExhibit No.
3.1S-1/AJune 23, 20003.1
3.28-KDecember 15, 20213.1
4.1S-1/AJune 23, 20004.1
4.210-KFebruary 11, 20204.2
4.310-QAugust 5, 202010.3
4.48-KApril 3, 20184.1
4.58-KOctober 23, 20194.1
4.68-KOctober 23, 20194.2
4.78-KMarch 23, 20214.1
4.88-KMarch 23, 20214.2
4.98-KMarch 23, 20214.3
4.108-KMarch 23, 20214.4
4.11S-3May 4, 20214.1
4.12S-3May 4, 20214.2
10.1*10-QAugust 3, 201610.1
10.2*
X
10.3*10-KFebruary 14, 201710.4
10.4*10-KFebruary 14, 201710.7
10.5*10-QAugust 5, 202010.1
10.6*X
10.7*10-QAugust 3, 201010.1
10.8*10-KFebruary 23, 200910.7
107

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Exhibit No.DescriptionFiled with this Form 10-KIncorporation by Reference
FormFiling DateExhibit No.
10.9*10-QMay 4, 201610.1
10.10*10-KMarch 9, 200510.23
10.11*8-KMay 18, 202199.1
10.12*10-QMay 4, 202110.2
10.13*10-QMay 4, 202110.3
10.148-KApril 23, 202110.1
10.15*8-KDecember 27, 202110.1
10.16*8-KDecember 27, 202110.2
10.17*†
10-QMay 4, 202210.1
19X
21.1X
23.1X
31.1X
31.2X
32.1X
97X
101.INSeXtensible Business Reporting Language (XBRL) Instance DocumentX
101.SCHInline XBRL Taxonomy Extension SchemaX
101.CALInline XBRL Taxonomy Extension Calculation LinkbaseX
101.DEFInline XBRL Taxonomy Extension Definition LinkbaseX
101.LABInline XBRL Taxonomy Extension Labels LinkbaseX
101.PREInline XBRL Taxonomy Extension Presentation LinkbaseX
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Management contract or compensatory plan, contract or arrangement.
† Certain information in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]
Item 16.    Form 10-K Summary
None.
108

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
February 14, 2024By:/s/ FLAVIA H. PEASE
Flavia H. Pease
Corporate Executive Vice President and Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.
SignaturesTitleDate
By:/s/ JAMES C. FOSTERChairman, President and Chief Executive OfficerFebruary 14, 2024
James C. Foster
By:/s/ FLAVIA H. PEASECorporate Executive Vice President andFebruary 14, 2024
Flavia H. PeaseChief Financial Officer
By:/s/ MICHAEL G. KNELLCorporate Senior Vice President andFebruary 14, 2024
Michael G. KnellChief Accounting Officer
By:/s/ NANCY C. ANDREWSDirectorFebruary 14, 2024
Nancy C. Andrews
By:/s/ ROBERT J. BERTOLINIDirectorFebruary 14, 2024
Robert J. Bertolini
By:
/s/ RESHEMA KEMPS-POLANCO
Director
February 14, 2024
Reshema Kemps-Polanco
By:/s/ DEBORAH T. KOCHEVARDirectorFebruary 14, 2024
Deborah T. Kochevar
By:/s/ GEORGE LLADODirectorFebruary 14, 2024
George Llado
By:/s/ MARTIN MACKAYDirectorFebruary 14, 2024
Martin Mackay
By:/s/ GEORGE E. MASSARODirectorFebruary 14, 2024
George E. Massaro
By:/s/ C. RICHARD REESEDirectorFebruary 14, 2024
C. Richard Reese
By:/s/ CRAIG B. THOMPSONDirectorFebruary 14, 2024
Craig B. Thompson
By:/s/ RICHARD F. WALLMANDirectorFebruary 14, 2024
Richard F. Wallman
By:/s/ VIRGINIA M. WILSONDirectorFebruary 14, 2024
Virginia M. Wilson

109
 EX-10.2 2 crl1230202310-kex102.htm EX-10.2 Document

Exhibit 10.2

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
AMENDED AND RESTATED 2018 INCENTIVE PLAN
Originally adopted by the Board of Directors
On March 20, 2018
Approved at Annual Meeting of Shareholders
On May 8, 2018
Amended by the Board of Directors
On March 14, 2020
Amendment and Restatement Approved at Annual Meeting of Shareholders
On May 6, 2020
Amended by the Administrator (the Compensation Committee of the Board of Directors)
On November 21, 2023


1.ADMINISTRATION
Subject to the express provisions of the Plan, the Administrator has the authority to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; prescribe forms, rules and procedures (which it may modify or waive); and otherwise do all things necessary to implement the Plan. Once an Award has been communicated in writing to a Participant, the Administrator may not, without the Participant’s consent, alter the terms of the Award so as to materially affect adversely the Participant’s rights under the Award, unless the Administrator has expressly reserved the right to do so or pursuant to Section 9.
2.LIMITS ON AWARDS UNDER THE PLAN
a.NUMBER OF SHARES. Subject to adjustments as provided in Section 5.b, the total number of shares of Stock subject to Awards granted under the Plan, in the aggregate, may not exceed 8,948,598 (the “Fungible Pool Limit”), which includes (A) a reserve of 439,798 shares of Stock remaining available for issuance under the 2016 Plan as in effect prior to the Original Effective Date and (B) an increase of 1,750,000 shares of Stock, as approved by the Board, subject to approval by the stockholders of the Company. Each share of Stock issued or to be issued in connection with any Full-Value Award shall be counted against the Fungible Pool Limit as 2.3 Fungible Pool Units. Stock Options, SARs and other Awards that do not deliver the full value at grant thereof of the underlying shares of Stock, that were granted prior to the Effective Date and that expire no more than seven (7) years from the date of grant, and such Stock Options, SARs and Other Awards that were granted on or after the Effective Date and that expire no more than ten (10) years from the date of grant, shall be counted against the Fungible Pool Limit as one (1.0) Fungible Pool Unit. (For these purposes, the number of shares of Stock taken into account with respect to a SAR shall be the number of shares of Stock underlying the SAR at grant (i.e., not the final number of shares of Stock delivered upon exercise of the SAR)). For purposes of the preceding sentence, shares that have been forfeited or cancelled in accordance with the terms of the applicable Award shall not be considered to have been delivered under the Plan, but shares held back in satisfaction of the exercise price or tax withholding requirements from shares that would otherwise have been delivered pursuant to an Award will be considered to have been delivered under the Plan. In addition, shares of Stock that have been repurchased by the Company with proceeds obtained in connection with the exercise of outstanding Awards shall not be added into the pool of available shares. Any shares of Stock that again become available for grant pursuant to this Section 2.a shall be added back to the pool of available shares. For purposes of clarity,

    Page 1 of 20    

in calculating the number of shares of Stock remaining under the Fungible Pool Limit, the Administrator will not increase the number of available Fungible Pool Units for shares of Stock delivered under an Award (i.e., previously acquired Shares tendered by the Participant in payment of the exercise price or of withholding taxes). The Administrator shall determine the appropriate methodology for calculating the number of shares of Stock issued pursuant to the Plan.
b.TYPE OF SHARES. Stock delivered by the Company under the Plan may be authorized but unissued Stock or previously issued Stock acquired by the Company and held in treasury. No fractional shares of Stock will be delivered under the Plan.
c.PARTICIPANT SHARE LIMIT. The maximum number of shares of Stock for which any Awards may be granted to any Participant annually from and after adoption of the Plan and prior to March 20, 2028 shall be 2,000,000, subject to adjustments as provided in Section 5.b. No Awards may be granted under the Plan after March 20, 2028, but previously granted Awards may extend beyond that date.
d.OTHER AWARD LIMITS. No more than $3,000,000 may be paid to any individual with respect to any Cash Performance Award (other than an Award expressed in terms of shares of Stock or units representing Stock, which shall instead be subject to the limit set forth in Section 2.c above). In applying the dollar limitation of the preceding sentence: (A) multiple Cash Performance Awards to the same individual that are determined by reference to performance periods of one year with or within the same fiscal year of the Company shall be subject in the aggregate to one limit of such amount, and (B) multiple Cash Performance Awards to the same individual that are determined by reference to one or more multi‑year performance periods ending in the same fiscal year of the Company shall be subject in the aggregate to a separate limit of such amount.
e.NON-EMPLOYEE DIRECTOR LIMIT. The aggregate grant date fair value (determined as of the date of grant) of any Award granted under the Plan to an individual upon becoming a non-employee member of the Board of Directors (“Initial Non-Employee Director Grant”) shall not exceed $600,000. Subject to adjustment as provided in Section 5.b, no Participant who is a non-employee member of the Board of Directors may receive under the Plan (or otherwise) in any calendar year Stock Options, SARs, Restricted Stock, Unrestricted Stock, Deferred Stock and Performance Awards denominated in shares of Stock with a grant date fair value (determined as of the date of grant) that, when combined with the aggregate amount of any Cash Performance Awards and any other compensation granted to such Participant in such calendar year, exceeds an aggregate of $800,000 (excluding an Initial Non-Employee Director Grant).
f.ISO SHARE LIMIT. Subject to adjustments as provided in Section 5.b, the maximum number of shares of Stock available for issuance with respect to ISOs under the Plan shall be 3,500,000.
3.ELIGIBILITY AND PARTICIPATION
The Administrator will select Participants from among those key Employees, directors and other individuals or entities providing services to the Company or its Affiliates who, in the opinion of the Administrator, are in a position to make a significant contribution to the success of the Company and its Affiliates. Eligibility for ISOs is further limited to those individuals whose employment status would qualify them for the tax treatment described in Sections 421 and 422 of the Code.
4.RULES APPLICABLE TO AWARDS
a.ALL AWARDS
    Page 2 of 20    


(1)TERMS OF AWARDS. All Awards of Stock Options and SARs granted hereunder shall have a term of not to exceed ten (10) years from the date of grant; PROVIDED that such Awards granted hereunder prior to the Effective Date shall have a term not to exceed seven (7) years from the date of grant. The Administrator shall determine all other terms of all Awards subject to the limitations provided herein.
(2)PERFORMANCE CRITERIA. Where rights under an Award depend in whole or in part on satisfaction of Performance Criteria, actions by the Company that have an effect, however material, on such Performance Criteria or on the likelihood that they will be satisfied will not be deemed an amendment or alteration of the Award.
(3)ALTERNATIVE SETTLEMENT. The Company may at any time extinguish rights under an Award in exchange for payment in cash, Stock (subject to the limitations of Section 2) or other property on such terms as the Administrator determines, PROVIDED the holder of the Award consents to such exchange, PROVIDED FURTHER, no such exchange will be made where the cash, Stock or property to be received has a fair market value greater than the Award being extinguished, or where any such exchange would violate Section 4.a(9) of this Plan.
(4)TRANSFERABILITY OF AWARDS. Awards may not be transferred other than by will or by the laws of descent and distribution and during a Participant’s lifetime an Award requiring exercise may be exercised only by the Participant (or in the event of the Participant’s incapacity, the person or persons legally appointed to act on the Participant’s behalf).
(5)VESTING, ETC. Without limiting the generality of Section 1, the Administrator may determine the time or times at which an Award will vest (i.e., become free of forfeiture restrictions) or become exercisable and the terms on which an Award requiring exercise will remain exercisable. Notwithstanding anything contained herein to the contrary, (1) Awards that are not Performance Awards to Participants shall vest (i.e., become free of forfeiture restrictions) over a period of time at least three years or more from the date of grant and no Award shall vest in part or in whole before 12 months from the date of grant, and (2) Full-Value Awards that are Performance Awards shall be subject to the attainment of Performance Criteria which require at least 12 months to achieve and no Award shall vest in part or in whole before 12 months from the date of grant; PROVIDED, however, that Awards that aggregate not more than 5% of the number of shares reserved for issuance under the Plan may be awarded without the vesting requirements set forth in clauses (1) and (2).
Unless otherwise provided by Section 4.d with respect to Performance Awards or if the Administrator expressly provides otherwise:
(A)immediately upon the cessation of a Participant’s employment or other service relationship with the Company and its Affiliates, all Awards (other than Stock Options and SARs) held by the Participant (or by a permitted transferee under Section 4.a(4)) immediately prior to such cessation of employment or other service relationship will be forfeited if not then vested and, where exercisability is relevant, will cease to be exercisable;
(B)except as provided in clauses (C) and (D) below, all Stock Options and SARs held by a Participant (or by a permitted transferee under Section 4.a(4)) immediately prior to the cessation of the Participant’s employment or other service relationship for reasons other than Disability or death, to the extent then exercisable, will remain exercisable for the lesser of (i) a period of three months or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 4.a(5), and shall thereupon terminate;
    Page 3 of 20    


(C)all Stock Options and SARs held by a Participant (or by a permitted transferee under Section 4.a(4)) immediately prior to the Participant’s Disability or death, to the extent then exercisable, will remain exercisable for the lesser of (i) the one‑year period ending with the first anniversary of the Participant’s Disability or death or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 4.a(5), and shall thereupon terminate; and
(D)all Stock Options and SARs held by a Participant (or by a permitted transferee of the Participant under Section 4.a(4)) whose cessation of employment or other service relationship is determined by the Administrator in its sole discretion to result from reasons which cast such discredit on the Participant as to justify immediate termination of the Award shall immediately terminate upon such cessation.
Unless the Administrator expressly provides otherwise, a Participant’s “employment or other service relationship with the Company and its Affiliates” will be deemed to have ceased, in the case of an employee Participant, upon termination of the Participant’s employment with the Company and its Affiliates (whether or not the Participant continues in the service of the Company or its Affiliates in some capacity other than that of an employee of the Company or its Affiliates), and in the case of any other Participant, when the service relationship in respect of which the Award was granted terminates (whether or not the Participant continues in the service of the Company or its Affiliates in some other capacity).
(6)TAXES. The Administrator will make such provision for the withholding of taxes as it deems necessary. The Administrator may, but need not, hold back shares of Stock from an Award or permit a Participant to tender previously owned shares of Stock in satisfaction of tax withholding requirements. For the avoidance of doubt, Stock may be tendered or held back by the Company in excess of the minimum amount required to be withheld for Federal, state, and local taxes.
As provided in Section 2.a of this Plan, in the event shares of Stock are held back from an Award in satisfaction of tax withholding requirements, such shares will nonetheless be considered to have been delivered under the Plan.
(7)DIVIDEND EQUIVALENTS, ETC. The Administrator may provide for the payment of amounts in lieu of cash dividends or other cash distributions with respect to Stock subject to any Full Value Award if and in such manner as it deems appropriate. Notwithstanding anything contained herein to the contrary, and without limiting the generality of Section 4.d(10), in no event shall an Award provide for any dividend or dividend equivalents to be payable to the Participant in respect of such Award prior to the time at which such Award (or the applicable portion thereof) vests (and, in the case of a Performance Award, the applicable performance condition is achieved).
(8)RIGHTS LIMITED. Nothing in the Plan shall be construed as giving any person the right to continued employment or service with the Company or its Affiliates, or any rights as a shareholder except as to shares of Stock actually issued under the Plan. The loss of existing or potential profit in Awards will not constitute an element of damages in the event of termination of employment or service for any reason, even if the termination is in violation of an obligation of the Company or Affiliate to the Participant. No Participant or other person shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of Participants under the Plan. The terms and conditions of Awards need not be the same with respect to each recipient. Any Award granted under the Plan shall be a one-time Award that does not constitute a promise of future grants. Any Award granted under the Plan shall not be a part of a Participant’s base salary or wages and will not be taken into account in determining any other employment-related rights such Participant may have, such as rights to pension or severance pay. The Company, in its sole discretion, maintains the right to make available future
    Page 4 of 20    

grants under the Plan. Unless stated herein, no Participant or other person shall acquire any rights, remedies, benefits or obligations. Nothing contained in the Plan shall prevent the Company from adopting or continuing in effect other or additional compensation arrangements, and such arrangements may be either generally applicable or applicable only in specific cases. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and a Participant or any other person. To the extent that any person acquires a right to receive payments from the Company pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company.
(9)OPTION AND SAR REPRICING. Options and SARs may not be repriced, or replaced with any other award (including full-value awards), or repurchased for cash without the approval of the shareholders of the Company.
(10)FORFEITURE/CLAWBACK. The Committee may determine that any Award under this Plan shall be subject to provisions for the forfeiture and/or reimbursement of all amounts received in connection with an Award in the event of breach of noncompetition, nonsolicitation or confidentiality agreements. All Awards granted under this Plan are subject to recoupment, to the extent applicable, under the Company’s Corporate Governance Guidelines, as may be revised from time to time, and/or any other recoupment, clawback or similar policy that may be approved by the Board or any committee thereof. Notwithstanding any other provision of this Plan, a Participant shall be required to reimburse the Company amounts received in connection with an Award to the extent required under Section 304 of the Sarbanes-Oxley Act of 2002 and Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.
(11)STOCK OWNERSHIP GUIDELINES/HOLDING PERIODS. The Committee may require that any Stock acquired by a Participant in connection with an Award granted under this Plan shall be subject to stock ownership guidelines, a minimum holding period or similar requirement under which a Participant shall not be permitted to transfer, sell, pledge, hedge, hypothecate or otherwise dispose of any such Stock.
b.AWARDS REQUIRING EXERCISE
(1)TIME AND MANNER OF EXERCISE. Unless the Administrator expressly provides otherwise, (a) an Award requiring exercise by the holder will not be deemed to have been exercised until the Administrator receives a written notice of exercise (in a form acceptable to the Administrator) signed by the appropriate person and accompanied by any payment required under the Award or adequate provision therefore, as set forth in Section 4.b(3); and (b) if the Award is exercised by any person other than the Participant, the Administrator may require satisfactory evidence that the person exercising the Award has the right to do so.
(2)EXERCISE PRICE. The Administrator shall determine the exercise price of each Stock Option and SAR; PROVIDED, that each Stock Option and SAR must have an exercise price that is not less than the fair market value of the Stock subject to the Stock Option and SAR, determined as of the date of grant. An ISO granted to an Employee described in Section 422(b)(6) of the Code must have an exercise price that is not less than 110% of such fair market value.
(3)PAYMENT OF EXERCISE PRICE, IF ANY. Where the exercise of an Award is to be accompanied by payment, the Administrator may determine the required or permitted forms of payment, subject to the following: (a) all payments will be by cash or check acceptable to the Administrator, or, if so permitted by the Administrator (with the consent of the optionee of an ISO if permitted after the grant), (i) through the
    Page 5 of 20    

delivery of shares of Stock which have been outstanding for at least six months (unless the Administrator approves a shorter period) and which have a fair market value equal to the exercise price, (ii) by delivery of a promissory note of the person exercising the Award to the Company, payable on such terms as are specified by the Administrator, (iii) if the Stock is publicly traded, by delivery of an unconditional and irrevocable undertaking by a broker to deliver promptly to the Company sufficient funds to pay the exercise price, (iv) or the withholding of shares of Stock from an Award, or (v) by any combination of the foregoing permissible forms of payment; and (b) where shares of Stock issued under an Award are part of an original issue of shares, the Award shall require an exercise price equal to at least the par value of such shares.
(4)GRANT OF STOCK OPTIONS. Each Stock Option awarded under the Plan shall be deemed to have been awarded as a non‑ISO (and to have been so designated by its terms) unless the Administrator expressly provides for ISO treatment that the Stock Option is to be treated as an ISO.
c.AWARDS NOT REQUIRING EXERCISE
Awards of Restricted Stock and Unrestricted Stock may be made in return for either (1) services determined by the Administrator to have a value not less than the par value of the Awarded shares of Stock, or (2) cash or other property having a value not less than the par value of the Awarded shares of Stock plus such additional amounts (if any) as the Administrator may determine payable in such combination and type of cash, other property (of any kind) or services as the Administrator may determine.
d.PERFORMANCE AWARDS
Performance Awards may be granted to Participants as follows:
(1)Prior to the grant of any Performance Award, the Administrator shall establish for each such award (i) performance levels at which 100% of the award shall be earned and a range (which need not be the same for all awards) within which greater and lesser percentages shall be earned and (ii) a performance period (which shall not be less than 12 months) which shall be determined at time of grant.
(2)With respect to the performance levels to be established pursuant to Section 4.d(1), the specific measures for each grant shall be established by the Administrator at the time of such grant. In creating these measures, the Administrator may establish the specific goals based upon or relating to any Performance Criteria (as defined below).
(3)Except as otherwise provided in Section 4.d(5), the percentage of each Performance Award to be distributed to an employee shall be determined by the Administrator on the basis of the performance levels established for such award and on the basis of individual performance in satisfaction of the Performance Award during such period. Any Performance Award, as determined and adjusted pursuant to this Section and Sections 4.d(5-8) is herein referred to as a “Final Award”. No distribution of any Final Award (or portion thereof) shall be made if the minimum performance level applicable to the related Performance Award is not achieved during the applicable performance period or, unless otherwise determined by the Administrator, if the employment of the employee to whom the related Performance Award was granted shall terminate for any reason whatsoever (including Disability and death) within 12 months after the date the Performance Award was granted.
(4)All Final Awards which have vested in accordance with the provisions of Sections 4.d.(5-10) shall be granted as soon as practicable following the end of the related vesting period. Final awards shall be
    Page 6 of 20    

granted in the form of Restricted Stock, Unrestricted Stock, Deferred Stock, Cash Performance Awards, or cash or any combination thereof, as the Administrator shall determine.
(5)Payment of any Final Award (or portion thereof) to an individual employee shall be subject to the continued rendering of services as an employee (unless this condition is waived by the Administrator). If the Administrator shall determine that such employee has failed to satisfy such conditions precedent, all Performance Awards granted to such employee which have not become Final Awards, and all Final Awards which have not been paid pursuant to Section 4.d(10) shall be immediately canceled. Upon termination of an employee’s employment other than by Disability or death (whether such termination is before or after a Performance Award shall have become a Final Award), the Administrator may, but shall not in any case be required to, waive the condition precedent of continuing to render services.
(6)If, upon termination of an employee’s employment prior to the end of any performance period for a reason other than Disability or death, the Administrator shall determine to waive the condition precedent of continuing to render services as provided in Section 4.d(5), the Performance Award granted to such employee with respect to such performance period shall be reduced pro rata based on the number of months remaining in the performance period after the month of such termination and such awards will be paid at the time they would have been paid absent an employment termination, unless otherwise determined by the Administrator or provided for in an award agreement. The Final Award for such employee shall be determined by the Administrator (i) on the basis of the performance levels established for such award (including the minimum performance level) and the performance level achieved through the end of the performance period and (ii) in the discretion of the Administrator, on the basis of individual performance during the period prior to such termination. A qualifying leave of absence, determined in accordance with procedures established by the Administrator, shall not be deemed to be a termination of employment but, except as otherwise determined by the Administrator, the employee’s Performance Award will be reduced pro rata based on the number of months during which such person was on such leave of absence during the performance period. A Performance Award shall not vest during a leave of absence granted an employee for local, state, provincial, or federal government service.
(7)Upon termination of an employee’s employment by reason of Disability or death prior to the end of any performance period, the Performance Award granted to such employee with respect to such performance period, except as otherwise provided in Section 4.d(3), shall be reduced pro rata based on the number of months remaining in the performance period after the month of such employee’s Disability or death. The percentage of the reduced Performance Award to be distributed to such employee shall be determined by the Administrator (i) on the basis of the performance levels established for such award (including the minimum performance level) and the performance level achieved through the end of the fiscal year during which such employee became Disabled or died and (ii) in the discretion of the Administrator, on the basis of individual performance during the applicable period. Such Final Awards will immediately vest and be paid as promptly as practicable.
(8)If an employee is promoted during the performance period with respect to any Performance Award, such Performance Award may, in the discretion of the Administrator, be increased to reflect such employee’s new responsibilities.
(9)Performance Awards that have become Final Awards may be subject to a vesting schedule established by the Administrator. Except as otherwise provided in this Plan, no Final Award (or portion thereof) subject to a vesting schedule shall be paid prior to vesting and the unpaid portion of any Final Award shall be subject to the provisions of Section 4.d(5). The Administrator shall have the authority to
    Page 7 of 20    

modify a vesting schedule as may be necessary or appropriate in order to implement the purposes of this Plan.
(10)No holder of a Performance Award shall have any rights to dividends or interest or other rights of a stockholder with respect to a Performance Award prior to such Performance Award’s becoming a Final Award.
(11)To the extent that any employee, former employee, or any other person acquires a right to receive payments or distributions under this Plan with respect to a Performance Award, such right shall be no greater than the right of a general unsecured creditor of the Company. All payments and distributions to be made hereunder shall be paid from the general assets of the Company. Nothing contained in this Plan, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship between the Company and any employee, former employee, or any other person.
5.EFFECT OF CERTAIN TRANSACTIONS
a.MERGERS, ETC. Other than in connection with Awards that are denominated and subject to settlement in cash, Awards shall not vest in connection with a Covered Transaction unless such Covered Transaction is accompanied by a “double trigger event”. For this purpose, a “double trigger event” occurs in connection with a Covered Transaction if (i) the Award is not appropriately assumed nor an equivalent award substituted by the surviving, continuing, successor or purchasing company or other business entity or parent thereof, as the case may be, (ii) cash or cash equivalents are the sole or primary form of consideration to be received by the shareholder of the Company and (iii) at the time of, or within 12 months following the Covered Transaction, the Participant incurs a termination of employment without Cause or for Good Reason.
Upon a Covered Transaction “double trigger event”: (i) in the case of a Stock Option or SAR, the Stock Option or SAR shall become fully vested and exercisable immediately upon the occurrence of the double trigger event; (ii) in the case of Restricted Stock, Deferred Stock or restricted stock units (in each case other than an award of Restricted Stock, award of Deferred Stock or award of restricted stock units that is a Performance Award), the restriction period shall lapse and the Restricted Stock, Deferred Stock or restricted stock unit (as applicable) shall fully vest immediately upon the occurrence of the double trigger event; and (iii) in the case of a Performance Award, payment under the Award shall be subject to the terms set forth in the applicable award agreement.
b.CHANGES IN AND DISTRIBUTIONS WITH RESPECT TO THE STOCK
(1)BASIC ADJUSTMENT PROVISIONS. In the event of a stock dividend, stock split or combination of shares, recapitalization or other change in the Company’s capital structure, the Administrator will make appropriate adjustments to the maximum number of shares that may be delivered under the Plan under Section 2.a and to the maximum share limits described in Section 2.c, and will also make appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding or subsequently granted, any exercise prices relating to Awards and any other provision of Awards affected by such change.
(2)CERTAIN OTHER ADJUSTMENTS. The Administrator may also make adjustments of the type described in paragraph (1) above to take into account distributions to common stockholders other than those provided for in Section 5.a and 5.b (1), or any other event, if the Administrator determines that adjustments are appropriate to avoid distortion in the operation of the Plan and to preserve the value of Awards made hereunder; PROVIDED, that no such adjustment shall be made to the maximum share
    Page 8 of 20    

limits described in Section 2.c nor shall any change be made to ISOs except to the extent consistent with their continued qualification under Section 422 of the Code.
(3)CONTINUING APPLICATION OF PLAN TERMS. References in the Plan to shares of Stock shall be construed to include any stock or securities resulting from an adjustment pursuant to Section 5.b(1) or 5.b(2) above.
6.LEGAL CONDITIONS ON DELIVERY OF STOCK
The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until the Company’s counsel has approved all legal matters in connection with the issuance and delivery of such shares; if the outstanding Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance; and all conditions of the Award have been satisfied or waived. If the sale of Stock has not been registered under the Securities Act of 1933, as amended, the Company may require, as a condition to exercise of the Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of such Act. The Company may require that certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock.
7.AMENDMENT AND TERMINATION
The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by law, or may at any time terminate the Plan as to any further grants of Awards; PROVIDED, that (except to the extent expressly required or permitted by the Plan) no such amendment will, without the approval of the stockholders of the Company, effectuate a change for which stockholder approval is required under the rules of the New York Stock Exchange (which includes any “material revision” as defined under the rules of the New York Stock Exchange) or in order for the Plan to continue to qualify under Section 422 of the Code and to have an Award comply with, or avoid adverse consequences under, Section 409A of the Code.
8.NON‑LIMITATION OF THE COMPANY’S RIGHTS
The existence of the Plan or the grant of any Award shall not in any way affect the Company’s right to award a person bonuses or other compensation in addition to Awards under the Plan.
9.COMPLIANCE WITH APPLICABLE LAW
If any provision of the Plan or any applicable award agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction, or as to any person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the applicable award agreement, such provision shall be stricken as to such jurisdiction, person or Award, and the remainder of the Plan and any such applicable award agreement shall remain in full force and effect.
10.DATA PRIVACY
The Company, any Affiliate and Committee may collect, process, transmit and store, in any
    Page 9 of 20    

form whatsoever, any data of a professional or personal nature described in the Plan, the applicable award agreement and any other grant or plan administration materials by and among, as applicable, the Company or any Affiliate that is necessary, in the discretion of the Company or any Affiliate, for the purposes of implementing, administering and managing the Participant’s participation in the Plan. The Company and any Affiliate may share such information with any third party in any country, including any trustee, registrar, administrative agent, broker, stock plan service provider or any other person assisting the Company with the implementation, administration, and management of the Awards and the Plan. The Company, any Affiliate, the Committee and any possible recipients described herein may receive, possess, use, retain and transfer the data in electronic or other form, for the sole purpose described herein. The Participant may refuse to provide consent or authorization, or may withdraw such consent or authorization, regarding the matters described in this Section 10; PROVIDED, however, that such refusal or withdrawal may affect the Participant’s ability to participate in the Plan.
11.GOVERNING LAW
The Plan shall be construed in accordance with the laws of The Commonwealth of Massachusetts without reference to principles of conflicts of laws.
12.DEFINED TERMS.
The following terms, when used in the Plan, shall have the meanings and be subject to the provisions set forth below:
“2007 Plan”. The Charles River Laboratories International, Inc. 2007 Incentive Plan as from time to time amended and in effect.
“2016 Plan”: The Charles River Laboratories International, Inc. 2016 Incentive Plan as from time to time amended and in effect.
“ADMINISTRATOR”: The Board or, if one or more has been appointed, the Committee. With respect to ministerial tasks deemed appropriate by the Board or Committee, the term “Administrator” shall also include such persons (including Employees) to whom the Board or Committee shall have delegated such tasks.
“AFFILIATE”: Any corporation or other entity owning, directly or indirectly, 50% or more of the outstanding Stock of the Company, or in which the Company or any such corporation or other entity owns, directly or indirectly, 50% of the outstanding capital stock (determined by aggregate voting rights) or other voting interests.
“AWARD”: Any or a combination of the following (which shall include any Final Award with respect to the following):
(i) Stock Options.
(ii) SARs.
(iii) Restricted Stock.
(iv) Unrestricted Stock.
(v) Deferred Stock.

    Page 10 of 20    

(vi) Cash Performance Awards.
(vii) Other Performance Awards.
“BOARD”: The Board of Directors of the Company.
“CASH PERFORMANCE AWARD”: A Performance Award payable in cash. The right of the Company under Section 4.a(3) (subject to the consent of the holder of the Award as therein provided) to extinguish an Award in exchange for cash or the exercise by the Company of such right shall not make an Award otherwise not payable in cash a Cash Performance Award.
“CAUSE”: Unless otherwise provided for in a Participant’s written agreement with the Company, “Cause”” for termination by the Company of the Participant’s employment shall mean (i) the willful and continued failure by the Participant to perform the Participant’s duties with the Company, (ii) a substantial and not de minimis violation of the Company’s Code of Business Conduct and Ethics (and any successor policy), as the same are in effect from time to time, (iii) the Participant’s conviction of a felony or (iv) engaging in conduct that constitutes a violation of any (x) confidential agreements with the Company or (y) confidentiality policies applicable to the Participant.
“CODE”: The U.S. Internal Revenue Code of 1986 as from time to time amended and in effect, or any successor statute as from time to time in effect.
“COMMITTEE”: One or more committees of the Board (including any subcommittee thereof) appointed or authorized to make Awards and otherwise to administer the Plan.
“COMPANY”: Charles River Laboratories International, Inc.
“COVERED TRANSACTION”: Any of (i) the consummation of a consolidation, merger or other transaction which results in any individual, entity or “group” (within the meaning of section 13(d) of the Securities Exchange Act of 1934) acquiring the beneficial ownership (within the meaning of Rule 13d‑3 promulgated under the Exchange Act) directly or indirectly of more than 50% of either the then outstanding shares of common stock of the Company or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors, (ii) at any time during a period of 12 consecutive months, individuals who at the beginning of such period constituted the Board and any new member of the Board whose election or nomination for election was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of such period or whose election or nomination for election was so approved, cease for any reason to constitute a majority of members of the Board, (iii) the consummation of a sale or transfer of all or substantially all the Company’s assets, or (iv) a dissolution or liquidation of the Company.
“DEFERRED STOCK”: A promise to deliver Stock, other securities or other property in the future on specified terms to a Participant (including, for the avoidance of doubt, a director of the Company).
“DISABILITY”: With respect to any Participant, “disability” as defined in such Participant’s employment agreement, if any, or if not so defined, except as otherwise provided in such Participant’s award agreement:
(i) a Participant’s inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months; or

    Page 11 of 20    

(ii) a Participant is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under the Company’s accident and health plan.
“EMPLOYEE”: Any person who is employed by the Company or an Affiliate.
“FULL-VALUE AWARD”: an Award other than an Option or SAR, and which is settled by the issuance of shares of Stock or the value of the stated number of shares in cash.
“FUNGIBLE POOL UNIT”: the measuring unit used for purposes of the Plan, as specified in Section 2, to determine the number of Shares which may be subject to Awards hereunder, which shall consist of Shares in the proportions (ranging from 1.0 to 2.3) as set forth in Section 2.a.
“GOOD REASON”: Unless otherwise provided for in a Participant’s written agreement with the Company, Good Reason for termination by the Participant of the Participant’s employment shall mean the occurrence (without the Participant’s express written consent) of any one of the following acts by the Company, or failures by the Company to act, unless in the case of any act or failure to act described in paragraph (i), (iii) or (iv) below, such act or failure to act is corrected prior to the date of termination:
(i) the assignment to the Participant of any duties inconsistent with the Participant’s position and responsibilities as in effect immediately prior to the Covered Transaction;
(ii) a reduction by the Company in the Participant’s annual base salary as in effect on the date of the Covered Transaction;
(iii) the failure by the Company to continue in effect any compensation plan in which the Participant participates immediately prior to the Covered Transaction which is material to the Participant’s total compensation, unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan, or the failure by the Company to continue the Participant’s participation therein (or in a substitute or alternative plan) on a basis not materially less favorable, both in terms of the amount of benefits provided and the level of the Participant’s participation relative to other participants, as existed at the time of the Covered Transaction;
(iv) the failure by the Company to continue to provide the Participant with benefits substantially similar to those enjoyed by the Participant under any of the Company’s pension, life insurance, medical, health and accident, or disability plans in which the Participant was participating at the time of the Covered Transaction, the taking of any action by the Company which would directly or indirectly materially reduce any of such benefits or deprive the Participant of any material fringe benefit enjoyed by the Participant at the time of the Covered Transaction, or the failure by the Company to provide the Participant with the number of paid vacation days to which the Participant is entitled on the basis of years of service with the Company in accordance with the Company’s normal vacation policy in effect at the time of the Covered Transaction; or
(v) the Company’s requiring the Participant to relocate to an office or location more than fifty (50) miles distant from the office or location at which the Participant was based immediately prior to the date of termination.
“ISO”: A Stock Option intended to be an “incentive stock option” within the meaning of Section 422 of the Code.

    Page 12 of 20    

“ORIGINAL EFFECTIVE DATE”: May 8, 2018.
“PARTICIPANT”: An Employee, director or other person providing services to the Company or its Affiliates who is granted an Award under the Plan.
“PERFORMANCE AWARD”: An Award subject to Performance Criteria (including any Award that is a Final Award distributed in satisfaction of the vesting of a Performance Award that was subject to Performance Criteria).
“PERFORMANCE CRITERIA”: Specified criteria the satisfaction of which is a condition for the exercisability, vesting or full enjoyment of an Award. A Performance Criterion measure and targets with respect thereto determined by the Administrator need not be based upon an increase, a positive or improved result or avoidance of loss.
“PLAN”: The Charles River Laboratories International, Inc. 2018 Incentive Plan, as amended and restated as of March 14, 2020, as from time to time further amended and in effect.
“PREEXISTING PLANS”: Any plan of the Company or its predecessors in existence at or prior to the Effective Date under which equity, equity-based or performance cash awards were granted, including, without limitation, the following: (1) the 2007 Plan and (2) the 2016 Plan. For the purposes of this definition, “preexisting plans” shall not refer to the Company’s Executive Incentive Compensation Plan (EICP).
“RESTRICTED STOCK”: An Award of Stock subject to restrictions requiring that such Stock be redelivered to the Company if specified conditions are not satisfied.
“SARS”: Rights entitling the holder upon exercise to receive cash or Stock, as the Administrator determines, equal to a function (determined by the Administrator using such factors as it deems appropriate) of the amount by which the Stock has appreciated in value since the date of the Award.
“STOCK”: Common Stock of the Company.
“STOCK OPTIONS”: Options entitling the recipient to acquire shares of Stock upon payment of the exercise price.
“UNRESTRICTED STOCK”: An Award of Stock not subject to any restrictions under the Plan.
13.SECTION 409A OF THE CODE
To the extent applicable, Awards granted under the Plan are intended to comply with or be exempt from Section 409A of the Code, and the Administrator shall interpret and administer the Plan in accordance therewith. In addition, any provision in this Plan document that is determined to violate the requirements of Section 409A shall be void and without effect. In addition, any provision that is required to appear in this Plan document that is not expressly set forth shall be deemed to be set forth herein, and such Plan shall be administered in all respects as if such provisions were expressly set forth. The Administrator shall have the authority unilaterally to accelerate or delay a payment to which the holder of any Award may be entitled to the extent necessary or desirable to comply with, or avoid adverse consequences under, Section 409A (including, for the avoidance of doubt, with regard to an individual deemed to be a “specified employee” under Section 409A of the Code who has received an amount hereunder deemed to be “deferred compensation” subject to Section 409A of the Code). Notwithstanding the foregoing, the Company does not guarantee that this Plan, any Awards or any
    Page 13 of 20    

payments with respect thereto are in compliance with Section 409A of the Code.
14.EFFECTIVE DATE OF THE PLAN
    The Plan, prior to its amendment and restatement, became effective as of the date of its approval by the Board on March 20, 2018, subject to its approval by the stockholders of the Company on the Original Effective Date. The Plan, as amended and restated, shall be effective as of the date of its approval by the Board, subject to its approval by the stockholders of the Company (the “Effective Date”).
15.AWARDS UNDER PREEXISTING PLANS
Upon approval of the Plan by stockholders of the Company as contemplated under Section 14, no further awards shall be granted under the Preexisting Plans; PROVIDED, however, that any shares that have been forfeited, cancelled or otherwise not delivered in accordance with the terms of the applicable award under a Preexisting Plan may be subsequently again awarded in accordance with the terms of the Plan. For purposes of clarity, the number of shares that relate to an Award under the Preexisting Plans is the maximum number of shares that can be delivered with respect to such Award. 

    Page 14 of 20    

French Schedule
1Application and Purpose
This French Schedule includes special terms and conditions applicable to Qualified Deferred Stock Awards granted to Participants situated and/or employed in France. These terms and conditions are in addition to, or if so indicated, in place of, the terms and conditions set forth in the Plan.
The purpose of this French Schedule is to make certain variations to the terms of the Plan, in order to satisfy French securities laws, exchange control, corporate law and tax requirements, especially the provisions of Articles L. 225-197-1 et seq. of the French Commercial Code and article 135 of the Macron Law (loi n° 2015-990 du 6 août 2015 pour la croissance, l’activité et l’égalité des chances économiques as amended by the 2017 and 2018 Finance bills respectively n° 2016-1917 dated December 29, 2016 and n° 2017-1837 dated December 30, 2017), so that Qualified Deferred Stock Awards may qualify for favorable income tax and social security treatment in France (provided by article 80 quaterdecies of the French Tax Code and article L242-1 of the French Social Security Code).
The rules of the Plan shall apply, subject to the modifications contained in this French Schedule, whenever the Administrator decides to grant Qualified Deferred Stock Awards to Eligible French Employees under this French Schedule. In all other circumstances, where other forms of Awards (other than Qualified Deferred Stock Award) are granted to Eligible French Employees, the rules of the Plan, unamended by this French Schedule, shall apply.
The amendments to the Plan set out in this French Schedule shall only apply in respect of Qualified Deferred Stock Awards granted in accordance with this French Schedule.
This French Schedule has been approved by the shareholders of the Company (as the empowered foreign corporate body) on 8 May 2018, as required by the French tax authorities.
2Terms and Meanings of Words Used
Unless provided otherwise or unless the context requires otherwise, capitalized terms used but not defined in this French Schedule shall have the meaning assigned to them in the Plan.
The terms of Qualified Deferred Stock Awards under this French Schedule shall be the same as those for Deferred Stock awards under the Plan, except to the extent that this French Schedule provides to the contrary. References to Deferred Stock awards in the Plan shall apply to, and include, Qualified Deferred Stock Awards, save where expressed not to apply, or save where modified by the terms of this French Schedule (in which case, the terms shall apply as modified).
References to eligible Employees in the Plan shall apply to Eligible French Employees and references to Participants in the Plan shall apply to French Participants, save where expressed not to apply, or save where modified by the terms of this French Schedule (in which case, the terms shall apply as modified).
The following definitions shall apply to Qualified Deferred Stock Awards granted in accordance with this French Schedule:
“CLOSED PERIOD”: has the meaning given in Article L. 225-197-1 of the French Commercial Code, as:
(i)ten quotation days preceding and three quotation days following the disclosure to the public of the consolidated financial statements or the annual statements of the Company; or
    Page 15 of 20    

(ii)any period during which the corporate management of the Company possesses material information which could, if disclosed to the public, significantly impact the quotation of the Stock, until ten quotation days after the day such information is disclosed to the public.
“ELIGIBLE FRENCH EMPLOYEE”: means an employee of a French Subsidiary (or a French branch of a non-French Group Member), or a corporate officer of a French Subsidiary (or a French branch of a non-French Group Member) who holds the duties of chairman of the board, general manager, deputy general manager, member of the directory board, or manager (respectively président du conseil d’administration, directeur général, directeur général délégué, membre du directoire or gérant).
“FRENCH PARTICIPANT”: means individuals who have been granted Qualified Deferred Stock Awards.
“GRANT DATE”: means the date on which a Qualified Deferred Stock Award is granted to an Eligible French Employee by the Administrator.
“GROUP”: means the Company and its Subsidiaries from time to time, and “Group Member” shall be interpreted accordingly.
“HOLDING PERIOD”: means such period (applicable under article L225-197-1 of the French commercial code) following the vesting of the Qualified Deferred Stock Award as the Administrator may determine, which shall not expire until at least 2 years after the Grant Date.
“QUALIFIED DEFERRED STOCK AWARD”: means a Deferred Stock award granted to an Eligible French Employee which is intended to satisfy French securities laws, exchange control, corporate law and tax requirements (especially the provisions of Articles L. 225-197-1 et seq. of the French Commercial Code) in order to qualify for favorable income tax and social security treatment in France (articles 80 quaterdecies of French Tax Code and L.242-1 of French Social Security Code) and which, for the avoidance of doubt, can be subject to Performance Criteria.
“SUBSIDIARY”: has the meaning given in Article L. 225-197-2 of the French Commercial Code, as:
(i)a company in which the Company holds, directly or indirectly, at least 10 per cent of the share capital or voting rights;
(ii)a company holding directly or indirectly at least 10 per cent of the share capital or voting rights of the Company; or
(iii)a company for which at least 50 per cent of the share capital or voting rights are held by a company which holds at least 50 per cent of the share capital of the Company.
“VESTING PERIOD”: means such period (applicable under article L225-197-1 of the French commercial code) as determined by the Administrator, which shall not be less than 12 months from the Grant Date, and at the end of which, the French Participant will become entitled to have the Stock delivered to or to the order of him/her.
The following definition shall apply to Qualified Deferred Stock Awards granted in accordance with this French Schedule and shall replace the definition as it appears at Section 12 of the Plan:
“DISABILITY”: has the meaning given in the second or third category of Article L.341-4 of the French Code of Social Security.

    Page 16 of 20    

3Limits on awards under the Plan
The following wording is inserted immediately following the end of the Section 2.a. of the Plan, as follows:
“Notwithstanding any other provisions of the Plan rules, if, at the Grant Date, the total number of Stock granted subject to Awards made under the Plan and any other employee stock plan of the Company, where such Awards are granted subject to and in accordance with the provisions of Articles L.225-197-1 et seq. of the French Commercial Code and are, or are similar in substance to, a conditional right to acquire stock (other than an option) for no or limited cost (up to 5 percent of the fair market value of the stock), shall exceed 10 percent of the issued ordinary share capital of the issuing Company, Qualified Deferred Stock Awards may only be granted over such number of Stock as does not exceed a ratio of one to five between the smallest and largest awards of Qualified Deferred Stock Awards.
However, this relevant percentage is increased to 30 percent, if at the same time, awards are granted under the Plan, or awards are granted under any other stock plan of a Group Member, to all Eligible French Employees employed by a French Group Member or a French branch of a non-French Group Member.”
The following wording is inserted immediately following the end of the Section 2.c. of the Plan, as follows:
“No Qualified Deferred Stock Award shall be granted to an Eligible French Employee who holds 10 percent or more (including any outstanding Awards) under the Plan or outstanding awards under any other employee share plan operated by the Group where such Awards or awards (as applicable) are, or are similar in substance to, a conditional right to acquire shares, other than non-exercised options) of the share capital of the Company, or who may hold, as the result of the Qualified Deferred Stock Award, 10 percent or more of the share capital of the Company.”
4Eligibility and Participation
Notwithstanding any other provision of the Plan rules, Qualified Deferred Stock Awards may only be granted to Eligible French Employees.
5Alternative Settlement
Section 4.a.(3) of the Plan is deleted in it its entirety.
6Vesting Period
The following wording is inserted immediately following Section 4.a.(5) of the Plan, as follows:
“The Vesting Period for Qualified Deferred Stock Award shall not be less than 12 months, so that the ownership of the Qualified Deferred Stock Award cannot be transferred to, or to the order of, the French Employees before the expiry of a minimum one year period from their Grant Date.
During the Vesting Period, the delivery of Stock must remain conditional and may also be subject to the Performance Criteria, which means that the Eligible French Employees only hold a contractual right towards the Company and are not entitled to any shareholder’s right during the Vesting Period (no rights to dividend (even through an equivalent bonus whose payment would be deferred), no voting rights).”

    Page 17 of 20    

7Dividend Equivalents
The first sentence of Section 4.a.(7) of the Plan is deleted in its entirety.
8Holding Period
A new Section 4.a.(12) is inserted immediately following Section 4.a.(11) of the Plan, as follows:
“HOLDING PERIOD. The Administrator may determine that a Holding Period shall apply to a Qualified Deferred Stock Award, during which period the Stock acquired by the French Participant following vesting of the Qualified Deferred Stock Award (or any interest in them) may not be sold, transferred, assigned, mortgaged, charged or otherwise disposed of by, or on behalf of, the French Participant, except for a transfer to the French Participant’s legal personal representatives in the event of his death.
To the extent that a Qualified Deferred Stock Award vests less than two years after the Grant Date, the Stock acquired on vesting shall be subject to a Holding Period, so that there is a two-year period between the Grant Date and the date that the Stock may be freely disposed of by the French Participant, as required by Article L.225-197-1 of the French Commercial Code.
During the Holding Period, the Stock may be delivered to the French Participant, provided he shall agree not to sell, transfer, assign, mortgage, charge or otherwise dispose of the Stock (or any interest in them) during the Holding Period; or a nominee on behalf of the French Participant, provided that the beneficial ownership of the Stock vests in the French Participant and subject to a restriction on sale, transfer, assignment, mortgaging, charging or other disposal of such Stock (or any interest in them).”
9Closed Period
A new Section 4.a.(13) is inserted immediately following Section 4.a.(12) of the Plan, as follows:
“CLOSED PERIOD. After the expiration of the Holding Period (if applicable), Stock transferred to a French Participant in satisfaction of a Qualified Deferred Stock Award cannot be sold or transferred by or on behalf of a French Employee during a Closed Period.”
10Cessation of employment
Sections 4.a.(5)(A), 4.d.(5) to 4.d.(7) of the Plan continue to apply to Qualified Deferred Stock Awards, where relevant, if a French Participant ceases to be employee, except that a new Section 4.d.(12) is inserted immediately following Section 4.d.(11) of the Plan, as follows:
“Notwithstanding any other provision of the Plan rules, the Plan shall, in no circumstances, have the effect of accelerating the Vesting Period or disapplying the Holding Period in circumstances where there would be a less than two year period between the Grant Date and the date that the Stock may be freely disposed of by the French Participant, except in the two following cases:
- Death of the French Participant
If a French Participant dies before his Qualified Deferred Stock Award has vested, his Qualified Deferred Stock Award shall vest immediately and any applicable Holding Period will fall away. The Qualified Deferred Stock Award may only be adjusted in such proportion as determined by the Administrator in its absolute discretion after taking into account the Performance Criteria. The Qualified Deferred Stock Award cannot be adjusted for any other criteria e.g. for time. The heirs of the deceased French Participant can require the vesting within six months from the date of death, as provided by the article L225-197-3 of the French commercial code.

    Page 18 of 20    

Where, after a Qualified Deferred Stock Award has vested but before the expiry of any applicable Holding Period, the French Participant dies, his Stock shall cease to be subject to the Holding Period.
- Disability of the French Participant
Notwithstanding any other provision of the Plan rules, if a French Participant ceases to be in employment due to Disability before his Qualified Deferred Stock Award has vested all or a proportion of his Qualified Deferred Stock Award may vest immediately, in such proportion as determined by the Administrator in its absolute discretion, having regard to the satisfaction of the Performance Criteria and any other condition as at the time of cessation of employment, and such other factors as the Administrator may consider relevant. If a French Participant ceases to be in employment due to Disability before his Qualified Deferred Stock Award has vested, the Holding Period shall fall away.
If the French Participant ceases to be in employment due to Disability after the vesting but before the expiry of any applicable Holding Period, his Stock shall cease to be subject to the Holding Period on the date of cessation of his employment.”
11Effect of certain transactions
The following wording is inserted immediately following the end of the Sections 5.a of the Plan, as follows:
“To the extent that the Administrator intends for the Qualified Deferred Stock Awards to retain favorable tax and social security treatment under this French Schedule, Sections 5.a and 5.b shall apply to Qualified Deferred Stock Awards in accordance with the provisions of Articles L. 225-197-1-III of the French Commercial Code and 80 quaterdecies of the French Tax Code, and shall be modified or interpreted in order to comply with these provisions.”
The following wording is inserted immediately following the end of the Section 5.b of the Plan, as follows:
“If the share capital of the Company is modified during the Vesting Period or Holding Period, the Qualified Deferred Stock Awards may be adjusted as appropriate to ensure that there is no impact on the French Participants’ Qualified Deferred Stock Awards, provided that such adjustment has the sole purpose and effect of preserving the value of Qualified Deferred Stock Awards and that additional Stock which could be issued as a result remains subject to the same requirements (including the vesting and holding requirements) as those applying to the original Qualified Deferred Stock Award”.
12Taxes
A new rule is inserted immediately following the end of Section 4.a.(6) of the Plan, as follows:
“The preceding paragraph does not apply to Qualified Deferred Stock Awards. A French Participant is responsible for paying any relevant taxes and reporting the receipt of any income under the French Schedule, however made, to the relevant tax authority”.
13Amendment and termination
The following wording is inserted immediately following the end of the Section 7 of the Plan, as follows:
“Except as permitted in this Section 7, an amendment to the provisions of the Plan may only be applied to Qualified Deferred Stock Awards already granted to the extent that:

    Page 19 of 20    

-the proposed change does not affect the qualifying status of the Qualified Deferred Stock Awards for French tax and social security purposes; and
-if the change would adversely affect the existing rights of the French Participants, affected French Participants’ prior consent is obtained.”
14Cross references
Unless specified otherwise, where a deletion, addition or amendment is made to the rules by this French Schedule, other references throughout the rules and this French Schedule to those additional, amended or deleted Rules (as appropriate) are deemed to be included, modified or deleted accordingly.
15Conclusion
The following paragraphs are inserted immediately following Section 11 in the Plan, as follows:
“It is intended that Deferred Stock awards granted to Eligible French Employees shall qualify for the special tax and social security treatment applicable to free shares granted under articles L. 225-197-1 to L.225-197-6 of the French Commercial Code and in accordance with the relevant provisions set forth by the French tax and social security laws (article 80 quaterdecies of the French Tax Code and article L.242-1 of the French Social security Code). Accordingly, the rules, the terms of the French Schedule and the terms upon which a Deferred Stock award has been granted shall be interpreted and, where necessary, deemed to be modified, in accordance with the relevant provisions set forth by French laws, as well as the relevant administrative provisions.
If for any reason a Deferred Stock award does not satisfy the requirements of the French tax authorities for favorable income tax and social security treatment, and therefore does not qualify as a Qualified Deferred Stock Award, the Company or Administrator can take such actions, including (but not limited to) changing the Vesting Period and/or the Holding Period of the Deferred Stock award, as it considers reasonably necessary to achieve such treatment, and the rules, the terms of the French Schedule and the terms of the Qualified Deferred Stock Award shall be interpreted and, where necessary, modified accordingly. The Company and any Group Member shall not be liable for any adverse consequences, legal, tax or otherwise, if and to the extent that Deferred Stock awards do not qualify as Qualified Deferred Stock Awards.”

    Page 20 of 20    
 EX-10.6 3 crl1230202310-kex106.htm EX-10.6 Document

Exhibit 10.6
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD


Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”).

Pursuant to Section 4(c) of the Plan, you have been granted restricted units of Common Stock on the following terms and subject to the provisions of the Plan, which is incorporated by reference. In the event of a conflict between the provisions of the Plan and this Award Document, the provisions of the Plan will prevail. Each unit entitles you to receive one share of the Company’s Common Stock at such time as your units vest in accordance with the schedule set forth below. The grant of the units to you does not transfer title to the underlying shares to you until such units have vested. Therefore, you do not have any voting or dividend rights relating to the underlying shares until such time as units vest; however any dividend equivalents on the unvested portion of your restricted stock units will be held in an escrow account until such shares vest.

Name:[Participant Name:First Name Last Name] Total Number of Units Granted:[Granted:Shares Granted]
Date of Grant:[Grant Date:Month DD, YYYY]

Vesting Schedule: Vesting is per below schedule


[Vesting Table:Month DD, YYYY, quantity]


This Restricted Stock Units Award is made to you expressly on the condition that the shares underlying such award are granted under and governed by the terms and conditions of the Plan and the terms and conditions set forth in the attached Exhibit A.


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
image_0a.jpg

Victoria Creamer
    CEVP & Chief People Officer














EXHIBIT A


TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT AWARD


Payment for Shares
No payment is required for the Restricted Stock Units (“RSU”s) that you receive under this Award, nor for the underlying Shares upon vesting of the RSUs.

Vesting
The RSUs that you receive under this Award will vest in accordance with the “Vesting Schedule” set forth in the Award Document.

Restricted Units

You may not sell, transfer, pledge or otherwise dispose of, make any short sale of, grant any option for the purchase of or enter into any hedging or similar transaction with the same economic effect as a sale, any RSUs, except as provided in the next paragraph.

Except as otherwise provided in the Plan, RSUs will not be transferable by you other than by will or by the laws of descent and distribution. With the consent of the Committee, you may transfer RSUs to: (i) your spouse, children or grandchildren (“Immediate Family Members”), (ii) a trust or trusts for the primary benefit of you and/or any or all of such Immediate Family Members or (iii) a partnership or other entity in which you and/or any or all of such Immediate Family Members or trusts are the only partners or equity participants; provided that a transferee of RSUs must agree in writing on a form prescribed by the Company to be bound by all provisions of this Award Document and subsequent transfers of RSUs will be prohibited except those in accordance with the Plan. Following transfer, RSUs will continue to be subject to the same terms and conditions as were applicable immediately before transfer, and the events of termination of the section below entitled “Termination” will continue to be applied with respect to you.

Termination

If you cease to be an employee of the Company or an Affiliate for any reason other than a termination by virtue of your death or a Full Career Retirement, then (1) you will forfeit all of the unvested RSUs that you receive under this Award without any consideration and (2) such shares of unvested RSUs covered by this Award will revert to the Plan.

If your employment with the Company is terminated by virtue of your death, all of the unvested RSUs that you receive under this Award shall vest and be settled on the date of such termination.

If your employment with the Company is terminated by virtue of a Full Career Retirement, the units shall continue to vest and be settled as they would have absent an employment termination, subject to your continued compliance with the restrictions set forth in below in “Retirement Restrictions.”

For purposes of this Award Document:

“Full Career Retirement” means your termination of employment from the Company and its subsidiaries and/or affiliates, other than for cause, on or after such time that you have become Retirement Eligible.

“Retirement Eligible” means that you (i) have attained age 55, (ii) have a minimum of 10 years of service with the Company and its subsidiaries and/or affiliates (such service only to have deemed to have commenced at such time as such subsidiary and/or affiliate became a subsidiary and/or affiliate of the Company, (iii) the numerical sum of your age and years of service (as calculated pursuant to clause (ii) above) is equal to at least 70, (iv) you have given notice, in form satisfactory to the Company, to the Chief People Officer of the Company (or, if you are the Chief People Officer, to the Chief Executive Officer) of your intent to retire specifying the exact intended date of retirement to the Company (provided that prior to such notice the Company had not already given you notice that you would be terminated), and remained employed by the Company until the earlier of (a) the one year anniversary of the date of such notice or (b) the date on which you experience a termination of employment due to death or disability or you are terminated by the Company without cause and (v) at the time you give such notice to the Company you also provide the Company with a signed acknowledgement, in a form satisfactory to the Company, reaffirming the covenants set forth below in “Retirement Restrictions”; provided, however, in the case of (b), the employee’s age and years of service


shall be calculated as if the employee was employed through the one-year anniversary of the date of such notice.

Retirement Restrictions

For the period beginning on the date of your Full Career Retirement and ending on the date on which the restricted unit would have become fully vested absent a termination of employment (the “Restricted Period”), you shall not, directly or indirectly, without the prior written consent of the Company,
(1)render services as an employee, consultant, director, partner or otherwise to any person, entity, division, subsidiary or subgroup whose primary business activity is in competition with the Company’s business, or
(2)assist with the creation of (a) any entity whose primary business activity is in competition with the Company’s business, or (b) any division, subsidiary or subgroup of an entity whose primary business activity is in competition with the Company’s business. Nothing herein shall prohibit you from pursuing employment with any corporation or entity engaged substantially in the discovery or development of pharmaceuticals or medical devices as long as such company also manufactures, markets and sells such products.

YOU ACKNOWLEDGE AND UNDERSTAND THAT THIS SECTION MAY AFFECT YOUR RIGHT TO ACCEPT EMPLOYMENT WITH OTHER COMPANIES SUBSEQUENT TO EMPLOYMENT BY THE COMPANY AND THAT THE RESTRICTIONS CONTAINED HEREIN ARE SEPARATE AND APART AND IN ADDITION TO ANY SIMILAR RESTRICTIONS, NON-COMPETE OR OTHERWISE, THAT YOU MAY BE SUBJECT TO PURSUANT ANY OTHER AGREEMENT WITH THE COMPANY OR ANY OF ITS AFFILIATES.

Shares

Upon the vesting of your RSUs, the underlying shares which have vested will be transferred from the transfer agent to your stock account at CRL’s stock plan administrator.

Withholding Taxes

No shares will be released to you unless you have made acceptable arrangements to pay any withholding taxes that may be due as a result of the receipt of Shares upon vesting of the RSUs that you receive under this Award. These arrangements may include withholding of Shares that otherwise would be released to you when the RSUs vest or surrendering of RSUs or shares that you already own. The Fair Market Value of RSUs or Shares that are withheld or that you surrender, determined as of the date when the taxes otherwise would have been withheld in cash, will be applied as a credit against the taxes.

Lock-Up Period

If requested by the Company, you hereby agree that you will not sell, transfer, pledge, otherwise dispose, make any short sale of, grant any option for the purchase of or enter into any hedging or similar transaction with the same economic effect as a sale, any Shares (or other securities of the Company) held by you (other than those included in the registration) for a period specified by the representative of the underwriters of the Common Stock (or other securities of the Company) not to exceed 180 days following the effective date of a registration statement of the Company filed under the Securities Act.

You agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, you will provide, within 10 days of the request, the information required by the Company or the
representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this section entitled “Lock-Up Period” will not apply to a registration relating solely to employee benefit plans on Form S-3 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the Shares (or other securities) subject to the foregoing restriction until the end of the 180-day period.

Recoupment

Shares awarded under this Award Agreement are subject to recoupment in accordance with the Company’s Corporate Governance Guidelines, as may be revised from time to time, and/or any other so-called recoupment, clawback or similar policy that may be approved by the Board of Directors of the Company or any committee thereof.

Section 409A of the Code
This Award is intended to exempt and/or comply with Section 409A of the Internal Revenue Code, as amended (the “Code”) and shall be administered, interpreted and construed accordingly. The Company may, in its sole discretion and without your consent, modify or amend the terms of this Award Agreement, impose conditions on


the timing and effectiveness of the issuance of the Restricted Stock Units, and/or take any other action it deems
necessary to cause this Award Agreement to be exempted from Section 409A (or to comply therewith to the extent the Company determines it is not excepted). Notwithstanding, you recognize and acknowledge that Section 409A may affect the timing and recognition of payments due hereunder, and may impose upon you certain taxes or other charges for which you are and shall remain solely responsible. If the Company considers you to be one of its “specified employees” and you are a U.S. taxpayer, in each case, at the time of your “separation from service” (as such terms are defined in the Code) from the Company, no conversion specified hereunder shall occur prior to the expiration of the six-month period measured from the date of your separation from service from the Company to the extent required to comply with Section 409A of the Code.

No Guarantee of Continued Service
YOU ACKNOWLEDGE AND AGREE THAT EXCEPT AS OTHERWISE PROVIDED HEREIN THE VESTING OF SHARES PURSUANT TO THE “VESTING SCHEDULE” HEREOF IS EARNED ONLY BY CONTINUING AS AN EMPLOYEE OF THE COMPANY OR ITS AFFILIATES. YOU FURTHER ACKNOWLEDGE AND AGREE THAT THIS AWARD DOCUMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE “VESTING SCHEDULE”
DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED EMPLOYMENT FOR THE VESTING PERIOD, FOR ANY PERIOD OR AT ALL AND WILL NOT INTERFERE IN ANY WAY WITH YOUR RIGHT OR THE COMPANY’S RIGHT OR ITS AFFILIATE'S RIGHT TO TERMINATE YOUR EMPLOYMENT AT ANY TIME, WITH OR WITHOUT CAUSE.

Entire Agreement; Governing Law
The Plan and this Award Document constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and you with respect to the subject matter hereof. This Award Document may not be modified in a manner that is materially adverse to your interest except by means of a writing signed by the Company and you. This Award Document is governed by the internal substantive laws of but not the choice of law rules of the Commonwealth of Massachusetts.


 EX-19 4 crl1230202310-kex19.htm EX-19 Document
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


PURPOSE

It is the policy of Charles River Laboratories International, Inc., its subsidiaries, and affiliates (together, the “Company” or “Charles River”) that it will comply with all applicable laws and regulations in conducting its business, without exception. All employees, directors, and officers of the Company are expected to abide by this policy. When carrying out Company business, employees, officers, and directors must avoid any activity that violates applicable laws or regulations. To avoid even an appearance of impropriety, the Company’s directors, officers, and certain other employees are subject to pre-approval requirements and other limitations on their ability to enter into transactions involving the Company’s securities. Although these limitations do not apply to transactions pursuant to written plans for trading securities that comply with Rule 10b5-1 (“Rule 10b5-1 Plan”) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”), the entry into amendment or termination of any such written trading plan is subject to pre-approval requirements and other limitations, as described below
SCOPE
This policy applies to all directors, officers, and employees of Charles River Laboratories International, Inc. (and its affiliates and subsidiaries), and to other people who gain access to that information. The prohibition applies to both domestic and international employees of the Company and its subsidiaries. Because of their access to confidential information on a regular basis, Company policy subjects its directors, corporate officers, employees at the level of Vice President or higher, and certain other employees (the “Window Group”) to additional restrictions on trading in the Company securities. The restrictions for the Window Group are discussed in the Guidelines section below. In addition, directors and certain employees with inside knowledge of material information may be subject to ad hoc restrictions on trading from time to time, as discussed in in the Event- Specific Trading Restriction Periods section below.

POLICY

THE USE OF INSIDE INFORMATION IN CONNECTION WITH TRADING IN SECURITIES

Page 1 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


General Rule
The U.S. securities laws regulate the sale and purchase of securities in the interest of protecting the investing public. U.S. securities laws give the Company, its officers and directors, and other employees the responsibility to ensure that information about the Company is not used unlawfully in the purchase and sale of securities.
All employees, officers, and directors should pay particularly close attention to the laws against trading on “inside” information. These laws are based upon the belief that all persons trading in a company’s securities should have equal access to all “material” information about that company. For example, if an employee, director, or officer of a company knows material non-public financial information, the individual is prohibited from buying or selling stock in the company until the information has been disclosed to the public. This is because the employee, director, or officer knows information that will probably cause the stock price to change, and it would be unfair for the employee, director, or officer to have an advantage (knowledge that the stock price will change) that the rest of the investing public does not have. In fact, it is more than unfair. It is considered to be fraudulent and illegal. Civil and criminal penalties for this kind of activity are severe.
The general rule can be stated as follows: It is a violation of the U.S. federal securities laws for any person to buy or sell securities if he or she is in possession of material inside information. Information is material if there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision. It is inside information if it has not been publicly disclosed in a manner making it available to investors generally on a broad-based non-exclusionary basis. Furthermore, it is illegal for any person in possession of material inside information to provide other people with such information or to recommend that they buy or sell the securities. (This is called “tipping”.) In that case, they may both be held liable.

The Securities and Exchange Commission (the “SEC”), the stock exchanges, and plaintiffs’ lawyers focus on uncovering insider trading. A breach of the insider trading laws could expose the insider to criminal fines per violation up to $5 million and imprisonment up to twenty years, in addition to civil penalties (up to three times the profits earned), and injunctive actions. In addition, punitive damages may be imposed under applicable state laws. Securities laws also subject controlling persons to civil penalties for illegal insider trading by employees, including employees located outside the United States. Controlling persons include directors, officers, and supervisors. These persons may be subject to fines up to the greater of $1 million-or three-times profit (or loss avoided) by the insider trader.

Inside information does not belong to the individual directors, officers, or other employees who may handle it or otherwise become knowledgeable about it. It is an asset of the Company. For any person to use such information for personal benefit or to disclose it to others outside the Company violates the Company’s interests. More particularly, in connection with trading in the Company securities, it is a fraud against members of the investing public and against the Company.

Other Companies' Stocks
Page 2 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


Employees, officers, and directors who learn material information about suppliers, customers, or competitors through their work at the Company should keep it confidential and not buy or sell stock in such companies until the information becomes public. Employees, officers, and directors should not give tips about such stocks.

Trading in Options

The insider trading prohibition also applies to trading in options, such as put and call options. Options trading is highly speculative and very risky. People who buy options are betting that the stock price will move rapidly. For that reason, when a person trades in options in his or her employer’s stock, it will arouse suspicion in the eyes of the SEC that the person was trading on the basis of inside information, particularly when the trading occurs before a Company announcement or major event. It is difficult for an employee, officer, or director to prove that he or she did not know about the announcement or event.

If the SEC or the stock exchanges were to notice active options trading by one or more employees, officers, or directors of the Company prior to an announcement, they would investigate. Such an investigation could be embarrassing to the Company (as well as expensive) and could result in severe penalties and expense for the persons involved. For all of these reasons, the Company prohibits its employees, officers, and directors from trading in options on the Company stock. This policy does not pertain to employee stock options granted by the Company, such as employee or director compensatory stock options (“employee stock options”) which cannot be traded to any extent.


Margin Accounts and Pledged Securities

Securities held in a margin account may be sold by the broker without the customer’s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because such a sale or foreclosure sale may occur at a time when an employee, director, or officer has material inside information or is otherwise not permitted to trade in Company securities, the Company prohibits employees, officers and directors from purchasing Company securities on margin or holding Company securities in a margin account or otherwise pledging Company securities as collateral for a loan. (Pledges of Company securities arising from certain types of hedging transactions are governed by the paragraph below entitled “Hedging Transactions.”)

Hedging Transactions

Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars, and exchange funds. Such hedging transactions may permit an employee, director, or officer to continue to own Company securities obtained through employee benefit plans or otherwise, but without the full risks and
Page 3 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


rewards of ownership. When that occurs, the employee, director, or officer may no longer have the same objectives as the Company’s other shareholders. Therefore, the employee, director, or officer is prohibited from engaging in any such transactions.

Guidelines

The following guidelines should be followed in order to ensure compliance with applicable antifraud laws and
with the Company’s policies:

1.Nondisclosure. Material inside information must not be disclosed to anyone, except to persons within the Company whose positions require them to know it.

2.Trading in the Company’s Securities. No employee, director, or officer should place a purchase or sale order or recommend that another person place a purchase or sale order in the Company’s securities, when he or she has knowledge of material information concerning the Company that has not been disclosed to the public. This includes orders for purchases and sales of stock and convertible securities. The exercise of employee stock options is not subject to this policy. However, stock that was acquired upon exercise of a stock option will be treated like any other stock, and may not be sold by an employee, officer, or director who is in possession of material inside information; accordingly, stock options may not be exercised pursuant to a net exercise program involving a broker or other third party and that is designed to cover the exercise price, withholding tax, and other related costs.

3.Avoid Speculation. Investing in the Company’s Common Stock provides an opportunity to share in the future growth of the Company. But investment in the Company and sharing in the growth of the Company does not mean short range speculation based on fluctuations in the market. Such activities put the personal gain of the employee, officer, or director in conflict with the best interests of the Company and its stockholders. Although this policy does not mean that employees, officers, or directors may never sell shares, the Company encourages employees and directors to avoid frequent trading in Company stock. Speculating in Company stock is not part of the Charles River culture.

4.Trading in Other Securities. No employee, director, or officer should place a purchase or sale order, or recommend that another person place a purchase or sale order, in the securities of another corporation if the employee, director, or officer learns during his or her employment confidential information about the other corporation that is likely to affect the value of those securities. For example, it would be a violation of the securities laws if an employee, officer, or director learned through Company sources that the Company intended to purchase assets from a company, and then bought or sold stock in that other company because of the likely increase or decrease in the value of its securities.

5.Employee Stock Purchase Plan. Employees are permitted to purchase Company Common Stock pursuant to the Employee Stock Purchase Plan (ESPP) provided that the election to participate in the ESPP is made when not in possession of material inside information or, for members of the Window
Page 4 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


Group (as defined below), during a Window (as defined below).

6.Restrictions on the Window Group. The Window Group consists of (a) directors and executive officers of the Company and their executive assistants, (b) officers and other employees of the Company with the title Vice President or higher and their executive assistants, and (c) such other persons as may be designated from time to time and informed of such status by the Company’s Office of the General Counsel. The Window Group also applies to such individual’s household members. The Window Group is subject to the following restrictions on trading in Company securities:
•any transactions involving Company securities, including bona fide gifts of Company securities by members of the Window group, (collectively, “trades”) are only permitted from the start of the first business day following an earnings release with respect to the preceding fiscal period until two weeks after the end of the second fiscal month of the then-current fiscal quarter (the “Window”), subject to the additional restrictions below;
•all trades are subject to prior review;
•clearance for all trades should be obtained from the Company’s Office of the General Counsel
(clearance will be given for no longer than three business days in advance of any trade);
•no trading outside the Window except for reasons of exceptional personal hardship and subject to prior review by the Office of the General Counsel or a legal department delegate; and
•individuals in the Window Group are also subject to the general restrictions on all employees.
Note that at times the Office of the General Counsel may determine that no trades may occur even during the Window when clearance is requested. In some cases, a reason may not be provided, and the closing of the Window itself may constitute material inside information that should not be communicated.
The foregoing Window Group restrictions do not apply to transactions pursuant to written plans for trading securities that comply with 10b5-1 Plans. However, Window Group members may not enter into, amend, or terminate a 10b5-1 Plan relating to Company securities without the prior approval of the Office of the General Counsel, which, in most cases, will only be given during a Window period. Additionally, Window Group members are permitted to enter into a 10b5-1 Plan only if such plan is entered into in good faith and in compliance with the provisions of Rule 10b5-1.

Applicability of U.S. Securities Laws to International Transactions

All employees of the Company’s subsidiaries are subject to the restrictions on trading in the Company securities and the securities of other companies. The U.S. securities laws may be applicable to the securities of the Company’s subsidiaries or affiliates, even if they are located outside the United States. Transactions involving securities of subsidiaries or affiliates should be carefully reviewed by counsel for compliance not only with local law but also for possible application of U.S. securities laws.
Page 5 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy



Event-Specific Trading Restriction Periods

From time to time, an event may occur that is material to the Company and is known by only a few directors, officers, and/or employees. So long as the event remains material and nonpublic, the persons designated by the Office of the General Counsel may not trade Company securities. In addition, the Company’s financial results may be sufficiently material in a particular fiscal quarter that, in the judgment of the Office of the General Counsel, designated persons should refrain from trading in Company securities even sooner than the typical end of the Window. In that situation, the Office of the General Counsel may notify these persons that they should not trade in the Company’s securities, without disclosing the reason for the restriction. The existence of an event-specific trading restriction period or reduction of a Window will not be announced to the Company as a whole and should not be communicated to any other person. Even if the Office of the General Counsel has not designated an individual as a person who should not trade due to an event-specific restriction, in no event should anyone trade while aware of material nonpublic information.

OTHER LIMITATIONS ON SECURITIES TRANSACTIONS

Public Resales - Rule 144

The Securities Act of 1933 (“1933 Act”) requires every person who offers or sells a security to register such transaction with the SEC unless an exemption from registration is available. Rule 144 under the 1933 Act is the exemption typically relied upon (a) for public resales by any person of “restricted securities” (i.e., securities acquired in a private offering or sale, excluding certain private issuances outside the United States) and (b) for public resales by directors, officers, and other controlling persons of a company (known as “affiliates”) of any of the Company’s securities, whether restricted or unrestricted.

Rule 144 contains a number of conditions, although the applicability of some of these conditions will depend on the circumstances of the sale:
1.Current Public Information. Current information about the Company must be publicly available before the sale can be made. The Company’s periodic reports filed with the SEC ordinarily satisfy this requirement. If the seller is not (and has not been for at least three months) an affiliate of the company issuing the securities and one year has passed since the securities were acquired from the issuer or an affiliate of the issuer (whichever is later), the seller can sell the securities without regard to the current public information requirement.
2.Holding Period. Restricted securities must be held and fully paid for by the seller for a period of at
Page 6 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


least six months prior to the sale. The holding period requirement, however, does not apply to securities held by affiliates that were acquired either in the open market or in a public offering of securities registered under the 1933 Act. If the seller acquired the securities from someone other than the Company or an affiliate of the Company, the holding period of the person from whom the seller acquired such securities can be “tacked” to the seller’s holding period in determining if the holding period has been satisfied.
Rule 144 also imposes the following additional conditions on sales by persons who are affiliates or who have been affiliates during the previous three months:
1.Volume Limitations. The amount of equity securities which can be sold during any three- month period cannot exceed the greater of (a) one percent of the outstanding shares of the class or (b) the average weekly reported trading volume for shares of the class during the four calendar weeks preceding the filing of the notice of sale referred to below. The amount of debt securities which can be sold by an affiliate during any three-month period cannot exceed ten percent of a tranche (or class when the securities are non-participatory preferred stock), together with all sales of securities of the same tranche sold for the account of the affiliate within a three-month period.
2.Manner of Sale. Equity securities must be sold in unsolicited brokers’ transactions, directly to a
market-maker or in riskless principal transactions.

3.Notice of Sale. The seller must file a notice of the proposed sale with the SEC at the time the order to sell is placed with the broker, unless the amount to be sold neither exceeds 5,000 shares nor involves sale proceeds greater than $50,000. See the Filing Requirements section below.
Bona fide gifts are not deemed to involve sales of stock for purposes of Rule 144, so they can be made at any time without limitation on the amount of the gift. Donees who receive restricted securities from an affiliate generally will be subject to the same restrictions under Rule 144 that would have applied to the donor for a period of up to two years following the gift, depending on the circumstances.

Private Resales
Directors and officers also may sell securities in a private transaction without registration. Although there is no statutory provision or SEC rule expressly dealing with private sales, the general view is that such sales can safely be made by affiliates if the party acquiring the securities is sophisticated and understands he or she is acquiring restricted securities that must be held for at least one year before the securities will be eligible for resale to the public under Rule 144. Private resales raise certain documentation requirements and other issues and must be reviewed in advance by the Company’s Office of the General Counsel.

Restrictions on Purchases of Company Securities
In order to prevent market manipulation, the SEC has adopted Regulation M under the 1934 Act. Regulation M generally prohibits the Company or any of its affiliates from buying Company stock during certain periods while a distribution is taking place. These rules set forth guidelines for purchases of Company stock by the
Page 7 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


Company or its affiliates while a stock buyback program is occurring. Affiliates should consult with the Company’s Office of the General Counsel if they desire to make purchases of Company stock during any period that the Company is making a distribution or buying stock from the public.

Disgorgement of Profits on Short-Swing Transactions Under Section 16(b)
Section 16 of the 1934 Act applies to directors and certain executive officers of the Company and to any person owning more than ten percent of any registered class of the Company’s equity securities. The section is intended to deter such persons (collectively referred to below as “Section 16 Insiders”) from misusing confidential information about their companies for personal trading gain. Section 16(a) requires Section 16 Insiders to publicly disclose any changes in their beneficial ownership of the Company’s equity securities (see the Filing Requirements section below). Section 16(b) requires Section 16 Insiders to disgorge to the Company any “profit” resulting from “short-swing” trades, as discussed more fully below. Section 16(c) effectively prohibits Section 16 Insiders from engaging in short sales (see the Prohibition of Short Sales section, below).

Under Section 16(b), any profit realized by a Section 16 Insider on a “short-swing” transaction (i.e., a purchase and sale, or sale and purchase, of the Company’s equity securities within a period of less than six months) must be disgorged to the Company upon demand by the Company or a stockholder acting on its behalf. By law, the Company cannot waive or release any claim it may have under Section 16(b) or enter into an enforceable agreement to provide indemnification for amounts recovered under the section. Liability under Section 16(b) is imposed in a mechanical fashion without regard to whether the Section 16 Insider intended to violate the section. Good faith, therefore, is not a defense. All that is necessary for a successful claim is to show that the Section 16 Insider realized “profits” on a short-swing transaction; however, profit, for this purpose, is calculated as the difference between the sale price and the purchase price in the matching transactions, and may be unrelated to the actual gain on the shares sold. When computing recoverable profits on multiple purchases and sales within a six month period, the courts maximize the recovery by matching the lowest purchase price with the highest sale price, the next lowest purchase price with the next highest sale price, and so on. The use of this method makes it possible for a Section 16 Insider to sustain a net loss on a series of transactions while having recoverable profits.
The terms “purchase” and “sale” are construed under Section 16(b) to cover a broad range of transactions, including acquisitions and dispositions in tender offers and certain corporate reorganizations. Moreover, purchases and sales by a Section 16 Insider may be matched with transactions by any person (such as certain family members) whose securities are deemed to be beneficially owned by the Section 16 Insider.
The Section 16 rules are complicated and present ample opportunity for inadvertent error. To avoid unnecessary costs and potential embarrassment for Section 16 Insiders and the Company, Section 16 Insiders are strongly urged to consult with the Company’s Office of the General Counsel prior to engaging in any transaction or other transfer of Company equity securities regarding the potential applicability of Section 16(b).

Prohibition of Short Sales


Page 8 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


Under Section 16(c), Section 16 Insiders are prohibited from effecting “short sales” of the Company’s equity securities. A “short sale” is one involving securities which the seller does not own at the time of sale, or, if owned, are not delivered within 20 days after the sale or deposited in the mail or other usual channels of transportation within five days after the sale. Wholly apart from Section 16(c), the Company prohibits directors, officers, and employees from selling the Company’s stock short. This type of activity is inherently speculative in nature and is contrary to the best interests of the Company and its shareholders.

Filing Requirements
1.Forms 3, 4, and 5. Under Section 16(a) of the 1934 Act, Section 16 Insiders must file with the SEC and any stock exchange on which the Company’s equity securities are listed (i.e., The New York Stock Exchange) public reports disclosing their holdings of and transactions involving the Company’s equity securities. Copies of these reports must also be submitted to the Company. An initial report on Form 3 must be filed by every Section 16 Insider within 10 days after election or appointment disclosing their holdings of and transactions involving the Company’s equity securities. Copies of these reports must also be submitted to the Company. An initial report on Form 3 must be filed by every Section 16 Insider within 10 days after election or appointment disclosing all equity securities of the Company beneficially owned by the reporting person on the date such person became a Section 16 Insider. Even if no securities were owned on that date, the Section 16 Insider must file a report. Any subsequent change in the nature or amount of beneficial ownership by the Section 16 Insider, including dispositions via bona fide gifts, must be reported on Form 4 and filed within two business days after the transaction date. Certain exempt transactions may be reported on Form 5 within 45 days after the end of the fiscal year. The fact that a Section 16 Insider’s transactions during the month resulted in no net change, or the fact that no securities were owned after the transactions were completed, does not provide a basis for failing to report.

All changes in the amount or the form (i.e., direct or indirect) of beneficial ownership (not just purchases and sales) must be reported. Thus, such transactions as gifts and stock dividends ordinarily are reportable. Moreover, an officer or director who has ceased to be an officer or director must report any transactions after termination which occurred within six months of a transaction that occurred while the person was a Section 16 Insider.
The reports under Section 16(a) are intended to cover all securities beneficially owned either directly by the Section 16 Insider or indirectly through others. A Section 16 Insider is considered the direct owner of all Company equity securities held in his or her own name or held jointly with others. A Section 16 Insider is considered the indirect owner of any securities from which he obtains benefits substantially equivalent to those of ownership. Thus, equity securities of the Company beneficially owned through partnerships, corporations, trusts, estates, and by family members generally are subject to reporting. Absent countervailing facts, a Section 16 Insider is presumed to be the beneficial owner of securities held by his or her spouse and other family members sharing the same home. But a Section 16 Insider is free to disclaim beneficial ownership of these or any other securities being reported if the Section 16 Insider believes there is a reasonable basis for doing so.
It is important that reports under Section 16(a) be prepared properly and filed on a timely basis. The reports must be received at the SEC by the filing deadline. There is no provision for an extension of the filing deadlines,


Page 9 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


and the SEC can take enforcement action against Section 16 Insiders who do not comply fully with the filing requirements. In addition, the Company is required to disclose in its annual proxy statement the names of Section 16 Insiders who failed to file Section 16(a) reports properly during the fiscal year, along with the particulars of such instances of noncompliance. Accordingly, the Company strongly urges all Section 16 Insiders to notify the Company’s Office of the General Counsel prior to any transactions or changes in their or their family members’ beneficial ownership involving Company stock and to avail themselves of the assistance available from the General Counsel’s office in satisfying the reporting requirements.

2.Schedule 13D and 13G. Section 13(d) of the 1934 Act requires the filing of a statement on Schedule 13D (or on Schedule 13G, in certain limited circumstances) by any person or group that acquires beneficial ownership of more than five percent of a class of equity securities registered under the 1934 Act. The threshold for reporting is met if the stock owned, when coupled with the amount of stock subject to options exercisable within 60 days, exceeds the five percent limit. A report on Schedule 13D is required to be filed with the SEC and submitted to the Company within ten days after the reporting threshold is reached. If a material change occurs in the facts set forth in the Schedule 13D, such as an increase or decrease of one percent or more in the percentage of stock beneficially owned, an amendment disclosing the change must be filed promptly. A decrease in beneficial ownership to less than five percent is per se material and must be reported.
A person is deemed the beneficial owner of securities for purposes of Section 13(d) if such person has or shares voting power (i.e., the power to vote or direct the voting of the securities) or dispositive power (i.e., the power to sell or direct the sale of the securities). As is true under Section 16(a) of the 1934 Act, a person filing a Schedule 13D may disclaim beneficial ownership of any securities attributed to him or her if he or she believes there is a reasonable basis for doing so.

3.Form 144. As described above under the discussion of Rule 144, an affiliate relying on Rule 144 must file a notice of proposed sale with the SEC at the time the order to sell is placed with the broker unless the amount to be sold in any three-month period neither exceeds 5,000 shares nor involves sale proceeds greater than $50,000.

GENERAL
The Company reserves the right to amend or terminate this policy as the Company deems necessary or warranted, in accordance with applicable laws.
ROLES AND RESPONSIBILITIES
Any questions related to the interpretation of this policy and/or a subject matter included in this policy shall be directed to the Office of the General Counsel.


Page 10 of 11
EXHIBIT 19

picture1.jpg
GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00060
Rev #: 3
Effective Date: 19/Jan/2024
Policy Sponsor: Corporate Legal
Title: Insider Trading Policy


EXCEPTIONS

Requests for waivers, exemptions, or exceptions to this policy must be submitted in writing to the Office of the General Counsel.

ENFORCEMENT
Legal will investigate any suspected violations of this policy. Any employee found to have violated this policy may be subject to disciplinary action, up to and including termination of employment. Any suspected criminal activity will also be referred to the appropriate law enforcement authorities.
RELATED DOCUMENTS


Records Management Policy
Code of Business Conduct and Ethics Disclosure Policy















Page 11 of 11
 EX-21.1 5 crl1230202310-kex211.htm EX-21.1 Document


Exhibit 21.1
SUBSIDIARIES
SubsidiaryJurisdiction of Organization
1Charles River Laboratories, Inc.Delaware
2Charles River UK LimitedUnited Kingdom (England)
3Charles River Laboratories Saint‑Constant S.A.Quebec, Canada
4Charles River Nederland B.V.Netherlands
5Charles River Laboratories Holding SASFrance
6Charles River Laboratories France C.R.L.F. SASFrance
7BioFocus DPI (Holdings) Ltd.United Kingdom (England)
8Charles River Laboratories Belgium SRLBelgium
9Charles River Laboratories España SASpain
10Charles River Laboratories Italia SrlItaly
11Charles River Laboratories Germany Holding GmbHGermany
12Charles River Laboratories Poland Sp. Z.o.o.Poland
13Charles River Laboratories Ireland LimitedIreland
14Charles River Laboratories Research Models and Services, Germany GmbHGermany
15Charles River Laboratories Luxembourg S.a.r.l.Luxembourg
16Charles River Laboratories GroupUnited Kingdom (Scotland)
17Charles River Laboratories Edinburgh Ltd.United Kingdom (Scotland)
18Charles River ULCNova Scotia, Canada
19Charles River Laboratories Montreal, ULCNova Scotia, Canada
20Charles River Laboratories Australia Pty. Ltd.Australia
21Zhanjiang A&C Biological Ltd.China
22Charles River Laboratories KoreaKorea
23Charles River Laboratories Asia Holdings LimitedHong Kong
24Charles River Laboratories Germany GmbHGermany
25Charles River Discovery Research Services, Inc.Michigan
26Charles River Laboratories India Private LimitedIndia
27Charles River Discovery Research Services FinlandFinland
28Accugenix Inc. LLCDelaware
29Beijing Vital River Laboratory Animal Technology Co. Ltd.China
30Charles River Detecçăo Microbiana e de Endotoxina Participaçơes LtdaBrazil
31Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd.Singapore
32Charles River Endotoxin Microbial Detection Europe SASFrance
33Charles River Laboratories Holdings LimitedUnited Kingdom (England)
34Charles River Discovery Research Services UK LimitedUnited Kingdom (England)
36Charles River Laboratories Cleveland, Inc.Delaware
37Charles River Endotoxin and Microbial Detection IsraelIsrael
38Celsis Group LimitedUnited Kingdom (England)
39Celsis International LimitedUnited Kingdom (England)
40Celsis LimitedUnited Kingdom (England)
41Celsis International B.V.Netherlands
42Charles River Microbial Solutions Germany GmbHGermany
43Charles River Laboratories France Safety Assessment SASFrance
44CRL Safety Assessment, Inc.Delaware
45Charles River Laboratories SA USA, Inc.Delaware


46Charles River Laboratories Ashland, LLCDelaware
47Charles River Laboratories SA Netherlands Holdings B.V.Netherlands
48Charles River Laboratories I Delaware Holdings, Inc.Delaware
49Charles River Laboratories II Delaware Holdings, Inc.Delaware
50Charles River Laboratories Den Bosch B.V.Netherlands
51Zhejiang Vital River Laboratory Animal Technology Co. Ltd.China
52Charles River Microbial Solutions International LimitedIreland
53KWS BioTest LimitedUnited Kingdom (England)
54Charles River Microbial Solutions (Shanghai) Company LimitedChina
55Charles River Laboratories Denmark ApSDenmark
56CRL Group International FranceFrance
57Charles River Laboratories EvreuxFrance
58Charles River Laboratories Saint NazaireFrance
59Charles River Laboratories HungaryHungary
60Charles River Laboratories Switzerland AGSwitzerland
61Charles River Laboratories Cell Solutions, Inc.California
62Cobra Biologics LimitedUnited Kingdom (England)
63Guangdong Vital River Laboratory Animal Technology Co. LtdChina
64Si Chuan Vital River Laboratory Animal Technologies Co. Ltd.China
65Charles River Laboratories Japan G.K.Japan
66Charles River Laboratories Sweden ABSweden
67Cobra Biologics Holding LimitedUnited Kingdom (England)
68MDRH Holdings, LLCDelaware
69Indigo, LLCDelaware
70Charles River Accelerator & Development Laboratories (Shanghai) Company LimitedChina
71Zhanjiang Puju Biological Co. Ltd.China
72Hainan New Source Biotech Ltd.China
73Charles River Nederland II B.V.Netherlands
74Kandurt LLCDelaware
75Kandurt Member LLCDelaware
76Charles River Laboratories New York LLCDelaware
77Noveprim LimitedMauritius
78Noveprim Property LimitedMauritius
79Chamouny Farming Ltd.Mauritius
80Camarney S.L. SpainSpain


 EX-23.1 6 crl1230202310-kex231.htm EX-23.1 Document


Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-255761) and Form S-8 (Nos. 333-238567, 333-225046 and 333-212507) of Charles River Laboratories International, Inc. of our report dated February 14, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 14, 2024

 EX-31.1 7 crl1230202310-kex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
AND RULE 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934
I, James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories International, Inc. (the registrant) certify that:
1.    I have reviewed this annual report on Form 10-K for the year ended December 30, 2023 of the registrant;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d.    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.    The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
/s/ James C. Foster
February 14, 2024
James C. Foster
Chairman, President and Chief Executive Officer
Charles River Laboratories International, Inc.


 EX-31.2 8 crl1230202310-kex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
AND RULE 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934
I, Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc. (the registrant) certify that:
1.    I have reviewed this annual report on Form 10-K for the year ended December 30, 2023 of the registrant;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.    designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.    designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.    evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d.    disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.    The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.    all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
/s/ Flavia H. Pease
February 14, 2024
Flavia H. Pease
Corporate Executive Vice President and Chief Financial Officer
Charles River Laboratories International, Inc.


 EX-32.1 9 crl1230202310-kex321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report on Form 10-K for the year ended December 30, 2023 of Charles River Laboratories International, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, James C. Foster, Chairman, President and Chief Executive Officer of the Company, and Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, to the best of his knowledge and pursuant to 18 U.S.C. Section 1350, that:
(1)    the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”); and
(2)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James C. Foster
February 14, 2024
James C. Foster
Chairman, President and Chief Executive Officer
Charles River Laboratories International, Inc.
/s/ Flavia H. Pease
February 14, 2024

Flavia H. Pease
Corporate Executive Vice President and Chief Financial Officer
Charles River Laboratories International, Inc.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.

 EX-97 10 crl1230202310-kex97.htm EX-97 Document
EXHIBIT 97

image_01.jpg

GLOBAL CORPORATE POLICY
Doc #: GLBL-POL-00093
Rev #: 1
Effective Date: 2023/10/23
Policy Sponsor: Corporate Legal
Title: Financial Statement Compensation Recoupment Policy


PURPOSE
This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under U.S. federal securities laws in accordance with the terms and conditions set forth herein. This Policy is intended to comply with the requirements of Section 10D of the Exchange Act and the Listing Rule.
SCOPE
This policy applies to all Executive Officers of Charles River, as defined below.
DEFINITIONS
“Adjusted Compensation” means the amount of Covered Compensation that would have otherwise been received by a Covered Executive if calculated based on the Financial Restatement.
“Awarded Compensation “ means the amount of any Covered Compensation received by a Covered Executive.
“Board” means the Board of Directors of Charles River Laboratories International, Inc.
“Code” means U.S. Internal Revenue Code of 1986, as amended.
“Committee” means the Compensation Committee of the Board or any successor committee thereof.
“Company” means Charles River Laboratories International, Inc.
“Covered Compensation” means any Incentive-based Compensation “received” by a Covered Executive during the applicable Recoupment Period; provided that:
(a)such Incentive-based Compensation was received by such Covered Executive (A) on or after the Effective Date, (B) after he or she commenced service as an Executive Officer and (C) while the Company had a class of securities publicly listed on a United States national securities exchange; and

Page 1 of 7




(b)such Covered Executive served as an Executive Officer at any time during the performance period applicable to such Incentive-based Compensation.

For purposes of this Policy, Incentive-based Compensation is “received” by a Covered Executive during the fiscal period in which the Financial Reporting Measure applicable to such Incentive-based Compensation (or portion thereof) is attained, even if the payment or grant of such Incentive-based Compensation is made thereafter.

“Covered Executive” means any current or former Executive Officer

“Effective Date” means the date on which the Listing Rule becomes effective.

“Erroneously Awarded Compensation” means the excess of the Awarded Compensation over the Adjusted Compensation.

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.

“Executive Officer” means, with respect to the Company, any person who is an "officer" within the meaning of Rule 16a-1(f) promulgated under the Securities Exchange Act of 1934, as amended, or any successor rule.

“Financial Reporting Measure” means any (i) measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, (ii) stock price measure or (iii) total shareholder return measure (and any measures that are derived wholly or in part from any measure referenced in clause (i), (ii) or (iii) above). For the avoidance of doubt, any such measure does not need to be presented within the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission to constitute a Financial Reporting Measure.

“Financial Restatement” means a restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under U.S. federal securities laws that is required in order to correct:

(a)an error in previously issued financial statements that is material to the previously issued financial statements; or
(b)     an error that would result in a material misstatement if the error were (A) corrected in the current     period or (B) left uncorrected in the current period.

For purposes of this Policy, a Financial Restatement shall not be deemed to occur in the event of a revision of the Company’s financial statements due to an out-of-period adjustment (i.e., when the error is immaterial to the previously issued financial statements and the correction of the error is also immaterial to the current period) or a retrospective (1) application of a change in accounting principles; (2) revision to reportable segment information due to a change in the structure of the Company’s internal organization; (3) reclassification due to a discontinued operation; (4) application of a change in reporting entity, such as from a reorganization of entities under common control; or (5) revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.

“Incentive-based Compensation” means any compensation (including, for the avoidance of doubt, any cash or equity or equity-based compensation, whether deferred or current) that is granted, earned and/or vested based wholly or in part upon the achievement of a Financial Reporting Measure. For purposes of this Policy, “Incentive-based Compensation” shall also be deemed to include any amounts which were determined based on (or were
Page 2 of 7


otherwise calculated by reference to) Incentive-based Compensation (including, without limitation, any amounts under any long-term disability, life insurance or supplemental retirement or severance plan or agreement or any notional account that is based on Incentive-based Compensation, as well as any earnings accrued thereon).
“JAMS” means Judicial Arbitration and Mediation Services, Inc.

“Listing Rule” means Section 303A.14 of the NYSE Listed Company Manual or any successor provision thereof.

“NYSE” means the New York Stock Exchange, or any successor thereof.

“Recoupment Period” means the three fiscal years completed immediately preceding the date of any applicable Recoupment Trigger Date. Notwithstanding the foregoing, the Recoupment Period additionally includes any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years, provided that a transition period between the last day of the Company’s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine (9) to twelve (12) months would be deemed a completed fiscal year.

“Recoupment Trigger Date” means the earlier of (i) the date that the Board (or a committee thereof or the officer(s) of the Company authorized to take such action if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement, and (ii) the date on which a court, regulator or other legally authorized body directs the Company to prepare a Financial Restatement.

POLICY

1.Recoupment of Erroneously Awarded Compensation
(a)In the event of a Financial Restatement, if the Awarded Compensation exceeds the amount of Adjusted Compensation, the Company shall reasonably promptly recover from such Covered Executive an amount equal to the Erroneously Awarded Compensation, each calculated on a pre-tax basis.

(b) If (i) the Financial Reporting Measure applicable to the relevant Covered Compensation is stock price or total shareholder return (or any measure derived wholly or in part from either of such measures) and (ii) the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the amount of Erroneously Awarded Compensation shall be determined (on a pre-tax basis) based on the Company’s reasonable estimate of the effect of the Financial Restatement on the Company’s stock price or total shareholder return (or the derivative measure thereof) upon which such Covered Compensation was received.

(c)For the avoidance of doubt, the Company’s obligation to recover Erroneously Awarded Compensation is not dependent on (i) if or when the restated financial statements are filed or (ii) any fault of any Covered Executive for the accounting errors or other actions leading to a Financial Restatement.

Page 3 of 7


(d)Notwithstanding anything to the contrary in Sections 1 (a) through (c) hereof, the Company shall not be required to recover any Erroneously Awarded Compensation if both (x) the conditions set forth in either of the following clauses (i) or (ii) are satisfied and (y) the Committee (or a majority of the independent directors serving on the Board) has determined that recovery of the Erroneously Awarded Compensation would be impracticable:

(i)the direct expense paid to a third party to assist in enforcing the recovery of the Erroneously Awarded Compensation under this Policy would exceed the amount of such Erroneously Awarded Compensation to be recovered; provided that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation pursuant to this Section 1(d), the Company shall have first made a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to make such recovery and provide that documentation to the NYSE; or

(ii)recovery of the Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Sections 401(a)(13) or 411(a) of the Code.

(e)The Company shall not indemnify any Covered Executive, directly or indirectly, for any losses that such Covered Executive may incur in connection with the recovery of Erroneously Awarded Compensation pursuant to this Policy, including through the payment of insurance premiums or gross-up payments.

(f)The Committee shall determine, in its sole discretion, the manner and timing in which any Erroneously Awarded Compensation shall be recovered from a Covered Executive in accordance with applicable law, including, without limitation, by (i) requiring reimbursement of Covered Compensation previously paid in cash; (ii) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity or equity-based awards; (iii) offsetting the Erroneously Awarded Compensation amount from any compensation otherwise owed by the Company or any of its affiliates to the Covered Executive; (iv) cancelling outstanding vested or unvested equity or equity-based awards; and/or (v) taking any other remedial and recovery action permitted by applicable law. For the avoidance of doubt, except as set forth in Section 1(d), in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation; provided that, to the extent necessary to avoid any adverse tax consequences to the Covered Executive pursuant to Section 409A of the Code, any offsets against amounts under any nonqualified deferred compensation plans (as defined under Section 409A of the Code) shall be made in compliance with Section 409A of the Code.

2.Administration
This Policy shall be administered by the Committee. All decisions of the Committee shall be final, conclusive and binding upon the Company and the Covered Executives, their beneficiaries, heirs, executors, administrators and any other legal representative. The Committee shall have full power and authority to (i) administer and interpret this Policy; (ii) correct any defect, supply any omission and reconcile any inconsistency in this Policy; and (iii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of this Policy and to comply with applicable law (including Section 10D of the Exchange Act) and applicable stock market or exchange rules and regulations. . Notwithstanding anything to the contrary contained herein, to the extent permitted by Section 10D of the Exchange Act and the Listing Rule, the Board may, in its sole discretion, at any time and from time to time, administer this Policy in the same manner as the Committee.

Page 4 of 7


3.Amendment/Termination
Subject to Section 10D of the Exchange Act and the Listing Rule, this Policy may be amended or terminated by the Committee at any time. To the extent that any applicable law, or stock market or exchange rules or regulations require recovery of Erroneously Awarded Compensation in circumstances in addition to those specified herein, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Erroneously Awarded Compensation to the fullest extent required by such applicable law, stock market or exchange rules and regulations. Unless otherwise required by applicable law, this Policy shall no longer be effective from and after the date that the Company no longer has a class of securities publicly listed on a United States national securities exchange.

4.Interpretation
Notwithstanding anything to the contrary herein, this Policy is intended to comply with the requirements of Section 10D of the Exchange Act and the Listing Rule (and any applicable regulations, administrative interpretations or stock market or exchange rules and regulations adopted in connection therewith). The provisions of this Policy shall be interpreted in a manner that satisfies such requirements and this Policy shall be operated accordingly. If any provision of this Policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict.
5.Other Compensation Clawback/Recoupment Rights.
Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies, rights or requirements with respect to the clawback or recoupment of any compensation that may be available to the Company pursuant to the terms of any other recoupment or clawback policy of the Company (or any of its affiliates) that may be in effect from time to time, any provisions in any employment agreement, offer letter, equity plan, equity award agreement or similar plan or agreement, and any other legal remedies available to the Company, as well as applicable law, stock market or exchange rules, listing standards or regulations; provided, however, that any amounts recouped or clawed back under any other policy that would be recoupable under this Policy shall count toward any required clawback or recoupment under this Policy and vice versa.

6.Exempt Compensation
Notwithstanding anything to the contrary herein, the Company has no obligation under this Policy to seek recoupment of amounts paid to a Covered Executive which are granted, vested or earned based solely upon the occurrence or non-occurrence of nonfinancial events. Such exempt compensation includes, without limitation, base salary, time-vesting awards, compensation awarded on the basis of the achievement of metrics that are not Financial Reporting Measures or compensation awarded solely at the discretion of the Committee or the Board, provided that such amounts are in no way contingent on, and were not in any way granted on the basis of, the achievement of any Financial Reporting Measure performance goal.
7.Miscellaneous
Page 5 of 7


(a)Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this Policy shall be deemed to include the restrictions imposed herein and incorporate this Policy by reference and, in the event of any inconsistency, the terms of this Policy will govern. For the avoidance of doubt, this Policy applies to all compensation that is received on or after the Effective Date, regardless of the date on which the award agreement or other document setting forth the terms and conditions of the Covered Executive’s compensation became effective, including, without limitation, compensation received under the Company’s Amended and Restated 2018 Incentive Plan , Executive Incentive Compensation Program, Deferred Compensation Plan and any successor plans or programs thereto.

(b)This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

(c)All issues concerning the construction, validity, enforcement and interpretation of this Policy and all related documents, including, without limitation, any employment agreement, offer letter, equity award agreement or similar agreement, shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.
(d)The Covered Executives, their beneficiaries, heirs, executors, administrators and any other legal representative and the Company shall initially attempt to resolve all claims, disputes or controversies arising under, out of or in connection with this Policy by conducting good faith negotiations amongst themselves. To ensure the timely and economical resolution of disputes that arise in connection with this Policy, any and all disputes, claims or causes of action arising from or relating to the enforcement, performance or interpretation of this Policy shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Boston, Massachusetts, conducted by JAMS the applicable JAMS rules. To the fullest extent permitted by law, the Covered Executives, their beneficiaries, heirs, executors, administrators and any other legal representative and the Company, shall waive (and shall hereby be deemed to have waived) (1) the right to resolve any such dispute through a trial by jury or judge or administrative proceeding; and (2) any objection to arbitration taking place in Boston, Massachusetts. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that any party would be entitled to seek in a court of law. Any such award rendered shall be enforceable by any court having jurisdiction and, to the fullest extent permitted by law, the Covered Executives, their beneficiaries, heirs, executors, administrators and any other legal representative and the Company shall waive (and shall hereby be deemed to have waived) the right to resolve any such dispute regarding enforcement of such award through a trial by jury.
(e)If any provision of this Policy is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.
Page 6 of 7



ROLES AND RESPONSIBILITIES
Any questions related to the interpretation of this policy and/or a subject matter included in this policy shall be directed to the Office of the General Counsel.

Page 7 of 7

 EX-101.SCH 11 crl-20231230.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Venture Capital Investments and Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - FAIR VALUE - Fair Value of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - FAIR VALUE - Rollforward of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - FAIR VALUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - FAIR VALUE - Schedule of Fair Value of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Long-term Debt, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Principal Maturities of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - INCOME TAXES - Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - INCOME TAXES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - INCOME TAXES - Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - INCOME TAXES - Change in Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activities (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954546 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954547 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954548 - Disclosure - LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 9954549 - Disclosure - LEASES - Components of Operating and Finance Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954550 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954551 - Disclosure - LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954552 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) link:presentationLink link:calculationLink link:definitionLink 9954552 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) link:presentationLink link:calculationLink link:definitionLink 9954553 - Disclosure - LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954554 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 crl-20231230_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 crl-20231230_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 crl-20231230_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Accrued liabilities Accrued Liabilities, Current Amount of credit facility Line of Credit Facility, Maximum Borrowing Capacity Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Stock options, expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Representation and warranty insurance, maximum deductible Representation And Warranty Insurance, Deductible Representation And Warranty Insurance, Deductible Redeemable noncontrolling interest, contractually defined redemption value Redeemable Noncontrolling Interest, Equity, Redemption Value Vital River Vital River [Member] Vital River [Member] Defined Benefit Plan, Funding Status Defined Benefit Plan, Funded Plan [Member] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Performance obligations expected to be satisfied, expected timing Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Investment, Name [Domain] Investment, Name [Domain] Cash portion of consideration transferred Payments to Acquire Businesses, Gross Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items] Stock Repurchases [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Schedule of Reconciliation of Benefit Obligations and Plans Assets of the Company's Pension Plans Schedule of Net Funded Status [Table Text Block] Customer contract deposits (included in Other current-liabilities) Contract With Customer Liability, Customer Deposits Contract With Customer Liability, Customer Deposits Total debt and finance leases Long-Term Debt, Gross And Lease Obligation Long-Term Debt, Gross And Lease Obligation Deferred tax liabilities Deferred Income Tax Liabilities, Net Foreign-derived intangible income Effective Income Tax Rate Reconciliation, FDII, Percent Non-deductible compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Purchases of investments and contributions to venture capital investments Payments to Acquire Investments Average Volatility Measurement Input, Price Volatility [Member] Insider Trading Policies and Procedures [Line Items] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Foreign currency adjustments Restructuring Reserve, Foreign Currency Translation Gain (Loss) Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] EQUITY AND NONCONTROLLING INTERESTS Equity [Text Block] Options expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Ownership [Axis] Ownership [Axis] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Reporting Unit [Domain] Reporting Unit [Domain] Currency translation and other Deferred Tax Asset, Valuation Allowance, Additions (Reductions) For Currency Translation and Other Deferred Tax Asset, Valuation Allowance, Additions (Reductions) For Currency Translation and Other Schedule of Weighted-average Assumptions Defined Benefit Plan, Assumptions [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Goodwill, impaired, accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Cash proceeds from divestiture Proceeds from Divestiture of Businesses Options canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Long-lived asset impairment charges Impairment, Long-Lived Asset, Held-for-Use Diluted (in dollars per share) Earnings Per Share, Diluted Restricted Stock Units Restricted Stock and Restricted Stock Units [Member] Restricted Stock and Restricted Stock Units [Member] Schedule of Investments [Table] Schedule of Investments [Table] 4.25% Senior Notes due 2028 Senior Notes Due 2028 [Member] Senior Notes Due 2028 [Member] Trade receivables and contract assets, net of allowances for credit losses of $25,722 and $11,278, respectively Trade receivables and contract assets, net Accounts Receivable, after Allowance for Credit Loss, Current Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Vigene Vigene Biosciences, Inc. [Member] Vigene Biosciences, Inc. Revolving Facility Line of Credit [Member] Ownership percentage not acquired Business Combination, Ownership Percentage Not Acquired Business Combination, Ownership Percentage Not Acquired Schedule of Components of Net Periodic Benefit Costs for the Company's Pension Plans Schedule of Net Benefit Costs [Table Text Block] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Payment for contingent consideration Payment for Contingent Consideration Liability, Operating Activities Income tax provision (benefit): Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Litigation Case [Axis] Litigation Case [Axis] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Redeemable noncontrolling interest Redeemable noncontrolling interests Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Letters of credit outstanding Letters of Credit Outstanding, Amount Purchase of investments Payments to Acquire Equity Method Investments Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Other Securities Other Other Plan Asset Categories [Member] Other Plan Asset Categories [Member] Fixed Income Securities Debt Securities Debt Securities [Member] Cash acquired Cash Acquired from Acquisition Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Machinery and equipment Machinery and Equipment [Member] Benefit payments Defined Benefit Plan, Plan Assets, Benefits Paid Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Additions due to acquisitions Deferred Tax Asset, Valuation Allowance, Additions For Acquisitions Deferred Tax Asset, Valuation Allowance, Additions For Acquisitions Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Prepaid taxes Prepaid Taxes Enacted tax rate changes Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Other Temporary Equity, Other Changes Other assets: Other Assets [Abstract] Other intangible assets Other Other Intangible Assets [Member] Schedule of Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Service cost Defined Benefit Plan, Service Cost Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Executive Category: Executive Category [Axis] Venture Capital Investments Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block] Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Net prior service cost (credit) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Book Value Reported Value Measurement [Member] Schedule of Composition of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Investment Type [Axis] Investment Type [Axis] 2025 Long-Term Debt, Maturity, Year Two Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Total benefit cost Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax Smaller Reporting Company Entity Small Business Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Revenue from contract with customer, payment terms Revenue From Contract With Customer, Payment Terms Revenue From Contract With Customer, Payment Terms Recovery of Erroneously Awarded Compensation Disclosure [Line Items] 2028 Finance Lease, Liability, to be Paid, Year Five Letter of Credit Letter of Credit [Member] Rollforward of Contingent Consideration Related to Previous Acquisitions Fair Value, Contingent Consideration [Table Text Block] [Table Text Block] for Fair Value, Contingent Consideration [Table] Long-term liabilities Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Notional amount Derivative, Notional Amount Number of life insurance contracts Life Settlement Contracts, Investment Method, Number of Contracts Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease right-of-use assets, net Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-use Assets, Net Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-use Assets, Net DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Business combination, redemption price Business Combination, Redemption Price Business Combination, Redemption Price Restricted Stock Units Restricted Stock Units (RSUs) [Member] Schedule of Restricted Stock and Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Income before income taxes Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Depreciation Depreciation Retirement Benefits [Abstract] Retirement Benefits [Abstract] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Value of shares acquired for individual minimum statutory tax withholding Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Schedule of Purchase Price Allocation Schedule of Business Acquisitions, by Acquisition [Table Text Block] Defined benefit plan, net periodic benefit cost (credit) excluding service cost, statement of income or comprehensive income [extensible enumeration] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Call option term, period after sixth anniversary Business Combination, Term, Period After Sixth Anniversary Business Combination, Term, Period After Sixth Anniversary Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] 4.00% Senior Notes due 2031 Senior Notes Due 2031 [Member] Senior Notes Due 2031 Biologic Solutions Biologic Solutions [Member] Biologic Solutions Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Beginning balance Ending balance Severance and retention costs liability Restructuring Reserve Award Type [Axis] Award Type [Axis] Antidilutive common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Minimum EBITDA less capital expenditures to consolidated cash interest expense Debt Instrument, Covenant, EBITDA Less Capital Expenditures To Consolidated Cash Interest Expense Ratio, Minimum Debt Instrument, Covenant, EBITDA Less Capital Expenditures To Consolidated Cash Interest Expense Ratio, Minimum PSUs granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Capital contributions Equity Method Investments, Capital Contributions Equity Method Investments, Capital Contributions Non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Reconciliation of Unrecognized Tax Benefits Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Property, plant and equipment, gross Property, Plant and Equipment, Gross Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Right-of-use lease assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Employer contributions to participants within plan assets Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount LEASES Lessee, Finance Leases [Text Block] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Other non-cash adjustments Restructuring Reserve, Settled without Cash Percentage of fair value in excess of carrying amount Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Other current liabilities Operating Lease, Liability, Current Prepaid assets Prepaid Expense, Current Interest on lease liabilities Finance Lease, Interest Expense 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Newly Adopted and Newly Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangible assets, net Net Finite-Lived Intangible Assets, Net Expected employer contributions in next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Adjustments to redemption value Temporary Equity, Accretion to Redemption Value, Adjustment Compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Terms for leases that have not yet commenced Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Value of debt instruments Debt Instrument, Fair Value Disclosure Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Non-U.S.  Income (Loss) from Continuing Operations before Income Taxes, Foreign Weighted-average assumptions used to determine projected benefit obligations Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Purchase price Business Combination, Consideration Transferred Deferred revenue Contract with Customer, Liability, Current Schedule of Weighted-average Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Pension and Other Post-Retirement Benefit Plans Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense US Fish and Wildlife Service US Fish and Wildlife Service [Member] US Fish and Wildlife Service Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Stock Options Options Employee Stock Option [Member] Maximum Maximum [Member] Schedule of Restructuring Costs Restructuring and Related Costs [Table Text Block] Document Type Document Type Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Tabular List, Table Tabular List [Table Text Block] Deferred tax assets, definite-lived and begin to expire Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Foreign currency translation Temporary Equity, Foreign Currency Translation Adjustments Thereafter Long-Term Debt, Maturity, after Year Five Inventories Inventory, Policy [Policy Text Block] Maximum number of common shares to be issued upon vesting of PSUs (in shares) Max PSU Shares Max PSU Shares 2026 Finance Lease, Liability, to be Paid, Year Three STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Other, net Other Noncash Income (Expense) Business Acquisition [Axis] Business Acquisition [Axis] Cash surrender value of life insurance policies Cash Surrender Value of Life Insurance Allowance for credit losses Less: Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Trademarks and trade names Trademarks and Trade Names [Member] Impact of acquisitions and restructuring Effective Income Tax Rate Reconciliation, Impact Of Acquisitions, Percent Effective Income Tax Rate Reconciliation, Impact Of Acquisitions, Percent Restricted cash included in Other assets Restricted Cash, Noncurrent State Deferred State and Local Income Tax Expense (Benefit) Variable Rate [Axis] Variable Rate [Axis] Costs and expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Defined Benefit Plan, Funding Status [Domain] Defined Benefit Plan, Funding Status [Domain] Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Sublease income Sublease Income Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling ownership interest Remaining ownership interest Subsidiary, Ownership Percentage, Noncontrolling Owner Operating Segments Operating Segments [Member] Balance at the beginning of the period (in dollars per share) Balance at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Derivative, fixed interest rate Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign exchange Goodwill, Foreign Currency Translation Gain (Loss) Venture Capital Funds Venture Capital Funds Investments [Member] Venture Capital Funds Investments Total lease costs Lease, Cost Capitalized stock-based compensation related costs Share-Based Payment Arrangement, Amount Capitalized Statistical Measurement [Axis] Statistical Measurement [Axis] Non-cash leases activity: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Put option term, period after first anniversary Business Combination, Put Option, Term, Period After First Anniversary Business Combination, Put Option, Term, Period After First Anniversary Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Cost of products sold (excluding amortization of intangible assets) Product [Member] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of businesses in reportable segment Number Of Subsegments Number Of Subsegments Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Tax on unremitted earnings Deferred Tax Liabilities, Tax On Unremitted Earnings Deferred Tax Liabilities, Tax On Unremitted Earnings Goodwill and other intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Certain property insurance, deductibles Property Insurance, Deductible Property Insurance, Deductible $3.0 Billion Credit Facility Three Billion Credit Facility [Member] Three Billion Credit Facility Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Pension and other post-retirement benefit plans (Note 14): Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax [Abstract] Total assets Disposal Group, Including Discontinued Operation, Assets Schedule of Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Performance Shares Grantee Group Two Performance Shares Grantee Group Two [Member] Performance Shares Grantee Group Two [Member] Derivatives Contracts Derivatives, Policy [Policy Text Block] Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Interest cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] Change in fair value of plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Employer contributions to participants outside of plan assets Defined Benefit Plan, Contributions By Employer To Participants Outside Of Plan Assets Defined Benefit Plan, Contributions By Employer To Participants Outside Of Plan Assets Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Purchase price of additional equity interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Interest Rate Swap Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Total liabilities Disposal Group, Including Discontinued Operation, Liabilities Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Schedule of Principal Maturities of Existing Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Total current Current Income Tax Expense (Benefit) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Strategic Investments Strategic Investments [Member] Strategic Investments Measurement Frequency [Domain] Measurement Frequency [Domain] PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] Other long-term liabilities measured at fair value: Liabilities, Noncurrent [Abstract] Title of Individual [Axis] Title of Individual [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Capitalized R&D Expenditures Deferred Tax Assets, in Process Research and Development Canada CANADA Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Weighted-average assumptions used to determine net periodic benefit cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Accrued income taxes Accrued Income Taxes DSA Discover And Safety Assessment Segment [Member] Discover And Safety Assessment Segment Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Decrease in unrecognized tax benefits that is reasonably possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Net current period other comprehensive (loss) income Other Comprehensive Income (Loss), before Tax Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Segment Reporting Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Other comprehensive income (loss): Other Comprehensive Income (Loss), before Tax [Abstract] Net periodic benefit cost (income) Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Equity Securities Equity Securities [Member] Contingent consideration Business Combination, Contingent Consideration, Liability Assets Disposal Group, Including Discontinued Operation, Assets [Abstract] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Restructuring Type [Axis] Restructuring Type [Axis] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Property, Plant, and Equipment Estimated Useful Lives Property, Plant And Equipment, Useful Lives [Table Text Block] Property, Plant and Equipment, Useful Lives [Table Text Block] Beginning balance Ending balance Fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of Changes to Each Component of Accumulated Other Comprehensive Income (Loss), Net of Income Taxes Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Life insurance policies Cash Surrender Value, Fair Value Disclosure State income taxes, net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Weighted average per share fair value (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Options canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Cognate Cognate BioServices, Inc. [Member] Cognate BioServices, Inc. 2027 Finance Lease, Liability, to be Paid, Year Four Trade Receivables and Contract Assets, Net Accounts Receivable [Policy Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability, Current Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Depreciation and amortization Depreciation, Depletion and Amortization Furniture and fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Medium-term Notes Medium-term Notes [Member] Services and products transferred over time Transferred over Time [Member] Adjustments for working capital/debt Business Combination, Adjustments for Working Capital/Debt Business Combination, Adjustments for Working Capital/Debt Business Combination and Asset Acquisition [Abstract] PSU Grantee Group One Performance Shares Grantee Group One [Member] Performance Shares Grantee Group One [Member] Accrued liabilities measured at fair value: Other Liabilities, Current, Fair Value Disclosure [Abstract] Other Liabilities, Current, Fair Value Disclosure Consolidation Items [Axis] Consolidation Items [Axis] Goodwill impairment Goodwill, Impairment Loss Long-lived assets Long-Lived Assets Valuation allowance Beginning balance Ending balance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Net Unrealized Gain (Loss) on Cash Flow Hedge Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term debt, net and finance leases Long-term debt, net and finance leases Long-Term Debt and Lease Obligation Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Key assumptions: Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Emerging Growth Company Entity Emerging Growth Company Redeemable noncontrolling interest Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest Value of consideration not acquired Business Combination, Value Of Consideration Not Acquired In Acquisition Business Combination, Value Of Consideration Not Acquired In Acquisition Definite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Common stock Common Stock [Member] Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Other Other [Member] Other [Member] Expiration of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Income Statement Location [Domain] Income Statement Location [Domain] Business combination, consideration transferred, other Business Combination, Consideration Transferred, Other Weighted average interest rate Debt, Weighted Average Interest Rate Unpaid advanced client billings Contract With Customer, Unpaid Advanced Client Billings Contract With Customer, Unpaid Advanced Client Billings Operating lease right-of-use liabilities (Long-term) Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Dividends declared to noncontrolling interest Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Minimum Minimum [Member] Property, plant and equipment, net Property, Plant and Equipment, Net Distributions Proceeds from Equity Method Investment, Distribution Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Proceeds from long-term debt and revolving credit facility Proceeds from Issuance of Long-Term Debt 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Weighted average probability percentage of achieving maximum target Fair Value, Measurement with Unobservable Inputs Reconciliation, Weighted Average Probability of Maximum Target Fair Value, Measurement with Unobservable Inputs Reconciliation, Weighted Average Probability of Maximum Target Deferred tax assets: Deferred Tax Assets, Net [Abstract] Other Deferred Tax Assets, Other Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Additions (reductions) charged to income tax provision, net Deferred Tax Asset, Valuation Allowance, Additions (Deductions) for Income Tax Expense (Benefit) Deferred Tax Asset, Valuation Allowance, Additions (Deductions) for Income Tax Expense (Benefit) Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Retirement Plan Type [Axis] Retirement Plan Type [Axis] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Other, net Payments for (Proceeds from) Other Investing Activities Unbilled revenue Contract with Customer, Asset, before Allowance for Credit Loss, Current Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Retained Earnings Retained Earnings [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Goodwill resulting from transaction Business Acquisition, Goodwill, Expected Tax Deductible Amount Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Other current assets (excluding cash) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other income (expense): Nonoperating Income (Expense) [Abstract] RMS RMS Research Models and Services [Member] Represents Research Models and Services segment of the entity which includes sales of research models, genetically engineered models and services (GEMS), consulting and staffing services (CSS), research animal diagnostics, discovery services, in vitro and avian vaccine services. Effect of foreign exchange Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Contingent liability Equity Method Investment, Contingent Liability Equity Method Investment, Contingent Liability Basic (in dollars per share) Earnings Per Share, Basic Unrecognized compensation cost related to unvested options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Payments for accrued interest Payments For Accrued Interest Payments For Accrued Interest Benefit payments Defined Benefit Plan, Benefit Obligation, Benefits Paid Pending Litigation Pending Litigation [Member] Future minimum lease payments for leases that have not yet commenced Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cash flows relating to investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest Expense Interest expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Technology Technology-Based Intangible Assets [Member] Accounts payable Increase (Decrease) in Accounts Payable Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Selling, general and administrative expenses Business Combination, Integration Related Costs And Transaction Costs Business Combination, Integration Related Costs And Transaction Costs Senior Notes Due 2029 And 2031 Senior Notes Due 2029 And 2031 [Member] Senior Notes Due 2029 And 2031 Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Total Long-Term Debt, Gross Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Redeemable noncontrolling interest, purchase price payable Redeemable Noncontrolling Interest, Purchase Price Payable Redeemable Noncontrolling Interest, Purchase Price Payable All Adjustments to Compensation All Adjustments to Compensation [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Compensation Amount Outstanding Recovery Compensation Amount Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Interest rate swap Derivative Asset Canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Divestitures Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Total deferred Deferred Income Tax Expense (Benefit) Proceeds from exercises of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Backlog Order or Production Backlog [Member] Finance leases Total lease liabilities Total lease liabilities Finance Lease, Liability Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Amounts recognized in balance sheet: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Tax Credit Carryforwards, by Expiration Period [Axis] Tax Credit Carryforwards, by Expiration Period [Axis] Tax Credit Carryforwards, by Expiration Period [Axis] Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Dividend fair value Redeemable Noncontrolling Interest, Dividend Receivable Fair Value Redeemable Noncontrolling Interest, Dividend Receivable Fair Value Strategic Equity Investments Equity Method Investments [Policy Text Block] Transfer in due to acquisition Defined Benefit Plan, Plan Assets, Business Combination 2024 Long-Term Debt, Maturity, Year One Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Asset Impairments and Other Costs Asset Impairment And Other Costs [Member] Asset Impairment And Other Costs [Member] Additional purchases reducing noncontrolling interest percentage Temporary Equity, Increase (Decrease) To Noncontrolling Interest Temporary Equity, Increase (Decrease) To Noncontrolling Interest Acquisition resulting in a 10% noncontrolling interest Temporary Equity, Acquisition Of Noncontrolling Interest Temporary Equity, Acquisition Of Noncontrolling Interest Stock options, restricted stock, restricted stock units and performance share units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Investments In Limited Partnerships [Text Block] Investments in Limited Partnerships [Text Block] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Payments on long-term debt, revolving credit facility, and finance lease obligations Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Payments / utilization Payments for Restructuring Document Period End Date Document Period End Date Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Adoption Date Trading Arrangement Adoption Date Audit Information [Abstract] Audit Information Finance lease Finance Lease, Weighted Average Discount Rate, Percent Long-term debt, net and finance leases Finance Lease, Liability, Noncurrent CDMO Sweden CDMO Site [Member] CDMO Site Treasury Stock Treasury Stock, Common [Member] Reductions due to divestitures, restructuring Deferred Tax Asset, Valuation Allowance, Reductions For Disposals, Restructuring Deferred Tax Asset, Valuation Allowance, Reductions For Disposals, Restructuring Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Provision for income taxes Total provision for income taxes Income Tax Expense (Benefit) Designated as Hedging Instrument Designated as Hedging Instrument [Member] Property, plant and equipment, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization FAIR VALUE Fair Value Disclosures [Text Block] Cash and Cash Equivalents [Abstract] (Gain) loss on venture capital and strategic equity investments, net Venture Capital And Equity Method Investments, Gain (Loss), Net Venture Capital And Equity Method Investments, Gain (Loss), Net Operating lease liability Deferred Tax Assets, Operating Lease Liability Deferred Tax Assets, Operating Lease Liability Equity: Equity [Abstract] INVENTORY Inventory Disclosure [Text Block] Operating lease Operating Lease, Weighted Average Remaining Lease Term Total purchase price allocation Total purchase price allocation Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Schedule of Rollforward of Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Table Text Block] Amortization of net loss Defined Benefit Plan, Amortization of Gain (Loss) Purchase obligation Disposal Group, Including Discontinued Operation, Purchase Obligation Disposal Group, Including Discontinued Operation, Purchase Obligation Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Shares acquired for individual minimum statutory tax withholding (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Acquisition of businesses and assets, net of cash acquired Payments to acquire businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Comprehensive income, net of income taxes Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Expected long-term return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Credit Facility [Domain] Credit Facility [Domain] Other Debt Other Long-term Debt [Member] Represents other debt instruments not elsewhere specified in the taxonomy. Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Current liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Interest rate Debt Instrument, Basis Spread on Variable Rate Estimated Useful Lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Customer contract deposits Increase (Decrease) In Contract With Customer Liability, Customer Deposits Increase (Decrease) In Contract With Customer Liability, Customer Deposits Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Avian Avian [Member] Avian Payments for repurchase of redeemable noncontrolling interest Payments for Repurchase of Redeemable Noncontrolling Interest Schedule of Client Receivables, Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Assets acquired under finance leases Right-of-use lease assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Trading day average stock price on grant date Trading Day Average Stock Price On Grant Date Trading Day Average Stock Price On Grant Date Equity interest acquired Business Combination, Step Acquisition, Equity Interest in Acquiree, Including Subsequent Acquisition, Percentage Less: Imputed interest Finance Lease, Liability, Undiscounted Excess Amount REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Additional paid-in capital Additional Paid in Capital, Common Stock Deferral period Deferred Compensation Arrangement With Individual, Deferral Period Deferred Compensation Arrangement With Individual, Deferral Period Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Vehicles Vehicles [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Gain (loss) Income (Loss) from Equity Method Investments Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover page. Cover [Abstract] Noveprim Group Noveprim Group [Member] Noveprim Group U.S. UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Total minimum future lease payments Lessee, Operating Lease, Liability, to be Paid Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Performance obligations expected to be satisfied Revenue, Remaining Performance Obligation, Amount Other income (expense) Other Nonoperating Income (Expense) [Member] Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization SEGMENT AND GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Net change in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued Compensation Accrued Compensation [Member] Accrued Compensation [Member] Renewal term for leases Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Current portion of finance leases Current portion of long-term debt and finance leases Finance Lease, Liability, Current Additional ownership percentage acquired by parent Noncontrolling Interest, Additional Ownership Percentage Acquired By Parent Noncontrolling Interest, Additional Ownership Percentage Acquired By Parent Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other Deferred Tax Liabilities, Other Entity Current Reporting Status Entity Current Reporting Status Operating income Operating income Operating Income (Loss) Foreign currency translation Equity Method Investment, Foreign Currency Translation Equity Method Investment, Foreign Currency Translation Total gains or losses (realized/unrealized): Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings [Abstract] SAMDI Tech, Inc. SAMDI Tech, Inc [Member] SAMDI Tech, Inc Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Cash and cash equivalents Cash and Cash Equivalents [Member] Total deferred tax liabilities Deferred Tax Liabilities, Gross Business combination, consideration liability contingent upon future performance, period Business Combination, Consideration Liability Contingent Upon Future Performance, Period Business Combination, Consideration Liability Contingent Upon Future Performance, Period Segments [Axis] Segments [Axis] Fair Value Estimate of Fair Value Measurement [Member] Business combination deferred purchase price Business Combination, Deferred Purchase Price Business Combination, Deferred Purchase Price Property, Plant and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Non-cash settlement charge related to pension losses, reclassified from AOCI to other expense Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Other Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Intangible assets, net Client relationships Customer Relationships [Member] Income before income taxes: Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] Biological assets, useful life Biological Assets, Useful Life Biological Assets, Useful Life Deferred income taxes Deferred Income Taxes and Tax Credits Variable Rate [Domain] Variable Rate [Domain] Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Balance at the beginning of the period (in shares) Balance at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number DEBT AND OTHER FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Multi-currency Revolving Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] PSUs Performance Shares [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Options exercisable, weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer hardware and software Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] U.S. statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Commitments and contingencies (Notes 2, 11, 13, 14 and 18) Commitments and Contingencies Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Operating lease right-of-use asset, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Assets Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] U.K. Plan Foreign Plan [Member] INCOME TAXES Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Leases Lessee, Leases [Policy Text Block] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Foreign currency translation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Birgit Girshick [Member] Birgit Girshick Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Payments of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Venture capital investments Deferred Tax Liabilities, Investment in Noncontrolled Affiliates Supplier Supplier [Member] Supplier [Member] Schedule of Finite-Lived and Indefinite-Lived Intangible Assets, by Major Class [Table] Schedule of Finite-Lived and Indefinite-Lived Intangible Assets, by Major Class [Table] Schedule of Finite-Lived and Indefinite-Lived Intangible Assets, by Major Class Gain in equity equal to the excess fair value of additional equity interest purchased Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Costs associated with deferred compensation plan and executive supplemental life insurance retirement plans Deferred Compensation Arrangement with Individual, Compensation Expense Goodwill [Roll Forward] Goodwill [Roll Forward] Options expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock, shares (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year One Client relationships, net Disposal Group, Client Relationships, Net Disposal Group, Client Relationships, Net Options outstanding, balance at the beginning of the period (in shares) Options outstanding, balance at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Buildings and building improvements Building and Building Improvements [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted-average grant date fair value of stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Less: Income tax (benefit) expense related to items of other comprehensive income (Note 12) Income tax (benefit) expense Other Comprehensive Income (Loss), Tax Net income attributable to common shareholders Net Income (Loss) Attributable to Parent Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Projected Benefit Obligation and Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] 2025 Finance Lease, Liability, to be Paid, Year Two Foreign Currency Contracts and Translation of Foreign Currencies Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name LEASES Lessee, Operating Leases [Text Block] Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Liabilities, Redeemable Noncontrolling Interests and Equity Liabilities and Equity [Abstract] Finite-lived intangible assets Finite-Lived Intangible Assets [Line Items] Effect of foreign exchange Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Federal Funds Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Unrealized gains (losses) on hedging instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax U.S.  Income (Loss) from Continuing Operations before Income Taxes, Domestic Cost of services provided and products sold Cost of Goods and Services Sold Operating lease right-of-use liabilities Disposal Group, Including Discontinued Operation, Operating Lease, Liability Disposal Group, Including Discontinued Operation, Operating Lease, Liability Income Tax Contingency [Table] Income Tax Contingency [Table] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Litigation Status [Domain] Litigation Status [Domain] Weighted Average Amortization Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Additions to tax positions for prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Authorized Share Repurchase Program Authorized Share Repurchase Program [Member] Authorized Share Repurchase Program [Member] Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Right-of-use assets Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset Expense (excluding non-cash charges) Restructuring and Related Cost, Incurred Cost Trade receivables and contract assets, net Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Selling, general and administrative Selling, General and Administrative Expenses [Member] Stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Services and products transferred at a point in time Transferred at Point in Time [Member] Operating lease right-of-use liabilities Operating lease right-of-use liabilities Operating Lease, Liability, Noncurrent Net income Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Excluding Redeemable Noncontrolling Interest Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Excluding Redeemable Noncontrolling Interest Long term deferred revenue (included in Other long-term liabilities) Contract With Customer Liability, Deferred Revenue, Noncurrent Contract With Customer Liability, Deferred Revenue, Noncurrent Distributed Bio Distributed Bio, Inc. [Member] Distributed Bio, Inc. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Net operating loss and credit carryforwards Deferred Tax Assets, Operating Loss and Credit Carryforwards Deferred Tax Assets, Operating Loss and Credit Carryforwards Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Stock-based compensation, net of income taxes Share-Based Payment Arrangement, Expense, after Tax Debt discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases After Adoption Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Change in projected benefit obligations: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Foreign Exchange Forward Foreign Exchange Forward [Member] Europe Europe [Member] Cash and Cash Equivalents, and Investments Cash and Cash Equivalents, Policy [Policy Text Block] Life Insurance Contracts Life Settlement Contracts, Policy [Policy Text Block] Weighted-average discount rate Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate [Abstract] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Litigation Status [Axis] Litigation Status [Axis] Other Acquisitions Other Acquisitions [Member] Other Acquisitions [Member] Interest expense Interest Expense Unrecognized compensation cost related to unvested awards, excluding options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities Capital Expenditures Incurred but Not yet Paid Loss on debt extinguishment and amortization of other financing costs Extinguishment costs Gain (Loss) on Extinguishment of Debt Maximum number of shares to be awarded (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Definite-Lived Intangible Assets Finite-Lived Intangible Assets Acquired Options outstanding weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Contingent consideration, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Schedule of Information about PSUs and Related Weighted-Average Assumptions Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reduction for acquisition of entities Equity Method Investments, Decrease Due To Acquisition Equity Method Investments, Decrease Due To Acquisition Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Consideration contingent upon future performance Business Combination, Consideration Liability Contingent Upon Future Performance Business Combination, Consideration Liability Contingent Upon Future Performance Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Weighted Average Cost of Capital Measurement Input, Discount Rate [Member] 2026 Long-Term Debt, Maturity, Year Three Reductions to tax positions for prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Total Equity Attributable to Common Shareholders Total Equity Attributable to Common Shareholders [Member] Total Equity Attributable to Common Shareholders [Member] Impact of tax uncertainties Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Restatement Determination Date Restatement Determination Date Defined Benefit Plan, Funding Status [Axis] Defined Benefit Plan, Funding Status [Axis] Dividends Temporary Equity, Dividends, Adjustment Additions to tax positions for current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash, cash equivalents, and restricted cash, beginning of period Cash, cash equivalents, and restricted cash, end of period Cash, cash equivalents, and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Variable lease costs Variable Lease, Cost Schedule of Accumulated Benefit Obligation and Fair of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Operating lease costs Operating Lease, Cost Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Valuation and Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Net actuarial loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Current portion of long-term debt and finance leases Long-Term Debt and Lease Obligation, Current Treasury stock, at cost, zero shares as of December 30, 2023 and December 31, 2022 Treasury Stock, Common, Value Total assets measured at fair value Assets, Fair Value Disclosure 2027 Long-Term Debt, Maturity, Year Four Foreign Currency Translation Adjustment and Other Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrecognized compensation cost related to unvested awards, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Other, net Proceeds from (Payments for) Other Financing Activities Comprehensive income attributable to common shareholders, net of income taxes Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Estimated Future Benefit Payments Over the Next Five Years Schedule of Expected Benefit Payments [Table Text Block] Total shareholder return of 20-trading day average stock price on grant date Share-based Compensation Arrangements By Share-based Payment Award, Fair Value Assumptions, Change in Weighted Average Stock Price Share-based Compensation Arrangements By Share-based Payment Award, Fair Value Assumptions, Change in Weighted Average Stock Price Net balance sheet liability Defined Benefit Plan, Funded (Unfunded) Status of Plan Short-term lease costs Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Ownership percentage Subsidiary, Ownership Percentage, Parent 2024 Finance Lease, Liability, to be Paid, Year One Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Net amount recognized Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Revenue, remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Adjustment of previously recorded contingent liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Previously Recorded Adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Previously Recorded Adjustment DSA DSA Discovery and Safety Assessment [Member] Net income Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Depreciation related Deferred tax liabilities, deferred expense, depreciation Deferred tax liabilities, deferred expense, depreciation Gross carrying amount, beginning balance Gross carrying amount, ending balance Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Other assets Disposal Group, Including Discontinued Operation, Other Assets Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Schedule of Rollforward of Company's Severance and Retention Costs Liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Interest rate swap Derivative Liability Numerator: Net Income (Loss) Attributable to Parent [Abstract] Biological assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Biological Assets, Noncurrent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Biological Assets, Noncurrent Issuance of stock under employee compensation plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Long-term debt and finance leases Long-Term Debt And Lease Obligation, Net Of Current Portion Long-Term Debt And Lease Obligation, Net Of Current Portion Noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Inventory shipment carrying value Inventory, Non-Human Primates Inventory, Non-Human Primates Ms. Girshick [Member] Ms. Girshick Venture capital and strategic equity investments Beginning balance Ending balance Equity Method Investments Inventories Inventories Inventory, Net Prior service cost and (losses) gains arising during the period Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax Land Land [Member] Other long-term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Property, plant, and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Purchase of treasury stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Foreign Deferred Foreign Income Tax Expense (Benefit) ACQUISITIONS AND DIVESTITURES Mergers, Acquisitions and Dispositions Disclosures [Text Block] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Contingent consideration Disposal Group, Including Discontinued Operation, Contingent Consideration Disposal Group, Including Discontinued Operation, Contingent Consideration Aggregate principal amount Debt Instrument, Face Amount Deferred tax liabilities: Deferred Tax Liabilities, Net [Abstract] Business combination, remaining equity to purchase Business Combination, Remaining Equity To Purchase Business Combination, Remaining Equity To Purchase Current assets: Current assets measured at fair value: Assets, Current [Abstract] Total Accounts Receivable, before Allowance for Credit Loss, Current Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Goodwill Disposal Group, Including Discontinued Operation, Goodwill Total minimum future lease payments Finance Lease, Liability, to be Paid Schedule of Revenues from External Customers and Long-Lived Assets Schedule of Revenues from External Customers and Long-Lived Assets [Table] Cash flows relating to operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Disposal Group Name [Domain] Disposal Group Name [Domain] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Maximum annual contributions per employee, percent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Schedule of Composition of Inventories Schedule of Inventory, Current [Table Text Block] RMS Japan RMS Japan Operations [Member] RMS Japan Operations Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Maximum consolidated indebtedness to consolidated EBITDA, with step downs Debt Instrument, Covenant, Consolidated Indebtedness To Consolidated EBITDA, Maximum Debt Instrument, Covenant, Consolidated Indebtedness To Consolidated EBITDA, Maximum Additional cash paid Payments To Acquire Businesses, Gross, Additional Cash Payment Payments To Acquire Businesses, Gross, Additional Cash Payment Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Settlement Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Cost of services provided (excluding amortization of intangible assets) Service [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Consideration received from divestiture Disposal Group, Including Discontinued Operation, Consideration Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Business combination, equity stake percentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Costs associated with employee savings plan Defined Contribution Plan, Cost All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Pension and Other Post-Retirement Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Provision for income taxes Share-Based Payment Arrangement, Expense, Tax Benefit Number of reportable segments Number of Reportable Segments Earnings per common share Earnings Per Share [Abstract] Common stock, $0.01 par value; 120,000 shares authorized; 51,338 shares issued and outstanding as of December 30, 2023 and 50,944 shares issued and outstanding as of December 31, 2022 Common Stock, Value, Issued Explore BioLabs Explora BioLabs [Member] Explora BioLabs Unconditional purchase obligations Unrecorded Unconditional Purchase Obligation Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Curtailment Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Senior Notes Senior Notes [Member] Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Finance cash flows from finance leases Finance Lease, Principal Payments Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Reconciliation of the Company's Beginning and Ending Unrecognized Income Tax Benefits Schedule of Unrecognized Tax Benefits Roll [Table Text Block] Tabular disclosure of the change in unrecognized tax benefits. Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases After Adoption Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Global intangible low-taxed income Effective Income Tax Rate Reconciliation, GILTI, Percent Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Tax Credit Carryforwards, by Expiration Period [Domain] Tax Credit Carryforwards, by Expiration Period [Domain] Tax Credit Carryforwards, by Expiration Period [Domain] Accrued penalties related to unrecognized income tax benefits Unrecognized Tax Benefits, Income Tax Penalties Accrued Litigation Case [Domain] Litigation Case [Domain] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Mutual Funds Equity Funds [Member] Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Aggregate authorization of share repurchase program Stock Repurchase Program, Authorized Amount Schedule of Reconciliations of the Statutory U.S. Federal Income Tax Rate to Effective Tax Rates Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Beginning balance Ending balance Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Asia Pacific Asia Pacific [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Transfer in due to acquisition Defined Benefit Plan, Benefit Obligation, Business Combination Restricted cash included in Other current assets Restricted Cash, Current 2029-2033 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Buildings Building [Member] Pension over funding and other post-closing adjustments Disposal Group, Including Discontinued Operation, Consideration, Pension Over Funding and Other Post Closing Adjustments Disposal Group, Including Discontinued Operation, Consideration, Pension Over Funding and Other Post Closing Adjustments Schedule of Rollforward of Goodwill Schedule of Goodwill [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Deferred tax assets for tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Unallocated corporate Corporate, Non-Segment [Member] Schedule of Amounts Recognized in Accumulated Other Comprehensive Loss Related to the Company's Pensions Plans Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block] Other assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Accrued compensation Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Loss (gain) on divestitures, net Gain on sale of business Gain (Loss) on Disposition of Business Current assets Disposal Group, Including Discontinued Operation, Assets, Current Total equity attributable to common shareholders Equity, Attributable to Parent Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Cash flows included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Restricted Stock Restricted Stock [Member] Reporting Unit [Axis] Reporting Unit [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Severance and Transition Costs Severance And Transition Costs [Member] Severance And Transition Costs [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current liabilities Liability, Defined Benefit Plan, Current Hedging Designation [Domain] Hedging Designation [Domain] Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] 3.75% Senior Notes due 2029 Senior Notes Due 2029 [Member] Senior Notes Due 2029 Level 2 Fair Value, Inputs, Level 2 [Member] Schedule of Reconciliation of Valuation Allowance Deferred Tax Assets, Valuation Allowance [Table Text Block] Deferred Tax Assets, Valuation Allowance Capital expenditures Capital expenditures Payments to Acquire Productive Assets Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Disposal Group Classification [Domain] Disposal Group Classification [Domain] Acquisitions Goodwill, Acquired During Period, Net Goodwill, Acquired During Period, Net Schedule of Derivative Instruments on Statements of Income Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Decrease in unrecognized income tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) RESTRUCTURING AND ASSET IMPAIRMENTS Restructuring, Impairment, and Other Activities Disclosure [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Options outstanding, balance at the beginning of the period (in dollars per share) Options outstanding, balance at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Fair Value of the Company's Pension Plan Assets by Asset Category Fair Value of Pension Plan Assets [Table Text Block] Fair Value of Pension Plan Assets [Table Text Block] Foreign Tax Authority Foreign Tax Authority [Member] City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] Company's ownership percentage Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Gain (loss) recognized in interest expense Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total liabilities measured at fair value Liabilities, Fair Value Disclosure Cash flows relating to financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Cash paid for income taxes Income Taxes Paid, Net Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Schedule of Financial Statement Line Items in Which Stock-based Compensation is Reflected Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities, redeemable noncontrolling interests and equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Number of shares employee is entitled to receive at no cost (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Per Employee Available to Purchase Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Per Employee Available to Purchase Operating lease right-of-use assets, net Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Deductible amount under insurance policies Insurance Policies, Deductible Insurance Policies, Deductible Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Foreign Current Foreign Tax Expense (Benefit) Payments to settle promissory note Payments To Settle Promissory Note Payments To Settle Promissory Note Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Revenue and Other Financial Information by Reportable Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Liabilities Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Adjustment to noncontrolling interest fair value Noncontrolling Interest, Increase (Decrease) in Redemption Value Noncontrolling Interest, Increase (Decrease) in Redemption Value Value of previously owned interest in acquiree Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Options expected to vest, weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred tax assets, operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Total Restructuring Charges Amount remaining on the authorized share repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Proceeds from sale of investments Proceeds from Sale and Maturity of Marketable Securities Common stock, shares authorized (in shares) Common Stock, Shares Authorized Purchases of additional equity interests, net Payments For Additional Equity Interests Payments For Additional Equity Interests Venture Capital Funds Venture Capital Funds [Member] Lease revenue Sales-type Lease, Revenue Measurement Input Type [Axis] Measurement Input Type [Axis] Schedule of Finite-Lived Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Award Timing Disclosures [Line Items] Estimated tax liability Indirect Tax Contingency, Current Indirect Tax Contingency, Current Title of Individual [Domain] Title of Individual [Domain] Less: Comprehensive income related to noncontrolling interests, net of income taxes Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Fair value of awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Senior Notes Due 2026 Senior Notes Due 2026 [Member] Senior Notes Due 2026 [Member] Treasury Shares Treasury Stock, Policy [Policy Text Block] Treasury Stock, Policy [Policy Text Block] Tax Credit Carryforwards, Carried Forward Indefinitely Tax Credit Carryforwards, Expiration Range 2 [Member] Tax Credit Carryforwards, Expiration Range 2 Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] SUPPLEMENTAL CASH FLOW INFORMATION Cash Flow, Supplemental Disclosures [Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Other current assets Prepaid Expense and Other Assets, Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Other comprehensive income (loss) Other Comprehensive Income (Loss), Including Portion Attributable To Noncontrolling Interest and Excluding Redeemable Noncontrolling Interest, Net of Tax Other Comprehensive Income (Loss), Including Portion Attributable To Noncontrolling Interest and Excluding Redeemable Noncontrolling Interest, Net of Tax Insider Trading Arrangements [Line Items] Proceeds from sale of businesses, net Proceeds from Divestiture of Businesses, Net of Cash Divested Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Retrogenix Retrogenix Limited [Member] Retrogenix Limited Amounts recognized in accumulated other comprehensive income (loss) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract] Issuance of stock under employee compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Foreign tax rate differences Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of revenue Cost of services provided and products sold (excluding amortization of intangible assets) Cost of Sales [Member] Changes in fair value of contingent consideration arrangements Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Noncontrolling interests (nonredeemable) Equity, Attributable to Noncontrolling Interest Schedule of Components of Income from Continuing Operations Before Income Taxes and the Related Provision for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign, and Components of Income Tax Expense (Benefit) [Table Text Block] Tabular disclosure of income before income tax between domestic and foreign jurisdictions and the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Auditor Name Auditor Name Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Disposal Group Name [Axis] Disposal Group Name [Axis] Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Prepayments of long-term debt Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Weighted-average remaining lease term (in years) Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term [Abstract] Share-based compensation, before income taxes Stock-based compensation, before income taxes Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Finite-Lived Intangible Assets, Gross Finished products Inventory, Finished Goods, Net of Reserves Trade receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Income Tax Authority [Domain] Income Tax Authority [Domain] Accrued compensation Employee-related Liabilities, Current Payment of debt extinguishment and financing costs Deferred financing costs expensed Payments of Financing Costs Name Trading Arrangement, Individual Name Deferred Tax Asset, Valuation Allowance [Roll Forward] Deferred Tax Asset, Valuation Allowance [Roll Forward] Deferred Tax Asset, Valuation Allowance Schedule of Disaggregation of Revenue Schedule of Revenue for Each Significant Product or Service Offering Disaggregation of Revenue [Table Text Block] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Total revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Decrease in benefit obligations from new morality improvement scales Defined Benefit Plan, Actuarial Gain (Loss), Change in Mortality Assumptions Defined Benefit Plan, Actuarial Gain (Loss), Change in Mortality Assumptions Operating lease Operating Lease, Weighted Average Discount Rate, Percent Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Business Combinations, Contingent Consideration Business Combinations Policy [Policy Text Block] Finance lease Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Leasehold improvements Leasehold Improvements [Member] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Net deferred taxes Deferred Tax Liabilities, Net Diluted (in shares) Weighted-average shares outstanding—Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Contingent Consideration Contingent Consideration [Member] Represents potential amounts payable by the entity as contingent consideration in connection with a business acquisition. Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Current deferred revenue Contract With Customer Liability, Deferred Revenue, Current Contract With Customer Liability, Deferred Revenue, Current Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Schedule of Major Classes of Assets and Liabilities Associated with Divestitures Disposal Groups, Including Discontinued Operations [Table Text Block] Period of highest consecutive years of compensation Deferred Compensation Arrangement With Individual, Period of Highest Consecutive Years of Compensation Used for Determination of Executive Supplemental Life Insurance Retirement Plan Benefit Deferred Compensation Arrangement With Individual, Period of Highest Consecutive Years of Compensation Used for Determination of Executive Supplemental Life Insurance Retirement Plan Benefit Schedule of Stock Repurchases [Table] Schedule of Stock Repurchases [Table] Schedule detailing information relating to stock repurchases. Divestitures Goodwill, Written off Related to Sale of Business Unit Company Selected Measure Amount Company Selected Measure Amount 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Thereafter Finance Lease, Liability, to be Paid, after Year Five Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 2028 Long-Term Debt, Maturity, Year Five Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Construction in progress Construction in Progress [Member] Client receivables Trade Receivables from Customers Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for billed goods or services. Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Manufacturing Manufacturing Manufacturing Support [Member] Manufacturing Support [Member] Pension Plans Pension Plans Pension Plan [Member] Tax on unremitted earnings Deferred Tax Liabilities, Tax On Unremitted Earnings, Percent Deferred Tax Liabilities, Tax On Unremitted Earnings, Percent Non-PEO NEO Non-PEO NEO [Member] Target asset allocation percentage Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Adjustment to Compensation: Adjustment to Compensation [Axis] Deferred tax assets for net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted-average shares outstanding—Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Gain on purchase of remaining equity interest of Vital River redeemable noncontrolling interest Redeemable Noncontrolling Interest, Decrease from Redemptions or Purchase of Remaining Equity Interest Redeemable Noncontrolling Interest, Decrease from Redemptions or Purchase of Remaining Equity Interest Other comprehensive income (loss), before income taxes Other Comprehensive Income (Loss), Before Income Taxes Other Comprehensive Income (Loss), Before Income Taxes Plans with Accumulated Benefit Obligations in Excess of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Estimated amortization expense for each of the next five fiscal years Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Research tax credits and enhanced deductions Effective Income Tax Rate Reconciliation, Tax Credits and Deductions Effective Income Tax Rate Reconciliation, Tax Credits and Deductions Statement [Line Items] Statement [Line Items] Accrued interest related to unrecognized income tax benefits Unrecognized Tax Benefits, Interest on Income Taxes Accrued Options expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number James Foster [Member] James Foster Face value of life insurance contracts Life Settlement Contracts, Investment Method, Face Value Schedule of Long-term Debt, Net Schedule of Debt [Table Text Block] Noncontrolling Interest Noncontrolling Interest [Member] EX-101.PRE 15 crl-20231230_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 crl-20231230_g1.jpg CRL LOGO begin 644 crl-20231230_g1.jpg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end GRAPHIC 17 crl-20231230_g2.jpg ITEM 5 PERFORMANCE GRAPH begin 644 crl-20231230_g2.jpg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image_01.jpg CRL LOGO begin 644 image_01.jpg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end GRAPHIC 19 image_0a.jpg SIGNATURE begin 644 image_0a.jpg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picture1.jpg CRL LOGO begin 644 picture1.jpg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end XML 21 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 30, 2023
Jan. 27, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 30, 2023    
Current Fiscal Year End Date --12-30    
Document Transition Report false    
Entity File Number 001-15943    
Entity Registrant Name CHARLES RIVER LABORATORIES INTERNATIONAL, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 06-1397316    
Entity Address, Address Line One 251 Ballardvale Street    
Entity Address, City or Town Wilmington    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01887    
City Area Code 781    
Local Phone Number 222-6000    
Title of 12(b) Security Common stock, $0.01 par value    
Trading Symbol CRL    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Smaller Reporting Company false    
Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 10,686,736,278
Entity Common Stock, Shares Outstanding   51,349,770  
Documents Incorporated by Reference
Portions of the registrant’s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders currently scheduled to be held on May 8, 2024, which will be filed with the Securities and Exchange Commission (SEC) not later than 120 days after December 30, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the 2024 Proxy Statement expressly incorporated into this Annual Report on Form 10-K by reference, such document shall not be deemed filed as part of this Form 10-K.
    
Entity Central Index Key 0001100682    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    

XML 22 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 30, 2023
Audit Information [Abstract]  
Auditor Firm ID 238
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Boston, Massachusetts
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Total revenue $ 4,129,409 $ 3,976,060 $ 3,540,160
Costs and expenses:      
Selling, general and administrative 747,855 665,098 619,919
Amortization of intangible assets 137,440 146,578 124,857
Operating income 617,261 650,975 589,862
Other income (expense):      
Interest income 5,196 780 652
Interest expense (136,710) (59,291) (73,910)
Other income (expense), net 95,537 30,523 (35,894)
Income before income taxes 581,284 622,987 480,710
Provision for income taxes 100,914 130,379 81,873
Net income 480,370 492,608 398,837
Less: Net income attributable to noncontrolling interests 5,746 6,382 7,855
Net income attributable to common shareholders $ 474,624 $ 486,226 $ 390,982
Earnings per common share      
Basic (in dollars per share) $ 9.27 $ 9.57 $ 7.77
Diluted (in dollars per share) $ 9.22 $ 9.48 $ 7.60
Weighted-average number of common shares outstanding:      
Basic (in shares) 51,227 50,812 50,293
Diluted (in shares) 51,451 51,301 51,425
Cost of services provided (excluding amortization of intangible assets)      
Total revenue $ 3,440,019 $ 3,216,904 $ 2,755,579
Costs and expenses:      
Cost of services provided and products sold 2,295,983 2,143,318 1,837,487
Cost of products sold (excluding amortization of intangible assets)      
Total revenue 689,390 759,156 784,581
Costs and expenses:      
Cost of services provided and products sold $ 330,870 $ 370,091 $ 368,035
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Statement of Comprehensive Income [Abstract]      
Net income $ 480,370 $ 492,608 $ 398,837
Other comprehensive income (loss):      
Foreign currency translation adjustment 70,651 (129,091) (29,493)
Pension and other post-retirement benefit plans (Note 14):      
Prior service cost and (losses) gains arising during the period (5,376) 24,471 (1,193)
Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans 736 3,337 1,678
Unrealized gains (losses) on hedging instruments 2,490 (1,523) 0
Other comprehensive income (loss), before income taxes 68,501 (102,806) (29,008)
Less: Income tax (benefit) expense related to items of other comprehensive income (Note 12) 4,071 (1,905) (3,965)
Comprehensive income, net of income taxes 544,800 391,707 373,794
Less: Comprehensive income related to noncontrolling interests, net of income taxes 4,546 2,798 8,678
Comprehensive income attributable to common shareholders, net of income taxes $ 540,254 $ 388,909 $ 365,116
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 276,771 $ 233,912
Trade receivables and contract assets, net of allowances for credit losses of $25,722 and $11,278, respectively 780,375 752,390
Inventories 380,259 255,809
Prepaid assets 87,879 89,341
Other current assets 83,378 107,580
Total current assets 1,608,662 1,439,032
Property, plant and equipment, net 1,639,741 1,465,655
Venture capital and strategic equity investments 243,811 311,602
Operating lease right-of-use assets, net 394,029 391,762
Goodwill 3,095,045 2,849,903
Intangible assets, net 864,051 955,275
Deferred tax assets 40,279 41,262
Other assets 309,383 148,279
Total assets 8,195,001 7,602,770
Current liabilities:    
Accounts payable 168,937 205,915
Accrued compensation 213,290 197,078
Deferred revenue 241,820 264,259
Accrued liabilities 227,825 219,758
Other current liabilities 203,210 204,575
Total current liabilities 1,055,082 1,091,585
Long-term debt, net and finance leases 2,647,147 2,707,531
Operating lease right-of-use liabilities 419,234 389,745
Deferred tax liabilities 191,349 215,582
Other long-term liabilities 223,191 174,822
Total liabilities 4,536,003 4,579,265
Commitments and contingencies (Notes 2, 11, 13, 14 and 18)
Redeemable noncontrolling interest 56,722 42,427
Equity:    
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.01 par value; 120,000 shares authorized; 51,338 shares issued and outstanding as of December 30, 2023 and 50,944 shares issued and outstanding as of December 31, 2022 513 509
Additional paid-in capital 1,905,578 1,804,940
Retained earnings 1,887,218 1,432,901
Treasury stock, at cost, zero shares as of December 30, 2023 and December 31, 2022 0 0
Accumulated other comprehensive loss (196,427) (262,057)
Total equity attributable to common shareholders 3,596,882 2,976,293
Noncontrolling interests (nonredeemable) 5,394 4,785
Total equity 3,602,276 2,981,078
Total liabilities, redeemable noncontrolling interests and equity $ 8,195,001 $ 7,602,770
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for credit losses $ 25,722 $ 11,278
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 20,000 20,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 120,000 120,000
Common stock, shares issued (in shares) 51,338 50,944
Common stock, shares outstanding (in shares) 51,338 50,944
Treasury stock, shares (in shares) 0 0
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Cash flows relating to operating activities      
Net income $ 480,370 $ 492,608 $ 398,837
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 314,124 303,870 265,540
Stock-based compensation 72,048 73,617 71,474
Loss on debt extinguishment and amortization of other financing costs 3,967 4,118 29,964
Deferred income taxes (50,903) (35,884) (24,006)
Long-lived asset impairment charges 41,911 5,816 733
(Gain) loss on venture capital and strategic equity investments, net (97,827) 26,775 30,420
Provision for credit losses 18,225 6,706 1,657
Loss (gain) on divestitures, net 961 (123,405) (25,026)
Changes in fair value of contingent consideration arrangements 1,810 (3,753) (34,303)
Other, net 1,592 21,726 2,567
Changes in assets and liabilities:      
Trade receivables and contract assets, net (33,434) (150,570) (26,633)
Inventories (62,301) (78,523) (25,159)
Accounts payable (20,427) (2,652) 44,901
Accrued compensation 12,447 (42,164) 44,304
Deferred revenue (21,743) 57,658 (13,402)
Customer contract deposits (15,564) 30,457 16,925
Other assets and liabilities, net 38,642 33,240 2,006
Net cash provided by operating activities 683,898 619,640 760,799
Cash flows relating to investing activities      
Acquisition of businesses and assets, net of cash acquired (194,785) (283,392) (1,293,095)
Capital expenditures (318,528) (324,733) (228,772)
Purchases of investments and contributions to venture capital investments (54,215) (158,274) (45,555)
Proceeds from sale of investments 6,667 4,549 6,532
Proceeds from sale of businesses, net 0 163,275 122,694
Other, net (2,294) (9,347) 264
Net cash used in investing activities (563,155) (607,922) (1,437,932)
Cash flows relating to financing activities      
Proceeds from long-term debt and revolving credit facility 776,353 2,952,430 6,951,113
Proceeds from exercises of stock options 25,597 25,110 45,652
Payments on long-term debt, revolving credit facility, and finance lease obligations (851,676) (2,932,636) (6,242,877)
Purchase of treasury stock (24,155) (38,651) (40,707)
Payment of debt extinguishment and financing costs 0 0 (38,255)
Payments of contingent consideration (2,711) (10,356) (2,328)
Purchases of additional equity interests, net (4,784) (30,533) 0
Other, net (4,145) (7,761) 0
Net cash (used in) provided by financing activities (85,521) (42,397) 672,598
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 8,044 25,579 17,730
Net change in cash, cash equivalents, and restricted cash 43,266 (5,100) 13,195
Cash, cash equivalents, and restricted cash, beginning of period 241,214 246,314 233,119
Cash, cash equivalents, and restricted cash, end of period $ 284,480 $ 241,214 $ 246,314
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock
Total Equity Attributable to Common Shareholders
Noncontrolling Interest
Beginning balance (in shares) at Dec. 26, 2020   49,767            
Beginning balance at Dec. 26, 2020 $ 2,118,169 $ 498 $ 1,627,564 $ 625,414 $ (138,874) $ 0 $ 2,114,602 $ 3,567
Beginning balance (in shares) at Dec. 26, 2020           0    
Increase (Decrease) in Stockholders' Equity                
Net income 393,462     390,982     390,982 2,480
Other comprehensive income (loss) (25,866)       (25,866)   (25,866)  
Dividends declared to noncontrolling interest (1,885)             (1,885)
Adjustment to noncontrolling interest fair value (21,312)   (21,312)       (21,312)  
Issuance of stock under employee compensation plans (in shares)   861            
Issuance of stock under employee compensation plans 45,647 $ 8 45,639       45,647  
Purchase of treasury shares (in shares)           148    
Purchase of treasury shares (40,707)         $ (40,707) (40,707)  
Retirement of treasury shares (in shares)   (148)       (148)    
Retirement of treasury shares 0 $ (1) (5,061) (35,645)   $ 40,707 0  
Stock-based compensation 71,474   71,474       71,474  
Ending balance (in shares) at Dec. 25, 2021   50,480            
Ending balance at Dec. 25, 2021 2,538,982 $ 505 1,718,304 980,751 (164,740) $ 0 2,534,820 4,162
Ending balance (in shares) at Dec. 25, 2021           0    
Increase (Decrease) in Stockholders' Equity                
Net income 488,588     486,226     486,226 2,362
Other comprehensive income (loss) (97,317)       (97,317)   (97,317)  
Dividends declared to noncontrolling interest (1,739)             (1,739)
Adjustment to noncontrolling interest fair value (7,507)   (7,507)       (7,507)  
Issuance of stock under employee compensation plans (in shares)   594            
Issuance of stock under employee compensation plans 25,105 $ 5 25,100       25,105  
Purchase of treasury shares (in shares)           130    
Purchase of treasury shares (38,651)         $ (38,651) (38,651)  
Retirement of treasury shares (in shares)   (130)       (130)    
Retirement of treasury shares 0 $ (1) (4,574) (34,076)   $ 38,651 0  
Stock-based compensation $ 73,617   73,617       73,617  
Ending balance (in shares) at Dec. 31, 2022 50,944 50,944            
Ending balance at Dec. 31, 2022 $ 2,981,078 $ 509 1,804,940 1,432,901 (262,057) $ 0 2,976,293 4,785
Ending balance (in shares) at Dec. 31, 2022 0         0    
Increase (Decrease) in Stockholders' Equity                
Net income $ 476,878     474,624     474,624 2,254
Other comprehensive income (loss) 65,630       65,630   65,630  
Dividends declared to noncontrolling interest (1,645)             (1,645)
Adjustment to noncontrolling interest fair value 5,694   5,694       5,694  
Gain on purchase of remaining equity interest of Vital River redeemable noncontrolling interest 1,151   1,151       1,151  
Issuance of stock under employee compensation plans (in shares)   499            
Issuance of stock under employee compensation plans 25,597 $ 5 25,592       25,597  
Purchase of treasury shares (in shares)           105    
Purchase of treasury shares (24,155)         $ (24,155) (24,155)  
Retirement of treasury shares (in shares)   (105)       (105)    
Retirement of treasury shares 0 $ (1) (3,847) (20,307)   $ 24,155 0  
Stock-based compensation $ 72,048   72,048       72,048  
Ending balance (in shares) at Dec. 30, 2023 51,338 51,338            
Ending balance at Dec. 30, 2023 $ 3,602,276 $ 513 $ 1,905,578 $ 1,887,218 $ (196,427) $ 0 $ 3,596,882 $ 5,394
Ending balance (in shares) at Dec. 30, 2023 0         0    
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Charles River Laboratories International, Inc. (the Company), together with its subsidiaries, is a full service, non-clinical global drug development partner. The Company has built upon its core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that enable the Company to support its clients from target identification through non-clinical development. The Company also provides a suite of products and services to support its clients’ manufacturing activities.
Principles of Consolidation
The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation.
The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which occurred in fiscal year 2022.
Segment Reporting
The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses.
Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities and utilizing our Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow.
The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.
The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO). In December of 2022, the Company sold the Avian Vaccine Services business (Avian), reported in the Manufacturing segment, which supplied specific-pathogen-free chicken eggs and chickens.
Use of Estimates
The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.
Newly Adopted Accounting Pronouncements
In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company participates in certain supplier finance programs that are immaterial to the consolidated financial statements and related disclosures.
Newly Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but does not believe there will be a material impact.
In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.
Cash, Cash Equivalents, and Investments
Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments.
Trade Receivables and Contract Assets, Net
The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 3.5% of revenue in fiscal years 2023, 2022, or 2021 or trade receivables as of December 30, 2023 or December 31, 2022.
Fair Value Measurements
The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy:
•Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,
•Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rate yield curves and foreign currency spot rates,
•Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.
Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:
•Cash equivalents - Valued at market prices determined through third-party pricing services;
•Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;
•Interest rate swap contracts - Valued using market observable inputs, such as interest rate yield curves;
•Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;
•Debt instruments - The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and
•Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes and certain option pricing models.
Inventories
The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell solutions, microbial solutions, and CDMO products. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with certain direct materials, costs of personnel directly involved in the care of the models, and allocation of facility overhead costs. For cell solutions inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions and CDMO inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold.
Property, Plant and Equipment, Net
Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.
Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset.
The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:
Estimated
Useful Lives
(in years)
LandIndefinite
Buildings and building improvements
10 - 40
Machinery and equipment
3 - 20
Furniture and fixtures
5 - 10
Computer hardware and software
3 - 8
Vehicles
3 - 5
Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned.
When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Business Combinations
The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets and certain biological assets, which can represent a significant portion of the purchase price. The determination of the fair value of intangible and certain biological assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such assets are amortizable or non-amortizable and, if the former, the period and the method by which the asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of assets. Typically, key assumptions include projections of cash flows that arise from identifiable assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets.
In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) and certain biological assets are the most significant identifiable asset acquired. To determine the fair value of these acquired assets, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue, cost of revenue, operating income margins, customer attrition rates, and productivity rates; as well as discount rates based on a market participant’s weighted average cost of capital.
Contingent Consideration
The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets.
Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market.
Divestitures
The Company records divestitures at fair value less cost to sell with any related gain or loss from sale recorded within Other income (expense) on the Company’s consolidated statements of income. If the sale price includes contingent payments, these
are fair valued using a probability weighted model. If the business divested is part of a reporting unit, goodwill from the reporting unit is reallocated based on the fair value of the divested business compared to the fair value of the reporting unit.
Goodwill and Intangible Assets
Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts.
The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded.
Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values.
Valuation and Impairment of Long-Lived Assets
Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.
Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values.
Long-lived assets to be disposed of are carried at fair value less costs to sell.
Venture Capital Investments
The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance.
Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in Other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information.
Strategic Equity Investments
The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Derivative Contracts
The Company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The Company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. The Company uses an interest rate swap to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility.
The Company uses short-term forward currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans. The currency-exchange contracts principally hedge transactions denominated in Canadian dollars and euros. The Company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Life Insurance Contracts
Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. Gains and losses from life insurance contracts are recorded in Other income (expense), net in the accompanying consolidated statements of income. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. The Company held 44 contracts at December 30, 2023 with a face value of $82.4 million and 44 contracts with a face value of $74.5 million at December 31, 2022, which are recorded in Other assets.
Leases
At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments.
The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.
Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.
Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors.
A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases.
The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements.
Stock-Based Compensation
The Company grants stock options, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period.
For stock options and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable.
The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of RSUs is based on the market value of the Company’s common stock on the date of grant.
Revenue Recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).
To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components.
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year, and recorded within service revenue. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the consolidated financial statements.
Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date.
The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Cumulative catch-up adjustments to revenue are periodically recorded that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration), or a contract modification.
Income Taxes
The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements carrying amounts and their respective tax basis. The Company measures deferred tax assets and liabilities using the enacted tax rates in effect when the temporary differences are expected to be settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Foreign Currency Contracts
Foreign currency contracts are recorded at fair value in the Company’s consolidated balance sheets and are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loan. Any gains or losses on forward contracts associated with the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity under the Company’s Credit Facility are recognized immediately in Interest expense. Gains or losses incurred on the remeasurement of the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency is recorded in Other (expense) income, net.
Translation of Foreign Currencies
For the Company’s subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive loss, a separate component of equity.
Pension and Other Post-Retirement Benefit Plans
The Company recognizes the funded status of its defined benefit pension and other post-retirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The Company measures plan assets and benefit obligations as of its fiscal year end.
The key assumptions used to calculate benefit obligations and related pension costs include expected long-term rate of return on plan assets, withdrawal and mortality rates, expected rate of increase in employee compensation levels and a discount rate. Assumptions are determined based on the Company’s data and appropriate market indicators, and evaluated each year as of the plan’s measurement date.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the Company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance.
The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and the current employee compensation strategy.
The Company is required to recognize as a component of Other comprehensive income, net of tax, the actuarial gains or losses and prior service costs or credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive income is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
The Company records the service cost component of the net periodic benefit cost within Cost of services provided and Selling, general, and administrative expenses and all other components of net periodic benefit cost within Other (expense) income, net in the consolidated statements of income.
The Company recognizes pension settlement gains or losses in the period when all of the following settlement criteria are met: there is an irrevocable action, the Company is relieved of primary responsibility for a benefit obligation, and significant risks related to the obligation and the assets used to effect the settlement are eliminated.
Earnings Per Share
Basic earnings per share is calculated by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Except where the result would be anti-dilutive to income from continuing operations, diluted earnings per share is computed using the treasury stock method, assuming the exercise of stock options and the vesting of RSUs, or evaluating the performance conditions for PSUs to assess whether the conditions have been met, as well as their related income tax effects.
Treasury Shares
The Company periodically retires treasury shares acquired through share repurchases and returns those shares to the status of authorized but unissued. The Company accounts for treasury stock transactions under the cost method. For each reacquisition of common stock, the number of shares and the acquisition price for those shares is added to the existing treasury stock count and total value. Thus, the average cost per share is re-averaged each time shares are acquired. When treasury shares are retired, the Company allocates the excess of the repurchase price over the par value of shares acquired to both retained earnings and additional paid-in-capital. The portion allocated to additional paid-in-capital is determined by applying a percentage, determined by dividing the number of shares to be retired by the number of shares issued, to the balance of additional paid-in-capital as of the retirement date.
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES
 12 Months Ended
Dec. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS AND DIVESTITURES ACQUISITIONS AND DIVESTITURES
Fiscal 2023 Acquisition
Noveprim Group
On November 30, 2023, the Company completed the acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest. The
Company had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance. The total consideration allocable to the Noveprim acquisition is $374.8 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $198.8 million which includes a remeasurement gain on the 49% equity investment of $103.2 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $13.8 million. The contingent consideration fair value is estimated using a Monte Carlo Simulation model and the maximum contingent contractual payments are up to $55.0 million based on future performance and milestone achievements from in fiscal years 2023 through 2025. The Company has the call option right to purchase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller. The redemption price for the call/put is fixed and ranges from $47.0 million to $54.0 million depending on when exercised. The noncontrolling interest is classified as a redeemable noncontrolling interest in the mezzanine section of the consolidated balance sheet. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers.
SAMDI Tech, Inc.
On January 27, 2023, the Company acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by the Company of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment.
Fiscal 2022 Acquisition
Explora BioLabs Holdings, Inc.
On April 5, 2022, the Company acquired Explora BioLabs Holdings, Inc. (Explora BioLabs), a provider of contract vivarium research services, providing biopharmaceutical clients with turnkey in vivo vivarium facilities, management and related services to efficiently conduct their early-stage research activities. The acquisition of Explora BioLabs complements the Company’s existing Insourcing Solutions business, specifically the CRADL™ (Charles River Accelerator and Development Lab) footprint, and offers incremental opportunities to partner with an emerging client base, many of which are engaged in cell and gene therapy development. The purchase price of Explora BioLabs was $284.5 million, net of $6.6 million in cash. The acquisition was funded through proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s RMS reportable segment.
Fiscal 2021 Acquisitions
Vigene Biosciences, Inc.
On June 28, 2021, the Company acquired Vigene Biosciences, Inc. (Vigene), a gene therapy CDMO, providing viral vector-based gene delivery solutions. The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The purchase price of Vigene was $323.9 million, net of $2.7 million in cash. Included in the purchase price are contingent payments fair valued at $34.5 million, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $57.5 million based on future performance). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s Manufacturing reportable segment. As of December 30, 2023 and December 31, 2022 the fair value of the contingent consideration was zero as certain financial targets have not and are not expected to be achieved.
Retrogenix Limited
On March 30, 2021, the Company acquired Retrogenix Limited (Retrogenix), an outsourced discovery services provider specializing in bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances the Company’s scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash. Included in the purchase price are contingent payments fair valued at $6.9 million, which is the maximum potential payout, and was based on a probability-weighted approach. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment.
Cognate BioServices, Inc.
On March 29, 2021, the Company acquired Cognate BioServices, Inc. (Cognate), a cell and gene therapy CDMO offering comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain. The acquisition of Cognate establishes the Company as a scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through cGMP production. The purchase price of Cognate was $877.9 million, net of $70.5 million in cash and includes $15.7 million of consideration for an approximate 2% ownership interest not initially acquired, but redeemed in April 2022 with the ultimate payout tied to performance in 2021. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility and senior notes (Senior Notes) issued in fiscal 2021. This business is reported as part of the Company’s Manufacturing reportable segment.
Distributed Bio, Inc.
On December 31, 2020, the Company acquired Distributed Bio, Inc. (Distributed Bio), a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. The acquisition of Distributed Bio expands the Company’s capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development. The purchase price of Distributed Bio was $97.0 million, net of $0.8 million in cash. The total consideration includes $80.8 million cash paid, settlement of $3.0 million in convertible promissory notes previously issued by the Company during prior fiscal years, and $14.1 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $21.0 million based on future performance and milestone achievements over a one-year period). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. During fiscal year 2022, $7.0 million of contingent consideration was paid as certain operational milestones were achieved. As of December 30, 2023, other financial targets associated with the contingent consideration were not met and the fair value of the remaining contingent consideration is zero.
Other Acquisition
On March 3, 2021, the Company acquired certain assets from a distributor that supports the Company’s DSA reportable segment. The purchase price was $35.4 million, which includes $19.5 million in cash paid ($5.5 million of which was paid in fiscal 2020), and $15.9 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $17.5 million based on future performance over a three-year period). The fair value of the net assets acquired included $17.3 million of goodwill, $15.2 million attributed to supplier relationships (to be amortized over a 4-year period), and $3.0 million of property, plant, and equipment. The business is reported as part of the Company’s DSA reportable segment. As of December 30, 2023, the fair value of the contingent consideration was zero as certain operational targets were not achieved.
Purchase price information
The purchase price allocation for acquisitions during fiscal years 2023 and 2022 was as follows:
Noveprim Group(1)
SAMDI Tech, Inc.Explora BioLabs
November 30, 2023January 27, 2023April 5, 2022
(in thousands)
Trade receivables$1,308 $513 $7,679 
Inventories66,500 — — 
Other current assets (excluding cash)3,965 75 1,067 
Property, plant and equipment35,831 593 37,369 
Operating lease right-of-use asset, net104 — 48,613 
Goodwill (2)
172,349 37,129 215,752 
Definite-lived intangible assets9,500 33,070 70,100 
Other long-term assets (3)
167,907 6 556 
Deferred revenue— (43)(3,507)
Other current liabilities (16,378)(351)(15,507)
Operating lease right-of-use liabilities (Long-term)(97)— (57,193)
Deferred tax liabilities(12,984)(8,191)(18,601)
Other long-term liabilities(7,797)— (1,807)
Redeemable noncontrolling interest (4)
(45,374)— — 
Total purchase price allocation$374,834 $62,801 $284,521 
(1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
(2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is deductible for tax purposes.
(3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight year useful life.
(4) Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.
The purchase price allocation for acquisitions during fiscal years 2021 was as follows:
VigeneRetrogenixCognateDistributed Bio
June 28, 2021March 30, 2021March 29, 2021December 31, 2020
(in thousands)
Trade receivables$3,548 $2,266 $18,566 $2,722 
Other current assets (excluding cash)1,657 209 14,128 221 
Property, plant and equipment7,649 400 52,082 2,382 
Operating lease right-of-use asset, net22,507 1,385 34,349 1,586 
Goodwill (1)
239,681 34,489 611,555 71,585 
Definite-lived intangible assets93,900 22,126 270,900 24,540 
Other long-term assets694 — 6,098 469 
Deferred revenue(4,260)(434)(20,539)(1,319)
Other current liabilities (2)
(6,319)(1,141)(45,388)(1,504)
Operating lease right-of-use liabilities (Long-term)(21,220)(1,205)(31,383)(1,123)
Deferred tax liabilities(13,958)(4,174)(32,503)(2,529)
Total purchase price allocation$323,879 $53,921 $877,865 $97,030 
(1) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes.
(2) In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17 million pertaining to indirect state sales taxes. During fiscal year 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period.
The definite-lived intangible assets acquired during fiscal years 2023 and 2022 were as follows:
Noveprim GroupSAMDI Tech, Inc.Explore BioLabs
Definite-Lived Intangible Assets(in thousands)
Client relationships$— $23,400 $64,000 
Other intangible assets9,500 9,670 6,100 
Total definite-lived intangible assets$9,500 $33,070 $70,100 
Weighted Average Amortization Life(in years)
Client relationships— 1513
Other intangible assets774
Total definite-lived intangible assets71212
The definite-lived intangible assets acquired during fiscal years 2021 were as follows:
VigeneRetrogenixCognateDistributed Bio
Definite-Lived Intangible Assets(in thousands)
Client relationships$87,500 $17,340 $257,200 $16,080 
Other intangible assets6,400 4,786 13,700 8,460 
Total definite-lived intangible assets$93,900 $22,126 $270,900 $24,540 
Weighted Average Amortization Life(in years)
Client relationships1213139
Other intangible assets2324
Total definite-lived intangible assets1111137
The transaction and integration costs incurred for fiscal years 2023, 2022 and 2021 were as follows:
202320222021
(in thousands)
Transaction and Integration Costs
Selling, general and administrative expenses$12,379 $8,470 $39,099 
Divestitures
The Company routinely evaluates the strategic fit and fundamental performance of its global businesses, divesting operations that do not meet key business criteria. As part of this ongoing assessment, the Company determined that certain capital could be better deployed in other long-term growth opportunities.
Avian Vaccine Services
On December 20, 2022, the Company sold its Avian Vaccine Services business (Avian) to a private investor group for a purchase price of $167.3 million in cash, subject to certain customary closing adjustments. The Company may also earn up to $30.0 million of contingent payments, which are tied to certain annual results of the Avian business from January 2024 through December 2027. The contingent payments have been fair valued at $10.3 million using a discounted probability weighted model. The Avian business was reported in the Company’s Manufacturing reportable segment. During the fiscal year 2022, the Company recorded a gain on the divestiture of Avian of $123.4 million within Other income (expense) on the Company’s consolidated statements of income.
RMS Japan
On October 12, 2021, the Company sold its RMS Japan operations to The Jackson Laboratory for a purchase price of $70.9 million, which included $7.9 million in cash, $3.8 million pension over funding, and certain post-closing adjustments. During the three months ended December 25, 2021, the Company recorded a gain on the divestiture of the RMS Japan business of $20.0 million, net of costs to sell, a currency translation adjustment, and other adjustments related to certain ongoing arrangements with the buyer, which was included in Other income (expense), net within the Company’s consolidated statements of income. The RMS Japan business was reported in the Company’s RMS reportable segment.
CDMO Sweden
On October 12, 2021, the Company sold its gene therapy CDMO site in Sweden to a private investor group for a purchase price of $59.6 million, net of $0.2 million in cash and other post-closing adjustments that may impact the purchase price. Included in the purchase price are contingent payments fair valued at $15.3 million, which were estimated using a probability weighted model (the maximum contingent contractual payments are up to $25.0 million based on future performance), as well as a purchase obligation of approximately $10.0 million between the parties. During fiscal year 2022 the fair value of the contingent payments receivable was reduced from $15.3 million to $7.5 million, which was the balance as of December 30, 2023, as certain financial targets are not expected to be achieved. CDMO Sweden was acquired in March 2021 as part of the acquisition of Cognate and was reported in the Company’s Manufacturing reportable segment.
The carrying amounts of the major classes of assets and liabilities associated with these divestitures were as follows:
December 19, 2022October 12, 2021
AvianRMS JapanCDMO Sweden
(in thousands)
Assets
Current assets
$30,545 $26,524 $8,187 
Property, plant, and equipment, net24,602 17,379 14,339 
Operating lease right-of-use assets, net611 — 19,733 
Goodwill3,168 4,129 27,764 
Client relationships, net1,629 — 14,089 
Other assets10 3,695 — 
Total assets$60,565 $51,727 $84,112 
Liabilities
Current liabilities$8,139 $8,705 $6,386 
Operating lease right-of-use liabilities331 — 18,221 
Long-term liabilities— 94 — 
Total liabilities$8,470 $8,799 $24,607 
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE FROM CONTRACTS WITH CUSTOMERS
 12 Months Ended
Dec. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE FROM CONTRACTS WITH CUSTOMERS REVENUE FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:
Timing of Revenue Recognition:202320222021
(in thousands)
RMS
Services and products transferred over time$377,947 $340,708 $263,659 
Services and products transferred at a point in time414,396 398,467 426,778 
Total RMS revenue792,343 739,175 690,437 
DSA
Services and products transferred over time2,611,564 2,440,646 2,103,415 
Services and products transferred at a point in time4,059 6,670 3,816 
Total DSA revenue2,615,623 2,447,316 2,107,231 
Manufacturing
Services and products transferred over time381,942 371,500 335,745 
Services and products transferred at a point in time339,501 418,069 406,747 
Total Manufacturing revenue721,443 789,569 742,492 
Total revenue$4,129,409 $3,976,060 $3,540,160 
Contract Balances from Contracts with Customers
The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:
December 30, 2023December 31, 2022
(in thousands)
Assets from contracts with customers
Client receivables$578,077 $559,410 
Unbilled revenue228,020 204,258 
Total806,097 763,668 
Less: Allowance for credit losses(25,722)(11,278)
Trade receivables and contract assets, net$780,375 $752,390 
Liabilities from contracts with customers
Current deferred revenue$241,820 $264,259 
Long term deferred revenue (included in Other long-term liabilities)30,919 25,795 
Customer contract deposits (included in Other current-liabilities)85,554 91,640 
The Company recognized substantially all of the current contract assets and liabilities balances at December 31, 2022 and December 25, 2021 in revenues during fiscal years 2023 and 2022, respectively.
When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $41 million and $54 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively. Net provisions were $18.2 million, $6.7 million, and $1.7 million in fiscal years 2023, 2022, and 2021, respectively.
Transaction Price Allocated to Future Performance Obligations
The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of December 30, 2023. Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed and service revenue recognized in accordance with ASC 842, “Leases”. The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of December 30, 2023 was $986.0 million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately 50% of which is expected to occur within the next twelve months and the remainder recognized thereafter during the remaining contract term.
Other Performance Obligations
As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year.
202320222021
(in thousands)Affected Line Item in the Consolidated Statements of Income
Lease revenue$93,103 $60,118 $18,118 Service revenue
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT AND GEOGRAPHIC INFORMATION
 12 Months Ended
Dec. 30, 2023
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
The Company’s three reportable segments are RMS, DSA, and Manufacturing. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker.
The following table presents revenue and other financial information by reportable segment:
202320222021
(in thousands)
RMS   
Revenue$792,343 $739,175 $690,437 
Operating income154,666 160,410 166,814 
Depreciation and amortization55,570 49,274 39,123 
Capital expenditures52,819 44,136 61,188 
DSA 
Revenue$2,615,623 $2,447,316 $2,107,231 
Operating income606,076 532,889 406,978 
Depreciation and amortization174,719 179,465 177,254 
Capital expenditures204,891 189,563 101,477 
Manufacturing
Revenue$721,443 $789,569 $742,492 
Operating income88,329 167,084 246,390 
Depreciation and amortization79,982 72,950 46,195 
Capital expenditures58,134 87,084 58,877 
Unallocated corporate
Operating income (1)
$(231,810)$(209,408)$(230,320)
Depreciation and amortization3,853 2,181 2,968 
Capital expenditures2,684 3,950 7,230 
Consolidated
Revenue$4,129,409 $3,976,060 $3,540,160 
Operating income617,261 650,975 589,862 
Depreciation and amortization314,124 303,870 265,540 
Capital expenditures318,528 324,733 228,772 
(1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.
Revenue and long-lived assets by geographic area are as follows:
U.S.EuropeCanadaAsia PacificOtherConsolidated
(in thousands)
2023
Revenue$2,347,486 $1,076,937 $487,305 $200,833 $16,848 $4,129,409 
Long-lived assets964,176 407,375 157,483 74,605 36,102 1,639,741 
2022      
Revenue$2,342,158 $1,032,125 $398,982 $192,837 $9,958 $3,976,060 
Long-lived assets896,235 349,361 135,300 82,778 1,981 1,465,655 
2021     
Revenue$1,934,404 $1,036,465 $339,098 $222,902 $7,291 $3,540,160 
Long-lived assets755,400 323,405 145,274 64,864 2,125 1,291,068 
Included in the Other category above are operations located in Brazil, Israel, and Mauritius. Revenue represents sales originating in entities physically located in the identified geographic area. Long-lived assets consist of property, plant, and equipment, net.
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION
 12 Months Ended
Dec. 30, 2023
Cash and Cash Equivalents [Abstract]  
SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION
Fiscal Year
202320222021
(in thousands)
Cash paid for income taxes$90,374 $75,909 $75,441 
Cash paid for interest132,101 100,754 70,775 
Non-cash investing and financing activities:
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities$69,139 $88,612 $72,043 
Assets acquired under finance leases— 8,179 1,567 
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
December 30, 2023December 31, 2022
(in thousands)
Supplemental cash flow information:
Cash and cash equivalents$276,771 $233,912 
Restricted cash included in Other current assets5,803 6,192 
Restricted cash included in Other assets1,906 1,110 
Cash, cash equivalents, and restricted cash, end of period$284,480 $241,214 
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY
 12 Months Ended
Dec. 30, 2023
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
The composition of inventories is as follows:
December 30, 2023December 31, 2022
(in thousands)
Raw materials and supplies$42,296 $38,892 
Work in process59,727 48,367 
Finished products278,236 168,550 
Inventories$380,259 $255,809 
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT, NET
 12 Months Ended
Dec. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT, NET PROPERTY, PLANT AND EQUIPMENT, NET
The composition of property, plant and equipment, net is as follows:
December 30, 2023December 31, 2022
(in thousands)
Land$79,546 $58,192 
Buildings (1)
1,053,915 963,717 
Machinery and equipment (1)
984,867 850,353 
Leasehold improvements366,556 294,275 
Furniture and fixtures31,284 27,317 
Computer hardware and software (1)
254,413 227,797 
Vehicles (1)
6,746 5,421 
Construction in progress197,723 199,713 
Total2,975,050 2,626,785 
Less: Accumulated depreciation(1,335,309)(1,161,130)
Property, plant and equipment, net$1,639,741 $1,465,655 
(1) These balances include assets under finance leases. See Note 17. Leases.
Depreciation expense in fiscal years 2023, 2022 and 2021 was $176.7 million, $157.3 million and $140.7 million, respectively.
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS
 12 Months Ended
Dec. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS
Venture capital investments are summarized below:
December 30, 2023December 31, 2022December 25, 2021
(in thousands)
Beginning balance$129,012 $149,640 $197,100 
Capital contributions17,410 14,485 18,023 
Distributions(15,685)(9,861)(40,205)
Gain (loss)(10,263)(24,398)(23,201)
Foreign currency translation684 (854)(2,077)
Ending balance$121,158 $129,012 $149,640 
The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. Strategic investments are summarized below:
December 30, 2023December 31, 2022December 25, 2021
(in thousands)
Beginning balance$182,590 $51,712 $24,704 
Purchase of investments34,028 142,477 35,540 
Distributions(9,381)(2,732)(789)
Gain (loss) (1)
108,090 (2,377)(7,219)
Reduction for acquisition of entities (1)
(197,753)— — 
Foreign currency translation5,079 (6,490)(524)
Ending balance$122,653 $182,590 $51,712 
(1) Refer to Note 2. Acquisitions for further discussion on the Noveprim and SAMDI acquisitions
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE
 12 Months Ended
Dec. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Assets and liabilities measured at fair value on a recurring basis are summarized below:
 December 30, 2023
 Level 1Level 2Level 3Total
Current assets measured at fair value:(in thousands)
Cash equivalents$— $29 $— $29 
Other assets:
Life insurance policies— 40,912 40,912 
Interest rate swap— 966 — 966 
Total assets measured at fair value$— $41,907 $— $41,907 
Other long-term liabilities measured at fair value:
Contingent consideration— — 33,265 33,265 
Interest rate swap— — — — 
Total liabilities measured at fair value$— $— $33,265 $33,265 
 December 31, 2022
 Level 1Level 2Level 3Total
Current assets measured at fair value:(in thousands)
Cash equivalents$— $78 $— $78 
Other assets:
Life insurance policies— 34,527 — 34,527 
Total assets measured at fair value$— $34,605 $— $34,605 
Accrued liabilities measured at fair value:
Contingent consideration$— $— $13,431 $13,431 
Other long-term liabilities measured at fair value:
Contingent consideration— — — — 
Interest rate swap— 1,523 — 1,523 
Total liabilities measured at fair value$— $1,523 $13,431 $14,954 
During fiscal years 2023 and 2022, there were no transfers between fair value levels.
Contingent Consideration
The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions.
Fiscal Year
202320222021
(in thousands)
Beginning balance$13,431 $37,244 $2,328 
Additions33,265 3,838 71,559 
Payments(15,130)(11,476)(2,889)
Total gains or losses (realized/unrealized):
Adjustment of previously recorded contingent liability1,810 (15,340)(33,386)
Foreign currency translation(111)(835)(368)
Ending balance$33,265 $13,431 $37,244 
The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $98 million, of which the value accrued as of December 30, 2023 is approximately $33 million. The weighted average probability of achieving the maximum target is approximately 34%. The average volatility and weighted average cost of capital are approximately 30% and 12%, respectively.
Cash Flow Hedge
The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In November 2022, the Company entered into an interest rate swap with a notional amount of $500 million to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.700%.
In March 2023 and in conjunction with an amendment of the Credit Agreement (Second Amendment), the Company modified the variable rate on its interest rate swap from 1-month LIBOR to 1-month adjusted term SOFR. Effective with the modification, the Company will pay a fixed rate of 4.65% on its swap maturing November 2, 2024. The Company elected to apply the optional expedient in ASC 848, Reference Rate Reform, in connection with modifying its interest rate swap from LIBOR to SOFR that enabled it to consider the modification a continuation of the existing contract. As a result, the transition did not have an impact on the Company’s hedge accounting or a material impact to the Company’s financial statements.
Debt Instruments
The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other
observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.
The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below:
December 30, 2023December 31, 2022
Book ValueFair ValueBook ValueFair Value
(in thousands)
4.25% Senior Notes due 2028
$500,000 $478,100 $500,000 $460,450 
3.75% Senior Notes due 2029
500,000 458,100 500,000 442,200 
4.00% Senior Notes due 2031
500,000 449,350 500,000 432,500 
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS
 12 Months Ended
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:
RMS
DSA(1)
ManufacturingTotal
(in thousands)
December 25, 2021$283,524 $1,472,506 $955,851 $2,711,881 
Acquisitions215,752 — (592)215,160 
Divestitures— — (3,168)(3,168)
Foreign exchange(1,566)(38,905)(33,499)(73,970)
December 31, 2022497,710 1,433,601 918,592 2,849,903 
Acquisitions— 209,478 — 209,478 
Divestitures— — — — 
Foreign exchange(236)19,355 16,545 35,664 
December 30, 2023$497,474 $1,662,434 $935,137 $3,095,045 
(1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.
Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2023, 2022 and 2021, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired. After completing the quantitative testing for fiscal year 2023, all reporting units exceeded the carrying value by a significant amount except for the Biologics Solutions reporting unit which had a fair value that exceeded its carrying value by approximately 20%.
The increase in goodwill during fiscal year 2023 related to the acquisitions of Noveprim and SAMDI in the DSA reportable segment. The increase in goodwill during fiscal year 2022 related to the acquisition of Explora in the RMS reportable segment, partially offset by a decrease due to the Avian divestiture impacting the Manufacturing reportable segment.
Intangible Assets, Net
The following table displays intangible assets, net by major class:
 December 30, 2023December 31, 2022
GrossAccumulated
Amortization 		NetGrossAccumulated
Amortization		Net
(in thousands)
Client relationships$1,528,780 $(721,322)$807,458 $1,491,926 $(591,417)$900,509 
Technology142,190 (111,764)30,426 129,626 (101,655)27,971 
Backlog$3,100 $(2,177)$923 $15,236 $(12,512)$2,724 
Trademarks and trade names11,878 (4,568)7,310 12,617 (4,410)8,207 
Other43,611 (25,677)17,934 37,985 (22,121)15,864 
Intangible assets$1,729,559 $(865,508)$864,051 $1,687,390 $(732,115)$955,275 
The decrease in intangible assets, net during fiscal year 2023 related primarily to normal amortization over the useful lives, partially offset by the acquisitions of Noveprim and SAMDI.
Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2023, 2022 and 2021 was $137.4 million, $146.6 million and $124.9 million, respectively. As of December 30, 2023, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:
Fiscal YearAmortization Expense
(in thousands)
2024$129,153 
2025$120,995 
2026$115,757 
2027$103,164 
2028$91,315 
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT AND OTHER FINANCING ARRANGEMENTS
 12 Months Ended
Dec. 30, 2023
Debt Disclosure [Abstract]  
DEBT AND OTHER FINANCING ARRANGEMENTS DEBT AND OTHER FINANCING ARRANGEMENTS
Long-term debt, net and finance leases consists of the following:
December 30, 2023December 31, 2022
(in thousands)
Revolving facility$1,129,243 $1,197,586 
4.25% Senior Notes due 2028
500,000 500,000 
3.75% Senior Notes due 2029
500,000 500,000 
4.00% Senior Notes due 2031
500,000 500,000 
Other debt9,575 1,594 
Finance leases 28,550 30,646 
Total debt and finance leases2,667,368 2,729,826 
Less:
Current portion of long-term debt3,172 1,347 
Current portion of finance leases2,398 2,330 
Current portion of long-term debt and finance leases5,570 3,677 
Long-term debt and finance leases2,661,798 2,726,149 
Debt discount and debt issuance costs(14,651)(18,618)
Long-term debt, net and finance leases$2,647,147 $2,707,531 
As of December 30, 2023 and December 31, 2022, the weighted average interest rate on the Company’s debt was 4.93% and 4.58%, respectively. In fiscal year 2021, the Company prepaid $500 million of Senior Notes due in 2026 along with $21 million of related debt extinguishment costs and $13 million of accrued interest using proceeds from additional senior notes issued on the same day. The payment of the 2026 Senior Notes was accounted for as a debt extinguishment. Approximately $21 million
of debt extinguishment costs and $5 million of deferred financing costs write-offs were recorded in Interest expense during fiscal year 2021.
Revolving facility (Credit Facility)
The Company has a revolving credit facility “Credit Facility” that provides for up to $3.0 billion of multi-currency revolving credit. The Credit Facility has a maturity date of April 2026, with no required scheduled payment before that date. The interest rates applicable to the revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at the Company’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1.0%) or the adjusted SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon the Company’s leverage ratio. In March 2023 and in conjunction with the Second Amendment the Company modified the variable rate on the Credit Facility from adjusted LIBOR to adjusted term SOFR. All outstanding U.S. dollar borrowings remained at adjusted LIBOR through their respective interest reset periods in April 2023 and were then set to term SOFR.
The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0. As of December 30, 2023 and December 31, 2022, the Company was compliant with all financial covenants under the Credit Facility. The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company.
2028 Senior Notes
In fiscal year 2019, the Company issued $500 million of 4.25% Senior Notes due in 2028 (2028 Senior Notes) in an unregistered offering. Interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1.
2029 Senior Notes and 2031 Senior Notes
In fiscal year 2021, the Company issued $1 billion of debt split between $500 million of 3.75% Senior Notes due in 2029 (2029 Senior Notes), and $500 million of 4.00% Senior Notes due in 2031 (2031 Senior Notes), in an unregistered offering. Interest on the 2029 and 2031 Senior Notes is payable semi-annually on March 15 and September 15. Approximately $10 million of deferred financing costs were capitalized as part of this debt issuance. Proceeds from the 2029 and 2031 Senior Notes were used as follows: prepay the $500 million 2026 Senior Notes, $21 million of debt extinguishment costs, and $13 million of accrued interest; prepay the $146.9 million remaining term loan; pay down $135 million of the revolving facility; and pay for a portion of the Cognate acquisition, which occurred on March 29, 2021.
Foreign currency transactions
During fiscal years 2022 and 2021, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility, which were between $250 million and $400 million each. To limit this foreign currency exposure, the Company entered into foreign exchange forward contracts, which are not designated as hedging instruments. The gains and losses incurred on these transactions were as follows:
December 31, 2022December 25, 2021Affected Line Item in the Consolidated Statements of Income
(in thousands)(in thousands)
Gain (loss) on foreign exchange forward contract$49,712 $34,131 Interest expense
Gain (loss) on foreign debt remeasurement(46,529)(31,830)Other income (expense)
The Company did not have any U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility during fiscal year 2023.
Principal Maturities
Principal maturities of existing debt for the periods set forth in the table below, are as follows:
Principal
(in thousands)
2024$3,172 
2025589 
20261,129,772 
20271,947 
2028501,947 
Thereafter1,001,391 
Total$2,638,818 
Letters of Credit
As of December 30, 2023 and December 31, 2022, the Company had $21.6 million and $18.6 million, respectively, in outstanding letters of credit.
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS
 12 Months Ended
Dec. 30, 2023
Equity [Abstract]  
EQUITY AND NONCONTROLLING INTERESTS EQUITY AND NONCONTROLLING INTERESTS
Earnings Per Share
The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:
Fiscal Year
202320222021
(in thousands)
Numerator:
Net income$480,370 $492,608 $398,837 
Less: Net income attributable to noncontrolling interests5,746 6,382 7,855 
Net income attributable to common shareholders$474,624 $486,226 $390,982 
Denominator:
Weighted-average shares outstanding—Basic51,227 50,812 50,293 
Effect of dilutive securities:
Stock options, restricted stock units and performance share units224 489 1,132 
Weighted-average shares outstanding—Diluted51,451 51,301 51,425 
Anti-dilutive common stock equivalents(1)
652 560 152 
(1) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Treasury Shares
The Company’s Board of Directors has authorized a $1.3 billion stock repurchase program. As of December 30, 2023, the Company had $129.1 million remaining on the authorized stock repurchase program.
The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired shares of 0.1 million in fiscal years 2023 and 2022, for $24.2 million and $38.7 million, respectively, from such netting.
Prior to the end of fiscal years 2023, 2022 and 2021, the Company’s Board of Directors approved the cancellation and return to the Company’s authorized and unissued capital stock, reducing treasury stock on the Company’s consolidated balance sheet. The Company allocated the excess of the repurchase price over the par value of shares acquired to reduce both retained earnings and additional paid-in capital.
Accumulated Other Comprehensive Income (Loss)
Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:
Foreign Currency Translation Adjustment and OtherPension and Other Post-Retirement Benefit Plans
Net Unrealized Gain (Loss) on Cash Flow Hedge
Total
(in thousands)
December 26, 2020$(73,884)$(64,990)$— $(138,874)
Other comprehensive income before reclassifications (1)
(30,316)(1,193)— (31,509)
Amounts reclassified from accumulated other comprehensive income— 1,678 — 1,678 
Net current period other comprehensive (loss) income(30,316)485 — (29,831)
Income tax (benefit) expense(6,027)2,062 — (3,965)
December 25, 2021(98,173)(66,567)— (164,740)
Other comprehensive income before reclassifications (1)
(125,507)24,471 (1,523)(102,559)
Amounts reclassified from accumulated other comprehensive income — 3,337 — 3,337 
Net current period other comprehensive (loss) income(125,507)27,808 (1,523)(99,222)
Income tax (benefit) expense(5,895)4,355 (365)(1,905)
December 31, 2022(217,785)(43,114)(1,158)(262,057)
Other comprehensive (loss) income before reclassifications (1)
71,851 (5,376)2,490 68,965 
Amounts reclassified from accumulated other comprehensive income — 736 — 736 
Net current period other comprehensive (loss) income71,851 (4,640)2,490 69,701 
Income tax (benefit) expense4,065 (587)593 4,071 
December 30, 2023$(149,999)$(47,167)$739 $(196,427)
(1) The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real.
Nonredeemable Noncontrolling Interest
The Company has an investment in an entity whose financial results are consolidated in the Company’s financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying consolidated balance sheets. The activity within the nonredeemable noncontrolling interest (net income less dividends declared) during fiscal years 2023, 2022, and 2021 was not significant.
Redeemable Noncontrolling Interests
The Company holds a 90% ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at a fixed redemption value that ranges from $47.0 million to $54.0 million depending on when exercised, which represents a derivative embedded within the equity instrument. The Company has the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing the 41% equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $54.0 million. Additionally, the 10% noncontrolling interest holders may receive a dividend disproportionate to their equity ownership, which has an approximate fair value of $8 million. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the accreted redemption value using the interest method and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 10% interest, the noncontrolling interest is classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities.
The Company held a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 31, 2022. The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. The redeemable noncontrolling interest was measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. The amount that the Company could be required to pay to purchase the remaining 8% equity interest was not limited. During the fourth quarter of fiscal 2023, the Company acquired the remaining 8% and as of December 2023, has paid $4.8 million of the total $24.4 million due. The remaining purchase price payable has been reclassified from the mezzanine section to Accrued liabilities on the consolidated balance sheet and is expected to be paid during fiscal year 2024.

In 2020, the Company acquired an 80% equity interest in a subsidiary, which included a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million, resulting in a remaining noncontrolling interest of 10%. Beginning in 2024, the Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at its appraised value. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest ($11.0 million as of December 30, 2023) or a predetermined floor, which represents a derivative embedded within the equity instrument. The amount that the Company could be required to pay to purchase the remaining 10% equity interest is not limited.
The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests:
Fiscal Year
202320222021
(in thousands)
Beginning balance$42,427 $53,010 $25,499 
Acquisition resulting in a 10% noncontrolling interest
45,374 — — 
Additional purchases reducing noncontrolling interest percentage
(24,148)(15,000)— 
Adjustments to redemption value(5,694)7,506 21,312 
Net income
3,492 4,020 5,375 
Dividends(2,378)(3,525)— 
Foreign currency translation(1,200)(3,584)824 
Other(1,151)— — 
Ending balance$56,722 $42,427 $53,010 
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES
 12 Months Ended
Dec. 30, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The components of income from operations before income taxes and the related provision for income taxes are presented below:
 Fiscal Year
 202320222021
(in thousands)
Income before income taxes:   
U.S. $185,667 $280,075 $129,598 
Non-U.S. 395,617 342,912 351,112 
Total income before income taxes$581,284 $622,987 $480,710 
Income tax provision (benefit):   
Current:   
Federal$49,090 $75,052 $32,728 
Foreign85,356 68,644 60,197 
State17,817 19,790 9,257 
Total current152,263 163,486 102,182 
Deferred:   
Federal(42,987)(27,230)(27,486)
Foreign779 (1,134)13,891 
State(9,141)(4,743)(6,714)
Total deferred(51,349)(33,107)(20,309)
Total provision for income taxes$100,914 $130,379 $81,873 
Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows:
Fiscal Year
202320222021
U.S. statutory income tax rate21.0 %21.0 %21.0 %
Foreign tax rate differences1.5 0.4 0.1 
State income taxes, net of federal tax benefit1.7 2.3 0.8 
Non-deductible compensation0.8 0.9 1.2 
Research tax credits and enhanced deductions(5.0)(3.8)(5.0)
Stock-based compensation(0.1)(1.4)(4.3)
Enacted tax rate changes(0.1)0.4 3.0 
Tax on unremitted earnings1.7 1.6 1.8 
Impact of tax uncertainties(0.3)(1.3)0.7 
Impact of acquisitions and restructuring(4.2)2.0 (1.6)
Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)0.2 (0.8)— 
Global intangible low-taxed income1.5 0.8 1.3 
Foreign-derived intangible income(1.4)(1.4)(1.2)
Other0.1 0.2 (0.8)
Effective income tax rate17.4 %20.9 %17.0 %
The components of deferred tax assets and liabilities are as follows:
December 30, 2023December 31, 2022
(in thousands)
Deferred tax assets:
Compensation$30,167 $26,341 
Accruals and reserves19,121 16,938 
Net operating loss and credit carryforwards379,959 382,932 
Operating lease liability117,449 100,156 
Capitalized R&D Expenditures
35,673 18,616 
Other12,190 8,516 
Valuation allowance(304,248)(294,753)
Total deferred tax assets290,311 258,746 
Deferred tax liabilities:
Goodwill and other intangibles(231,020)(256,234)
Depreciation related(57,791)(48,965)
Venture capital investments(8,350)(12,007)
Tax on unremitted earnings(25,080)(16,407)
Right-of-use assets(102,620)(91,716)
Other(16,520)(7,737)
Total deferred tax liabilities(441,381)(433,066)
Net deferred taxes$(151,070)$(174,320)
The Company has recognized its deferred tax assets on the belief that it is more likely than not that they will be realized. Exceptions primarily relate to deferred tax assets for net operating losses in Luxembourg, Sweden, state research and development tax credits, certain capital losses, and fixed assets in the U.K.
A reconciliation of the Company’s beginning and ending valuation allowance are as follows:
Fiscal Year
202320222021
Beginning balance$294,753 $315,645 $334,845 
Additions (reductions) charged to income tax provision, net963 1,929 1,023 
Additions due to acquisitions— — 7,747 
Reductions due to divestitures, restructuring— (5,337)(4,706)
Currency translation and other8,532 (17,484)(23,264)
Ending balance$304,248 $294,753 $315,645 
As of December 30, 2023, the Company had tax-effected deferred tax assets for net operating loss carryforwards of $336.0 million, as compared to $336.6 million as of December 31, 2022. Of this amount, $25.9 million are definite-lived and begin to expire in 2027, and the remainder of $310.1 million can be carried forward indefinitely. The Company has deferred tax assets for tax credit carryforwards of $41.5 million. The entire $41.5 million are definite-lived and begin to expire after 2039. Additionally, the Company records a benefit to operating income for research and development and other credits in Quebec, France, the Netherlands, and the U.K. related to its DSA facilities.
A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows:
Fiscal Year
202320222021
(in thousands)
Beginning balance$23,242 $32,592 $24,970 
Additions to tax positions for current year3,093 4,756 9,544 
Additions to tax positions for prior years721 962 2,476 
Reductions to tax positions for prior years(4,058)(1,420)(1,330)
Settlements— (10,514)(1,870)
Expiration of statute of limitations(296)(3,134)(1,198)
Ending balance$22,702 $23,242 $32,592 
The $0.5 million decrease in unrecognized income tax benefits during fiscal year 2023 as compared to the corresponding period in 2022 is primarily attributable to prior year reductions to Canadian Scientific Research and Experimental Development (SR&ED) credits, partially offset by an additional year of SR&ED credit additions. The amount of unrecognized income tax benefits that, if recognized, would favorably impact the effective tax rate was $20.3 million as of December 30, 2023 and $20.3 million as of December 31, 2022. It is reasonably possible as of December 30, 2023 that the liability for unrecognized tax benefits for the uncertain tax position will decrease by approximately $5.2 million over the next twelve-month period. The Company continues to recognize interest and penalties related to unrecognized income tax benefits in income tax expense. The total amount of cumulative accrued interest related to unrecognized income tax benefits as of December 30, 2023 and December 31, 2022 was $1.3 million and $1.4 million, respectively. Interest expense recorded as a component of income taxes was immaterial for all periods. There were no accrued penalties related to unrecognized income tax benefits as of December 30, 2023 or as of December 31, 2022.
The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2019.
The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, France, and India. The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.
Prepaid income tax of $59.7 million and $88.6 million has been presented within Other current assets in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively. Accrued income taxes of $38.8 million and $39.9 million have been presented within Other current liabilities in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively.
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS
 12 Months Ended
Dec. 30, 2023
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
Pension Plans
The Charles River Pension Plan (U.K. Pension Plan) is a defined contribution and defined benefit pension plan covering certain U.K. employees. Benefits are based on participants’ final pensionable salary and years of service. Participants’ rights vest immediately. The plan was previously amended to exclude new participants from joining the defined benefit section of the plan and a defined contribution section was established for new entrants. Contributions under the defined contribution plan are determined as a percentage of gross salary. Additionally, the U.K. Pension Plan was amended such that the members of the defined benefit section of the plan ceased to accrue additional benefits; however, their benefits continue to be adjusted for changes in their final pensionable salary or a specified inflation index, as applicable. During fiscal 2023, the Company made no contributions to the U.K. Pension Plan. As of fiscal 2023 year-end, this plan was in a funded status of $35.7 million.
During 2022, the Company terminated a non-contributory defined benefit plan that covered certain employees in Canada (Canada Pension Plan). Upon settlement of the pension liability in fiscal year 2022, the Company recognized a $1.0 million loss related to the net periodic benefit cost recorded in Other expense in the consolidated statements of income.
In addition, the Company has several defined benefit plans in certain other countries in which it maintains an operating presence, including Canada, France, Germany, Italy, Mauritius, Netherlands, and Japan.
The net periodic benefit cost (income) associated with these plans for fiscal years 2023, 2022 and 2021 totaled $2.8 million, $0.1 million and $0.5 million, respectively.
Charles River Laboratories Deferred Compensation Plan and Executive Supplemental Life Insurance Retirement Plan
The Company maintains a non-qualified deferred compensation plan, known as the Charles River Laboratories Deferred Compensation Plan (DCP), which allows a select group of eligible employees to defer a portion of their compensation. At the present time, no contributions are credited to the DCP, except as set forth below. Participants must specify the distribution date for deferred amounts at the time of deferral, in accordance with applicable IRS regulations. Generally, amounts may be paid in lump sum or installments upon retirement or termination of employment, or later if the employee terminates employment after age 55 and before age 65. Amounts may also be distributed during employment, subject to a minimum deferral requirement of three years.
The Company provides certain active employees an annual contribution into their DCP account of 10% of the employee’s base salary plus the lesser of their target annual bonus or actual annual bonus.
In addition to the DCP, certain officers and key employees also participate, or in the past participated, in the Company’s Executive Supplemental Life Insurance Retirement Plan (ESLIRP), which is a non-funded, non-qualified arrangement. Annual benefits under this plan will equal a percentage of the highest five consecutive years of compensation, offset by amounts payable under the U.S. Pension Plan and Social Security. In connection with the establishment of the DCP, certain active ESLIRP participants, who agreed to convert their accrued ESLIRP benefit to a comparable deferred compensation benefit, discontinued their direct participation in the ESLIRP. Instead, the present values of the accrued benefits of ESLIRP participants were credited to their DCP accounts, and future accruals are converted to present values and credited to their DCP accounts annually.
The net periodic benefit cost associated with these plans for fiscal years 2023, 2022 and 2021 totaled $2.8 million, $4.3 million and $4.3 million, respectively.
The Company has invested in several corporate-owned key-person life insurance policies with the intention of using these investments to fund the ESLIRP and the DCP. Participants have no interest in any such investments. As of December 30, 2023 and December 31, 2022, the cash surrender value of these life insurance policies were $48.4 million and $41.9 million, respectively.
The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans:
 December 30, 2023December 31, 2022
(in thousands)
Change in projected benefit obligations:  
Benefit obligation at beginning of year$205,551 $372,599 
Service cost2,474 3,213 
Interest cost9,941 6,140 
Benefit payments(6,239)(6,469)
Curtailment— (2,477)
Settlements— (11,939)
Transfer in due to acquisition1,106 — 
Actuarial (gain) loss3,600 (134,923)
Effect of foreign exchange8,442 (20,593)
Benefit obligation at end of year$224,875 $205,551 
Change in fair value of plan assets:
Fair value of plan assets at beginning of year$192,540 $335,631 
Actual return on plan assets5,578 (105,749)
Employer contributions1,744 4,558 
Settlements— (11,939)
Transfer in due to acquisition181 — 
Benefit payments(6,239)(6,469)
Effect of foreign exchange9,853 (23,492)
Fair value of plan assets at end of year$203,657 $192,540 
Net balance sheet liability$21,218 $13,011 
Amounts recognized in balance sheet:
Noncurrent assets$36,957 $39,185 
Current liabilities1,164 1,151 
Noncurrent liabilities57,011 51,045 
Actuarial gains and losses are driven by changes in economic assumptions, principally discount rates. Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows:
Fiscal Year
 20232022
(in thousands)
Net actuarial loss$58,855 $54,509 
Net prior service cost (credit)(121)(585)
Net amount recognized$58,734 $53,924 
The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows:
 December 30, 2023December 31, 2022
(in thousands)
Accumulated benefit obligation$54,310 $48,414 
Fair value of plan assets2,824 2,258 
The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows:
 December 30, 2023December 31, 2022
(in thousands)
Projected benefit obligation$61,671 $55,304 
Fair value of plan assets3,496 3,108 
Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows:
Fiscal Year
 202320222021
(in thousands)
Service cost$2,474 $3,213 $3,455 
Interest cost9,941 6,140 5,492 
Expected return on plan assets(7,556)(7,322)(8,058)
Amortization of prior service credit(464)(506)(531)
Amortization of net loss1,231 2,869 4,528 
Net periodic benefit cost5,626 4,394 4,886 
Settlement— 981 (2,320)
Total benefit cost$5,626 $5,375 $2,566 
Assumptions
Weighted-average assumptions used to determine projected benefit obligations are as follows:
 December 30, 2023December 31, 2022
Discount rate4.7 %4.8 %
Rate of compensation increase3.2 %3.2 %
The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations.
Weighted-average assumptions used to determine net periodic benefit cost are as follows:
 December 30, 2023December 31, 2022December 25, 2021
Discount rate4.8 %1.8 %1.5 %
Expected long-term return on plan assets3.9 %2.4 %2.5 %
Rate of compensation increase3.2 %3.7 %3.0 %
In fiscal years 2023 and 2022, new mortality improvement scales were issued in the U.S. and the United Kingdom (U.K.) reflecting a decline in longevity projection from previous releases the Company adopted, which decreased the Company’s benefit obligations by $3.5 million and $0.2 million as of December 30, 2023 and December 31, 2022, respectively.
Plan Assets
The Company invests its pension assets with the objective of achieving a total long-term rate of return sufficient to fund future pension obligations and to minimize future pension contributions. The Company is willing to tolerate a commensurate level of risk to achieve this objective. The Company controls its risk by maintaining a diversified portfolio of asset classes. Plan assets did not include any of the Company’s common stock as of December 30, 2023 or December 31, 2022. The weighted-average target asset allocations are 7.0% to equity securities, 84.1% to fixed income securities and 8.9% to other securities.
The fair value of the Company’s pension plan assets by asset category are as follows:
 December 30, 2023December 31, 2022
Level 1 Level 2Level 3Total Level 1 Level 2Level 3Total
(in thousands)
Cash and cash equivalents$446 $798 $— $1,244 $362 $5,153 $— $5,515 
Equity securities (1)
— 10,701 — 10,701 — 9,308 — 9,308 
Debt securities (2)
— 144,822 — 144,822 — 123,638 — 123,638 
Mutual funds (3)
9,207 10,368 — 19,575 8,380 9,372 — 17,752 
Other (4)
— 27,254 61 27,315 — 36,268 59 36,327 
Total$9,653 $193,943 $61 $203,657 $8,742 $183,739 $59 $192,540 
(1) This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end.
(2) This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations.
(3) This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end.
(4) This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end.
The activity within the Level 3 pension plan assets was not significant during the periods presented.
During fiscal year 2023, the Company did not contribute to the pension plans and expects to make $2.0 million in contributions in fiscal year 2024. During fiscal year 2023, the Company paid $1.7 million directly to certain participants outside of plan assets.
Expected benefit payments are estimated using the same assumptions used in determining the Company’s benefit obligation as of 2023. Benefit payments will depend on future employment and compensation levels, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for fiscal years 2029 through 2033, are as follows.
Fiscal YearPension Plans
(in thousands)
2024$6,558 
20256,703 
202646,898 
20277,633 
20288,843 
2029-203355,416 
Charles River Laboratories Employee Savings Plan
The Charles River Laboratories Employee Savings Plan is a defined contribution plan in the form of a qualified 401(k) plan in which substantially all U.S. employees are eligible to participate upon employment. The plan contains a provision whereby the Company matches a percentage of employee contributions. During fiscal years 2023, 2022 and 2021, the costs associated with this defined contribution plan totaled $31.6 million, $28.8 million and $24.0 million, respectively.
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION
 12 Months Ended
Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
The Company has stock-based compensation plans under which employees and non-employee directors are granted stock-based awards such as stock options, RSUs, and PSUs.
During fiscal years 2023, 2022 and 2021, the primary share-based awards and their general terms and conditions are as follows:
•Stock options, which entitle the holder to purchase a specified number of shares of common stock at an exercise price equal to the closing market price of common stock on the date of grant; typically vest over 4 years; and typically expire 5 or 10 years from date of grant.
•RSUs, which represent an unsecured promise to grant at no cost a set number of shares of common stock upon the completion of the vesting schedule, and principally vest over 4 years. With respect to RSUs, recipients are not entitled to cash dividends and have no voting rights on the stock during the vesting period.
•PSUs, which entitle the holder to receive at no cost, a specified number of shares of common stock within a range of shares from zero to a specified maximum and typically vest over 3 years. Payout of this award is contingent upon achievement of certain performance and market conditions.
As of December 30, 2023, approximately 4.1 million shares were authorized for future grants under the Company’s share-based compensation plans. The Company settles employee share-based compensation awards with newly issued shares. The following table provides stock-based compensation by the financial statement line item in which it is reflected:
Fiscal Year
202320222021
(in thousands)
Cost of revenue$15,052 $14,853 $13,087 
Selling, general and administrative56,996 58,764 58,387 
Stock-based compensation, before income taxes72,048 73,617 71,474 
Provision for income taxes(10,907)(10,969)(10,299)
Stock-based compensation, net of income taxes$61,141 $62,648 $61,175 
No stock-based compensation related costs were capitalized in fiscal years 2023, 2022 and 2021.
Stock Options
The following table summarizes stock option activity under the Company’s stock-based compensation plans:
Number of sharesWeighted Average
Exercise Price		Weighted Average
Remaining
Contractual Life		Aggregate
Intrinsic
Value
(in thousands)(in years)(in thousands)
Options outstanding as of December 31, 2022882 $204.41   
Options granted130 $194.27   
Options exercised(195)$130.91   
Options canceled(28)$259.63   
Options outstanding as of December 30, 2023789 $218.97 6.5$28,935 
Options exercisable as of December 30, 2023408 $205.50 4.8$20,521 
Options expected to vest as of December 30, 2023381 $233.37 8.3$8,414 
The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Fiscal Year
202320222021
Expected life (in years)6.06.06.0
Expected volatility36 %33 %32 %
Risk-free interest rate3.8 %2.7 %1.0 %
Expected dividend yield0 %0 %0 %
The weighted-average grant date fair value of stock options granted was $80.98, $90.05 and $108.61 for fiscal years 2023, 2022 and 2021, respectively.
As of December 30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $18.5 million. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.4 years.
The total intrinsic value of options exercised during fiscal years 2023, 2022 and 2021 was $18.2 million, $33.2 million and $94.4 million, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the exercise price.
Restricted Stock Units
The following table summarizes the restricted stock units activity for fiscal year 2023:
Restricted Stock UnitsWeighted Average Grant Date Fair Value
(in thousands)
December 31, 2022364 $226.43 
Granted265 $194.84 
Vested(134)$212.34 
Canceled(26)$231.70 
December 30, 2023469 $212.30 
As of December 30, 2023, the unrecognized compensation cost related to shares of unvested RSUs expected to vest was $65.8 million, which is expected to be recognized over an estimated weighted-average amortization period of 2.8 years. The total fair value of RSU grants that vested during fiscal years 2023, 2022 and 2021 was $28.4 million, $24.8 million and $22.8 million, respectively.
Performance Based Stock Award Program
The Company issues PSUs to certain corporate officers. The number of shares of common stock issued for each PSU is adjusted based on a performance condition linked to the Company’s financial performance. Certain awards are further adjusted based on a market condition, which is calculated based on the Company’s stock performance relative to a peer group over the three-year vesting period. The fair value of the market condition is reflected in the fair value of the award at grant date.
The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows:
Fiscal Year
202320222021
(shares in thousands)
PSUs granted146 134 64 
Weighted average grant date fair value$204.40 $210.42 $407.76 
Key assumptions:
Expected volatility 37 %39 %37 %
Risk-free interest rate4.2 %2.6 %0.2 %
Expected dividend yield0 %0 %0 %
Total shareholder return of 20-trading day average stock price on grant date
(9.8)%(32.7)%39.9 %
The maximum number of common shares to be issued upon vesting of PSUs is 0.3 million. For fiscal years 2023, 2022 and 2021, the Company recognized stock-based compensation related to PSUs of $28.1 million, $31.2 million and $31.8 million, respectively. The total fair value of PSUs that vested during fiscal years 2023, 2022 and 2021 was $34.4 million, $31.0 million and $26.0 million, respectively.
In fiscal year 2021, the Company also issued approximately 5,000 PSUs using a weighted-average grant date fair value per share of $477.52. These PSUs vest upon the achievement of financial targets and other performance measures.
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING AND ASSET IMPAIRMENTS
 12 Months Ended
Dec. 30, 2023
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND ASSET IMPAIRMENTS RESTRUCTURING AND ASSET IMPAIRMENTS
The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment and accelerated depreciation charges.
The following table presents restructuring costs by reportable segment:
Fiscal Year
202320222021
(in thousands)
RMS$3,479 $1,007 $7 
DSA16,176 851 3,114 
Manufacturing9,138 5,126 3,663 
Unallocated corporate889 1,229 72 
Total$29,682 $8,213 $6,856 
The following table presents restructuring costs as included within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
2023
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$7,408 $14,812 $22,220 
Cost of products sold (excluding amortization of intangible assets)1,146 3,262 4,408 
Selling, general and administrative3,054 — 3,054 
Total restructuring costs$11,608 $18,074 $29,682 
Fiscal Year
2022
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$928 $1,784 $2,712 
Cost of products sold (excluding amortization of intangible assets)532 1,765 2,297 
Selling, general and administrative2,441 763 3,204 
Total restructuring costs$3,901 $4,312 $8,213 
Fiscal Year
2021
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$1,898 $934 $2,832 
Cost of products sold (excluding amortization of intangible assets)— — — 
Selling, general and administrative2,819 1,205 4,024 
Total restructuring costs$4,717 $2,139 $6,856 
Rollforward of Restructuring Activities
The following table provides a rollforward for all of the Company’s severance and transition costs related to all restructuring activities:
Fiscal Year
202320222021
(in thousands)
Beginning balance$1,300 $4,011 $5,818 
Expense (excluding non-cash charges)11,539 6,732 5,695 
Payments / utilization(7,800)(6,973)(5,604)
Other non-cash adjustments— (2,350)(1,831)
Foreign currency adjustments11 (120)(67)
Ending balance$5,050 $1,300 $4,011 
As of December 30, 2023 and December 31, 2022, $5.1 million and $1.3 million, respectively, of severance and other personnel related costs liabilities were included in accrued compensation and accrued liabilities within the Company’s consolidated balance sheets.
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES
 12 Months Ended
Dec. 30, 2023
Leases [Abstract]  
LEASES LEASES
Operating and Finance Leases
Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:
December 30, 2023December 31, 2022
(in thousands)
Operating leases
Operating lease right-of-use assets, net$394,029 $391,762 
Other current liabilities$54,908 $46,526 
Operating lease right-of-use liabilities419,234 389,745 
Total operating lease liabilities$474,142 $436,271 
Finance leases
Property, plant and equipment, net$29,422$31,875
Current portion of long-term debt and finance leases$2,398$2,330
Long-term debt, net and finance leases26,15228,316
Total finance lease liabilities$28,550$30,646
The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
202320222021
(in thousands)
Operating lease costs$65,380 $59,671 $45,728 
Finance lease costs:
Amortization of right-of-use assets2,745 3,035 3,337 
Interest on lease liabilities1,477 1,441 1,280 
Short-term lease costs3,581 2,954 2,441 
Variable lease costs22,159 13,965 4,623 
Sublease income(2,067)(1,912)(2,008)
Total lease costs$93,275 $79,154 $55,401 
Other information related to leases was as follows:
Supplemental cash flow information
Fiscal Year
202320222021
(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases$60,239 $48,360 $42,576 
Operating cash flows from finance leases1,476 1,442 1,282 
Finance cash flows from finance leases2,297 2,257 3,202 
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities$75,987 $189,134 $142,764 
Right-of-use lease assets obtained in exchange for new finance lease liabilities— 8,179 1,567 
Lease term and discount rate
December 30, 2023December 31, 2022December 25, 2021
Weighted-average remaining lease term (in years)
Operating lease9.69.89.0
Finance lease12.713.611.7
Weighted-average discount rate
Operating lease4.7 %4.3 %3.6 %
Finance lease5.3 %5.3 %4.4 %
At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.
As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:
Operating LeasesFinance Leases
(in thousands)
2024$70,578 $3,796 
202563,433 3,513 
202658,494 3,038 
202759,946 2,999 
202857,953 2,988 
Thereafter286,215 23,562 
Total minimum future lease payments596,619 39,896 
Less: Imputed interest122,477 11,346 
Total lease liabilities$474,142 $28,550 
Total minimum future lease payments (predominantly operating leases) of approximately $161 million for leases that have not commenced as of December 30, 2023, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2024 and 2025 with lease terms of approximately 5 to 15 years.
LEASES LEASES
Operating and Finance Leases
Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:
December 30, 2023December 31, 2022
(in thousands)
Operating leases
Operating lease right-of-use assets, net$394,029 $391,762 
Other current liabilities$54,908 $46,526 
Operating lease right-of-use liabilities419,234 389,745 
Total operating lease liabilities$474,142 $436,271 
Finance leases
Property, plant and equipment, net$29,422$31,875
Current portion of long-term debt and finance leases$2,398$2,330
Long-term debt, net and finance leases26,15228,316
Total finance lease liabilities$28,550$30,646
The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
202320222021
(in thousands)
Operating lease costs$65,380 $59,671 $45,728 
Finance lease costs:
Amortization of right-of-use assets2,745 3,035 3,337 
Interest on lease liabilities1,477 1,441 1,280 
Short-term lease costs3,581 2,954 2,441 
Variable lease costs22,159 13,965 4,623 
Sublease income(2,067)(1,912)(2,008)
Total lease costs$93,275 $79,154 $55,401 
Other information related to leases was as follows:
Supplemental cash flow information
Fiscal Year
202320222021
(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases$60,239 $48,360 $42,576 
Operating cash flows from finance leases1,476 1,442 1,282 
Finance cash flows from finance leases2,297 2,257 3,202 
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities$75,987 $189,134 $142,764 
Right-of-use lease assets obtained in exchange for new finance lease liabilities— 8,179 1,567 
Lease term and discount rate
December 30, 2023December 31, 2022December 25, 2021
Weighted-average remaining lease term (in years)
Operating lease9.69.89.0
Finance lease12.713.611.7
Weighted-average discount rate
Operating lease4.7 %4.3 %3.6 %
Finance lease5.3 %5.3 %4.4 %
At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.
As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:
Operating LeasesFinance Leases
(in thousands)
2024$70,578 $3,796 
202563,433 3,513 
202658,494 3,038 
202759,946 2,999 
202857,953 2,988 
Thereafter286,215 23,562 
Total minimum future lease payments596,619 39,896 
Less: Imputed interest122,477 11,346 
Total lease liabilities$474,142 $28,550 
Total minimum future lease payments (predominantly operating leases) of approximately $161 million for leases that have not commenced as of December 30, 2023, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2024 and 2025 with lease terms of approximately 5 to 15 years.
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Insurance
The Company maintains certain insurance policies that maintain large deductibles up to approximately $2 million, some with or without stop-loss limits, depending on market availability. Insurance policies at certain locations are based on a percentage of the insured assets, for which deductibles for certain property may exceed $22.0 million in the event of a catastrophic event. In addition, the Company purchased representation and warranty insurance in support of some acquisitions, in which deductibles could reach $4.0 million.
Litigation
On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain recent shipments in the United States. The carrying value of the inventory related to these shipments is approximately $27 million as of December 30, 2023, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena, primarily related to the sourcing of non-human primates, and the Company is cooperating with the request. We are not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities.
A putative securities class action was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. The Company filed a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.
On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The Company intends to file a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the derivative lawsuit to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.
Aside from the matter above, the Company believes there are no other matters pending against the Company that could have a material impact on the Company’s business, financial condition, or results of operations.
Guarantees
The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.
Purchase Obligations
The Company enters into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. These unconditional purchase obligations exclude agreements that are cancellable at any time without penalty. The aggregate amount of the Company’s unconditional purchase obligations totaled approximately $390 million as of December 30, 2023 and the majority of these obligations are expected to be settled during 2024.
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Pay vs Performance Disclosure      
Net Income (Loss) Attributable to Parent $ 474,624 $ 486,226 $ 390,982
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 30, 2023
shares
Dec. 30, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Non-Rule 10b5-1 Arrangement Terminated false  
James Foster [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On November 14, 2023, James Foster, our Chair, President, and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement, dated February 23, 2023 for the sale of up to 112,341 shares of common stock. Mr. Foster did not sell any shares pursuant to such plan, which, absent such termination, would have expired on March 1, 2025.
Name James Foster  
Title Chair, President, and Chief Executive Officer  
Rule 10b5-1 Arrangement Terminated true  
Termination Date November 14, 2023  
Aggregate Available 112,341 112,341
Birgit Girshick [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On November 15, 2023, Birgit Girshick, our Corporate Executive Vice President & Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement, dated February 24, 2023 for the sale of up to 25,320 shares of common stock. Ms. Girshick did not sell any shares pursuant to such plan, which, absent such termination, would have expired on February 28, 2024.
Name Birgit Girshick  
Title Corporate Executive Vice President & Chief Operating Officer  
Rule 10b5-1 Arrangement Terminated true  
Termination Date November 15, 2023  
Aggregate Available 25,320 25,320
Ms. Girshick [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On November 22, 2023, Ms. Girshick entered into a Rule 10b5-1 trading arrangement for the sale of up to 22,362 shares of common stock, subject to certain conditions. The arrangement’s expiration date is February 28, 2025.
Name Ms. Girshick  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 22, 2023  
Aggregate Available 22,362 22,362
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of Consolidation
Principles of Consolidation
The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation.
The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which occurred in fiscal year 2022.
Segment Reporting
Segment Reporting
The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses.
Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities and utilizing our Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow.
The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.
The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO). In December of 2022, the Company sold the Avian Vaccine Services business (Avian), reported in the Manufacturing segment, which supplied specific-pathogen-free chicken eggs and chickens.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.
Newly Adopted and Newly Issued Accounting Pronouncements
Newly Adopted Accounting Pronouncements
In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company participates in certain supplier finance programs that are immaterial to the consolidated financial statements and related disclosures.
Newly Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but does not believe there will be a material impact.
In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.
Cash and Cash Equivalents, and Investments
Cash, Cash Equivalents, and Investments
Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments.
Trade Receivables and Contract Assets, Net
Trade Receivables and Contract Assets, Net
The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance.
Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 3.5% of revenue in fiscal years 2023, 2022, or 2021 or trade receivables as of December 30, 2023 or December 31, 2022.
Fair Value Measurements
Fair Value Measurements
The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy:
•Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,
•Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rate yield curves and foreign currency spot rates,
•Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter.
Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:
•Cash equivalents - Valued at market prices determined through third-party pricing services;
•Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;
•Interest rate swap contracts - Valued using market observable inputs, such as interest rate yield curves;
•Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;
•Debt instruments - The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and
•Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes and certain option pricing models.
Inventories
Inventories
The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell solutions, microbial solutions, and CDMO products. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with certain direct materials, costs of personnel directly involved in the care of the models, and allocation of facility overhead costs. For cell solutions inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions and CDMO inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold.
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net
Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.
Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset.
The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:
Estimated
Useful Lives
(in years)
LandIndefinite
Buildings and building improvements
10 - 40
Machinery and equipment
3 - 20
Furniture and fixtures
5 - 10
Computer hardware and software
3 - 8
Vehicles
3 - 5
Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned.
When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Business Combinations, Contingent Consideration
Business Combinations
The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets and certain biological assets, which can represent a significant portion of the purchase price. The determination of the fair value of intangible and certain biological assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such assets are amortizable or non-amortizable and, if the former, the period and the method by which the asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of assets. Typically, key assumptions include projections of cash flows that arise from identifiable assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets.
In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) and certain biological assets are the most significant identifiable asset acquired. To determine the fair value of these acquired assets, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue, cost of revenue, operating income margins, customer attrition rates, and productivity rates; as well as discount rates based on a market participant’s weighted average cost of capital.
Contingent Consideration
The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets.
Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market.
Divestitures
Divestitures
The Company records divestitures at fair value less cost to sell with any related gain or loss from sale recorded within Other income (expense) on the Company’s consolidated statements of income. If the sale price includes contingent payments, these
are fair valued using a probability weighted model. If the business divested is part of a reporting unit, goodwill from the reporting unit is reallocated based on the fair value of the divested business compared to the fair value of the reporting unit.
Goodwill and Intangible Assets
Goodwill and Intangible Assets
Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts.
The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded.
Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values.
Valuation and Impairment of Long-Lived Assets
Valuation and Impairment of Long-Lived Assets
Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.
Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values.
Long-lived assets to be disposed of are carried at fair value less costs to sell.
Venture Capital Investments
Venture Capital Investments
The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance.
Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in Other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information.
Strategic Equity Investments
Strategic Equity Investments
The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Derivatives Contracts
Derivative Contracts
The Company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The Company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. The Company uses an interest rate swap to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility.
The Company uses short-term forward currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans. The currency-exchange contracts principally hedge transactions denominated in Canadian dollars and euros. The Company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Life Insurance Contracts
Life Insurance Contracts
Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. Gains and losses from life insurance contracts are recorded in Other income (expense), net in the accompanying consolidated statements of income. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows.
Leases
Leases
At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments.
The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.
Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.
Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors.
A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases.
The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements.
Stock-Based Compensation
Stock-Based Compensation
The Company grants stock options, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period.
For stock options and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable.
The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of RSUs is based on the market value of the Company’s common stock on the date of grant.
Revenue Recognition
Revenue Recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).
To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components.
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year, and recorded within service revenue. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the consolidated financial statements.
Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date.
The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Cumulative catch-up adjustments to revenue are periodically recorded that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration), or a contract modification.
Income Taxes
Income Taxes
The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements carrying amounts and their respective tax basis. The Company measures deferred tax assets and liabilities using the enacted tax rates in effect when the temporary differences are expected to be settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Foreign Currency Contracts and Translation of Foreign Currencies
Foreign Currency Contracts
Foreign currency contracts are recorded at fair value in the Company’s consolidated balance sheets and are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loan. Any gains or losses on forward contracts associated with the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity under the Company’s Credit Facility are recognized immediately in Interest expense. Gains or losses incurred on the remeasurement of the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency is recorded in Other (expense) income, net.
Translation of Foreign Currencies
For the Company’s subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive loss, a separate component of equity.
Pension and Other Post-Retirement Benefit Plans
Pension and Other Post-Retirement Benefit Plans
The Company recognizes the funded status of its defined benefit pension and other post-retirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The Company measures plan assets and benefit obligations as of its fiscal year end.
The key assumptions used to calculate benefit obligations and related pension costs include expected long-term rate of return on plan assets, withdrawal and mortality rates, expected rate of increase in employee compensation levels and a discount rate. Assumptions are determined based on the Company’s data and appropriate market indicators, and evaluated each year as of the plan’s measurement date.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the Company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance.
The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and the current employee compensation strategy.
The Company is required to recognize as a component of Other comprehensive income, net of tax, the actuarial gains or losses and prior service costs or credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive income is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
The Company records the service cost component of the net periodic benefit cost within Cost of services provided and Selling, general, and administrative expenses and all other components of net periodic benefit cost within Other (expense) income, net in the consolidated statements of income.
The Company recognizes pension settlement gains or losses in the period when all of the following settlement criteria are met: there is an irrevocable action, the Company is relieved of primary responsibility for a benefit obligation, and significant risks related to the obligation and the assets used to effect the settlement are eliminated.
Earnings Per Share
Earnings Per Share
Basic earnings per share is calculated by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Except where the result would be anti-dilutive to income from continuing operations, diluted earnings per share is computed using the treasury stock method, assuming the exercise of stock options and the vesting of RSUs, or evaluating the performance conditions for PSUs to assess whether the conditions have been met, as well as their related income tax effects.
Treasury Shares
Treasury Shares
The Company periodically retires treasury shares acquired through share repurchases and returns those shares to the status of authorized but unissued. The Company accounts for treasury stock transactions under the cost method. For each reacquisition of common stock, the number of shares and the acquisition price for those shares is added to the existing treasury stock count and total value. Thus, the average cost per share is re-averaged each time shares are acquired. When treasury shares are retired, the Company allocates the excess of the repurchase price over the par value of shares acquired to both retained earnings and additional paid-in-capital. The portion allocated to additional paid-in-capital is determined by applying a percentage, determined by dividing the number of shares to be retired by the number of shares issued, to the balance of additional paid-in-capital as of the retirement date.
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Property, Plant, and Equipment Estimated Useful Lives
The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:
Estimated
Useful Lives
(in years)
LandIndefinite
Buildings and building improvements
10 - 40
Machinery and equipment
3 - 20
Furniture and fixtures
5 - 10
Computer hardware and software
3 - 8
Vehicles
3 - 5
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES (Tables)
 12 Months Ended
Dec. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Purchase Price Allocation
The purchase price allocation for acquisitions during fiscal years 2023 and 2022 was as follows:
Noveprim Group(1)
SAMDI Tech, Inc.Explora BioLabs
November 30, 2023January 27, 2023April 5, 2022
(in thousands)
Trade receivables$1,308 $513 $7,679 
Inventories66,500 — — 
Other current assets (excluding cash)3,965 75 1,067 
Property, plant and equipment35,831 593 37,369 
Operating lease right-of-use asset, net104 — 48,613 
Goodwill (2)
172,349 37,129 215,752 
Definite-lived intangible assets9,500 33,070 70,100 
Other long-term assets (3)
167,907 6 556 
Deferred revenue— (43)(3,507)
Other current liabilities (16,378)(351)(15,507)
Operating lease right-of-use liabilities (Long-term)(97)— (57,193)
Deferred tax liabilities(12,984)(8,191)(18,601)
Other long-term liabilities(7,797)— (1,807)
Redeemable noncontrolling interest (4)
(45,374)— — 
Total purchase price allocation$374,834 $62,801 $284,521 
(1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
(2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is deductible for tax purposes.
(3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight year useful life.
(4) Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.
The purchase price allocation for acquisitions during fiscal years 2021 was as follows:
VigeneRetrogenixCognateDistributed Bio
June 28, 2021March 30, 2021March 29, 2021December 31, 2020
(in thousands)
Trade receivables$3,548 $2,266 $18,566 $2,722 
Other current assets (excluding cash)1,657 209 14,128 221 
Property, plant and equipment7,649 400 52,082 2,382 
Operating lease right-of-use asset, net22,507 1,385 34,349 1,586 
Goodwill (1)
239,681 34,489 611,555 71,585 
Definite-lived intangible assets93,900 22,126 270,900 24,540 
Other long-term assets694 — 6,098 469 
Deferred revenue(4,260)(434)(20,539)(1,319)
Other current liabilities (2)
(6,319)(1,141)(45,388)(1,504)
Operating lease right-of-use liabilities (Long-term)(21,220)(1,205)(31,383)(1,123)
Deferred tax liabilities(13,958)(4,174)(32,503)(2,529)
Total purchase price allocation$323,879 $53,921 $877,865 $97,030 
(1) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes.
(2) In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17 million pertaining to indirect state sales taxes. During fiscal year 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period.
Schedule of Finite-Lived Intangible Assets Acquired
The definite-lived intangible assets acquired during fiscal years 2023 and 2022 were as follows:
Noveprim GroupSAMDI Tech, Inc.Explore BioLabs
Definite-Lived Intangible Assets(in thousands)
Client relationships$— $23,400 $64,000 
Other intangible assets9,500 9,670 6,100 
Total definite-lived intangible assets$9,500 $33,070 $70,100 
Weighted Average Amortization Life(in years)
Client relationships— 1513
Other intangible assets774
Total definite-lived intangible assets71212
The definite-lived intangible assets acquired during fiscal years 2021 were as follows:
VigeneRetrogenixCognateDistributed Bio
Definite-Lived Intangible Assets(in thousands)
Client relationships$87,500 $17,340 $257,200 $16,080 
Other intangible assets6,400 4,786 13,700 8,460 
Total definite-lived intangible assets$93,900 $22,126 $270,900 $24,540 
Weighted Average Amortization Life(in years)
Client relationships1213139
Other intangible assets2324
Total definite-lived intangible assets1111137
The transaction and integration costs incurred for fiscal years 2023, 2022 and 2021 were as follows:
202320222021
(in thousands)
Transaction and Integration Costs
Selling, general and administrative expenses$12,379 $8,470 $39,099 
Schedule of Major Classes of Assets and Liabilities Associated with Divestitures
The carrying amounts of the major classes of assets and liabilities associated with these divestitures were as follows:
December 19, 2022October 12, 2021
AvianRMS JapanCDMO Sweden
(in thousands)
Assets
Current assets
$30,545 $26,524 $8,187 
Property, plant, and equipment, net24,602 17,379 14,339 
Operating lease right-of-use assets, net611 — 19,733 
Goodwill3,168 4,129 27,764 
Client relationships, net1,629 — 14,089 
Other assets10 3,695 — 
Total assets$60,565 $51,727 $84,112 
Liabilities
Current liabilities$8,139 $8,705 $6,386 
Operating lease right-of-use liabilities331 — 18,221 
Long-term liabilities— 94 — 
Total liabilities$8,470 $8,799 $24,607 
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)
 12 Months Ended
Dec. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:
Timing of Revenue Recognition:202320222021
(in thousands)
RMS
Services and products transferred over time$377,947 $340,708 $263,659 
Services and products transferred at a point in time414,396 398,467 426,778 
Total RMS revenue792,343 739,175 690,437 
DSA
Services and products transferred over time2,611,564 2,440,646 2,103,415 
Services and products transferred at a point in time4,059 6,670 3,816 
Total DSA revenue2,615,623 2,447,316 2,107,231 
Manufacturing
Services and products transferred over time381,942 371,500 335,745 
Services and products transferred at a point in time339,501 418,069 406,747 
Total Manufacturing revenue721,443 789,569 742,492 
Total revenue$4,129,409 $3,976,060 $3,540,160 
Revenue and long-lived assets by geographic area are as follows:
U.S.EuropeCanadaAsia PacificOtherConsolidated
(in thousands)
2023
Revenue$2,347,486 $1,076,937 $487,305 $200,833 $16,848 $4,129,409 
Long-lived assets964,176 407,375 157,483 74,605 36,102 1,639,741 
2022      
Revenue$2,342,158 $1,032,125 $398,982 $192,837 $9,958 $3,976,060 
Long-lived assets896,235 349,361 135,300 82,778 1,981 1,465,655 
2021     
Revenue$1,934,404 $1,036,465 $339,098 $222,902 $7,291 $3,540,160 
Long-lived assets755,400 323,405 145,274 64,864 2,125 1,291,068 
Schedule of Client Receivables, Contract Assets and Contract Liabilities
The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:
December 30, 2023December 31, 2022
(in thousands)
Assets from contracts with customers
Client receivables$578,077 $559,410 
Unbilled revenue228,020 204,258 
Total806,097 763,668 
Less: Allowance for credit losses(25,722)(11,278)
Trade receivables and contract assets, net$780,375 $752,390 
Liabilities from contracts with customers
Current deferred revenue$241,820 $264,259 
Long term deferred revenue (included in Other long-term liabilities)30,919 25,795 
Customer contract deposits (included in Other current-liabilities)85,554 91,640 
The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year.
202320222021
(in thousands)Affected Line Item in the Consolidated Statements of Income
Lease revenue$93,103 $60,118 $18,118 Service revenue
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
 12 Months Ended
Dec. 30, 2023
Segment Reporting [Abstract]  
Schedule of Revenue and Other Financial Information by Reportable Segment
The following table presents revenue and other financial information by reportable segment:
202320222021
(in thousands)
RMS   
Revenue$792,343 $739,175 $690,437 
Operating income154,666 160,410 166,814 
Depreciation and amortization55,570 49,274 39,123 
Capital expenditures52,819 44,136 61,188 
DSA 
Revenue$2,615,623 $2,447,316 $2,107,231 
Operating income606,076 532,889 406,978 
Depreciation and amortization174,719 179,465 177,254 
Capital expenditures204,891 189,563 101,477 
Manufacturing
Revenue$721,443 $789,569 $742,492 
Operating income88,329 167,084 246,390 
Depreciation and amortization79,982 72,950 46,195 
Capital expenditures58,134 87,084 58,877 
Unallocated corporate
Operating income (1)
$(231,810)$(209,408)$(230,320)
Depreciation and amortization3,853 2,181 2,968 
Capital expenditures2,684 3,950 7,230 
Consolidated
Revenue$4,129,409 $3,976,060 $3,540,160 
Operating income617,261 650,975 589,862 
Depreciation and amortization314,124 303,870 265,540 
Capital expenditures318,528 324,733 228,772 
(1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.
Schedule of Revenue for Each Significant Product or Service Offering
The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:
Timing of Revenue Recognition:202320222021
(in thousands)
RMS
Services and products transferred over time$377,947 $340,708 $263,659 
Services and products transferred at a point in time414,396 398,467 426,778 
Total RMS revenue792,343 739,175 690,437 
DSA
Services and products transferred over time2,611,564 2,440,646 2,103,415 
Services and products transferred at a point in time4,059 6,670 3,816 
Total DSA revenue2,615,623 2,447,316 2,107,231 
Manufacturing
Services and products transferred over time381,942 371,500 335,745 
Services and products transferred at a point in time339,501 418,069 406,747 
Total Manufacturing revenue721,443 789,569 742,492 
Total revenue$4,129,409 $3,976,060 $3,540,160 
Revenue and long-lived assets by geographic area are as follows:
U.S.EuropeCanadaAsia PacificOtherConsolidated
(in thousands)
2023
Revenue$2,347,486 $1,076,937 $487,305 $200,833 $16,848 $4,129,409 
Long-lived assets964,176 407,375 157,483 74,605 36,102 1,639,741 
2022      
Revenue$2,342,158 $1,032,125 $398,982 $192,837 $9,958 $3,976,060 
Long-lived assets896,235 349,361 135,300 82,778 1,981 1,465,655 
2021     
Revenue$1,934,404 $1,036,465 $339,098 $222,902 $7,291 $3,540,160 
Long-lived assets755,400 323,405 145,274 64,864 2,125 1,291,068 
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION (Tables)
 12 Months Ended
Dec. 30, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures
Fiscal Year
202320222021
(in thousands)
Cash paid for income taxes$90,374 $75,909 $75,441 
Cash paid for interest132,101 100,754 70,775 
Non-cash investing and financing activities:
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities$69,139 $88,612 $72,043 
Assets acquired under finance leases— 8,179 1,567 
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
December 30, 2023December 31, 2022
(in thousands)
Supplemental cash flow information:
Cash and cash equivalents$276,771 $233,912 
Restricted cash included in Other current assets5,803 6,192 
Restricted cash included in Other assets1,906 1,110 
Cash, cash equivalents, and restricted cash, end of period$284,480 $241,214 
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY (Tables)
 12 Months Ended
Dec. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Composition of Inventories
The composition of inventories is as follows:
December 30, 2023December 31, 2022
(in thousands)
Raw materials and supplies$42,296 $38,892 
Work in process59,727 48,367 
Finished products278,236 168,550 
Inventories$380,259 $255,809 
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)
 12 Months Ended
Dec. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Composition of Property, Plant and Equipment, Net
The composition of property, plant and equipment, net is as follows:
December 30, 2023December 31, 2022
(in thousands)
Land$79,546 $58,192 
Buildings (1)
1,053,915 963,717 
Machinery and equipment (1)
984,867 850,353 
Leasehold improvements366,556 294,275 
Furniture and fixtures31,284 27,317 
Computer hardware and software (1)
254,413 227,797 
Vehicles (1)
6,746 5,421 
Construction in progress197,723 199,713 
Total2,975,050 2,626,785 
Less: Accumulated depreciation(1,335,309)(1,161,130)
Property, plant and equipment, net$1,639,741 $1,465,655 
(1) These balances include assets under finance leases. See Note 17. Leases.
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Tables)
 12 Months Ended
Dec. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Method Investments
Venture capital investments are summarized below:
December 30, 2023December 31, 2022December 25, 2021
(in thousands)
Beginning balance$129,012 $149,640 $197,100 
Capital contributions17,410 14,485 18,023 
Distributions(15,685)(9,861)(40,205)
Gain (loss)(10,263)(24,398)(23,201)
Foreign currency translation684 (854)(2,077)
Ending balance$121,158 $129,012 $149,640 
The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. Strategic investments are summarized below:
December 30, 2023December 31, 2022December 25, 2021
(in thousands)
Beginning balance$182,590 $51,712 $24,704 
Purchase of investments34,028 142,477 35,540 
Distributions(9,381)(2,732)(789)
Gain (loss) (1)
108,090 (2,377)(7,219)
Reduction for acquisition of entities (1)
(197,753)— — 
Foreign currency translation5,079 (6,490)(524)
Ending balance$122,653 $182,590 $51,712 
(1) Refer to Note 2. Acquisitions for further discussion on the Noveprim and SAMDI acquisitions
XML 58 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE (Tables)
 12 Months Ended
Dec. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis
Assets and liabilities measured at fair value on a recurring basis are summarized below:
 December 30, 2023
 Level 1Level 2Level 3Total
Current assets measured at fair value:(in thousands)
Cash equivalents$— $29 $— $29 
Other assets:
Life insurance policies— 40,912 40,912 
Interest rate swap— 966 — 966 
Total assets measured at fair value$— $41,907 $— $41,907 
Other long-term liabilities measured at fair value:
Contingent consideration— — 33,265 33,265 
Interest rate swap— — — — 
Total liabilities measured at fair value$— $— $33,265 $33,265 
 December 31, 2022
 Level 1Level 2Level 3Total
Current assets measured at fair value:(in thousands)
Cash equivalents$— $78 $— $78 
Other assets:
Life insurance policies— 34,527 — 34,527 
Total assets measured at fair value$— $34,605 $— $34,605 
Accrued liabilities measured at fair value:
Contingent consideration$— $— $13,431 $13,431 
Other long-term liabilities measured at fair value:
Contingent consideration— — — — 
Interest rate swap— 1,523 — 1,523 
Total liabilities measured at fair value$— $1,523 $13,431 $14,954 
During fiscal years 2023 and 2022, there were no transfers between fair value levels.
The book value and fair value of the Company’s Senior Notes is summarized below:
December 30, 2023December 31, 2022
Book ValueFair ValueBook ValueFair Value
(in thousands)
4.25% Senior Notes due 2028
$500,000 $478,100 $500,000 $460,450 
3.75% Senior Notes due 2029
500,000 458,100 500,000 442,200 
4.00% Senior Notes due 2031
500,000 449,350 500,000 432,500 
Rollforward of Contingent Consideration Related to Previous Acquisitions
The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions.
Fiscal Year
202320222021
(in thousands)
Beginning balance$13,431 $37,244 $2,328 
Additions33,265 3,838 71,559 
Payments(15,130)(11,476)(2,889)
Total gains or losses (realized/unrealized):
Adjustment of previously recorded contingent liability1,810 (15,340)(33,386)
Foreign currency translation(111)(835)(368)
Ending balance$33,265 $13,431 $37,244 
XML 59 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Rollforward of Goodwill
The following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:
RMS
DSA(1)
ManufacturingTotal
(in thousands)
December 25, 2021$283,524 $1,472,506 $955,851 $2,711,881 
Acquisitions215,752 — (592)215,160 
Divestitures— — (3,168)(3,168)
Foreign exchange(1,566)(38,905)(33,499)(73,970)
December 31, 2022497,710 1,433,601 918,592 2,849,903 
Acquisitions— 209,478 — 209,478 
Divestitures— — — — 
Foreign exchange(236)19,355 16,545 35,664 
December 30, 2023$497,474 $1,662,434 $935,137 $3,095,045 
(1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.
Schedule of Finite-Lived Intangible Assets
The following table displays intangible assets, net by major class:
 December 30, 2023December 31, 2022
GrossAccumulated
Amortization 		NetGrossAccumulated
Amortization		Net
(in thousands)
Client relationships$1,528,780 $(721,322)$807,458 $1,491,926 $(591,417)$900,509 
Technology142,190 (111,764)30,426 129,626 (101,655)27,971 
Backlog$3,100 $(2,177)$923 $15,236 $(12,512)$2,724 
Trademarks and trade names11,878 (4,568)7,310 12,617 (4,410)8,207 
Other43,611 (25,677)17,934 37,985 (22,121)15,864 
Intangible assets$1,729,559 $(865,508)$864,051 $1,687,390 $(732,115)$955,275 
Schedule of Estimated Amortization Expense As of December 30, 2023, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:
Fiscal YearAmortization Expense
(in thousands)
2024$129,153 
2025$120,995 
2026$115,757 
2027$103,164 
2028$91,315 
XML 60 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)
 12 Months Ended
Dec. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt, Net
Long-term debt, net and finance leases consists of the following:
December 30, 2023December 31, 2022
(in thousands)
Revolving facility$1,129,243 $1,197,586 
4.25% Senior Notes due 2028
500,000 500,000 
3.75% Senior Notes due 2029
500,000 500,000 
4.00% Senior Notes due 2031
500,000 500,000 
Other debt9,575 1,594 
Finance leases 28,550 30,646 
Total debt and finance leases2,667,368 2,729,826 
Less:
Current portion of long-term debt3,172 1,347 
Current portion of finance leases2,398 2,330 
Current portion of long-term debt and finance leases5,570 3,677 
Long-term debt and finance leases2,661,798 2,726,149 
Debt discount and debt issuance costs(14,651)(18,618)
Long-term debt, net and finance leases$2,647,147 $2,707,531 
Schedule of Derivative Instruments on Statements of Income The gains and losses incurred on these transactions were as follows:
December 31, 2022December 25, 2021Affected Line Item in the Consolidated Statements of Income
(in thousands)(in thousands)
Gain (loss) on foreign exchange forward contract$49,712 $34,131 Interest expense
Gain (loss) on foreign debt remeasurement(46,529)(31,830)Other income (expense)
The Company did not have any U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility during fiscal year 2023.
Schedule of Principal Maturities of Existing Debt
Principal maturities of existing debt for the periods set forth in the table below, are as follows:
Principal
(in thousands)
2024$3,172 
2025589 
20261,129,772 
20271,947 
2028501,947 
Thereafter1,001,391 
Total$2,638,818 
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS (Tables)
 12 Months Ended
Dec. 30, 2023
Equity [Abstract]  
Schedule of Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings per Share
The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:
Fiscal Year
202320222021
(in thousands)
Numerator:
Net income$480,370 $492,608 $398,837 
Less: Net income attributable to noncontrolling interests5,746 6,382 7,855 
Net income attributable to common shareholders$474,624 $486,226 $390,982 
Denominator:
Weighted-average shares outstanding—Basic51,227 50,812 50,293 
Effect of dilutive securities:
Stock options, restricted stock units and performance share units224 489 1,132 
Weighted-average shares outstanding—Diluted51,451 51,301 51,425 
Anti-dilutive common stock equivalents(1)
652 560 152 
(1) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Schedule of Changes to Each Component of Accumulated Other Comprehensive Income (Loss), Net of Income Taxes
Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:
Foreign Currency Translation Adjustment and OtherPension and Other Post-Retirement Benefit Plans
Net Unrealized Gain (Loss) on Cash Flow Hedge
Total
(in thousands)
December 26, 2020$(73,884)$(64,990)$— $(138,874)
Other comprehensive income before reclassifications (1)
(30,316)(1,193)— (31,509)
Amounts reclassified from accumulated other comprehensive income— 1,678 — 1,678 
Net current period other comprehensive (loss) income(30,316)485 — (29,831)
Income tax (benefit) expense(6,027)2,062 — (3,965)
December 25, 2021(98,173)(66,567)— (164,740)
Other comprehensive income before reclassifications (1)
(125,507)24,471 (1,523)(102,559)
Amounts reclassified from accumulated other comprehensive income — 3,337 — 3,337 
Net current period other comprehensive (loss) income(125,507)27,808 (1,523)(99,222)
Income tax (benefit) expense(5,895)4,355 (365)(1,905)
December 31, 2022(217,785)(43,114)(1,158)(262,057)
Other comprehensive (loss) income before reclassifications (1)
71,851 (5,376)2,490 68,965 
Amounts reclassified from accumulated other comprehensive income — 736 — 736 
Net current period other comprehensive (loss) income71,851 (4,640)2,490 69,701 
Income tax (benefit) expense4,065 (587)593 4,071 
December 30, 2023$(149,999)$(47,167)$739 $(196,427)
(1) The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real.
Schedule of Rollforward of Redeemable Noncontrolling Interest
The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests:
Fiscal Year
202320222021
(in thousands)
Beginning balance$42,427 $53,010 $25,499 
Acquisition resulting in a 10% noncontrolling interest
45,374 — — 
Additional purchases reducing noncontrolling interest percentage
(24,148)(15,000)— 
Adjustments to redemption value(5,694)7,506 21,312 
Net income
3,492 4,020 5,375 
Dividends(2,378)(3,525)— 
Foreign currency translation(1,200)(3,584)824 
Other(1,151)— — 
Ending balance$56,722 $42,427 $53,010 
XML 62 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components of Income from Continuing Operations Before Income Taxes and the Related Provision for Income Taxes
The components of income from operations before income taxes and the related provision for income taxes are presented below:
 Fiscal Year
 202320222021
(in thousands)
Income before income taxes:   
U.S. $185,667 $280,075 $129,598 
Non-U.S. 395,617 342,912 351,112 
Total income before income taxes$581,284 $622,987 $480,710 
Income tax provision (benefit):   
Current:   
Federal$49,090 $75,052 $32,728 
Foreign85,356 68,644 60,197 
State17,817 19,790 9,257 
Total current152,263 163,486 102,182 
Deferred:   
Federal(42,987)(27,230)(27,486)
Foreign779 (1,134)13,891 
State(9,141)(4,743)(6,714)
Total deferred(51,349)(33,107)(20,309)
Total provision for income taxes$100,914 $130,379 $81,873 
Schedule of Reconciliations of the Statutory U.S. Federal Income Tax Rate to Effective Tax Rates
Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows:
Fiscal Year
202320222021
U.S. statutory income tax rate21.0 %21.0 %21.0 %
Foreign tax rate differences1.5 0.4 0.1 
State income taxes, net of federal tax benefit1.7 2.3 0.8 
Non-deductible compensation0.8 0.9 1.2 
Research tax credits and enhanced deductions(5.0)(3.8)(5.0)
Stock-based compensation(0.1)(1.4)(4.3)
Enacted tax rate changes(0.1)0.4 3.0 
Tax on unremitted earnings1.7 1.6 1.8 
Impact of tax uncertainties(0.3)(1.3)0.7 
Impact of acquisitions and restructuring(4.2)2.0 (1.6)
Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)0.2 (0.8)— 
Global intangible low-taxed income1.5 0.8 1.3 
Foreign-derived intangible income(1.4)(1.4)(1.2)
Other0.1 0.2 (0.8)
Effective income tax rate17.4 %20.9 %17.0 %
Schedule of Components of Deferred Tax Assets and Liabilities
The components of deferred tax assets and liabilities are as follows:
December 30, 2023December 31, 2022
(in thousands)
Deferred tax assets:
Compensation$30,167 $26,341 
Accruals and reserves19,121 16,938 
Net operating loss and credit carryforwards379,959 382,932 
Operating lease liability117,449 100,156 
Capitalized R&D Expenditures
35,673 18,616 
Other12,190 8,516 
Valuation allowance(304,248)(294,753)
Total deferred tax assets290,311 258,746 
Deferred tax liabilities:
Goodwill and other intangibles(231,020)(256,234)
Depreciation related(57,791)(48,965)
Venture capital investments(8,350)(12,007)
Tax on unremitted earnings(25,080)(16,407)
Right-of-use assets(102,620)(91,716)
Other(16,520)(7,737)
Total deferred tax liabilities(441,381)(433,066)
Net deferred taxes$(151,070)$(174,320)
Schedule of Reconciliation of Valuation Allowance
A reconciliation of the Company’s beginning and ending valuation allowance are as follows:
Fiscal Year
202320222021
Beginning balance$294,753 $315,645 $334,845 
Additions (reductions) charged to income tax provision, net963 1,929 1,023 
Additions due to acquisitions— — 7,747 
Reductions due to divestitures, restructuring— (5,337)(4,706)
Currency translation and other8,532 (17,484)(23,264)
Ending balance$304,248 $294,753 $315,645 
Schedule of Reconciliation of the Company's Beginning and Ending Unrecognized Income Tax Benefits
A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows:
Fiscal Year
202320222021
(in thousands)
Beginning balance$23,242 $32,592 $24,970 
Additions to tax positions for current year3,093 4,756 9,544 
Additions to tax positions for prior years721 962 2,476 
Reductions to tax positions for prior years(4,058)(1,420)(1,330)
Settlements— (10,514)(1,870)
Expiration of statute of limitations(296)(3,134)(1,198)
Ending balance$22,702 $23,242 $32,592 
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS (Tables)
 12 Months Ended
Dec. 30, 2023
Retirement Benefits [Abstract]  
Schedule of Reconciliation of Benefit Obligations and Plans Assets of the Company's Pension Plans
The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans:
 December 30, 2023December 31, 2022
(in thousands)
Change in projected benefit obligations:  
Benefit obligation at beginning of year$205,551 $372,599 
Service cost2,474 3,213 
Interest cost9,941 6,140 
Benefit payments(6,239)(6,469)
Curtailment— (2,477)
Settlements— (11,939)
Transfer in due to acquisition1,106 — 
Actuarial (gain) loss3,600 (134,923)
Effect of foreign exchange8,442 (20,593)
Benefit obligation at end of year$224,875 $205,551 
Change in fair value of plan assets:
Fair value of plan assets at beginning of year$192,540 $335,631 
Actual return on plan assets5,578 (105,749)
Employer contributions1,744 4,558 
Settlements— (11,939)
Transfer in due to acquisition181 — 
Benefit payments(6,239)(6,469)
Effect of foreign exchange9,853 (23,492)
Fair value of plan assets at end of year$203,657 $192,540 
Net balance sheet liability$21,218 $13,011 
Amounts recognized in balance sheet:
Noncurrent assets$36,957 $39,185 
Current liabilities1,164 1,151 
Noncurrent liabilities57,011 51,045 
Schedule of Amounts Recognized in Accumulated Other Comprehensive Loss Related to the Company's Pensions Plans Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows:
Fiscal Year
 20232022
(in thousands)
Net actuarial loss$58,855 $54,509 
Net prior service cost (credit)(121)(585)
Net amount recognized$58,734 $53,924 
Schedule of Accumulated Benefit Obligation and Fair of Plan Assets
The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows:
 December 30, 2023December 31, 2022
(in thousands)
Accumulated benefit obligation$54,310 $48,414 
Fair value of plan assets2,824 2,258 
Schedule of Projected Benefit Obligation and Fair Value of Plan Assets
The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows:
 December 30, 2023December 31, 2022
(in thousands)
Projected benefit obligation$61,671 $55,304 
Fair value of plan assets3,496 3,108 
Schedule of Components of Net Periodic Benefit Costs for the Company's Pension Plans
Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows:
Fiscal Year
 202320222021
(in thousands)
Service cost$2,474 $3,213 $3,455 
Interest cost9,941 6,140 5,492 
Expected return on plan assets(7,556)(7,322)(8,058)
Amortization of prior service credit(464)(506)(531)
Amortization of net loss1,231 2,869 4,528 
Net periodic benefit cost5,626 4,394 4,886 
Settlement— 981 (2,320)
Total benefit cost$5,626 $5,375 $2,566 
Schedule of Weighted-average Assumptions
Weighted-average assumptions used to determine projected benefit obligations are as follows:
 December 30, 2023December 31, 2022
Discount rate4.7 %4.8 %
Rate of compensation increase3.2 %3.2 %
The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations.
Weighted-average assumptions used to determine net periodic benefit cost are as follows:
 December 30, 2023December 31, 2022December 25, 2021
Discount rate4.8 %1.8 %1.5 %
Expected long-term return on plan assets3.9 %2.4 %2.5 %
Rate of compensation increase3.2 %3.7 %3.0 %
Schedule of Fair Value of the Company's Pension Plan Assets by Asset Category
The fair value of the Company’s pension plan assets by asset category are as follows:
 December 30, 2023December 31, 2022
Level 1 Level 2Level 3Total Level 1 Level 2Level 3Total
(in thousands)
Cash and cash equivalents$446 $798 $— $1,244 $362 $5,153 $— $5,515 
Equity securities (1)
— 10,701 — 10,701 — 9,308 — 9,308 
Debt securities (2)
— 144,822 — 144,822 — 123,638 — 123,638 
Mutual funds (3)
9,207 10,368 — 19,575 8,380 9,372 — 17,752 
Other (4)
— 27,254 61 27,315 — 36,268 59 36,327 
Total$9,653 $193,943 $61 $203,657 $8,742 $183,739 $59 $192,540 
(1) This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end.
(2) This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations.
(3) This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end.
(4) This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end.
Schedule of Estimated Future Benefit Payments Over the Next Five Years Estimated future benefit payments during the next five years and in the aggregate for fiscal years 2029 through 2033, are as follows.
Fiscal YearPension Plans
(in thousands)
2024$6,558 
20256,703 
202646,898 
20277,633 
20288,843 
2029-203355,416 
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Financial Statement Line Items in Which Stock-based Compensation is Reflected The following table provides stock-based compensation by the financial statement line item in which it is reflected:
Fiscal Year
202320222021
(in thousands)
Cost of revenue$15,052 $14,853 $13,087 
Selling, general and administrative56,996 58,764 58,387 
Stock-based compensation, before income taxes72,048 73,617 71,474 
Provision for income taxes(10,907)(10,969)(10,299)
Stock-based compensation, net of income taxes$61,141 $62,648 $61,175 
Schedule of Stock Option Activity
The following table summarizes stock option activity under the Company’s stock-based compensation plans:
Number of sharesWeighted Average
Exercise Price		Weighted Average
Remaining
Contractual Life		Aggregate
Intrinsic
Value
(in thousands)(in years)(in thousands)
Options outstanding as of December 31, 2022882 $204.41   
Options granted130 $194.27   
Options exercised(195)$130.91   
Options canceled(28)$259.63   
Options outstanding as of December 30, 2023789 $218.97 6.5$28,935 
Options exercisable as of December 30, 2023408 $205.50 4.8$20,521 
Options expected to vest as of December 30, 2023381 $233.37 8.3$8,414 
Schedule of Weighted-average Assumptions
The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Fiscal Year
202320222021
Expected life (in years)6.06.06.0
Expected volatility36 %33 %32 %
Risk-free interest rate3.8 %2.7 %1.0 %
Expected dividend yield0 %0 %0 %
Schedule of Restricted Stock and Restricted Stock Unit Activity
The following table summarizes the restricted stock units activity for fiscal year 2023:
Restricted Stock UnitsWeighted Average Grant Date Fair Value
(in thousands)
December 31, 2022364 $226.43 
Granted265 $194.84 
Vested(134)$212.34 
Canceled(26)$231.70 
December 30, 2023469 $212.30 
Schedule of Information about PSUs and Related Weighted-Average Assumptions
The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows:
Fiscal Year
202320222021
(shares in thousands)
PSUs granted146 134 64 
Weighted average grant date fair value$204.40 $210.42 $407.76 
Key assumptions:
Expected volatility 37 %39 %37 %
Risk-free interest rate4.2 %2.6 %0.2 %
Expected dividend yield0 %0 %0 %
Total shareholder return of 20-trading day average stock price on grant date
(9.8)%(32.7)%39.9 %
XML 65 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)
 12 Months Ended
Dec. 30, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Costs
The following table presents restructuring costs by reportable segment:
Fiscal Year
202320222021
(in thousands)
RMS$3,479 $1,007 $7 
DSA16,176 851 3,114 
Manufacturing9,138 5,126 3,663 
Unallocated corporate889 1,229 72 
Total$29,682 $8,213 $6,856 
The following table presents restructuring costs as included within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
2023
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$7,408 $14,812 $22,220 
Cost of products sold (excluding amortization of intangible assets)1,146 3,262 4,408 
Selling, general and administrative3,054 — 3,054 
Total restructuring costs$11,608 $18,074 $29,682 
Fiscal Year
2022
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$928 $1,784 $2,712 
Cost of products sold (excluding amortization of intangible assets)532 1,765 2,297 
Selling, general and administrative2,441 763 3,204 
Total restructuring costs$3,901 $4,312 $8,213 
Fiscal Year
2021
Severance and Transition CostsAsset Impairments and Other CostsTotal
(in thousands)
Twelve Months Ended
Cost of services provided (excluding amortization of intangible assets)$1,898 $934 $2,832 
Cost of products sold (excluding amortization of intangible assets)— — — 
Selling, general and administrative2,819 1,205 4,024 
Total restructuring costs$4,717 $2,139 $6,856 
Schedule of Rollforward of Company's Severance and Retention Costs Liability
The following table provides a rollforward for all of the Company’s severance and transition costs related to all restructuring activities:
Fiscal Year
202320222021
(in thousands)
Beginning balance$1,300 $4,011 $5,818 
Expense (excluding non-cash charges)11,539 6,732 5,695 
Payments / utilization(7,800)(6,973)(5,604)
Other non-cash adjustments— (2,350)(1,831)
Foreign currency adjustments11 (120)(67)
Ending balance$5,050 $1,300 $4,011 
XML 66 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES (Tables)
 12 Months Ended
Dec. 30, 2023
Leases [Abstract]  
Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements
Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:
December 30, 2023December 31, 2022
(in thousands)
Operating leases
Operating lease right-of-use assets, net$394,029 $391,762 
Other current liabilities$54,908 $46,526 
Operating lease right-of-use liabilities419,234 389,745 
Total operating lease liabilities$474,142 $436,271 
Finance leases
Property, plant and equipment, net$29,422$31,875
Current portion of long-term debt and finance leases$2,398$2,330
Long-term debt, net and finance leases26,15228,316
Total finance lease liabilities$28,550$30,646
Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information
The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:
Fiscal Year
202320222021
(in thousands)
Operating lease costs$65,380 $59,671 $45,728 
Finance lease costs:
Amortization of right-of-use assets2,745 3,035 3,337 
Interest on lease liabilities1,477 1,441 1,280 
Short-term lease costs3,581 2,954 2,441 
Variable lease costs22,159 13,965 4,623 
Sublease income(2,067)(1,912)(2,008)
Total lease costs$93,275 $79,154 $55,401 
Other information related to leases was as follows:
Supplemental cash flow information
Fiscal Year
202320222021
(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases$60,239 $48,360 $42,576 
Operating cash flows from finance leases1,476 1,442 1,282 
Finance cash flows from finance leases2,297 2,257 3,202 
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities$75,987 $189,134 $142,764 
Right-of-use lease assets obtained in exchange for new finance lease liabilities— 8,179 1,567 
Lease term and discount rate
December 30, 2023December 31, 2022December 25, 2021
Weighted-average remaining lease term (in years)
Operating lease9.69.89.0
Finance lease12.713.611.7
Weighted-average discount rate
Operating lease4.7 %4.3 %3.6 %
Finance lease5.3 %5.3 %4.4 %
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases After Adoption
As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:
Operating LeasesFinance Leases
(in thousands)
2024$70,578 $3,796 
202563,433 3,513 
202658,494 3,038 
202759,946 2,999 
202857,953 2,988 
Thereafter286,215 23,562 
Total minimum future lease payments596,619 39,896 
Less: Imputed interest122,477 11,346 
Total lease liabilities$474,142 $28,550 
Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases After Adoption
As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:
Operating LeasesFinance Leases
(in thousands)
2024$70,578 $3,796 
202563,433 3,513 
202658,494 3,038 
202759,946 2,999 
202857,953 2,988 
Thereafter286,215 23,562 
Total minimum future lease payments596,619 39,896 
Less: Imputed interest122,477 11,346 
Total lease liabilities$474,142 $28,550 
XML 67 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 30, 2023
USD ($)
segment
subsegment
contract
Dec. 31, 2022
USD ($)
contract
Debt Instrument [Line Items]    
Number of reportable segments | segment 3  
Number of life insurance contracts | contract 44 44
Face value of life insurance contracts | $ $ 82.4 $ 74.5
Revenue from contract with customer, payment terms 30 days  
DSA    
Debt Instrument [Line Items]    
Number of businesses in reportable segment | subsegment 2  
Minimum    
Debt Instrument [Line Items]    
Renewal term for leases 1 year  
Minimum | Venture Capital Funds    
Debt Instrument [Line Items]    
Company's ownership percentage 1.00%  
Maximum    
Debt Instrument [Line Items]    
Renewal term for leases 5 years  
Maximum | Venture Capital Funds    
Debt Instrument [Line Items]    
Company's ownership percentage 12.00%  
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Life (Details)
Dec. 30, 2023
Minimum | Buildings and building improvements  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 10 years
Minimum | Machinery and equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 3 years
Minimum | Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 5 years
Minimum | Computer hardware and software  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 3 years
Minimum | Vehicles  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 3 years
Maximum | Buildings and building improvements  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 40 years
Maximum | Machinery and equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 20 years
Maximum | Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 10 years
Maximum | Computer hardware and software  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 8 years
Maximum | Vehicles  
Property, Plant and Equipment [Line Items]  
Estimated Useful Lives 5 years
XML 69 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended 23 Months Ended
Nov. 30, 2023
Jan. 27, 2023
Apr. 05, 2022
Oct. 12, 2021
Jun. 28, 2021
Mar. 30, 2021
Mar. 29, 2021
Mar. 03, 2021
Dec. 31, 2020
Dec. 25, 2021
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Nov. 30, 2023
Dec. 20, 2022
Business Acquisition [Line Items]                                
Payments to acquire businesses, net of cash acquired                     $ 194,785,000 $ 283,392,000 $ 1,293,095,000      
Goodwill                     3,095,045,000 2,849,903,000        
Gain on sale of business                     (961,000) 123,405,000 $ 25,026,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Avian                                
Business Acquisition [Line Items]                                
Consideration received from divestiture                               $ 167,300,000
Contingent consideration                     10,300,000         $ 30,000,000
Gain on sale of business                       123,400,000        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | RMS Japan                                
Business Acquisition [Line Items]                                
Consideration received from divestiture       $ 70,900,000                        
Gain on sale of business                   $ 20,000,000            
Cash proceeds from divestiture       7,900,000                        
Pension over funding and other post-closing adjustments       3,800,000                        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | CDMO Sweden                                
Business Acquisition [Line Items]                                
Consideration received from divestiture       59,600,000                        
Contingent consideration       15,300,000               $ 7,500,000        
Cash proceeds from divestiture       200,000                        
Maximum | Disposal Group, Disposed of by Sale, Not Discontinued Operations | CDMO Sweden                                
Business Acquisition [Line Items]                                
Contingent consideration       25,000,000                        
Purchase obligation       $ 10,000,000                        
Noveprim Group                                
Business Acquisition [Line Items]                                
Percentage of voting interests acquired 41.00%                           41.00%  
Equity interest acquired 90.00%                           90.00%  
Business combination, equity stake percentage 49.00%                     49.00%     49.00%  
Purchase of investments                       $ 90,000,000        
Contingent liability                       5,000,000        
Purchase price                             $ 374,800,000  
Additional cash paid                             144,600,000  
Business combination, consideration transferred, other                             198,800,000  
Gain in equity equal to the excess fair value of additional equity interest purchased                             103,200,000  
Contingent consideration $ 33,300,000                           33,300,000  
Business combination deferred purchase price 12,000,000                           12,000,000  
Adjustments for working capital/debt 13,800,000                           13,800,000  
Consideration contingent upon future performance $ 55,000,000                           $ 55,000,000  
Business combination, remaining equity to purchase 10.00%                           10.00%  
Call option term, period after sixth anniversary 1 month                           1 month  
Put option term, period after first anniversary 12 months                           12 months  
Total purchase price allocation $ 374,834,000                           $ 374,834,000  
Goodwill 172,349,000                           172,349,000  
Definite-lived intangible assets $ 9,500,000                           9,500,000  
Weighted Average Amortization Life 7 years                              
Property, plant and equipment $ 35,831,000                           35,831,000  
Noveprim Group | Minimum                                
Business Acquisition [Line Items]                                
Business combination, redemption price 47,000,000                           47,000,000  
Noveprim Group | Maximum                                
Business Acquisition [Line Items]                                
Business combination, redemption price $ 54,000,000                           $ 54,000,000  
SAMDI Tech, Inc.                                
Business Acquisition [Line Items]                                
Business combination, equity stake percentage   20.00%                            
Payments to acquire businesses, net of cash acquired   $ 62,800,000                            
Cash acquired   400,000                            
Value of previously owned interest in acquiree   12,600,000                            
Total purchase price allocation   62,801,000                            
Goodwill   37,129,000                            
Definite-lived intangible assets   $ 33,070,000                            
Weighted Average Amortization Life   12 years                            
Property, plant and equipment   $ 593,000                            
Explore BioLabs                                
Business Acquisition [Line Items]                                
Cash acquired     $ 6,600,000                          
Total purchase price allocation     284,521,000                          
Goodwill     215,752,000                          
Definite-lived intangible assets     $ 70,100,000                          
Weighted Average Amortization Life     12 years                          
Property, plant and equipment     $ 37,369,000                          
Vigene                                
Business Acquisition [Line Items]                                
Purchase price         $ 323,900,000                      
Contingent consideration         34,500,000           0 0        
Cash acquired         2,700,000                      
Total purchase price allocation         323,879,000                      
Goodwill         239,681,000                      
Definite-lived intangible assets         $ 93,900,000                      
Weighted Average Amortization Life         11 years                      
Property, plant and equipment         $ 7,649,000                      
Vigene | Maximum                                
Business Acquisition [Line Items]                                
Consideration contingent upon future performance         $ 57,500,000                      
Retrogenix                                
Business Acquisition [Line Items]                                
Purchase price           $ 53,900,000                    
Contingent consideration           6,900,000                    
Cash acquired           8,500,000                    
Total purchase price allocation           53,921,000                    
Goodwill           34,489,000                    
Definite-lived intangible assets           $ 22,126,000                    
Weighted Average Amortization Life           11 years                    
Property, plant and equipment           $ 400,000                    
Cognate                                
Business Acquisition [Line Items]                                
Purchase price             $ 877,900,000                  
Cash acquired             70,500,000                  
Total purchase price allocation             877,865,000                  
Value of consideration not acquired             $ 15,700,000                  
Ownership percentage not acquired             2.00%                  
Goodwill             $ 611,555,000                  
Definite-lived intangible assets             $ 270,900,000                  
Weighted Average Amortization Life             13 years                  
Property, plant and equipment             $ 52,082,000                  
Distributed Bio                                
Business Acquisition [Line Items]                                
Purchase price                 $ 97,000,000              
Contingent consideration                 14,100,000   0          
Cash acquired                 800,000              
Total purchase price allocation                 97,030,000              
Cash portion of consideration transferred                 80,800,000              
Payments to settle promissory note                 $ 3,000,000              
Business combination, consideration liability contingent upon future performance, period                 1 year              
Payment for contingent consideration                       $ 7,000,000        
Goodwill                 $ 71,585,000              
Definite-lived intangible assets                 $ 24,540,000              
Weighted Average Amortization Life                 7 years              
Property, plant and equipment                 $ 2,382,000              
Distributed Bio | Maximum                                
Business Acquisition [Line Items]                                
Consideration contingent upon future performance                 $ 21,000,000              
Other Acquisitions                                
Business Acquisition [Line Items]                                
Purchase price               $ 35,400,000                
Contingent consideration               15,900,000     $ 0          
Consideration contingent upon future performance               17,500,000                
Cash portion of consideration transferred               $ 19,500,000           $ 5,500,000    
Business combination, consideration liability contingent upon future performance, period               3 years                
Goodwill               $ 17,300,000                
Definite-lived intangible assets               $ 15,200,000                
Weighted Average Amortization Life               4 years                
Property, plant and equipment               $ 3,000,000                
XML 70 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Nov. 30, 2023
Jan. 27, 2023
Dec. 31, 2022
Apr. 05, 2022
Jun. 28, 2021
Mar. 30, 2021
Mar. 29, 2021
Dec. 31, 2020
Business Acquisition [Line Items]                  
Inventories     $ 0   $ 0        
Goodwill $ 3,095,045     $ 2,849,903          
Redeemable noncontrolling interest     0   0        
Noveprim Group                  
Business Acquisition [Line Items]                  
Noncontrolling ownership interest 10.00%                
Noveprim Group                  
Business Acquisition [Line Items]                  
Trade receivables   $ 1,308              
Inventories   66,500              
Other current assets (excluding cash)   3,965              
Property, plant and equipment   35,831              
Operating lease right-of-use asset, net   104              
Goodwill   172,349              
Definite-lived intangible assets   9,500              
Other long-term assets   167,907              
Deferred revenue   0              
Other current liabilities   (16,378)              
Operating lease right-of-use liabilities (Long-term)   (97)              
Deferred tax liabilities   (12,984)              
Other long-term liabilities   (7,797)              
Redeemable noncontrolling interest   (45,374)              
Total purchase price allocation   374,834              
Biological assets   $ 167,800              
Biological assets, useful life   8 years              
SAMDI Tech, Inc.                  
Business Acquisition [Line Items]                  
Trade receivables     513            
Other current assets (excluding cash)     75            
Property, plant and equipment     593            
Operating lease right-of-use asset, net     0            
Goodwill     37,129            
Definite-lived intangible assets     33,070            
Other long-term assets     6            
Deferred revenue     (43)            
Other current liabilities     (351)            
Operating lease right-of-use liabilities (Long-term)     0            
Deferred tax liabilities     (8,191)            
Other long-term liabilities     0            
Total purchase price allocation     $ 62,801            
Explore BioLabs                  
Business Acquisition [Line Items]                  
Trade receivables         7,679        
Other current assets (excluding cash)         1,067        
Property, plant and equipment         37,369        
Operating lease right-of-use asset, net         48,613        
Goodwill         215,752        
Definite-lived intangible assets         70,100        
Other long-term assets         556        
Deferred revenue         (3,507)        
Other current liabilities         (15,507)        
Operating lease right-of-use liabilities (Long-term)         (57,193)        
Deferred tax liabilities         (18,601)        
Other long-term liabilities         (1,807)        
Total purchase price allocation         284,521        
Goodwill resulting from transaction         $ 5,000        
Vigene                  
Business Acquisition [Line Items]                  
Trade receivables           $ 3,548      
Other current assets (excluding cash)           1,657      
Property, plant and equipment           7,649      
Operating lease right-of-use asset, net           22,507      
Goodwill           239,681      
Definite-lived intangible assets           93,900      
Other long-term assets           694      
Deferred revenue           (4,260)      
Other current liabilities           (6,319)      
Operating lease right-of-use liabilities (Long-term)           (21,220)      
Deferred tax liabilities           (13,958)      
Total purchase price allocation           $ 323,879      
Retrogenix                  
Business Acquisition [Line Items]                  
Trade receivables             $ 2,266    
Other current assets (excluding cash)             209    
Property, plant and equipment             400    
Operating lease right-of-use asset, net             1,385    
Goodwill             34,489    
Definite-lived intangible assets             22,126    
Other long-term assets             0    
Deferred revenue             (434)    
Other current liabilities             (1,141)    
Operating lease right-of-use liabilities (Long-term)             (1,205)    
Deferred tax liabilities             (4,174)    
Total purchase price allocation             $ 53,921    
Cognate                  
Business Acquisition [Line Items]                  
Trade receivables               $ 18,566  
Other current assets (excluding cash)               14,128  
Property, plant and equipment               52,082  
Operating lease right-of-use asset, net               34,349  
Goodwill               611,555  
Definite-lived intangible assets               270,900  
Other long-term assets               6,098  
Deferred revenue               (20,539)  
Other current liabilities               (45,388)  
Operating lease right-of-use liabilities (Long-term)               (31,383)  
Deferred tax liabilities               (32,503)  
Total purchase price allocation               877,865  
Estimated tax liability               $ 17,000  
Distributed Bio                  
Business Acquisition [Line Items]                  
Trade receivables                 $ 2,722
Other current assets (excluding cash)                 221
Property, plant and equipment                 2,382
Operating lease right-of-use asset, net                 1,586
Goodwill                 71,585
Definite-lived intangible assets                 24,540
Other long-term assets                 469
Deferred revenue                 (1,319)
Other current liabilities                 (1,504)
Operating lease right-of-use liabilities (Long-term)                 (1,123)
Deferred tax liabilities                 (2,529)
Total purchase price allocation                 $ 97,030
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Nov. 30, 2023
Jan. 27, 2023
Apr. 05, 2022
Jun. 28, 2021
Mar. 30, 2021
Mar. 29, 2021
Dec. 31, 2020
Noveprim Group              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets $ 9,500            
Weighted Average Amortization Life 7 years            
SAMDI Tech, Inc.              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets   $ 33,070          
Weighted Average Amortization Life   12 years          
Explore BioLabs              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets     $ 70,100        
Weighted Average Amortization Life     12 years        
Vigene              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets       $ 93,900      
Weighted Average Amortization Life       11 years      
Retrogenix              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets         $ 22,126    
Weighted Average Amortization Life         11 years    
Cognate              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets           $ 270,900  
Weighted Average Amortization Life           13 years  
Distributed Bio              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets             $ 24,540
Weighted Average Amortization Life             7 years
Client relationships | Noveprim Group              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets $ 0            
Weighted Average Amortization Life 0 years            
Client relationships | SAMDI Tech, Inc.              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets   $ 23,400          
Weighted Average Amortization Life   15 years          
Client relationships | Explore BioLabs              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets     $ 64,000        
Weighted Average Amortization Life     13 years        
Client relationships | Vigene              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets       $ 87,500      
Weighted Average Amortization Life       12 years      
Client relationships | Retrogenix              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets         $ 17,340    
Weighted Average Amortization Life         13 years    
Client relationships | Cognate              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets           $ 257,200  
Weighted Average Amortization Life           13 years  
Client relationships | Distributed Bio              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets             $ 16,080
Weighted Average Amortization Life             9 years
Other intangible assets | Noveprim Group              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets $ 9,500            
Weighted Average Amortization Life 7 years            
Other intangible assets | SAMDI Tech, Inc.              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets   $ 9,670          
Weighted Average Amortization Life   7 years          
Other intangible assets | Explore BioLabs              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets     $ 6,100        
Weighted Average Amortization Life     4 years        
Other intangible assets | Vigene              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets       $ 6,400      
Weighted Average Amortization Life       2 years      
Other intangible assets | Retrogenix              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets         $ 4,786    
Weighted Average Amortization Life         3 years    
Other intangible assets | Cognate              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets           $ 13,700  
Weighted Average Amortization Life           2 years  
Other intangible assets | Distributed Bio              
Business Acquisition [Line Items]              
Definite-Lived Intangible Assets             $ 8,460
Weighted Average Amortization Life             4 years
XML 72 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Business Combination and Asset Acquisition [Abstract]      
Selling, general and administrative expenses $ 12,379 $ 8,470 $ 39,099
XML 73 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - USD ($)
$ in Thousands
Dec. 19, 2022
Oct. 12, 2021
Avian    
Assets    
Current assets $ 30,545  
Property, plant, and equipment, net 24,602  
Operating lease right-of-use assets, net 611  
Goodwill 3,168  
Client relationships, net 1,629  
Other assets 10  
Total assets 60,565  
Liabilities    
Current liabilities 8,139  
Operating lease right-of-use liabilities 331  
Long-term liabilities 0  
Total liabilities $ 8,470  
RMS Japan    
Assets    
Current assets   $ 26,524
Property, plant, and equipment, net   17,379
Operating lease right-of-use assets, net   0
Goodwill   4,129
Client relationships, net   0
Other assets   3,695
Total assets   51,727
Liabilities    
Current liabilities   8,705
Operating lease right-of-use liabilities   0
Long-term liabilities   94
Total liabilities   8,799
CDMO Sweden    
Assets    
Current assets   8,187
Property, plant, and equipment, net   14,339
Operating lease right-of-use assets, net   19,733
Goodwill   27,764
Client relationships, net   14,089
Other assets   0
Total assets   84,112
Liabilities    
Current liabilities   6,386
Operating lease right-of-use liabilities   18,221
Long-term liabilities   0
Total liabilities   $ 24,607
XML 74 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Disaggregation of Revenue [Line Items]      
Revenue $ 4,129,409 $ 3,976,060 $ 3,540,160
RMS      
Disaggregation of Revenue [Line Items]      
Revenue 792,343 739,175 690,437
RMS | Services and products transferred over time      
Disaggregation of Revenue [Line Items]      
Revenue 377,947 340,708 263,659
RMS | Services and products transferred at a point in time      
Disaggregation of Revenue [Line Items]      
Revenue 414,396 398,467 426,778
DSA      
Disaggregation of Revenue [Line Items]      
Revenue 2,615,623 2,447,316 2,107,231
DSA | Services and products transferred over time      
Disaggregation of Revenue [Line Items]      
Revenue 2,611,564 2,440,646 2,103,415
DSA | Services and products transferred at a point in time      
Disaggregation of Revenue [Line Items]      
Revenue 4,059 6,670 3,816
Manufacturing      
Disaggregation of Revenue [Line Items]      
Revenue 721,443 789,569 742,492
Manufacturing | Services and products transferred over time      
Disaggregation of Revenue [Line Items]      
Revenue 381,942 371,500 335,745
Manufacturing | Services and products transferred at a point in time      
Disaggregation of Revenue [Line Items]      
Revenue $ 339,501 $ 418,069 $ 406,747
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Client receivables $ 578,077 $ 559,410
Unbilled revenue 228,020 204,258
Total 806,097 763,668
Less: Allowance for credit losses (25,722) (11,278)
Trade receivables and contract assets, net 780,375 752,390
Current deferred revenue 241,820 264,259
Long term deferred revenue (included in Other long-term liabilities) 30,919 25,795
Customer contract deposits (included in Other current-liabilities) $ 85,554 $ 91,640
XML 76 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Disaggregation of Revenue [Line Items]      
Unpaid advanced client billings $ 41,000 $ 54,000  
Provision for credit losses 18,225 6,706 $ 1,657
Performance obligations expected to be satisfied 986,000    
Lease revenue $ 93,103 $ 60,118 $ 18,118
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-12-31      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, percentage 50.00%    
Performance obligations expected to be satisfied, expected timing 12 months    
XML 77 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 25, 2021
USD ($)
Segment Reporting [Abstract]      
Number of reportable segments | segment 3    
Segment Reporting Information [Line Items]      
Revenue $ 4,129,409 $ 3,976,060 $ 3,540,160
Operating income 617,261 650,975 589,862
Depreciation and amortization 314,124 303,870 265,540
Capital expenditures 318,528 324,733 228,772
Unallocated corporate      
Segment Reporting Information [Line Items]      
Operating income (231,810) (209,408) (230,320)
Depreciation and amortization 3,853 2,181 2,968
Capital expenditures 2,684 3,950 7,230
RMS      
Segment Reporting Information [Line Items]      
Revenue 792,343 739,175 690,437
RMS | Operating Segments      
Segment Reporting Information [Line Items]      
Revenue 792,343 739,175 690,437
Operating income 154,666 160,410 166,814
Depreciation and amortization 55,570 49,274 39,123
Capital expenditures 52,819 44,136 61,188
DSA      
Segment Reporting Information [Line Items]      
Revenue 2,615,623 2,447,316 2,107,231
DSA | Operating Segments      
Segment Reporting Information [Line Items]      
Revenue 2,615,623 2,447,316 2,107,231
Operating income 606,076 532,889 406,978
Depreciation and amortization 174,719 179,465 177,254
Capital expenditures 204,891 189,563 101,477
Manufacturing      
Segment Reporting Information [Line Items]      
Revenue 721,443 789,569 742,492
Manufacturing | Operating Segments      
Segment Reporting Information [Line Items]      
Revenue 721,443 789,569 742,492
Operating income 88,329 167,084 246,390
Depreciation and amortization 79,982 72,950 46,195
Capital expenditures $ 58,134 $ 87,084 $ 58,877
XML 78 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Segment Reporting Information [Line Items]      
Revenue $ 4,129,409 $ 3,976,060 $ 3,540,160
Long-lived assets 1,639,741 1,465,655 1,291,068
U.S.      
Segment Reporting Information [Line Items]      
Revenue 2,347,486 2,342,158 1,934,404
Long-lived assets 964,176 896,235 755,400
Europe      
Segment Reporting Information [Line Items]      
Revenue 1,076,937 1,032,125 1,036,465
Long-lived assets 407,375 349,361 323,405
Canada      
Segment Reporting Information [Line Items]      
Revenue 487,305 398,982 339,098
Long-lived assets 157,483 135,300 145,274
Asia Pacific      
Segment Reporting Information [Line Items]      
Revenue 200,833 192,837 222,902
Long-lived assets 74,605 82,778 64,864
Other      
Segment Reporting Information [Line Items]      
Revenue 16,848 9,958 7,291
Long-lived assets $ 36,102 $ 1,981 $ 2,125
XML 79 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Cash and Cash Equivalents [Abstract]      
Cash paid for income taxes $ 90,374 $ 75,909 $ 75,441
Cash paid for interest 132,101 100,754 70,775
Non-cash investing and financing activities:      
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities 69,139 88,612 72,043
Assets acquired under finance leases $ 0 $ 8,179 $ 1,567
XML 80 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 276,771 $ 233,912    
Restricted cash included in Other current assets 5,803 6,192    
Restricted cash included in Other assets 1,906 1,110    
Cash, cash equivalents, and restricted cash, end of period $ 284,480 $ 241,214 $ 246,314 $ 233,119
XML 81 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials and supplies $ 42,296 $ 38,892
Work in process 59,727 48,367
Finished products 278,236 168,550
Inventories $ 380,259 $ 255,809
XML 82 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 2,975,050 $ 2,626,785  
Less: Accumulated depreciation (1,335,309) (1,161,130)  
Property, plant and equipment, net 1,639,741 1,465,655  
Depreciation 176,700 157,300 $ 140,700
Land      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 79,546 58,192  
Buildings      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 1,053,915 963,717  
Machinery and equipment      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 984,867 850,353  
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 366,556 294,275  
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 31,284 27,317  
Computer hardware and software      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 254,413 227,797  
Vehicles      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 6,746 5,421  
Construction in progress      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 197,723 $ 199,713  
XML 83 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Venture Capital Investments and Strategic Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Schedule of Equity Method Investments [Line Items]      
Beginning balance $ 311,602    
Ending balance 243,811 $ 311,602  
Venture Capital Funds      
Schedule of Equity Method Investments [Line Items]      
Beginning balance 129,012 149,640 $ 197,100
Capital contributions 17,410 14,485 18,023
Distributions (15,685) (9,861) (40,205)
Gain (loss) (10,263) (24,398) (23,201)
Foreign currency translation 684 (854) (2,077)
Ending balance 121,158 129,012 149,640
Strategic Investments      
Schedule of Equity Method Investments [Line Items]      
Beginning balance 182,590 51,712 24,704
Purchase of investments 34,028 142,477 35,540
Distributions (9,381) (2,732) (789)
Gain (loss) 108,090 (2,377) (7,219)
Reduction for acquisition of entities (197,753) 0 0
Foreign currency translation 5,079 (6,490) (524)
Ending balance $ 122,653 $ 182,590 $ 51,712
XML 84 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Fair Value of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Other assets:    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other income (expense), net  
Other long-term liabilities measured at fair value:    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other assets Other assets
Fair Value, Recurring    
Current assets measured at fair value:    
Cash equivalents $ 29 $ 78
Other assets:    
Life insurance policies 40,912 34,527
Interest rate swap 966  
Total assets measured at fair value 41,907 34,605
Accrued liabilities measured at fair value:    
Contingent consideration   13,431
Other long-term liabilities measured at fair value:    
Contingent consideration 33,265 0
Interest rate swap 0 1,523
Total liabilities measured at fair value 33,265 14,954
Level 1 | Fair Value, Recurring    
Current assets measured at fair value:    
Cash equivalents 0 0
Other assets:    
Life insurance policies 0 0
Interest rate swap 0  
Total assets measured at fair value 0 0
Accrued liabilities measured at fair value:    
Contingent consideration   0
Other long-term liabilities measured at fair value:    
Contingent consideration 0 0
Interest rate swap 0 0
Total liabilities measured at fair value 0 0
Level 2 | Fair Value, Recurring    
Current assets measured at fair value:    
Cash equivalents 29 78
Other assets:    
Life insurance policies 40,912 34,527
Interest rate swap 966  
Total assets measured at fair value 41,907 34,605
Accrued liabilities measured at fair value:    
Contingent consideration   0
Other long-term liabilities measured at fair value:    
Contingent consideration 0 0
Interest rate swap 0 1,523
Total liabilities measured at fair value 0 1,523
Level 3 | Fair Value, Recurring    
Current assets measured at fair value:    
Cash equivalents 0 0
Other assets:    
Life insurance policies 0
Interest rate swap 0  
Total assets measured at fair value 0 0
Accrued liabilities measured at fair value:    
Contingent consideration   13,431
Other long-term liabilities measured at fair value:    
Contingent consideration 33,265 0
Interest rate swap 0 0
Total liabilities measured at fair value $ 33,265 $ 13,431
XML 85 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Rollforward of Contingent Consideration (Details) - Contingent Consideration - Level 3 - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Beginning balance $ 13,431 $ 37,244 $ 2,328
Additions 33,265 3,838 71,559
Payments (15,130) (11,476) (2,889)
Total gains or losses (realized/unrealized):      
Adjustment of previously recorded contingent liability 1,810 (15,340) (33,386)
Foreign currency translation (111) (835) (368)
Ending balance $ 33,265 $ 13,431 $ 37,244
XML 86 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Narrative (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Mar. 30, 2023
Dec. 31, 2022
Nov. 30, 2022
Dec. 25, 2021
Dec. 26, 2020
Interest Rate Swap | Designated as Hedging Instrument            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Notional amount       $ 500,000    
Derivative, fixed interest rate   4.65%   4.70%    
Level 3 | Contingent Consideration            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair value of contingent consideration $ 33,265   $ 13,431   $ 37,244 $ 2,328
Weighted average probability percentage of achieving maximum target 34.00%          
Level 3 | Contingent Consideration | Average Volatility            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration, measurement input 0.30          
Level 3 | Contingent Consideration | Weighted Average Cost of Capital            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration, measurement input 0.12          
Maximum | Level 3 | Contingent Consideration            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair value of contingent consideration $ 98,000          
XML 87 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Schedule of Fair Value of Debt (Details) - Senior Notes - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 28, 2019
4.25% Senior Notes due 2028        
Debt Instrument [Line Items]        
Stated interest rate 4.25% 4.25%   4.25%
4.25% Senior Notes due 2028 | Book Value        
Debt Instrument [Line Items]        
Value of debt instruments $ 500,000 $ 500,000    
4.25% Senior Notes due 2028 | Fair Value        
Debt Instrument [Line Items]        
Value of debt instruments $ 478,100 $ 460,450    
3.75% Senior Notes due 2029        
Debt Instrument [Line Items]        
Stated interest rate 3.75% 3.75% 3.75%  
3.75% Senior Notes due 2029 | Book Value        
Debt Instrument [Line Items]        
Value of debt instruments $ 500,000 $ 500,000    
3.75% Senior Notes due 2029 | Fair Value        
Debt Instrument [Line Items]        
Value of debt instruments $ 458,100 $ 442,200    
4.00% Senior Notes due 2031        
Debt Instrument [Line Items]        
Stated interest rate 4.00% 4.00% 4.00%  
4.00% Senior Notes due 2031 | Book Value        
Debt Instrument [Line Items]        
Value of debt instruments $ 500,000 $ 500,000    
4.00% Senior Notes due 2031 | Fair Value        
Debt Instrument [Line Items]        
Value of debt instruments $ 449,350 $ 432,500    
XML 88 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Goodwill [Roll Forward]    
Gross carrying amount, beginning balance $ 2,849,903 $ 2,711,881
Acquisitions 209,478 215,160
Divestitures 0 (3,168)
Foreign exchange 35,664 (73,970)
Gross carrying amount, ending balance 3,095,045 2,849,903
Goodwill, impaired, accumulated impairment loss   1,000,000
RMS    
Goodwill [Roll Forward]    
Gross carrying amount, beginning balance 497,710 283,524
Acquisitions 0 215,752
Divestitures 0 0
Foreign exchange (236) (1,566)
Gross carrying amount, ending balance 497,474 497,710
DSA    
Goodwill [Roll Forward]    
Gross carrying amount, beginning balance 1,433,601 1,472,506
Acquisitions 209,478 0
Divestitures 0 0
Foreign exchange 19,355 (38,905)
Gross carrying amount, ending balance 1,662,434 1,433,601
Manufacturing    
Goodwill [Roll Forward]    
Gross carrying amount, beginning balance 918,592 955,851
Acquisitions 0 (592)
Divestitures 0 (3,168)
Foreign exchange 16,545 (33,499)
Gross carrying amount, ending balance $ 935,137 $ 918,592
XML 89 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Goodwill [Line Items]      
Goodwill impairment $ 0 $ 0 $ 0
Amortization of intangible assets $ 137,440,000 $ 146,578,000 $ 124,857,000
Biologic Solutions      
Goodwill [Line Items]      
Percentage of fair value in excess of carrying amount 20.00%    
XML 90 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Finite-lived intangible assets    
Gross $ 1,729,559 $ 1,687,390
Accumulated Amortization (865,508) (732,115)
Net 864,051 955,275
Client relationships    
Finite-lived intangible assets    
Gross 1,528,780 1,491,926
Accumulated Amortization (721,322) (591,417)
Net 807,458 900,509
Technology    
Finite-lived intangible assets    
Gross 142,190 129,626
Accumulated Amortization (111,764) (101,655)
Net 30,426 27,971
Backlog    
Finite-lived intangible assets    
Gross 3,100 15,236
Accumulated Amortization (2,177) (12,512)
Net 923 2,724
Trademarks and trade names    
Finite-lived intangible assets    
Gross 11,878 12,617
Accumulated Amortization (4,568) (4,410)
Net 7,310 8,207
Other    
Finite-lived intangible assets    
Gross 43,611 37,985
Accumulated Amortization (25,677) (22,121)
Net $ 17,934 $ 15,864
XML 91 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details)
$ in Thousands
Dec. 30, 2023
USD ($)
Estimated amortization expense for each of the next five fiscal years  
2024 $ 129,153
2025 120,995
2026 115,757
2027 103,164
2028 $ 91,315
XML 92 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT AND OTHER FINANCING ARRANGEMENTS - Long-term Debt, Net (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 28, 2019
Debt Instrument [Line Items]        
Long-term debt, gross $ 2,638,818      
Finance leases 28,550 $ 30,646    
Total debt and finance leases 2,667,368 2,729,826    
Current portion of long-term debt 3,172 1,347    
Current portion of finance leases 2,398 2,330    
Current portion of long-term debt and finance leases 5,570 3,677    
Long-term debt and finance leases 2,661,798 2,726,149    
Debt discount and debt issuance costs (14,651) (18,618)    
Long-term debt, net and finance leases 2,647,147 2,707,531    
Revolving Facility        
Debt Instrument [Line Items]        
Long-term debt, gross 1,129,243 1,197,586    
Other Debt        
Debt Instrument [Line Items]        
Long-term debt, gross $ 9,575 $ 1,594    
4.25% Senior Notes due 2028 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate 4.25% 4.25%   4.25%
Long-term debt, gross $ 500,000 $ 500,000    
3.75% Senior Notes due 2029 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate 3.75% 3.75% 3.75%  
Long-term debt, gross $ 500,000 $ 500,000    
4.00% Senior Notes due 2031 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate 4.00% 4.00% 4.00%  
Long-term debt, gross $ 500,000 $ 500,000    
XML 93 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) - USD ($)
 12 Months Ended
Jun. 26, 2021
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 28, 2019
Dec. 29, 2018
Debt Instrument [Line Items]            
Weighted average interest rate   4.93% 4.58%      
Extinguishment costs   $ (3,967,000) $ (4,118,000) $ (29,964,000)    
Deferred financing costs expensed   0 0 38,255,000    
Letter of Credit            
Debt Instrument [Line Items]            
Letters of credit outstanding   $ 21,600,000 $ 18,600,000      
Multi-currency Revolving Facility            
Debt Instrument [Line Items]            
Prepayments of long-term debt       135,000,000    
Multi-currency Revolving Facility | $3.0 Billion Credit Facility            
Debt Instrument [Line Items]            
Amount of credit facility $ 3,000,000,000          
Minimum EBITDA less capital expenditures to consolidated cash interest expense   3.50        
Maximum consolidated indebtedness to consolidated EBITDA, with step downs   4.25        
Multi-currency Revolving Facility | $3.0 Billion Credit Facility | Federal Funds Rate            
Debt Instrument [Line Items]            
Interest rate 0.50%          
Multi-currency Revolving Facility | $3.0 Billion Credit Facility | SOFR            
Debt Instrument [Line Items]            
Interest rate 1.00%          
Senior Notes | 4.25% Senior Notes due 2028            
Debt Instrument [Line Items]            
Aggregate principal amount         $ 500,000,000  
Stated interest rate   4.25% 4.25%   4.25%  
Senior Notes | 3.75% Senior Notes due 2029            
Debt Instrument [Line Items]            
Aggregate principal amount       $ 500,000,000    
Stated interest rate   3.75% 3.75% 3.75%    
Senior Notes | 4.00% Senior Notes due 2031            
Debt Instrument [Line Items]            
Aggregate principal amount       $ 500,000,000    
Stated interest rate   4.00% 4.00% 4.00%    
Senior Notes | Senior Notes Due 2026            
Debt Instrument [Line Items]            
Prepayments of long-term debt       $ 500,000,000    
Extinguishment costs       21,000,000    
Payments for accrued interest       13,000,000    
Deferred financing costs expensed       5,000,000    
Aggregate principal amount           $ 500,000,000
Senior Notes | Senior Notes Due 2029 And 2031            
Debt Instrument [Line Items]            
Extinguishment costs       21,000,000    
Payments for accrued interest       13,000,000    
Deferred financing costs expensed       10,000,000    
Aggregate principal amount       1,000,000,000    
Medium-term Notes            
Debt Instrument [Line Items]            
Prepayments of long-term debt       146,900,000    
Foreign Exchange Forward | Maximum            
Debt Instrument [Line Items]            
Notional amount     $ 400,000,000 400,000,000    
Foreign Exchange Forward | Minimum            
Debt Instrument [Line Items]            
Notional amount     $ 250,000,000 $ 250,000,000    
XML 94 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details) - Foreign Exchange Forward - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 25, 2021
Interest expense    
Derivatives, Fair Value [Line Items]    
Gain (loss) recognized in interest expense $ 49,712 $ 34,131
Other income (expense)    
Derivatives, Fair Value [Line Items]    
Gain (loss) recognized in interest expense $ (46,529) $ (31,830)
XML 95 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT AND OTHER FINANCING ARRANGEMENTS - Principal Maturities of Long Term Debt (Details)
$ in Thousands
Dec. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
2024 $ 3,172
2025 589
2026 1,129,772
2027 1,947
2028 501,947
Thereafter 1,001,391
Total $ 2,638,818
XML 96 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Numerator:      
Net income $ 480,370 $ 492,608 $ 398,837
Less: Net income attributable to noncontrolling interests 5,746 6,382 7,855
Net income attributable to common shareholders $ 474,624 $ 486,226 $ 390,982
Denominator:      
Weighted-average shares outstanding—Basic (in shares) 51,227 50,812 50,293
Effect of dilutive securities:      
Stock options, restricted stock, restricted stock units and performance share units (in shares) 224 489 1,132
Weighted-average shares outstanding—Diluted (in shares) 51,451 51,301 51,425
Antidilutive common stock equivalents (in shares) 652 560 152
XML 97 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) - USD ($)
shares in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]    
Shares acquired for individual minimum statutory tax withholding (in shares) 0.1 0.1
Value of shares acquired for individual minimum statutory tax withholding $ 24,200,000 $ 38,700,000
Authorized Share Repurchase Program    
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]    
Aggregate authorization of share repurchase program 1,300,000,000  
Amount remaining on the authorized share repurchase program $ 129,100,000  
XML 98 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Increase (Decrease) in Stockholders' Equity      
Beginning balance $ 2,981,078 $ 2,538,982 $ 2,118,169
Income tax (benefit) expense 4,071 (1,905) (3,965)
Ending balance 3,602,276 2,981,078 2,538,982
Foreign Currency Translation Adjustment and Other      
Increase (Decrease) in Stockholders' Equity      
Beginning balance (217,785) (98,173) (73,884)
Other comprehensive income (loss) before reclassifications 71,851 (125,507) (30,316)
Amounts reclassified from accumulated other comprehensive income 0 0 0
Net current period other comprehensive (loss) income 71,851 (125,507) (30,316)
Income tax (benefit) expense 4,065 (5,895) (6,027)
Ending balance (149,999) (217,785) (98,173)
Pension and Other Post-Retirement Benefit Plans      
Increase (Decrease) in Stockholders' Equity      
Beginning balance (43,114) (66,567) (64,990)
Other comprehensive income (loss) before reclassifications (5,376) 24,471 (1,193)
Amounts reclassified from accumulated other comprehensive income 736 3,337 1,678
Net current period other comprehensive (loss) income (4,640) 27,808 485
Income tax (benefit) expense (587) 4,355 2,062
Ending balance (47,167) (43,114) (66,567)
Net Unrealized Gain (Loss) on Cash Flow Hedge      
Increase (Decrease) in Stockholders' Equity      
Beginning balance (1,158) 0 0
Other comprehensive income (loss) before reclassifications 2,490 (1,523) 0
Amounts reclassified from accumulated other comprehensive income 0 0 0
Net current period other comprehensive (loss) income 2,490 (1,523) 0
Income tax (benefit) expense 593 (365) 0
Ending balance 739 (1,158) 0
Accumulated Other Comprehensive Income (Loss)      
Increase (Decrease) in Stockholders' Equity      
Beginning balance (262,057) (164,740) (138,874)
Other comprehensive income (loss) before reclassifications 68,965 (102,559) (31,509)
Amounts reclassified from accumulated other comprehensive income 736 3,337 1,678
Net current period other comprehensive (loss) income 69,701 (99,222) (29,831)
Income tax (benefit) expense 4,071 (1,905) (3,965)
Ending balance $ (196,427) $ (262,057) $ (164,740)
XML 99 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jun. 30, 2022
Dec. 30, 2023
Nov. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Schedule of Investments [Line Items]            
Redeemable noncontrolling interests   $ 56,722   $ 42,427 $ 53,010 $ 25,499
Noveprim Group            
Schedule of Investments [Line Items]            
Percentage of voting interests acquired     41.00%      
Noveprim Group            
Schedule of Investments [Line Items]            
Ownership percentage   90.00%        
Remaining ownership interest   10.00%        
Dividend fair value   $ 8,000        
Noveprim Group | Minimum            
Schedule of Investments [Line Items]            
Redeemable noncontrolling interest, contractually defined redemption value   47,000        
Noveprim Group | Maximum            
Schedule of Investments [Line Items]            
Redeemable noncontrolling interest, contractually defined redemption value   $ 54,000        
Vital River            
Schedule of Investments [Line Items]            
Ownership percentage       92.00%    
Remaining ownership interest   8.00%        
Payments for repurchase of redeemable noncontrolling interest   $ 4,800        
Redeemable noncontrolling interest, purchase price payable   24,400        
Supplier            
Schedule of Investments [Line Items]            
Ownership percentage           80.00%
Remaining ownership interest 10.00%         20.00%
Purchase price of additional equity interest $ 15,000          
Additional ownership percentage acquired by parent 10.00%          
Redeemable noncontrolling interests   $ 11,000        
XML 100 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Increase (Decrease) in Temporary Equity [Roll Forward]      
Beginning balance $ 42,427 $ 53,010 $ 25,499
Acquisition resulting in a 10% noncontrolling interest 45,374 0 0
Additional purchases reducing noncontrolling interest percentage (24,148) (15,000) 0
Adjustments to redemption value (5,694) 7,506 21,312
Net income 3,492 4,020 5,375
Dividends (2,378) (3,525) 0
Foreign currency translation (1,200) (3,584) 824
Other (1,151) 0 0
Ending balance $ 56,722 $ 42,427 $ 53,010
XML 101 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Income before income taxes:      
U.S.  $ 185,667 $ 280,075 $ 129,598
Non-U.S.  395,617 342,912 351,112
Income before income taxes 581,284 622,987 480,710
Current:      
Federal 49,090 75,052 32,728
Foreign 85,356 68,644 60,197
State 17,817 19,790 9,257
Total current 152,263 163,486 102,182
Deferred:      
Federal (42,987) (27,230) (27,486)
Foreign 779 (1,134) 13,891
State (9,141) (4,743) (6,714)
Total deferred (51,349) (33,107) (20,309)
Total provision for income taxes $ 100,914 $ 130,379 $ 81,873
XML 102 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Income Tax Disclosure [Abstract]      
U.S. statutory income tax rate 21.00% 21.00% 21.00%
Foreign tax rate differences 1.50% 0.40% 0.10%
State income taxes, net of federal tax benefit 1.70% 2.30% 0.80%
Non-deductible compensation 0.80% 0.90% 1.20%
Research tax credits and enhanced deductions (5.00%) (3.80%) (5.00%)
Stock-based compensation (0.10%) (1.40%) (4.30%)
Enacted tax rate changes (0.10%) 0.40% 3.00%
Tax on unremitted earnings 1.70% 1.60% 1.80%
Impact of tax uncertainties (0.30%) (1.30%) 0.70%
Impact of acquisitions and restructuring (4.20%) 2.00% (1.60%)
Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA) 0.20% (0.80%) 0.00%
Global intangible low-taxed income 1.50% 0.80% 1.30%
Foreign-derived intangible income (1.40%) (1.40%) (1.20%)
Other 0.10% 0.20% (0.80%)
Effective income tax rate 17.40% 20.90% 17.00%
XML 103 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Deferred Taxes (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Deferred tax assets:        
Compensation $ 30,167 $ 26,341    
Accruals and reserves 19,121 16,938    
Net operating loss and credit carryforwards 379,959 382,932    
Operating lease liability 117,449 100,156    
Capitalized R&D Expenditures 35,673 18,616    
Other 12,190 8,516    
Valuation allowance (304,248) (294,753) $ (315,645) $ (334,845)
Total deferred tax assets 290,311 258,746    
Deferred tax liabilities:        
Goodwill and other intangibles (231,020) (256,234)    
Depreciation related (57,791) (48,965)    
Venture capital investments (8,350) (12,007)    
Tax on unremitted earnings (25,080) (16,407)    
Right-of-use assets (102,620) (91,716)    
Other (16,520) (7,737)    
Total deferred tax liabilities (441,381) (433,066)    
Net deferred taxes $ (151,070) $ (174,320)    
XML 104 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Income Tax Contingency [Line Items]    
Decrease in unrecognized income tax benefits $ 500,000  
Unrecognized tax benefits that would impact effective tax rate 20,300,000 $ 20,300,000
Decrease in unrecognized tax benefits that is reasonably possible 5,200,000  
Accrued interest related to unrecognized income tax benefits 1,300,000 1,400,000
Accrued penalties related to unrecognized income tax benefits 0 0
Prepaid taxes 59,700,000 88,600,000
Accrued income taxes 38,800,000 39,900,000
Foreign Tax Authority    
Income Tax Contingency [Line Items]    
Deferred tax assets for net operating loss carryforwards 336,000,000 $ 336,600,000
Deferred tax assets, definite-lived and begin to expire 25,900,000  
Deferred tax assets, operating loss carryforwards, not subject to expiration 310,100,000  
Deferred tax assets for tax credit carryforwards 41,500,000  
Foreign Tax Authority | Tax Credit Carryforwards, Carried Forward Indefinitely    
Income Tax Contingency [Line Items]    
Deferred tax assets for tax credit carryforwards $ 41,500,000  
XML 105 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Valuation Allowance (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Deferred Tax Asset, Valuation Allowance [Roll Forward]      
Beginning balance $ 294,753 $ 315,645 $ 334,845
Additions (reductions) charged to income tax provision, net 963 1,929 1,023
Additions due to acquisitions 0 0 7,747
Reductions due to divestitures, restructuring 0 (5,337) (4,706)
Currency translation and other 8,532 (17,484) (23,264)
Ending balance $ 304,248 $ 294,753 $ 315,645
XML 106 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Change in Tax Positions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Reconciliation of Unrecognized Tax Benefits      
Beginning balance $ 23,242 $ 32,592 $ 24,970
Additions to tax positions for current year 3,093 4,756 9,544
Additions to tax positions for prior years 721 962 2,476
Reductions to tax positions for prior years (4,058) (1,420) (1,330)
Settlements 0 (10,514) (1,870)
Expiration of statute of limitations (296) (3,134) (1,198)
Ending balance $ 22,702 $ 23,242 $ 32,592
XML 107 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Defined Benefit Plan Disclosure [Line Items]      
Employer contributions to participants within plan assets $ 1,744,000 $ 4,558,000  
Net periodic benefit cost (income) $ 5,626,000 4,394,000 $ 4,886,000
Deferral period 3 years    
Maximum annual contributions per employee, percent 10.00%    
Period of highest consecutive years of compensation 5 years    
Costs associated with deferred compensation plan and executive supplemental life insurance retirement plans $ 2,800,000 4,300,000 4,300,000
Cash surrender value of life insurance policies 48,400,000 41,900,000  
Decrease in benefit obligations from new morality improvement scales 3,500,000 200,000  
Expected employer contributions in next fiscal year 2,000,000    
Costs associated with employee savings plan 31,600,000 28,800,000 24,000,000
U.K. Plan      
Defined Benefit Plan Disclosure [Line Items]      
Employer contributions to participants within plan assets 0    
Non-cash settlement charge related to pension losses, reclassified from AOCI to other expense   1,000,000  
U.K. Plan | Defined Benefit Plan, Funding Status      
Defined Benefit Plan Disclosure [Line Items]      
Employer contributions to participants within plan assets 35,700,000    
Pension Plans      
Defined Benefit Plan Disclosure [Line Items]      
Employer contributions to participants within plan assets 0    
Net periodic benefit cost (income) 2,800,000 $ 100,000 $ 500,000
Employer contributions to participants outside of plan assets $ 1,700,000    
Equity Securities      
Defined Benefit Plan Disclosure [Line Items]      
Target asset allocation percentage 7.00%    
Fixed Income Securities      
Defined Benefit Plan Disclosure [Line Items]      
Target asset allocation percentage 84.10%    
Other Securities      
Defined Benefit Plan Disclosure [Line Items]      
Target asset allocation percentage 8.90%    
XML 108 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Change in projected benefit obligations:      
Benefit obligation at beginning of year $ 205,551 $ 372,599  
Service cost 2,474 3,213 $ 3,455
Interest cost 9,941 6,140 5,492
Benefit payments (6,239) (6,469)  
Curtailment 0 (2,477)  
Settlements 0 (11,939)  
Transfer in due to acquisition 1,106 0  
Actuarial (gain) loss 3,600 (134,923)  
Effect of foreign exchange 8,442 (20,593)  
Benefit obligation at end of year 224,875 205,551 372,599
Change in fair value of plan assets:      
Fair value of plan assets at beginning of year 192,540 335,631  
Actual return on plan assets 5,578 (105,749)  
Employer contributions 1,744 4,558  
Settlements 0 (11,939)  
Transfer in due to acquisition 181 0  
Benefit payments (6,239) (6,469)  
Effect of foreign exchange 9,853 (23,492)  
Fair value of plan assets at end of year 203,657 192,540 $ 335,631
Net balance sheet liability 21,218 13,011  
Amounts recognized in balance sheet:      
Noncurrent assets 36,957 39,185  
Current liabilities 1,164 1,151  
Noncurrent liabilities $ 57,011 $ 51,045  
XML 109 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Amounts recognized in accumulated other comprehensive income (loss)    
Net actuarial loss $ 58,855 $ 54,509
Net prior service cost (credit) (121) (585)
Net amount recognized $ 58,734 $ 53,924
XML 110 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Plans with Accumulated Benefit Obligations in Excess of Plan Assets    
Accumulated benefit obligation $ 54,310 $ 48,414
Fair value of plan assets $ 2,824 $ 2,258
XML 111 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]    
Projected benefit obligation $ 61,671 $ 55,304
Fair value of plan assets $ 3,496 $ 3,108
XML 112 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Retirement Benefits [Abstract]      
Service cost $ 2,474 $ 3,213 $ 3,455
Defined benefit plan, net periodic benefit cost (credit) excluding service cost, statement of income or comprehensive income [extensible enumeration] Other income (expense), net    
Interest cost $ 9,941 6,140 5,492
Expected return on plan assets (7,556) (7,322) (8,058)
Amortization of prior service credit (464) (506) (531)
Amortization of net loss 1,231 2,869 4,528
Net periodic benefit cost 5,626 4,394 4,886
Settlement 0 981 (2,320)
Total benefit cost $ 5,626 $ 5,375 $ 2,566
XML 113 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Weighted-average assumptions used to determine projected benefit obligations      
Discount rate 4.70% 4.80%  
Rate of compensation increase 3.20% 3.20%  
Weighted-average assumptions used to determine net periodic benefit cost      
Discount rate 4.80% 1.80% 1.50%
Expected long-term return on plan assets 3.90% 2.40% 2.50%
Rate of compensation increase 3.20% 3.70% 3.00%
XML 114 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 203,657 $ 192,540 $ 335,631
Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,244 5,515  
Equity Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 10,701 9,308  
Debt Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 144,822 123,638  
Mutual Funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 19,575 17,752  
Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 27,315 36,327  
Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9,653 8,742  
Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 446 362  
Level 1 | Equity Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 1 | Debt Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 1 | Mutual Funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9,207 8,380  
Level 1 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 193,943 183,739  
Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 798 5,153  
Level 2 | Equity Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 10,701 9,308  
Level 2 | Debt Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 144,822 123,638  
Level 2 | Mutual Funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 10,368 9,372  
Level 2 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 27,254 36,268  
Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 61 59  
Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 3 | Equity Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 3 | Debt Securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 3 | Mutual Funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Level 3 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 61 $ 59  
XML 115 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details) - Pension Plans
$ in Thousands
Dec. 30, 2023
USD ($)
Defined Benefit Plan Disclosure [Line Items]  
2024 $ 6,558
2025 6,703
2026 46,898
2027 7,633
2028 8,843
2029-2033 $ 55,416
XML 116 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Maximum number of shares to be awarded (in shares) 4,100,000    
Capitalized stock-based compensation related costs $ 0 $ 0 $ 0
Weighted-average grant date fair value of stock options granted (in dollars per share) $ 80.98 $ 90.05 $ 108.61
Share-based compensation, before income taxes $ 72,048,000 $ 73,617,000 $ 71,474,000
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years 4 years 4 years
Unrecognized compensation cost related to unvested options $ 18,500,000    
Unrecognized compensation cost related to unvested awards, period for recognition 2 years 4 months 24 days    
Intrinsic value of options exercised $ 18,200,000 $ 33,200,000 $ 94,400,000
Stock Options | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock options, expiration period 5 years 5 years 5 years
Stock Options | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock options, expiration period 10 years 10 years 10 years
Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost related to unvested awards, period for recognition 2 years 9 months 18 days    
Unrecognized compensation cost related to unvested awards, excluding options $ 65,800,000    
Fair value of awards vested $ 28,400,000 $ 24,800,000 $ 22,800,000
Restricted Stock Units | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years 4 years 4 years
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Fair value of awards vested $ 34,400,000 $ 31,000,000 $ 26,000,000
Maximum number of common shares to be issued upon vesting of PSUs (in shares) 300,000    
Share-based compensation, before income taxes $ 28,100,000 $ 31,200,000 $ 31,800,000
PSUs | Performance Shares Grantee Group Two      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
PSUs granted (in shares)     5,000
Weighted average per share fair value (in dollars per share)     $ 477.52
PSUs | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years 3 years 3 years
Number of shares employee is entitled to receive at no cost (in shares) 0 0 0
XML 117 R97.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Stock-based compensation, before income taxes $ 72,048 $ 73,617 $ 71,474
Provision for income taxes (10,907) (10,969) (10,299)
Stock-based compensation, net of income taxes 61,141 62,648 61,175
Cost of revenue      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Stock-based compensation, before income taxes 15,052 14,853 13,087
Selling, general and administrative      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Stock-based compensation, before income taxes $ 56,996 $ 58,764 $ 58,387
XML 118 R98.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Stock Option Activities (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 30, 2023
USD ($)
$ / shares
shares
Number of shares  
Options outstanding, balance at the beginning of the period (in shares) | shares 882
Options granted (in shares) | shares 130
Options exercised (in shares) | shares (195)
Options canceled (in shares) | shares (28)
Options outstanding, balance at the end of the period (in shares) | shares 789
Weighted Average Exercise Price  
Options outstanding, balance at the beginning of the period (in dollars per share) | $ / shares $ 204.41
Options granted (in dollars per share) | $ / shares 194.27
Options exercised (in dollars per share) | $ / shares 130.91
Options canceled (in dollars per share) | $ / shares 259.63
Options outstanding, balance at the end of the period (in dollars per share) | $ / shares $ 218.97
Other Disclosures  
Options outstanding weighted average remaining contractual life 6 years 6 months
Options outstanding, aggregate intrinsic value | $ $ 28,935
Options exercisable (in shares) | shares 408
Options exercisable (in dollars per share) | $ / shares $ 205.50
Options exercisable, weighted average remaining contractual life 4 years 9 months 18 days
Options exercisable, aggregate intrinsic value | $ $ 20,521
Options expected to vest (in shares) | shares 381
Options expected to vest (in dollars per share) | $ / shares $ 233.37
Options expected to vest, weighted average remaining contractual life 8 years 3 months 18 days
Options expected to vest, aggregate intrinsic value | $ $ 8,414
XML 119 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Share-Based Payment Arrangement [Abstract]      
Expected life (in years) 6 years 6 years 6 years
Expected volatility 36.00% 33.00% 32.00%
Risk-free interest rate 3.80% 2.70% 1.00%
Expected dividend yield 0.00% 0.00% 0.00%
XML 120 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units
shares in Thousands
 12 Months Ended
Dec. 30, 2023
$ / shares
shares
Restricted Stock Units  
Balance at the beginning of the period (in shares) | shares 364
Granted (in shares) | shares 265
Vested (in shares) | shares (134)
Canceled (in shares) | shares (26)
Balance at the end of the period (in shares) | shares 469
Weighted Average Grant Date Fair Value  
Balance at the beginning of the period (in dollars per share) | $ / shares $ 226.43
Granted (in dollars per share) | $ / shares 194.84
Vested (in dollars per share) | $ / shares 212.34
Canceled (in dollars per share) | $ / shares 231.70
Balance at the end of the period (in dollars per share) | $ / shares $ 212.30
XML 121 R101.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details) - $ / shares
shares in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Key assumptions:      
Expected volatility 36.00% 33.00% 32.00%
Risk-free interest rate 3.80% 2.70% 1.00%
Expected dividend yield 0.00% 0.00% 0.00%
Trading day average stock price on grant date 20 days    
PSUs      
Key assumptions:      
Expected volatility 37.00% 39.00% 37.00%
Risk-free interest rate 4.20% 2.60% 0.20%
Expected dividend yield 0.00% 0.00% 0.00%
Total shareholder return of 20-trading day average stock price on grant date (9.80%) (32.70%) 39.90%
PSUs | PSU Grantee Group One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
PSUs granted (in shares) 146 134 64
Weighted average per share fair value (in dollars per share) $ 204.40 $ 210.42 $ 407.76
XML 122 R102.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Segment Reporting Information [Line Items]      
Total $ 29,682 $ 8,213 $ 6,856
Operating Segments | RMS      
Segment Reporting Information [Line Items]      
Total 3,479 1,007 7
Operating Segments | DSA      
Segment Reporting Information [Line Items]      
Total 16,176 851 3,114
Operating Segments | Manufacturing      
Segment Reporting Information [Line Items]      
Total 9,138 5,126 3,663
Unallocated corporate      
Segment Reporting Information [Line Items]      
Total $ 889 $ 1,229 $ 72
XML 123 R103.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Restructuring Cost and Reserve [Line Items]      
Total $ 29,682 $ 8,213 $ 6,856
Cost of services provided and products sold (excluding amortization of intangible assets) | Cost of services provided (excluding amortization of intangible assets)      
Restructuring Cost and Reserve [Line Items]      
Total 22,220 2,712 2,832
Cost of services provided and products sold (excluding amortization of intangible assets) | Cost of products sold (excluding amortization of intangible assets)      
Restructuring Cost and Reserve [Line Items]      
Total 4,408 2,297 0
Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total 3,054 3,204 4,024
Severance and Transition Costs      
Restructuring Cost and Reserve [Line Items]      
Total 11,608 3,901 4,717
Severance and Transition Costs | Cost of services provided and products sold (excluding amortization of intangible assets) | Cost of services provided (excluding amortization of intangible assets)      
Restructuring Cost and Reserve [Line Items]      
Total 7,408 928 1,898
Severance and Transition Costs | Cost of services provided and products sold (excluding amortization of intangible assets) | Cost of products sold (excluding amortization of intangible assets)      
Restructuring Cost and Reserve [Line Items]      
Total 1,146 532 0
Severance and Transition Costs | Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total 3,054 2,441 2,819
Asset Impairments and Other Costs      
Restructuring Cost and Reserve [Line Items]      
Total 18,074 4,312 2,139
Asset Impairments and Other Costs | Cost of services provided and products sold (excluding amortization of intangible assets) | Cost of services provided (excluding amortization of intangible assets)      
Restructuring Cost and Reserve [Line Items]      
Total 14,812 1,784 934
Asset Impairments and Other Costs | Cost of services provided and products sold (excluding amortization of intangible assets) | Cost of products sold (excluding amortization of intangible assets)      
Restructuring Cost and Reserve [Line Items]      
Total 3,262 1,765 0
Asset Impairments and Other Costs | Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total $ 0 $ 763 $ 1,205
XML 124 R104.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Restructuring Reserve [Roll Forward]      
Beginning balance $ 1,300 $ 4,011 $ 5,818
Expense (excluding non-cash charges) 11,539 6,732 5,695
Payments / utilization (7,800) (6,973) (5,604)
Other non-cash adjustments 0 (2,350) (1,831)
Foreign currency adjustments 11 (120) (67)
Ending balance $ 5,050 $ 1,300 $ 4,011
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of services provided and products sold, Selling, general and administrative Cost of services provided and products sold, Selling, general and administrative Cost of services provided and products sold, Selling, general and administrative
XML 125 R105.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Segment Reporting Information [Line Items]        
Severance and retention costs liability $ 5,050 $ 1,300 $ 4,011 $ 5,818
Accrued Compensation | Severance and Transition Costs        
Segment Reporting Information [Line Items]        
Severance and retention costs liability $ 5,100 $ 1,300    
XML 126 R106.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Operating lease right-of-use assets, net $ 394,029 $ 391,762
Other current liabilities 54,908 46,526
Operating lease right-of-use liabilities 419,234 389,745
Total operating lease liabilities 474,142 436,271
Property, plant and equipment, net 29,422 31,875
Current portion of long-term debt and finance leases 2,398 2,330
Long-term debt, net and finance leases 26,152 28,316
Total lease liabilities $ 28,550 $ 30,646
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other current liabilities Other current liabilities
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Property, plant and equipment, net Property, plant and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Long-term debt, net and finance leases Long-term debt, net and finance leases
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term debt, net and finance leases Long-term debt, net and finance leases
XML 127 R107.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Components of Operating and Finance Lease Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Leases [Abstract]      
Operating lease costs $ 65,380 $ 59,671 $ 45,728
Amortization of right-of-use assets 2,745 3,035 3,337
Interest on lease liabilities 1,477 1,441 1,280
Short-term lease costs 3,581 2,954 2,441
Variable lease costs 22,159 13,965 4,623
Sublease income (2,067) (1,912) (2,008)
Total lease costs $ 93,275 $ 79,154 $ 55,401
XML 128 R108.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Cash flows included in the measurement of lease liabilities:      
Operating cash flows from operating leases $ 60,239 $ 48,360 $ 42,576
Operating cash flows from finance leases 1,476 1,442 1,282
Finance cash flows from finance leases 2,297 2,257 3,202
Non-cash leases activity:      
Right-of-use lease assets obtained in exchange for new operating lease liabilities 75,987 189,134 142,764
Right-of-use lease assets obtained in exchange for new finance lease liabilities $ 0 $ 8,179 $ 1,567
XML 129 R109.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Weighted-average remaining lease term (in years)      
Operating lease 9 years 7 months 6 days 9 years 9 months 18 days 9 years
Finance lease 12 years 8 months 12 days 13 years 7 months 6 days 11 years 8 months 12 days
Weighted-average discount rate      
Operating lease 4.70% 4.30% 3.60%
Finance lease 5.30% 5.30% 4.40%
XML 130 R110.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Operating Leases    
2024 $ 70,578  
2025 63,433  
2026 58,494  
2027 59,946  
2028 57,953  
Thereafter 286,215  
Total minimum future lease payments 596,619  
Less: Imputed interest 122,477  
Total operating lease liabilities 474,142 $ 436,271
Finance Leases    
2024 3,796  
2025 3,513  
2026 3,038  
2027 2,999  
2028 2,988  
Thereafter 23,562  
Total minimum future lease payments 39,896  
Less: Imputed interest 11,346  
Total lease liabilities $ 28,550 $ 30,646
XML 131 R111.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Additional Information (Details)
$ in Millions
Dec. 30, 2023
USD ($)
Lessor, Lease, Description [Line Items]  
Future minimum lease payments for leases that have not yet commenced $ 161.0
Minimum  
Lessor, Lease, Description [Line Items]  
Terms for leases that have not yet commenced 5 years
Maximum  
Lessor, Lease, Description [Line Items]  
Terms for leases that have not yet commenced 15 years
XML 132 R112.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES - Additional Information (Details)
$ in Millions
 12 Months Ended
Dec. 30, 2023
USD ($)
Loss Contingencies [Line Items]  
Deductible amount under insurance policies $ 2.0
Certain property insurance, deductibles 22.0
Representation and warranty insurance, maximum deductible 4.0
Unconditional purchase obligations 390.0
Pending Litigation | US Fish and Wildlife Service  
Loss Contingencies [Line Items]  
Inventory shipment carrying value $ 27.0
EXCEL 134 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 135 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 136 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 138 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 491 663 1 false 117 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.crl.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.crl.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 8 false false R9.htm 0000009 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - ACQUISITIONS AND DIVESTITURES Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURES ACQUISITIONS AND DIVESTITURES Notes 10 false false R11.htm 0000011 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS Sheet http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS REVENUE FROM CONTRACTS WITH CUSTOMERS Notes 11 false false R12.htm 0000012 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Sheet http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATION SEGMENT AND GEOGRAPHIC INFORMATION Notes 12 false false R13.htm 0000013 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Sheet http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATION SUPPLEMENTAL CASH FLOW INFORMATION Notes 13 false false R14.htm 0000014 - Disclosure - INVENTORY Sheet http://www.crl.com/role/INVENTORY INVENTORY Notes 14 false false R15.htm 0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET Sheet http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNET PROPERTY, PLANT AND EQUIPMENT, NET Notes 15 false false R16.htm 0000016 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Sheet http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTS VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Notes 16 false false R17.htm 0000017 - Disclosure - FAIR VALUE Sheet http://www.crl.com/role/FAIRVALUE FAIR VALUE Notes 17 false false R18.htm 0000018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 18 false false R19.htm 0000019 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS Sheet http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTS DEBT AND OTHER FINANCING ARRANGEMENTS Notes 19 false false R20.htm 0000020 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTS EQUITY AND NONCONTROLLING INTERESTS Notes 20 false false R21.htm 0000021 - Disclosure - INCOME TAXES Sheet http://www.crl.com/role/INCOMETAXES INCOME TAXES Notes 21 false false R22.htm 0000022 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 22 false false R23.htm 0000023 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 23 false false R24.htm 0000024 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS Sheet http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTS RESTRUCTURING AND ASSET IMPAIRMENTS Notes 24 false false R25.htm 0000025 - Disclosure - LEASES Sheet http://www.crl.com/role/LEASES LEASES Notes 25 false false R26.htm 0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.crl.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 26 false false R27.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 27 false false R28.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 28 false false R29.htm 9954471 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 29 false false R30.htm 9954472 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 30 false false R31.htm 9954473 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables) Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTables ACQUISITIONS AND DIVESTITURES (Tables) Tables http://www.crl.com/role/ACQUISITIONSANDDIVESTITURES 31 false false R32.htm 9954474 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) Sheet http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) Tables http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS 32 false false R33.htm 9954475 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Sheet http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Tables http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATION 33 false false R34.htm 9954476 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Sheet http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Tables http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATION 34 false false R35.htm 9954477 - Disclosure - INVENTORY (Tables) Sheet http://www.crl.com/role/INVENTORYTables INVENTORY (Tables) Tables http://www.crl.com/role/INVENTORY 35 false false R36.htm 9954478 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) Sheet http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETTables PROPERTY, PLANT AND EQUIPMENT, NET (Tables) Tables http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNET 36 false false R37.htm 9954479 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Tables) Sheet http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSTables VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Tables) Tables http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTS 37 false false R38.htm 9954480 - Disclosure - FAIR VALUE (Tables) Sheet http://www.crl.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.crl.com/role/FAIRVALUE 38 false false R39.htm 9954481 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETS 39 false false R40.htm 9954482 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS (Tables) Sheet http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSTables DEBT AND OTHER FINANCING ARRANGEMENTS (Tables) Tables http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTS 40 false false R41.htm 9954483 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS (Tables) Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSTables EQUITY AND NONCONTROLLING INTERESTS (Tables) Tables http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTS 41 false false R42.htm 9954484 - Disclosure - INCOME TAXES (Tables) Sheet http://www.crl.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.crl.com/role/INCOMETAXES 42 false false R43.htm 9954485 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables EMPLOYEE BENEFIT PLANS (Tables) Tables http://www.crl.com/role/EMPLOYEEBENEFITPLANS 43 false false R44.htm 9954486 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.crl.com/role/STOCKBASEDCOMPENSATION 44 false false R45.htm 9954487 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS (Tables) Sheet http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSTables RESTRUCTURING AND ASSET IMPAIRMENTS (Tables) Tables http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTS 45 false false R46.htm 9954488 - Disclosure - LEASES (Tables) Sheet http://www.crl.com/role/LEASESTables LEASES (Tables) Tables http://www.crl.com/role/LEASES 46 false false R47.htm 9954489 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 47 false false R48.htm 9954490 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Life (Details) Sheet http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Life (Details) Details 48 false false R49.htm 9954491 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details) Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails ACQUISITIONS AND DIVESTITURES - Narrative (Details) Details 49 false false R50.htm 9954492 - Disclosure - ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details) Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details) Details 50 false false R51.htm 9954493 - Disclosure - ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details) Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details) Details 51 false false R52.htm 9954494 - Disclosure - ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details) Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTransactionandIntegrationCostsDetails ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details) Details 52 false false R53.htm 9954495 - Disclosure - ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details) Sheet http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details) Details 53 false false R54.htm 9954496 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) Sheet http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) Details 54 false false R55.htm 9954497 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) Sheet http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) Details 55 false false R56.htm 9954498 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Sheet http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Details 56 false false R57.htm 9954499 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details) Sheet http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details) Details 57 false false R58.htm 9954500 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details) Sheet http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details) Details 58 false false R59.htm 9954501 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details) Sheet http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details) Details 59 false false R60.htm 9954502 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 60 false false R61.htm 9954503 - Disclosure - INVENTORY (Details) Sheet http://www.crl.com/role/INVENTORYDetails INVENTORY (Details) Details http://www.crl.com/role/INVENTORYTables 61 false false R62.htm 9954504 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Details) Sheet http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails PROPERTY, PLANT AND EQUIPMENT, NET (Details) Details http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETTables 62 false false R63.htm 9954505 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Venture Capital Investments and Strategic Investments (Details) Sheet http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Venture Capital Investments and Strategic Investments (Details) Details 63 false false R64.htm 9954506 - Disclosure - FAIR VALUE - Fair Value of Assets and Liabilities (Details) Sheet http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails FAIR VALUE - Fair Value of Assets and Liabilities (Details) Details 64 false false R65.htm 9954507 - Disclosure - FAIR VALUE - Rollforward of Contingent Consideration (Details) Sheet http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails FAIR VALUE - Rollforward of Contingent Consideration (Details) Details 65 false false R66.htm 9954508 - Disclosure - FAIR VALUE - Narrative (Details) Sheet http://www.crl.com/role/FAIRVALUENarrativeDetails FAIR VALUE - Narrative (Details) Details 66 false false R67.htm 9954509 - Disclosure - FAIR VALUE - Schedule of Fair Value of Debt (Details) Sheet http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails FAIR VALUE - Schedule of Fair Value of Debt (Details) Details 67 false false R68.htm 9954510 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details) Sheet http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details) Details 68 false false R69.htm 9954511 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 69 false false R70.htm 9954512 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details) Sheet http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details) Details 70 false false R71.htm 9954513 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details) Sheet http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details) Details 71 false false R72.htm 9954514 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Long-term Debt, Net (Details) Sheet http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails DEBT AND OTHER FINANCING ARRANGEMENTS - Long-term Debt, Net (Details) Details 72 false false R73.htm 9954515 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) Sheet http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) Details 73 false false R74.htm 9954516 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details) Sheet http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details) Details 74 false false R75.htm 9954517 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Principal Maturities of Long Term Debt (Details) Sheet http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails DEBT AND OTHER FINANCING ARRANGEMENTS - Principal Maturities of Long Term Debt (Details) Details 75 false false R76.htm 9954518 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details) Details 76 false false R77.htm 9954519 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) Details 77 false false R78.htm 9954520 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details) Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details) Details 78 false false R79.htm 9954521 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details) Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details) Details 79 false false R80.htm 9954522 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) Sheet http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) Details 80 false false R81.htm 9954523 - Disclosure - INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details) Sheet http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details) Details 81 false false R82.htm 9954524 - Disclosure - INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details) Sheet http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details) Details 82 false false R83.htm 9954525 - Disclosure - INCOME TAXES - Deferred Taxes (Details) Sheet http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails INCOME TAXES - Deferred Taxes (Details) Details 83 false false R84.htm 9954526 - Disclosure - INCOME TAXES - Additional Information (Details) Sheet http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails INCOME TAXES - Additional Information (Details) Details 84 false false R85.htm 9954527 - Disclosure - INCOME TAXES - Valuation Allowance (Details) Sheet http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails INCOME TAXES - Valuation Allowance (Details) Details 85 false false R86.htm 9954528 - Disclosure - INCOME TAXES - Change in Tax Positions (Details) Sheet http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails INCOME TAXES - Change in Tax Positions (Details) Details 86 false false R87.htm 9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Additional Information (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails EMPLOYEE BENEFIT PLANS - Additional Information (Details) Details 87 false false R88.htm 9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details) Details 88 false false R89.htm 9954531 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) Details 89 false false R90.htm 9954532 - Disclosure - EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSAccumulatedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithAccumulatedBenefitObligationsinExcessofPlanAssetsDetails EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details) Details 90 false false R91.htm 9954533 - Disclosure - EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSProjectedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithProjectedBenefitObligationsinExcessofPlanAssetsDetails EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details) Details 91 false false R92.htm 9954534 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details) Details 92 false false R93.htm 9954535 - Disclosure - EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details) Details 93 false false R94.htm 9954536 - Disclosure - EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details) Details 94 false false R95.htm 9954537 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details) Sheet http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details) Details 95 false false R96.htm 9954538 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails STOCK-BASED COMPENSATION - Additional Information (Details) Details 96 false false R97.htm 9954539 - Disclosure - STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details) Details 97 false false R98.htm 9954540 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activities (Details) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails STOCK-BASED COMPENSATION - Stock Option Activities (Details) Details 98 false false R99.htm 9954541 - Disclosure - STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionsWeightedAverageAssumptionsDetails STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details) Details 99 false false R100.htm 9954542 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details) Details 100 false false R101.htm 9954543 - Disclosure - STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details) Sheet http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details) Details 101 false false R102.htm 9954544 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details) Sheet http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details) Details 102 false false R103.htm 9954545 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details) Sheet http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details) Details 103 false false R104.htm 9954546 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) Sheet http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) Details 104 false false R105.htm 9954547 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) Sheet http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) Details 105 false false R106.htm 9954548 - Disclosure - LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) Sheet http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) Details 106 false false R107.htm 9954549 - Disclosure - LEASES - Components of Operating and Finance Lease Costs (Details) Sheet http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails LEASES - Components of Operating and Finance Lease Costs (Details) Details 107 false false R108.htm 9954550 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 108 false false R109.htm 9954551 - Disclosure - LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details) Sheet http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details) Details 109 false false R110.htm 9954552 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) Sheet http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) Details 110 false false R111.htm 9954553 - Disclosure - LEASES - Additional Information (Details) Sheet http://www.crl.com/role/LEASESAdditionalInformationDetails LEASES - Additional Information (Details) Details 111 false false R112.htm 9954554 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Sheet http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Details 112 false false All Reports Book All Reports crl-20231230.htm crl-20231230.xsd crl-20231230_cal.xml crl-20231230_def.xml crl-20231230_lab.xml crl-20231230_pre.xml crl-20231230_g1.jpg crl-20231230_g2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 141 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "crl-20231230.htm": { "nsprefix": "crl", "nsuri": "http://www.crl.com/20231230", "dts": { "inline": { "local": [ "crl-20231230.htm" ] }, "schema": { "local": [ "crl-20231230.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "crl-20231230_cal.xml" ] }, "definitionLink": { "local": [ "crl-20231230_def.xml" ] }, "labelLink": { "local": [ "crl-20231230_lab.xml" ] }, "presentationLink": { "local": [ "crl-20231230_pre.xml" ] } }, "keyStandard": 573, "keyCustom": 90, "axisStandard": 42, "axisCustom": 1, "memberStandard": 72, "memberCustom": 44, "hidden": { "total": 22, "http://fasb.org/us-gaap/2023": 16, "http://xbrl.sec.gov/dei/2023": 4, "http://www.crl.com/20231230": 2 }, "contextCount": 491, "entityCount": 1, "segmentCount": 117, "elementCount": 1070, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1881, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 19 }, "report": { "R1": { "role": "http://www.crl.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.crl.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R4": { "role": "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R5": { "role": "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R6": { "role": "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R7": { "role": "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R8": { "role": "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURES", "longName": "0000010 - Disclosure - ACQUISITIONS AND DIVESTITURES", "shortName": "ACQUISITIONS AND DIVESTITURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS", "longName": "0000011 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATION", "longName": "0000012 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATION", "longName": "0000013 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.crl.com/role/INVENTORY", "longName": "0000014 - Disclosure - INVENTORY", "shortName": "INVENTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNET", "longName": "0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTS", "longName": "0000016 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS", "shortName": "VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "crl:InvestmentsInLimitedPartnershipsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:InvestmentsInLimitedPartnershipsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.crl.com/role/FAIRVALUE", "longName": "0000017 - Disclosure - FAIR VALUE", "shortName": "FAIR VALUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "0000018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTS", "longName": "0000019 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS", "shortName": "DEBT AND OTHER FINANCING ARRANGEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTS", "longName": "0000020 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS", "shortName": "EQUITY AND NONCONTROLLING INTERESTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.crl.com/role/INCOMETAXES", "longName": "0000021 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANS", "longName": "0000022 - Disclosure - EMPLOYEE BENEFIT PLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATION", "longName": "0000023 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTS", "longName": "0000024 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS", "shortName": "RESTRUCTURING AND ASSET IMPAIRMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.crl.com/role/LEASES", "longName": "0000025 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000026 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-482", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-482", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "crl:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTables", "longName": "9954473 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables)", "shortName": "ACQUISITIONS AND DIVESTITURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables", "longName": "9954474 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R33": { "role": "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables", "longName": "9954475 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables", "longName": "9954476 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.crl.com/role/INVENTORYTables", "longName": "9954477 - Disclosure - INVENTORY (Tables)", "shortName": "INVENTORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETTables", "longName": "9954478 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSTables", "longName": "9954479 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Tables)", "shortName": "VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.crl.com/role/FAIRVALUETables", "longName": "9954480 - Disclosure - FAIR VALUE (Tables)", "shortName": "FAIR VALUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954481 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSTables", "longName": "9954482 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)", "shortName": "DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSTables", "longName": "9954483 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS (Tables)", "shortName": "EQUITY AND NONCONTROLLING INTERESTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.crl.com/role/INCOMETAXESTables", "longName": "9954484 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "crl:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables", "longName": "9954485 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)", "shortName": "EMPLOYEE BENEFIT PLANS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954486 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSTables", "longName": "9954487 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)", "shortName": "RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.crl.com/role/LEASESTables", "longName": "9954488 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "crl:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9954489 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:LifeSettlementContractsInvestmentMethodNumberOfContracts", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R48": { "role": "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "longName": "9954490 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Life (Details)", "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-66", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "crl:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-66", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "crl:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "longName": "9954491 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R50": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "longName": "9954492 - Disclosure - ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-107", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "longName": "9954493 - Disclosure - ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-117", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-117", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTransactionandIntegrationCostsDetails", "longName": "9954494 - Disclosure - ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Transaction and Integration Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "crl:BusinessCombinationIntegrationRelatedCostsAndTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:BusinessCombinationIntegrationRelatedCostsAndTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails", "longName": "9954495 - Disclosure - ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-136", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "longName": "9954496 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details)", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-137", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R55": { "role": "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails", "longName": "9954497 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details)", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-12", "name": "crl:TradeReceivablesFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "crl:TradeReceivablesFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "longName": "9954498 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-12", "name": "crl:ContractWithCustomerUnpaidAdvancedClientBillings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "crl:ContractWithCustomerUnpaidAdvancedClientBillings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails", "longName": "9954499 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-174", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R58": { "role": "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails", "longName": "9954500 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R59": { "role": "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails", "longName": "9954501 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails", "longName": "9954502 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R61": { "role": "http://www.crl.com/role/INVENTORYDetails", "longName": "9954503 - Disclosure - INVENTORY (Details)", "shortName": "INVENTORY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails", "longName": "9954504 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails", "longName": "9954505 - Disclosure - VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Venture Capital Investments and Strategic Investments (Details)", "shortName": "VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Venture Capital Investments and Strategic Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:EquityMethodInvestmentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R64": { "role": "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails", "longName": "9954506 - Disclosure - FAIR VALUE - Fair Value of Assets and Liabilities (Details)", "shortName": "FAIR VALUE - Fair Value of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-240", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-240", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails", "longName": "9954507 - Disclosure - FAIR VALUE - Rollforward of Contingent Consideration (Details)", "shortName": "FAIR VALUE - Rollforward of Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-245", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:FairValueContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-248", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:FairValueContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R66": { "role": "http://www.crl.com/role/FAIRVALUENarrativeDetails", "longName": "9954508 - Disclosure - FAIR VALUE - Narrative (Details)", "shortName": "FAIR VALUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-255", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-255", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails", "longName": "9954509 - Disclosure - FAIR VALUE - Schedule of Fair Value of Debt (Details)", "shortName": "FAIR VALUE - Schedule of Fair Value of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-257", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-259", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R68": { "role": "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails", "longName": "9954510 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R69": { "role": "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "longName": "9954511 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails", "longName": "9954512 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails", "longName": "9954513 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "longName": "9954514 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Long-term Debt, Net (Details)", "shortName": "DEBT AND OTHER FINANCING ARRANGEMENTS - Long-term Debt, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "crl:LongTermDebtGrossAndLeaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R73": { "role": "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "longName": "9954515 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details)", "shortName": "DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DebtWeightedAverageInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DebtWeightedAverageInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "longName": "9954516 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details)", "shortName": "DEBT AND OTHER FINANCING ARRANGEMENTS - Cross Currency Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-316", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-316", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails", "longName": "9954517 - Disclosure - DEBT AND OTHER FINANCING ARRANGEMENTS - Principal Maturities of Long Term Debt (Details)", "shortName": "DEBT AND OTHER FINANCING ARRANGEMENTS - Principal Maturities of Long Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails", "longName": "9954518 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details)", "shortName": "EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R77": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails", "longName": "9954519 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details)", "shortName": "EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails", "longName": "9954520 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details)", "shortName": "EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-323", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R79": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails", "longName": "9954521 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details)", "shortName": "EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R80": { "role": "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails", "longName": "9954522 - Disclosure - EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details)", "shortName": "EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:TemporaryEquityAcquisitionOfNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R81": { "role": "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails", "longName": "9954523 - Disclosure - INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details)", "shortName": "INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails", "longName": "9954524 - Disclosure - INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details)", "shortName": "INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails", "longName": "9954525 - Disclosure - INCOME TAXES - Deferred Taxes (Details)", "shortName": "INCOME TAXES - Deferred Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails", "longName": "9954526 - Disclosure - INCOME TAXES - Additional Information (Details)", "shortName": "INCOME TAXES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails", "longName": "9954527 - Disclosure - INCOME TAXES - Valuation Allowance (Details)", "shortName": "INCOME TAXES - Valuation Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:DeferredTaxAssetValuationAllowanceAdditionsDeductionsForIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:DeferredTaxAssetsValuationAllowanceTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R86": { "role": "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails", "longName": "9954528 - Disclosure - INCOME TAXES - Change in Tax Positions (Details)", "shortName": "INCOME TAXES - Change in Tax Positions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:ScheduleOfUnrecognizedTaxBenefitsRollTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:ScheduleOfUnrecognizedTaxBenefitsRollTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R87": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "longName": "9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Additional Information (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:DeferredCompensationArrangementWithIndividualDeferralPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R88": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails", "longName": "9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R89": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "longName": "9954531 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAccumulatedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithAccumulatedBenefitObligationsinExcessofPlanAssetsDetails", "longName": "9954532 - Disclosure - EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSProjectedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithProjectedBenefitObligationsinExcessofPlanAssetsDetails", "longName": "9954533 - Disclosure - EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails", "longName": "9954534 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R93": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails", "longName": "9954535 - Disclosure - EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "longName": "9954536 - Disclosure - EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:FairValueofPensionPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-368", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:FairValueofPensionPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R95": { "role": "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails", "longName": "9954537 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-408", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-408", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "longName": "9954538 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)", "shortName": "STOCK-BASED COMPENSATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails", "longName": "9954539 - Disclosure - STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details)", "shortName": "STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R98": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails", "longName": "9954540 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activities (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock Option Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionsWeightedAverageAssumptionsDetails", "longName": "9954541 - Disclosure - STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails", "longName": "9954542 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-434", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-434", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "longName": "9954543 - Disclosure - STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details)", "shortName": "STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:TradingDayAverageStockPriceOnGrantDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R102": { "role": "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "longName": "9954544 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details)", "shortName": "RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R103": { "role": "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails", "longName": "9954545 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details)", "shortName": "RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-451", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R104": { "role": "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails", "longName": "9954546 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details)", "shortName": "RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R105": { "role": "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "longName": "9954547 - Disclosure - RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details)", "shortName": "RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-479", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R106": { "role": "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails", "longName": "9954548 - Disclosure - LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details)", "shortName": "LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "crl:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "unique": true } }, "R107": { "role": "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails", "longName": "9954549 - Disclosure - LEASES - Components of Operating and Finance Lease Costs (Details)", "shortName": "LEASES - Components of Operating and Finance Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails", "longName": "9954550 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails", "longName": "9954551 - Disclosure - LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)", "shortName": "LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails", "longName": "9954552 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details)", "shortName": "LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R111": { "role": "http://www.crl.com/role/LEASESAdditionalInformationDetails", "longName": "9954553 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-12", "name": "crl:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "crl:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } }, "R112": { "role": "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "longName": "9954554 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-1", "name": "crl:InsurancePoliciesDeductible", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "crl:InsurancePoliciesDeductible", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "crl-20231230.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r56", "r1097" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r313", "r421", "r422", "r1051" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and contract assets, net of allowances for credit losses of $25,722 and $11,278, respectively", "totalLabel": "Trade receivables and contract assets, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r421", "r422" ] }, "crl_AccruedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "AccruedCompensationMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Compensation", "label": "Accrued Compensation [Member]", "documentation": "Accrued Compensation [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxes", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes." } } }, "auth_ref": [ "r196", "r197", "r257", "r268", "r823" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r59" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Post-Retirement Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r12", "r35", "r69", "r1213", "r1214", "r1215" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r101", "r307", "r834" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Unrealized Gain (Loss) on Cash Flow Hedge", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r324", "r332", "r333", "r736", "r1057", "r1213" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r331", "r332", "r772", "r774", "r775", "r776", "r777", "r778" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r68", "r69", "r210", "r314", "r829", "r869", "r870" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r331", "r332", "r772", "r774", "r775", "r776", "r777", "r778" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r9", "r35", "r69", "r746", "r749", "r803", "r865", "r866", "r1213", "r1214", "r1215", "r1226", "r1227", "r1228" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustment and Other", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r11", "r35", "r69", "r332", "r333", "r774", "r775", "r776", "r777", "r778", "r1213" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Amortization Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r231" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1156" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r202" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r683", "r684", "r685", "r879", "r1226", "r1227", "r1228", "r1347", "r1370" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1162" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1162" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1162" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1162" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of shares acquired for individual minimum statutory tax withholding", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r130", "r131", "r644" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1126", "r1138", "r1148", "r1174" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1129", "r1141", "r1151", "r1177" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1162" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1169" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1133", "r1142", "r1152", "r1169", "r1178", "r1182", "r1190" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1188" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation, before income taxes", "terseLabel": "Stock-based compensation, before income taxes", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r677", "r690" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation, net of income taxes", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "negatedLabel": "Less: Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r315", "r425", "r438" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r23", "r95", "r98" ] }, "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total benefit cost", "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive common stock equivalents (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r377" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1372", "r1374", "r1375", "r1376" ] }, "crl_AssetImpairmentAndOtherCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "AssetImpairmentAndOtherCostsMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairments and Other Costs", "label": "Asset Impairment And Other Costs [Member]", "documentation": "Asset Impairment And Other Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r266", "r311", "r349", "r385", "r406", "r412", "r432", "r483", "r484", "r486", "r487", "r488", "r490", "r492", "r494", "r495", "r732", "r738", "r766", "r822", "r915", "r1097", "r1115", "r1258", "r1259", "r1357" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "crl_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.crl.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r302", "r319", "r349", "r432", "r483", "r484", "r486", "r487", "r488", "r490", "r492", "r494", "r495", "r732", "r738", "r766", "r1097", "r1258", "r1259", "r1357" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "verboseLabel": "Current assets measured at fair value:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r170" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r8", "r185", "r191", "r238", "r300", "r301" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r8", "r185", "r191", "r235", "r238", "r300", "r301" ] }, "crl_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.crl.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1120", "r1121", "r1134" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.crl.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1120", "r1121", "r1134" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.crl.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1120", "r1121", "r1134" ] }, "crl_AuthorizedShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "AuthorizedShareRepurchaseProgramMember", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized Share Repurchase Program", "label": "Authorized Share Repurchase Program [Member]", "documentation": "Authorized Share Repurchase Program [Member]" } } }, "auth_ref": [] }, "crl_AvianMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "AvianMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avian", "label": "Avian [Member]", "documentation": "Avian" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1185" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1186" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1181" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1181" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1181" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1181" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1181" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1181" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r648", "r649", "r650", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r673", "r674", "r675", "r676" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1184" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1183" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1182" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1182" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r160", "r164" ] }, "crl_BiologicSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BiologicSolutionsMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biologic Solutions", "label": "Biologic Solutions [Member]", "documentation": "Biologic Solutions" } } }, "auth_ref": [] }, "crl_BiologicalAssetsUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BiologicalAssetsUsefulLife", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biological assets, useful life", "label": "Biological Assets, Useful Life", "documentation": "Biological Assets, Useful Life" } } }, "auth_ref": [] }, "crl_BirgitGirshickMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BirgitGirshickMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Birgit Girshick [Member]", "documentation": "Birgit Girshick" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and building improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r236" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r727", "r1084", "r1087" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r138", "r141", "r727", "r1084", "r1087" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r727" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interests acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r139" ] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill resulting from transaction", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": [ "r148" ] }, "crl_BusinessCombinationAdjustmentsForWorkingCapitalDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationAdjustmentsForWorkingCapitalDebt", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for working capital/debt", "label": "Business Combination, Adjustments for Working Capital/Debt", "documentation": "Business Combination, Adjustments for Working Capital/Debt" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "crl_BusinessCombinationConsiderationLiabilityContingentUponFuturePerformance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationConsiderationLiabilityContingentUponFuturePerformance", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration contingent upon future performance", "label": "Business Combination, Consideration Liability Contingent Upon Future Performance", "documentation": "Business Combination, Consideration Liability Contingent Upon Future Performance" } } }, "auth_ref": [] }, "crl_BusinessCombinationConsiderationLiabilityContingentUponFuturePerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationConsiderationLiabilityContingentUponFuturePerformancePeriod", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, consideration liability contingent upon future performance, period", "label": "Business Combination, Consideration Liability Contingent Upon Future Performance, Period", "documentation": "Business Combination, Consideration Liability Contingent Upon Future Performance, Period" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r3", "r4", "r31" ] }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredOther1", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, consideration transferred, other", "label": "Business Combination, Consideration Transferred, Other", "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash." } } }, "auth_ref": [ "r32" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of contingent consideration arrangements", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r730", "r1220" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r5", "r147", "r729" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r6", "r147" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, measurement input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r760" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r6", "r147" ] }, "crl_BusinessCombinationDeferredPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationDeferredPurchasePrice", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination deferred purchase price", "label": "Business Combination, Deferred Purchase Price", "documentation": "Business Combination, Deferred Purchase Price" } } }, "auth_ref": [] }, "crl_BusinessCombinationIntegrationRelatedCostsAndTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationIntegrationRelatedCostsAndTransactionCosts", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTransactionandIntegrationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Business Combination, Integration Related Costs And Transaction Costs", "documentation": "Business Combination, Integration Related Costs And Transaction Costs" } } }, "auth_ref": [] }, "crl_BusinessCombinationOwnershipPercentageNotAcquired": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationOwnershipPercentageNotAcquired", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage not acquired", "label": "Business Combination, Ownership Percentage Not Acquired", "documentation": "Business Combination, Ownership Percentage Not Acquired" } } }, "auth_ref": [] }, "crl_BusinessCombinationPutOptionTermPeriodAfterFirstAnniversary": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationPutOptionTermPeriodAfterFirstAnniversary", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Put option term, period after first anniversary", "label": "Business Combination, Put Option, Term, Period After First Anniversary", "documentation": "Business Combination, Put Option, Term, Period After First Anniversary" } } }, "auth_ref": [] }, "crl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBiologicalAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBiologicalAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biological assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Biological Assets, Noncurrent", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Biological Assets, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease right-of-use liabilities (Long-term)", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets (excluding cash)", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred revenue", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definite-lived intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r142", "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r142", "r143" ] }, "crl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseAssets", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other long-term liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r143" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r142", "r143" ] }, "crl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRedeemableNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Redeemable noncontrolling interest", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price allocation", "totalLabel": "Total purchase price allocation", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r143" ] }, "crl_BusinessCombinationRedemptionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationRedemptionPrice", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, redemption price", "label": "Business Combination, Redemption Price", "documentation": "Business Combination, Redemption Price" } } }, "auth_ref": [] }, "crl_BusinessCombinationRemainingEquityToPurchase": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationRemainingEquityToPurchase", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, remaining equity to purchase", "label": "Business Combination, Remaining Equity To Purchase", "documentation": "Business Combination, Remaining Equity To Purchase" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of previously owned interest in acquiree", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r43" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest acquired", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Including Subsequent Acquisition, Percentage", "documentation": "Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, equity stake percentage", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain in equity equal to the excess fair value of additional equity interest purchased", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": [ "r140" ] }, "crl_BusinessCombinationTermPeriodAfterSixthAnniversary": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationTermPeriodAfterSixthAnniversary", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Call option term, period after sixth anniversary", "label": "Business Combination, Term, Period After Sixth Anniversary", "documentation": "Business Combination, Term, Period After Sixth Anniversary" } } }, "auth_ref": [] }, "crl_BusinessCombinationValueOfConsiderationNotAcquiredInAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "BusinessCombinationValueOfConsiderationNotAcquiredInAcquisition", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of consideration not acquired", "label": "Business Combination, Value Of Consideration Not Acquired In Acquisition", "documentation": "Business Combination, Value Of Consideration Not Acquired In Acquisition" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations, Contingent Consideration", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r137" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CA", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } }, "auth_ref": [] }, "crl_CDMOSiteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "CDMOSiteMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CDMO Sweden", "label": "CDMO Site [Member]", "documentation": "CDMO Site" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r81", "r82", "r83" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r173", "r174" ] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash acquired", "label": "Cash Acquired from Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": [ "r71" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r78", "r305", "r1049" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents, and Investments", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r79" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "totalLabel": "Cash, cash equivalents, and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r78", "r223", "r346" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r7", "r223" ] }, "crl_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r221" ] }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashSurrenderValueFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Life insurance policies", "label": "Cash Surrender Value, Fair Value Disclosure", "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI)." } } }, "auth_ref": [] }, "us-gaap_CashSurrenderValueOfLifeInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashSurrenderValueOfLifeInsurance", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash surrender value of life insurance policies", "label": "Cash Surrender Value of Life Insurance", "documentation": "Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity." } } }, "auth_ref": [ "r1210" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1160" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1161" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1161" ] }, "crl_CognateBioServicesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "CognateBioServicesIncMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cognate", "label": "Cognate BioServices, Inc. [Member]", "documentation": "Cognate BioServices, Inc." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Notes 2, 11, 13, 14 and 18)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r64", "r180", "r826", "r901" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r243", "r474", "r476", "r1033", "r1252" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1100", "r1101", "r1102", "r1104", "r1105", "r1106", "r1109", "r1226", "r1227", "r1347", "r1367", "r1370" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r201" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r201", "r902" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r201" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r37", "r201", "r902", "r921", "r1370", "r1371" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value; 120,000 shares authorized; 51,338 shares issued and outstanding as of December\u00a030, 2023 and 50,944 shares issued and outstanding as of December\u00a031, 2022", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r201", "r828", "r1097" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1166" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1165" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1167" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1164" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]", "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision (benefit):", "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to common shareholders, net of income taxes", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r70", "r327", "r329", "r338", "r818", "r844" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: Comprehensive income related to noncontrolling interests, net of income taxes", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r20", "r151", "r155", "r327", "r329", "r337", "r817", "r843" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income, net of income taxes", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r155", "r262", "r327", "r329", "r336", "r816", "r842" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer hardware and software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r182", "r286" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r353", "r387", "r404", "r405", "r406", "r407", "r408", "r410", "r414", "r483", "r484", "r485", "r486", "r488", "r489", "r491", "r493", "r494", "r1258", "r1259" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r353", "r387", "r404", "r405", "r406", "r407", "r408", "r410", "r414", "r483", "r484", "r485", "r486", "r488", "r489", "r491", "r493", "r494", "r1258", "r1259" ] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of additional equity interest", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent", "documentation": "Represents the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary." } } }, "auth_ref": [ "r36", "r116", "r156" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r152", "r1058" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "crl_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Represents potential amounts payable by the entity as contingent consideration in connection with a business acquisition." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Client Receivables, Contract Assets and Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1264" ] }, "us-gaap_ContractWithCustomerAssetGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetGrossCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails": { "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled revenue", "label": "Contract with Customer, Asset, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r1262", "r1263" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r539", "r540", "r559" ] }, "crl_ContractWithCustomerLiabilityCustomerDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ContractWithCustomerLiabilityCustomerDeposits", "crdr": "credit", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contract deposits (included in Other current-liabilities)", "label": "Contract With Customer Liability, Customer Deposits", "documentation": "Contract With Customer Liability, Customer Deposits" } } }, "auth_ref": [] }, "crl_ContractWithCustomerLiabilityDeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ContractWithCustomerLiabilityDeferredRevenueCurrent", "crdr": "credit", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current deferred revenue", "label": "Contract With Customer Liability, Deferred Revenue, Current", "documentation": "Contract With Customer Liability, Deferred Revenue, Current" } } }, "auth_ref": [] }, "crl_ContractWithCustomerLiabilityDeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ContractWithCustomerLiabilityDeferredRevenueNoncurrent", "crdr": "credit", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term deferred revenue (included in Other long-term liabilities)", "label": "Contract With Customer Liability, Deferred Revenue, Noncurrent", "documentation": "Contract With Customer Liability, Deferred Revenue, Noncurrent" } } }, "auth_ref": [] }, "crl_ContractWithCustomerUnpaidAdvancedClientBillings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ContractWithCustomerUnpaidAdvancedClientBillings", "crdr": "credit", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid advanced client billings", "label": "Contract With Customer, Unpaid Advanced Client Billings", "documentation": "Contract With Customer, Unpaid Advanced Client Billings" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unallocated corporate", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r46", "r405", "r406", "r407", "r408", "r414", "r1231" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services provided and products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r217", "r811" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "verboseLabel": "Cost of services provided and products sold (excluding amortization of intangible assets)", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Divestitures", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": [ "r51", "r241", "r242" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1207", "r1225", "r1339" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1207", "r1225" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r259", "r713", "r719", "r1225" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1207", "r1225", "r1339" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "verboseLabel": "Client relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r146" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT AND OTHER FINANCING ARRANGEMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r244", "r347", "r496", "r502", "r503", "r504", "r505", "r506", "r507", "r512", "r519", "r520", "r522" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r52", "r195", "r196", "r267", "r270", "r353", "r497", "r498", "r499", "r500", "r501", "r503", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r518", "r780", "r1067", "r1068", "r1069", "r1070", "r1071", "r1223" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r52", "r270", "r523" ] }, "crl_DebtInstrumentCovenantConsolidatedIndebtednessToConsolidatedEBITDAMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DebtInstrumentCovenantConsolidatedIndebtednessToConsolidatedEBITDAMaximum", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum consolidated indebtedness to consolidated EBITDA, with step downs", "label": "Debt Instrument, Covenant, Consolidated Indebtedness To Consolidated EBITDA, Maximum", "documentation": "Debt Instrument, Covenant, Consolidated Indebtedness To Consolidated EBITDA, Maximum" } } }, "auth_ref": [] }, "crl_DebtInstrumentCovenantEBITDALessCapitalExpendituresToConsolidatedCashInterestExpenseRatioMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DebtInstrumentCovenantEBITDALessCapitalExpendituresToConsolidatedCashInterestExpenseRatioMinimum", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum EBITDA less capital expenditures to consolidated cash interest expense", "label": "Debt Instrument, Covenant, EBITDA Less Capital Expenditures To Consolidated Cash Interest Expense Ratio, Minimum", "documentation": "Debt Instrument, Covenant, EBITDA Less Capital Expenditures To Consolidated Cash Interest Expense Ratio, Minimum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r177", "r179", "r497", "r780", "r1068", "r1069" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of debt instruments", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r510", "r765", "r1068", "r1069" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r61", "r498" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r353", "r497", "r498", "r499", "r500", "r501", "r503", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r518", "r521", "r780", "r1067", "r1068", "r1069", "r1070", "r1071", "r1223" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r62", "r353", "r497", "r498", "r499", "r500", "r501", "r503", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r518", "r780", "r1067", "r1068", "r1069", "r1070", "r1071", "r1223" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r62", "r114", "r115", "r176", "r177", "r179", "r181", "r246", "r247", "r353", "r497", "r498", "r499", "r500", "r501", "r503", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r518", "r521", "r780", "r1067", "r1068", "r1069", "r1070", "r1071", "r1223" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt discount and debt issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r178", "r508", "r524", "r1068", "r1069" ] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fixed Income Securities", "terseLabel": "Debt Securities", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r93", "r1102", "r1373" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in unrecognized tax benefits that is reasonably possible", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r133" ] }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs associated with deferred compensation plan and executive supplemental life insurance retirement plans", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }, "auth_ref": [ "r125", "r249" ] }, "crl_DeferredCompensationArrangementWithIndividualDeferralPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredCompensationArrangementWithIndividualDeferralPeriod", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferral period", "label": "Deferred Compensation Arrangement With Individual, Deferral Period", "documentation": "Deferred Compensation Arrangement With Individual, Deferral Period" } } }, "auth_ref": [] }, "crl_DeferredCompensationArrangementWithIndividualPeriodOfHighestConsecutiveYearsOfCompensationUsedForDeterminationOfExecutiveSupplementalLifeInsuranceRetirementPlanBenefit": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredCompensationArrangementWithIndividualPeriodOfHighestConsecutiveYearsOfCompensationUsedForDeterminationOfExecutiveSupplementalLifeInsuranceRetirementPlanBenefit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of highest consecutive years of compensation", "label": "Deferred Compensation Arrangement With Individual, Period of Highest Consecutive Years of Compensation Used for Determination of Executive Supplemental Life Insurance Retirement Plan Benefit", "documentation": "Deferred Compensation Arrangement With Individual, Period of Highest Consecutive Years of Compensation Used for Determination of Executive Supplemental Life Insurance Retirement Plan Benefit" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1225", "r1338", "r1339" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r259", "r1225", "r1338" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r695", "r696" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r23", "r259", "r294", "r718", "r719", "r1225" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r198", "r199", "r269", "r708" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r695", "r696", "r824" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r225" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1225", "r1338", "r1339" ] }, "crl_DeferredTaxAssetValuationAllowanceAdditionsDeductionsForIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetValuationAllowanceAdditionsDeductionsForIncomeTaxExpenseBenefit", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions (reductions) charged to income tax provision, net", "label": "Deferred Tax Asset, Valuation Allowance, Additions (Deductions) for Income Tax Expense (Benefit)", "documentation": "Deferred Tax Asset, Valuation Allowance, Additions (Deductions) for Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "crl_DeferredTaxAssetValuationAllowanceAdditionsForAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetValuationAllowanceAdditionsForAcquisitions", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions due to acquisitions", "label": "Deferred Tax Asset, Valuation Allowance, Additions For Acquisitions", "documentation": "Deferred Tax Asset, Valuation Allowance, Additions For Acquisitions" } } }, "auth_ref": [] }, "crl_DeferredTaxAssetValuationAllowanceAdditionsReductionsForCurrencyTranslationAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetValuationAllowanceAdditionsReductionsForCurrencyTranslationAndOther", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation and other", "label": "Deferred Tax Asset, Valuation Allowance, Additions (Reductions) For Currency Translation and Other", "documentation": "Deferred Tax Asset, Valuation Allowance, Additions (Reductions) For Currency Translation and Other" } } }, "auth_ref": [] }, "crl_DeferredTaxAssetValuationAllowanceReductionsForDisposalsRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetValuationAllowanceReductionsForDisposalsRestructuring", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reductions due to divestitures, restructuring", "label": "Deferred Tax Asset, Valuation Allowance, Reductions For Disposals, Restructuring", "documentation": "Deferred Tax Asset, Valuation Allowance, Reductions For Disposals, Restructuring" } } }, "auth_ref": [] }, "crl_DeferredTaxAssetValuationAllowanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetValuationAllowanceRollForward", "presentation": [ "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset, Valuation Allowance [Roll Forward]", "label": "Deferred Tax Asset, Valuation Allowance [Roll Forward]", "documentation": "Deferred Tax Asset, Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized R&D Expenditures", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1336" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "crl_DeferredTaxAssetsOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetsOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Deferred Tax Assets, Operating Lease Liability", "documentation": "Deferred Tax Assets, Operating Lease Liability" } } }, "auth_ref": [] }, "crl_DeferredTaxAssetsOperatingLossAndCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetsOperatingLossAndCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss and credit carryforwards", "label": "Deferred Tax Assets, Operating Loss and Credit Carryforwards", "documentation": "Deferred Tax Assets, Operating Loss and Credit Carryforwards" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets for net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, operating loss carryforwards, not subject to expiration", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, definite-lived and begin to expire", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets for tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r134", "r135", "r1337" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals and reserves", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails", "http://www.crl.com/role/INCOMETAXESValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation allowance", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r709" ] }, "crl_DeferredTaxAssetsValuationAllowanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxAssetsValuationAllowanceTableTextBlock", "presentation": [ "http://www.crl.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Valuation Allowance", "label": "Deferred Tax Assets, Valuation Allowance [Table Text Block]", "documentation": "Deferred Tax Assets, Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred taxes", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r132", "r1336" ] }, "crl_DeferredTaxLiabilitiesDeferredExpenseDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxLiabilitiesDeferredExpenseDepreciation", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation related", "label": "Deferred tax liabilities, deferred expense, depreciation", "documentation": "Deferred tax liabilities, deferred expense, depreciation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Goodwill and other intangibles", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Venture capital investments", "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated." } } }, "auth_ref": [ "r135", "r1337" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Deferred Tax Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "crl_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use assets", "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset", "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r135", "r1337" ] }, "crl_DeferredTaxLiabilitiesTaxOnUnremittedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxLiabilitiesTaxOnUnremittedEarnings", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax on unremitted earnings", "label": "Deferred Tax Liabilities, Tax On Unremitted Earnings", "documentation": "Deferred Tax Liabilities, Tax On Unremitted Earnings" } } }, "auth_ref": [] }, "crl_DeferredTaxLiabilitiesTaxOnUnremittedEarningsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DeferredTaxLiabilitiesTaxOnUnremittedEarningsPercent", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax on unremitted earnings", "label": "Deferred Tax Liabilities, Tax On Unremitted Earnings, Percent", "documentation": "Deferred Tax Liabilities, Tax On Unremitted Earnings, Percent" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amount recognized", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r13", "r69", "r1307" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts recognized in accumulated other comprehensive income (loss)", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net actuarial loss", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r69", "r607" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net prior service cost (credit)", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r69", "r607" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r577", "r1082" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial (gain) loss", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r570" ] }, "crl_DefinedBenefitPlanActuarialGainLossChangeinMortalityAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DefinedBenefitPlanActuarialGainLossChangeinMortalityAssumptions", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in benefit obligations from new morality improvement scales", "label": "Defined Benefit Plan, Actuarial Gain (Loss), Change in Mortality Assumptions", "documentation": "Defined Benefit Plan, Actuarial Gain (Loss), Change in Mortality Assumptions" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of net loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r564", "r602", "r628", "r1082", "r1083" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of prior service credit", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r564", "r603", "r629", "r1082", "r1083" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts recognized in balance sheet:", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r265", "r562", "r563", "r585", "r914", "r1082", "r1365" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r610" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected long-term return on plan assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r611", "r633" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r610" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails_1": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Benefit obligation at beginning of year", "periodEndLabel": "Benefit obligation at end of year", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r565" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit payments", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r572", "r636" ] }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer in due to acquisition", "label": "Defined Benefit Plan, Benefit Obligation, Business Combination", "documentation": "Amount of increase in benefit obligation of defined benefit plan from business combination." } } }, "auth_ref": [ "r574" ] }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer in due to acquisition", "label": "Defined Benefit Plan, Plan Assets, Business Combination", "documentation": "Amount of increase in plan assets of defined benefit plan from business combination." } } }, "auth_ref": [ "r582" ] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r614", "r1080", "r1081", "r1082" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in projected benefit obligations:", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of plan assets:", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contributions to participants within plan assets", "verboseLabel": "Employer contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r579", "r589", "r632", "r1080", "r1081", "r1082", "r1083" ] }, "crl_DefinedBenefitPlanContributionsByEmployerToParticipantsOutsideOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DefinedBenefitPlanContributionsByEmployerToParticipantsOutsideOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contributions to participants outside of plan assets", "label": "Defined Benefit Plan, Contributions By Employer To Participants Outside Of Plan Assets", "documentation": "Defined Benefit Plan, Contributions By Employer To Participants Outside Of Plan Assets" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanCurtailments", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailment", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees." } } }, "auth_ref": [ "r567" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "verboseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2029-2033", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected employer contributions in next fiscal year", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r597", "r1083" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r564", "r601", "r627", "r1082", "r1083" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails_1": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value of plan assets at beginning of year", "periodEndLabel": "Fair value of plan assets at end of year", "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r576", "r587", "r589", "r590", "r1080", "r1081", "r1082" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Effect of foreign exchange", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r571" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net balance sheet liability", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r562", "r585", "r1082" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r564", "r568", "r600", "r626", "r1082", "r1083" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit cost (income)", "totalLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r598", "r624", "r1082", "r1083" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plan, net periodic benefit cost (credit) excluding service cost, statement of income or comprehensive income [extensible enumeration]", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan." } } }, "auth_ref": [ "r598", "r624" ] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSProjectedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithProjectedBenefitObligationsinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r621", "r1082" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAccumulatedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithAccumulatedBenefitObligationsinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plans with Accumulated Benefit Obligations in Excess of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAccumulatedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithAccumulatedBenefitObligationsinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r621", "r622", "r1082" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAccumulatedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithAccumulatedBenefitObligationsinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r621", "r622", "r1082" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSProjectedBenefitObligationandFairValueofPlanAssetsforPensionPlanswithProjectedBenefitObligationsinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1315" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit payments", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r581", "r1327" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r578" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target asset allocation percentage", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r586", "r1082" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r566", "r599", "r625", "r1082", "r1083" ] }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": [ "r567" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r584" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average assumptions used to determine projected benefit obligations", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs associated with employee savings plan", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r637" ] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum annual contributions per employee, percent", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r23", "r100" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r23", "r390" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r740" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r320", "r321", "r765", "r881", "r882", "r883", "r885", "r886", "r888", "r889", "r890", "r892", "r893", "r908", "r909", "r995", "r998", "r1001", "r1002", "r1003", "r1004", "r1056", "r1102", "r1368" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r890", "r893", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r916", "r917", "r918", "r919", "r930", "r931", "r932", "r933", "r936", "r937", "r938", "r939", "r995", "r996", "r1001", "r1003", "r1100", "r1102" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, fixed interest rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r161", "r163", "r165", "r167", "r890", "r893", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r916", "r917", "r918", "r919", "r930", "r931", "r932", "r933", "r936", "r937", "r938", "r939", "r995", "r996", "r1001", "r1003", "r1056", "r1100", "r1102" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) recognized in interest expense", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r166", "r1205" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r320", "r321", "r765", "r881", "r882", "r883", "r885", "r888", "r889", "r890", "r892", "r893", "r916", "r918", "r919", "r996", "r997", "r998", "r1001", "r1002", "r1003", "r1004", "r1056", "r1368" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r740" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1344", "r1345" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Contracts", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r38", "r157", "r158", "r159", "r168", "r352" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r558", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r558", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Disaggregation of Revenue", "terseLabel": "Schedule of Revenue for Each Significant Product or Service Offering", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1265" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r642", "r647", "r679", "r680", "r682", "r1091" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "crl_DiscoverAndSafetyAssessmentSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DiscoverAndSafetyAssessmentSegmentMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DSA", "label": "Discover And Safety Assessment Segment [Member]", "documentation": "Discover And Safety Assessment Segment" } } }, "auth_ref": [] }, "crl_DiscoveryandSafetyAssessmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DiscoveryandSafetyAssessmentMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DSA", "verboseLabel": "DSA", "label": "Discovery and Safety Assessment [Member]", "documentation": "" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r300" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "crl_DisposalGroupClientRelationshipsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DisposalGroupClientRelationshipsNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Client relationships, net", "label": "Disposal Group, Client Relationships, Net", "documentation": "Disposal Group, Client Relationships, Net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r24", "r45" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration received from divestiture", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "crl_DisposalGroupIncludingDiscontinuedOperationConsiderationPensionOverFundingAndOtherPostClosingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationPensionOverFundingAndOtherPostClosingAdjustments", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension over funding and other post-closing adjustments", "label": "Disposal Group, Including Discontinued Operation, Consideration, Pension Over Funding and Other Post Closing Adjustments", "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Pension Over Funding and Other Post Closing Adjustments" } } }, "auth_ref": [] }, "crl_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration", "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r8", "r185", "r191", "r238" ] }, "crl_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use liabilities", "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability" } } }, "auth_ref": [] }, "crl_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets, net", "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-use Assets, Net", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-use Assets, Net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r8", "r185", "r191", "r238" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r8", "r185", "r191", "r238" ] }, "crl_DisposalGroupIncludingDiscontinuedOperationPurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DisposalGroupIncludingDiscontinuedOperationPurchaseObligation", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation", "label": "Disposal Group, Including Discontinued Operation, Purchase Obligation", "documentation": "Disposal Group, Including Discontinued Operation, Purchase Obligation" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r1084", "r1087" ] }, "crl_DistributedBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "DistributedBioIncMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributed Bio", "label": "Distributed Bio, Inc. [Member]", "documentation": "Distributed Bio, Inc." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1120", "r1121", "r1134" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1120", "r1121", "r1134", "r1170" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1155" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1118" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r339", "r359", "r360", "r361", "r362", "r363", "r367", "r369", "r374", "r375", "r376", "r378", "r753", "r754", "r819", "r845", "r1060" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r339", "r359", "r360", "r361", "r362", "r363", "r369", "r374", "r375", "r376", "r378", "r753", "r754", "r819", "r845", "r1060" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r84", "r85" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r770" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r698" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. statutory income tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r351", "r698", "r721" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1333", "r1340" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enacted tax rate changes", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r721", "r1333" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign-derived intangible income", "label": "Effective Income Tax Rate Reconciliation, FDII, Percent", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r1333" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign tax rate differences", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r1333", "r1340" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global intangible low-taxed income", "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent", "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": [ "r1333" ] }, "crl_EffectiveIncomeTaxRateReconciliationImpactOfAcquisitionsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "EffectiveIncomeTaxRateReconciliationImpactOfAcquisitionsPercent", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of acquisitions and restructuring", "label": "Effective Income Tax Rate Reconciliation, Impact Of Acquisitions, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Impact Of Acquisitions, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1333", "r1340" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1333", "r1340" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1199", "r1333" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal tax benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1333", "r1340" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of tax uncertainties", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r1333", "r1340" ] }, "crl_EffectiveIncomeTaxRateReconciliationTaxCreditsAndDeductions": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsAndDeductions", "calculation": { "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESReconciliationofUSStatutoryTaxRateandEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research tax credits and enhanced deductions", "label": "Effective Income Tax Rate Reconciliation, Tax Credits and Deductions", "documentation": "Effective Income Tax Rate Reconciliation, Tax Credits and Deductions" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r59" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Capitalized stock-based compensation related costs", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r678" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrecognized compensation cost related to unvested awards, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r681" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost related to unvested awards, excluding options", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1332" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrecognized compensation cost related to unvested options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1332" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for income taxes", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r677" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock Options", "terseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1117" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1117" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1117" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1195" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1117" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1117" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1117" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1117" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1196" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r37", "r297", "r331", "r332", "r333", "r354", "r355", "r356", "r358", "r364", "r366", "r380", "r436", "r437", "r538", "r683", "r684", "r685", "r714", "r715", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r772", "r774", "r775", "r776", "r777", "r778", "r803", "r865", "r866", "r867", "r879", "r942" ] }, "us-gaap_EquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityFundsMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mutual Funds", "label": "Equity Funds [Member]", "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments." } } }, "auth_ref": [ "r1289" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r429", "r430", "r431" ] }, "crl_EquityMethodInvestmentContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "EquityMethodInvestmentContingentLiability", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability", "label": "Equity Method Investment, Contingent Liability", "documentation": "Equity Method Investment, Contingent Liability" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r21", "r23", "r213", "r836" ] }, "crl_EquityMethodInvestmentForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "EquityMethodInvestmentForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Equity Method Investment, Foreign Currency Translation", "documentation": "Equity Method Investment, Foreign Currency Translation" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company's ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r429" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture capital and strategic equity investments", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r395", "r427", "r1209", "r1233" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "crl_EquityMethodInvestmentsCapitalContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "EquityMethodInvestmentsCapitalContributions", "crdr": "debit", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contributions", "label": "Equity Method Investments, Capital Contributions", "documentation": "Equity Method Investments, Capital Contributions" } } }, "auth_ref": [] }, "crl_EquityMethodInvestmentsDecreaseDueToAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "EquityMethodInvestmentsDecreaseDueToAcquisition", "crdr": "debit", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reduction for acquisition of entities", "label": "Equity Method Investments, Decrease Due To Acquisition", "documentation": "Equity Method Investments, Decrease Due To Acquisition" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Equity Investments", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r21", "r175", "r430" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r428" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r93", "r1110", "r1111", "r1112", "r1373" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1163" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1126", "r1138", "r1148", "r1174" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1123", "r1135", "r1145", "r1171" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r510", "r765", "r1068", "r1069" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [ "r1372", "r1374", "r1375", "r1376" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1169" ] }, "crl_ExploraBioLabsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ExploraBioLabsMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Explore BioLabs", "label": "Explora BioLabs [Member]", "documentation": "Explora BioLabs" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r756", "r757", "r762" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r756", "r757", "r762" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract", "presentation": [ "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gains or losses (realized/unrealized):", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r510", "r589", "r590", "r591", "r592", "r593", "r594", "r757", "r804", "r805", "r806", "r1068", "r1069", "r1080", "r1081", "r1082" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r172", "r264" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r48", "r170", "r510", "r1068", "r1069" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r756", "r757", "r759", "r760", "r763" ] }, "crl_FairValueContingentConsiderationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "FairValueContingentConsiderationTableTextBlock", "presentation": [ "http://www.crl.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Rollforward of Contingent Consideration Related to Previous Acquisitions", "label": "Fair Value, Contingent Consideration [Table Text Block]", "documentation": "[Table Text Block] for Fair Value, Contingent Consideration [Table]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r510", "r1068", "r1069" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.crl.com/role/FAIRVALUE" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r755" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r510", "r589", "r594", "r757", "r804", "r1080", "r1081", "r1082" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r510", "r589", "r594", "r757", "r805", "r1068", "r1069", "r1080", "r1081", "r1082" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r510", "r589", "r590", "r591", "r592", "r593", "r594", "r757", "r806", "r1068", "r1069", "r1080", "r1081", "r1082" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r40" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r761" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": [ "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Additions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r171" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r171" ] }, "crl_FairValueMeasurementWithUnobservableInputsReconciliationWeightedAverageProbabilityOfMaximumTarget": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationWeightedAverageProbabilityOfMaximumTarget", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average probability percentage of achieving maximum target", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Weighted Average Probability of Maximum Target", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Weighted Average Probability of Maximum Target" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Fair value of contingent consideration", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r40" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails", "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r510", "r589", "r590", "r591", "r592", "r593", "r594", "r804", "r805", "r806", "r1068", "r1069", "r1080", "r1081", "r1082" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r755", "r763" ] }, "crl_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInPreviouslyRecordedAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInPreviouslyRecordedAdjustment", "crdr": "debit", "presentation": [ "http://www.crl.com/role/FAIRVALUERollforwardofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment of previously recorded contingent liability", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Previously Recorded Adjustment", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Previously Recorded Adjustment" } } }, "auth_ref": [] }, "crl_FairValueofPensionPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "FairValueofPensionPlanAssetsTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of the Company's Pension Plan Assets by Asset Category", "label": "Fair Value of Pension Plan Assets [Table Text Block]", "documentation": "Fair Value of Pension Plan Assets [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r160", "r162", "r169" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Funds Rate", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1346" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r785", "r791", "r1096" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r787", "r796" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails", "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance leases", "totalLabel": "Total lease liabilities", "terseLabel": "Total lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r783", "r800" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of finance leases", "verboseLabel": "Current portion of long-term debt and finance leases", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r783" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r784" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.crl.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases After Adoption", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1355" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net and finance leases", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r783" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r784" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum future lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r800" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r786", "r796" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r782" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r785", "r791", "r1096" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r784" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r799", "r1096" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r798", "r1096" ] }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets Acquired", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r309", "r461" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r233" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r233" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r233" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r233" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r233" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r458", "r460", "r461", "r462", "r812", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedAmortizationExpenseforIntangibleAssetsforNextFiveFiscalYearsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense for each of the next five fiscal years", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r232", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite-lived intangible assets", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r812" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r96", "r97" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r232", "r812" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definite-Lived Intangible Assets", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Contracts and Translation of Foreign Currencies", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r767" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r908", "r912", "r918", "r932", "r938", "r999", "r1000", "r1001", "r1102" ] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignPlanMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.K. Plan", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1328", "r1329", "r1330" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1178" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1178" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1178" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1178" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1178" ] }, "us-gaap_FundedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FundedPlanMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Funding Status", "label": "Defined Benefit Plan, Funded Plan [Member]", "documentation": "Defined benefit plan in which retirement benefits are payable directly from plan assets segregated and restricted to provide such benefits." } } }, "auth_ref": [ "r1202", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (gain) on divestitures, net", "terseLabel": "Gain on sale of business", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r737", "r1221" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on debt extinguishment and amortization of other financing costs", "terseLabel": "Extinguishment costs", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r23", "r108", "r109" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r308", "r445", "r814", "r1066", "r1097", "r1237", "r1244" ] }, "crl_GoodwillAcquiredDuringPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "GoodwillAcquiredDuringPeriodNet", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period, Net", "documentation": "Goodwill, Acquired During Period, Net" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r230" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r29", "r94" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r453" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Gross carrying amount, beginning balance", "periodEndLabel": "Gross carrying amount, ending balance", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r448", "r455", "r1066" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, impaired, accumulated impairment loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r448", "r455", "r1066" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r23", "r446", "r452", "r457", "r1066" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r1066" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Divestitures", "label": "Goodwill, Written off Related to Sale of Business Unit", "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r451", "r1066" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r38", "r743" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r38" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1120", "r1121", "r1134" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived asset impairment charges", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r23", "r99", "r237" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation and Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r1", "r240" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r350", "r720" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r2", "r212", "r274", "r385", "r405", "r411", "r414", "r820", "r837", "r1062" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-U.S.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r350", "r720" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "presentation": [ "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income before income taxes:", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss)", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r23", "r213", "r273", "r392", "r427", "r836" ] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r215", "r1215" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r1084", "r1087" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r27", "r45", "r54", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r239" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r463", "r467", "r926" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r467", "r926" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r34", "r136", "r257", "r258" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r351", "r691", "r699", "r706", "r711", "r716", "r722", "r725", "r726", "r876" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/INCOMETAXESComponentsofIncomefromContinuingOperationsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "totalLabel": "Total provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r281", "r295", "r365", "r366", "r393", "r697", "r717", "r846" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r330", "r693", "r694", "r706", "r707", "r710", "r712", "r872" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r80" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade receivables and contract assets, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r809", "r1220" ] }, "crl_IncreaseDecreaseInContractWithCustomerLiabilityCustomerDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "IncreaseDecreaseInContractWithCustomerLiabilityCustomerDeposits", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contract deposits", "label": "Increase (Decrease) In Contract With Customer Liability, Customer Deposits", "documentation": "Increase (Decrease) In Contract With Customer Liability, Customer Deposits" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets and liabilities, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, restricted stock, restricted stock units and performance share units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r370", "r371", "r372", "r376", "r646" ] }, "crl_IndirectTaxContingencyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "IndirectTaxContingencyCurrent", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated tax liability", "label": "Indirect Tax Contingency, Current", "documentation": "Indirect Tax Contingency, Current" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1133", "r1142", "r1152", "r1169", "r1178", "r1182", "r1190" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1188" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1122", "r1194" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1122", "r1194" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1122", "r1194" ] }, "crl_InsurancePoliciesDeductible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "InsurancePoliciesDeductible", "crdr": "debit", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deductible amount under insurance policies", "label": "Insurance Policies, Deductible", "documentation": "Insurance Policies, Deductible" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r178", "r276", "r334", "r389", "r779", "r927", "r1113", "r1369" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest Expense", "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r47" ] }, "us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestInUnincorporatedJointVenturesOrPartnershipsPolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Venture Capital Investments", "label": "Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for interest in an unincorporated joint venture or partnership that is included in the enterprise's financial statements using the proportionate consolidation method of accounting." } } }, "auth_ref": [ "r0" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r341", "r344", "r345" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r1046", "r1107", "r1108" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/INVENTORY" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORY", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r440" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.crl.com/role/INVENTORYDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished products", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r229", "r1054" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.crl.com/role/INVENTORYDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r317", "r1050", "r1097" ] }, "crl_InventoryNonHumanPrimates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "InventoryNonHumanPrimates", "crdr": "debit", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory shipment carrying value", "label": "Inventory, Non-Human Primates", "documentation": "Inventory, Non-Human Primates" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r283", "r304", "r316", "r440", "r441", "r442", "r810", "r1059" ] }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.crl.com/role/INVENTORYDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth_ref": [ "r229", "r1211" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.crl.com/role/INVENTORYDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r229", "r1055" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r219", "r388" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r882", "r884", "r885", "r888", "r891", "r947", "r956", "r970", "r978", "r991", "r1005", "r1006", "r1022", "r1026", "r1027", "r1028", "r1029", "r1102" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r882", "r884", "r885", "r888", "r891", "r947", "r956", "r970", "r978", "r991", "r1005", "r1006", "r1022", "r1026", "r1027", "r1028", "r1029", "r1102" ] }, "crl_InvestmentsInLimitedPartnershipsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "InvestmentsInLimitedPartnershipsTextBlock", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS", "label": "Investments In Limited Partnerships [Text Block]", "documentation": "Investments in Limited Partnerships [Text Block]" } } }, "auth_ref": [] }, "crl_JamesFosterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "JamesFosterMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "James Foster [Member]", "documentation": "James Foster" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1266" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r790", "r1096" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.crl.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1354" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r236" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "crl_LeasesWeightedAverageDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "LeasesWeightedAverageDiscountRateAbstract", "presentation": [ "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Leases, Weighted Average Discount Rate [Abstract]", "documentation": "Leases, Weighted Average Discount Rate [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.crl.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r781" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r789" ] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [ "http://www.crl.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terms for leases that have not yet commenced", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1353" ] }, "crl_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "crdr": "credit", "presentation": [ "http://www.crl.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum lease payments for leases that have not yet commenced", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.crl.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases After Adoption", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1355" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum future lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r800" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term for leases", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1352" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.crl.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r781" ] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.crl.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Line Items]", "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r801" ] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.crl.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessor, Lease, Description [Table]", "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r801" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r58", "r349", "r432", "r483", "r484", "r486", "r487", "r488", "r490", "r492", "r494", "r495", "r733", "r738", "r739", "r766", "r900", "r1061", "r1115", "r1258", "r1357", "r1358" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, redeemable noncontrolling interests and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r206", "r272", "r832", "r1097", "r1224", "r1234", "r1349" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Redeemable Noncontrolling Interests and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r60", "r303", "r349", "r432", "r483", "r484", "r486", "r487", "r488", "r490", "r492", "r494", "r495", "r733", "r738", "r739", "r766", "r1097", "r1258", "r1357", "r1358" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities measured at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r170" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities measured at fair value:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r8", "r185", "r191", "r238", "r300", "r301" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r8", "r185", "r191", "r235", "r238", "r300", "r301" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r8", "r14", "r185", "r191", "r238", "r300", "r301" ] }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LifeSettlementContractsInvestmentMethodFaceValue", "crdr": "debit", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face value of life insurance contracts", "label": "Life Settlement Contracts, Investment Method, Face Value", "documentation": "Face value (death benefits) of the life insurance policies underlying the life settlement contracts accounted for under the investment method." } } }, "auth_ref": [ "r435" ] }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LifeSettlementContractsInvestmentMethodNumberOfContracts", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of life insurance contracts", "label": "Life Settlement Contracts, Investment Method, Number of Contracts", "documentation": "Number of life settlement contracts accounted for under the investment method." } } }, "auth_ref": [ "r434" ] }, "us-gaap_LifeSettlementContractsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LifeSettlementContractsPolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Life Insurance Contracts", "label": "Life Settlement Contracts, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for life settlement contracts including the classification of cash receipts and cash disbursements in the statement of cash flows." } } }, "auth_ref": [ "r433" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of credit facility", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r57" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Facility", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusAxis", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1253" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusDomain", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1253" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net and finance leases", "totalLabel": "Long-term debt, net and finance leases", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r52", "r825" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": "crl_LongTermDebtGrossAndLeaseObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current portion of long-term debt and finance leases", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r59" ] }, "crl_LongTermDebtAndLeaseObligationNetOfCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "LongTermDebtAndLeaseObligationNetOfCurrentPortion", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt and finance leases", "label": "Long-Term Debt And Lease Obligation, Net Of Current Portion", "documentation": "Long-Term Debt And Lease Obligation, Net Of Current Portion" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r312" ] }, "crl_LongTermDebtGrossAndLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "LongTermDebtGrossAndLeaseObligation", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt and finance leases", "label": "Long-Term Debt, Gross And Lease Obligation", "documentation": "Long-Term Debt, Gross And Lease Obligation" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r26", "r353", "r1261" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r26", "r353", "r514" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r26", "r353", "r514" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r26", "r353", "r514" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r26", "r353", "r514" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSPrincipalMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r26", "r353", "r514" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r62" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r62", "r107" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r477", "r478", "r479", "r482", "r1254", "r1255" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r477", "r478", "r479", "r482", "r1254", "r1255" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "crl_ManufacturingSupportMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ManufacturingSupportMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing", "verboseLabel": "Manufacturing", "label": "Manufacturing Support [Member]", "documentation": "Manufacturing Support [Member]" } } }, "auth_ref": [] }, "crl_MaxPsuShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.crl.com/20231230", "localname": "MaxPsuShares", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maximum number of common shares to be issued upon vesting of PSUs (in shares)", "label": "Max PSU Shares", "documentation": "Max PSU Shares" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/LEASESAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r640", "r808", "r864", "r892", "r893", "r950", "r969", "r974", "r975", "r1016", "r1043", "r1044", "r1064", "r1072", "r1090", "r1099", "r1260", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1161" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1161" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Cost of Capital", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1348" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r1348" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r758" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.crl.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_MediumTermNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MediumTermNotesMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medium-term Notes", "label": "Medium-term Notes [Member]", "documentation": "Debt instruments with maturities ranging from five to ten years." } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURES" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS AND DIVESTITURES", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r184", "r260" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails", "http://www.crl.com/role/LEASESAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r640", "r808", "r864", "r892", "r893", "r950", "r969", "r974", "r975", "r1016", "r1043", "r1044", "r1064", "r1072", "r1090", "r1099", "r1260", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests (nonredeemable)", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r67", "r271", "r349", "r432", "r483", "r486", "r487", "r488", "r494", "r495", "r766", "r831", "r904" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends declared to noncontrolling interest", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r248" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling ownership interest", "verboseLabel": "Remaining ownership interest", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1181" ] }, "crl_MsGirshickMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "MsGirshickMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Ms. Girshick [Member]", "documentation": "Ms. Girshick" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1189" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1162" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r343" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows relating to financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r343" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows relating to investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r223", "r224", "r225" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows relating to operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to common shareholders", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r214", "r225", "r275", "r301", "r326", "r328", "r333", "r349", "r357", "r359", "r360", "r361", "r362", "r365", "r366", "r373", "r385", "r405", "r411", "r414", "r432", "r483", "r484", "r486", "r487", "r488", "r490", "r492", "r494", "r495", "r754", "r766", "r840", "r923", "r940", "r941", "r1062", "r1113", "r1258" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r154", "r263", "r326", "r328", "r365", "r366", "r839", "r1215" ] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net income", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref": [ "r216" ] }, "crl_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndExcludingRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndExcludingRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Excluding Redeemable Noncontrolling Interest", "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Excluding Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Newly Adopted and Newly Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1161" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1130", "r1142", "r1152", "r1169", "r1178" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1159" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1158" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1169" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1189" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1189" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "crl_NoncontrollingInterestAdditionalOwnershipPercentageAcquiredByParent": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "NoncontrollingInterestAdditionalOwnershipPercentageAcquiredByParent", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional ownership percentage acquired by parent", "label": "Noncontrolling Interest, Additional Ownership Percentage Acquired By Parent", "documentation": "Noncontrolling Interest, Additional Ownership Percentage Acquired By Parent" } } }, "auth_ref": [] }, "crl_NoncontrollingInterestIncreaseDecreaseInRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "NoncontrollingInterestIncreaseDecreaseInRedemptionValue", "crdr": "debit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Adjustment to noncontrolling interest fair value", "label": "Noncontrolling Interest, Increase (Decrease) in Redemption Value", "documentation": "Noncontrolling Interest, Increase (Decrease) in Redemption Value" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r149", "r538", "r1226", "r1227", "r1228", "r1370" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r419" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "crl_NoveprimGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "NoveprimGroupMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noveprim Group", "label": "Noveprim Group [Member]", "documentation": "Noveprim Group" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1230" ] }, "crl_NumberOfSubsegments": { "xbrltype": "integerItemType", "nsuri": "http://www.crl.com/20231230", "localname": "NumberOfSubsegments", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of businesses in reportable segment", "label": "Number Of Subsegments", "documentation": "Number Of Subsegments" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "terseLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r385", "r405", "r411", "r414", "r1062" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r792", "r1096" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails", "http://www.crl.com/role/LEASESScheduleofFutureMinimumLeasePaymentsUnderNonCancellableLeasesAfterAdoptionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "terseLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r783" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r783" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r784" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use liabilities", "verboseLabel": "Operating lease right-of-use liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r783" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r788", "r796" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/LEASESRightofUseLeaseAssetsandLeaseLiabilitiesinCondensedConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets, net", "verboseLabel": "Operating lease right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r782" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r799", "r1096" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r798", "r1096" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r408", "r414" ] }, "us-gaap_OrderOrProductionBacklogMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrderOrProductionBacklogMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Backlog", "label": "Order or Production Backlog [Member]", "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination." } } }, "auth_ref": [ "r145" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r183", "r226", "r227", "r261" ] }, "crl_OtherAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherAcquisitionsMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Acquisitions", "label": "Other Acquisitions [Member]", "documentation": "Other Acquisitions [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsAbstract", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets:", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r310" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other post-retirement benefit plans (Note 14):", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "crl_OtherComprehensiveIncomeLossBeforeIncomeTaxes", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r10", "r210", "r768", "r769", "r771" ] }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "crl_OtherComprehensiveIncomeLossBeforeIncomeTaxes", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r17", "r210", "r325", "r606" ] }, "crl_OtherComprehensiveIncomeLossBeforeIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherComprehensiveIncomeLossBeforeIncomeTaxes", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), before income taxes", "label": "Other Comprehensive Income (Loss), Before Income Taxes", "documentation": "Other Comprehensive Income (Loss), Before Income Taxes" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r69", "r332", "r772", "r775", "r778", "r841", "r1213" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net current period other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), before Tax", "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r335", "r772", "r773", "r778", "r815", "r841", "r1213", "r1214" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "crl_OtherComprehensiveIncomeLossBeforeIncomeTaxes", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on hedging instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r322", "r323", "r741", "r742", "r744" ] }, "crl_OtherComprehensiveIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndExcludingRedeemableNoncontrollingInterestNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherComprehensiveIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndExcludingRedeemableNoncontrollingInterestNetOfTax", "crdr": "credit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Including Portion Attributable To Noncontrolling Interest and Excluding Redeemable Noncontrolling Interest, Net of Tax", "documentation": "Other Comprehensive Income (Loss), Including Portion Attributable To Noncontrolling Interest and Excluding Redeemable Noncontrolling Interest, Net of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "crl_OtherComprehensiveIncomeLossBeforeIncomeTaxes", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prior service cost and (losses) gains arising during the period", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax", "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r13", "r210" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails": { "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r13", "r210", "r1082", "r1306" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash settlement charge related to pension losses, reclassified from AOCI to other expense", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r17", "r210", "r325", "r606" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Income tax (benefit) expense related to items of other comprehensive income (Note 12)", "verboseLabel": "Income tax (benefit) expense", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r331", "r335", "r697", "r723", "r724", "r772", "r776", "r778", "r815", "r841" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "verboseLabel": "Other", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r59", "r1097" ] }, "crl_OtherLiabilitiesCurrentFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherLiabilitiesCurrentFairValueDisclosureAbstract", "presentation": [ "http://www.crl.com/role/FAIRVALUEFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities measured at fair value:", "label": "Other Liabilities, Current, Fair Value Disclosure [Abstract]", "documentation": "Other Liabilities, Current, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r63" ] }, "crl_OtherLongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherLongTermDebtMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Debt", "label": "Other Long-term Debt [Member]", "documentation": "Represents other debt instruments not elsewhere specified in the taxonomy." } } }, "auth_ref": [] }, "crl_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherMember", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r225" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r220" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSCrossCurrencyLoansDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1161" ] }, "crl_OtherPlanAssetCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "OtherPlanAssetCategoriesMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Securities", "terseLabel": "Other", "label": "Other Plan Asset Categories [Member]", "documentation": "Other Plan Asset Categories [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1128", "r1140", "r1150", "r1176" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1131", "r1143", "r1153", "r1179" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1131", "r1143", "r1153", "r1179" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1157" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for contingent consideration", "label": "Payment for Contingent Consideration Liability, Operating Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r19" ] }, "crl_PaymentsForAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PaymentsForAccruedInterest", "crdr": "credit", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for accrued interest", "label": "Payments For Accrued Interest", "documentation": "Payments For Accrued Interest" } } }, "auth_ref": [] }, "crl_PaymentsForAdditionalEquityInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PaymentsForAdditionalEquityInterests", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of additional equity interests, net", "label": "Payments For Additional Equity Interests", "documentation": "Payments For Additional Equity Interests" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1200", "r1216" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r75" ] }, "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for repurchase of redeemable noncontrolling interest", "label": "Payments for Repurchase of Redeemable Noncontrolling Interest", "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests." } } }, "auth_ref": [ "r1218" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments / utilization", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r466", "r1219" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt extinguishment and financing costs", "terseLabel": "Deferred financing costs expensed", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r74" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash portion of consideration transferred", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r72", "r728" ] }, "crl_PaymentsToAcquireBusinessesGrossAdditionalCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PaymentsToAcquireBusinessesGrossAdditionalCashPayment", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional cash paid", "label": "Payments To Acquire Businesses, Gross, Additional Cash Payment", "documentation": "Payments To Acquire Businesses, Gross, Additional Cash Payment" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of businesses and assets, net of cash acquired", "terseLabel": "Payments to acquire businesses, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r72" ] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of investments", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r72" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments and contributions to venture capital investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r222" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "terseLabel": "Capital expenditures", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r280", "r1341", "r1342", "r1343" ] }, "crl_PaymentsToSettlePromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PaymentsToSettlePromissoryNote", "crdr": "credit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to settle promissory note", "label": "Payments To Settle Promissory Note", "documentation": "Payments To Settle Promissory Note" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1160" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1160" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PendingLitigationMember", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1253" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFIT PLANS", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r561", "r586", "r588", "r594", "r613", "r615", "r616", "r617", "r618", "r619", "r634", "r635", "r637", "r1082" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r196", "r562", "r563", "r585", "r1082" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSReconciliationofBenefitObligationsandPlanAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncurrent liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r197", "r562", "r563", "r585", "r1082" ] }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Post-Retirement Benefit Plans", "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r28", "r30", "r39", "r124" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plans", "verboseLabel": "Pension Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r611", "r612", "r614", "r617", "r620", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r637", "r638", "r641", "r1082", "r1083", "r1087", "r1088", "r1089" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1159" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1169" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1162" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1158" ] }, "crl_PerformanceSharesGranteeGroupOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PerformanceSharesGranteeGroupOneMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSU Grantee Group One", "label": "Performance Shares Grantee Group One [Member]", "documentation": "Performance Shares Grantee Group One [Member]" } } }, "auth_ref": [] }, "crl_PerformanceSharesGranteeGroupTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PerformanceSharesGranteeGroupTwoMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares Grantee Group Two", "label": "Performance Shares Grantee Group Two [Member]", "documentation": "Performance Shares Grantee Group Two [Member]" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PSUs", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r614", "r1080", "r1081", "r1082" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r764" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r200", "r526" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r200", "r902" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r200", "r526" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r200", "r902", "r921", "r1370", "r1371" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r200", "r827", "r1097" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1212" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid assets", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r318", "r443", "r444", "r1052" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1053", "r1065", "r1235" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from divestiture", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of businesses, net", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term debt and revolving credit facility", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r73", "r873" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1201", "r1217" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of investments", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercises of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r16", "r44" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold (excluding amortization of intangible assets)", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1073" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r416", "r811", "r858", "r859", "r860", "r861", "r862", "r863", "r1047", "r1073", "r1098", "r1206", "r1256", "r1257", "r1265", "r1366" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r416", "r811", "r858", "r859", "r860", "r861", "r862", "r863", "r1047", "r1073", "r1098", "r1206", "r1256", "r1257", "r1265", "r1366" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r301", "r326", "r328", "r342", "r349", "r357", "r365", "r366", "r385", "r405", "r411", "r414", "r432", "r483", "r484", "r486", "r487", "r488", "r490", "r492", "r494", "r495", "r731", "r734", "r735", "r754", "r766", "r820", "r838", "r878", "r923", "r940", "r941", "r1062", "r1094", "r1095", "r1114", "r1215", "r1258" ] }, "crl_PropertyInsuranceDeductible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PropertyInsuranceDeductible", "crdr": "debit", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certain property insurance, deductibles", "label": "Property Insurance, Deductible", "documentation": "Property Insurance, Deductible" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r1204", "r1247" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r25" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNET" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r234", "r287", "r292", "r293" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r236", "r306", "r835" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r25", "r821", "r835", "r1097" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r25", "r287", "r292", "r833" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Composition of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r25" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r236" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "crl_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant, and Equipment Estimated Useful Lives", "label": "Property, Plant And Equipment, Useful Lives [Table Text Block]", "documentation": "Property, Plant and Equipment, Useful Lives [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r340", "r439" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1157" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1157" ] }, "crl_RMSJapanOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RMSJapanOperationsMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESScheduleofDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RMS Japan", "label": "RMS Japan Operations [Member]", "documentation": "RMS Japan Operations" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/LEASESAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r586", "r640", "r673", "r674", "r675", "r807", "r808", "r864", "r892", "r893", "r950", "r969", "r974", "r975", "r1016", "r1043", "r1044", "r1064", "r1072", "r1090", "r1099", "r1102", "r1248", "r1260", "r1360", "r1361", "r1362", "r1363", "r1364" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails", "http://www.crl.com/role/FAIRVALUENarrativeDetails", "http://www.crl.com/role/LEASESAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r586", "r640", "r673", "r674", "r675", "r807", "r808", "r864", "r892", "r893", "r950", "r969", "r974", "r975", "r1016", "r1043", "r1044", "r1064", "r1072", "r1090", "r1099", "r1102", "r1248", "r1260", "r1360", "r1361", "r1362", "r1363", "r1364" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r69", "r332", "r772", "r777", "r778", "r841", "r1213" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1123", "r1135", "r1145", "r1171" ] }, "crl_RedeemableNoncontrollingInterestDecreaseFromRedemptionsOrPurchaseOfRemainingEquityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RedeemableNoncontrollingInterestDecreaseFromRedemptionsOrPurchaseOfRemainingEquityInterest", "crdr": "debit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on purchase of remaining equity interest of Vital River redeemable noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Decrease from Redemptions or Purchase of Remaining Equity Interest", "documentation": "Redeemable Noncontrolling Interest, Decrease from Redemptions or Purchase of Remaining Equity Interest" } } }, "auth_ref": [] }, "crl_RedeemableNoncontrollingInterestDividendReceivableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RedeemableNoncontrollingInterestDividendReceivableFairValue", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend fair value", "label": "Redeemable Noncontrolling Interest, Dividend Receivable Fair Value", "documentation": "Redeemable Noncontrolling Interest, Dividend Receivable Fair Value" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "verboseLabel": "Redeemable noncontrolling interests", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r110", "r111", "r112", "r113" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest, contractually defined redemption value", "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value", "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date." } } }, "auth_ref": [ "r53" ] }, "crl_RedeemableNoncontrollingInterestPurchasePricePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RedeemableNoncontrollingInterestPurchasePricePayable", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest, purchase price payable", "label": "Redeemable Noncontrolling Interest, Purchase Price Payable", "documentation": "Redeemable Noncontrolling Interest, Purchase Price Payable" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rollforward of Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r77", "r874" ] }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on long-term debt, revolving credit facility, and finance lease obligations", "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security", "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitAxis", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r456", "r457", "r1066" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitDomain", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r456", "r457", "r1066" ] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair value in excess of carrying amount", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "crl_RepresentationAndWarrantyInsuranceDeductible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RepresentationAndWarrantyInsuranceDeductible", "crdr": "debit", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Representation and warranty insurance, maximum deductible", "label": "Representation And Warranty Insurance, Deductible", "documentation": "Representation And Warranty Insurance, Deductible" } } }, "auth_ref": [] }, "crl_ResearchModelsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ResearchModelsAndServicesMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RMS", "verboseLabel": "RMS", "label": "Research Models and Services [Member]", "documentation": "Represents Research Models and Services segment of the entity which includes sales of research models, genetically engineered models and services (GEMS), consulting and staffing services (CSS), research animal diagnostics, discovery services, in vitro and avian vaccine services." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1124", "r1136", "r1146", "r1172" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1125", "r1137", "r1147", "r1173" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1132", "r1144", "r1154", "r1180" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in Other current assets", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1208", "r1222" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in Other assets", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r282", "r1210", "r1222" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r84" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "crl_RestrictedStockandRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RestrictedStockandRestrictedStockUnitsMember", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock and Restricted Stock Units [Member]", "documentation": "Restricted Stock and Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense (excluding non-cash charges)", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r465", "r468", "r471", "r473" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r23", "r469", "r471", "r1249" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r465", "r466", "r471", "r472" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r471", "r472", "r473" ] }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING AND ASSET IMPAIRMENTS", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs." } } }, "auth_ref": [ "r1197", "r1198" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Severance and retention costs liability", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r466", "r470" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash adjustments", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r466", "r472" ] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSRollforwardofSeveranceandTransitionandLeaseObligationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency adjustments", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": [ "r1250", "r1251" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r203", "r248", "r830", "r868", "r870", "r875", "r903", "r1097" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r297", "r354", "r355", "r356", "r358", "r364", "r366", "r436", "r437", "r683", "r684", "r685", "r714", "r715", "r745", "r747", "r748", "r750", "r752", "r865", "r867", "r879", "r1370" ] }, "us-gaap_RetirementPlanFundingStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanFundingStatusAxis", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Funding Status [Axis]", "label": "Defined Benefit Plan, Funding Status [Axis]", "documentation": "Information by status of funding for defined benefit plan designed to provide retirement benefits." } } }, "auth_ref": [ "r1202", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326" ] }, "us-gaap_RetirementPlanFundingStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanFundingStatusDomain", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Funding Status [Domain]", "label": "Defined Benefit Plan, Funding Status [Domain]", "documentation": "Status of funding for defined benefit plan designed to provide retirement benefits." } } }, "auth_ref": [ "r1202", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r610", "r611", "r612", "r614", "r617", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r1328", "r1329", "r1330" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r610", "r611", "r612", "r614", "r617", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r1328", "r1329", "r1330" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r611", "r612", "r614", "r617", "r620", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r637", "r638", "r639", "r641", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r609", "r611", "r612", "r614", "r617", "r620", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r637", "r638", "r639", "r641", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089" ] }, "crl_RetrogenixLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RetrogenixLimitedMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retrogenix", "label": "Retrogenix Limited [Member]", "documentation": "Retrogenix Limited" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "verboseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r386", "r387", "r404", "r409", "r410", "r416", "r418", "r420", "r557", "r558", "r811" ] }, "crl_RevenueFromContractWithCustomerPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RevenueFromContractWithCustomerPaymentTerms", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contract with customer, payment terms", "label": "Revenue From Contract With Customer, Payment Terms", "documentation": "Revenue From Contract With Customer, Payment Terms" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r296", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r1045" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE FROM CONTRACTS WITH CUSTOMERS", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r296", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r560" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations expected to be satisfied", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r290" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations expected to be satisfied, expected timing", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r291" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r291" ] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r1203" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Multi-currency Revolving Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails", "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofNonCashInvestingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets acquired under finance leases", "verboseLabel": "Right-of-use lease assets obtained in exchange for new finance lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r797", "r1096" ] }, "crl_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash leases activity:", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.crl.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use lease assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r797", "r1096" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1189" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1189" ] }, "crl_SAMDITechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SAMDITechIncMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SAMDI Tech, Inc.", "label": "SAMDI Tech, Inc [Member]", "documentation": "SAMDI Tech, Inc" } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseRevenue", "crdr": "credit", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease revenue", "label": "Sales-type Lease, Revenue", "documentation": "Amount of sales-type lease revenue." } } }, "auth_ref": [ "r379", "r802" ] }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Benefit Obligation and Fair of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1082", "r1315", "r1316" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes to Each Component of Accumulated Other Comprehensive Income (Loss), Net of Income Taxes", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r69", "r1350", "r1351" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted-average Assumptions", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r608" ] }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Projected Benefit Obligation and Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1082", "r1315" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r138", "r141", "r727" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Purchase Price Allocation", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r138", "r141" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://www.crl.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt, Net", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.crl.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r256" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSAdditionalInformationDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureBenefitPaymentsDetails", "http://www.crl.com/role/EMPLOYEEBENEFITPLANSFairValueofCompanysPensionPlanAssetsbyAssetCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r28", "r120", "r121", "r122", "r123" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments on Statements of Income", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r161", "r165", "r743" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Major Classes of Assets and Liabilities Associated with Divestitures", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r27", "r45", "r54", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r239" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1229" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.crl.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliations of the Statutory U.S. Federal Income Tax Rate to Effective Tax Rates", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r255" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r129" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Statement Line Items in Which Stock-based Compensation is Reflected", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r129" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r429", "r430", "r431" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r349", "r429", "r430", "r431", "r432", "r766" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r301", "r349", "r429", "r430", "r431", "r432", "r766" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Benefit Payments Over the Next Five Years", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.crl.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r756", "r757" ] }, "crl_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets, by Major Class [Table]", "label": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets, by Major Class [Table]", "documentation": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets, by Major Class" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r96", "r97" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r1066" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rollforward of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1066", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246" ] }, "crl_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.crl.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income from Continuing Operations Before Income Taxes and the Related Provision for Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign, and Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions and the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.crl.com/role/INVENTORYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Composition of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r55", "r207", "r208", "r209" ] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r1007", "r1008", "r1009", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Principal Maturities of Existing Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net Periodic Benefit Costs for the Company's Pension Plans", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r251" ] }, "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetFundedStatusTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Benefit Obligations and Plans Assets of the Company's Pension Plans", "label": "Schedule of Net Funded Status [Table Text Block]", "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans." } } }, "auth_ref": [ "r119" ] }, "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "presentation": [ "http://www.crl.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Accumulated Other Comprehensive Loss Related to the Company's Pensions Plans", "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]", "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation." } } }, "auth_ref": [ "r252" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r471", "r472", "r473" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r102", "r104", "r105" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rollforward of Company's Severance and Retention Costs Liability", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r103", "r106" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r92", "r211" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r89", "r90", "r91", "r94" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue and Other Financial Information by Reportable Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r89", "r90", "r91", "r94" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r643", "r645", "r648", "r649", "r650", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r673", "r674", "r675", "r676" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r41", "r42", "r127" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted-average Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r254" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock and Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "crl_ScheduleOfStockRepurchasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ScheduleOfStockRepurchasesTable", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Repurchases [Table]", "label": "Schedule of Stock Repurchases [Table]", "documentation": "Schedule detailing information relating to stock repurchases." } } }, "auth_ref": [] }, "crl_ScheduleOfUnrecognizedTaxBenefitsRollTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollTableTextBlock", "presentation": [ "http://www.crl.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Company's Beginning and Ending Unrecognized Income Tax Benefits", "label": "Schedule of Unrecognized Tax Benefits Roll [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r97" ] }, "crl_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1116" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1119" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r382", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r420", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r468", "r473", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r1066", "r1206", "r1366" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r418", "r419", "r883", "r887", "r889", "r956", "r970", "r991", "r1022", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1048", "r1074", "r1102", "r1265", "r1366" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r397", "r408", "r412", "r413", "r414", "r415", "r416", "r417", "r420" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r398", "r399", "r400", "r401", "r402", "r403", "r418", "r1063" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r218" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONFinancialStatementLineItemsinWhichStockBasedCompensationisLocatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "crl_SeniorNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SeniorNotesDue2026Member", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes Due 2026", "label": "Senior Notes Due 2026 [Member]", "documentation": "Senior Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "crl_SeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SeniorNotesDue2028Member", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.25% Senior Notes due 2028", "label": "Senior Notes Due 2028 [Member]", "documentation": "Senior Notes Due 2028 [Member]" } } }, "auth_ref": [] }, "crl_SeniorNotesDue2029And2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SeniorNotesDue2029And2031Member", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes Due 2029 And 2031", "label": "Senior Notes Due 2029 And 2031 [Member]", "documentation": "Senior Notes Due 2029 And 2031" } } }, "auth_ref": [] }, "crl_SeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SeniorNotesDue2029Member", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.75% Senior Notes due 2029", "label": "Senior Notes Due 2029 [Member]", "documentation": "Senior Notes Due 2029" } } }, "auth_ref": [] }, "crl_SeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SeniorNotesDue2031Member", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.00% Senior Notes due 2031", "label": "Senior Notes Due 2031 [Member]", "documentation": "Senior Notes Due 2031" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSLongtermDebtNetDetails", "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails", "http://www.crl.com/role/FAIRVALUEScheduleofFairValueofDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of services provided (excluding amortization of intangible assets)", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r1073" ] }, "crl_SeveranceAndTransitionCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SeveranceAndTransitionCostsMember", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance and Transition Costs", "label": "Severance And Transition Costs [Member]", "documentation": "Severance And Transition Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1091" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "PSUs granted (in shares)", "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average per share fair value (in dollars per share)", "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period (in shares)", "periodEndLabel": "Balance at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r660", "r661" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the period (in dollars per share)", "periodEndLabel": "Balance at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r660", "r661" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r667" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key assumptions:", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r674" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r673" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r675" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r643", "r645", "r648", "r649", "r650", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r673", "r674", "r675", "r676" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maximum number of shares to be awarded (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1093" ] }, "crl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerEmployeeAvailableToPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerEmployeeAvailableToPurchase", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares employee is entitled to receive at no cost (in shares)", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Per Employee Available to Purchase", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Per Employee Available to Purchase" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r654" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r654" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r667" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r659" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options canceled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1331" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r656" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average grant date fair value of stock options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r666" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, balance at the beginning of the period (in shares)", "periodEndLabel": "Options outstanding, balance at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r652", "r653" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, balance at the beginning of the period (in dollars per share)", "periodEndLabel": "Options outstanding, balance at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r652", "r653" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options expected to vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r668" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r668" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r668" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONRestrictedStockandRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r648", "r649", "r650", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r673", "r674", "r675", "r676" ] }, "crl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardFairValueAssumptionsChangeInWeightedAverageStockPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardFairValueAssumptionsChangeInWeightedAverageStockPrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total shareholder return of 20-trading day average stock price on grant date", "label": "Share-based Compensation Arrangements By Share-based Payment Award, Fair Value Assumptions, Change in Weighted Average Stock Price", "documentation": "Share-based Compensation Arrangements By Share-based Payment Award, Fair Value Assumptions, Change in Weighted Average Stock Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r657" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r656" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r642", "r651", "r670", "r671", "r672", "r673", "r676", "r686", "r687", "r688", "r689" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information about PSUs and Related Weighted-Average Assumptions", "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options, expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1092" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r672" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r126" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, weighted average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r126" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options outstanding weighted average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r253" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options expected to vest, weighted average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r668" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares acquired for individual minimum statutory tax withholding (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease costs", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r793", "r1096" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSRollforwardofCompanysGoodwillDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsbyReportableSegmentDetails", "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails", "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONFinancialInformationbyReportableBusinessSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r299", "r382", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r420", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r464", "r468", "r473", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r1066", "r1206", "r1366" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r37", "r65", "r297", "r331", "r332", "r333", "r354", "r355", "r356", "r358", "r364", "r366", "r380", "r436", "r437", "r538", "r683", "r684", "r685", "r714", "r715", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r772", "r774", "r775", "r776", "r777", "r778", "r803", "r865", "r866", "r867", "r879", "r942" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r418", "r419", "r883", "r887", "r889", "r956", "r970", "r991", "r1022", "r1032", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1048", "r1074", "r1102", "r1265", "r1366" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r354", "r355", "r356", "r380", "r811", "r871", "r880", "r894", "r895", "r896", "r897", "r898", "r899", "r902", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r916", "r917", "r918", "r919", "r920", "r922", "r924", "r925", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r942", "r1103" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r354", "r355", "r356", "r380", "r811", "r871", "r880", "r894", "r895", "r896", "r897", "r898", "r899", "r902", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r916", "r917", "r918", "r919", "r920", "r922", "r924", "r925", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r942", "r1103" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1127", "r1139", "r1149", "r1175" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock under employee compensation plans (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r37", "r200", "r201", "r248" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r37", "r200", "r201", "r248", "r657" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock under employee compensation plans", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r128", "r200", "r201", "r248" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate authorization of share repurchase program", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount remaining on the authorized share repurchase program", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "crl_StockRepurchasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "StockRepurchasesLineItems", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]", "label": "Stock Repurchases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity attributable to common shareholders", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r201", "r204", "r205", "r228", "r904", "r921", "r943", "r944", "r1097", "r1115", "r1224", "r1234", "r1349", "r1370" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSChangestoAccumulatedOtherComprehensiveIncomeLossNetofIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r149", "r150", "r153", "r297", "r298", "r332", "r354", "r355", "r356", "r358", "r364", "r436", "r437", "r538", "r683", "r684", "r685", "r714", "r715", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r772", "r774", "r778", "r803", "r866", "r867", "r877", "r904", "r921", "r943", "r944", "r1030", "r1114", "r1224", "r1234", "r1349", "r1370" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTS" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY AND NONCONTROLLING INTERESTS", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r245", "r348", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r751", "r945", "r946", "r1031" ] }, "crl_StrategicInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "StrategicInvestmentsMember", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Investments", "label": "Strategic Investments [Member]", "documentation": "Strategic Investments" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r795", "r1096" ] }, "crl_SupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "SupplierMember", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier", "label": "Supplier [Member]", "documentation": "Supplier [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1168" ] }, "crl_TaxCreditCarryforwardsByExpirationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TaxCreditCarryforwardsByExpirationPeriodAxis", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforwards, by Expiration Period [Axis]", "label": "Tax Credit Carryforwards, by Expiration Period [Axis]", "documentation": "Tax Credit Carryforwards, by Expiration Period [Axis]" } } }, "auth_ref": [] }, "crl_TaxCreditCarryforwardsByExpirationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TaxCreditCarryforwardsByExpirationPeriodDomain", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforwards, by Expiration Period [Domain]", "label": "Tax Credit Carryforwards, by Expiration Period [Domain]", "documentation": "Tax Credit Carryforwards, by Expiration Period [Domain]" } } }, "auth_ref": [] }, "crl_TaxCreditCarryforwardsExpirationRange2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TaxCreditCarryforwardsExpirationRange2Member", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforwards, Carried Forward Indefinitely", "label": "Tax Credit Carryforwards, Expiration Range 2 [Member]", "documentation": "Tax Credit Carryforwards, Expiration Range 2" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r50" ] }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to redemption value", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders." } } }, "auth_ref": [] }, "crl_TemporaryEquityAcquisitionOfNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TemporaryEquityAcquisitionOfNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition resulting in a 10% noncontrolling interest", "label": "Temporary Equity, Acquisition Of Noncontrolling Interest", "documentation": "Temporary Equity, Acquisition Of Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityDividendsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityDividendsAdjustment", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends", "label": "Temporary Equity, Dividends, Adjustment", "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends)." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments." } } }, "auth_ref": [] }, "crl_TemporaryEquityIncreaseDecreaseToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TemporaryEquityIncreaseDecreaseToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Additional purchases reducing noncontrolling interest percentage", "label": "Temporary Equity, Increase (Decrease) To Noncontrolling Interest", "documentation": "Temporary Equity, Increase (Decrease) To Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityOtherChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityOtherChanges", "crdr": "credit", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSRollforwardofRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Temporary Equity, Other Changes", "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other." } } }, "auth_ref": [] }, "crl_ThreeBillionCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "ThreeBillionCreditFacilityMember", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$3.0 Billion Credit Facility", "label": "Three Billion Credit Facility [Member]", "documentation": "Three Billion Credit Facility" } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Axis]", "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r1078", "r1265" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Domain]", "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r1078", "r1265" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r1232", "r1356" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetails", "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "crl_TotalEquityAttributabletoCommonShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TotalEquityAttributabletoCommonShareholdersMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total Equity Attributable to Common Shareholders", "label": "Total Equity Attributable to Common Shareholders [Member]", "documentation": "Total Equity Attributable to Common Shareholders [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1160" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1167" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Receivables and Contract Assets, Net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r277", "r278", "r279", "r423", "r424", "r426" ] }, "crl_TradeReceivablesFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TradeReceivablesFromCustomers", "crdr": "debit", "calculation": { "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails": { "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofClientReceivablesContractAssetsandContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Client receivables", "label": "Trade Receivables from Customers", "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for billed goods or services." } } }, "auth_ref": [] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.crl.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsNetbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks and trade names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r144" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1188" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1190" ] }, "crl_TradingDayAverageStockPriceOnGrantDate": { "xbrltype": "durationItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TradingDayAverageStockPriceOnGrantDate", "presentation": [ "http://www.crl.com/role/STOCKBASEDCOMPENSATIONPerformanceBasedStockAwardProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading day average stock price on grant date", "label": "Trading Day Average Stock Price On Grant Date", "documentation": "Trading Day Average Stock Price On Grant Date" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.crl.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services and products transferred at a point in time", "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredOverTimeMember", "presentation": [ "http://www.crl.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofRevenuesbyMajorBusinessLineDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services and products transferred over time", "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r1078" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1191" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1192" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1190" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1190" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1193" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1191" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r117" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r117" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost, zero shares as of December\u00a030, 2023 and December\u00a031, 2022", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66", "r117", "r118" ] }, "crl_TreasuryStockPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.crl.com/20231230", "localname": "TreasuryStockPolicyPolicyTextBlock", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Shares", "label": "Treasury Stock, Policy [Policy Text Block]", "documentation": "Treasury Stock, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Retirement of treasury shares", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r37", "r116", "r201" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of treasury shares (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r37", "r201", "r248" ] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesRetired", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Retirement of treasury shares (in shares)", "label": "Treasury Stock, Shares, Retired", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": [ "r37", "r201", "r248" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of treasury shares", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r37", "r117", "r248" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSNarrativeDetails", "http://www.crl.com/role/RESTRUCTURINGANDASSETIMPAIRMENTSSeveranceandRetentionCostsByClassificationontheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r465", "r466", "r471", "r472" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.crl.com/role/SEGMENTANDGEOGRAPHICINFORMATIONRevenueandLongLivedAssetsbyGeographicSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "crl_USFishAndWildlifeServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "USFishAndWildlifeServiceMember", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US Fish and Wildlife Service", "label": "US Fish and Wildlife Service [Member]", "documentation": "US Fish and Wildlife Service" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1187" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r692", "r700" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reductions to tax positions for prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r701" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r703" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued penalties related to unrecognized income tax benefits", "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return." } } }, "auth_ref": [ "r1334" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to tax positions for current year", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r702" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to tax positions for prior years", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r701" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest related to unrecognized income tax benefits", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r1334" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in unrecognized income tax benefits", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r1335" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.crl.com/role/INCOMETAXESChangeinTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expiration of statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r704" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.crl.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r705" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "presentation": [ "http://www.crl.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconditional purchase obligations", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts)." } } }, "auth_ref": [ "r475" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r86", "r87", "r88", "r284", "r285", "r288", "r289" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.crl.com/role/LEASESComponentsofOperatingandFinanceLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r794", "r1096" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.crl.com/role/DEBTANDOTHERFINANCINGARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLifeDetails", "http://www.crl.com/role/PROPERTYPLANTANDEQUIPMENTNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicles", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "crl_VentureCapitalAndEquityMethodInvestmentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.crl.com/20231230", "localname": "VentureCapitalAndEquityMethodInvestmentsGainLossNet", "crdr": "credit", "calculation": { "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on venture capital and strategic equity investments, net", "label": "Venture Capital And Equity Method Investments, Gain (Loss), Net", "documentation": "Venture Capital And Equity Method Investments, Gain (Loss), Net" } } }, "auth_ref": [] }, "crl_VentureCapitalFundsInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "VentureCapitalFundsInvestmentsMember", "presentation": [ "http://www.crl.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture Capital Funds", "label": "Venture Capital Funds Investments [Member]", "documentation": "Venture Capital Funds Investments" } } }, "auth_ref": [] }, "us-gaap_VentureCapitalFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VentureCapitalFundsMember", "presentation": [ "http://www.crl.com/role/VENTURECAPITALANDSTRATEGICEQUITYINVESTMENTSVentureCapitalInvestmentsandStrategicInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture Capital Funds", "label": "Venture Capital Funds [Member]", "documentation": "Funds that primarily invests in early stage enterprises or provides expansion capital in exchange for an equity stake and active management role in the invested enterprise." } } }, "auth_ref": [ "r1289" ] }, "crl_VigeneBiosciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "VigeneBiosciencesIncMember", "presentation": [ "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESDefiniteLivedIntangibleAssetsDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://www.crl.com/role/ACQUISITIONSANDDIVESTITURESPurchasePriceAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vigene", "label": "Vigene Biosciences, Inc. [Member]", "documentation": "Vigene Biosciences, Inc." } } }, "auth_ref": [] }, "crl_VitalRiverMember": { "xbrltype": "domainItemType", "nsuri": "http://www.crl.com/20231230", "localname": "VitalRiverMember", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSNonredeemableandRedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vital River", "label": "Vital River [Member]", "documentation": "Vital River [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average shares outstanding\u2014Diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r368", "r376" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted-average shares outstanding\u2014Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r367", "r376" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.crl.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.crl.com/role/EQUITYANDNONCONTROLLINGINTERESTSReconciliationofNumeratorandDenominatorintheComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "crl_WeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.crl.com/20231230", "localname": "WeightedAverageRemainingLeaseTermAbstract", "presentation": [ "http://www.crl.com/role/LEASESWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (in years)", "label": "Weighted Average Remaining Lease Term [Abstract]", "documentation": "Weighted Average Remaining Lease Term [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "SubTopic": "323", "Topic": "932", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482452/932-323-05-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(ee)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "24(b)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a),(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.18)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r239": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r240": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r241": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r242": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r243": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r244": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r245": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r246": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r247": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r248": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r249": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r250": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r251": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r252": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(j)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r253": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r256": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r257": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r258": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r259": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r260": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r261": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r262": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r263": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r264": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r265": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r266": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r267": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r268": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r269": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r270": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r271": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r272": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r273": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r274": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r275": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r276": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r277": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r278": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r279": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "325", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1197": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r1198": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 142 0001100682-24-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001100682-24-000007-xbrl.zip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�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�)SI/GYD+RD)AG2=#60KO-KNW: M_?K&.V35W96WK8 :KJSE:*YVCV1+01,2%%M8#6 F"$4&8#&ZE+@N3K?>VN] MZ)7!MT>*;".9=@[R_ -.:7"3VWR]PL20TX-U 2L+$B8O("@R4DMQ1C/-/,?6 MBO5I1&L:@#\J=QJ*K:&F^43#JL MFF!53B&2+S!H1(48I M&" R95":5FXT)-J$K'AC]$ MKMNE]O\5QTAS,9!1)4WN&@CI(X%!1JN:YB%D;YPT7DK3VOU^!$JO++ZF3-EN MUN]0X-]^N3L_K^CGAN?BAR>OW[X[^LO1F]/C/XZ:'Y(_].D=G9@_.Y!&Q^>' MD_./4_Q \AU^PJ7$W^#\I-0X"=?*Z6 Y),L]>7-(:]V3R25LH$U4LZ)%:1Y$ M?Q3.]J<%CW[T:M:(3H(64 +DC&B?DP&G#?THC#?,%:=2:[=R2\B].I!J1;3[ MYP^[$VO#DZM'06^T*VN=/:-]F31\H4&0>PW!*P$<0PS!FE12ZS2!QD-8

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end XML 143 crl-20231230_htm.xml IDEA: XBRL DOCUMENT 0001100682 2023-01-01 2023-12-30 0001100682 2023-06-30 0001100682 2024-01-27 0001100682 us-gaap:ServiceMember 2023-01-01 2023-12-30 0001100682 us-gaap:ServiceMember 2021-12-26 2022-12-31 0001100682 us-gaap:ServiceMember 2020-12-27 2021-12-25 0001100682 us-gaap:ProductMember 2023-01-01 2023-12-30 0001100682 us-gaap:ProductMember 2021-12-26 2022-12-31 0001100682 us-gaap:ProductMember 2020-12-27 2021-12-25 0001100682 2021-12-26 2022-12-31 0001100682 2020-12-27 2021-12-25 0001100682 2023-12-30 0001100682 2022-12-31 0001100682 2021-12-25 0001100682 2020-12-26 0001100682 us-gaap:CommonStockMember 2020-12-26 0001100682 us-gaap:AdditionalPaidInCapitalMember 2020-12-26 0001100682 us-gaap:RetainedEarningsMember 2020-12-26 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-26 0001100682 us-gaap:TreasuryStockCommonMember 2020-12-26 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2020-12-26 0001100682 us-gaap:NoncontrollingInterestMember 2020-12-26 0001100682 us-gaap:RetainedEarningsMember 2020-12-27 2021-12-25 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2020-12-27 2021-12-25 0001100682 us-gaap:NoncontrollingInterestMember 2020-12-27 2021-12-25 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-27 2021-12-25 0001100682 us-gaap:AdditionalPaidInCapitalMember 2020-12-27 2021-12-25 0001100682 us-gaap:CommonStockMember 2020-12-27 2021-12-25 0001100682 us-gaap:TreasuryStockCommonMember 2020-12-27 2021-12-25 0001100682 us-gaap:CommonStockMember 2021-12-25 0001100682 us-gaap:AdditionalPaidInCapitalMember 2021-12-25 0001100682 us-gaap:RetainedEarningsMember 2021-12-25 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-25 0001100682 us-gaap:TreasuryStockCommonMember 2021-12-25 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2021-12-25 0001100682 us-gaap:NoncontrollingInterestMember 2021-12-25 0001100682 us-gaap:RetainedEarningsMember 2021-12-26 2022-12-31 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2021-12-26 2022-12-31 0001100682 us-gaap:NoncontrollingInterestMember 2021-12-26 2022-12-31 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-26 2022-12-31 0001100682 us-gaap:AdditionalPaidInCapitalMember 2021-12-26 2022-12-31 0001100682 us-gaap:CommonStockMember 2021-12-26 2022-12-31 0001100682 us-gaap:TreasuryStockCommonMember 2021-12-26 2022-12-31 0001100682 us-gaap:CommonStockMember 2022-12-31 0001100682 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001100682 us-gaap:RetainedEarningsMember 2022-12-31 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001100682 us-gaap:TreasuryStockCommonMember 2022-12-31 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2022-12-31 0001100682 us-gaap:NoncontrollingInterestMember 2022-12-31 0001100682 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-30 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2023-01-01 2023-12-30 0001100682 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-30 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-30 0001100682 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-30 0001100682 us-gaap:CommonStockMember 2023-01-01 2023-12-30 0001100682 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-30 0001100682 us-gaap:CommonStockMember 2023-12-30 0001100682 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0001100682 us-gaap:RetainedEarningsMember 2023-12-30 0001100682 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-30 0001100682 us-gaap:TreasuryStockCommonMember 2023-12-30 0001100682 crl:TotalEquityAttributabletoCommonShareholdersMember 2023-12-30 0001100682 us-gaap:NoncontrollingInterestMember 2023-12-30 0001100682 crl:DiscoverAndSafetyAssessmentSegmentMember 2023-01-01 2023-12-30 0001100682 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-12-30 0001100682 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-12-30 0001100682 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-30 0001100682 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-30 0001100682 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-30 0001100682 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-30 0001100682 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-12-30 0001100682 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-12-30 0001100682 srt:MinimumMember us-gaap:VehiclesMember 2023-12-30 0001100682 srt:MaximumMember us-gaap:VehiclesMember 2023-12-30 0001100682 srt:MinimumMember crl:VentureCapitalFundsInvestmentsMember 2023-12-30 0001100682 srt:MaximumMember crl:VentureCapitalFundsInvestmentsMember 2023-12-30 0001100682 srt:MinimumMember 2023-12-30 0001100682 srt:MaximumMember 2023-12-30 0001100682 crl:NoveprimGroupMember 2023-11-30 0001100682 crl:NoveprimGroupMember 2022-12-31 0001100682 crl:NoveprimGroupMember 2021-12-26 2022-12-31 0001100682 crl:NoveprimGroupMember 2021-12-26 2023-11-30 0001100682 srt:MinimumMember crl:NoveprimGroupMember 2023-11-30 0001100682 srt:MaximumMember crl:NoveprimGroupMember 2023-11-30 0001100682 crl:SAMDITechIncMember 2023-01-27 2023-01-27 0001100682 crl:SAMDITechIncMember 2023-01-27 0001100682 crl:ExploraBioLabsMember 2022-04-05 0001100682 crl:ExploraBioLabsMember 2022-04-05 2022-04-05 0001100682 crl:VigeneBiosciencesIncMember 2021-06-28 2021-06-28 0001100682 crl:VigeneBiosciencesIncMember 2021-06-28 0001100682 srt:MaximumMember crl:VigeneBiosciencesIncMember 2021-06-28 0001100682 crl:VigeneBiosciencesIncMember 2022-12-31 0001100682 crl:VigeneBiosciencesIncMember 2023-12-30 0001100682 crl:RetrogenixLimitedMember 2021-03-30 2021-03-30 0001100682 crl:RetrogenixLimitedMember 2021-03-30 0001100682 crl:CognateBioServicesIncMember 2021-03-29 2021-03-29 0001100682 crl:DistributedBioIncMember 2020-12-31 2020-12-31 0001100682 crl:DistributedBioIncMember 2020-12-31 0001100682 srt:MaximumMember crl:DistributedBioIncMember 2020-12-31 0001100682 crl:DistributedBioIncMember 2021-12-26 2022-12-31 0001100682 crl:DistributedBioIncMember 2023-12-30 0001100682 crl:OtherAcquisitionsMember 2021-03-03 2021-03-03 0001100682 crl:OtherAcquisitionsMember 2019-12-29 2020-12-26 0001100682 crl:OtherAcquisitionsMember 2021-03-03 0001100682 crl:OtherAcquisitionsMember 2023-12-30 0001100682 2023-01-27 0001100682 2022-04-05 0001100682 crl:NoveprimGroupMember 2023-12-30 0001100682 crl:CognateBioServicesIncMember 2021-03-29 0001100682 crl:NoveprimGroupMember us-gaap:CustomerRelationshipsMember 2023-11-30 2023-11-30 0001100682 crl:SAMDITechIncMember us-gaap:CustomerRelationshipsMember 2023-01-27 2023-01-27 0001100682 crl:ExploraBioLabsMember us-gaap:CustomerRelationshipsMember 2022-04-05 2022-04-05 0001100682 crl:NoveprimGroupMember us-gaap:OtherIntangibleAssetsMember 2023-11-30 2023-11-30 0001100682 crl:SAMDITechIncMember us-gaap:OtherIntangibleAssetsMember 2023-01-27 2023-01-27 0001100682 crl:ExploraBioLabsMember us-gaap:OtherIntangibleAssetsMember 2022-04-05 2022-04-05 0001100682 crl:NoveprimGroupMember 2023-11-30 2023-11-30 0001100682 crl:VigeneBiosciencesIncMember us-gaap:CustomerRelationshipsMember 2021-06-28 2021-06-28 0001100682 crl:RetrogenixLimitedMember us-gaap:CustomerRelationshipsMember 2021-03-30 2021-03-30 0001100682 crl:CognateBioServicesIncMember us-gaap:CustomerRelationshipsMember 2021-03-29 2021-03-29 0001100682 crl:DistributedBioIncMember us-gaap:CustomerRelationshipsMember 2020-12-31 2020-12-31 0001100682 crl:VigeneBiosciencesIncMember us-gaap:OtherIntangibleAssetsMember 2021-06-28 2021-06-28 0001100682 crl:RetrogenixLimitedMember us-gaap:OtherIntangibleAssetsMember 2021-03-30 2021-03-30 0001100682 crl:CognateBioServicesIncMember us-gaap:OtherIntangibleAssetsMember 2021-03-29 2021-03-29 0001100682 crl:DistributedBioIncMember us-gaap:OtherIntangibleAssetsMember 2020-12-31 2020-12-31 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:AvianMember 2022-12-20 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:AvianMember 2023-12-30 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:AvianMember 2021-12-26 2022-12-31 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:RMSJapanOperationsMember 2021-10-12 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:RMSJapanOperationsMember 2021-10-12 2021-10-12 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:RMSJapanOperationsMember 2021-09-26 2021-12-25 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:CDMOSiteMember 2021-10-12 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:CDMOSiteMember 2021-10-12 2021-10-12 0001100682 srt:MaximumMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:CDMOSiteMember 2021-10-12 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:CDMOSiteMember 2022-12-31 0001100682 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember crl:AvianMember 2022-12-19 0001100682 crl:ResearchModelsAndServicesMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-30 0001100682 crl:ResearchModelsAndServicesMember us-gaap:TransferredOverTimeMember 2021-12-26 2022-12-31 0001100682 crl:ResearchModelsAndServicesMember us-gaap:TransferredOverTimeMember 2020-12-27 2021-12-25 0001100682 crl:ResearchModelsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-30 0001100682 crl:ResearchModelsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2021-12-26 2022-12-31 0001100682 crl:ResearchModelsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2020-12-27 2021-12-25 0001100682 crl:ResearchModelsAndServicesMember 2023-01-01 2023-12-30 0001100682 crl:ResearchModelsAndServicesMember 2021-12-26 2022-12-31 0001100682 crl:ResearchModelsAndServicesMember 2020-12-27 2021-12-25 0001100682 crl:DiscoveryandSafetyAssessmentMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-30 0001100682 crl:DiscoveryandSafetyAssessmentMember us-gaap:TransferredOverTimeMember 2021-12-26 2022-12-31 0001100682 crl:DiscoveryandSafetyAssessmentMember us-gaap:TransferredOverTimeMember 2020-12-27 2021-12-25 0001100682 crl:DiscoveryandSafetyAssessmentMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-30 0001100682 crl:DiscoveryandSafetyAssessmentMember us-gaap:TransferredAtPointInTimeMember 2021-12-26 2022-12-31 0001100682 crl:DiscoveryandSafetyAssessmentMember us-gaap:TransferredAtPointInTimeMember 2020-12-27 2021-12-25 0001100682 crl:DiscoveryandSafetyAssessmentMember 2023-01-01 2023-12-30 0001100682 crl:DiscoveryandSafetyAssessmentMember 2021-12-26 2022-12-31 0001100682 crl:DiscoveryandSafetyAssessmentMember 2020-12-27 2021-12-25 0001100682 crl:ManufacturingSupportMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-30 0001100682 crl:ManufacturingSupportMember us-gaap:TransferredOverTimeMember 2021-12-26 2022-12-31 0001100682 crl:ManufacturingSupportMember us-gaap:TransferredOverTimeMember 2020-12-27 2021-12-25 0001100682 crl:ManufacturingSupportMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-30 0001100682 crl:ManufacturingSupportMember us-gaap:TransferredAtPointInTimeMember 2021-12-26 2022-12-31 0001100682 crl:ManufacturingSupportMember us-gaap:TransferredAtPointInTimeMember 2020-12-27 2021-12-25 0001100682 crl:ManufacturingSupportMember 2023-01-01 2023-12-30 0001100682 crl:ManufacturingSupportMember 2021-12-26 2022-12-31 0001100682 crl:ManufacturingSupportMember 2020-12-27 2021-12-25 0001100682 2023-12-31 2023-12-30 0001100682 us-gaap:OperatingSegmentsMember crl:ResearchModelsAndServicesMember 2023-01-01 2023-12-30 0001100682 us-gaap:OperatingSegmentsMember crl:ResearchModelsAndServicesMember 2021-12-26 2022-12-31 0001100682 us-gaap:OperatingSegmentsMember crl:ResearchModelsAndServicesMember 2020-12-27 2021-12-25 0001100682 us-gaap:OperatingSegmentsMember crl:DiscoveryandSafetyAssessmentMember 2023-01-01 2023-12-30 0001100682 us-gaap:OperatingSegmentsMember crl:DiscoveryandSafetyAssessmentMember 2021-12-26 2022-12-31 0001100682 us-gaap:OperatingSegmentsMember crl:DiscoveryandSafetyAssessmentMember 2020-12-27 2021-12-25 0001100682 us-gaap:OperatingSegmentsMember crl:ManufacturingSupportMember 2023-01-01 2023-12-30 0001100682 us-gaap:OperatingSegmentsMember crl:ManufacturingSupportMember 2021-12-26 2022-12-31 0001100682 us-gaap:OperatingSegmentsMember crl:ManufacturingSupportMember 2020-12-27 2021-12-25 0001100682 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-30 0001100682 us-gaap:CorporateNonSegmentMember 2021-12-26 2022-12-31 0001100682 us-gaap:CorporateNonSegmentMember 2020-12-27 2021-12-25 0001100682 country:US 2023-01-01 2023-12-30 0001100682 srt:EuropeMember 2023-01-01 2023-12-30 0001100682 country:CA 2023-01-01 2023-12-30 0001100682 srt:AsiaPacificMember 2023-01-01 2023-12-30 0001100682 crl:OtherMember 2023-01-01 2023-12-30 0001100682 country:US 2023-12-30 0001100682 srt:EuropeMember 2023-12-30 0001100682 country:CA 2023-12-30 0001100682 srt:AsiaPacificMember 2023-12-30 0001100682 crl:OtherMember 2023-12-30 0001100682 country:US 2021-12-26 2022-12-31 0001100682 srt:EuropeMember 2021-12-26 2022-12-31 0001100682 country:CA 2021-12-26 2022-12-31 0001100682 srt:AsiaPacificMember 2021-12-26 2022-12-31 0001100682 crl:OtherMember 2021-12-26 2022-12-31 0001100682 country:US 2022-12-31 0001100682 srt:EuropeMember 2022-12-31 0001100682 country:CA 2022-12-31 0001100682 srt:AsiaPacificMember 2022-12-31 0001100682 crl:OtherMember 2022-12-31 0001100682 country:US 2020-12-27 2021-12-25 0001100682 srt:EuropeMember 2020-12-27 2021-12-25 0001100682 country:CA 2020-12-27 2021-12-25 0001100682 srt:AsiaPacificMember 2020-12-27 2021-12-25 0001100682 crl:OtherMember 2020-12-27 2021-12-25 0001100682 country:US 2021-12-25 0001100682 srt:EuropeMember 2021-12-25 0001100682 country:CA 2021-12-25 0001100682 srt:AsiaPacificMember 2021-12-25 0001100682 crl:OtherMember 2021-12-25 0001100682 us-gaap:LandMember 2023-12-30 0001100682 us-gaap:LandMember 2022-12-31 0001100682 us-gaap:BuildingMember 2023-12-30 0001100682 us-gaap:BuildingMember 2022-12-31 0001100682 us-gaap:MachineryAndEquipmentMember 2023-12-30 0001100682 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001100682 us-gaap:LeaseholdImprovementsMember 2023-12-30 0001100682 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001100682 us-gaap:FurnitureAndFixturesMember 2023-12-30 0001100682 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001100682 us-gaap:ComputerEquipmentMember 2023-12-30 0001100682 us-gaap:ComputerEquipmentMember 2022-12-31 0001100682 us-gaap:VehiclesMember 2023-12-30 0001100682 us-gaap:VehiclesMember 2022-12-31 0001100682 us-gaap:ConstructionInProgressMember 2023-12-30 0001100682 us-gaap:ConstructionInProgressMember 2022-12-31 0001100682 us-gaap:VentureCapitalFundsMember 2022-12-31 0001100682 us-gaap:VentureCapitalFundsMember 2021-12-25 0001100682 us-gaap:VentureCapitalFundsMember 2020-12-26 0001100682 us-gaap:VentureCapitalFundsMember 2023-01-01 2023-12-30 0001100682 us-gaap:VentureCapitalFundsMember 2021-12-26 2022-12-31 0001100682 us-gaap:VentureCapitalFundsMember 2020-12-27 2021-12-25 0001100682 us-gaap:VentureCapitalFundsMember 2023-12-30 0001100682 crl:StrategicInvestmentsMember 2022-12-31 0001100682 crl:StrategicInvestmentsMember 2021-12-25 0001100682 crl:StrategicInvestmentsMember 2020-12-26 0001100682 crl:StrategicInvestmentsMember 2023-01-01 2023-12-30 0001100682 crl:StrategicInvestmentsMember 2021-12-26 2022-12-31 0001100682 crl:StrategicInvestmentsMember 2020-12-27 2021-12-25 0001100682 crl:StrategicInvestmentsMember 2023-12-30 0001100682 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001100682 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001100682 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001100682 us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001100682 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001100682 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001100682 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001100682 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2022-12-31 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2021-12-25 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2020-12-26 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2023-01-01 2023-12-30 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2021-12-26 2022-12-31 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2020-12-27 2021-12-25 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2023-12-30 0001100682 srt:MaximumMember us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember 2023-12-30 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-30 0001100682 us-gaap:FairValueInputsLevel3Member crl:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2023-12-30 0001100682 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-11-30 0001100682 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-30 0001100682 crl:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2031Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2031Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2023-12-30 0001100682 crl:SeniorNotesDue2031Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:SeniorNotesDue2031Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-12-31 0001100682 crl:ResearchModelsAndServicesMember 2021-12-25 0001100682 crl:DiscoveryandSafetyAssessmentMember 2021-12-25 0001100682 crl:ManufacturingSupportMember 2021-12-25 0001100682 crl:ResearchModelsAndServicesMember 2022-12-31 0001100682 crl:DiscoveryandSafetyAssessmentMember 2022-12-31 0001100682 crl:ManufacturingSupportMember 2022-12-31 0001100682 crl:ResearchModelsAndServicesMember 2023-12-30 0001100682 crl:DiscoveryandSafetyAssessmentMember 2023-12-30 0001100682 crl:ManufacturingSupportMember 2023-12-30 0001100682 crl:BiologicSolutionsMember 2023-12-30 0001100682 us-gaap:CustomerRelationshipsMember 2023-12-30 0001100682 us-gaap:CustomerRelationshipsMember 2022-12-31 0001100682 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-30 0001100682 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0001100682 us-gaap:OrderOrProductionBacklogMember 2023-12-30 0001100682 us-gaap:OrderOrProductionBacklogMember 2022-12-31 0001100682 us-gaap:TrademarksAndTradeNamesMember 2023-12-30 0001100682 us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001100682 us-gaap:OtherIntangibleAssetsMember 2023-12-30 0001100682 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001100682 us-gaap:LineOfCreditMember 2023-12-30 0001100682 us-gaap:LineOfCreditMember 2022-12-31 0001100682 crl:OtherLongTermDebtMember 2023-12-30 0001100682 crl:OtherLongTermDebtMember 2022-12-31 0001100682 crl:SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2020-12-27 2021-12-25 0001100682 us-gaap:RevolvingCreditFacilityMember crl:ThreeBillionCreditFacilityMember 2021-06-26 0001100682 us-gaap:RevolvingCreditFacilityMember crl:ThreeBillionCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2021-06-26 2021-06-26 0001100682 us-gaap:RevolvingCreditFacilityMember crl:ThreeBillionCreditFacilityMember crl:SecuredOvernightFinancingRateSOFRMember 2021-06-26 2021-06-26 0001100682 us-gaap:RevolvingCreditFacilityMember crl:ThreeBillionCreditFacilityMember 2023-12-30 0001100682 crl:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2019-12-28 0001100682 crl:SeniorNotesDue2029And2031Member us-gaap:SeniorNotesMember 2021-12-25 0001100682 crl:SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2021-12-25 0001100682 crl:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2021-12-25 0001100682 crl:SeniorNotesDue2029And2031Member us-gaap:SeniorNotesMember 2020-12-27 2021-12-25 0001100682 crl:SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2018-12-29 0001100682 us-gaap:MediumTermNotesMember 2020-12-27 2021-12-25 0001100682 us-gaap:RevolvingCreditFacilityMember 2020-12-27 2021-12-25 0001100682 srt:MinimumMember us-gaap:ForeignExchangeForwardMember 2021-12-25 0001100682 srt:MinimumMember us-gaap:ForeignExchangeForwardMember 2022-12-31 0001100682 srt:MaximumMember us-gaap:ForeignExchangeForwardMember 2021-12-25 0001100682 srt:MaximumMember us-gaap:ForeignExchangeForwardMember 2022-12-31 0001100682 us-gaap:ForeignExchangeForwardMember us-gaap:InterestExpenseMember 2021-12-26 2022-12-31 0001100682 us-gaap:ForeignExchangeForwardMember us-gaap:InterestExpenseMember 2020-12-27 2021-12-25 0001100682 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-12-26 2022-12-31 0001100682 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-12-27 2021-12-25 0001100682 us-gaap:LetterOfCreditMember 2023-12-30 0001100682 us-gaap:LetterOfCreditMember 2022-12-31 0001100682 crl:AuthorizedShareRepurchaseProgramMember 2023-12-30 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-26 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-26 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-26 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-27 2021-12-25 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-27 2021-12-25 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-27 2021-12-25 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-25 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-25 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-25 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-26 2022-12-31 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-26 2022-12-31 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-26 2022-12-31 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-30 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-30 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-30 0001100682 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-30 0001100682 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-30 0001100682 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-30 0001100682 crl:NoveprimGroupMember srt:MinimumMember 2023-12-30 0001100682 crl:NoveprimGroupMember srt:MaximumMember 2023-12-30 0001100682 crl:VitalRiverMember 2022-12-31 0001100682 crl:VitalRiverMember 2023-12-30 0001100682 crl:VitalRiverMember 2023-10-01 2023-12-30 0001100682 crl:SupplierMember 2020-12-26 0001100682 crl:SupplierMember 2022-06-30 0001100682 crl:SupplierMember 2022-06-01 2022-06-30 0001100682 crl:SupplierMember 2023-12-30 0001100682 us-gaap:ForeignCountryMember 2023-12-30 0001100682 us-gaap:ForeignCountryMember 2022-12-31 0001100682 us-gaap:ForeignCountryMember crl:TaxCreditCarryforwardsExpirationRange2Member 2023-12-30 0001100682 us-gaap:ForeignPlanMember 2023-01-01 2023-12-30 0001100682 us-gaap:FundedPlanMember us-gaap:ForeignPlanMember 2023-01-01 2023-12-30 0001100682 us-gaap:ForeignPlanMember 2021-12-26 2022-12-31 0001100682 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-30 0001100682 us-gaap:PensionPlansDefinedBenefitMember 2021-12-26 2022-12-31 0001100682 us-gaap:PensionPlansDefinedBenefitMember 2020-12-27 2021-12-25 0001100682 us-gaap:EquitySecuritiesMember 2023-12-30 0001100682 us-gaap:DebtSecuritiesMember 2023-12-30 0001100682 crl:OtherPlanAssetCategoriesMember 2023-12-30 0001100682 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2023-12-30 0001100682 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2023-12-30 0001100682 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2023-12-30 0001100682 us-gaap:CashAndCashEquivalentsMember 2023-12-30 0001100682 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001100682 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001100682 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001100682 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0001100682 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-12-30 0001100682 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-30 0001100682 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-12-30 0001100682 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001100682 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001100682 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001100682 us-gaap:EquitySecuritiesMember 2022-12-31 0001100682 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-12-30 0001100682 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-30 0001100682 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-12-30 0001100682 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001100682 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001100682 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001100682 us-gaap:DebtSecuritiesMember 2022-12-31 0001100682 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-30 0001100682 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member 2023-12-30 0001100682 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member 2023-12-30 0001100682 us-gaap:EquityFundsMember 2023-12-30 0001100682 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001100682 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001100682 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001100682 us-gaap:EquityFundsMember 2022-12-31 0001100682 crl:OtherPlanAssetCategoriesMember us-gaap:FairValueInputsLevel1Member 2023-12-30 0001100682 crl:OtherPlanAssetCategoriesMember us-gaap:FairValueInputsLevel2Member 2023-12-30 0001100682 crl:OtherPlanAssetCategoriesMember us-gaap:FairValueInputsLevel3Member 2023-12-30 0001100682 crl:OtherPlanAssetCategoriesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001100682 crl:OtherPlanAssetCategoriesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001100682 crl:OtherPlanAssetCategoriesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001100682 crl:OtherPlanAssetCategoriesMember 2022-12-31 0001100682 us-gaap:FairValueInputsLevel1Member 2023-12-30 0001100682 us-gaap:FairValueInputsLevel2Member 2023-12-30 0001100682 us-gaap:FairValueInputsLevel3Member 2023-12-30 0001100682 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001100682 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001100682 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001100682 us-gaap:PensionPlansDefinedBenefitMember 2023-12-30 0001100682 us-gaap:EmployeeStockOptionMember 2020-12-27 2021-12-25 0001100682 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-30 0001100682 us-gaap:EmployeeStockOptionMember 2021-12-26 2022-12-31 0001100682 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-12-26 2022-12-31 0001100682 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-30 0001100682 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-12-27 2021-12-25 0001100682 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-30 0001100682 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-12-27 2021-12-25 0001100682 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-12-26 2022-12-31 0001100682 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-30 0001100682 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2021-12-26 2022-12-31 0001100682 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2020-12-27 2021-12-25 0001100682 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-12-30 0001100682 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-12-25 0001100682 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-12-31 0001100682 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-12-26 2022-12-31 0001100682 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-30 0001100682 srt:MinimumMember us-gaap:PerformanceSharesMember 2020-12-27 2021-12-25 0001100682 us-gaap:CostOfSalesMember 2023-01-01 2023-12-30 0001100682 us-gaap:CostOfSalesMember 2021-12-26 2022-12-31 0001100682 us-gaap:CostOfSalesMember 2020-12-27 2021-12-25 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-30 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-12-26 2022-12-31 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-12-27 2021-12-25 0001100682 us-gaap:EmployeeStockOptionMember 2023-12-30 0001100682 crl:RestrictedStockandRestrictedStockUnitsMember 2022-12-31 0001100682 crl:RestrictedStockandRestrictedStockUnitsMember 2023-01-01 2023-12-30 0001100682 crl:RestrictedStockandRestrictedStockUnitsMember 2023-12-30 0001100682 us-gaap:RestrictedStockMember 2023-12-30 0001100682 us-gaap:RestrictedStockMember 2023-01-01 2023-12-30 0001100682 us-gaap:RestrictedStockMember 2021-12-26 2022-12-31 0001100682 us-gaap:RestrictedStockMember 2020-12-27 2021-12-25 0001100682 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-30 0001100682 crl:PerformanceSharesGranteeGroupOneMember us-gaap:PerformanceSharesMember 2023-01-01 2023-12-30 0001100682 crl:PerformanceSharesGranteeGroupOneMember us-gaap:PerformanceSharesMember 2021-12-26 2022-12-31 0001100682 crl:PerformanceSharesGranteeGroupOneMember us-gaap:PerformanceSharesMember 2020-12-27 2021-12-25 0001100682 us-gaap:PerformanceSharesMember 2021-12-26 2022-12-31 0001100682 us-gaap:PerformanceSharesMember 2020-12-27 2021-12-25 0001100682 us-gaap:PerformanceSharesMember 2023-12-30 0001100682 crl:PerformanceSharesGranteeGroupTwoMember us-gaap:PerformanceSharesMember 2020-12-27 2021-12-25 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember crl:SeveranceAndTransitionCostsMember 2023-01-01 2023-12-30 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember crl:AssetImpairmentAndOtherCostsMember 2023-01-01 2023-12-30 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-30 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember crl:SeveranceAndTransitionCostsMember 2023-01-01 2023-12-30 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember crl:AssetImpairmentAndOtherCostsMember 2023-01-01 2023-12-30 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-30 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember crl:SeveranceAndTransitionCostsMember 2023-01-01 2023-12-30 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember crl:AssetImpairmentAndOtherCostsMember 2023-01-01 2023-12-30 0001100682 crl:SeveranceAndTransitionCostsMember 2023-01-01 2023-12-30 0001100682 crl:AssetImpairmentAndOtherCostsMember 2023-01-01 2023-12-30 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember crl:SeveranceAndTransitionCostsMember 2021-12-26 2022-12-31 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember crl:AssetImpairmentAndOtherCostsMember 2021-12-26 2022-12-31 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember 2021-12-26 2022-12-31 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember crl:SeveranceAndTransitionCostsMember 2021-12-26 2022-12-31 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember crl:AssetImpairmentAndOtherCostsMember 2021-12-26 2022-12-31 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember 2021-12-26 2022-12-31 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember crl:SeveranceAndTransitionCostsMember 2021-12-26 2022-12-31 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember crl:AssetImpairmentAndOtherCostsMember 2021-12-26 2022-12-31 0001100682 crl:SeveranceAndTransitionCostsMember 2021-12-26 2022-12-31 0001100682 crl:AssetImpairmentAndOtherCostsMember 2021-12-26 2022-12-31 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember crl:SeveranceAndTransitionCostsMember 2020-12-27 2021-12-25 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember crl:AssetImpairmentAndOtherCostsMember 2020-12-27 2021-12-25 0001100682 us-gaap:ServiceMember us-gaap:CostOfSalesMember 2020-12-27 2021-12-25 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember crl:SeveranceAndTransitionCostsMember 2020-12-27 2021-12-25 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember crl:AssetImpairmentAndOtherCostsMember 2020-12-27 2021-12-25 0001100682 us-gaap:ProductMember us-gaap:CostOfSalesMember 2020-12-27 2021-12-25 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember crl:SeveranceAndTransitionCostsMember 2020-12-27 2021-12-25 0001100682 us-gaap:SellingGeneralAndAdministrativeExpensesMember crl:AssetImpairmentAndOtherCostsMember 2020-12-27 2021-12-25 0001100682 crl:SeveranceAndTransitionCostsMember 2020-12-27 2021-12-25 0001100682 crl:AssetImpairmentAndOtherCostsMember 2020-12-27 2021-12-25 0001100682 crl:AccruedCompensationMember crl:SeveranceAndTransitionCostsMember 2023-12-30 0001100682 crl:AccruedCompensationMember crl:SeveranceAndTransitionCostsMember 2022-12-31 0001100682 crl:USFishAndWildlifeServiceMember us-gaap:PendingLitigationMember 2023-12-30 0001100682 2023-10-01 2023-12-30 0001100682 crl:JamesFosterMember 2023-01-01 2023-12-30 0001100682 crl:JamesFosterMember 2023-10-01 2023-12-30 0001100682 crl:JamesFosterMember 2023-12-30 0001100682 crl:BirgitGirshickMember 2023-01-01 2023-12-30 0001100682 crl:BirgitGirshickMember 2023-10-01 2023-12-30 0001100682 crl:BirgitGirshickMember 2023-12-30 0001100682 crl:MsGirshickMember 2023-01-01 2023-12-30 0001100682 crl:MsGirshickMember 2023-10-01 2023-12-30 0001100682 crl:MsGirshickMember 2023-12-30 iso4217:USD shares iso4217:USD shares crl:segment crl:subsegment pure crl:contract 0001100682 2023 FY false P8Y P0Y http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent P5Y http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations 10-K true 2023-12-30 --12-30 false 001-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. DE 06-1397316 251 Ballardvale Street Wilmington MA 01887 781 222-6000 Common stock, $0.01 par value CRL NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 10686736278 51349770 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Portions of the registrant’s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders currently scheduled to be held on May 8, 2024, which will be filed with the Securities and Exchange Commission (SEC) not later than 120 days after December 30, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the 2024 Proxy Statement expressly incorporated into this Annual Report on Form 10-K by reference, such document shall not be deemed filed as part of this Form 10-K.</span></div> 238 PricewaterhouseCoopers LLP Boston, Massachusetts 3440019000 3216904000 2755579000 689390000 759156000 784581000 4129409000 3976060000 3540160000 2295983000 2143318000 1837487000 330870000 370091000 368035000 747855000 665098000 619919000 137440000 146578000 124857000 617261000 650975000 589862000 5196000 780000 652000 136710000 59291000 73910000 95537000 30523000 -35894000 581284000 622987000 480710000 100914000 130379000 81873000 480370000 492608000 398837000 5746000 6382000 7855000 474624000 486226000 390982000 9.27 9.57 7.77 9.22 9.48 7.60 51227000 50812000 50293000 51451000 51301000 51425000 480370000 492608000 398837000 70651000 -129091000 -29493000 5376000 -24471000 1193000 736000 3337000 1678000 2490000 -1523000 0 68501000 -102806000 -29008000 4071000 -1905000 -3965000 544800000 391707000 373794000 4546000 2798000 8678000 540254000 388909000 365116000 276771000 233912000 25722000 11278000 780375000 752390000 380259000 255809000 87879000 89341000 83378000 107580000 1608662000 1439032000 1639741000 1465655000 243811000 311602000 394029000 391762000 3095045000 2849903000 864051000 955275000 40279000 41262000 309383000 148279000 8195001000 7602770000 168937000 205915000 213290000 197078000 241820000 264259000 227825000 219758000 203210000 204575000 1055082000 1091585000 2647147000 2707531000 419234000 389745000 191349000 215582000 223191000 174822000 4536003000 4579265000 56722000 42427000 0.01 0.01 20000000 20000000 0 0 0 0 0 0 0.01 0.01 120000000 120000000 51338000 51338000 50944000 50944000 513000 509000 1905578000 1804940000 1887218000 1432901000 0 0 0 0 -196427000 -262057000 3596882000 2976293000 5394000 4785000 3602276000 2981078000 8195001000 7602770000 480370000 492608000 398837000 314124000 303870000 265540000 72048000 73617000 71474000 -3967000 -4118000 -29964000 -50903000 -35884000 -24006000 41911000 5816000 733000 97827000 -26775000 -30420000 18225000 6706000 1657000 -961000 123405000 25026000 1810000 -3753000 -34303000 -1592000 -21726000 -2567000 33434000 150570000 26633000 62301000 78523000 25159000 -20427000 -2652000 44901000 12447000 -42164000 44304000 -21743000 57658000 -13402000 -15564000 30457000 16925000 -38642000 -33240000 -2006000 683898000 619640000 760799000 194785000 283392000 1293095000 318528000 324733000 228772000 54215000 158274000 45555000 6667000 4549000 6532000 0 163275000 122694000 2294000 9347000 -264000 -563155000 -607922000 -1437932000 776353000 2952430000 6951113000 25597000 25110000 45652000 851676000 2932636000 6242877000 24155000 38651000 40707000 0 0 38255000 2711000 10356000 2328000 4784000 30533000 0 -4145000 -7761000 0 -85521000 -42397000 672598000 8044000 25579000 17730000 43266000 -5100000 13195000 241214000 246314000 233119000 284480000 241214000 246314000 49767000 498000 1627564000 625414000 -138874000 0 0 2114602000 3567000 2118169000 390982000 390982000 2480000 393462000 -25866000 -25866000 -25866000 1885000 1885000 21312000 21312000 21312000 861000 8000 45639000 45647000 45647000 148000 40707000 40707000 40707000 148000 1000 5061000 35645000 148000 -40707000 0 0 71474000 71474000 71474000 50480000 505000 1718304000 980751000 -164740000 0 0 2534820000 4162000 2538982000 486226000 486226000 2362000 488588000 -97317000 -97317000 -97317000 1739000 1739000 7507000 7507000 7507000 594000 5000 25100000 25105000 25105000 130000 38651000 38651000 38651000 130000 1000 4574000 34076000 130000 -38651000 0 0 73617000 73617000 73617000 50944000 509000 1804940000 1432901000 -262057000 0 0 2976293000 4785000 2981078000 474624000 474624000 2254000 476878000 65630000 65630000 65630000 1645000 1645000 -5694000 -5694000 -5694000 -1151000 -1151000 -1151000 499000 5000 25592000 25597000 25597000 105000 24155000 24155000 24155000 105000 1000 3847000 20307000 105000 -24155000 0 0 72048000 72048000 72048000 51338000 513000 1905578000 1887218000 -196427000 0 0 3596882000 5394000 3602276000 DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charles River Laboratories International, Inc. (the Company), together with its subsidiaries, is a full service, non-clinical global drug development partner. The Company has built upon its core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that enable the Company to support its clients from target identification through non-clinical development. The Company also provides a suite of products and services to support its clients’ manufacturing activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which occurred in fiscal year 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">esearch Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities and utilizing our Charles River Accelerator and Development Lab (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRADL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO). In December of 2022, the Company sold the Avian Vaccine Services business (Avian), reported in the Manufacturing segment, which supplied specific-pathogen-free chicken eggs and chickens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company participates in certain supplier finance programs that are immaterial to the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but does not believe there will be a material impact. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables and Contract Assets, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 3.5% of revenue in fiscal years 2023, 2022, or 2021 or trade receivables as of December 30, 2023 or December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rate yield curves and foreign currency spot rates,</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash equivalents - Valued at market prices determined through third-party pricing services;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest rate swap contracts - Valued using market observable inputs, such as interest rate yield curves; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments - The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain option pricing models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell solutions, microbial solutions, and CDMO products. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with certain direct materials, costs of personnel directly involved in the care of the models, and allocation of facility overhead costs. For cell solutions inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions and CDMO inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.847%"><tr><td style="width:1.0%"></td><td style="width:75.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10 - 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5 - 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 5</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets and certain biological assets, which can represent a significant portion of the purchase price. The determination of the fair value of intangible and certain biological assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such assets are amortizable or non-amortizable and, if the former, the period and the method by which the asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of assets. Typically, key assumptions include projections of cash flows that arise from identifiable assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) and certain biological assets are the most significant identifiable asset acquired. To determine the fair value of these acquired assets, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue, cost of revenue, operating income margins, customer attrition rates, and productivity rates; as well as discount rates based on a market participant’s weighted average cost of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records divestitures at fair value less cost to sell with any related gain or loss from sale recorded within Other income (expense) on the Company’s consolidated statements of income. If the sale price includes contingent payments, these </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are fair valued using a probability weighted model. If the business divested is part of a reporting unit, goodwill from the reporting unit is reallocated based on the fair value of the divested business compared to the fair value of the reporting unit. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Impairment of Long-Lived Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Venture Capital Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in Other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Equity Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The Company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. The Company uses an interest rate swap to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses short-term forward currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans. The currency-exchange contracts principally hedge transactions denominated in Canadian dollars and euros. The Company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Life Insurance Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from life insurance contracts are recorded in Other income (expense), net in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of income. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. The Company held 44 contracts at December 30, 2023 with a face value of $82.4 million and 44 contracts with a face value of $74.5 million at December 31, 2022, which are recorded in Other assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock options and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of RSUs is based on the market value of the Company’s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year, and recorded within service revenue. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Cumulative catch-up adjustments to revenue are periodically recorded that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration), or a contract modification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements carrying amounts and their respective tax basis. The Company measures deferred tax assets and liabilities using the enacted tax rates in effect when the temporary differences are expected to be settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency contracts are recorded at fair value in the Company’s consolidated balance sheets and are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loan. Any gains or losses on forward contracts associated with the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity under the Company’s Credit Facility are recognized immediately in Interest expense. Gains or losses incurred on the remeasurement of the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency is recorded in Other (expense) income, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive loss, a separate component of equity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension and Other Post-Retirement Benefit Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the funded status of its defined benefit pension and other post-retirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The Company measures plan assets and benefit obligations as of its fiscal year end. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key assumptions used to calculate benefit obligations and related pension costs include expected long-term rate of return on plan assets, withdrawal and mortality rates, expected rate of increase in employee compensation levels and a discount rate. Assumptions are determined based on the Company’s data and appropriate market indicators, and evaluated each year as of the plan’s measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the Company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and the current employee compensation strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to recognize as a component of Other comprehensive income, net of tax, the actuarial gains or losses and prior service costs or credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive income is adjusted as these amounts are later recognized in income as components of net periodic benefit cost. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the service cost component of the net periodic benefit cost within Cost of services provided and Selling, general, and administrative expenses and all other components of net periodic benefit cost within Other (expense) income, net in the consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes pension settlement gains or losses in the period when all of the following settlement criteria are met: there is an irrevocable action, the Company is relieved of primary responsibility for a benefit obligation, and significant risks related to the obligation and the assets used to effect the settlement are eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Except where the result would be anti-dilutive to income from continuing operations, diluted earnings per share is computed using the treasury stock method, assuming the exercise of stock options and the vesting of RSUs, or evaluating the performance conditions for PSUs to assess whether the conditions have been met, as well as their related income tax effects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically retires treasury shares acquired through share repurchases and returns those shares to the status of authorized but unissued. The Company accounts for treasury stock transactions under the cost method. For each reacquisition of common stock, the number of shares and the acquisition price for those shares is added to the existing treasury stock count and total value. Thus, the average cost per share is re-averaged each time shares are acquired. When treasury shares are retired, the Company allocates the excess of the repurchase price over the par value of shares acquired to both retained earnings and additional paid-in-capital. The portion allocated to additional paid-in-capital is determined by applying a percentage, determined by dividing the number of shares to be retired by the number of shares issued, to the balance of additional paid-in-capital as of the retirement date.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which occurred in fiscal year 2022.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">esearch Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities and utilizing our Charles River Accelerator and Development Lab (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRADL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO). In December of 2022, the Company sold the Avian Vaccine Services business (Avian), reported in the Manufacturing segment, which supplied specific-pathogen-free chicken eggs and chickens.</span></div> 3 2 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASU 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” ASU 2022-04 requires quantitative and qualitative disclosures about the use of supplier finance programs. The ASU is effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years for selected disclosures, and will be applied on a prospective basis. The Company participates in certain supplier finance programs that are immaterial to the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but does not believe there will be a material impact. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables and Contract Assets, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 3.5% of revenue in fiscal years 2023, 2022, or 2021 or trade receivables as of December 30, 2023 or December 31, 2022.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rate yield curves and foreign currency spot rates,</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash equivalents - Valued at market prices determined through third-party pricing services;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest rate swap contracts - Valued using market observable inputs, such as interest rate yield curves; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments - The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain option pricing models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell solutions, microbial solutions, and CDMO products. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with certain direct materials, costs of personnel directly involved in the care of the models, and allocation of facility overhead costs. For cell solutions inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions and CDMO inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.847%"><tr><td style="width:1.0%"></td><td style="width:75.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10 - 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5 - 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 5</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.847%"><tr><td style="width:1.0%"></td><td style="width:75.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10 - 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5 - 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 - 5</span></div></td></tr></table></div> P10Y P40Y P3Y P20Y P5Y P10Y P3Y P8Y P3Y P5Y <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets and certain biological assets, which can represent a significant portion of the purchase price. The determination of the fair value of intangible and certain biological assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such assets are amortizable or non-amortizable and, if the former, the period and the method by which the asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of assets. Typically, key assumptions include projections of cash flows that arise from identifiable assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) and certain biological assets are the most significant identifiable asset acquired. To determine the fair value of these acquired assets, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue, cost of revenue, operating income margins, customer attrition rates, and productivity rates; as well as discount rates based on a market participant’s weighted average cost of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records divestitures at fair value less cost to sell with any related gain or loss from sale recorded within Other income (expense) on the Company’s consolidated statements of income. If the sale price includes contingent payments, these </span></div>are fair valued using a probability weighted model. If the business divested is part of a reporting unit, goodwill from the reporting unit is reallocated based on the fair value of the divested business compared to the fair value of the reporting unit. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Impairment of Long-Lived Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Venture Capital Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in Other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information.</span></div> 0.01 0.12 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Equity Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of income.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The Company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. The Company uses an interest rate swap to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses short-term forward currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans. The currency-exchange contracts principally hedge transactions denominated in Canadian dollars and euros. The Company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Life Insurance Contracts</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from life insurance contracts are recorded in Other income (expense), net in the accompanying </span>consolidated statements of income. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. 44 82400000 44 74500000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements.</span></div> P1Y P5Y <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock options and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of RSUs is based on the market value of the Company’s common stock on the date of grant.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year, and recorded within service revenue. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Cumulative catch-up adjustments to revenue are periodically recorded that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration), or a contract modification.</span></div> P30D <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements carrying amounts and their respective tax basis. The Company measures deferred tax assets and liabilities using the enacted tax rates in effect when the temporary differences are expected to be settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency contracts are recorded at fair value in the Company’s consolidated balance sheets and are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loan. Any gains or losses on forward contracts associated with the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity under the Company’s Credit Facility are recognized immediately in Interest expense. Gains or losses incurred on the remeasurement of the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency is recorded in Other (expense) income, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive loss, a separate component of equity.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension and Other Post-Retirement Benefit Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the funded status of its defined benefit pension and other post-retirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The Company measures plan assets and benefit obligations as of its fiscal year end. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key assumptions used to calculate benefit obligations and related pension costs include expected long-term rate of return on plan assets, withdrawal and mortality rates, expected rate of increase in employee compensation levels and a discount rate. Assumptions are determined based on the Company’s data and appropriate market indicators, and evaluated each year as of the plan’s measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the Company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and the current employee compensation strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to recognize as a component of Other comprehensive income, net of tax, the actuarial gains or losses and prior service costs or credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive income is adjusted as these amounts are later recognized in income as components of net periodic benefit cost. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the service cost component of the net periodic benefit cost within Cost of services provided and Selling, general, and administrative expenses and all other components of net periodic benefit cost within Other (expense) income, net in the consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes pension settlement gains or losses in the period when all of the following settlement criteria are met: there is an irrevocable action, the Company is relieved of primary responsibility for a benefit obligation, and significant risks related to the obligation and the assets used to effect the settlement are eliminated.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Except where the result would be anti-dilutive to income from continuing operations, diluted earnings per share is computed using the treasury stock method, assuming the exercise of stock options and the vesting of RSUs, or evaluating the performance conditions for PSUs to assess whether the conditions have been met, as well as their related income tax effects.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically retires treasury shares acquired through share repurchases and returns those shares to the status of authorized but unissued. The Company accounts for treasury stock transactions under the cost method. For each reacquisition of common stock, the number of shares and the acquisition price for those shares is added to the existing treasury stock count and total value. Thus, the average cost per share is re-averaged each time shares are acquired. When treasury shares are retired, the Company allocates the excess of the repurchase price over the par value of shares acquired to both retained earnings and additional paid-in-capital. The portion allocated to additional paid-in-capital is determined by applying a percentage, determined by dividing the number of shares to be retired by the number of shares issued, to the balance of additional paid-in-capital as of the retirement date.</span></div> ACQUISITIONS AND DIVESTITURES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal 2023 Acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noveprim Group</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the Company completed the acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance. The total consideration allocable to the Noveprim acquisition is $374.8 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $198.8 million which includes a remeasurement gain on the 49% equity investment of $103.2 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $13.8 million. The contingent consideration fair value is estimated using a Monte Carlo Simulation model and the maximum contingent contractual payments are up to $55.0 million based on future performance and milestone achievements from in fiscal years 2023 through 2025. The Company has the call option right to purchase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller. The redemption price for the call/put is fixed and ranges from $47.0 million to $54.0 million depending on when exercised. The noncontrolling interest is classified as a redeemable noncontrolling interest in the mezzanine section of the consolidated balance sheet. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SAMDI Tech, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2023, the Company acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by the Company of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal 2022 Acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Explora BioLabs Holdings, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, the Company acquired Explora BioLabs Holdings, Inc. (Explora BioLabs), a provider of contract vivarium research services, providing biopharmaceutical clients with turnkey </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vivarium facilities, management and related services to efficiently conduct their early-stage research activities. The acquisition of Explora BioLabs complements the Company’s existing Insourcing Solutions business, specifically the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRADL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™ (Charles River Accelerator and Development Lab) footprint, and offers incremental opportunities to partner with an emerging client base, many of which are engaged in cell and gene therapy development. The purchase price of Explora BioLabs was $284.5 million, net of $6.6 million in cash. The acquisition was funded through proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s RMS reportable segment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal 2021 Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vigene Biosciences, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2021, the Company acquired Vigene Biosciences, Inc. (Vigene), a gene therapy CDMO, providing viral vector-based gene delivery solutions. The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The purchase price of Vigene was $323.9 million, net of $2.7 million in cash. Included in the purchase price are contingent payments fair valued at $34.5 million, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $57.5 million based on future performance). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s Manufacturing reportable segment. As of December 30, 2023 and December 31, 2022 the fair value of the contingent consideration was zero as certain financial targets have not and are not expected to be achieved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retrogenix Limited</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2021, the Company acquired Retrogenix Limited (Retrogenix), an outsourced discovery services provider specializing in bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances the Company’s scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash. Included in the purchase price are contingent payments fair valued at $6.9 million, which is the maximum potential payout, and was based on a probability-weighted approach. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cognate BioServices, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2021, the Company acquired Cognate BioServices, Inc. (Cognate), a cell and gene therapy CDMO offering comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain. The acquisition of Cognate establishes the Company as a scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through cGMP production. The purchase price of Cognate was $877.9 million, net of $70.5 million in cash and includes $15.7 million of consideration for an approximate 2% ownership interest not initially acquired, but redeemed in April 2022 with the ultimate payout tied to performance in 2021. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility and senior notes (Senior Notes) issued in fiscal 2021. This business is reported as part of the Company’s Manufacturing reportable segment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributed Bio, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company acquired Distributed Bio, Inc. (Distributed Bio), a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. The acquisition of Distributed Bio expands the Company’s capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development. The purchase price of Distributed Bio was $97.0 million, net of $0.8 million in cash. The total consideration includes $80.8 million cash paid, settlement of $3.0 million in convertible promissory notes previously issued by the Company during prior fiscal years, and $14.1 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $21.0 million based on future performance and milestone achievements over a one-year period). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. During fiscal year 2022, $7.0 million of contingent consideration was paid as certain operational milestones were achieved. As of December 30, 2023, other financial targets associated with the contingent consideration were not met and the fair value of the remaining contingent consideration is zero.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2021, the Company acquired certain assets from a distributor that supports the Company’s DSA reportable segment. The purchase price was $35.4 million, which includes $19.5 million in cash paid ($5.5 million of which was paid in fiscal 2020), and $15.9 million of contingent consideration, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $17.5 million based on future performance over a three-year period). The fair value of the net assets acquired included $17.3 million of goodwill, $15.2 million attributed to supplier relationships (to be amortized over a 4-year period), and $3.0 million of property, plant, and equipment. The business is reported as part of the Company’s DSA reportable segment. As of December 30, 2023, the fair value of the contingent consideration was zero as certain operational targets were not achieved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase price information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation for acquisitions during fiscal years 2023 and 2022 was as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:43.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noveprim Group</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SAMDI Tech, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Explora BioLabs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 27, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 5, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets (excluding cash)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use liabilities (Long-term)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase price allocation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is deductible for tax purposes. </span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated <span style="-sec-ix-hidden:f-637">eight</span> year useful life.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation for acquisitions during fiscal years 2021 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:29.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vigene</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retrogenix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cognate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distributed Bio</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 28, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 29, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use liabilities (Long-term)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,958)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase price allocation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,921 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877,865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,030 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes. </span></div></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17 million pertaining to indirect state sales taxes. During fiscal year 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period. </span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definite-lived intangible assets acquired during fiscal years 2023 and 2022 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:44.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noveprim Group</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SAMDI Tech, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Explore BioLabs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-Lived Intangible Assets</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,070 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,100 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Amortization Life</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definite-lived intangible assets acquired during fiscal years 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:36.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vigene</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retrogenix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cognate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distributed Bio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-Lived Intangible Assets</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,900 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,126 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,900 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Amortization Life</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction and integration costs incurred for fiscal years 2023, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:50.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction and Integration Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company routinely evaluates the strategic fit and fundamental performance of its global businesses, divesting operations that do not meet key business criteria. As part of this ongoing assessment, the Company determined that certain capital could be better deployed in other long-term growth opportunities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avian Vaccine Services</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2022, the Company sold its Avian Vaccine Services business (Avian) to a private investor group for a purchase price of $167.3 million in cash, subject to certain customary closing adjustments. The Company may also earn up to $30.0 million of contingent payments, which are tied to certain annual results of the Avian business from January 2024 through December 2027. The contingent payments have been fair valued at $10.3 million using a discounted probability weighted model. The Avian business was reported in the Company’s Manufacturing reportable segment. During the fiscal year 2022, the Company recorded a gain on the divestiture of Avian of $123.4 million within Other income (expense) on the Company’s consolidated statements of income. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RMS Japan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the Company sold its RMS Japan operations to The Jackson Laboratory for a purchase price of $70.9 million, which included $7.9 million in cash, $3.8 million pension over funding, and certain post-closing adjustments. During the three months ended December 25, 2021, the Company recorded a gain on the divestiture of the RMS Japan business of $20.0 million, net of costs to sell, a currency translation adjustment, and other adjustments related to certain ongoing arrangements with the buyer, which was included in Other income (expense), net within the Company’s consolidated statements of income. The RMS Japan business was reported in the Company’s RMS reportable segment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CDMO Sweden</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the Company sold its gene therapy CDMO site in Sweden to a private investor group for a purchase price of $59.6 million, net of $0.2 million in cash and other post-closing adjustments that may impact the purchase price. Included in the purchase price are contingent payments fair valued at $15.3 million, which were estimated using a probability weighted model (the maximum contingent contractual payments are up to $25.0 million based on future performance), as well as a purchase obligation of approximately $10.0 million between the parties. During fiscal year 2022 the fair value of the contingent payments receivable was reduced from $15.3 million to $7.5 million, which was the balance as of December 30, 2023, as certain financial targets are not expected to be achieved. CDMO Sweden was acquired in March 2021 as part of the acquisition of Cognate and was reported in the Company’s Manufacturing reportable segment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the major classes of assets and liabilities associated with these divestitures were as follows:</span></div><div style="margin-bottom:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:39.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 19, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 12, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avian</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMS Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CDMO Sweden</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:107%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Current assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,565 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,727 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:107%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,470 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,607 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.41 0.90 0.49 90000000 5000000 374800000 144600000 0.41 198800000 0.49 103200000 33300000 12000000 13800000 55000000 0.10 P1M 0.41 P12M 47000000 54000000 62800000 400000 0.20 12600000 284500000 6600000 323900000 2700000 34500000 57500000 0 0 53900000 8500000 6900000 877900000 70500000 15700000 0.02 97000000 800000 80800000 3000000 14100000 21000000 P1Y 7000000 0 35400000 19500000 5500000 15900000 17500000 P3Y 17300000 15200000 P4Y 3000000 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation for acquisitions during fiscal years 2023 and 2022 was as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:43.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noveprim Group</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SAMDI Tech, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Explora BioLabs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">November 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 27, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 5, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets (excluding cash)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use liabilities (Long-term)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase price allocation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to a prior asset acquisition that is deductible for tax purposes. </span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated <span style="-sec-ix-hidden:f-637">eight</span> year useful life.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation for acquisitions during fiscal years 2021 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:29.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vigene</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retrogenix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cognate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distributed Bio</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 28, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 29, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611,555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use liabilities (Long-term)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,958)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase price allocation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,921 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877,865 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,030 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses and the assembled workforce of the acquirees, thus is not deductible for tax purposes. </span></div></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In connection with its acquisitions of businesses, the Company routinely records liabilities related to indirect state and local taxes for preacquisition periods when such liabilities are estimable and deemed probable. The Company may or may not be indemnified for such indirect tax liabilities under terms of the acquisitions. As these indirect tax contingencies are resolved, actual obligations, and any indemnifications, may differ from the recorded amounts and any differences are reflected in reported results in the period in which these are resolved. Specifically for Cognate, as of March 29, 2021, the Company recorded an estimated liability of $17 million pertaining to indirect state sales taxes. During fiscal year 2022, the Company received a favorable ruling from the applicable state in which the indirect state sales tax liability arose and, accordingly, this liability was reduced in full, resulting in a gain recorded through selling, general and administrative expenses in the period. </span></div></td></tr></table></div> 1308000 513000 7679000 66500000 0 0 3965000 75000 1067000 35831000 593000 37369000 104000 0 48613000 172349000 37129000 215752000 9500000 33070000 70100000 167907000 6000 556000 0 43000 3507000 16378000 351000 15507000 97000 0 57193000 12984000 8191000 18601000 7797000 0 1807000 45374000 0 0 374834000 62801000 284521000 5000000 167800000 0.10 3548000 2266000 18566000 2722000 1657000 209000 14128000 221000 7649000 400000 52082000 2382000 22507000 1385000 34349000 1586000 239681000 34489000 611555000 71585000 93900000 22126000 270900000 24540000 694000 0 6098000 469000 4260000 434000 20539000 1319000 6319000 1141000 45388000 1504000 21220000 1205000 31383000 1123000 13958000 4174000 32503000 2529000 323879000 53921000 877865000 97030000 17000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definite-lived intangible assets acquired during fiscal years 2023 and 2022 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:44.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noveprim Group</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SAMDI Tech, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Explore BioLabs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-Lived Intangible Assets</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,070 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,100 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Amortization Life</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definite-lived intangible assets acquired during fiscal years 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:36.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vigene</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retrogenix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cognate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distributed Bio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-Lived Intangible Assets</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,900 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,126 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,900 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Amortization Life</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction and integration costs incurred for fiscal years 2023, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:50.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction and Integration Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 23400000 64000000 9500000 9670000 6100000 9500000 33070000 70100000 P15Y P13Y P7Y P7Y P4Y P7Y P12Y P12Y 87500000 17340000 257200000 16080000 6400000 4786000 13700000 8460000 93900000 22126000 270900000 24540000 P12Y P13Y P13Y P9Y P2Y P3Y P2Y P4Y P11Y P11Y P13Y P7Y 12379000 8470000 39099000 167300000 30000000 10300000 123400000 70900000 7900000 3800000 20000000 59600000 200000 15300000 25000000 10000000 15300000 7500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the major classes of assets and liabilities associated with these divestitures were as follows:</span></div><div style="margin-bottom:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:39.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 19, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 12, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avian</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMS Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CDMO Sweden</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:107%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Current assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client relationships, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,565 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,727 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:107%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,470 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,607 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30545000 26524000 8187000 24602000 17379000 14339000 611000 0 19733000 3168000 4129000 27764000 1629000 0 14089000 10000 3695000 0 60565000 51727000 84112000 8139000 8705000 6386000 331000 0 18221000 0 94000 0 8470000 8799000 24607000 REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:47.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Timing of Revenue Recognition:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RMS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred over time</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">377,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">263,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred at a point in time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">426,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total RMS revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690,437 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DSA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,611,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,440,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,103,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred at a point in time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total DSA revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,615,623 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,447,316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,107,231 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">371,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">335,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred at a point in time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Manufacturing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,569 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742,492 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,129,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,976,060 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,540,160 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances from Contracts with Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"><tr><td style="width:1.0%"></td><td style="width:60.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets from contracts with customers</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Client receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">578,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">559,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unbilled revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">806,097 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">763,668 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables and contract assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">780,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">752,390 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities from contracts with customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long term deferred revenue (included in Other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer contract deposits (included in Other current-liabilities)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized substantially all of the current contract assets and liabilities balances at December 31, 2022 and December 25, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in revenues during fiscal years 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $41 million and $54 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively. Net provisions were $18.2 million, $6.7 million, and $1.7 million in fiscal years 2023, 2022, and 2021, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to Future Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of December 30, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed and service revenue recognized in accordance with ASC 842, “Leases”.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $986.0 million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately 50% of which is expected to occur within the next twelve months and the remainder recognized thereafter during the remaining contract term. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:21.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenue</span></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:47.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Timing of Revenue Recognition:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RMS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred over time</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">377,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">263,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred at a point in time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">426,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total RMS revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690,437 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DSA</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,611,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,440,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,103,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred at a point in time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total DSA revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,615,623 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,447,316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,107,231 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">371,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">335,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services and products transferred at a point in time</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Manufacturing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789,569 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742,492 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,129,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,976,060 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,540,160 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and long-lived assets by geographic area are as follows:</span></div><div style="margin-bottom:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:24.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Canada</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asia Pacific</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,347,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,076,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">487,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,129,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">964,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">407,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">157,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,639,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,342,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,032,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,976,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">349,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,465,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,934,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">339,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">222,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,540,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">755,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">323,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,291,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 377947000 340708000 263659000 414396000 398467000 426778000 792343000 739175000 690437000 2611564000 2440646000 2103415000 4059000 6670000 3816000 2615623000 2447316000 2107231000 381942000 371500000 335745000 339501000 418069000 406747000 721443000 789569000 742492000 4129409000 3976060000 3540160000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"><tr><td style="width:1.0%"></td><td style="width:60.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets from contracts with customers</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Client receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">578,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">559,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unbilled revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">806,097 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">763,668 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Allowance for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables and contract assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">780,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">752,390 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities from contracts with customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long term deferred revenue (included in Other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer contract deposits (included in Other current-liabilities)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:21.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenue</span></td></tr></table></div> 578077000 559410000 228020000 204258000 806097000 763668000 25722000 11278000 780375000 752390000 241820000 264259000 30919000 25795000 85554000 91640000 41000000 54000000 18200000 6700000 1700000 986000000 0.50 P12M 93103000 60118000 18118000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s three reportable segments are RMS, DSA, and Manufacturing. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue and other financial information by reportable segment:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:45.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.233%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">792,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">739,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">154,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DSA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,615,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,447,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,107,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">606,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">532,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">179,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">177,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">721,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">789,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">742,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">246,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unallocated corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(231,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(209,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,129,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,976,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,540,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">617,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">650,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">589,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">314,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303,870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">265,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">324,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and long-lived assets by geographic area are as follows:</span></div><div style="margin-bottom:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:24.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Canada</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asia Pacific</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,347,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,076,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">487,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,129,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">964,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">407,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">157,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,639,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,342,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,032,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,976,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">349,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,465,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,934,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">339,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">222,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,540,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">755,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">323,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,291,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Other category above are operations located in Brazil, Israel, and Mauritius. Revenue represents sales originating in entities physically located in the identified geographic area. Long-lived assets consist of property, plant, and equipment, net.</span></div> 3 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue and other financial information by reportable segment:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:45.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.233%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">792,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">739,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">154,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DSA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,615,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,447,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,107,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">606,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">532,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">406,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">179,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">177,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">721,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">789,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">742,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">246,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unallocated corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(231,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(209,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,129,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,976,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,540,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">617,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">650,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">589,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">314,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303,870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">265,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">324,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.</span></div></td></tr></table></div> 792343000 739175000 690437000 154666000 160410000 166814000 55570000 49274000 39123000 52819000 44136000 61188000 2615623000 2447316000 2107231000 606076000 532889000 406978000 174719000 179465000 177254000 204891000 189563000 101477000 721443000 789569000 742492000 88329000 167084000 246390000 79982000 72950000 46195000 58134000 87084000 58877000 -231810000 -209408000 -230320000 3853000 2181000 2968000 2684000 3950000 7230000 4129409000 3976060000 3540160000 617261000 650975000 589862000 314124000 303870000 265540000 318528000 324733000 228772000 2347486000 1076937000 487305000 200833000 16848000 4129409000 964176000 407375000 157483000 74605000 36102000 1639741000 2342158000 1032125000 398982000 192837000 9958000 3976060000 896235000 349361000 135300000 82778000 1981000 1465655000 1934404000 1036465000 339098000 222902000 7291000 3540160000 755400000 323405000 145274000 64864000 2125000 1291068000 SUPPLEMENTAL CASH FLOW INFORMATION<div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets acquired under finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:53.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets acquired under finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:53.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 90374000 75909000 75441000 132101000 100754000 70775000 69139000 88612000 72043000 0 8179000 1567000 276771000 233912000 5803000 6192000 1906000 1110000 284480000 241214000 INVENTORY<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of inventories is as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">278,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255,809 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of inventories is as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">278,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255,809 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 42296000 38892000 59727000 48367000 278236000 168550000 380259000 255809000 PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of property, plant and equipment, net is as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,053,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963,717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">984,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">850,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">366,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">294,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer hardware and software </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">254,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">227,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vehicles </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">197,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199,713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,975,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,626,785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,335,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,161,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,639,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,465,655 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">These balances include assets under finance leases. See Note 17. Leases.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense in fiscal years 2023, 2022 and 2021 was $176.7 million, $157.3 million and $140.7 million, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of property, plant and equipment, net is as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,053,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963,717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">984,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">850,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">366,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">294,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer hardware and software </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">254,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">227,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vehicles </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">197,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199,713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,975,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,626,785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,335,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,161,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,639,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,465,655 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">These balances include assets under finance leases. See Note 17. Leases.</span></div></td></tr></table></div> 79546000 58192000 1053915000 963717000 984867000 850353000 366556000 294275000 31284000 27317000 254413000 227797000 6746000 5421000 197723000 199713000 2975050000 2626785000 1335309000 1161130000 1639741000 1465655000 176700000 157300000 140700000 VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS<div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venture capital investments are summarized below:</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:44.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,861)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,158 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,012 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,640 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strategic investments are summarized below:</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:44.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reduction for acquisition of entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197,753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,653 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,590 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,712 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Refer to Note 2. Acquisitions for further discussion on the Noveprim and SAMDI acquisitions</span></div></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venture capital investments are summarized below:</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:44.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,861)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,158 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,012 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,640 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strategic investments are summarized below:</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:44.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reduction for acquisition of entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197,753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,653 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,590 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,712 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Refer to Note 2. Acquisitions for further discussion on the Noveprim and SAMDI acquisitions</span></div></td></tr></table></div> 129012000 149640000 197100000 17410000 14485000 18023000 15685000 9861000 40205000 -10263000 -24398000 -23201000 684000 -854000 -2077000 121158000 129012000 149640000 182590000 51712000 24704000 34028000 142477000 35540000 9381000 2732000 789000 108090000 -2377000 -7219000 197753000 0 0 5079000 -6490000 -524000 122653000 182590000 51712000 FAIR VALUE<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:46.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="21" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets measured at fair value:</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Life insurance policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1049">Interest rate swap</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other long-term liabilities measured at fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1062">Interest rate swap</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:46.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets measured at fair value:</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Life insurance policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,605 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,605 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities measured at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities measured at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1091">Interest rate swap</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2023 and 2022, there were no transfers between fair value levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions.</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:53.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total gains or losses (realized/unrealized):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustment of previously recorded contingent liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,244 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $98 million, of which the value accrued as of December 30, 2023 is approximately $33 million. The weighted average probability of achieving the maximum target is approximately 34%. The average volatility and weighted average cost of capital are approximately 30% and 12%, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedge</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In November 2022, the Company entered into an interest rate swap with a notional amount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$500 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.700%. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 and in conjunction with an amendment of the Credit Agreement (Second Amendment), the Company modified the variable rate on its interest rate swap from 1-month LIBOR to 1-month adjusted term SOFR. Effective with the modification, the Company will pay a fixed rate of 4.65% on its swap maturing November 2, 2024. The Company elected to apply the optional expedient in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 848, Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with modifying its interest rate swap from LIBOR to SOFR that enabled it to consider the modification a continuation of the existing contract. As a result, the transition did not have an impact on the Company’s hedge accounting or a material impact to the Company’s financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.040%"><tr><td style="width:1.0%"></td><td style="width:45.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25% Senior Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">478,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.75% Senior Notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">458,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:46.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="21" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets measured at fair value:</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Life insurance policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1049">Interest rate swap</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other long-term liabilities measured at fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1062">Interest rate swap</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:46.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets measured at fair value:</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Life insurance policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,605 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,605 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities measured at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities measured at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1091">Interest rate swap</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,954 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2023 and 2022, there were no transfers between fair value levels.</span></div>The book value and fair value of the Company’s Senior Notes is summarized below:<div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.040%"><tr><td style="width:1.0%"></td><td style="width:45.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25% Senior Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">478,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.75% Senior Notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">458,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 29000 0 29000 0 40912000 40912000 0 966000 0 966000 0 41907000 0 41907000 0 0 33265000 33265000 0 0 0 0 0 0 33265000 33265000 0 78000 0 78000 0 34527000 0 34527000 0 34605000 0 34605000 0 0 13431000 13431000 0 0 0 0 0 1523000 0 1523000 0 1523000 13431000 14954000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions.</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:53.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total gains or losses (realized/unrealized):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustment of previously recorded contingent liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,244 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 13431000 37244000 2328000 33265000 3838000 71559000 15130000 11476000 2889000 1810000 -15340000 -33386000 -111000 -835000 -368000 33265000 13431000 37244000 98000000 33000000 0.34 0.30 0.12 500000000 0.04700 0.0465 0.0425 0.0425 500000000 478100000 500000000 460450000 0.0375 0.0375 500000000 458100000 500000000 442200000 0.0400 0.0400 500000000 449350000 500000000 432500000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:20.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 25, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,711,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,433,601 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">918,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,849,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,662,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">935,137 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,095,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2023, 2022 and 2021, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired. After completing the quantitative testing for fiscal year 2023, all reporting units exceeded the carrying value by a significant amount except for the Biologics Solutions reporting unit which had a fair value that exceeded its carrying value by approximately 20%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in goodwill during fiscal year 2023 related to the acquisitions of Noveprim and SAMDI in the DSA reportable segment. The increase in goodwill during fiscal year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the acquisition of Explora in the RMS reportable segment, partially offset by a decrease due to the Avian divestiture impacting the Manufacturing reportable segment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays intangible assets, net by major class:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:24.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Client relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,528,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(721,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">807,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,491,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(591,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">900,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(111,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Backlog</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks and trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,729,559 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(865,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">864,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,687,390 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(732,115)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">955,275 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The decrease in intangible assets, net during fiscal year 2023 related primarily to normal amortization over the useful lives, partially offset by the acquisitions of Noveprim and SAMDI. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2023, 2022 and 2021 was $137.4 million, $146.6 million and $124.9 million, respectively. As of December 30, 2023, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.695%"><tr><td style="width:1.0%"></td><td style="width:47.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:20.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 25, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,711,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,433,601 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">918,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,849,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,662,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">935,137 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,095,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.</span></div></td></tr></table></div> 283524000 1472506000 955851000 2711881000 215752000 0 -592000 215160000 0 0 3168000 3168000 -1566000 -38905000 -33499000 -73970000 497710000 1433601000 918592000 2849903000 0 209478000 0 209478000 0 0 0 0 -236000 19355000 16545000 35664000 497474000 1662434000 935137000 3095045000 1000000000 0 0 0 0.20 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays intangible assets, net by major class:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:24.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Client relationships</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,528,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(721,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">807,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,491,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(591,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">900,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(111,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Backlog</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks and trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,729,559 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(865,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">864,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,687,390 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(732,115)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">955,275 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1528780000 721322000 807458000 1491926000 591417000 900509000 142190000 111764000 30426000 129626000 101655000 27971000 3100000 2177000 923000 15236000 12512000 2724000 11878000 4568000 7310000 12617000 4410000 8207000 43611000 25677000 17934000 37985000 22121000 15864000 1729559000 865508000 864051000 1687390000 732115000 955275000 137400000 146600000 124900000 As of December 30, 2023, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.695%"><tr><td style="width:1.0%"></td><td style="width:47.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 129153000 120995000 115757000 103164000 91315000 DEBT AND OTHER FINANCING ARRANGEMENTS<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net and finance leases consists of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revolving facility</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,129,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,197,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.75% Senior Notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total debt and finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,667,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,729,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of long-term debt and finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt and finance leases</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,661,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,726,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net and finance leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,647,147 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,707,531 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023 and December 31, 2022, the weighted average interest rate on the Company’s debt was 4.93% and 4.58%, respectively. In fiscal year 2021, the Company prepaid $500 million of Senior Notes due in 2026 along with $21 million of related debt extinguishment costs and $13 million of accrued interest using proceeds from additional senior notes issued on the same day. The payment of the 2026 Senior Notes was accounted for as a debt extinguishment. Approximately $21 million </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of debt extinguishment costs and $5 million of deferred financing costs write-offs were recorded in Interest expense during fiscal year 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving facility (Credit Facility)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a revolving credit facility “Credit Facility” that provides for up to $3.0 billion of multi-currency revolving credit. The Credit Facility has a maturity date of April 2026, with no required scheduled payment before that date. The interest rates applicable to the revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at the Company’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1.0%) or the adjusted SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon the Company’s leverage ratio. In March 2023 and in conjunction with the Second Amendment the Company modified the variable rate on the Credit Facility from adjusted LIBOR to adjusted term SOFR. All outstanding U.S. dollar borrowings remained at adjusted LIBOR through their respective interest reset periods in April 2023 and were then set to term SOFR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0. As of December 30, 2023 and December 31, 2022, the Company was compliant with all financial covenants under the Credit Facility. The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2028 Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2019, the Company issued $500 million of 4.25% Senior Notes due in 2028 (2028 Senior Notes) in an unregistered offering. Interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2029 Senior Notes and 2031 Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2021, the Company issued $1 billion of debt split between $500 million of 3.75% Senior Notes due in 2029 (2029 Senior Notes), and $500 million of 4.00% Senior Notes due in 2031 (2031 Senior Notes), in an unregistered offering. Interest on the 2029 and 2031 Senior Notes is payable semi-annually on March 15 and September 15. Approximately $10 million of deferred financing costs were capitalized as part of this debt issuance. Proceeds from the 2029 and 2031 Senior Notes were used as follows: prepay the $500 million 2026 Senior Notes, $21 million of debt extinguishment costs, and $13 million of accrued interest; prepay the $146.9 million remaining term loan; pay down $135 million of the revolving facility; and pay for a portion of the Cognate acquisition, which occurred on March 29, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency transactions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2022 and 2021, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility, which were between $250 million and $400 million each. To limit this foreign currency exposure, the Company entered into foreign exchange forward contracts, which are not designated as hedging instruments. The gains and losses incurred on these transactions were as follows: </span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:40.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on foreign exchange forward contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on foreign debt remeasurement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility during fiscal year 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Maturities </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal maturities of existing debt for the periods set forth in the table below, are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.017%"><tr><td style="width:1.0%"></td><td style="width:67.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Principal</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,129,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">501,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,001,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,638,818 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023 and December 31, 2022, the Company had $21.6 million and $18.6 million, respectively, in outstanding letters of credit.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net and finance leases consists of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revolving facility</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,129,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,197,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.75% Senior Notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total debt and finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,667,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,729,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of long-term debt and finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt and finance leases</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,661,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,726,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net and finance leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,647,147 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,707,531 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1129243000 1197586000 0.0425 0.0425 500000000 500000000 0.0375 0.0375 500000000 500000000 0.0400 0.0400 500000000 500000000 9575000 1594000 28550000 30646000 2667368000 2729826000 3172000 1347000 2398000 2330000 5570000 3677000 2661798000 2726149000 14651000 18618000 2647147000 2707531000 0.0493 0.0458 500000000 21000000 13000000 21000000 5000000 3000000000 0.0050 0.010 3.50 4.25 500000000 0.0425 1000000000 500000000 0.0375 500000000 0.0400 10000000 500000000 21000000 13000000 146900000 135000000 250000000 250000000 400000000 400000000 The gains and losses incurred on these transactions were as follows: <div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:40.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on foreign exchange forward contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on foreign debt remeasurement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility during fiscal year 2023.</span></div> 49712000 34131000 -46529000 -31830000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal maturities of existing debt for the periods set forth in the table below, are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.017%"><tr><td style="width:1.0%"></td><td style="width:67.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Principal</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,129,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">501,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,001,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,638,818 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3172000 589000 1129772000 1947000 501947000 1001391000 2638818000 21600000 18600000 EQUITY AND NONCONTROLLING INTERESTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:50.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">480,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">492,608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">486,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">390,982 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average shares outstanding—Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options, restricted stock units and performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average shares outstanding—Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Board of Directors has authorized a $1.3 billion stock repurchase program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 30, 2023, the Company had $129.1 million remaining on the authorized stock repurchase program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired shares of 0.1 million in fiscal years 2023 and 2022, for $24.2 million and $38.7 million, respectively, from such netting.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the end of fiscal years 2023, 2022 and 2021, the Company’s Board of Directors approved the cancellation and return to the Company’s authorized and unissued capital stock, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reducing treasury stock on the Company’s consolidated balance sheet. The Company allocated the excess of the repurchase price over the par value of shares acquired to reduce both retained earnings and additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:42.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustment and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Other Post-Retirement Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gain (Loss) on Cash Flow Hedge</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 26, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(73,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(138,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,316)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(29,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 25, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(98,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(66,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164,740)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,507)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,523)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(99,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(217,785)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43,114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(262,057)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive (loss) income before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69,701 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(149,999)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47,167)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">739 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(196,427)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real.</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonredeemable Noncontrolling Interest</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an investment in an entity whose financial results are consolidated in the Company’s financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying consolidated balance sheets. The activity within the nonredeemable noncontrolling interest (net income less dividends declared) during fiscal years 2023, 2022, and 2021 was not significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Noncontrolling Interests</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds a 90% ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at a fixed redemption value that ranges from $47.0 million to $54.0 million depending on when exercised, which represents a derivative embedded within the equity instrument. The Company has the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing the 41% equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $54.0 million. Additionally, the 10% noncontrolling interest holders may receive a dividend disproportionate to their equity ownership, which has an approximate fair value of $8 million. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the accreted redemption value using the interest method and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 10% interest, the noncontrolling interest is classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. The redeemable noncontrolling interest was measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. The amount that the Company could be required to pay to purchase the remaining 8% equity interest was not limited. During the fourth quarter of fiscal 2023, the Company acquired the remaining 8% and as of December 2023, has paid $4.8 million of the total $24.4 million due. The remaining purchase price payable has been reclassified from the mezzanine section to Accrued liabilities on the consolidated balance sheet and is expected to be paid during fiscal year 2024.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, the Company acquired an 80% equity interest in a subsidiary, which included a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million, resulting in a remaining noncontrolling interest of 10%. Beginning in 2024, the Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at its appraised value. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest ($11.0 million as of December 30, 2023) or a predetermined floor, which represents a derivative embedded within the equity instrument. The amount that the Company could be required to pay to purchase the remaining 10% equity interest is not limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following table provi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">des a rollforward of the activity related to the Company’s redeemable noncontrolling interests:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:54.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition resulting in a 10% noncontrolling interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional purchases reducing noncontrolling interest percentage</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to redemption value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,722 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,010 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:50.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">480,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">492,608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">486,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">390,982 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average shares outstanding—Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options, restricted stock units and performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average shares outstanding—Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div></td></tr></table></div> 480370000 492608000 398837000 5746000 6382000 7855000 474624000 486226000 390982000 51227000 50812000 50293000 224000 489000 1132000 51451000 51301000 51425000 652000 560000 152000 1300000000 129100000 100000 100000 24200000 38700000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:42.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustment and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension and Other Post-Retirement Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gain (Loss) on Cash Flow Hedge</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 26, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(73,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(138,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,316)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">485 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(29,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 25, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(98,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(66,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164,740)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,507)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,523)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(99,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(217,785)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43,114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(262,057)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive (loss) income before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,851 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69,701 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(149,999)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47,167)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">739 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(196,427)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real.</span></div></td></tr></table></div> -73884000 -64990000 0 -138874000 -30316000 -1193000 0 -31509000 0 -1678000 0 -1678000 -30316000 485000 0 -29831000 -6027000 2062000 0 -3965000 -98173000 -66567000 0 -164740000 -125507000 24471000 -1523000 -102559000 0 -3337000 0 -3337000 -125507000 27808000 -1523000 -99222000 -5895000 4355000 -365000 -1905000 -217785000 -43114000 -1158000 -262057000 71851000 -5376000 2490000 68965000 0 -736000 0 -736000 71851000 -4640000 2490000 69701000 4065000 -587000 593000 4071000 -149999000 -47167000 739000 -196427000 0.90 0.10 47000000 54000000 0.10 0.41 54000000 0.10 8000000 0.10 0.92 0.08 0.08 0.08 4800000 24400000 0.80 0.20 0.10 15000000 0.10 0.10 11000000 0.10 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following table provi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">des a rollforward of the activity related to the Company’s redeemable noncontrolling interests:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:54.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition resulting in a 10% noncontrolling interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional purchases reducing noncontrolling interest percentage</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to redemption value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,722 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,010 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 42427000 53010000 25499000 45374000 0 0 24148000 15000000 0 -5694000 7506000 21312000 -3492000 -4020000 -5375000 2378000 3525000 0 -1200000 -3584000 824000 -1151000 0 0 56722000 42427000 53010000 INCOME TAXES <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income from operations before income taxes and the related provision for income taxes are presented below:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:55.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">185,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">351,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total income before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">581,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">622,987 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">480,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">152,263 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">163,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102,182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(42,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(51,349)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,309)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130,379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:58.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign tax rate differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credits and enhanced deductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Enacted tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of tax uncertainties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of acquisitions and restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:61.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net operating loss and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">379,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">382,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capitalized R&amp;D Expenditures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(304,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(294,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">258,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(231,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(256,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(57,791)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(48,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Venture capital investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(91,716)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(441,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(433,066)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(151,070)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(174,320)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized its deferred tax assets on the belief that it is more likely than not that they will be realized. Exceptions primarily relate to deferred tax assets for net operating losses in Luxembourg, Sweden, state research and development tax credits, certain capital losses, and fixed assets in the U.K. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company’s beginning and ending valuation allowance are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:57.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">294,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">315,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions (reductions) charged to income tax provision, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions due to acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reductions due to divestitures, restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17,484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">304,248 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">294,753 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">315,645 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, the Company had tax-effected deferred tax assets for net operating loss carryforwards of $336.0 million, as compared to $336.6 million as of December 31, 2022. Of this amount, $25.9 million are definite-lived and begin to expire in 2027, and the remainder of $310.1 million can be carried forward indefinitely. The Company has deferred tax assets for tax credit carryforwards of $41.5 million. The entire $41.5 million are definite-lived and begin to expire after 2039. Additionally, the Company records a benefit to operating income for research and development and other credits in Quebec, France, the Netherlands, and the U.K. related to its DSA facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:45.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.233%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions to tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,702 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,242 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,592 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $0.5 million decrease in unrecognized income tax benefits during fiscal year 2023 as compared to the corresponding period in 2022 is primarily attributable to prior year reductions to Canadian Scientific Research and Experimental Development (SR&amp;ED) credits, partially offset by an additional year of SR&amp;ED credit additions. The amount of unrecognized income tax benefits that, if recognized, would favorably impact the effective tax rate was $20.3 million as of December 30, 2023 and $20.3 million as of December 31, 2022. It is reasonably possible as of December 30, 2023 that the liability for unrecognized tax benefits for the uncertain tax position will decrease by approximately $5.2 million over the next twelve-month period. The Company continues to recognize interest and penalties related to unrecognized income tax benefits in income tax expense. The total amount of cumulative accrued interest related to unrecognized income tax benefits as of December 30, 2023 and December 31, 2022 was $1.3 million and $1.4 million, respectively. Interest expense recorded as a component of income taxes was immaterial for all periods. There were no accrued penalties related to unrecognized income tax benefits as of December 30, 2023 or as of December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, France, and India. The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid income tax of $59.7 million and $88.6 million has been presented within Other current assets in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively. Accrued income taxes of $38.8 million and $39.9 million have been presented within Other current liabilities in the accompanying consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income from operations before income taxes and the related provision for income taxes are presented below:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:55.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">185,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">351,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total income before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">581,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">622,987 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">480,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">152,263 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">163,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102,182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(42,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(51,349)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,309)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130,379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 185667000 280075000 129598000 395617000 342912000 351112000 581284000 622987000 480710000 49090000 75052000 32728000 85356000 68644000 60197000 17817000 19790000 9257000 152263000 163486000 102182000 -42987000 -27230000 -27486000 779000 -1134000 13891000 -9141000 -4743000 -6714000 -51349000 -33107000 -20309000 100914000 130379000 81873000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:58.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign tax rate differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credits and enhanced deductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Enacted tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of tax uncertainties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of acquisitions and restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.015 0.004 0.001 0.017 0.023 0.008 0.008 0.009 0.012 0.050 0.038 0.050 -0.001 -0.014 -0.043 -0.001 0.004 0.030 0.017 0.016 0.018 -0.003 -0.013 0.007 -0.042 0.020 -0.016 0.002 -0.008 0 0.015 0.008 0.013 0.014 0.014 0.012 0.001 0.002 -0.008 0.174 0.209 0.170 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:61.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net operating loss and credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">379,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">382,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capitalized R&amp;D Expenditures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(304,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(294,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">258,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(231,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(256,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(57,791)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(48,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Venture capital investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(91,716)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(441,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(433,066)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(151,070)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(174,320)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30167000 26341000 19121000 16938000 379959000 382932000 117449000 100156000 35673000 18616000 12190000 8516000 304248000 294753000 290311000 258746000 231020000 256234000 57791000 48965000 8350000 12007000 25080000 16407000 102620000 91716000 16520000 7737000 441381000 433066000 151070000 174320000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company’s beginning and ending valuation allowance are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:57.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">294,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">315,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions (reductions) charged to income tax provision, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions due to acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reductions due to divestitures, restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17,484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">304,248 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">294,753 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">315,645 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 294753000 315645000 334845000 963000 1929000 1023000 0 0 7747000 0 5337000 4706000 8532000 -17484000 -23264000 304248000 294753000 315645000 336000000 336600000 25900000 310100000 41500000 41500000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:45.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.233%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions to tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,702 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,242 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,592 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 23242000 32592000 24970000 3093000 4756000 9544000 721000 962000 2476000 4058000 1420000 1330000 0 10514000 1870000 296000 3134000 1198000 22702000 23242000 32592000 -500000 20300000 20300000 5200000 1300000 1400000 0 0 59700000 88600000 38800000 39900000 EMPLOYEE BENEFIT PLANS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Charles River Pension Plan (U.K. Pension Plan) is a defined contribution and defined benefit pension plan covering certain U.K. employees. Benefits are based on participants’ final pensionable salary and years of service. Participants’ rights vest immediately. The plan was previously amended to exclude new participants from joining the defined benefit section of the plan and a defined contribution section was established for new entrants. Contributions under the defined contribution plan are determined as a percentage of gross salary. Additionally, the U.K. Pension Plan was amended such that the members of the defined benefit section of the plan ceased to accrue additional benefits; however, their benefits continue to be adjusted for changes in their final pensionable salary or a specified inflation index, as applicable. During fiscal 2023, the Company made no contributions to the U.K. Pension Plan. As of fiscal 2023 year-end, this plan was in a funded status of $35.7 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company terminated a non-contributory defined benefit plan that covered certain employees in Canada (Canada Pension Plan). Upon settlement of the pension liability in fiscal year 2022, the Company recognized a $1.0 million loss related to the net periodic benefit cost recorded in Other expense in the consolidated statements of income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has several defined benefit plans in certain other countries in which it maintains an operating presence, including Canada, France, Germany, Italy, Mauritius, Netherlands, and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (income) associated with these plans for fiscal years 2023, 2022 and 2021 totaled $2.8 million, $0.1 million and $0.5 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charles River Laboratories Deferred Compensation Plan and Executive Supplemental Life Insurance Retirement Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a non-qualified deferred compensation plan, known as the Charles River Laboratories Deferred Compensation Plan (DCP), which allows a select group of eligible employees to defer a portion of their compensation. At the present time, no contributions are credited to the DCP, except as set forth below. Participants must specify the distribution date for deferred amounts at the time of deferral, in accordance with applicable IRS regulations. Generally, amounts may be paid in lump sum or installments upon retirement or termination of employment, or later if the employee terminates employment after age 55 and before age 65. Amounts may also be distributed during employment, subject to a minimum deferral requirement of three years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain active employees an annual contribution into their DCP account of 10% of the employee’s base salary plus the lesser of their target annual bonus or actual annual bonus.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the DCP, certain officers and key employees also participate, or in the past participated, in the Company’s Executive Supplemental Life Insurance Retirement Plan (ESLIRP), which is a non-funded, non-qualified arrangement. Annual benefits under this plan will equal a percentage of the highest <span style="-sec-ix-hidden:f-1643">five</span> consecutive years of compensation, offset by amounts payable under the U.S. Pension Plan and Social Security. In connection with the establishment of the DCP, certain active ESLIRP participants, who agreed to convert their accrued ESLIRP benefit to a comparable deferred compensation benefit, discontinued their direct participation in the ESLIRP. Instead, the present values of the accrued benefits of ESLIRP participants were credited to their DCP accounts, and future accruals are converted to present values and credited to their DCP accounts annually. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost associated with these plans for fiscal years 2023, 2022 and 2021 totaled $2.8 million, $4.3 million and $4.3 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested in several corporate-owned key-person life insurance policies with the intention of using these investments to fund the ESLIRP and the DCP. Participants have no interest in any such investments. As of December 30, 2023 and December 31, 2022, the cash surrender value of these life insurance policies were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $48.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $41.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"></td><td style="width:50.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in projected benefit obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">372,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer in due to acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(134,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">335,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(105,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer in due to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">203,657 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net balance sheet liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized in balance sheet:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial gains and losses are driven by changes in economic assumptions, principally discount rates. Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"></td><td style="width:50.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net prior service cost (credit)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net amount recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,734 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:46.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:46.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"><tr><td style="width:1.0%"></td><td style="width:46.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1715">Interest cost</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,626 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,886 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">981 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,375 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assumptions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to determine projected benefit obligations are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:46.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to determine net periodic benefit cost are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:40.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal years 2023 and 2022, new mortality improvement scales were issued in the U.S. and the United Kingdom (U.K.) reflecting a decline in longevity projection from previous releases the Company adopted, which decreased the Company’s benefit obligations by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.5 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its pension assets with the objective of achieving a total long-term rate of return sufficient to fund future pension obligations and to minimize future pension contributions. The Company is willing to tolerate a commensurate level of risk to achieve this objective. The Company controls its risk by maintaining a diversified portfolio of asset classes. Plan assets did not include any of the Company’s common stock as of December 30, 2023 or December 31, 2022. The weighted-average target asset allocations are 7.0% to equity securities, 84.1% to fixed income securities and 8.9% to other securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s pension plan assets by asset category are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:16.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mutual funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,653 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">193,943 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">203,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,742 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183,739 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,540 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end.</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations.</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end.</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity within the Level 3 pension plan assets was not significant during the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the Company did not contribute to the pension plans and expects to make $2.0 million in contributions in fiscal year 2024. During fiscal year 2023, the Company paid $1.7 million directly to certain participants outside of plan assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated using the same assumptions used in determining the Company’s benefit obligation as of 2023. Benefit payments will depend on future employment and compensation levels, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for fiscal years 2029 through 2033, are as follows.</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.695%"><tr><td style="width:1.0%"></td><td style="width:46.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,703 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029-2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,416 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charles River Laboratories Employee Savings Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Charles River Laboratories Employee Savings Plan is a defined contribution plan in the form of a qualified 401(k) plan in which substantially all U.S. employees are eligible to participate upon employment. The plan contains a provision whereby the Company matches a percentage of employee contributions. During fiscal years 2023, 2022 and 2021, the costs associated with this defined contribution plan totaled $31.6 million, $28.8 million and $24.0 million, respectively.</span></div> 0 35700000 -1000000 2800000 100000 500000 P3Y 0.10 2800000 4300000 4300000 48400000 41900000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"></td><td style="width:50.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in projected benefit obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">372,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer in due to acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(134,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">335,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(105,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer in due to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefit payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">203,657 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net balance sheet liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized in balance sheet:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 205551000 372599000 2474000 3213000 9941000 6140000 6239000 6469000 0 2477000 0 11939000 1106000 0 -3600000 134923000 -8442000 20593000 224875000 205551000 192540000 335631000 5578000 -105749000 1744000 4558000 0 11939000 181000 0 6239000 6469000 9853000 -23492000 203657000 192540000 -21218000 -13011000 36957000 39185000 1164000 1151000 57011000 51045000 Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows:<div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"></td><td style="width:50.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net prior service cost (credit)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net amount recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,734 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -58855000 -54509000 -121000 -585000 58734000 53924000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:46.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 54310000 48414000 2824000 2258000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:46.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 61671000 55304000 3496000 3108000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"><tr><td style="width:1.0%"></td><td style="width:46.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1715">Interest cost</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,626 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,886 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">981 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,375 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2474000 3213000 3455000 9941000 6140000 5492000 7556000 7322000 8058000 -464000 -506000 -531000 -1231000 -2869000 -4528000 5626000 4394000 4886000 0 981000 -2320000 5626000 5375000 2566000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to determine projected benefit obligations are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:46.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to determine net periodic benefit cost are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:40.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 0.047 0.048 0.032 0.032 0.048 0.018 0.015 0.039 0.024 0.025 0.032 0.037 0.030 -3500000 -200000 0.070 0.841 0.089 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s pension plan assets by asset category are as follows:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:16.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mutual funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,653 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">193,943 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">203,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,742 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183,739 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">192,540 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end.</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations.</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end.</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end.</span></div></td></tr></table></div> 446000 798000 0 1244000 362000 5153000 0 5515000 0 10701000 0 10701000 0 9308000 0 9308000 0 144822000 0 144822000 0 123638000 0 123638000 9207000 10368000 0 19575000 8380000 9372000 0 17752000 0 27254000 61000 27315000 0 36268000 59000 36327000 9653000 193943000 61000 203657000 8742000 183739000 59000 192540000 0 2000000 1700000 Estimated future benefit payments during the next five years and in the aggregate for fiscal years 2029 through 2033, are as follows.<div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.695%"><tr><td style="width:1.0%"></td><td style="width:46.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pension Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,703 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,633 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029-2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,416 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6558000 6703000 46898000 7633000 8843000 55416000 31600000 28800000 24000000 STOCK-BASED COMPENSATION<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has stock-based compensation plans under which employees and non-employee directors are granted stock-based awards such as stock options, RSUs, and PSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2023, 2022 and 2021, the primary share-based awards and their general terms and conditions are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock options, which entitle the holder to purchase a specified number of shares of common stock at an exercise price equal to the closing market price of common stock on the date of grant; typically vest over 4 years; and typically expire 5 or 10 years from date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RSUs, which represent an unsecured promise to grant at no cost a set number of shares of common stock upon the completion of the vesting schedule, and principally vest over 4 years. With respect to RSUs, recipients are not entitled to cash dividends and have no voting rights on the stock during the vesting period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PSUs, which entitle the holder to receive at no cost, a specified number of shares of common stock within a range of shares from zero to a specified maximum and typically vest over 3 years. Payout of this award is contingent upon achievement of certain performance and market conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, approximately 4.1 million shares were authorized for future grants under the Company’s share-based compensation plans. The Company settles employee share-based compensation awards with newly issued shares. The following table provides stock-based compensation by the financial statement line item in which it is reflected:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:50.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation, before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation, net of income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,141 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,648 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation related costs were capitalized in fiscal years 2023, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company’s stock-based compensation plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:38.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining<br/>Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">259.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options outstanding as of December 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">789 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercisable as of December 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options expected to vest as of December 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">233.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:46.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted was $80.98, $90.05 and $108.61 for fiscal years 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $18.5 million. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.4 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insic value of options exercised during fiscal years 2023, 2022 and 2021 was $18.2 million, $33.2 million and $94.4 million, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the exercise price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock units activity for fiscal year 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:52.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">226.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, the unrecognized compensation cost related to shares of unvested RSUs expected to vest was $65.8 million, which is expected to be recognized over an estimated weighted-average amortization period of 2.8 years. The total f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">air value of RSU grants that vested during fiscal years 2023, 2022 and 2021 was $28.4 million, $24.8 million and $22.8 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Based Stock Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues PSUs to certain corporate officers. The number of shares of common stock issued for each PSU is adjusted based on a performance condition linked to the Company’s financial performance. Certain awards are further adjusted based on a market condition, which is calculated based on the Company’s stock performance relative to a peer group over the three-year vesting period. The fair value of the market condition is reflected in the fair value of the award at grant date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:48.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.866%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PSUs granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">407.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Key assumptions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total shareholder return of 20-trading day average stock price on grant date</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maxim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">um number of common shares to be issued upon vesting of PSUs is 0.3 million. For fiscal years 2023, 2022 and 2021, the Company recognized stock-based compensation related to PSUs of $28.1 million, $31.2 million and $31.8 million, respectively. The total fair value of PSUs that vested during fiscal years 2023, 2022 and 2021 was $34.4 million, $31.0 million and $26.0 million, respectively.</span></div>In fiscal year 2021, the Company also issued approximately 5,000 PSUs using a weighted-average grant date fair value per share of $477.52. These PSUs vest upon the achievement of financial targets and other performance measures. P4Y P4Y P4Y P5Y P5Y P5Y P10Y P10Y P10Y P4Y P4Y P4Y 0 0 0 P3Y P3Y P3Y 4100000 The following table provides stock-based compensation by the financial statement line item in which it is reflected:<div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:50.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation, before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation, net of income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,141 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,648 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15052000 14853000 13087000 56996000 58764000 58387000 72048000 73617000 71474000 10907000 10969000 10299000 61141000 62648000 61175000 0 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company’s stock-based compensation plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:38.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining<br/>Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">259.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options outstanding as of December 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">789 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercisable as of December 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options expected to vest as of December 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">233.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 882000 204.41 130000 194.27 195000 130.91 28000 259.63 789000 218.97 P6Y6M 28935000 408000 205.50 P4Y9M18D 20521000 381000 233.37 P8Y3M18D 8414000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:46.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> P6Y P6Y P6Y 0.36 0.33 0.32 0.038 0.027 0.010 0 0 0 80.98 90.05 108.61 18500000 P2Y4M24D 18200000 33200000 94400000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock units activity for fiscal year 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:52.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">226.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 364000 226.43 265000 194.84 134000 212.34 26000 231.70 469000 212.30 65800000 P2Y9M18D 28400000 24800000 22800000 P3Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:48.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.866%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PSUs granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">407.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Key assumptions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total shareholder return of 20-trading day average stock price on grant date</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 146000 134000 64000 204.40 210.42 407.76 0.37 0.39 0.37 0.042 0.026 0.002 0 0 0 P20D -0.098 -0.327 0.399 300000 28100000 31200000 31800000 34400000 31000000 26000000 5000 477.52 RESTRUCTURING AND ASSET IMPAIRMENTS<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment and accelerated depreciation charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents restructuring costs by reportable segment:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RMS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DSA</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,176 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">851 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,114 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unallocated corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">889 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,682 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents restructuring costs as included within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Severance and Transition Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Impairments and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services provided (excluding amortization of intangible assets)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,608 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,074 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,682 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Transition Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Impairments and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services provided (excluding amortization of intangible assets)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Transition Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Impairments and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services provided (excluding amortization of intangible assets)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,898 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,139 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Restructuring Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward for all of the Company’s severance and transition costs related to all restructuring activities:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2002"><span style="-sec-ix-hidden:f-2003"><span style="-sec-ix-hidden:f-2004">Expense (excluding non-cash charges)</span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments / utilization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-cash adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,050 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>As of December 30, 2023 and December 31, 2022, $5.1 million and $1.3 million, respectively, of severance and other personnel related costs liabilities were included in accrued compensation and accrued liabilities within the Company’s consolidated balance sheets. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents restructuring costs by reportable segment:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RMS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DSA</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,176 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">851 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,114 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unallocated corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">889 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,682 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents restructuring costs as included within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Severance and Transition Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Impairments and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services provided (excluding amortization of intangible assets)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,608 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,074 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,682 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Transition Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Impairments and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services provided (excluding amortization of intangible assets)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Transition Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Impairments and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services provided (excluding amortization of intangible assets)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,898 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,139 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3479000 1007000 7000 16176000 851000 3114000 9138000 5126000 3663000 889000 1229000 72000 29682000 8213000 6856000 7408000 14812000 22220000 1146000 3262000 4408000 3054000 0 3054000 11608000 18074000 29682000 928000 1784000 2712000 532000 1765000 2297000 2441000 763000 3204000 3901000 4312000 8213000 1898000 934000 2832000 0 0 0 2819000 1205000 4024000 4717000 2139000 6856000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward for all of the Company’s severance and transition costs related to all restructuring activities:</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2002"><span style="-sec-ix-hidden:f-2003"><span style="-sec-ix-hidden:f-2004">Expense (excluding non-cash charges)</span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments / utilization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-cash adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,050 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1300000 4011000 5818000 11539000 6732000 5695000 7800000 6973000 5604000 0 2350000 1831000 -11000 120000 67000 5050000 1300000 4011000 5100000 1300000 LEASES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating and Finance Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">394,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">391,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2027"><span style="-sec-ix-hidden:f-2028">Other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">419,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">436,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2035"><span style="-sec-ix-hidden:f-2036">Property, plant and equipment, net</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2039"><span style="-sec-ix-hidden:f-2040">Current portion of long-term debt and finance leases</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,330</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2043"><span style="-sec-ix-hidden:f-2044">Long-term debt, net and finance leases</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,152</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,316</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:49.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease costs:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93,275 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:49.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash leases activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use lease assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use lease assets obtained in exchange for new finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease term and discount rate</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:49.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:64.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,433 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,513 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,946 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,953 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">286,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">596,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum future lease payments (predominantly operating leases) of approximately $161 million for leases that have not commenced as of December 30, 2023, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2024 and 2025 with lease terms of approximately 5 to 15 years.</span></div> LEASES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating and Finance Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">394,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">391,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2027"><span style="-sec-ix-hidden:f-2028">Other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">419,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">436,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2035"><span style="-sec-ix-hidden:f-2036">Property, plant and equipment, net</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2039"><span style="-sec-ix-hidden:f-2040">Current portion of long-term debt and finance leases</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,330</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2043"><span style="-sec-ix-hidden:f-2044">Long-term debt, net and finance leases</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,152</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,316</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:49.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease costs:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93,275 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:49.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash leases activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use lease assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use lease assets obtained in exchange for new finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease term and discount rate</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:49.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:64.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,433 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,513 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,946 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,953 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">286,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">596,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum future lease payments (predominantly operating leases) of approximately $161 million for leases that have not commenced as of December 30, 2023, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2024 and 2025 with lease terms of approximately 5 to 15 years.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">394,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">391,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2027"><span style="-sec-ix-hidden:f-2028">Other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">419,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">436,271 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2035"><span style="-sec-ix-hidden:f-2036">Property, plant and equipment, net</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2039"><span style="-sec-ix-hidden:f-2040">Current portion of long-term debt and finance leases</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,330</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-2043"><span style="-sec-ix-hidden:f-2044">Long-term debt, net and finance leases</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,152</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,316</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div> 394029000 391762000 54908000 46526000 419234000 389745000 474142000 436271000 29422000 31875000 2398000 2330000 26152000 28316000 28550000 30646000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of operating and finance lease costs within the Company’s consolidated statements of income for fiscal years 2023, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:49.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease costs:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93,275 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:49.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash leases activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use lease assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use lease assets obtained in exchange for new finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease term and discount rate</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:49.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 25, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 65380000 59671000 45728000 2745000 3035000 3337000 1477000 1441000 1280000 3581000 2954000 2441000 22159000 13965000 4623000 2067000 1912000 2008000 93275000 79154000 55401000 60239000 48360000 42576000 1476000 1442000 1282000 2297000 2257000 3202000 75987000 189134000 142764000 0 8179000 1567000 P9Y7M6D P9Y9M18D P9Y P12Y8M12D P13Y7M6D P11Y8M12D 0.047 0.043 0.036 0.053 0.053 0.044 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:64.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,433 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,513 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,946 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,953 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">286,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">596,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 30, 2023, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:64.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,433 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,513 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,946 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,953 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">286,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">596,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">474,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,550 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 70578000 3796000 63433000 3513000 58494000 3038000 59946000 2999000 57953000 2988000 286215000 23562000 596619000 39896000 122477000 11346000 474142000 28550000 161000000 P5Y P15Y COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains certain insurance policies that maintain large deductibles up to approximately $2 million, some with or without stop-loss limits, depending on market availability. Insurance policies at certain locations are based on a percentage of the insured assets, for which deductibles for certain property may exceed $22.0 million in the event of a catastrophic event. In addition, the Company purchased representation and warranty insurance in support of some acquisitions, in which deductibles could reach $4.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain recent shipments in the United States. The carrying value of the inventory related to these shipments is approximately $27 million as of December 30, 2023, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena, primarily related to the sourcing of non-human primates, and the Company is cooperating with the request. We are not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A putative securities class action was filed on May 19, 2023 against the Company and a number of its current/former officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. The Company filed a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The Company intends to file a motion to dismiss. While the Company cannot predict the outcome of this matter, it believes the derivative lawsuit to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aside from the matter above, the Company believes there are no other matters pending against the Company that could have a material impact on the Company’s business, financial condition, or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. These unconditional purchase obligations exclude agreements that are cancellable at any time without penalty. The aggregate amount of the Company’s unconditional purchase obligations totaled approximately $390 million as of December 30, 2023 and the majority of these obligations are expected to be settled during 2024.</span></div> 2000000 22000000 4000000 27000000 390000000 false false <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On November 14, 2023, James Foster, our Chair, President, and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement, dated February 23, 2023 for the sale of up to 112,341 shares of common stock. Mr. Foster did not sell any shares pursuant to such plan, which, absent such termination, would have expired on March 1, 2025.</span> November 14, 2023 James Foster Chair, President, and Chief Executive Officer true 112341 On November 15, 2023, Birgit Girshick, our Corporate Executive Vice President &amp; Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement, dated February 24, 2023 for the sale of up to 25,320 shares of common stock. Ms. Girshick did not sell any shares pursuant to such plan, which, absent such termination, would have expired on February 28, 2024. November 15, 2023 Birgit Girshick Corporate Executive Vice President & Chief Operating Officer true 25320 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On November 22, 2023, Ms. Girshick entered into a Rule 10b5-1 trading arrangement for the sale of up to 22,362 shares of common stock, subject to certain conditions. The arrangement’s expiration date is February 28, 2025.</span> November 22, 2023 Ms. Girshick true 22362

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